<SEC-DOCUMENT>0001493152-24-017318.txt : 20240501
<SEC-HEADER>0001493152-24-017318.hdr.sgml : 20240501
<ACCEPTANCE-DATETIME>20240430204312
ACCESSION NUMBER:		0001493152-24-017318
CONFORMED SUBMISSION TYPE:	S-1/A
PUBLIC DOCUMENT COUNT:		17
FILED AS OF DATE:		20240501
DATE AS OF CHANGE:		20240430

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Kairos Pharma, LTD.
		CENTRAL INDEX KEY:			0001962011
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				462993314
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-1/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-274805
		FILM NUMBER:		24899577

	BUSINESS ADDRESS:	
		STREET 1:		2355 WESTWOOD BLVD. #139
		CITY:			LOS ANGELES
		STATE:			CA
		ZIP:			90064
		BUSINESS PHONE:		818-404-5541

	MAIL ADDRESS:	
		STREET 1:		2355 WESTWOOD BLVD. #139
		CITY:			LOS ANGELES
		STATE:			CA
		ZIP:			90064
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-1/A
<SEQUENCE>1
<FILENAME>forms-1a.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>As filed with the Securities and Exchange Commission
on April 30, 2024.</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Registration
No. 333-274805</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>UNITED
STATES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>WASHINGTON,
D.C. 20549</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>AMENDMENT NO. 3 </B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>FORM
S-1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>REGISTRATION
STATEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>UNDER</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>THE
SECURITIES ACT OF 1933</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>Kairos
Pharma, Ltd.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Exact
name of registrant as specified in its charter)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2834</B></FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; width: 32%"><P STYLE="margin: 0; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"><B>46-2993314</B></FONT></P>

</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(State
    or other jurisdiction of<BR>
</B> <B>incorporation or organization)</B></FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Primary
    Standard Industrial<BR>
</B> <B>Classification Code Number)</B></FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(I.R.S.
    Employer</B> <BR>
<B>Identification Number)</B></FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Kairos
Pharma, Ltd.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2355
Westwood Blvd., #139</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Los
Angeles CA 90064</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(310)
948-2356</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Address,
including zip code, and telephone number, including area code, of registrant&rsquo;s principal executive offices)</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>John
S. Yu, M.D.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Chief
Executive Officer</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Kairos
Pharma, Ltd.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2355
Westwood Blvd., #139</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Los
Angeles CA 90064</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(310)
948-2356</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Name,
address, including zip code, and telephone number, including area code, of agent for service)</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Copies
to: </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Megan J. Penick, Esq.</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Dorsey &amp; Whitney LLP</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>51 West 52<SUP>nd</SUP> Street</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>New York, New York 10019</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Tel: (212) 415-9200</B></P></TD>
    <TD STYLE="width: 50%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Spencer G. Feldman, Esq.</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Dakota J. Forsyth, Esq.</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Olshan Frome Wolosky LLP</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>1325 Avenue of the Americas</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>15th Floor</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>New York, New York 10019</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Tel: (212) 451-2300</B></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Approximate
date of commencement of proposed sale to the public: </B>As soon as practicable after this registration statement becomes effective.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the
Securities Act of 1933 check the following box: &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the
following box and list the Securities Act registration statement number of the earlier effective registration statement for the same
offering. &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the
Securities Act registration statement number of the earlier effective registration statement for the same offering. &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the
Securities Act registration statement number of the earlier effective registration statement for the same offering. &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company
or an emerging growth company. See the definitions of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer,&rdquo; &ldquo;smaller
reporting company,&rdquo; and &ldquo;emerging growth company&rdquo; in Rule 12b-2 of the Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 25%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large
    accelerated filer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 30%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated
    filer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-accelerated
    filer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;
    </FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller
    reporting company</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
    growth company</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the
Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective
in accordance with Section 8(a) of the Securities Act of 1933 or until the Registration Statement shall become effective on such date
as the Commission, acting pursuant to said Section 8(a), may determine.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; border-bottom: Black 4pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Red">The
information in this preliminary prospectus is not complete and may be changed. These securities may not be sold until the registration
statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell nor does
it seek an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Red">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>1,550,000
</B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>Shares</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><IMG SRC="logo_003.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>Kairos
Pharma, Ltd.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>Common
Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
is a firm commitment initial public offering of shares of common stock, par value $.001 per share, of Kairos Pharma, Ltd. We are offering
1,550,000 shares of our common stock and currently expect that the initial public offering price will be $4.00 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Prior to this offering, there has been no public
market for our common stock. We are seeking to have our common stock listed for trading on the NYSE American LLC, or NYSE American,
under the symbol &ldquo;KAPA.&rdquo; The closing of this offering is contingent on obtaining approval of our listing application
from NYSE American and there is no assurance that our common stock will be approved for listing on such exchange.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We are an &ldquo;emerging growth company&rdquo; as defined under the federal securities laws and, as such, will be subject to reduced public company reporting requirements. See &ldquo;Prospectus Summary &mdash; Implications of Being an Emerging Growth Company&rdquo; for additional information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investing
in our common stock involves a high degree of risk. You should carefully consider the risk factors beginning on page 10 of this prospectus
prior to making a decision to invest in our common stock.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Neither
the Securities and Exchange Commission nor any other regulatory body has approved or disapproved of these securities or passed upon the
accuracy or adequacy of this prospectus. Any representation to the contrary is a criminal offense.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Per
                                            Share </I></B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Total </I></B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Initial
    public</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> offering price</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">4.00</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>$</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,200,000</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Underwriting
    discounts and commissions(1)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>$</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.28</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>$</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">434,000</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds
    to us, before expenses</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>$</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3.72</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>$</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">5,766,000</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have agreed to pay the underwriters a cash fee equal to 7.0% of the aggregate gross proceeds from the sale of the common stock. The
    underwriters will also be entitled to warrants to purchase up to 7.0% of the aggregate number of shares of our common stock
    sold in this offering and a 1% non-accountable expense allowance, which amount is not included above. We have also agreed to reimburse
    the underwriters for certain expenses incurred by them. See &ldquo;Underwriting&rdquo; beginning on page 130 of this prospectus for
    more information about the compensation payable to the underwriters.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have granted the underwriters an option for a period of 45 days to purchase up to an additional &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
shares of common stock from us at the initial public offering price less underwriting discounts and commissions to cover over-allotments,
if any. If the underwriters exercise the option in full, the total underwriting discounts and commissions payable by us will be $
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, and the total proceeds to us, before expenses, will be $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">Delivery of the shares is
expected to be made on or about &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 14pt">Boustead
Securities, LLC</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prospectus
dated &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2024</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TABLE
OF CONTENTS</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page
    </B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><A HREF="#a_020">About This Prospectus</A></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">i</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#S1_001"><FONT STYLE="font-size: 10pt">Prospectus
    Summary</FONT></A></FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">1</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#S1_002"><FONT STYLE="font-size: 10pt">Risk
    Factors</FONT></A></FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">10</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ak_001">Special Note Regarding Forward-looking Statements</A></FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">69</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ak_003">Use of Proceeds</A></FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">70</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ak_004">Dividend Policy</A></FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">71</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ak_005">Capitalization</A></FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">72</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ak_006">Dilution</A></FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">73</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ak_007">Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations</A> </FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">75</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ak_008">Business</A></FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">81</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ak_009">Management</A></FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">111</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ak_010">Executive Compensation</A></FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">116</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ak_011">Certain Relationships and Related Person Transactions</A></FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">119</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ak_012">Principal Stockholders</A></FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">120</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ak_013">Description of Capital Stock</A></FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">121</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ak_014">Shares Eligible for Future Sale</A></FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">125</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ak_015">Certain
    Material U.S. Federal Income Tax Consequences to Non-U.S. Holders of Our Common Stock</A></FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">127</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ak_016">Underwriting</A></FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">130</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ak_017">Legal Matters</A></FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">134</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ak_018">Experts</A></FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">134</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ak_019">Where You Can Find Additional Information</A></FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">134</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><A HREF="#a_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Index to Financial Statements</FONT></A></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">F-1</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><A NAME="a_020"></A>ABOUT THIS PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Neither
we nor the underwriters have authorized anyone to provide you any information or make any representations other than those contained
in this prospectus or in any free writing prospectuses prepared by or on behalf of us or to which we have referred you. We and the underwriters
take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give
you. We and the underwriters are not making an offer to sell these securities in any jurisdiction where the offer or sale is not permitted.
You should assume that the information appearing in this prospectus or in any applicable free writing prospectus is current only as of
its date, regardless of its time of delivery or any sale of shares of our common stock. Our business, financial condition, results of
operations, and prospects may have changed since that date.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>For
investors outside of the United States: we have not, and the underwriters have not, done anything that would permit this offering or
possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than the United States.
Persons outside of the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions
relating to, the offering of the shares of common stock and the distribution of this prospectus outside of the United States.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<DIV STYLE="padding-right: 0.1in; padding-left: 0.1in; border: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="S1_001"></A><B>PROSPECTUS
SUMMARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>This
summary highlights selected information contained elsewhere in this prospectus and is qualified in its entirety by the more detailed
information and financial statements included elsewhere in this prospectus. This summary does not contain all of the information you
should consider before investing in our common stock. You should carefully read this entire prospectus, including the information under
the sections titled &ldquo;Risk Factors,&rdquo; &ldquo;Special Note Regarding Forward-Looking Statements,&rdquo; and &ldquo;Management&rsquo;s
Discussion and Analysis of Financial Condition and Results of Operations&rdquo; and our financial statements and the related notes included
elsewhere in this prospectus, before making an investment decision. Unless otherwise necessary or appropriate in the context, references
in this prospectus to &ldquo;Kairos,&rdquo; the &ldquo;Company,&rdquo; &ldquo;we,&rdquo; &ldquo;us,&rdquo; and &ldquo;our&rdquo; refer
to Kairos Pharma, Ltd., a Delaware corporation, and our wholly owned subsidiary, Enviro Therapeutics, Inc., a California
corporation.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Our Company</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Overview</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a clinical-stage biopharmaceutical company advancing therapeutics for cancer patients that are designed to overcome key hurdles in
immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer,
lung cancer, breast cancer and glioblastoma. <FONT STYLE="background-color: white">We are driven by innovative
science to develop novel and transformative drug therapies to treat cancer.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white">Our mission
is to advance our portfolio of innovative therapeutics to transform the way cancer is treated. We have leveraged molecular insights to
develop a new class of novel drugs that we expect will target drug resistance and checkpoints of immune suppression. &ldquo;Checkpoints&rdquo;
refer to molecules on certain immune cells that need to be activated (or inactivated) to start an immune response. Our portfolio of seven
drug candidates offers diversification and mitigates the overall exposure to many of the inherent risks of drug development. Our
key patents are licensed from Cedars-Sinai Medical Center, the largest academic medical center in the Western United States, and
Tracon Pharmaceuticals, Inc., a clinical stage public biopharmaceutical company based in California. The science underlying the
patents was developed at Cedars-Sinai Medical Center and was licensed to us from this institution.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
human immune system can tell the difference between normal cells in the body and those it sees as &ldquo;foreign,&rdquo; which allows
it to focus an attack on the foreign cells while leaving the normal cells alone. To do this, our immune system uses checkpoints. Cancer cells can find
ways to use these checkpoints to avoid being attacked by the immune system.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are developing small molecules that we believe can specifically target these central checkpoints. In addition, we are developing
an activated T cell therapy that is designed to transform a patient&rsquo;s T cells into killer activated T cells against cancerous
stem cells. These activated T cells are induced to target several antigen targets on glioblastoma cancer stem cells, the initiators
and propagators of glioblastoma tumors.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2021, Kairos acquired Enviro Therapeutics, Inc., a California corporation (&ldquo;Enviro&rdquo;), through a share
exchange. Enviro&rsquo;s shareholders exchanged 100% of the outstanding shares of Enviro for 6,000,000 shares of newly issued restricted
shares of common stock of Kairos. After the closing, Enviro became a wholly owned subsidiary of Kairos. The acquisition allowed us to
incorporate into our company Enviro&rsquo;s advanced pipeline of drug candidates in Phase 1 and Phase 2 trials. The pipeline includes
two therapeutic agents addressing what we believe to be significant unmet needs in the prostate and lung cancer markets and that we believe
can help address cancer progression in</FONT> those cancers that develop resistance to standard therapies.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our drug candidate portfolio currently consists of
a pipeline of seven drug candidates, including KROS drugs, which are immunotherapeutics, and ENV antibodies, which are designed to reverse
drug resistance that often results as a consequence of the use of cancer therapeutics. Our pipeline is summarized below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&#9679;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Five pre-clinical or clinical-trial stage drug candidates developed by us and designed to target immune response, including KROS 101, 102, 201, 301, and 401, which are designed to reverse immunosuppression of T cells that is caused by cancer.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">-</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">KROS 101 and 102 are small molecules that are agonist
    and antagonist for the GITR (glucocorticoid induced TNF-like receptor) ligand, which respectively promote and inhibit T cell growth
    and function. GITR is a checkpoint central to control the numbers of T cells of the immune system. These molecules are in the preclinical
    stage and are being developed for clinical trials.</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">-</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">KROS 201 is an autologous T cell therapy targeting cancer
    stem cells of glioblastoma. This therapy has received an IND from the FDA for clinical trial and is undergoing preparation for a
    Phase 1 clinical trial for patients with recurrent glioblastoma.</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">-</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">KROS 301 is a small molecule that targets the NF-&#312;&beta;
    pathway, a cancer growth and immune suppressive molecule in triple negative breast cancer. This molecule is in preclinical testing.</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">-</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">KROS 401 is a cyclic peptide which inhibits the IL-4
    and IL-13 (cytokines that play a critical role in the suppression of T cells by macrophages at the site of the tumor) receptor and
    is designed to reverse the immunosuppression induced by macrophages in the tumor microenvironment.</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&#9679;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Two
    therapeutic agents developed by our Enviro subsidiary and designed to increase anti-tumor response in
    conjunction with cancer therapies by addressing resistance to these agents.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">-</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">ENV 105 is an antibody that targets CD105 / Endoglin which
    is expressed in tumor cells and surrounding cells as the tumor becomes resistant to therapeutics in prostate cancer and lung cancer.
    This therapy is being tested in a randomized multicenter Phase 2 trial for prostate cancer and a Phase 1 trial
    in lung cancer, both of which began enrolling patients in September 2023. ENV 105 has received an IND from the FDA.</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">-</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">ENV 205 is an antibody that targets mitochondrial DNA
    which is elevated as patients become resistant to chemotherapies. This therapy is in preclinical testing.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<DIV STYLE="padding-right: 0.1in; padding-left: 0.1in; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this prospectus, our product candidates have not been approved as safe or effective by the FDA or any other comparable
foreign regulator.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>Our
In-Development Products and Pipeline</B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">We
develop a broad </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">portfolio of <FONT>novel
and transformative drug therapies to treat cancer. Our current portfolio consists of seven drug therapies consisting of </FONT>therapeutic
agents <FONT>ENV 105 and 205 to counter drug resistance</FONT> and cancer immunotherapeutic <FONT>KROS
101, 102, 201, 301, and 401, as described above.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="background-color: white">&nbsp;</FONT></FONT></P>

<P STYLE="margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-bottom: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ENV 105 biologic drug seeks to address unmet medical needs in large markets of prostate and lung cancers. ENV 105 targets endoglin and
reverses resistance to androgen targeted drugs and EGFR inhibitors. A Phase 2 trial involving a heavily pre-treated population suffering
from prostate cancer was initiated at Cedars-Sinai Medical Center in 2018 with an IND from the FDA. The primary objective of the study
was to measure the proportion of patients at two months who had either disease stabilization or regression (i.e., complete or partial
response), referred to as the clinical benefit rate. A clinical benefit rate of 62% was observed. The trial enrolled 11 patients of which
nine were evaluable. This investigator-initiated trial closed to accrual prior to its planned enrollment of 40 patients due to limitations
of the drug supply from the manufacturer. The drug supply has since been expanded and obtained by Kairos Pharma. This Phase 2 trial involved
the use of enzalutamide (Xtandi<SUP>&reg;</SUP>, Pfizer) and abiraterone (ZYTIGA<SUP>&reg;</SUP>, Janssen), two forms of hormone therapy
that blocks the androgen receptor and its target ligand, testosterone, respectively. These two agents are considered standard of care
for nearly all recurrent prostate cancer patients. The trial accrued patients who were resistant to the very androgen targeted therapy
(enzalutamide or abiraterone) that was given in the trial in addition to ENV105. Importantly, ENV105 administration alone has no clinical
benefit, based on pre-clinical findings (conducted by us) and previous clinical findings (performed by the National Cancer Institute).
However, two agents that apparently have no clinical effect, when combined result in halting tumor progression in the majority of patients.
The finding is supported by numerous publications reporting on studies that demonstrated hormone therapy resistance develops through
the induction of CD105, the target of ENV105. In addition, all of the patients participating in the trial were not only resistant to
the two hormone therapy agents but also resistant to at least one other intervention after surgical or radiation progression. Some patients
failed to respond to as many as five other drugs. The responders to the combination therapy were patients who, at that point, had exceedingly
few other options for survival. While ENV105 has neither been declared safe or effective by the FDA, the efficacy and safety data
from the clinical trial are available for review at the clinicaltrials.gov website:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="margin: 0; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">https://www.clinicaltrials.gov/study/NCT03418324?cond=PROSTATE%20CANCER&amp;intr=TRC105&amp;rank=1&amp;tab=results.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
three-gene panel was identified to serve as a companion biomarker for patient selection. Depending on the level of expression of three
genes, this testing identified potential drug responders prior to therapy. Our Enviro subsidiary will aim to co-develop companion biomarkers
with all drugs in its portfolio, enabling identification of potential drug responders prior to therapy. Separate approvals will be
required for the development and approval of companion diagnostics. These approvals may be delayed or not issued by the FDA. As of the
date of this prospectus, our companion diagnostics are in development and have not been approved by the FDA. In addition, there is
no guarantee that these companion diagnostics will be approved by the FDA or comparable foreign regulatory agencies. The ENV 105
Phase 2 multi-center trial in prostate cancer will be randomized with and without ENV 105 in patients treated with apalutamide (Janssen).
The Phase 1 trial in lung cancer will be conducted with Tagrisso (AstraZeneca).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe ENV 205 is a molecule found to limit the process of muscle wasting through the capture and excretion of mitochondrial DNA in
circulation. Although as of the date of this prospectus, ENV 205 has not been approved by the FDA or any other comparable foreign regulator.
However, we are not aware of any other biologic that is further along than ENV 205 in the development process that targets prostate
cancers that have become otherwise resistant to chemotherapy. ENV 205 is an antibody that targets the excretion of mitochondrial DNA
found elevated in circulation when patients are on chemotherapy. Higher blood levels of mitochondrial DNA are not only associated with
chemotherapy resistance, but more widely recognized as a mediator of cardiac toxicity and other systemic inflammatory events contributing
to the negative side effects of chemotherapy use. Thus, depleting mitochondrial DNA with the administration of ENV 205 restores
chemotherapy sensitivity in animal models that received ENV 205 along with chemotherapy with the aim of reducing its toxic side effects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this prospectus, all of our operations have been conducted virtually as we attempt to be efficient with our capital
resources. Going forward, we intend to leverage our history with premier academic medical centers to efficiently enroll and execute clinical
trials.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<DIV STYLE="padding-right: 0.1in; padding-left: 0.1in; border: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">We have filed an Investigational
New Drug, or IND, application with the FDA that has become effective for <B>ENV 105</B>. As a result, in September 2023 we
began enrolling patients for a Phase 1 trial for non-small cell lung cancer and also began enrolling patients in a randomized, multi-institutional Phase 2 trial for prostate cancer. The mechanism of action for <B>ENV 105 </B>addresses the resistance
mechanism of tumor dormancy. This is only possible because <B>ENV 105 </B>targets both the cancer cells as well as its supportive non-cancer
environment. The advantage of targeting the unique environment supporting the tumor cells is that their capacity to adapt and evade therapy
is significantly lower than that of the cancer itself. As such, <B>ENV 105</B> is designed to address resistance to chemotherapy, radiation
therapy, androgen targeted therapy, EGFR inhibitors, or checkpoint inhibition when given in combination. Since the target of <B>ENV 105</B>,
endoglin, is upregulated by the tumor and supporting cells in response to androgen targeted therapy and EGFR inhibitors as a proven mechanism
of resistance, we believe that the co-administration of <B>ENV 105 </B>specifically targets this mechanism of resistance.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Through
the Enviro acquisition, we also obtained <B>ENV 205</B>, a pre-clinical therapeutic for treating diseases and conditions by depletion
of mitochondrial DNA from circulation and for detection of mitochondrial DNA. We intend to use this antibody technology to treat chemotherapy
resistance and for cachexia, which is a wasting syndrome that leads to loss of skeletal muscle and fat that occurs in up to 30%
of people with advanced cancer according to the National Cancer Institute.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Our
Strategy</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
goal is to unlock the power of the immune system on the two most pervasive problems in cancer treatment: resistance to therapy and immune
suppression by cancer. We believe this road will lead to major improvement in the quality of life of cancer patients and will transform
patient outcomes. Our strategy consists of the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Creating
    a</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> multi-pronged toolkit of potent and life changing
    therapeutics with differing modalities, targets, and stages of development. Their commonality is targeting key mechanisms of drug
    resistance and immune suppression caused by cancer.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leverage
    our academic research and clinical connections with our industry collaborations.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advance
    our lead resistance candidate, ENV105, to complete a randomized multi-institutional Phase 2 trial in prostate cancer (enrollment
    began in September 2023).</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Complete
    enrollment in a</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> Phase 1 trial of ENV105 in patients
    with non-small lung cancer on Tagrisso (enrollment commenced in September 2023).</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Initiate
    a Phase 1 trial of activated T cell therapy for KROS 201 in patients with glioblastoma.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Complete
    pre-IND studies for the checkpoint inhibitor KROS 101.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Continue
    to advance our pipeline of immunotherapeutics for clinical trials.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maintain
    a portfolio of innovative therapeutics to mitigate risk.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leverage
    virtual infrastructure for efficient execution of collaborative clinical and translational research.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Utilize
    internal development capabilities to leverage close academic partnerships.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>Our
Key Team Leaders</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
company is led by Dr. John S. Yu, our Chairman and Chief Executive Officer, Dr. Neil Bhowmick, our Chief Scientific Officer, and
Dr. Ramachandran Murali, our Vice President of Research and Development. Dr. Yu is a Professor in the Department of Neurosurgery
and Director of Surgical Neuro-Oncology at Cedars-Sinai Medical Center in Los Angeles, California. Dr. Bhowmick is a Professor of the
Department of Medicine and a Research Scientist in Cancer Biology at Cedars-Sinai Medical Center. Dr. Murali is a Professor of
Biomedical Sciences and Director of the Molecular Therapeutics Core at Cedars-Sinai Medical Center. The group of founding scientists
generating our initial drug candidates have combined their pioneering contributions in structural, biology, immunology and cancer therapy
to bring what we believe are life changing therapeutics to unmet medical needs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<DIV STYLE="padding-right: 0.2in; padding-left: 0.1in; border: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>License
Agreements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>License
Agreements with Cedars-Sinai</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">On June
2, 2021, Enviro entered into two Exclusive License Agreements with Cedars-Sinai, which granted Enviro exclusive licensing rights (including
the right to sublicense) with respect to certain patent rights owned by Cedars-Sinai, as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
    Exclusive License Agreement (the &ldquo;Enviro-Cedars License Agreement (Mitochondrial DNA)&rdquo;) for Enviro to develop, manufacture,
    use and sell products utilized or derived from patent rights worldwide related to the &ldquo;Compositions and Methods for Treating
    Diseases and Conditions by Depletion of Mitochondrial DNA from Circulation and for Detection of Mitochondrial DNA&rdquo; invented
    by Dr. Neil Bhowmick and others; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
    Exclusive License Agreement (the &ldquo;Enviro-Cedars License Agreement (Endoglin Antagonism)&rdquo; and, together with the
    Enviro-Cedars License Agreement (Mitochondrial DNA), the &ldquo;Enviro-Cedars License Agreements&rdquo;) for Enviro to develop, manufacture,
    use and sell products utilized or derived from the patent rights and technical information worldwide related to the &ldquo;Sensitization
    of Tumors to Therapies Through Endoglin Antagonism&rdquo; invented by Dr. Neil Bhowmick and others.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>License
Agreement with Tracon Pharmaceutical, Inc.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 21, 2021, Enviro entered into a License Agreement with Tracon Pharmaceutical, Inc. (&ldquo;Tracon&rdquo;). Pursuant to the Tracon
License Agreement, Tracon granted Enviro access to inactive IND filings for &ldquo;TRC105&rdquo; in the United States; ownership of &ldquo;TRC105&rdquo;
stored vials of drug product manufactured to GMP standards stored at Fisher Clinical or their designee; and assignment of Tracon&rsquo;s
patent rights to its &ldquo;CD105 technologies&rdquo; (all as defined or described in the Tracon License Agreement).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">All
of our patent rights are in-licensed from third parties under license agreements that require meeting certain milestones for continuation
of those agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Our
Development Programs</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
drug development programs for <B>KROS 101</B>, <B>102</B>, <B>201</B>, <B>301</B>, and <B>401</B> as well as therapeutic agents <B>ENV105
</B>and <B>ENV 205</B> are summarized in the following table.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><IMG SRC="chart_002.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Pre-IPO Bridge Financing</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; margin: 0; font: 10pt Times New Roman, Times, Serif">In June and September 2022, we completed a $450,000
convertible note offering and a $225,000 convertible note offering, respectively, to certain accredited investors. The notes are automatically
convertible upon the effectiveness of this offering into shares of common stock (the &ldquo;Conversion Shares&rdquo;) at a conversion
price equal to 60% of the initial public offering price. The convertible note offerings were completed pursuant to an exemption
from registration under Rule 506(b) of the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;). Boustead Securities,
LLC acted as placement agent in each of the June and September 2022 private placements and received $86,893 and $19,315 cash compensation,
respectively, and five-year warrants to purchase shares of common stock equal to 7.0% of the number of the Conversion Shares at an exercise
price equal to the conversion price.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<DIV STYLE="padding-right: 0.1in; padding-left: 0.1in; border: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.7pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Summary
of Risk Factors</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.7pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.7pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business is subject to a number of risks and uncertainties of which you should be aware before making an investment decision.
You should consider all of the information set forth in this prospectus and, in particular, the specific factors set forth
under &ldquo;Risk Factors&rdquo; in deciding whether to invest in our securities. These risks include, without limitation,
the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.7pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    require substantial additional funding to meet our financial needs and to pursue our business objectives. If we are unable to raise
    capital when needed, we could be forced to delay, reduce, or altogether cease our current and future product development programs
    or future commercialization efforts.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    limited operating history may make it difficult for you to evaluate the success of our business to date and to assess our future
    viability.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    face substantial competition, which may result in others discovering, developing, or commercializing products before or more successfully
    than we do.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    are relying exclusively on the skills and expertise of our management team in conducting our business, not all of the management
    team will devote all of their time to managing the Company, and we currently have no full-time employees, which may
    impede our ability to carry on our business.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    operate with a small team and our future success depends on our ability to retain key executives and to attract, retain, and motivate
    qualified personnel.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    exclusive licensing rights to our intellectual property are subject to agreements with third parties and we may not meet milestones
    set forth in those agreements or our exclusive licensing rights may be terminated.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    we are unable to obtain and maintain patent and other intellectual property protection for our technology, or for any our current
    in-development products or our future product candidates, or if the scope of the patent and other intellectual property protection
    obtained is not sufficiently broad, our competitors could develop and commercialize technology and drugs similar or identical to
    ours, and our ability to successfully commercialize our technology and product candidates may be impaired.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
    an organization, we have limited experience designing and implementing clinical trials and we have never conducted pivotal clinical
    trials. Failure to adequately design a trial, or incorrect assumptions about the design of the trial, could adversely affect the
    ability to initiate the trial, enroll patients, complete the trial, or obtain regulatory approval on the basis of the trial results,
    as well as lead to increased or unexpected costs and in delayed timelines.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    we are not able to obtain, or if there are delays in obtaining, required regulatory approvals, we will not be able to commercialize
    our current in-development products or our future product candidates, and our ability to generate revenue will be materially impaired.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">If we are unable to successfully develop any required
    companion diagnostic tests for our product candidates, experience significant delays in doing so, or rely on third parties in the
    development of such companion diagnostic tests, we may not realize the full commercial potential of our product candidates.</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preclinical
    development is uncertain. Our preclinical programs may experience delays or may never advance to clinical trials, which would adversely
    affect our ability to obtain regulatory approvals or commercialize these programs on a timely basis or at all.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time-consuming and inherently unpredictable,
    and if we are ultimately unable to obtain regulatory approval for our product candidates, our business will be materially harmed.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have identified material weaknesses in our internal control over financial reporting. If we are unable to remediate these material
    weaknesses, or if we identify additional material weaknesses in the future or otherwise fail to maintain effective internal control
    over financial reporting, we may not be able to accurately or timely report our financial condition or results of operations, which
    may adversely affect our business.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    closing of this offering is contingent on our obtaining listing on the NYSE American.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    you purchase common stock in this offering, you will suffer immediate dilution of your investment.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    trading price of our common stock may be volatile, and you could lose all or part of your investment.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Corporate
History and Information</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kairos
Pharma, Ltd. was originally incorporated on June 17, 2013 under the laws of the State of California as NanoGB13, Inc. We
changed our name to &ldquo;Kairos Pharma, Ltd.&rdquo; on July 15, 2016. On May 10, 2023, we filed a certificate of conversion
with the Secretary of State of the State of California and, on the same date, we also filed with the Secretary of State of the State
of Delaware a certificate of conversion from a non-Delaware corporation to a Delaware corporation pursuant to the Delaware General Corporation
Law. In addition, on May 10, 2023, we also filed a certificate of incorporation with the Secretary of State of the State of Delaware
and became a Delaware corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In conjunction with the Company&rsquo;s conversion
into a Delaware corporation, on May 10, 2023, the Company conducted a 1-for-2.5 reverse stock split (the &ldquo;Reverse Stock Split&rdquo;).
After the Reverse Stock Split, effective as of May 10, 2023, there were 10,334,357 shares of our common stock outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We presently conduct all of our operations
virtually when possible. Our registered corporate address is 2355 Westwood Blvd., #139, Los Angeles, California 90064
and our corporate website is <U>https://kairospharma.com.</U> The information contained in, or accessible from, our website or any
other website does not constitute a part of this prospectus.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<DIV STYLE="padding-right: 0.1in; padding-left: 0.1in; border: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Implications
of Being an Emerging Growth Company and Smaller Reporting Company</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are an &ldquo;emerging growth company&rdquo; and a &ldquo;as defined in the Jumpstart Our Business Startups Act of 2012, or JOBS
Act. We may take advantage of certain exemptions from various public company reporting requirements, including not being required to
have our internal control over financial reporting audited by our independent registered public accounting firm under Section 404 of
the Sarbanes-Oxley Act of 2002, or Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in our periodic
reports and proxy statements and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and
any golden parachute payments. We may take advantage of these exemptions for up to five years or until we are no longer an &ldquo;emerging
growth company,&rdquo; whichever is earlier. We will cease to be an emerging growth company prior to the end of such five-year period
if certain earlier events occur, including if (i) we become a &ldquo;large accelerated filer&rdquo; as defined in Rule 12b-2 under the
Securities Exchange Act of 1934, as amended, or Exchange Act, (ii) our annual gross revenues exceed $1.07 billion, or (iii) we issue
more than $1.0 billion of non-convertible debt in any three-year period. In particular, in this prospectus, we have provided only two
years of audited financial statements and have not included all of the executive compensation-related information that would be required
if we were not an emerging growth company. Accordingly, the information contained herein may be different than the information you receive
from other public companies in which you hold stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period to comply with
new or revised accounting standards. This provision allows an emerging growth company to delay the adoption of accounting standards
that have different effective dates for public and private companies until those standards would otherwise apply to private
companies. We have elected to avail ourselves of this exemption and, therefore, we will not be subject to the same requirements to
adopt new or revised accounting standards as other public companies that are not &ldquo;emerging growth companies.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are also a &ldquo;smaller reporting company&rdquo; as defined in the Exchange Act. We may continue to be a smaller reporting company
even after we are no longer an emerging growth company. We may continue to be a smaller reporting company after this offering if either
(i) the market value of our shares held by non-affiliates is less than $250 million as measured on the last business day of our second
fiscal quarter or (ii) our annual revenue was less than $100 million during the most recently completed fiscal year and the market value
of our shares held by non-affiliates is less than $700 million as measured on the last business day of our second fiscal quarter. Specifically,
as a smaller reporting company, we may choose to present only the two most recent fiscal years of audited financial statements in our
Annual Report on Form 10-K and have reduced disclosure obligations regarding executive compensation. Further, if we are a smaller reporting
company with less than $100 million in annual revenue, we would not be required to obtain an attestation report on internal control over
financial reporting issued by our independent registered public accounting firm.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Market, Industry, and Other Data </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">We obtained the industry, market,
and competitive position data used throughout this prospectus from our own internal estimates and research, as well as from independent
market research, industry, and general publications and surveys, governmental agencies, and publicly available information in addition
to research, surveys, and studies conducted by third parties. Internal estimates are derived from publicly available information released
by industry analysts and third-party sources, our internal research and our industry experience, and are based on assumptions made by
us based on such data and our knowledge of our industry and market, which we believe to be reasonable. In some cases, we do not expressly
refer to the sources from which this data is derived. In that regard, when we refer to one or more sources of this type of data in any
paragraph, you should assume that other data of this type appearing in the same paragraph is derived from the same sources, unless otherwise
expressly stated or the context otherwise requires. In addition, while we believe the industry, market, and competitive position data
included in this prospectus is reliable and based on reasonable assumptions, such data involve risks and uncertainties and are subject
to change based on various factors, including those discussed in the section titled &ldquo;Risk Factors.&rdquo; These and other factors
could cause results to differ materially from those expressed in the estimates made by the independent parties or by us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<DIV STYLE="padding-right: 0.1in; padding-left: 0.1in; border: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
Offering</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    stock offered by us </FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 65%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,550,000
    </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Underwriters&rsquo;
    over-allotment option</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have granted the underwriters an option for a period of 45 days to purchase up to an additional 232,500 shares of our common
    stock from us at the initial public offering price less underwriting discounts and commissions to cover over-allotments, if any.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="margin-top: 0; margin-bottom: 0">Common stock outstanding</P>
                                                         <P STYLE="margin-top: 0; margin-bottom: 0">immediately before this offering</P></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"> 10,562,640 shares of common stock</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    stock outstanding immediately after this offering</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12,761,179
</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares (or 12,993,679 shares if the underwriters&rsquo;
over-allotment option to purchase additional shares from us is exercised in full).</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Use
    of proceeds</FONT></TD>
    <TD COLSPAN="3"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We estimate that we will receive net proceeds from
this offering of approximately $5.6 million (or approximately $6.4 million if the underwriters&rsquo; option
to purchase additional shares of our common stock is exercised in full) based on the assumed initial public offering price of $4.00
per share, after deducting underwriting discounts and commissions and estimated offering expenses payable by us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">We intend to use the net proceeds from this offering
to fund Phase 1 and Phase 2 clinical trials of our product candidates, including ENV 105 and preclinical product candidates including
KROS 101, potential acquisition or in-licensing activities, and working capital and general corporate purposes. The funds are expected
to be used as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35%">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 59%">approximately $1.0 million, or 18% of the net
    proceeds, will be used to fund the clinical development of our lead product candidate in phase 1 and phase 2 trials, ENV
    105; </TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">approximately $0.7 million to pay outstanding accounts
    payable; and</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">any remaining proceeds for working capital and
    general corporate purposes.</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="3"><P STYLE="text-align: justify; margin-top: 0; margin-bottom: 0">The use of proceeds could differ from the estimates
                    set forth above in the event enrollment in our clinical trials is greater than expected in the first 12 months. If
                    that happens, we may need to use additional proceeds to fund our clinical trials. See the section titled &ldquo;Use
                    of Proceeds&rdquo; for additional information.</P></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk
    factors</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 65%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
    the section titled &ldquo;Risk Factors&rdquo; and other information included in this prospectus for a discussion of factors you should
    consider carefully before deciding to invest in our common stock.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NYSE
American proposed trading symbol</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;KAPA&rdquo;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.7pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.7pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
12,761,179 shares of our common stock to be issued and outstanding immediately after this offering is based on 10,562,640
shares of common stock issued and outstanding as of April 30, 2024 and gives effect to the automatic conversion of all convertible
notes payable and accrued interest into 334,375 shares of our common stock upon the effectiveness of this offering, 1,664 shares
of our common stock upon the conversion of amounts due to related parties, and 312,500 shares of our common stock upon the conversion
of certain accounts payable upon the effectiveness of this offering (see &ldquo;Our Company Pre-IPO Bridge Financing&rdquo; above), and
excludes:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.7pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">150,000
    </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of our common stock issuable upon the
    exercise of outstanding common stock purchase warrants with a weighted-average exercise price of $4.17
    per share; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">1,650,000 shares of common stock reserved for future issuance under our equity incentive plan.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 39.25pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.7pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
otherwise indicated, this prospectus assumes or gives effect to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.7pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">no
    exercise of the outstanding warrants described above;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">no
    exercise by the underwriters of their option to purchase additional shares of common stock from us in this offering;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
    assumed initial public offering price of $4.00 per shares; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">no
    exercise of the warrants expected to be issued to the underwriters as compensation for this offering.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36.75pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<DIV STYLE="border: Black 1.5pt solid; padding-right: 0.1in; padding-left: 0.1in">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Summary
Financial Data</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following tables set forth our summary financial data for the periods and as of the dates indicated. The following summary statements
of operations for the years ended December 31, 2022 and 2023 have been derived from our audited consolidated financial statements
included elsewhere in this prospectus. You should read the following summary financial data together with the section titled &ldquo;Management&rsquo;s
Discussion and Analysis of Financial Condition and Results of Operations&rdquo; and our financial statements and the related notes included
elsewhere in this prospectus. The summary financial data included in this section are not intended to replace the financial statements
and are qualified in their entirety by our financial statements and the related notes included elsewhere in this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD STYLE="font-weight: bold"> &nbsp; </TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center"> Years Ended </TD><TD STYLE="font-weight: bold"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD STYLE="font-weight: bold"> &nbsp; </TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> December 31, </TD><TD STYLE="font-weight: bold"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD STYLE="font-weight: bold"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> 2022 </TD><TD STYLE="font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> 2023 </TD><TD STYLE="font-weight: bold"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD><TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold"></TD><TD STYLE="font-weight: bold"> &nbsp; </TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center"> (In thousands, except share and per share amounts) </TD><TD STYLE="font-weight: bold"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> <B>Statements of Operations Data</B> </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Operating expenses: </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; width: 60%; text-align: left"> Research and development </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 16%; text-align: right"> 87 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 16%; text-align: right"> 82 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left"> General and administrative </TD><TD> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 484 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 1,632 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Total operating expenses </TD><TD> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 571 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 1,714 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Loss from operations </TD><TD> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> (571 </TD><TD STYLE="text-align: left"> ) </TD><TD> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> (1,714 </TD><TD STYLE="text-align: left"> ) </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Other expenses: </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left"> Interest expense </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (51 </TD><TD STYLE="text-align: left"> ) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (42 </TD><TD STYLE="text-align: left"> ) </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left"> Debt discount amortization </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (408 </TD><TD STYLE="text-align: left"> ) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (56 </TD><TD STYLE="text-align: left"> ) </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left"> Financing costs </TD><TD> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> (20 </TD><TD STYLE="text-align: left"> ) </TD><TD> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Total other expenses </TD><TD> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> (479 </TD><TD STYLE="text-align: left"> ) </TD><TD> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> (98 </TD><TD STYLE="text-align: left"> ) </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Net loss </TD><TD> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> (1,050 </TD><TD STYLE="text-align: left"> ) </TD><TD> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> (1,812 </TD><TD STYLE="text-align: left"> ) </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Basic and diluted loss per share (1) </TD><TD> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> (0.10 </TD><TD STYLE="text-align: left"> ) </TD><TD> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> (0.17 </TD><TD STYLE="text-align: left"> ) </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0pt; text-align: left"> Weighted-average common shares outstanding - basic and diluted (1) </TD><TD> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> 10,236,764 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> 10,382,515 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Pro forma net loss per share, basic and diluted (unaudited) (1) </TD><TD> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> (0.10 </TD><TD STYLE="text-align: left"> ) </TD><TD> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> (0.16 </TD><TD STYLE="text-align: left"> ) </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"></TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD> Pro forma weighted-average common shares outstanding (unaudited) (1) </TD><TD> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> 10,839,452 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> 11,031,054 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
    Note 2 to our financial statements included elsewhere in this prospectus for a description of how we compute basic and diluted net
    loss per common share and the number of shares used in computing these amounts. </FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<DIV STYLE="padding-right: 0.1in; padding-left: 0.1in; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> As of December 31, 2023 </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> Actual </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> Pro Forma (1) </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> Pro Forma As Adjusted (2)(3) </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD STYLE="font-weight: bold"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center"> (Unaudited) </TD><TD STYLE="font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center"> (Unaudited) </TD><TD STYLE="font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center"> (Unaudited) </TD><TD STYLE="font-weight: bold"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left"> Balance Sheet Data (in thousands): </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 46%"> Cash </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 14%; text-align: right"> 93 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 14%; text-align: right"> 93 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 14%; text-align: right"> 5,693 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Working capital (4) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (2,304 </TD><TD STYLE="text-align: left"> ) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (1,490 </TD><TD STYLE="text-align: left"> ) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 4,110 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Total assets </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 965 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 965 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 6,565 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Total liabilities </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 3,043 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 1,591 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 1,591 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Convertible notes payable, net of debt discount of $105 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 638 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Additional paid-in capital </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 4,123 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 5,680 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 11,278 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Accumulated deficit </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (6,212 </TD><TD STYLE="text-align: left"> ) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (6,317 </TD><TD STYLE="text-align: left"> ) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (6,317 </TD><TD STYLE="text-align: left"> ) </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Total shareholders&rsquo; equity (deficit) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (2,078 </TD><TD STYLE="text-align: left"> ) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (626 </TD><TD STYLE="text-align: left"> ) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 4,974 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    pro forma column in the balance sheet data gives effect to (i) the automatic conversion of all convertible notes payable and accrued
    interest into 334,375 shares of common stock, (ii) the issuance of 312,500 shares of common stock upon the conversion
    of certain accounts payable, upon the effectiveness of this offering, and (iii) the issuance of 1,664 shares of common stock upon
    the conversion of amounts due to related parties. </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    pro forma, as adjusted column in the balance sheet data gives effect to (i) the items described in footnote (1) above and (ii) the
    issuance and sale of 1,550,000 shares of our common stock in this offering at the assumed initial public offering price of
    $4.00 per share after deducting underwriting discounts and commissions and estimated offering expenses payable by us.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    pro forma, as adjusted information is illustrative only and will depend on the actual initial public offering price and other
    terms of this offering determined at pricing.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Working
    capital is defined as current assets less current liabilities. See our financial statements and the related notes included elsewhere
    in this prospectus for further details regarding our current assets and current liabilities.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</DIV>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="S1_002"></A>RISK
FACTORS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Investing
in our common stock involves a high degree of risk. Before you invest in our common stock, you should carefully consider the risks described
below together with all of the other information contained in this prospectus, including our audited financial statements and unaudited
condensed financial statements and the related notes and the section titled &ldquo;Management&rsquo;s Discussion and Analysis of Financial
Condition and Results of Operations&rdquo; in this prospectus. The occurrence of any of the events or developments described below could
harm our business, financial condition, results of operations, and growth prospects. Unless otherwise indicated, references in these
risk factors to our business being harmed will include harm to our business, reputation, financial condition, results of operations,
and prospects. In such an event, the market price of our common stock could decline, and you may lose all or part of your investment.
Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to Our Financial Position and Capital Needs</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
are a small development-stage biopharmaceutical company with a limited operating history and no products approved for commercial sale.
We have incurred significant losses since our inception. We expect to incur losses over the next several years and may never achieve
or maintain profitability.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a small development-stage biopharmaceutical company with a limited operating history and no products approved for commercial sale.
There can be no assurance that we will, or if we do, when we will, obtain approval to commercialize our products and potentially generate
revenue. We have incurred significant losses since our inception and we expect to incur losses over the next several years and may never
achieve or maintain profitability. Even if we achieve profitability, we may not be able to sustain or increase profitability on a quarterly
or annual basis. Our failure to become and remain profitable would depress the value of our common stock and could impair our ability
to raise capital, expand our business, maintain our research and development efforts, or continue our operations. A decline in the value
of our common stock could also cause you to lose all or part of your investment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
require substantial additional funding to meet our financial needs and to pursue our business objectives. If we are unable to raise capital
when needed, we could be forced to delay, reduce, or altogether cease our current and future product development programs or future commercialization
efforts.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that the net proceeds from this offering will enable us to fund our operating expenses and
capital expenditure requirements for at least the next 12 months. However, we will need to obtain substantial additional funding in connection
with our continuing operations and planned activities. Our future capital requirements will depend on many factors, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    timing, progress, and results of our ongoing and future clinical trials of our current in-development products;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs, timing, and outcome of regulatory review of our current in-development products and any of our future product candidates;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    scope, progress, results, and costs of identifying, obtaining, and conducting preclinical development, laboratory testing, and clinical
    trials of future product candidates that we may pursue;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    cost and timetable of manufacturing processes for development, clinical trials, and potential commercial use;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    number and development requirements of future product candidates that we may pursue;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    amount of funding that we receive under our non-dilutive funding opportunities, including government awards and government awards,
    if any, that we may apply for;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs and timing of future commercialization activities, including product manufacturing, marketing, sales, and distribution, for
    our current in-development products or any future product candidates that receive marketing approval;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    pricing and revenue, if any, received from commercial sales of our current in-development products or any future product candidates
    that receive marketing approval;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs and timing of preparing, filing, and prosecuting patent applications, maintaining, and enforcing our intellectual property
    rights, and defending any intellectual property-related claims;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs of operating as a public company; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    extent to which we acquire or in-license other product candidates and technologies.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36.75pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identifying
potential product candidates and conducting preclinical testing and clinical trials is a time-consuming, expensive, and uncertain process
that takes years to complete, and we may never generate the necessary data or results required to obtain regulatory approval and achieve
product sales. In addition, our current in-development products and any of our future product candidates, if approved, may not achieve
commercial success. Our commercial revenues, if any, will be derived from sales of drugs that we do not expect to be commercially available
for several years, if at all. Accordingly, we will need to continue to rely on additional financing to achieve our business objectives.
Adequate additional financing may not be available to us on acceptable terms, or at all. In addition, we may seek additional capital
due to favorable market conditions or strategic considerations even if we believe we have sufficient funds for our current or future
operating plans. If we are unable to raise capital when needed or on attractive terms, we could be forced to delay, reduce or altogether
cease our research and development programs or future commercialization efforts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Raising
additional capital will likely cause dilution to our stockholders, including purchasers of shares of our common stock in this offering,
restrict our operations, or require us to relinquish rights to our current in-development products or technologies or any of our future
product candidates.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Until
such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity
offerings and debt financings. To the extent that we raise additional capital through the sale of equity or convertible debt securities,
your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely
affect your rights as a stockholder. Debt financing and preferred equity financing, if available, may involve agreements that include
covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures,
or declaring dividends.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we raise additional funds through collaborations, strategic alliances, or marketing, distribution, or licensing arrangements with third
parties, we may be required to relinquish valuable rights to our technologies, future revenue streams, research programs, or our current
in-development products or any future product candidates, or to grant licenses on terms that may not be favorable to us. If we are unable
to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce, or terminate our
development of our current in-development products or any future product candidate or future commercialization efforts or grant rights
to a third party to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
limited operating history may make it difficult for you to evaluate the success of our business to date and to assess our future viability.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have limited resources and limited operating history. There is only a limited basis upon which to evaluate our prospects for achieving
our intended business objectives. We have not yet demonstrated the ability to successfully complete a large-scale, pivotal clinical
trial, obtain marketing approval, manufacture a commercial scale product, arrange for a third party to do so on our behalf, or conduct
sales and marketing activities necessary for successful product commercialization. Consequently, predictions about our future success
or viability may not be as accurate as they could be if we had a history of successfully developing and commercializing pharmaceutical
products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, as a business with a limited operating history, we may encounter unforeseen expenses, difficulties, complications, delays and
other known and unknown factors. We will eventually need to transition from a company with a research focus to a company capable of supporting
commercial activities. We may not be successful in such a transition and, as a result, our business may be adversely affected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
of the numerous risks and uncertainties associated with drug development, we are unable to accurately predict the timing or amount of
expenses or when, or if, we will be able to achieve profitability. If we are required by regulatory authorities to perform studies in
addition to those currently expected, or if there are any delays in the initiation and completion of our clinical trials or the development
of our current in-development products or any of our future product candidates, our expenses could increase.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates
or indications that may be more profitable or have a greater likelihood of success.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
we have limited financial and management resources, we focus on research programs and product candidates that we identify for specific
indications. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that
later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial
drugs or profitable market opportunities. Our spending on current and future research and development programs and product candidates
for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or
target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration,
licensing, or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and
commercialization rights to such product candidate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
report of our independent registered public accounting firm included a &ldquo;going concern&rdquo; explanatory paragraph.</I></B></FONT></P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
report of our independent registered public accounting firm on our financial statements as of and for the years ended December 31, 2022
and 2023 included an explanatory paragraph indicating that there was substantial doubt about our ability to continue as a
going concern. If we are unable to raise additional capital as and when needed, our business, financial condition and results of operations
will be materially and adversely affected, and we may be forced to delay our development efforts, limit our activities and reduce research
and development costs. If we are unable to continue as a going concern, we may have to liquidate our assets, and the values we receive
for our assets in liquidation or dissolution could be significantly lower than the values reflected in our financial statements. The
inclusion of a going concern explanatory paragraph by our independent registered public accounting firm, our lack of cash resources and
our potential inability to continue as a going concern may materially adversely affect our share price and our ability to raise new capital,
enter into licensing and collaboration arrangements or other contractual relationships with third parties and otherwise execute our development
strategy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to Development, Clinical Testing, Manufacturing and Regulatory Approval</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
are heavily dependent on the success of our initial drug candidates, which are still under clinical development, and if any of these
drugs does not receive regulatory approval or is not successfully commercialized, our business may be harmed.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not have any products that have gained regulatory approval by the FDA or comparable foreign regulatory authorities. As a result, our
business is dependent on our ability to successfully complete clinical development of, obtain regulatory approval for, and, if approved,
successfully commercialize one or more drug therapies in a timely manner. We cannot commercialize our drug therapies in the United States
without first obtaining regulatory approval from the FDA; similarly, we cannot commercialize our drug therapies outside of the United
States without obtaining regulatory approval from comparable foreign regulatory authorities. Before obtaining regulatory approvals for
the commercial sale of our drug therapies for a target indication, we must demonstrate with substantial evidence gathered in preclinical
studies and clinical trials, generally including two adequate and well-controlled clinical trials, and, with respect to approval in the
United States, to the satisfaction of the FDA, that a drug candidate is safe and effective for use for that target indication and that
the manufacturing facilities, processes and controls are adequate. Even if we were to successfully obtain approval of one of our drug
therapies from the FDA or comparable foreign regulatory authorities, any approval might contain significant limitations related to use
restrictions for specified age groups, warnings, precautions or contraindications, or may be subject to burdensome post-approval study
or risk management requirements. If we are unable to obtain regulatory approval for one or more of our drug therapies in one or more
jurisdictions, or any approval contains significant limitations, we may not be able to obtain sufficient funding or generate sufficient
revenue to continue the development of any other candidate that we may in-license, develop or acquire in the future. Furthermore, even
if we obtain regulatory approval for one of our drug therapies, we will still need to develop a commercial organization, establish commercially
viable pricing and obtain approval for adequate reimbursement from third-party and government payors. If we are unable to successfully
commercialize one or more of our drug therapies, we may not be able to earn sufficient revenue to continue our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we are not able to obtain, or if there are delays in obtaining, required regulatory approvals, we will not be able to commercialize our
current in-development products or our future product candidates, and our ability to generate revenue will be materially impaired.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
current in-development products and our future product candidates and the activities associated with their development and commercialization,
including their design, testing, manufacture, safety, efficacy, record-keeping, labeling, storage, approval, advertising, promotion,
sale, and distribution, are subject to comprehensive regulation by the FDA and other regulatory agencies in the United States and by
comparable foreign regulatory authorities, with regulations differing from country to country. Failure to obtain marketing approval for
a product candidate will prevent us from commercializing the product candidate. We currently do not have any products approved for sale
in any jurisdiction. We as a company only have limited experience in filing and supporting the applications necessary to gain marketing
approvals and may rely on third-party contract research organizations to assist us in this process.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
time required to obtain approval, if any, by the FDA and comparable foreign authorities is unpredictable but typically takes many years
following the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory
authorities, government budget, and funding levels and statutory, regulatory, and policy changes. Average review times at the FDA have
fluctuated in recent years, and disruptions at the FDA and other agencies may slow the time necessary for new drugs to be reviewed and/or
approved. For example, over the last several years, including for 35 days beginning on December 22, 2018, the U.S. government has shut
down several times and certain regulatory agencies, including the FDA, have had to furlough nonessential employees and stop routine activities.
Events like this could significantly impact the ability of the FDA to timely review and process our regulatory submissions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Approval
policies, regulations, or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate&rsquo;s
clinical development. For instance, recent changes to leadership, enhanced focus on countermeasures related to the COVID-19 pandemic,
and the reorganization and rededication of critical resources, at the FDA and within similar governmental health authorities across the
world, may impact the ability of new products and services from being developed or commercialized in a timely manner. Regulations and
requirements vary among jurisdictions, including in Europe and Japan. We have not obtained regulatory approval for any product candidate,
and it is possible that none of our current in-development products or any product candidates we may seek to develop in the future will
ever obtain regulatory approval. We are not permitted to market any product candidate in the United States until we receive regulatory
approval of an NDA from the FDA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to obtain approval to commercialize a product candidate in the United States or abroad, we or our collaborators must demonstrate
to the satisfaction of the FDA or foreign regulatory agencies, that such product candidates are safe and effective for their intended
uses. Results from nonclinical studies and clinical trials can be interpreted in different ways. Even if we believe that the nonclinical
or clinical data for a product candidate is promising, such data may not be sufficient to support approval by the FDA and other regulatory
authorities. The FDA may also require us to conduct additional nonclinical studies or clinical trials for product candidates either prior
to or post-approval, and it may otherwise object to elements of our clinical development program.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not submitted a marketing application for any product candidates in any country or region. Any marketing application must include
extensive preclinical, nonclinical, and clinical data and supporting information to establish the product candidate&rsquo;s safety and
efficacy for each desired indication. The marketing application(s) must also include significant information regarding the chemistry,
manufacturing, and controls for the product candidate. Obtaining marketing authorization is a lengthy, expensive, and uncertain process.
The FDA, EMA, PMDA, TGA, and other comparable regulatory authorities have substantial discretion in the review and approval process and
may refuse to accept for filing any application or may decide that our data are insufficient for approval and require additional nonclinical,
clinical, or other studies. Foreign regulatory authorities have differing requirements for approval of drugs with which we must comply
prior to marketing. There can be no assurance that any foreign regulatory authorities will accept FDA approval as sufficient to support
approval in that country. Obtaining marketing approval for marketing of a product candidate in one country does not ensure that we will
be able to obtain marketing approval in other countries, but the failure to obtain marketing approval in one jurisdiction could negatively
affect our ability to obtain marketing approval in other jurisdictions. The FDA or any foreign regulatory bodies can delay, limit or
deny approval of our current in-development products or other future product candidates or require us to conduct additional nonclinical
or clinical testing or abandon a program for many reasons, including:</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">disagreement
    with the design or implementation of our clinical trials;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">negative
    or ambiguous results from our clinical trials or results that may not meet the level of statistical significance required by the
    FDA or comparable foreign regulatory agencies for approval (for example, otherwise positive clinical results may be called into question
    if patient reported outcomes introduce ambiguity due to factors such as co-morbidities and other underlying patient issues);</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">serious
    and unexpected drug-related side effects experienced by participants in our clinical trials or by individuals using drugs similar
    to our product candidates;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    inability to demonstrate to the satisfaction of the FDA or the applicable foreign regulatory body that our product candidates are
    safe and effective for the proposed indication;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">disagreement
    with the interpretation of data from nonclinical studies or clinical trials;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    inability to demonstrate the clinical and other benefits of our product candidates outweigh any safety or other perceived risks;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">requirements
    for additional nonclinical studies or clinical trials;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">disagreement
    regarding the formulation, labeling, and/or the specifications we propose for our product candidates; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in a policies, requirements, or regulations rendering our clinical data insufficient for approval.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Of
the large number of drugs in development, only a small percentage complete the FDA or foreign regulatory approval processes and are successfully
commercialized. The lengthy review process as well as the unpredictability of future clinical trial results may result in our failing
to obtain regulatory approval, which would significantly harm our business, financial condition, results of operations, and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if we eventually receive approval of an NDA or foreign marketing application for our product candidates, the FDA, or the applicable foreign
regulatory agency may grant approval contingent on the performance of costly additional clinical trials, often referred to as Phase 4
clinical trials, and the FDA may require the implementation of a REMS, which may be required to ensure safe use of the drug after approval.
The FDA or the applicable foreign regulatory agency also may approve a product candidate for a more limited indication or patient population
than we originally requested, and the FDA or applicable foreign regulatory agency may not approve the labeling that we believe is necessary
or desirable for the successful commercialization of a product candidate. Any delay in obtaining, or inability to obtain, applicable
regulatory approval would delay or prevent commercialization of that product candidate and would materially adversely impact our business
and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Preclinical
development is uncertain. Our preclinical programs may experience delays or may never advance to clinical trials, which would adversely
affect our ability to obtain regulatory approvals or commercialize these programs on a timely basis or at all.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Most
of our product candidates are still in the preclinical stage, and the risk of failure for such product candidates is high. In order to
obtain FDA approval to market a new biologic we must demonstrate proof of safety, purity and potency, including efficacy, in humans.
To meet these requirements we will have to conduct adequate and well-controlled clinical trials. Before we can commence clinical trials
for a product candidate, we must complete extensive preclinical testing and studies that support our planned clinical trials in humans.
We cannot be certain of the timely completion or outcome of our preclinical testing and studies and cannot predict if the FDA will accept
our proposed clinical programs or if the outcome of our preclinical testing and studies will ultimately support the further development
of our current or future product candidates. As a result, we cannot be sure that we will be able to submit INDs or similar applications
for our preclinical programs on the timelines we expect, if at all, and we cannot be sure that submission of INDs or similar applications
will result in the FDA or other regulatory authorities allowing clinical trials to begin.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conducting
preclinical testing is a lengthy, time-consuming and expensive process. The length of time of such testing may vary substantially according
to the type, complexity and novelty of the program, and often can be several years or more per program. Delays associated with programs
for which we are conducting preclinical testing and studies may cause us to incur additional operating expenses. The commencement and
rate of completion of preclinical studies and clinical trials for a product candidate may be delayed by many factors, including but not
limited to: an inability to generate sufficient preclinical or other in vivo or in vitro data to support the initiation of clinical studies;
delays in reaching a consensus with regulatory agencies on study design; any setbacks or delays on account of the COVID-19 pandemic;
and the FDA or foreign regulatory authorities not permitting the reliance on preclinical or other data from published scientific literature.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Clinical
trials are expensive, time-consuming and difficult to design and implement, and involve an uncertain outcome.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
obtain the requisite regulatory approvals to commercialize any of our product candidates, we must demonstrate through extensive preclinical
studies and clinical trials that our product candidates are safe, pure and potent in humans. Clinical testing is expensive and can take
many years to complete, and its outcome is highly uncertain. Failure can occur at any time during the clinical trial process and our
future clinical trial results may not be successful. We may also experience numerous unforeseen events during our clinical trials that
could delay or prevent our ability to receive marketing approval or commercialize the product candidates we develop.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Failure
can occur at any time during the clinical trial process. Because the results of preclinical studies and early clinical trials are not
necessarily predictive of future results, our drug therapies may not have favorable results in later preclinical and clinical studies
or receive regulatory approval. We may experience delays in initiating and completing any clinical trials that we intend to conduct,
and we do not know whether planned clinical trials will begin on time, need to be redesigned, enroll patients on time or be completed
on schedule, or at all. Many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may
also ultimately lead to the denial of marketing approval of our product candidates. Clinical trials can be delayed for a variety of reasons,
including delays related to:</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA or other regulatory authorities may change the requirements for approval even after they have reviewed and commented on the design
    for our clinical trials;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA or comparable foreign regulatory authorities disagreeing as to the design or implementation of our clinical studies;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining
    regulatory approval to commence and/or continue to conduct a trial, including but not limited to obtaining IND approval by FDA;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reaching
    an agreement on acceptable terms with prospective contract research organizations, or CROs, and clinical trial sites, the terms of
    which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining
    Institutional Review Board, or IRB, approval at each site, or Independent Ethics Committee, or IEC, approval at sites outside the
    United States;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">recruiting
    suitable patients to participate in a trial in a timely manner and in sufficient numbers;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">having
    patients complete a trial or return for post-treatment follow-up;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">imposition
    of a clinical hold by regulatory authorities, or IRBs, including as a result of unforeseen safety issues or side effects or failure
    of trial sites to adhere to regulatory requirements or follow trial protocols;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">clinical
    sites deviating from trial protocol, failing to adequately enroll study subjects, committing fraud or other violations of regulatory
    requirements, or dropping out of a trial, which can render data from that site unusable in support of regulatory approval;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">addressing
    patient safety concerns that arise during the course of a trial;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">adding
    a sufficient number of clinical trial sites; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">manufacturing
    sufficient quantities of our drug therapies for use in clinical trials.</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
could also encounter delays if a clinical trial is suspended or terminated by us, the IRBs or IECs of the institutions in which such
trials are being conducted, the Data Safety Monitoring Board, or DSMB, for such trial or the FDA or other regulatory authorities. Such
authorities may impose such a suspension or termination due to a number of factors, including failure to conduct the clinical trial in
accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA
or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure
to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions or lack of adequate funding
to continue the clinical trial. Furthermore, we rely on CROs and clinical trial sites to ensure the proper and timely conduct of our
clinical trials and, while we have agreements governing their committed activities, we have limited influence over their actual performance,
as described in &ldquo;&mdash; Risks Related to Our Dependence on Third Parties.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Treatment
of cancer patients with our oncology product candidates may be used in combination with other cancer drugs, such as other immuno-oncology
agents, monoclonal antibodies or other protein-based drugs or small molecule anti-cancer agent such as targeted agents or chemotherapy,
which can cause side effects or adverse events that are unrelated to our product candidate but may still impact the success of our clinical
trials. Additionally, our product candidates could potentially cause adverse events. The inclusion of critically ill patients in our
clinical trials may result in deaths or other adverse medical events due to other therapies or medications that such patients may be
using. As described above, any of these events could prevent us from obtaining regulatory approval or achieving or maintaining market
acceptance of our product candidates and impair our ability to commercialize our products. Because all of our product candidates are
derived from our platform technologies, a clinical failure of one of our product candidates may also increase the actual or perceived
likelihood that our other product candidates will experience similar failures.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Of
the large number of products in development, only a small percentage successfully complete the FDA or comparable foreign regulatory authorities&rsquo;
approval processes and are commercialized. The lengthy approval process as well as the unpredictability of future clinical trial results
may result in our failing to obtain regulatory approval to market our product candidates, which would significantly harm our business,
financial condition, results of operations and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if we eventually complete clinical testing and receive approval of a marketing application for our product candidates, the FDA or the
comparable foreign regulatory authorities may grant approval contingent on the performance of costly additional clinical trials, including
post-market clinical trials. The FDA or the comparable foreign regulatory authorities also may approve a product candidate for a more
limited indication or patient population than we originally request, and the FDA or comparable foreign regulatory authorities may not
approve the labeling that we believe is necessary or desirable for the successful commercialization of a product candidate. Any delay
in obtaining, or inability to obtain, applicable regulatory approval would delay or prevent commercialization of that product candidate
and would adversely impact our business and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the FDA or comparable foreign regulatory authorities may change their policies, adopt additional regulations or revise existing
regulations or take other actions, which may prevent or delay approval of our future product candidates under development on a timely
basis. Such policy or regulatory changes could impose additional requirements upon us that could delay our ability to obtain approvals,
increase the costs of compliance or restrict our ability to maintain any marketing authorizations we may have obtained.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we experience delays in the completion, or termination, of any clinical trial of our product candidates, including as a result of the
COVID-19 pandemic, the commercial prospects of our product candidates will be harmed and our ability to generate product revenues from
any of these product candidates will be delayed. In addition, any delays in completing our clinical trials will increase our costs, slow
down the development and approval process for our product candidates and jeopardize our ability to commence product sales and generate
revenues. Significant clinical trial delays could also allow our competitors to bring products to market before we do or shorten any
periods during which we have the exclusive right to commercialize our product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Future
legislation, and/or regulations and policies adopted by the FDA, the EMA, or comparable regulatory authorities, may increase the time
and cost required for us to conduct and complete clinical trials of our current in-development products or other future product candidates.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA has established regulations to govern the drug development and approval process, as have foreign regulatory authorities. The policies
of the FDA and other regulatory authorities may change and additional laws may be enacted or government regulations may be promulgated
that could prevent, limit, delay, or alternatively accelerate regulatory review of our current in-development products or other future
product candidates. Further, disruptions at the FDA and other agencies may prolong the time necessary for new drugs to be reviewed and/or
approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, the U.S.
government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical employees and
stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review
and process our regulatory submissions, which could have a material adverse effect on our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
product candidates are based on novel technologies, which make it difficult to predict the timing, results and cost of product candidate
development and likelihood of obtaining regulatory approval.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not yet succeeded and may not succeed in demonstrating efficacy and safety for any product candidates in clinical trials or in obtaining
marketing approval thereafter and use of our platform technologies may not ever result in marketable products. We may also experience
delays in developing a sustainable, reproducible, and scalable manufacturing process or transferring that process to commercial partners
or establishing our own commercial manufacturing capabilities, which may prevent us from completing our clinical trials or commercializing
any products on a timely or profitable basis, if at all.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Serious
adverse events, undesirable side effects or other unexpected properties of our product candidates may be identified during development
or after approval, which could lead to the discontinuation of our clinical development programs, refusal by regulatory authorities to
approve our product candidates or, if discovered following marketing approval, revocation of marketing authorizations or limitations
on the use of our product candidates thereby limiting the commercial potential of such product candidate.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
we develop our drug therapies and initiate clinical trials of our additional drug therapies, serious adverse events, or SAEs, undesirable
side effects, relapse of disease or unexpected characteristics may emerge causing us to abandon these product candidates or limit their
development to more narrow uses or subpopulations in which the SAEs or undesirable side effects or other characteristics are less prevalent,
less severe or more acceptable from a risk-benefit perspective or in which efficacy is more pronounced or durable. Should we observe
SAEs in our clinical trials or identify other undesirable side effects or other unexpected findings depending on their severity, our
trials could be delayed or even stopped, and our development programs may be halted entirely.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if our product candidates initially show promise in early clinical trials, the side effects of drug therapies are frequently only detectable
after they are tested in larger, longer and more extensive clinical trials or, in some cases, after they are made available to patients
on a commercial scale after approval. Sometimes, it can be difficult to determine if the serious adverse or unexpected side effects were
caused by the drug therapy or another factor, especially in oncology subjects who may suffer from other medical conditions and be taking
other medications. If serious adverse or unexpected side effects are identified during development or after approval and are determined
to be attributed to our product candidate, we may be required to develop a Risk Evaluation and Mitigation Strategy, or REMS, to ensure
that the benefits of treatment with such product candidate outweigh the risks for each potential patient, which may include, among other
things, a communication plan to health care practitioners, patient education, extensive patient monitoring or distribution systems and
processes that are highly controlled, restrictive and more costly than what is typical for the industry. Product-related side effects
could also result in potential product liability claims. Any of these occurrences may harm our business, financial condition and prospects
significantly.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, if one or more of our product candidates receives marketing approval, and we or others later identify undesirable side effects
or ADA caused by such products, a number of potentially significant negative consequences could result, including:</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
    authorities may suspend, withdraw or limit approvals of such product, or seek an injunction against its manufacture or distribution;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
    authorities may require additional warnings on the label, including &ldquo;boxed&rdquo; warnings, or issue safety alerts, &ldquo;Dear
    Healthcare Provider&rdquo; letters, press releases or other communications containing warnings or other safety information about
    the product;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may be required to create a medication guide outlining the risks of such side effects for distribution to patients;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may be required to change the way a product is administered or conduct additional clinical trials;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    product may become less competitive, and our reputation may suffer;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may decide to remove the product from the marketplace; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may be subject to fines, injunctions or the imposition of civil or criminal penalties.</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Positive
results from preclinical studies and early-stage clinical trials may not be predictive of future results. Initial positive results in
any of our clinical trials may not be indicative of results obtained when the trial is completed or in later stage trials.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
results of preclinical studies may not be predictive of the results of clinical trials. Preclinical studies and early-stage clinical
trials are primarily designed to test safety, to study pharmacokinetics and pharmacodynamics and to understand the side effects of product
candidates at various doses and schedules, and the results of any early-stage clinical trials may not be predictive of the results of
later-stage, large-scale efficacy clinical trials. In addition, initial success in clinical trials may not be indicative of results obtained
when such trials are completed. There can be no assurance that any of our current or future clinical trials will ultimately be successful
or support further clinical development of any of our product candidates. There is a high failure rate for drugs and biological products
proceeding through clinical trials. A number of companies in the pharmaceutical and biotechnology industries have suffered significant
setbacks in clinical development even after achieving promising results in earlier studies, and any such setbacks in our clinical development
could have a material adverse effect on our business and operating results.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if our clinical trials are completed, the results may not be sufficient to obtain regulatory approval for our product candidates. Data
obtained from preclinical and clinical activities are subject to varying interpretations, which may delay, limit or prevent regulatory
approval. In addition, the results of our preclinical studies may not be predictive of the results of outcomes in human clinical trials.
For example, our current or future product candidates may demonstrate different chemical, biological and pharmacological properties in
patients than they do in laboratory studies or may interact with human biological systems in unforeseen or harmful ways. Product candidates
in later stages of clinical trials may fail to show desired pharmacological properties or produce the necessary safety and efficacy results
despite having progressed through preclinical studies and initial clinical trials. Even if we are able to initiate and complete clinical
trials, the results may not be sufficient to obtain regulatory approval for our product candidates. In addition, we may experience regulatory
delays or rejections as a result of many factors, including changes in regulatory policy during the period of our product candidate development.
Any such delays could negatively impact our business, financial condition, results of operations and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>As
an organization, we have limited experience designing and implementing clinical trials and we have never conducted pivotal clinical trials.
Failure to adequately design a trial, or incorrect assumptions about the design of the trial, could adversely affect the ability to initiate
the trial, enroll patients, complete the trial, or obtain regulatory approval on the basis of the trial results, as well as lead to increased
or unexpected costs and in delayed timelines.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
design and implementation of clinical trials is a complex process. We have limited experience designing and implementing clinical trials,
and we may not successfully or cost-effectively design and implement clinical trials that achieve our desired clinical endpoints efficiently,
or at all. A clinical trial that is not well designed may delay or even prevent initiation of the trial, can lead to increased difficulty
in enrolling patients, may make it more difficult to obtain regulatory approval for the product candidate on the basis of the study results,
or, even if a product candidate is approved, could make it more difficult to commercialize the product successfully or obtain reimbursement
from third-party payors. Additionally, a trial that is not well-designed could be inefficient or more expensive than it otherwise would
have been, or we may incorrectly estimate the costs to implement the clinical trial, which could lead to a shortfall in funding. We also
expect to continue to rely on third parties to conduct our clinical trials. If these third parties do not successfully carry out their
contractual duties, comply with regulatory requirements or meet expected deadlines, we may not be able to obtain marketing approval for
or commercialize our current or future product candidates we develop and our business could be materially harmed. Consequently, we may
be unable to successfully and efficiently execute and complete clinical trials that are required for BLA submission and FDA approval
of our current or future product candidates. We may require more time and incur greater costs than our competitors and may not succeed
in obtaining regulatory approvals of product candidates that we develop.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
business is dependent on our ability to advance our current and future product candidates through clinical trials, obtain marketing approval
and ultimately commercialize them.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are early in our development efforts. Most of our product candidates are not yet in clinical trials. Our ability to generate product
revenues, which we do not expect will occur for several years, if ever, will depend heavily on the successful development and eventual
commercialization of our current product candidates and any other current or future product candidates we develop, which may never occur.
Our current product candidates and any future product candidates we develop will require additional preclinical or clinical development,
management of clinical, preclinical and manufacturing activities, marketing approval in the United States and other jurisdictions, demonstration
of effectiveness to pricing and reimbursement authorities, sufficient manufacturing supply for both preclinical and clinical development
and commercial production, building of a commercial organization and substantial investment and significant marketing efforts before
we generate any revenues from product sales.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
clinical and commercial success of our current and future product candidates will depend on several factors, including the following:
timely and successful completion of preclinical studies and our clinical trials; sufficiency of our financial and other resources to
complete the necessary preclinical studies and clinical trials; our plans to successfully submit IND applications with the FDA for our
current and future product candidates; our ability to complete preclinical studies for current or future product candidates; successful
enrollment in, including maintaining or reaching target enrollment levels during the COVID-19 pandemic, and completion of clinical trials;
successful data from our clinical program that supports an acceptable risk-benefit profile of our product candidates in the intended
patient populations; our ability to establish agreements with third-party manufacturers on a timely and cost efficient manner; whether
we are required by the FDA or comparable foreign regulatory authorities to conduct additional clinical trials or other studies beyond
those planned or anticipated to support approval of our product candidates; acceptance of our proposed indications and the primary endpoint
assessments evaluated in the clinical trials of our product candidates by the FDA and comparable foreign regulatory authorities; receipt
and maintenance of timely marketing approvals from applicable regulatory authorities; successfully launching commercial sales of our
product candidates, if approved; the prevalence, duration and severity of potential side effects or other safety issues experienced with
our product candidates, if approved; entry into collaborations to further the development of our product candidates; obtaining and maintaining
patent and trade secret protection or regulatory exclusivity for our product candidates; acceptance of the benefits and uses of our product
candidates, if approved, by patients, the medical community and third-party payors; maintaining a continued acceptable safety, tolerability
and efficacy profile of the product candidates following approval; our compliance with any post-approval requirements imposed on our
products, such as post-marketing studies, a Risk Evaluation and Mitigation Strategy, or REMS, or additional requirements that might limit
the promotion, advertising, distribution or sales of our products or make the products cost prohibitive; competing effectively with other
therapies; obtaining and maintaining healthcare coverage and adequate reimbursement from third-party payors; and enforcing and defending
intellectual property rights and claims. There are multiple risks associated with developing companion diagnostics to ENV 105, ENV
205, and KROS 301 and there is no guarantee that these companion diagnostics will be approved by the FDA or comparable foreign regulatory
agencies.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
factors, many of which are beyond our control, could cause us to experience significant delays or an inability to obtain regulatory approvals
or commercialize our current or future product candidates, and could otherwise materially harm our business. Successful completion of
preclinical studies and clinical trials does not mean that any of our current or future product candidates we develop will receive regulatory
approval. Even if regulatory approvals are obtained, we could experience significant delays or an inability to successfully commercialize
our current and any future product candidates we develop, which would materially harm our business. If we are not able to generate sufficient
revenue through the sale of any current or future product candidate, we may not be able to continue our business operations or achieve
profitability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Interim,
topline and preliminary data from our clinical trials may change as more patient data become available and are subject to audit and verification
procedures that could result in material changes in the final data.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, we may publicly disclose preliminary, interim or topline data from our preclinical studies and clinical trials, which is
based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change as
patient enrollment and treatment continues and more patient data become available. Adverse differences between previous preliminary or
interim data and future interim or final data could significantly harm our business prospects. We may also announce topline data following
the completion of a preclinical study or clinical trial, which may be subject to change following a more comprehensive review of the
data related to the particular study or trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses
of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the interim, topline
or preliminary results that we report may differ from future results of the same studies, or different conclusions or considerations
may qualify such results, once additional data have been received and fully evaluated. Topline data also remain subject to audit and
verification procedures that may result in the final data being materially different from the preliminary data we previously published.
As a result, interim, topline and preliminary data should be viewed with caution until the final data are available.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses
or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability
or commercialization of the particular product candidate or product and our company in general. In addition, the information we choose
to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others
may not agree with what we determine to be material or otherwise appropriate information to include in our disclosure, and any information
we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or
otherwise regarding a particular product candidate or our business. If the interim, topline, or preliminary data that we report differ
from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval
for and commercialize our product candidates, our business, operating results, prospects or financial condition may be harmed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may face future business disruption and related risks resulting from the outbreak of the coronavirus (COVID-19) or from another pandemic,
epidemic or outbreak of an infectious disease, any of which could have a material adverse effect on our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
development of our drug candidates could be disrupted and materially adversely affected in the future by a pandemic, epidemic or outbreak
of an infectious disease like the outbreak of COVID-19. For example, as a result of measures imposed by the governments in regions affected
by COVID-19 businesses and schools have been suspended due to quarantines or &ldquo;stay at home&rdquo; orders intended to contain this
outbreak. The spread of COVID-19 from China to other countries has resulted in the Director General of the World Health Organization
declaring the outbreak of COVID-19 as a Public Health Emergency of International Concern (PHEIC), based on the advice of the Emergency
Committee under the International Health Regulations (2005). In March 2020, and subsequently, various international travel restrictions
were imposed and modified between the US and foreign countries and such restrictions may continue, be reimposed, or be expanded or otherwise
further modified for the foreseeable future. COVID-19 continues to spread globally, including with the advent of the new &ldquo;delta&rdquo;
and &ldquo;omicron&rdquo; variants in 2021 and 2022. The COVID-19 outbreak has impacted international stock markets, which continue to
reflect the uncertainty associated with the slow-down in global economies and the reduced levels of international travel experienced
since the beginning of January 2020. We continue to assess our business plans and the impact COVID-19 may have on our ability to advance
the development of our drug candidates, including delays in starting or completing clinical trials, or to raise financing to support
the development of our drug candidates, but no assurances can be given that this analysis will enable us to avoid part or all of any
impact from the spread of COVID-19 or its consequences, including downturns in business sentiment generally or in our sector in particular.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
spread of an infectious disease, including COVID-19, may also result in the inability of our suppliers to deliver components or raw materials
on a timely basis or materially and adversely affect our collaborators and out-license partners&rsquo; ability to perform preclinical
studies and clinical trials. In addition, hospitals may reduce staffing and reduce or postpone certain treatments in response to the
spread of an infectious disease. Such events may result in a period of business and manufacturing disruption, and in reduced operations,
any of which could materially affect our business, financial condition and results of operations. The extent to which the coronavirus
impacts our business will depend on future developments, which are highly uncertain and cannot be predicted, including new information
which may emerge concerning the severity of the coronavirus and the actions to contain the coronavirus or treat its impact, among others.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Disruptions
at the FDA and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire, retain
or deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, or approved or commercialized
in a timely manner or at all, which could negatively impact our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding
levels, statutory, regulatory, and policy changes, the FDA&rsquo;s ability to hire and retain key personnel and accept the payment of
user fees, and other events that may otherwise affect the FDA&rsquo;s ability to perform routine functions. Average review times at the
agency have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and
development activities is subject to the political process, which is inherently fluid and unpredictable. Disruptions at the FDA and other
agencies may also slow the time necessary for new biologics to be reviewed and/or approved by necessary government agencies, which would
adversely affect our business. For example, over the last several years, including for 35 days beginning on December 22, 2018, the U.S.
government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees
and stop critical activities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Separately,
in response to the global COVID-19 pandemic, on March 10, 2020 the FDA announced its intention to postpone most foreign inspections of
manufacturing facilities and products, and on March 18, 2020, the FDA announced its intention to temporarily postpone routine surveillance
inspections of domestic manufacturing facilities. Subsequently, on July 10, 2020 the FDA announced its intention to resume certain on-site
inspections of domestic manufacturing facilities subject to a risk-based prioritization system. The FDA intends to use this risk-based
assessment system to identify the categories of regulatory activity that can occur within a given geographic area, ranging from mission
critical inspections to resumption of all regulatory activities. Regulatory authorities outside the United States may adopt similar restrictions
or other policy measures in response to the COVID-19 pandemic. If a prolonged government shutdown occurs, or if global health concerns
continue to prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities,
it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions,
which could have a material adverse effect on our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates
or indications that may be more profitable or for which there is a greater likelihood of success.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
we have limited financial and managerial resources, we must prioritize our research programs and will need to focus our discovery and
development on select product candidates and indications. Correctly prioritizing our research and development activities is particularly
important for us due to the breadth of potential product candidates and indications that we believe could be pursued using our platform
technologies. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that
later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial
products or profitable market opportunities. Our spending on current and future research and development programs and product candidates
for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or
target market for a particular product candidate, we may also relinquish valuable rights to that product candidate through collaboration,
licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and
commercialization rights to such product candidate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may not be successful in our efforts to identify or discover additional product candidates in the future.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
research programs may initially show promise in identifying potential product candidates, yet fail to yield product candidates for clinical
development for a number of reasons, including:</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    inability to design such product candidates with the properties that we desire; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">potential
    product candidates may, on further study, be shown to have harmful side effects or other characteristics that indicate that they
    are unlikely to be products that will receive marketing approval and achieve market acceptance.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
programs to identify new product candidates require substantial technical, financial and human resources. If we are unable to identify
suitable additional candidates for preclinical and clinical development, our opportunities to successfully develop and commercialize
therapeutic products will be limited.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time consuming, expensive, and inherently unpredictable,
and if we are ultimately unable to obtain regulatory approval for our drug therapy candidates, our business will be substantially harmed.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
time required to obtain approval by the FDA and comparable foreign authorities is unpredictable but typically takes many years following
the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities.
In addition, approval policies, regulations or the type and amount of clinical data necessary to gain approval may change during the
course of a candidate&rsquo;s clinical development and may vary among jurisdictions. We have not obtained regulatory approval for any
product candidate and it is possible that we will never obtain regulatory approval for any of our drug therapy candidates. We are not
permitted to market any of our product candidates in the United States until we receive regulatory approval of a NDA from the FDA. Our
ability to obtain approval by the FDA or other regulatory authorities can be adversely impacted for various reasons including:</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that a candidate is safe
    and effective for its proposed indication;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">serious
    and unexpected drug-related side effects experienced by participants in our clinical trials or by individuals using drugs similar
    to our candidates, or other products containing the active ingredient in our candidates;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">negative
    or ambiguous results from our clinical trials or results that may not meet the level of statistical significance required by the
    FDA or comparable foreign regulatory authorities for approval;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may be unable to demonstrate that a candidate&rsquo;s clinical and other benefits outweigh its safety risks;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical
    trials;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    data collected from clinical trials of our development candidates may not be acceptable or sufficient to support the submission of
    an NDA or other submission or to obtain regulatory approval in the United States or elsewhere, and we may be required to conduct
    additional clinical&nbsp;trials;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA or comparable foreign authorities may disagree regarding the formulation, labeling and/or the specifications of our candidates;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA or comparable foreign regulatory authorities may fail to approve or find deficiencies with the manufacturing processes or facilities
    of third-party manufacturers with which we contract for clinical and commercial supplies;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA or comparable foreign regulatory authorities may inspect and find deficiencies at the clinical trial sites we use to conduct
    our clinical studies; and </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering
    our clinical data insufficient for approval.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to obtaining approval to commercialize a candidate in the United States or abroad, we must demonstrate with substantial evidence from
well-controlled clinical trials, and to the satisfaction of the FDA or foreign regulatory agencies, that such candidates are safe and
effective for their intended uses. Results from preclinical studies and clinical trials can be interpreted in different ways. Even if
we believe the preclinical or clinical data for our candidates are promising, such data may not be sufficient to support approval by
the FDA and other regulatory authorities. A single-study approach is permissible in certain circumstances, particularly in oncology,
but such circumstances are exceptional and FDA may not agree with that proposed approach, and thus we may be required to conduct two
phase 3 trials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA or any foreign regulatory bodies can delay, limit or deny approval of our candidates or require us to conduct additional preclinical
or clinical testing or abandon a program for many reasons, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA or comparable foreign regulatory authorities may disagree with the adequacy of the design or implementation of our clinical trials;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA or comparable foreign regulatory authorities may disagree with our safety interpretation of our drug;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA or comparable foreign regulatory authorities may disagree with our efficacy interpretation of our drug; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA or comparable foreign regulatory authorities may regard our CMC package as inadequate, and more particularly:</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    our NDA does not include adequate tests by all methods reasonably applicable to show whether or not such drug is safe for use under
    the conditions prescribed, recommended, or suggested in the proposed labeling thereof;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    the results of such tests show that such drug is unsafe for use under such conditions or do not show that such drug is safe for use
    under such conditions;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    the methods used in, and the facilities and controls used for, the manufacture, processing, and packing of such drug are inadequate
    to preserve its identity, strength, quality, and purity;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    the FDA determines that it has insufficient information to determine whether such drug is safe for use under such conditions;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    based on information we submit and any other information before the FDA, the FDA determines there is a lack of substantial evidence
    that the drug will have the effect it purports or is represented to have under the conditions of use prescribed, recommended, or
    suggested in the proposed labeling thereof; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    the FDA determines that our labeling is false or misleading in any particular way.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Of
the large number of drugs that enter clinical development, only a small percentage successfully complete the regulatory approval processes
and are approved and commercialized. This lengthy approval process, as well as the unpredictability of future clinical trial results,
may result in our failing to obtain regulatory approval to market of any of our drug therapy candidates, which would significantly harm
our business, results of operations and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the FDA or an applicable foreign regulatory agency also may approve a product candidate for a more limited indication or patient
population than we originally requested, the FDA or foreign regulatory agency may approve a product candidate with a label that does
not include the labeling claims necessary or desirable for the successful commercialization of that product candidate, or may require
warnings, other safety-related labeling information, or impose post-market safety requirements, including distribution restrictions,
that negatively impact the commercial potential of the drug. Any of the foregoing scenarios could materially harm the commercial prospects
for our product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Enrollment
and retention of patients in clinical trials is an expensive and time-consuming process and could be made more difficult or rendered
impossible by multiple factors outside our control.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
timely completion of clinical trials in accordance with their protocols depends, among other things, on our ability to enroll a sufficient
number of patients who remain in the study until its conclusion. We may encounter delays in enrolling, or be unable to enroll, a sufficient
number of patients to complete any of our clinical trials, and even once enrolled, we may be unable to retain a sufficient number of
patients to complete any of our trials. Patient enrollment and retention in clinical trials depends on many factors, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    patient eligibility criteria defined in the protocol;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    size of the patient population required for analysis of the trial&rsquo;s primary endpoints;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    nature of the trial protocol;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    existing body of safety and efficacy data with respect to the product candidate;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    proximity of patients to clinical sites;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to recruit clinical trial investigators with the appropriate competencies and experience;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">clinicians&rsquo;
    and patients&rsquo; perceptions as to the potential advantages of the product candidate being studied in relation to other available
    therapies, including any new drugs that may be approved for the indications we are investigating;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">competing
    clinical trials being conducted by other companies or institutions;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to maintain patient consents;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    risk that patients enrolled in clinical trials will drop out of the trials before completion; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    or difficulties in enrollment and completion of studies due to the COVID 19 pandemic.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Results
of preclinical studies, early clinical trials or analyses may not be indicative of results obtained in later trials.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
results of preclinical studies, early clinical trials or analyses of our product candidates may not be predictive of the results of later-stage
clinical trials. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite
having progressed through preclinical studies and initial clinical trials. A number of companies in the pharmaceutical industry have
suffered significant setbacks in advanced clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding promising
results in earlier trials. In addition, conclusions based on promising data from analyses of clinical results may be shown to be incorrect
when implemented in prospective clinical trials. Even if our clinical trials for our drug therapy candidates are completed as planned,
we cannot be certain that their results will support the safety and efficacy sufficient to obtain regulatory approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Serious
adverse events or undesirable side effects caused by any of our drug therapy candidates could cause us or regulatory authorities to interrupt,
delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or
other comparable foreign authorities. Results of any clinical trial we conduct could reveal a high and unacceptable severity and prevalence
of side effects or unexpected characteristics.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
unacceptable side effects arise in the development of our candidates, we, the FDA or the IRBs at the institutions in which our studies
are conducted, or the DSMB, if constituted for our clinical trials, could recommend a suspension or termination of our clinical trials,
or the FDA or comparable foreign regulatory authorities could order us to cease further development of or deny approval of a product
candidate for any or all targeted indications. In addition, drug-related side effects could affect patient recruitment or the ability
of enrolled patients to complete a trial or result in potential product liability claims. In addition, these side effects may not be
appropriately recognized or managed by the treating medical staff. We expect to have to train medical personnel using our development
candidates to understand the side effect profiles for our clinical trials and upon any commercialization of any of our product candidates.
Inadequate training in recognizing or managing the potential side effects of our product candidates could result in patient injury or
death. Any of these occurrences may harm our business, financial condition and prospects significantly.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
if one or more of our product candidates receives marketing approval, and we or others later identify undesirable side effects caused
by such products, a number of potentially significant negative consequences could result, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
    authorities may withdraw approvals of such product;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
    authorities may require additional warnings on the label, such as a &ldquo;black box&rdquo; warning or contraindication;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">additional
    restrictions may be imposed on the marketing of the particular product or the manufacturing processes for the product or any component
    thereof;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may be required to implement a Risk Evaluation and Mitigation Strategy, or REMS, or create a medication guide outlining the risks
    of such side effects for distribution to patients;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    could be sued and held liable for harm caused to patients;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    product may become less competitive; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    reputation may suffer.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
of these events could prevent us from achieving or maintaining market acceptance of a product candidate, if approved, and could significantly
harm our business, results of operations and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
market opportunities for any current or future product candidate we develop, if approved, may be limited to those patients who are ineligible
for established therapies or for whom prior therapies have failed, and may be small.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cancer
therapies are sometimes characterized as first-line, second-line or third-line, and the FDA often approves new therapies initially only
for third-line use. Second- and third-line therapies are administered to patients when prior therapy is not effective. The number of
patients who receive second- and third-line treatment is significantly smaller than the number of patients who receive first-line treatment.
We may initially seek approval for our product candidates we develop as second- or third-line therapies. If we do so, for those products
that prove to be sufficiently beneficial, if any, we would expect potentially to seek approval as a first-line therapy, but there is
no guarantee that any product candidate we develop, even if approved, would be approved for first-line therapy, and, prior to any such
approvals, we may have to conduct additional clinical trials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
number of patients who have the types of cancer or autoimmune diseases we are targeting may turn out to be lower than expected. Even
if we obtain significant market share for any product candidate, if and when approved, if the potential target populations are small,
we may never achieve profitability without obtaining marketing approval for additional indications, including to be used as first- or
second-line therapy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
have never obtained marketing approval for a drug therapy candidate and we may be unable to obtain, or may be delayed in obtaining, marketing
approval for any of our development candidates.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have never obtained marketing approval for a product candidate. It is possible that the FDA may refuse to accept for substantive review
any NDAs that we submit for our development candidates or may conclude after review of our data that our application is insufficient
to obtain marketing approval of our development candidates. If the FDA does not accept or approve our NDAs for our development candidates,
it may require that we conduct additional clinical, preclinical or manufacturing validation studies and submit that data before it will
reconsider our applications. Depending on the extent of these or any other FDA-required studies, approval of any NDA that we submit may
be delayed or may require us to expend more resources than we have available. It is also possible that additional studies, if performed
and completed, may not be considered sufficient by the FDA to approve our NDAs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
delay in obtaining, or an inability to obtain, marketing approvals would prevent us from commercializing our development candidates,
generating revenues and achieving and sustaining profitability. If any of these outcomes occur, we may be forced to abandon our development
efforts for our product candidates, which could significantly harm our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Even
if we obtain FDA approval for any of our drug therapy candidates in the United States, we may never obtain approval for or commercialize
them in any other jurisdiction, which would limit our ability to realize their full global market potential.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to market any products in any particular jurisdiction, we must establish and comply with numerous and varying regulatory requirements
on a country-by-country basis regarding safety and efficacy. Approval by the FDA in the United States does not ensure approval by regulatory
authorities in other countries or jurisdictions. However, the failure to obtain approval in one jurisdiction may negatively impact our
ability to obtain approval elsewhere. In addition, clinical trials conducted in one country may not be accepted by regulatory authorities
in other countries, and regulatory approval in one country does not guarantee regulatory approval in any other country.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Approval
processes vary among countries and can involve additional product testing and validation and additional administrative review periods.
Seeking foreign regulatory approval could result in difficulties and increased costs for us and require additional preclinical studies
or clinical trials which could be costly and time consuming. Regulatory requirements can vary widely from country to country and could
delay or prevent the introduction of our products in those countries. We do not have any product candidates approved for sale in any
jurisdiction, including in international markets, and we do not have experience in obtaining regulatory approval in international markets.
If we fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, or if regulatory
approvals in international markets are delayed, our target market will be reduced and our ability to realize the full market potential
of any product we develop will be unrealized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Even
if we obtain regulatory approval for any development candidate, we will still face extensive and ongoing regulatory requirements and
obligations and any development candidates, if approved, may face future development and regulatory difficulties.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA and other federal and state agencies, including the U.S. Department of Justice, or the DOJ, closely regulate compliance with all
requirements governing prescription drug products, including requirements pertaining to marketing and promotion of drugs in accordance
with the provisions of the approved labeling and manufacturing of products in accordance with cGMP requirements. The FDA and DOJ impose
stringent restrictions on manufacturers&rsquo; communications regarding off-label use and if we do not market our current in-development
products or our future product candidates for their approved indications, we may be subject to enforcement action for off-label marketing.
Violations of such requirements may lead to investigations alleging violations of the Food, Drug and Cosmetic Act and other statutes,
including the False Claims Act and other federal and state health care fraud and abuse laws as well as state consumer protection laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
candidate for which we obtain marketing approval, along with the manufacturing processes, post-approval clinical data, labeling, packaging,
distribution, adverse event reporting, storage, recordkeeping, export, import, advertising and promotional activities for such product,
among other things, will be subject to extensive and ongoing requirements of and review by the FDA and other regulatory authorities.
These requirements include submissions of safety and other post-marketing information and reports, establishment registration and drug
listing requirements, continued compliance with current Good Manufacturing Practice, or cGMP, requirements relating to manufacturing,
quality control, quality assurance and corresponding maintenance of records and documents, requirements regarding the distribution of
samples to physicians and recordkeeping and Good Clinical Practice, or GCP, requirements for any clinical trials that we conduct post-approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if marketing approval of a product candidate is granted, the approval may be subject to limitations on the indicated uses for which the
product candidate may be marketed or to the conditions of approval, including a requirement to implement a REMS. If any of our product
candidates receive marketing approval, the accompanying label may limit the approved indicated use of the product candidate, which could
limit sales of the product candidate. The FDA may also impose requirements for costly post-marketing studies or clinical trials and surveillance
to monitor the safety or efficacy of a product. The FDA closely regulates the post-approval marketing and promotion of drugs to ensure
drugs are marketed only for the approved indications and in accordance with the provisions of the approved labeling. The FDA imposes
stringent restrictions on manufacturers&rsquo; communications regarding off-label use, and if we market our products for uses beyond
their approved indications, we may be subject to enforcement action for off-label marketing. Violations of the Federal Food, Drug, and
Cosmetic Act, or FDCA, relating to the promotion of prescription drugs may lead to FDA enforcement actions and investigations alleging
violations of federal and state healthcare fraud and abuse laws, as well as state consumer protection laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, later discovery of previously unknown adverse events or other problems with our products, manufacturers or manufacturing processes
or failure to comply with regulatory requirements, may yield various results, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">litigation
    involving patients taking our product candidates;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions
    on such products, manufacturers, or manufacturing processes;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions
    on the labeling or marketing of products;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions
    on product distribution or use;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">requirements
    to conduct post-marketing studies or clinical trials;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">warning
    letters or untitled letters;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">withdrawal
    of the products from the market;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusal
    to approve pending applications or supplements to approved applications that we submit;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">recall
    of products;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">fines,
    restitution or disgorgement of profits or revenues;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspension
    or withdrawal of marketing approvals;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusal
    to permit the import or export of our products;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">damage
    to relationships with any potential collaborators;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">unfavorable
    press coverage and damage to our reputation;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusal
    to permit the import or export of our product candidates;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">product
    seizure; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">injunctions
    or the imposition of civil or criminal penalties.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
the FDA&rsquo;s policies may change, and additional government regulations may be enacted that could prevent, limit or delay regulatory
approval of our product candidates. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements
or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained, which
would adversely affect our business, prospects and ability to achieve or sustain profitability. We also cannot predict the likelihood,
nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the
United States or abroad.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Even
if we obtain marketing approvals for our current in-development products or any future product candidates, the terms of approvals and
ongoing regulation of such product candidates may limit how we manufacture and market the product candidates and compliance with such
requirements may involve substantial resources, which could materially impair our ability to generate revenue.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if marketing approval of any of our current in-development products or any future product candidates is granted, an approved product
and its manufacturer and marketer are subject to ongoing review and extensive regulation, including the potential requirements to implement
a risk evaluation and mitigation strategy or to conduct costly post-marketing studies or clinical trials and surveillance to monitor
the safety or efficacy of the product. We must also comply with requirements concerning advertising and promotion for any of our product
candidates for which we obtain marketing approval. Promotional communications with respect to prescription drugs are subject to a variety
of legal and regulatory restrictions and must be consistent with the information in the product&rsquo;s approved labeling. Thus, we will
not be able to promote any products we develop for indications or uses for which they are not approved. In addition, manufacturers of
approved products and those manufacturers&rsquo; facilities are required to comply with extensive FDA requirements including ensuring
that quality control and manufacturing procedures conform to cGMP, which include requirements relating to quality control and quality
assurance as well as the corresponding maintenance of records and documentation and reporting requirements. We and our contract manufacturers
could be subject to periodic unannounced inspections by the FDA to monitor and ensure compliance with cGMP.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accordingly,
assuming we receive marketing approval for one or more product candidates, we and our contract manufacturers will continue to expend
time, money, and effort in all areas of regulatory compliance, including manufacturing, production, product surveillance, and quality
control. If we are not able to comply with post-approval regulatory requirements, we could have the marketing approvals for our product
candidates withdrawn by regulatory authorities and our ability to market any future products could be limited, which could adversely
affect our ability to achieve or sustain profitability. Thus, the cost of compliance with post-approval regulations may have a negative
effect on our operating results and financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-compliance
by us or any future collaborator with regulatory requirements regarding safety monitoring or pharmacovigilance, and with requirements
related to the development of products for the pediatric population, can also result in significant financial penalties. Similarly, failure
to comply with regulatory requirements regarding the protection of personal information can also lead to significant penalties and sanctions.
Non-compliance with EU requirements regarding safety monitoring or pharmacovigilance, and with requirements related to the development
of products for the pediatric population, also can result in significant financial penalties. Similarly, failure to comply with the EU&rsquo;s
requirements regarding the protection of personal information can also lead to significant penalties and sanctions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may seek a Breakthrough Therapy designation for one of our drug therapy candidates from the FDA. However, we might not seek such designation
or be granted the designation by the FDA if sought, and even if we are granted the designation, it may not lead to a faster development
or regulatory review or approval process.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may seek a Breakthrough Therapy designation for one or more of our drug therapy candidates. Breakthrough Therapy designation is a process
designed to expedite the development and review of drugs that are intended to treat a serious condition and preliminary clinical evidence
indicates that the drug may demonstrate substantial improvement over available therapy on a clinically significant endpoint(s). For purposes
of Breakthrough Therapy designation, clinically significant endpoint generally refers to an endpoint that measures an effect on irreversible
morbidity or mortality (IMM) or on symptoms that represent serious consequences of the disease. A clinically significant endpoint can
also refer to findings that suggest an effect on IMM or serious symptoms. For drugs that have been designated as breakthrough therapies,
interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical
development while minimizing the number of patients placed in ineffective control regimens. Drugs designated as breakthrough therapies
by the FDA may also be eligible for&nbsp;fast-track&nbsp;designation (under a separate request), priority review, or accelerated approval,
if supported by clinical data at the time the NDA is submitted to the FDA. FDA encourages a Breakthrough Therapy designation request
to be submitted, and received by FDA, no later than the end-of-phase-2 meetings.&nbsp;Even if granted, accelerated approval status does
not guarantee an accelerated review or marketing approval by the FDA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designation
as a Breakthrough Therapy is within the discretion of the FDA both at the time of the submission of such a request, and during FDA&rsquo;s
review of the drug and supporting data. Even if we believe that one of our candidates meets the criteria for designation as a Breakthrough
Therapy, the FDA may disagree and instead determine not to make such designation or may grant such a designation and subsequently rescind
the designation prior to approval. Even if we receive and maintain Breakthrough Therapy designation, the receipt of such designation
for a product candidate may not result in a faster development or regulatory review or approval process compared to drugs considered
for approval under conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, even if one or more of
our product candidates qualify as breakthrough therapies, the FDA may later decide that the product candidates no longer meet the conditions
for qualification or decide that the time period for FDA review or approval will not be shortened.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to the Commercialization of Our Current In-Development Products and Our Future Product Candidates</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Even
if any of our current in-development products or any of our future product candidates receives marketing approval, it may fail to achieve
the degree of market acceptance by physicians, patients, third-party payors, and others in the medical community necessary for commercial
success.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if we obtain approvals from the FDA, the EMA, the PMDA, the TGA, or other comparable regulatory agencies and are able to initiate commercialization
of our current in-development products or any future product candidates we develop, the product candidate may not achieve market acceptance
among physicians, patients, and third-party payors and, ultimately, may not be commercially successful. The degree of market acceptance
of our product candidates, if approved for commercial sale, will depend on a number of factors, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the market size of any product candidate that obtains regulatory approval is significantly smaller than we anticipate, it may not achieve
market acceptance or commercial success. This could significantly and negatively impact our business, financial condition, and results
of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we are unable to establish sales, marketing, and distribution capabilities for our current in-development products or our future product
candidates, or enter into sales, marketing, and distribution agreements with third parties, we may not be successful in commercializing
our product candidates, if and when they are approved.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not have a sales or marketing infrastructure and have limited experience in the sale, marketing, or distribution of pharmaceutical
products. To achieve commercial success for any product candidate for which we may obtain marketing approval, we will need to establish
a sales and marketing organization or enter into collaboration, distribution, and other marketing arrangements with one or more third
parties to commercialize such product candidate. In the United States, we intend to build a commercial organization to target areas with
the greatest incidence of treatments for cancers and other indications to which our drugs and therapies are targeted and recruit experienced
sales, marketing, and distribution professionals. The development of sales, marketing, and distribution capabilities will require substantial
resources, will be time-consuming, and could delay any product launch. We may decide to work with regional specialty pharmacies, distributors,
and/or multi-national pharmaceutical companies to leverage their commercialization capabilities to commercialize any product candidate
for which we may obtain regulatory approval outside of the United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the commercial launch of a product candidate for which we recruit a sales force and establish marketing and distribution capabilities
is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization costs. This
may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel. In addition, we
may not be able to hire a sales force in the United States that is sufficient in size or has adequate expertise to target the areas that
we intend to target. If we are unable to establish a sales force and marketing and distribution capabilities, our operating results may
be adversely affected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Factors
that may inhibit our efforts to commercialize our drugs on our own include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    inability to recruit, train, and retain adequate numbers of effective sales and marketing personnel;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    inability of sales personnel to obtain access to physicians or persuade adequate numbers of physicians to prescribe any future products;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage compared to companies
    with more extensive product lines;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">unforeseen
    costs and expenses associated with creating an independent sales and marketing organization; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">unforeseen
    costs and limitations with regard to setting up a distribution network.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are unable to establish our own sales, marketing, and distribution capabilities in the United States and other jurisdictions in which
our current in-development products or any future product candidates are approved and, instead, enter into arrangements with third parties
to perform these services, our revenues and profitability, if any, are likely to be lower than if we were to sell, market, and distribute
any product candidates that we develop ourselves. We may not be successful in entering into arrangements with third parties to sell,
market, and distribute our product candidates or may be unable to do so on terms that are favorable to us. We likely will have limited
control over such third parties, and any of them may fail to devote the necessary resources and attention to sell and market our product
candidates effectively. If we do not establish sales, marketing, and distribution capabilities successfully, either on our own or in
collaboration with third parties, we will not be successful in commercializing any product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Coverage
and adequate reimbursement may not be available for any of our in-development products or any future product candidates, which could
make it difficult for us to sell profitably, if approved.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Market
acceptance and sales of any product candidates that we commercialize, if approved, will depend in part on the extent to which reimbursement
for these drugs and related treatments will be available from third-party payors, including government health administration authorities,
managed care organizations and other private health insurers. Third-party payors decide which therapies they will pay for and establish
reimbursement levels. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own coverage
and reimbursement policies. However, decisions regarding the extent of coverage and amount of reimbursement to be provided for any product
candidates that we develop will be made on a payor-by-payor basis. One payor&rsquo;s determination to provide coverage for a drug does
not assure that other payors will also provide coverage and adequate reimbursement for the drug. Additionally, a third-party payor&rsquo;s
decision to provide coverage for a therapy does not imply that an adequate reimbursement rate will be approved. Each payor determines
whether or not it will provide coverage for a therapy, what amount it will pay the manufacturer for the therapy, and on what tier of
its list of covered drugs, or formulary, it will be placed. The position on a payor&rsquo;s formulary generally determines the co-payment
that a patient will need to make to obtain the therapy and can strongly influence the adoption of such therapy by patients and physicians.
Patients who are prescribed treatments for their conditions and providers prescribing such services generally rely on third-party payors
to reimburse all or part of the associated healthcare costs. Patients are unlikely to use our drugs, and providers are unlikely to prescribe
our drugs, unless coverage is provided, and reimbursement is adequate to cover a significant portion of the cost of our drugs and their
administration.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
primary trend in the U.S. healthcare industry and elsewhere is cost containment. Third-party payors have attempted to control costs by
limiting coverage and the amount of reimbursement for particular medications. We cannot be sure that coverage and reimbursement will
be available for any drug that we commercialize and, if reimbursement is available, what the level of reimbursement will be. Inadequate
coverage and reimbursement may impact the demand for, or the price of, any drug for which we obtain marketing approval. If coverage and
adequate reimbursement are not available, or are available only to limited levels, we may not be able to successfully commercialize any
of our current in-development products and any future product candidates that we develop.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>If we are unable to successfully develop
any required companion diagnostic tests for our product candidates, experience significant delays in doing so, or rely on third parties
in the development of such companion diagnostic tests, we may be unable to realize the full commercial potential of our product candidates.</I></B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">We will strive, in conjunction with
our wholly-owned subsidiary Enviro Therapeutics, to co-develop companion biomarkers with all drugs in its portfolio and to evaluate whether
a companion diagnostic test will be required for any of our product candidates. In general, the FDA expects to review and approve simultaneously
NDA and pre-market approval submissions for a therapeutic and its companion diagnostic, respectively, so any delay in diagnostic approval
could delay drug approval. On April 13, 2020, the FDA issued new guidance on developing and labeling companion diagnostics for a specific
group of oncology therapeutic products, including recommendations to support a broader labeling claim rather than individual therapeutic
products. We will continue to evaluate the impact of this guidance on our companion diagnostic development and strategy. This guidance
and future issuances from the FDA and other regulatory authorities may impact our development of a companion diagnostic for our product
candidates and result in delays in regulatory approval. We may be required to conduct additional studies to support a broader claim.
Also, to the extent other approved diagnostics are able to broaden their labeling claims to include our approved drug products, if any,
we may be forced to abandon any of our companion diagnostic&nbsp;development plans or we may not be able to compete effectively upon
approval, which could adversely impact our ability to generate revenue from the sale of our to be approved products, if any, and our
business operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">We may rely on third parties for the
design, development, and manufacture of companion diagnostic tests for our product candidates that require such tests. To be successful,
we or our collaborators will need to address a number of scientific, technical, regulatory and logistical challenges. If we or such third
parties are unable to successfully develop companion diagnostics, or experience delays in doing so, we may be unable to enroll enough
patients for our current and planned clinical trials, the development of our product candidates may be adversely affected or we may not
obtain marketing approval, and we may not realize the full commercial potential of our product candidates.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>


<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Product
liability lawsuits against us could cause us to incur substantial liabilities and to limit commercialization of any products that we
may develop.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
use of any</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> of our drug therapy candidates
we may develop in clinical trials and the sale of any products for which we obtain marketing approval exposes us to
the risk of product liability claims. Product liability claims might be brought against us by patients, healthcare providers, pharmaceutical
companies or others selling or otherwise coming into contact with our products. On occasion, large judgments have been awarded in class
action lawsuits based on drugs that had unanticipated adverse effects. If we cannot successfully defend against product liability
claims, we could incur substantial liability and costs. In addition, regardless of merit or eventual outcome, product
liability claims may result in:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">impairment
    </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">of our business </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">reputation and significant negative media attention;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">withdrawal
    of participants from our clinical trials;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">significant
    costs to defend the litigation;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">distraction
    of management&rsquo;s attention from our primary business;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">substantial
    monetary awards to patients or other claimants;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">inability to commercialize THIO or any other product
    candidate;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">product
    recalls, withdrawals or labeling, marketing or promotional restrictions;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">decreased
    market demand for any product; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><P STYLE="margin: 0">loss of revenue.</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
product liability insurance coverage carry may not be sufficient to reimburse us for any expenses or losses
we may suffer. We intend to acquire insurance coverage to include larger clinical studies, different countries and the potential sale
of commercial products; however, we may be unable to obtain product liability insurance on commercially reasonable terms or in adequate
amounts. A successful product liability claim, or series of claims, brought against us could cause our share price to decline and, if
judgments exceed our insurance coverage, could adversely affect the results of our operations and business, including preventing or limiting
the commercialization of any product candidates we develop.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
 hold $5 million in global product liability insurance coverage with a per incident limit of $5 million annually,
which may not be adequate to cover all liabilities that we may incur. We may need to increase our insurance coverage as we expand
our clinical trials or if we commence commercialization of any product candidates. Insurance coverage is increasingly expensive. We may
not be able to obtain or maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that
may arise, if at all. Product liability insurance policies contain various exclusions, and we may be subject to a product
liability claim for which we have no coverage. We may have to pay any amounts awarded by a court or negotiated in a settlement that exceed
our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay
such amounts. Even if our agreements with current or future collaborators entitle us to indemnification against losses, such indemnification
may not be available or adequate should any claim arise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>There
are a variety of risks associated with marketing our current in-development products or any future product candidates internationally,
which could affect our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may seek regulatory approvals for ENV 105 and/or any of our product candidates outside of the United States and, accordingly,
we expect that we will be subject to additional risks related to operating in foreign countries if we obtain the necessary approvals,
including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">differing
    regulatory requirements and reimbursement landscapes in foreign countries;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    potential for so-called parallel importing, which is what happens when a local seller, faced with high or higher local prices, opts
    to import goods from a foreign market with low or lower prices rather than buying them locally;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">unexpected
    changes in tariffs, trade barriers, price and exchange controls, and other regulatory requirements;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">economic
    weakness, including inflation, or political instability in particular foreign economies and markets;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">compliance
    with tax, employment, immigration, and labor laws for employees living or traveling abroad;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">foreign
    taxes, including withholding of payroll taxes;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">foreign
    currency fluctuations, which could result in increased operating expenses and reduced revenues, and other obligations incident to
    doing business in another country;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulties
    staffing and managing foreign operations;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">workforce
    uncertainty in countries where labor unrest is more common than in the United States;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">potential
    liability under the U.S. Foreign Corrupt Practices Act of 1977, as amended, or the FCPA, or comparable foreign regulations;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">challenges
    enforcing our contractual and intellectual property rights, especially in those foreign countries that do not respect and protect
    intellectual property rights to the same extent as the United States;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">production
    shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">business
    interruptions resulting from geo-political actions, including war and terrorism.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
and other risks associated with our international operations may compromise our ability to achieve or maintain profitability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to Our Dependence on Third Parties</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
employees and independent contractors, including principal investigators, clinical trial sites, contract research organizations, or CROs,
consultants, vendors, and any third parties we may engage in connection with development and commercialization, may engage in misconduct
or other improper activities, including noncompliance with regulatory standards and requirements, which could have a material adverse
effect on our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
employees and independent contractors, including principal investigators, clinical trial sites, consultants, vendors and any third parties
we may engage in connection with development and commercialization of our product candidates, could engage in misconduct, including intentional,
reckless or negligent conduct or unauthorized activities that violate: the laws and regulations of the FDA or other similar regulatory
requirements of other authorities, including those laws that require the reporting of true, complete and accurate information to such
authorities; manufacturing standards; data privacy, security, fraud and abuse and other healthcare laws and regulations; or laws that
require the reporting of true, complete and accurate financial information and data. Specifically, sales, marketing and business arrangements
in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing
and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and
promotion, sales commission, customer incentive programs and other business arrangements. Activities subject to these laws could also
involve the improper use or misrepresentation of information obtained in the course of clinical trials, creation of fraudulent data in
preclinical studies or clinical trials or illegal misappropriation of drug product, which could result in regulatory sanctions and cause
serious harm to our reputation. It is not always possible to identify and deter misconduct by employees and other third parties, and
the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses
or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with such laws or
regulations. Additionally, we are subject to the risk that a person or government could allege such fraud or other misconduct, even if
none occurred. If any such actions are instituted against us and we are not successful in defending ourselves or asserting our rights,
those actions could have a significant impact on our business and results of operations, including the imposition of significant civil,
criminal and administrative penalties, damages, monetary fines, disgorgements, possible exclusion from participation in Medicare, Medicaid,
other U.S. federal healthcare programs or healthcare programs in other jurisdictions, individual imprisonment, other sanctions, contractual
damages, reputational harm, diminished profits and future earnings, and curtailment of our operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
rely on single-sourced third parties to conduct the preclinical and nonclinical studies, clinical trials, and manufacture of our clinical
trial material for our current in-development products and our future product candidates, and those third parties may not perform satisfactorily,
including failing to meet deadlines for the completion of such studies, trials, and manufacturing services or failing to comply with
applicable regulatory requirements.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have engaged contract research organizations, or CROs, to conduct our ongoing and planned preclinical and nonclinical studies, clinical
trials and manufacture of our clinical trial material. We also expect to engage CROs for any of our other future product candidates that
may progress to clinical development. We expect to rely on CROs, as well as other third parties, such as clinical data management organizations,
medical institutions, and clinical investigators, to conduct those preclinical and nonclinical studies, clinical trials, and manufacture
of our clinical trial material. Currently, we rely on single source third-party research institutions, laboratories, clinical research
and manufacturing organizations for research and development. Agreements with such third parties might terminate for a variety of reasons,
including a failure to perform by the third parties. If we need to enter into alternative arrangements or fail to enter into alternative
arrangements in a timely manner, our product development activities would be delayed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
reliance on these third parties for research and development activities will reduce our control over these activities but will not relieve
us of our responsibilities. For example, we will remain responsible for ensuring that each of our clinical trials is conducted in accordance
with the general investigational plan and protocols for the trial. Moreover, the FDA requires us to comply with regulatory standards,
commonly referred to as good clinical practices, or GCPs, for conducting, recording, and reporting the results of clinical trials to
assure that data and reported results are credible and accurate and that the rights, integrity, and confidentiality of trial participants
are protected. Similar regulatory requirements apply outside the United States, including the International Council for Harmonisation
of Technical Requirements for the Registration of Pharmaceuticals for Human Use, or the ICH. We are also required to register certain
ongoing clinical trials and post the results of certain completed clinical trials on a government-sponsored database, ClinicalTrials.gov,
within specified timeframes. Failure to do so by us or third parties can result in FDA refusal to approve applications based on the clinical
data, enforcement actions, adverse publicity, and civil and criminal sanctions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
these third parties may also have relationships with other entities, some of which may be our competitors. If these third parties do
not successfully carry out their contractual duties, meet expected deadlines, or conduct our clinical trials in accordance with regulatory
requirements or our stated protocols, we will not be able to obtain, or may be delayed in obtaining, marketing approvals for our current
in-development products and our future product candidates and will not be able to, or may be delayed in our efforts to, successfully
commercialize such product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and
may receive cash compensation in connection with such services. If these relationships and any related compensation result in perceived
or actual conflicts of interest, or the FDA concludes that the financial relationship may have affected the interpretation of the trial,
the integrity of the data generated at the applicable clinical trial site may be questioned and the utility of the clinical trial itself
may be jeopardized, which could result in the delay or rejection by the FDA of any New Drug Application, or NDA, we submit. Any such
delay or rejection could prevent us from commercializing our current in-development products or any future product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
will rely on third-party contract manufacturing organizations, or CMOs,&nbsp;for the production of&nbsp;clinical supply of our drug therapy
candidates and intend to rely on CMOs for the production of commercial supply our drug therapies, if approved. Our dependence on CMOs
may impair the development and commercialization of the drug, which would adversely impact our business and financial position.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have limited personnel with experience in manufacturing, and we do not own facilities for manufacturing. Instead, we rely on and expect
to continue to rely on CMOs for the supply of cGMP grade clinical trial materials and commercial quantities of any candidates we develop,
if approved. Reliance on CMOs may expose us to more risk than if we were to manufacture our product candidates ourselves. We intend to
have manufactured a sufficient clinical supply of our drug therapy substances to enable us to complete our clinical trials, and we have
also engaged a CMO to provide clinical and commercial supply of the drug product.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0; background-color: white"></P>

<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
facilities used to manufacture our product candidates must be inspected by the FDA and comparable foreign authorities. While we provide
oversight of manufacturing activities, we do not and will not control the execution of manufacturing activities by, and are or will be
essentially dependent on, our CMOs for compliance with cGMP requirements for the manufacture of our product candidates. As a result,
we are subject to the risk that our product candidates may have manufacturing defects that we have limited ability to prevent. If a CMO
cannot successfully manufacture material that conforms to our specifications and the regulatory requirements, we will not be able to
secure or maintain regulatory approval for the use of our product candidates in clinical trials, or for commercial distribution of our
product candidates, if approved. In addition, we have limited control over the ability of our CMOs to maintain adequate quality control,
quality assurance and qualified personnel. If the FDA or comparable foreign regulatory authority finds deficiencies with or does not
approve these facilities for the manufacture of our product candidates or if it withdraws any such approval or finds deficiencies in
the future, we may need to find alternative manufacturing facilities, which would delay our development program and significantly impact
our ability to develop, obtain regulatory approval for or commercialize our product candidates, if approved. In addition, any failure
to achieve and maintain compliance with these laws, regulations and standards could subject us to the risk that we may have to suspend
the manufacture of our product candidates or that obtained approvals could be revoked. Furthermore, CMOs may breach existing agreements
they have with us because of factors beyond our control. They may also terminate or refuse to renew their agreement at a time that is
costly or otherwise inconvenient for us. If we were unable to find an adequate CMO or another acceptable solution in time, our clinical
trials could be delayed, or our commercial activities could be harmed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
rely on and will continue to rely on CMOs to purchase from third-party suppliers the raw materials necessary to produce our product candidates.
We do not and will not have control over the process or timing of the acquisition of these raw materials by our CMOs. Moreover, we currently
do not have any agreements for the production of these raw materials. Supplies of raw material could be interrupted from time to time
and we cannot be certain that alternative supplies could be obtained within a reasonable timeframe, at an acceptable cost, or at all.
In addition, a disruption in the supply of raw materials could delay the commercial launch of our product candidates, if approved, or
result in a shortage in supply, which would impair our ability to generate revenues from the sale of our product candidates. Growth in
the costs and expenses of raw materials may also impair our ability to cost effectively manufacture our product candidates. There are
a limited number of suppliers for the raw materials that we may use to manufacture our product candidates and we may need to assess alternative
suppliers to prevent a possible disruption of the manufacture of our product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Finding
new CMOs or third-party suppliers involves additional cost and requires our management&rsquo;s time and focus. In addition, there is
typically a transition period when a new CMO commences work. Although we generally have not, and do not intend to, begin a clinical trial
unless we believe we have on hand, or will be able to obtain, a sufficient supply of our product candidates to complete the clinical
trial, any significant delay in the supply of our product candidates or the raw materials needed to produce our product candidates, could
considerably delay conducting our clinical trials and potential regulatory approval of our product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
part of their manufacture of our product candidates, our CMOs and third-party suppliers are expected to comply with and respect the proprietary
rights of others. If a CMO or third-party supplier fails to acquire the proper licenses or otherwise infringes the proprietary rights
of others in the course of providing services to us, we may have to find alternative CMOs or third-party suppliers or defend against
claims of infringement, either of which would significantly impact our ability to develop, obtain regulatory approval for or commercialize
our product candidates, if approved.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
performance failure or regulatory noncompliance on the part of CMOs could delay clinical development or marketing approval of our current
in-development products or any future product candidates or commercialization of such product candidates, resulting in additional losses,
and depriving us of potential product revenue.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
reliance on single-sourced third parties to manufacture our product candidates increases the risk that we will not have sufficient quantities
of our product candidates or products or such quantities at an acceptable cost, which could delay, prevent, or impair our development
or commercialization efforts.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not own or operate manufacturing facilities for the production of clinical or commercial supplies of the product candidates that we
are developing or evaluating, nor are we contemplating plans to do so. We have limited personnel with experience in drug manufacturing
and lack the resources and the capabilities to manufacture any of our product candidates on a clinical or commercial scale. We currently
rely on third parties, such as Fisher Clinical Services for drug supply and drug product manufacture of our current product candidate,
and our strategy is to continue to outsource all manufacturing of our product candidates and approved products, if any, to third parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to conduct clinical trials of our product candidates and prepare for commercialization, we will need to identify suitable manufacturers
with the capabilities to manufacture our compounds in large quantities in a manner consistent with existing regulations. Our future plans
include the identifying, qualifying, and contracting with a U.S. manufacturing site to manufacture ENV 105, assuming we have adequate
financial resources to pursue contingency manufacturing plans. Our current and future third-party manufacturers may be unable to successfully
increase the manufacturing capacity for any of our product candidates in a timely or cost-effective manner, or at all. In addition, quality
issues may arise during scale-up activities at any other time. If our manufacturers are unable to successfully scale up the manufacture
of our product candidates in sufficient quality and quantity, the development, testing, and clinical trials of that product candidate
may be delayed or infeasible, and regulatory approval or commercial launch of that product candidate may be delayed or not obtained,
which could significantly harm our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not currently have any agreements with third-party manufacturers for the long-term commercial supply of our current in-development
products or any of our future product candidates. In the future, we may be unable to enter into agreements with third-party manufacturers
for commercial supplies of such product candidates or may be unable to do so on acceptable terms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if we are able to establish and maintain arrangements with third-party manufacturers, reliance on third-party manufacturers entails risks,
including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reliance
                                            on the third party for regulatory compliance and quality assurance;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            possible breach of the manufacturing agreement by the third party;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            possible misappropriation of our proprietary information, including our trade secrets and
                                            know-how; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            possible termination or nonrenewal of the agreement by the third party at a time that is
                                            costly or inconvenient for us.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third-party
manufacturers may not be able to comply with current Good Manufacturing Practice, or cGMP, regulations or similar regulatory requirements
outside the United States. Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could
result in sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspension, or withdrawal of approvals,
license revocation, seizures, or recalls of product candidates or products, operating restrictions, and criminal prosecutions, any of
which could significantly and adversely affect supplies of our product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
current in-development products and our future products and product candidates may compete with other product candidates and products
for access to manufacturing facilities. There are a limited number of manufacturers that operate under cGMP regulations and that might
be capable of manufacturing for us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the third parties that we engage to supply any materials or manufacture product for our preclinical and nonclinical studies and clinical
trials should cease to continue to do so for any reason, we likely would experience delays in advancing these studies and trials while
we identify and qualify replacement suppliers, and we may be unable to obtain replacement supplies on terms that are favorable to us.
In addition, if we are not able to obtain adequate supplies of our current in-development products or any future product candidates or
the substances used to manufacture them, it will be more difficult for us to develop such product candidates and compete effectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
current and anticipated future dependence upon others for the manufacture of our product candidates may adversely affect our future profit
margins and our ability to develop product candidates and commercialize any products that receive marketing approval on a timely and
competitive basis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
intend to&nbsp;continue to&nbsp;rely on third parties to conduct, supervise and monitor our clinical trials. If those third parties do
not successfully carry out their contractual duties, or if they perform in an unsatisfactory manner, it may harm our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
rely, and will continue to rely, on CROs, CRO-contracted vendors and clinical trial sites to ensure the proper and timely conduct of
our clinical trials, including our Phase 2 trials. Our reliance on CROs for clinical development activities limits our control over these
activities, but we remain responsible for ensuring that each of our trials is conducted in accordance with the applicable protocol and
legal, regulatory and scientific standards.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0; background-color: white"></P>

<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
and our CROs will be required to comply with the good laboratory practice requirements for our preclinical studies and GCP requirements
for our clinical trials, which are regulations and guidelines enforced by the FDA and are also required by comparable foreign regulatory
authorities. Regulatory authorities enforce GCP requirements through periodic inspections of trial sponsors, principal investigators
and clinical trial sites. If we or our CROs fail to comply with GCP requirements, the clinical data generated in our clinical trials
may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials
before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory
authority will determine that any of our clinical trials comply with GCP requirements. In addition, our clinical trials must be conducted
with product produced under cGMP requirements. Accordingly, if our CROs fail to comply with these requirements, we may be required to
repeat clinical trials, which would delay the regulatory approval process.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
CROs are not our employees, and we do not control whether or not they devote sufficient time and resources to our clinical trials. Our
CROs may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical
trials, or other drug development activities, which could harm our competitive position. We face the risk of potential unauthorized disclosure
or misappropriation of our intellectual property by CROs, which may reduce our trade secret protection and allow our potential competitors
to access and exploit our proprietary technology. If our CROs do not successfully carry out their contractual duties or obligations,
fail to meet expected deadlines, or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to
adhere to our clinical protocols or regulatory requirements or for any other reason, our clinical trials may be extended, delayed or
terminated, and we may not be able to obtain regulatory approval for, or successfully commercialize any product candidate that we develop.
As a result, our financial results and the commercial prospects for any product candidate that we develop would be harmed, our costs
could increase, and our ability to generate revenue could be delayed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
our relationship with any CROs terminates, we may not be able to enter into arrangements with alternative CROs or do so on commercially
reasonable terms. Switching or adding additional CROs involves substantial cost and requires management&rsquo;s time and focus. In addition,
there is a natural transition period when a new CRO commences work. As a result, delays occur, which can materially impact our ability
to meet our desired clinical development timelines. Though we intend to carefully manage our relationships with our CROs, there can be
no assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not have an adverse
impact on our business, financial condition and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
number and type of our collaborations could adversely affect our attractiveness to future collaborators or acquirers and the loss of,
or a disruption in our relationship with, any one or more collaborators could harm our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any collaborations do not result in the successful development and commercialization of products or if one of our collaborators terminates
its agreement with us, we may not receive any future research and development funding or milestone or royalty payments under such collaborations.
If we do not receive the funding we expect under these agreements, our continued development of our product candidates could be delayed,
and we may need additional resources to develop additional product candidates. All of the risks relating to product development, regulatory
approval and commercialization described in this prospectus also apply to the activities of any collaborators and there can be no assurance
that our collaborations will produce positive results or successful products on a timely basis or at all.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, subject to its contractual obligations to us, if one of our collaborators is involved in a business combination or otherwise
changes its business priorities, the collaborator might deemphasize or terminate the development or commercialization of our product
candidates. If a collaborator terminates its agreement with us, we may find it more difficult to attract new collaborators and the perception
of our business and our stock price could be adversely affected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may in the future collaborate with additional pharmaceutical and biotechnology companies for development and potential commercialization
of therapeutic products. We face significant competition in seeking appropriate collaborators. Our ability to reach a definitive agreement
for a collaboration will depend, among other things, upon our assessment of the collaborator&rsquo;s resources and expertise, the terms
and conditions of the proposed collaboration and the proposed collaborator&rsquo;s evaluation of a number of factors. If we are unable
to reach agreements with suitable collaborators on a timely basis, on acceptable terms, or at all, we may have to curtail the development
of a product candidate, reduce or delay its development program or one or more of our other development programs, delay its potential
commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or
commercialization activities at our own expense. If we elect to fund and undertake development or commercialization activities on our
own, we may need to obtain additional expertise and additional capital, which may not be available to us on acceptable terms or at all.
If we fail to enter into collaborations and do not have sufficient funds or expertise to undertake the necessary development and commercialization
activities, we may not be able to further develop our product candidates or bring them to market or continue to develop our programs,
and our business may be materially and adversely affected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
are relying exclusively on the skills and expertise of our management team in conducting our business, not all of whom will devote all
of their time to managing the Company, and we currently have no full-time employees,  which may impede our ability to carry on
our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are relying exclusively on the skills and expertise of our management team in conducting our business. Not all of our management
team presently devotes all of their time to managing the Company. Although upon the effectiveness of this registration statement,
our Chief Financial Officer will serve on a full-time basis, we presently have no full-time employees, which may impede our ability
to carry on our business. The lack of full-time employees among our officers may very well prevent the Company&rsquo;s operations from
being efficient, and may impair the business progress and growth, which is a risk to any investor. Our lack of full-time management may
be an impediment to our business development. Without full-time officers, we may not have sufficient devoted time and effort to
our commercialization efforts, or efforts to find and raise additional capital, or manage our business, which could impair our ability
to succeed in our business plan and could cause investment in our Company to lose value.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
operate with a small team and our future success depends on our ability to retain key executives and to attract, retain, and motivate
qualified personnel.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
future success depends on our ability to retain our key officers and employees and to attract, retain and motivate highly qualified management
and scientific personnel.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently have limited personnel. As of April 30, 2024, we had three part-time employees, including our Chief
Executive officer, and our Chief Financial Officer is a part-time contractor. Upon the effectiveness of this registration statement,
our Chief Financial Officer will serve on a full-time basis. We are highly dependent on the management, research and development, clinical,
financial, and business development expertise of Dr. Yu and Dr. Bhowmick. Each of them may currently terminate their employment with
us at any time and will continue to be able to do so after the completion of this offering. We do not maintain &ldquo;key person&rdquo;
insurance for any of our executives or employees.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will need to attract, hire and retain qualified officers and employees to achieve the Company&rsquo;s objectives. Recruiting and retaining
qualified scientific personnel and sales and marketing personnel will be critical to our success. We may not be able to attract and retain
these personnel on acceptable terms given the competition among pharmaceutical, biotechnology and diagnostic companies for similar personnel.
Furthermore, current officers or employees may decide to leave the Company, and current or former officers or employees may decide to
sue the Company for owed but unpaid compensation. The loss of any of these persons&rsquo; expertise would be difficult to replace and
could have a material adverse effect on our ability to achieve our business goals.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
limited personnel and resources may result in greater workloads for our employees compared to those at companies with which we compete
for personnel, which may lead to higher levels of employee dissatisfaction and turnover. Recruiting and retaining qualified research,
development, and business personnel and, if we progress the development of any of our current in-development products or any future product
candidates, commercialization, manufacturing, and sales and marketing personnel, will be critical to our success. The loss of the services
of our executive officers or other key employees could impede the achievement of our research, development and commercialization objectives
and seriously harm our ability to successfully implement our business strategy. Furthermore, replacing executive officers and key employees
may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth
of skills and experience required to successfully develop, gain regulatory approval of and commercialize our product candidates. Competition
to hire from this limited pool is intense, and we may be unable to hire, train, retain, or motivate these key personnel on acceptable
terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition
for the hiring of research and development personnel from universities and research institutions. In addition, we rely on consultants
and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization
strategy. Our consultants and advisors may have commitments under consulting or advisory contracts with other entities that may limit
their availability to us. If we are unable to continue to attract and retain high-quality personnel, our ability to pursue our growth
strategy will be limited.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
face substantial competition from large, well-funded, and experienced competitors, which may result in others discovering, developing
or commercializing products before or more successfully than we do.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
pharmaceutical and biotechnology industries are characterized by rapidly advancing technologies, intense competition, and a strong emphasis
on proprietary products. The immuno-oncology segment of the industry is in particular highly competitive. We face potential competition
from many different sources, including major pharmaceutical, specialty pharmaceutical, and biotechnology companies, academic institutions
and governmental agencies, and public and private research institutions. Regardless of the degree of success in development of our technology,
the Company faces competition from much larger enterprises and different technologies, disadvantages inherent in attempting to negotiate
licensing or other transactions with companies with vastly larger financial, scientific and other resources, lack of management experienced
in commercial business operations, reliance on contract laboratories and other third party service providers, lack of financial and other
resources, challenges to the validity of intellectual property, potential product liabilities, and regulatory risks including product
and reimbursement permits and regulations. Many of our competitors and potential competitors have substantially greater financial, technological,
managerial and research and development resources and experience than we do. We are aware of other products under development, which,
if successfully developed and commercialized, would compete with our products. We may be unable to keep pace with the rapid technological
changes in the biotechnology/medical device industry and as a result, our technologies may become obsolete. Smaller or early-stage companies
may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
commercial opportunity could be reduced or eliminated if our competitors develop and commercialize medicines that are safer, are more
effective, have fewer or less severe side effects, are more convenient or are less expensive than any medicines we may develop. Our competitors
also may obtain FDA or other regulatory approval for their medicines more rapidly than we may obtain approval for ours, which could result
in our competitors establishing a strong market position before we are able to enter the market. In addition, our ability to compete
may be affected in many cases by insurers or other third-party payors seeking to encourage the use of generic medicines.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
business could be adversely affected by the effects of health epidemics, including the ongoing COVID-19 pandemic.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business could be adversely affected by health epidemics, including the COVID-19 pandemic, in regions where we or third parties on which
we rely have manufacturing facilities, concentrations of potential clinical trial sites or other business operations. We continue to evaluate
our protocols and practices as the global response to the COVID-19 pandemic continues to evolve. There can be no assurance that we will
be able to avoid part or all of any impact from the spread of COVID-19 or its consequences.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, our current preclinical and nonclinical studies and current and future clinical trial plans may be affected by the COVID-19
pandemic. Site initiation and patient enrollment may be delayed due to prioritization of hospital resources toward the COVID-19 pandemic,
which may delay enrollment in our future global clinical trials, and some patients may not be able to comply with clinical trial protocols
if quarantines impede patient movement or interrupt healthcare services. Further, some of our suppliers may experience disruption to
their respective supply chain due to the effects of health epidemics, including the COVID-19 pandemic, which could delay, prevent, or
impair our development or commercialization efforts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ultimate impact of the COVID-19 pandemic or a similar health epidemic is highly uncertain and subject to change. Several measures are
currently being implemented by the United States and other governments to address the current COVID-19 pandemic and its economic impacts.
At this time, it is impossible to predict the impact of these measures and whether or not they will have unforeseen negative consequences
for our business. We do not yet know the full extent of potential delays or impacts on our business, our planned preclinical studies
or clinical trials, healthcare systems or the global economy as a whole; nor do we know when and how such regulations may be eased. The
foregoing and other continued disruptions to our business as a result of COVID-19 could result in an adverse effect on our business,
results of operations, financial condition and cash flows. Furthermore, the COVID-19 pandemic could heighten the risks in certain of
the other risk factors described herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
have identified material weaknesses in our internal control over financial reporting. If we are unable to remediate these material weaknesses,
or if we identify additional material weaknesses in the future or otherwise fail to maintain effective internal control over financial
reporting, we may not be able to accurately or timely report our financial condition or results of operations, which may adversely affect
our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to the completion of this offering, we have been a private company with limited accounting personnel to adequately execute our accounting
processes and other supervisory resources with which to address our internal control over financial reporting. In connection with the
preparation of our financial statements, we identified material weaknesses in our internal control over financial reporting. A material
weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable
possibility that a material misstatement of the annual or interim financial statements will not be prevented or detected on a timely
basis. The material weaknesses are as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    did not design and maintain an effective control environment commensurate with our financial reporting requirements. Specifically,
    we lacked a sufficient complement of resources with (i) an appropriate level of accounting knowledge, experience and training to
    appropriately analyze, record and disclose accounting matters timely and accurately, and (ii) an appropriate level of knowledge and
    experience to establish effective processes and controls. Additionally, the lack of a sufficient number of professionals resulted
    in an inability to consistently establish appropriate authorities and responsibilities in pursuit of our financial reporting objectives,
    as demonstrated by, among other things, insufficient segregation of duties in our finance and accounting functions. This material
    weakness contributed to the following additional material weaknesses.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    did not design and maintain effective controls related to the period-end financial reporting process, including designing and maintaining
    formal accounting policies, procedures and controls to achieve complete, accurate and timely financial accounting, reporting and
    disclosures. Additionally, we did not design and maintain controls over the preparation and review of account reconciliations and
    journal entries, including maintaining appropriate segregation of duties.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    did not design and maintain effective controls related to the accounting for certain non-routine or complex transactions, including
    the proper application of U.S. GAAP to such transactions.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
    these material weaknesses could result in a misstatement of substantially all of our accounts or disclosures that would result in
    a material misstatement to the annual or interim financial statements that would not be prevented or detected.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    did not design and maintain effective controls over information technology, or IT, general controls for information systems that
    are relevant to the preparation of our financial statements. Specifically, we did not design and maintain (i) program change management
    controls to ensure that information technology program and data changes affecting financial IT applications and underlying accounting
    records are identified, tested, authorized and implemented appropriately, (ii) user access controls to ensure appropriate segregation
    of duties and that adequately restrict user and privileged access to financial applications, programs, and data to appropriate Company
    personnel, (iii) computer operations controls to ensure that critical batch jobs are monitored and data backups are authorized and
    monitored, and (iv) testing and approval controls for program development to ensure that new software development is aligned with
    business and IT requirements.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
IT deficiencies did not result in adjustments to the financial statements. However, the IT deficiencies, when aggregated, could impact
maintaining effective segregation of duties, as well as the effectiveness of IT-dependent controls (such as automated controls that address
the risk of material misstatement to one or more assertions, along with the IT controls and underlying data that support the effectiveness
of system-generated data and reports) that could result in misstatements potentially impacting all financial statement accounts and disclosures
that would not be prevented or detected. Accordingly, management has determined the IT deficiencies in the aggregate constitute a material
weakness.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
address our material weaknesses, we are in the process of implementing measures designed to improve our internal control over financial
reporting and remediate the control deficiencies that led to the material weaknesses. These measures include (i) the ongoing hiring of
additional accounting personnel; (ii), initiating design and implementation of our financial control environment, including the establishment
of formal accounting policies and procedures, financial reporting controls and controls to account for and disclose complex transactions;
and (iii) initiating and designing IT controls to insure appropriate and restricted access to our accounting applications, programs,
and data.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are working to remediate the material weaknesses as efficiently and effectively as possible. We cannot assure you that there will not
be future material weaknesses in our internal control over financial reporting in the future. Any failure to maintain internal control
over financial reporting could severely inhibit our ability to accurately report our financial condition, results of operations, or cash
flows. If we fail to remediate our identified material weaknesses, or identify additional material weaknesses, in our internal control
over financial reporting investors may lose confidence in the accuracy and completeness of our financial reports, the market price of
our common stock could decline, and we could be subject to sanctions or investigations by the exchange we are listed on, the NYSE
American, the Securities and Exchange Commission, or SEC, or other regulatory authorities. Failure to remedy any material weakness
in our internal control over financial reporting, or to implement or maintain other effective control systems required of public companies,
could also restrict our future access to the capital markets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 38; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
expect to expand our research, development, and business capabilities and potentially implement sales, marketing, and distribution capabilities,
and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
the clinical development of our current in-development products and any of our future product candidates progresses, we also expect to
experience significant growth in the number of our employees and the scope of our operations, particularly in the areas of research,
drug development, regulatory affairs and, if any of our current in-development products or any future product candidate receives marketing
approval, sales, marketing, and distribution. To manage our anticipated future growth, we must continue to implement and improve our
managerial, operational, and financial systems, expand our facilities, and continue to recruit and train additional qualified personnel.
Due to our limited financial resources and the limited experience of our management team in managing a company with such anticipated
growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel.
The expansion of our operations may lead to significant costs and may divert our management and research and development resources. Any
inability to manage growth could delay the execution of our business plans or disrupt our operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we engage in future acquisitions or strategic collaborations, this may increase our capital requirements, dilute our stockholders, cause
us to incur debt or assume contingent liabilities, and subject us to other risks.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, we may evaluate various acquisitions and strategic collaborations, including licensing or acquiring complementary drug
products, intellectual property rights, technologies, or businesses, as deemed appropriate to carry out our business plan. Any potential
acquisition or strategic collaboration may entail numerous risks, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">increased
    operating expenses and cash requirements;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    assumption of additional indebtedness or contingent liabilities;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">assimilation
    of operations, intellectual property, and drug products of an acquired company, including difficulties associated with integrating
    new personnel;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    diversion of our management&rsquo;s attention from our existing drug programs and initiatives in pursuing such a strategic partnership,
    merger, or acquisition;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">retention
    of key employees, the loss of key personnel and uncertainties in our ability to maintain key business relationships;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">risks
    and uncertainties associated with the other party to such a transaction, including the prospects of that party and their existing
    drugs or drug candidates and regulatory approvals; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    inability to generate revenue from acquired technology and/or drugs sufficient to meet our objectives in undertaking the acquisition
    or even to offset the associated acquisition and maintenance costs.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to Our Intellectual Property</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
exclusive licensing rights to our intellectual property are subject to agreements with third parties and we may not meet milestones set
forth in those agreements; our exclusive licensing rights may be terminated; these third-party licensors also own equity with certain
anti-dilution and participation rights.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
agreements with Cedars-Sinai Medical Center and Tracon Pharmaceuticals, Inc. are contingent on our ability to make payments and meet
commercialization goals, which we may not be able to meet based on innumerable factors. If we do not make such payments or meet such
milestones, our exclusive licensing rights to our intellectual property may be terminated. Even if we meet certain milestones, we may
not be able to make the required payments, which may cause us to breach such agreements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Enviro-Cedars license agreements, Enviro would also issue to Cedars shares of Enviro&rsquo;s common stock equal
to, in the aggregate between the two Enviro-Cedars license agreements, 2.0% of Enviro&rsquo;s outstanding equity on a fully diluted basis.
Cedars also has certain anti-dilution protections, whereby Enviro shall issue to Cedars, without consideration, additional shares necessary
to ensure that Cedars maintains at least 2.0% of the equity issued and outstanding on a fully diluted basis until the earlier of (i)
Enviro&rsquo;s initial public offering or (ii) Enviro having raised at least $20,000,000 in capital. Cedars shall also have a right to
participate in any private offering of Enviro&rsquo;s equity securities and purchase for cash that number of securities issued to maintain
Cedars&rsquo; pro rata ownership in Enviro on a fully diluted basis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant a license and supply agreement between Enviro and Tracon Pharmaceuticals,
Inc., Enviro issued Tracon equity ownership in Enviro equal to a number of shares of restricted common stock of Enviro equal to 7% on
a fully diluted and converted basis of all common and preferred shares of Enviro. Until such time as Tracon has received all of the Cash
Consideration (as defined in the Enviro-Tracon license agreement), Enviro or its successor in interest, shall issue to Tracon, without
further consideration, any additional common stock of Enviro, or such successor in interest, necessary so that Tracon maintains ownership
of shares of Enviro, or such successor in interest, equal to 7% on a fully diluted and converted basis of all common and preferred shares
of Enviro (or its successor). Cash Consideration under the Enviro-Tracon license agreement consists of an upfront fee of $100,000, an
additional $500,000 upon it&rsquo;s or its successor&rsquo;s completion of one or more financings through the sale of equity (or debt
convertible to equity) in an amount of $10,000,000, and an additional $500,000 within 10 days of it&rsquo;s or its successor&rsquo;s completion
of one or more financings through the sale of equity (or debt convertible to equity) in an amount of $22,000,000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 39; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the Company is not able to raise funds sufficient to terminate these anti-dilution rights granted to Cedars and Tracon, then investors
in the Company&rsquo;s securities could experience severe dilution in proportion to Cedars and Tracon. The presence of these anti-dilution
rights granted to Cedars and Tracon may also discourage third-party investors from investing in the Company&rsquo;s securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we are unable to obtain and maintain patent and other intellectual property protection for our technology, or for any our current in-development
products or our future product candidates, or if the scope of the patent and other intellectual property protection obtained is not sufficiently
broad, our competitors could develop and commercialize technology and drugs similar or identical to ours, and our ability to successfully
commercialize our technology and product candidates may be impaired.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not own any issued patents and we in-license patents and patent applications for ENV 105, our lead drug compounds, and our
success depends in large part on our ability to obtain and maintain patent protection in the United States and other countries with respect
to ENV 105 and any of our future product candidates. We seek to protect our proprietary position by in-licensing intellectual
property relating to our product candidates including patent applications in the United States and abroad related to our technology and
product candidates that are important to our business. If we or our licensors do not adequately protect the intellectual property, we
in-license or own, competitors may be able to use our technologies and erode or negate any competitive advantage that we may have, which
could harm our business and ability to achieve profitability. To protect our proprietary positions, we and our licensors file patent
applications in the United States and abroad related to our novel technologies and product candidates that are important to our business.
The patent application and prosecution process is expensive and time-consuming. We and our current licensors and licensees, or any future
licensors and licensees may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or
in a timely manner. We or our current licensors and licensees, or any future licensors or licensees may also fail to identify patentable
aspects of our research and development before it is too late to obtain patent protection or fail to continue to prosecute patents relating
to our product candidates. Therefore, these and any of our in-licensed patents and patent applications may not be prosecuted and enforced
in a manner consistent with the best interests of our business. It is possible that defects of form in the preparation or filing of our
licensors&rsquo; patents or our patent applications may exist, or may arise in the future, such as with respect to proper priority claims,
inventorship, claim scope, or patent term adjustments. If our current licensors and licensees, or any future licensors or licensees,
are not fully cooperative or disagree with us as to the prosecution, maintenance or enforcement of any patent rights, such patent rights
could be compromised and we might not be able to prevent third parties from making, using, and selling competing products. We cannot
predict whether the patent applications we and our licensors or licensees are currently pursuing will issue as patents in any particular
jurisdiction or whether the claims of any issued patents will provide sufficient protection from competitors. If there are material defects
in the form or preparation of our or our licensors&rsquo; patents or patent applications, such patents or applications may be invalid
and unenforceable. Moreover, our competitors may independently develop equivalent knowledge, methods, and know-how and we may not be
able to prevent such competitors from commercializing such equivalent knowledge, methods, and know-how. Any of these outcomes could impair
our ability to prevent competition from third parties and could have a material adverse effect on our business, financial condition,
results of operations, or prospects. The patent position of biotechnology and pharmaceutical companies generally is highly uncertain
and has been the subject of much litigation in recent years. Changes in either the patent laws or interpretation of the patent laws in
the United States and other countries may diminish the value of our patents or narrow the scope of our patent protection. In addition,
the laws of foreign countries may not protect our rights to the same extent as the laws of the United States. No consistent policy regarding
the breadth of claims allowed in biotechnology and pharmaceutical patents has emerged to date in the United States or in many foreign
jurisdictions. In addition, the determination of patent rights with respect to pharmaceutical compounds and technologies commonly involves
complex legal and factual questions, which has in recent years been the subject of much litigation. As a result, the issuance, scope,
validity, enforceability, and commercial value of our patent rights are highly uncertain. Furthermore, recent changes in patent laws
in the United States, including the America Invents Act of 2011, and future changes in patent laws in or outside the United States may
affect the scope, strength, and enforceability of our patent rights or the nature of proceedings that may be brought by us related to
our patent rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may not be aware of all third-party intellectual property rights potentially relating to our current in-development products or our future
product candidates. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications
in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore,
we cannot be certain that we or our licensors were the first to make the inventions claimed in patents or pending patent applications
that we in-license or own, or that we or our licensors were the first to file for patent protection of such inventions. As a result,
the issuance, scope, validity, and commercial value of our patent rights cannot be predicted with any certainty. Moreover, we or our
licensors may be subject to a third-party pre-issuance submission of prior art to the U.S. Patent and Trademark Office, or USPTO, or
become involved in opposition, derivation, reexamination, <I>inter partes</I> review, or interference proceedings, in the United States
or elsewhere, challenging our patent rights or the patent rights of others. An adverse determination in any such submission, proceeding,
or litigation could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our technology or product
candidates, and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize product candidates
without infringing third-party patent rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 40; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
licensors&rsquo; pending and future patent applications and our own pending and future patent applications may not result in patents
being issued that protect our technology or product candidates, in whole or in part, or which effectively prevent others from commercializing
competitive technologies and products. Even if our or our licensors&rsquo; patent applications issue as patents, they may not issue in
a form that will provide us with any meaningful protection against competing products or processes sufficient to achieve our business
objectives, prevent competitors from competing with us or otherwise provide us with any competitive advantage. Our competitors may be
able to circumvent our in-licensed patents or any patents we may own in the future by developing similar or alternative technologies
or products in a non-infringing manner. Our competitors may seek to market generic versions of any approved products by submitting abbreviated
NDAs to the FDA in which they claim that patents licensed by us or may be owned by us in the future are invalid, unenforceable, and/or
not infringed. Alternatively, our competitors may seek approval to market their own products similar to or otherwise competitive with
our product candidates. In these circumstances, we may need to defend and/or assert our in-licensed or owned patents, including by filing
lawsuits alleging patent infringement. In any of these types of proceedings, a court, or other agency with jurisdiction may find our
in-licensed patents or any owned patents, should such patents issue in the future, invalid and/or unenforceable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
issuance of a patent is not conclusive as to its inventorship, scope, validity, or enforceability, and our in-licensed patents or patents
we may own in the future may be challenged in the courts or patent offices in the United States and abroad. Such challenges may result
in loss of exclusivity or freedom to operate or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part,
which could limit our ability to stop others from using or commercializing similar or identical technology and product candidates, or
limit the duration of the patent protection of our technology and product candidates. In addition, given the amount of time required
for the development, testing, and regulatory review of new product candidates, patents protecting such candidates might expire before
or shortly after such candidates are commercialized. Any impairment of our intellectual property rights, or our failure to protect our
intellectual property rights adequately, could give third parties access to our technology and product candidates and could materially
and adversely impact our business, financial condition, results of operations, and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
rights to develop and commercialize our technology, our current in-development products, and our other future product candidates are
subject, in large part, to the terms and conditions of licenses granted to us by others, such as Cedars-Sinai Medical Center and Tracon
Pharmaceuticals, Inc. If we fail to comply with our obligations in the agreements under which we in-license or acquire development or
commercialization rights to products, technology, or data from third parties, we could lose such rights that are important to our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are heavily reliant upon licenses to certain patent rights and other intellectual property that are important or necessary to the development
of our current in-development products or our future product candidates. For example, we depend on license agreements from Cedars-Sinai
Medical Center and Tracon Pharmaceuticals, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cedars-Sinai
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">and Tracon have relied upon, and any future licensors
may have relied upon, third-party companies, consultants or collaborators, or on funds from third parties such that our licensors are
not the sole and exclusive owners of the patents we in-licensed. We have sublicensed certain patents from Cedars-Sinai and Tracon.
If third-party institutions such as Cedars-Sinai or Tracon fail to prosecute, maintain, enforce, and defend such patents,
or lose rights to those patents, the rights we have licensed may be reduced or eliminated, and our right to develop and commercialize
our current in-development products or our other future product candidates that are the subject of such licensed rights could be adversely
affected. Further development and commercialization of ENV 105, and development of any future product candidates may, require
us to enter into additional license or collaboration agreements. For example, our licensors or other third parties may develop intellectual
property covering ENV 105 which we have not licensed. Our future licenses may not provide us with exclusive rights
to use the licensed patent rights and other intellectual property or may not provide us with exclusive rights to use such patent rights
and intellectual property in all relevant fields of use and in all territories in which we wish to develop or commercialize our current
in-development products or our future product candidates in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
license agreements with Cedars-Sinai and Tracon, and other intellectual property-related agreements we may enter into in the
future may impose diligence and other obligations, including payment of milestones and royalties. For example, our license
agreement from Cedars requires us to satisfy diligence requirements, including using commercially reasonable efforts to
develop and commercialize products. If we fail to comply with our obligations to our present or future licensors, those
counterparties may have the right to terminate the license agreements, in which event we might not be able to develop, manufacture,
or market any product candidate licensed under the agreements, which could materially adversely affect the value of the product
candidate being developed under any such agreement and further involve termination of our rights to important intellectual property
or technology.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
spite of our efforts, Cedars-Sinai, Tracon or any future licensors might conclude that we are in material breach of obligations under
our license agreements and may therefore have the right to terminate the license agreements, thereby removing our ability to develop
and commercialize product candidates and technology covered by such license agreements. If such in-licenses are terminated, or if the
underlying patents fail to provide the intended exclusivity, our competitors would have the freedom to seek regulatory approval of, and
to market, products identical to our product candidates and the licensors to such in-licenses could prevent us from commercializing product
candidates that rely upon the patents or other intellectual property rights which were the subject matter of such terminated agreements.
In addition, we may seek to obtain additional licenses from our licensors and, in connection with obtaining such licenses, we may agree
to amend our existing licenses in a manner that may be more favorable to the licensors, including by agreeing to terms that could enable
third parties (potentially including our competitors) to receive licenses to a portion of the intellectual property that is subject to
our existing licenses. Any of these events could have a material adverse effect on our business, financial condition, results of operations,
and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 41; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
our license agreements with Cedars-Sinai and Tracon, and any future license agreements, disputes may arise regarding intellectual property
subject to a licensing agreement, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    scope of rights granted under the license agreement and other interpretation-related issues;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing
    agreement;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    sublicensing of patent and other rights under our collaborative development relationships;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    diligence obligations under the license agreement and what activities satisfy those diligence obligations;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors
    and us and our partners; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    priority of invention of patented technology.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the license agreements involving intellectual property or technology from third parties are complex, and certain provisions
in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may
arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology or increase what
we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect
on our business, financial condition, results of operations, and prospects. Moreover, if disputes over intellectual property that we
have licensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, we may be
unable to successfully develop and commercialize the affected product candidates, which could have a material adverse effect on our business,
financial condition, results of operations and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may not be successful in obtaining necessary rights to any product candidates we may develop through acquisitions and in-licenses.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently have rights to intellectual property, through licenses from third parties, to identify and develop product candidates. We may
find it necessary or prudent to obtain licenses from such third-party intellectual property holders in order to avoid infringing these
third-party patents. For example, many pharmaceutical companies, biotechnology companies, and academic institutions compete with us and
may be filing patent applications potentially relevant to our business. The licensing or acquisition of third-party intellectual property
rights is a competitive area, and several more established companies may pursue strategies to license or acquire third-party intellectual
property rights that we may consider attractive or necessary. These established companies may have a competitive advantage over us due
to their size, capital resources and greater clinical development and commercialization capabilities. In addition, companies that perceive
us to be a competitor may be unwilling to license rights to us. We also may be unable to license or acquire third-party intellectual
property rights on terms that would allow us to make an appropriate return on our investment or at all. If we are unable to successfully
obtain rights to required third-party intellectual property rights or maintain the existing intellectual property rights we have, we
may have to abandon development of the relevant program or product candidate, which could have a material adverse effect on our business,
financial condition, results of operations, and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may become involved in lawsuits to protect or enforce our owned or in-licensed patents or other intellectual property, which could be
expensive, time-consuming, and unsuccessful.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Competitors
or other third parties may infringe, misappropriate or otherwise violate our in-licensed issued patents or our other intellectual property
we may own. To counter such infringement, misappropriation, or other unauthorized use, we may be required to file infringement claims,
which can be expensive and time-consuming and divert the time and attention of our management and scientific personnel. Any claims we
assert against third parties could provoke these parties to assert counterclaims against us alleging that we infringe, misappropriate
or otherwise violate their patents, trademarks, copyrights, or other intellectual property. In addition, our in-licensed patents may
become involved in inventorship or priority disputes. Third parties may raise challenges to the validity of certain of our or our in-licensed
patent claims and may in the future raise similar claims before administrative bodies in the United States or abroad, even outside the
context of litigation. For example, we may be subject to a third-party pre-issuance submission of prior art to the USPTO, or become involved
in derivation, revocation, reexamination, post-grant review, or PGR, <I>inter partes</I> review, or IPR, interference proceedings, and
equivalent proceedings in foreign jurisdictions, such as opposition proceedings challenging any patents that we may own or in-license.
Such submissions may also be made prior to a patent&rsquo;s issuance, precluding the granting of a patent based on one of our owned or
licensed pending patent applications. A third party may also claim that our potential future owned patents or licensed patent rights
are invalid or unenforceable in a litigation. The outcome following legal assertions of invalidity and unenforceability is unpredictable.
An adverse determination in any such submission, proceeding, or litigation could reduce the scope of, invalidate, or render unenforceable,
our potential future owned patents or licensed patent rights, allow third parties to commercialize our current in-development products
or our other future product candidates and compete directly with us, without payment to us, or result in our inability to manufacture
or commercialize products without infringing third-party patent rights In a patent infringement proceeding, there is a risk that a court
will decide that a patent we in-license is invalid or unenforceable, in whole or in part, and that we do not have the right to stop the
other party from using the invention at issue. There is also a risk that, even if the validity of such patents are upheld, the court
will construe the patent&rsquo;s claims narrowly or decide that we do not have the right to stop the other party from using the invention
at issue on the grounds that our in-licensed patents do not cover the invention. An adverse outcome in a litigation or proceeding involving
our in-licensed patents could limit our ability to assert our in-licensed patents against those parties or other competitors and may
curtail or preclude our ability to exclude third parties from making and selling similar or competitive products. Similarly, in the future,
we expect to rely on trademarks to distinguish our current in-development products and any of our other future product candidates that
are approved for marketing, and if we assert trademark infringement claims, a court may determine that the marks we have asserted are
invalid or unenforceable, or that the party against whom we have asserted trademark infringement has superior rights to the marks in
question. In this case, we could ultimately be forced to cease use of such trademarks.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 42; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
any infringement litigation, any award of monetary damages we receive may not be commercially valuable. Furthermore, because of the substantial
amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information
could be compromised by disclosure during litigation. In addition, there could be public announcements of the results of hearings, motions,
or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could
have a substantial adverse effect on the price of our common stock. Moreover, there can be no assurance that we will have sufficient
financial or other resources to adequately file and pursue such infringement claims, which typically last for years before they are concluded.
Some of our competitors and other third parties may be able to sustain the costs of such litigation or proceedings more effectively than
we can because of their greater financial resources and more mature and developed intellectual property portfolios. Even if we ultimately
prevail in such claims, the monetary cost of such litigation and the diversion of the attention of our management and scientific personnel
could outweigh any benefit we receive as a result of the proceedings. Accordingly, despite our efforts, we may not be able to prevent
third parties from infringing, misappropriating, or successfully challenging our intellectual property rights. Uncertainties resulting
from the initiation and continuation of patent litigation or other proceedings could have a negative impact on our ability to compete
in the marketplace, which could have a material adverse effect on our business, financial condition, results of operations, and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Third
parties may initiate legal proceedings alleging that we are infringing misappropriating, or otherwise violating their intellectual property
rights, the outcome of which would be uncertain and could significantly harm our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
commercial success depends, in part, on our ability to develop, manufacture, market, and sell our current in-development products or
other future product candidates and use our proprietary chemistry technology without infringing, misappropriating or otherwise violating
the intellectual property of third parties. Numerous third-party U.S. and non-U.S. issued patents exist in the area of cancer therapies
and other therapies our drugs are targeted to treat.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is a substantial amount of intellectual property litigation in the biotechnology and pharmaceutical industries, and we may become party
to, or threatened with, litigation, or other adversarial proceedings regarding intellectual property rights with respect to our technology
or product candidates, including interference proceedings before the USPTO. Third parties may assert claims against us based on existing
or future intellectual property rights. The outcome of intellectual property litigation is subject to uncertainties that cannot be adequately
quantified in advance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are found to have infringed, misappropriated, or otherwise violated any third party&rsquo;s intellectual property rights, we could
be forced, including by court order, to cease developing, manufacturing, or commercializing our current in-development products or other
future product candidates. Alternatively, we may be required to obtain a license from such third party in order to use technology and
continue developing, manufacturing or marketing product candidates that infringe or violate such third party&rsquo;s intellectual property.
However, we may not be able to obtain any such required license on commercially reasonable terms or at all. Even if we were able to obtain
a license, it could be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. We may also be required
to pay substantial ongoing royalty or license payments, fees, or comply with other unfavorable terms. In addition, we could be found
liable for monetary damages, including treble damages and attorneys&rsquo; fees if we are found to have willfully infringed a patent
or other intellectual property right. A finding of infringement could prevent us from commercializing our current in-development products
or other future product candidates or force us to cease some of our business operations. Claims that we have misappropriated the confidential
information or trade secrets of third parties could have a similar negative effect on our business. Even if we were to prevail in such
a dispute, any litigation regarding our intellectual property could be costly and time-consuming and divert the attention of our management
and key personnel from our business operations. Furthermore, because of the substantial amount of discovery required in connection with
intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during
this type of litigation. During the court of litigation, there could be public announcements or the results of hearings, motions, or
other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a
substantial adverse effect on the price of our common stock. Negative publicity related to a decision by us to initiate such enforcement
actions against a customer or former customer, regardless of its accuracy, may adversely impact our other customer relationships or prospective
customer relationships, harm our brand and business and could cause the market price of our common stock to decline. Any of the foregoing
arising from uncertainty in legal proceedings could materially and adversely impact our business, financial condition, results of operations,
and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 43; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may be subject to claims by third parties asserting that we or our employees, consultants, and advisors have misappropriated their intellectual
property or claiming ownership of what we regard as our own intellectual property.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
of our employees, consultants, and advisors were previously employed at universities or other biotechnology or pharmaceutical companies,
including our competitors or potential competitors. Although we try to ensure that our employees, consultants, and advisors do not use
the proprietary information or know-how of third parties in their work for us, we may be subject to claims that we or such employees,
consultants, and advisors have inadvertently or otherwise used or disclosed intellectual property, including trade secrets or other proprietary
information, of any such individual&rsquo;s former employer. We may also in the future be subject to claims that we have caused an employee
to breach the terms of his or her non-competition or non-solicitation agreement. Litigation may be necessary to defend against these
potential claims.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, while it is our policy to require our employees and contractors who may be involved in the development of intellectual property
to execute agreements assigning such intellectual property to us, such employees and contractors may breach the agreement and claim the
developed intellectual property as their own. Further, we may be unsuccessful in executing such agreements with each party who, in fact,
conceives, or develops intellectual property that we regard as our own. The assignment of intellectual property rights may not be self-executing
and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership
of what we regard as our intellectual property.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we fail in prosecuting or defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property
rights or personnel. A court could prohibit us from using technologies or features that are essential to our current in-development products
or other future product candidates if such technologies or features are found to incorporate or be derived from the trade secrets or
other proprietary information of the former employers. Even if we are successful in prosecuting or defending against such claims, litigation
could result in substantial costs and could be a distraction to management. In addition, any litigation or threat thereof may adversely
affect our ability to hire employees or contract with independent service providers. Moreover, a loss of key personnel or their work
product could hamper or prevent our ability to commercialize our product candidates. Any of the foregoing could have a material adverse
impact on our business, financial condition, results of operations, and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Changes
in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our products.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
is the case with other pharmaceutical companies, our success is heavily dependent on our intellectual property rights, and particularly
on our in-licensed patent rights. Obtaining and enforcing patents in the pharmaceutical industry involves both technological and legal
complexity, and is therefore costly, time consuming and inherently uncertain. In addition, the U.S. has recently enacted and is currently
implementing wide-ranging patent reform legislation. Certain U.S. Supreme Court rulings have narrowed the scope of patent protection
available in certain circumstances and weakened the rights of patent owners in certain situations. In addition to increasing uncertainty
with regard to our ability to obtain rights to patents in the future, this combination of events has created uncertainty with respect
to the value of patents once rights are obtained. Depending on decisions by the U.S. Congress, the federal courts and the USPTO, the
laws and regulations governing patents could change in unpredictable ways that could further negatively impact the value of patent rights,
narrow the scope of available patent protection or weaken the rights of patent owners.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Any
trademarks we may obtain may be infringed or successfully challenged, resulting in harm to our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect to rely on trademarks as one means to distinguish any of our product candidates that are approved for marketing from the products
of our competitors. We have not yet selected trademarks for our product candidates and have not yet begun the process of applying to
register trademarks for our product candidates. Once we select trademarks and apply to register them, our trademark applications may
not be approved. Third parties who have prior rights to our trademarks or third parties who have prior rights to similar trademarks may
oppose our trademark applications, or otherwise challenge our use of the trademarks. In the event that our trademarks are successfully
challenged, we could be forced to rebrand our product candidates, which could result in loss of brand recognition and could require us
to devote resources to advertising and marketing new brands. At times, competitors may adopt trade names or trademarks similar to ours,
thereby diluting or impeding our ability to build brand identity and possibly leading to market confusion. Our competitors may infringe
our trademarks and we may not have adequate resources to enforce our trademarks and may not be able to prevent such third parties from
using and marketing any such trademarks.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, any proprietary name we propose to use with our current in-development products or any future product candidate in the United
States must be approved by the FDA, regardless of whether we have registered it, or applied to register it, as a trademark. The FDA typically
conducts a review of proposed product names, including an evaluation of the potential for confusion with other product names. If the
FDA objects to any of our proposed proprietary product names, we may be required to expend significant additional resources in an effort
to identify a suitable proprietary product name that would qualify under applicable trademark laws, not infringe the existing rights
of third parties and be acceptable to the FDA. If we are unable to establish name recognition based on our trademarks, we may not be
able to compete effectively and our business, financial condition, results of operations, and prospects may be adversely affected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we are unable to protect the confidentiality of our proprietary information, know-how, and trade secrets, the value of our current in-development
products or other future product candidates could be adversely affected, and our business and competitive position would be harmed.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to seeking patent protection for our current in-development products or other future product candidates, we also rely on trade
secrets, including unpatented know-how, technology, and other proprietary information, to maintain our competitive position. We seek
to protect our trade secrets, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to
them, such as our employees, corporate collaborators, outside scientific collaborators, contract manufacturers, consultants, advisors,
and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants.
However, these agreements may be inadequate to protect our proprietary and intellectual property rights. Despite these efforts, any of
these parties may breach the agreements and disclose our proprietary information, including our trade secrets. In addition, we may not
be able to obtain adequate remedies for any such breaches. Although we use reasonable efforts to protect this proprietary information
and technology, we also cannot guarantee that we have entered into such agreements with each party that may have or have had access to
our confidential information, know-how, trade secrets, or other proprietary information or each individual who has developed intellectual
property on our behalf. Monitoring unauthorized uses and disclosures of our intellectual property is difficult, and we do not know whether
the steps we have taken to protect our intellectual property will be effective. Enforcing a claim that a party illegally disclosed or
misappropriated a trade secret is difficult, expensive, distracting to management, and time-consuming, and the outcome is unpredictable
and varied depending on the jurisdiction. In addition, some courts inside and outside the United States, in countries in which we operate
or intend to operate, are less willing, or unwilling, to protect trade secrets, know-how, and other proprietary information. Any claims
or litigation could cause us to incur significant expenses. Some third parties may be able to sustain the costs of complex litigation
more effectively than we can because they have substantially greater resources.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 44; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
employees, consultants, and other parties may unintentionally or willfully disclose our information or technology to competitors and
there can be no assurance that the legal protections and precaution taken by us will be adequate to prevent misappropriation of our technology
or that competitors will not independently develop technologies equivalent or superior to ours. Trade secrets and know-how can be difficult
to protect. Our competitors or other third parties may independently develop knowledge, methods and know-how equivalent to our trade
secrets. Additionally, competitors could purchase our product candidates and replicate some or all of the competitive advantages we derive
from our development efforts for technologies on which we do not have patent protection. If any of our trade secrets were to be lawfully
obtained or independently developed by a competitor, we would have no right to prevent them, or those to whom they communicate, from
using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed
by a competitor, our competitive position would be harmed, which could have a material adverse effect on our business, financial condition,
results of operations, and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we or our licensors do not obtain patent term extension and data exclusivity for any product candidates we or our licensors may develop,
our business may be materially harmed.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Given
the amount of time required for the development, testing, and regulatory review of new product candidates, patents we license or may
own in the future protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our
intellectual property may not provide us with sufficient rights to exclude others from commercializing products similar or identical
to our product candidates. Depending upon the timing, duration, and specifics of any FDA marketing approval of any of our product candidates,
one or more of our in-licensed U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent
Term Restoration Action of 1984, or Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent extension term of up to five
years as compensation for patent term lost during the FDA regulatory review process. A patent term extension cannot extend the remaining
term of a patent beyond a total of 14 years from the date of product approval, only one patent may be extended and only those claims
covering the approved drug, a method for using it, or a method for manufacturing it may be extended. However, we may not be granted an
extension because of, for example, failing to exercise due diligence during the testing phase or regulatory review process, failing to
apply within applicable deadlines, failing to apply prior to expiration of relevant patents, or otherwise failing to satisfy applicable
requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. If we are
unable to obtain patent term extension or term of any such extension is less than we request, our competitors may obtain approval of
competing products following our patent expiration, and our business, financial condition, results of operations, and prospects could
be materially harmed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Obtaining
and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment, and other requirements
imposed by government patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Periodic
maintenance fees, renewal fees, annuity fees, and various other government fees on patents and applications will be due to be paid to
the USPTO and various government patent agencies outside of the United States over the lifetime of our owned or in-licensed patents and
applications. In certain circumstances, we rely on our licensing partners to pay these fees due to U.S. and non-U.S. patent agencies.
The USPTO and various non-U.S. government agencies require compliance with several procedural, documentary, fee payment, and other similar
provisions during the patent application process. We are also dependent on our licensors to take the necessary action to comply with
these requirements with respect to our licensed intellectual property. In some cases, an inadvertent lapse can be cured by payment of
a late fee or by other means in accordance with the applicable rules. There are situations, however, in which non-compliance can result
in abandonment or lapse of the patent or patent application, resulting in a partial or complete loss of patent rights in the relevant
jurisdiction. In such an event, potential competitors might be able to enter the market with similar or identical products or technology,
which could have a material adverse effect on our business, financial condition, results of operations, and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may not be able to protect our intellectual property rights throughout the world.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filing,
prosecuting, and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and
our intellectual property rights in some countries outside the United States could be less extensive than those in the United States.
In some cases, we or our licensors may not be able to obtain patent protection for certain licensed technology outside the United States.
In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws
in the United States, even in jurisdictions where we or our licensors do pursue patent protection. Consequently, we may not be able to
prevent third parties from practicing our in-licensed inventions in all countries outside the United States, even in jurisdictions where
our licensors do pursue patent protection or from selling or importing products made using our inventions in and into the United States
or other jurisdictions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Competitors
may use our technologies in jurisdictions where we or our licensors have not pursued and obtained patent protection to develop their
own products and, further, may export otherwise infringing products to territories where we have patent protection, but enforcement is
not as strong as that in the United States. These products may compete with our current in-development products, our future product candidates,
and our preclinical programs. Our in-licensed patents or other intellectual property rights may not be effective or sufficient to prevent
them from competing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 45; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The
legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets,
and other intellectual property protection, particularly those relating to biotechnology products, which could make it difficult for
us to stop the infringement of our in-licensed patents, if pursued and obtained, or the marketing of competing products in violation
of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs
and divert our efforts and attention from other aspects of our business, could put our in-licensed patents at risk of being invalidated
or interpreted narrowly and our in-licensed patent applications at risk of not issuing and could provoke third parties to assert claims
against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially
meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant
commercial advantage from the intellectual property that we develop or license.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition,
many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent
owner may have limited remedies, which could materially diminish the value of such patent. If we or any of our licensors are forced to
grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and
our business, financial condition, results of operations, and prospects may be adversely affected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to Healthcare Laws and Other Legal Compliance Matters</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we successfully commercialize our current in-development products or one of our future product candidates, failure to comply with our
reporting and payment obligations under U.S. governmental pricing programs could have a material adverse effect on our business, financial
condition, and results of operations.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we participate in the Medicaid Drug Rebate Program, Part D, if and when we successfully commercialize a product candidate, we will be
required to report certain pricing information for such product candidate to the Centers for Medicare &amp; Medicaid Services, the federal
agency that administers the Medicaid and Medicare programs. We may also be required to report pricing information to the U.S. Department
of Veterans Affairs. If we become subject to these reporting requirements, we will be liable for errors associated with our submission
of pricing data, for failure to report pricing data in a timely manner, and for overcharging government payers, which can result in civil
monetary penalties under the Medicaid statute, the federal civil False Claims Act, and other laws and regulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
current and future relationships with healthcare professionals, principal investigators, consultants, customers, and third-party payors
in the United States and elsewhere may be subject, directly or indirectly, to applicable anti-kickback, fraud and abuse, false claims,
physician payment transparency, health information privacy and security, and other healthcare laws and regulations, which could expose
us to penalties.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Healthcare
providers, physicians, and third-party payors in the United States and elsewhere will play a primary role in the recommendation and prescription
of any product candidates for which we obtain marketing approval. Our current and future arrangements with healthcare professionals,
principal investigators, consultants, customers, and third-party payors may expose us to broadly applicable fraud and abuse and other
healthcare laws, including, without limitation, the federal Anti-Kickback Statute and the federal False Claims Act, that may constrain
the business or financial arrangements and relationships through which we research, sell, market, and distribute any product candidates
for which we obtain marketing approval. In addition, we may be subject to physician payment transparency laws and patient privacy and
security regulation by the federal government and by the states and foreign jurisdictions in which we conduct our business. The applicable
federal, state, and foreign healthcare laws that may affect our ability to operate include the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, offering, receiving
    or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral
    of an individual for, or the purchase, lease, order, or recommendation of, any good, facility, item or service, for which payment
    may be made, in whole or in part, under federal and state healthcare programs such as Medicare and Medicaid;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 46; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">federal
    civil and criminal false claims laws, including the federal False Claims Act, which impose criminal and civil penalties, including
    through civil whistleblower or <I>qui tam</I> actions, against individuals or entities for, among other things, knowingly presenting,
    or causing to be presented, to the federal government, including the Medicare and Medicaid programs, claims for payment that are
    false or fraudulent or making a false statement to avoid, decrease, or conceal an obligation to pay money to the federal government;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    federal civil monetary penalties statute, which imposes penalties against any person or entity who, among other things, is determined
    to have presented or caused to be presented a claim to a federal health program that the person knows or should know is for an item
    or service that was not provided as claimed or is false or fraudulent;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created additional federal criminal statutes
    that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or
    obtain, by means of false or fraudulent pretenses, representations or promises, any of the money or property owned by, or under the
    custody or control of, any healthcare benefit program, regardless of whether the payor is public or private, knowingly and willfully
    embezzling or stealing from a health care benefit program, willfully obstructing a criminal investigation of a health care offense
    and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially
    false statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare
    matters;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HIPAA,
    as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, and their respective implementing
    regulations, which impose obligations on &ldquo;covered entities,&rdquo; including certain healthcare providers, health plans, and
    healthcare clearinghouses, as well as their respective &ldquo;business associates&rdquo; and their respective subcontractors that
    create, receive, maintain, or transmit individually identifiable health information for or on behalf of a covered entity, with respect
    to safeguarding the privacy, security, and transmission of individually identifiable health information;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    federal Physician Payments Sunshine Act, created under Section 6002 of Patient Protection and Affordable Care Act, as amended by
    the Health Care and Education Reconciliation Act, or collectively, the ACA, and its implementing regulations, created annual reporting
    requirements for manufacturers of drugs, devices, biologicals, and medical supplies for certain payments and &ldquo;transfers of
    value&rdquo; provided to physicians (defined to include doctors, dentists, optometrists, podiatrists, and chiropractors) and teaching
    hospitals, as well as ownership and investment interests held by physicians and their immediate family members. As of January 1,
    2022, these reporting obligations will extend to include transfers of value made in the previous year to certain non-physician providers
    such as physician assistants and nurse practitioners; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">analogous
    state and foreign laws, such as state anti-kickback and false claims laws, which may apply to sales or marketing arrangements and
    claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers; state
    and foreign laws that require pharmaceutical companies to comply with the pharmaceutical industry&rsquo;s voluntary compliance guidelines
    and the relevant compliance guidance promulgated by the federal government or to adopt compliance programs as prescribed by state
    laws and regulations, or that otherwise restrict payments that may be made to healthcare providers; state and foreign laws that require
    drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers
    or marketing expenditures; state and local laws requiring the licensure of pharmaceutical sales representatives; and state and foreign
    laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant
    ways and often are not preempted by HIPAA, thus complicating compliance efforts.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
the ACA, among other things, amended the intent requirement of the federal Anti-Kickback Statute and certain criminal statutes governing
healthcare fraud. A person or entity no longer needs to have actual knowledge of the statute or specific intent to violate it. In addition,
the ACA provided that the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback
Statute constitutes a false or fraudulent claim for purposes of the False Claims Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Efforts
to ensure that our future business arrangements with third parties will comply with applicable healthcare laws and regulations may involve
substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current
or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws. If our operations are found
to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant
civil, criminal, and administrative penalties, including, without limitation, damages, monetary fines, disgorgement, possible exclusion
from participation in Medicare, Medicaid, and other federal healthcare programs, contractual damages, reputational harm, diminished profits
and future earnings, additional reporting or oversight obligations if we become subject to a corporate integrity agreement or other agreement
to resolve allegations of non-compliance with the law and curtailment or restructuring of our operations, any of which could adversely
affect our ability to operate our business and pursue our strategy. If any of the physicians or other healthcare providers or entities
with whom we expect to do business, including future collaborators, are found not to be in compliance with applicable laws, they may
be subject to criminal, civil, or administrative sanctions, including exclusions from participation in government healthcare programs,
which could also affect our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, there has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing
practices. Specifically, there have been Congressional inquiries and proposed federal and state legislation designed to bring more transparency
to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient
programs and reform government program reimbursement methodologies for drugs. Moreover, payment methodologies may be subject to changes
in healthcare legislation and regulatory initiatives. We expect that additional U.S. federal healthcare reform measures will be adopted
in the future, any of which could limit the amounts that the U.S. federal government will pay for healthcare products and services, which
could result in reduced demand for our product candidates or additional pricing pressures.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Individual
states in the United States have also become increasingly aggressive in passing legislation and implementing regulations designed to
control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions
on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation
from other countries and bulk purchasing. Legally mandated price controls on payment amounts by third-party payors or other restrictions
could harm our business, results of operations, financial condition and prospects. In addition, regional healthcare authorities and individual
hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in
their prescription drug and other healthcare programs. This could reduce the ultimate demand for our product candidates or put pressure
on our product pricing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
markets outside of the United States, reimbursement and healthcare payment systems vary significantly by country, and many countries
have instituted price ceilings on specific products and therapies. We cannot predict the likelihood, nature, or extent of government
regulation that may arise from future legislation or administrative action in the United States or any other jurisdiction. If we or any
third parties we may engage are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies,
or if we or such third parties are not able to maintain regulatory compliance, our product candidates may lose any regulatory approval
that may have been obtained and we may not achieve or sustain profitability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 47; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Changes
in healthcare policies, laws, and regulations may impact our ability to obtain approval for, or commercialize our current in-development
products or our future product candidates, if approved.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States and some foreign jurisdictions there have been, and continue to be, several legislative and regulatory changes and
proposed reforms of the healthcare system in an effort to contain costs, improve quality, and expand access to care. In the United States,
there have been and continue to be a number of healthcare-related legislative initiatives, as well as executive, judicial, and Congressional
challenges to existing healthcare laws that have significantly affected, and could continue to significantly affect, the healthcare industry.
For example, on June 17, 2021, the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the ACA is unconstitutional
in its entirety because the &ldquo;individual mandate&rdquo; was repealed by Congress. Thus, the Affordable Care Act will remain in effect
in its current form. Further, prior to the U.S. Supreme Court ruling, on January 28, 2021, President Biden issued an executive order
that initiated a special enrollment period for purposes of obtaining health insurance coverage through the ACA marketplace, which began
on February 15, 2021, and remained open through August 15, 2021. The executive order also instructed certain governmental agencies to
review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid
demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining
access to health insurance coverage through Medicaid or the ACA. It is possible that the Affordable Care Act will be subject to judicial
or Congressional challenges in the future. In addition, recently there has been heightened governmental scrutiny over the manner in which
manufacturers set prices for their marketed products, which has resulted in several U.S. Congressional inquiries and proposed and enacted
federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription
drugs under government payor programs and review the relationship between pricing and manufacturer patient programs. Further, based on
a recent executive order, the Biden administration expressed its intent to pursue certain policy initiatives to reduce drug prices. We
expect that additional U.S. federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that
the U.S. federal government will pay for healthcare products and services, which could result in reduced demand for our current in-development
products or our future product candidates or additional pricing pressures.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
are subject to privacy and data security laws, rules, regulations, policies, industry standards, and contractual obligations, and our
failure to comply with them could harm our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
maintain a large quantity of sensitive information, including confidential business information and information related to our employees
and we expect to maintain personal information in connection</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">with
the conduct of our clinical trials. As such, we are subject to laws and regulations governing the privacy and security of such information.
In the United States, there are numerous federal and state privacy and data security laws and regulations governing the collection, use,
disclosure, and protection of personal information, including federal and state health information privacy laws, federal and state security
breach notification laws, and federal and state consumer protection laws. The legislative and regulatory landscape for privacy and data
protection continues to evolve, and there has been an increasing focus on privacy and data protection issues, which may affect our business
and is expected to increase our compliance costs and exposure to liability. In the United States, numerous federal and state laws and
regulations could apply to our operations or the operations of our partners, including state data breach notification laws, state health
information privacy laws, and federal and state consumer protection laws and regulations, including Section 5 of the Federal Trade Commission
Act, that govern the collection, use, disclosure, and protection of health-related and other personal information. In addition, we may
obtain health information from third parties, including research institutions from which we obtain clinical trial data, that are subject
to privacy and security requirements under HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act,
and the regulations promulgated thereunder. Depending on the facts and circumstances, we could be subject to significant penalties if
we obtain, use or disclose individually identifiable health information in a manner that is not authorized or permitted by HIPAA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compliance
with these and any other applicable privacy and data security laws and regulations we may be subject to in the future is a rigorous and
time-intensive process, and we may be required to put in place additional mechanisms ensuring compliance with the new data protection
rules. If we fail to comply with any such laws or regulations, we may face significant fines and penalties that could adversely affect
our business, financial condition, results of operations or prospects. Any failure by us or our third-party processors to comply with
these data protection and privacy laws and regulations could result in significant government enforcement actions, which could include
civil, criminal, and administrative penalties, orders requiring that we change our practices, claims for damages, and other liabilities,
regulatory investigations and enforcement action, private litigation, significant costs of remediation, and adverse publicity, any of
which could negatively affect our operating results and business. Furthermore, the laws are not consistent, and compliance in the event
of a widespread data breach is costly. In addition, states are constantly adopting new laws or amending existing laws, requiring attention
to frequently changing regulatory requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
laws, regulations, and other obligations relating to privacy and data protection imposing new and relatively burdensome obligations,
and with the substantial uncertainty over the interpretation and application of these and other obligations, we may face challenges in
addressing their requirements and making necessary changes to our policies and practices and may incur significant costs and expenses
in an effort to do so. We are currently in the process of developing and updating our policies and procedures in accordance with requirements
under applicable data privacy and protection laws and regulations. We do not currently have any formal data privacy policies and procedures
in place and have not completed formal assessments of whether we are in compliance with all applicable data privacy laws and regulations.
Additionally, if third parties with which we work, such as vendors or service providers, violate applicable laws, rules or regulations
or our policies, such violations may also put our or our clinical trial and employee data, including personal data, at risk, and our
business, financial condition, results of operations, and prospects may be adversely affected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Any
clinical trial programs we conduct or research collaborations we enter into in the European Economic Area may subject us to the General
Data Protection Regulation.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we conduct clinical trial programs or enter into research collaborations in the European Economic Area, or EEA, we may be subject to
the General Data Protection regulation, or GDPR. The GDPR applies extraterritorially and implements stringent operational requirements
for processors and controllers of personal data, including, for example, high standards for obtaining consent from individuals to process
their personal data, robust disclosures to individuals, a comprehensive individual data rights regime, data export restrictions governing
transfers of data from the EEA/European Union, or EU, to other jurisdictions, short timelines for data breach notifications, limitations
on retention of information, increased requirements pertaining to health data, other special categories of personal data and coded data
and additional obligations if we contract third-party processors in connection with the processing of personal data. The United Kingdom
has implemented its own version of the GDPR, which contains similar requirements. The GDPR provides that EU member states may establish
their own laws and regulations limiting the processing of personal data, including genetic, biometric or health data, which could limit
our ability to use and share personal data or could cause our costs to increase. If our or our partners&rsquo; or service providers&rsquo;
privacy or data security measures fail to comply with the GDPR requirements, we may be subject to litigation, regulatory investigations,
enforcement notices requiring us to change the way we use personal data and/or fines of up to 20 million Euros or up to 4% of the total
worldwide annual turnover of the preceding financial year, whichever is higher, as well as compensation claims by affected individuals,
negative publicity, reputational harm and a potential loss of business and goodwill.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>


<!-- Field: Page; Sequence: 48; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
product candidates may be subject to government price controls that may affect our revenue.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
has been heightened governmental scrutiny in the United States and abroad of pharmaceutical pricing practices in light of the rising
cost of prescription drugs and biologics. In the United States, such scrutiny has resulted in several recent Congressional inquiries
and proposed and enacted federal legislation designed to, among other things, bring more transparency to product pricing, review the
relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products.
At the state level, legislatures have become increasingly aggressive in passing legislation and implementing regulations designed to
control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions
on certain product access, and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation
from other countries and bulk purchasing. Outside of the United States, particularly in the European Union, the pricing of prescription
pharmaceuticals is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable
time after the receipt of marketing approval for a product. To obtain coverage and reimbursement or pricing approval in some countries,
we may be required to conduct a clinical trial that compares the cost-effectiveness of our current in-development products or our future
product candidates to other available therapies. If reimbursement of our product candidates is unavailable or limited in scope or amount,
or if pricing is set at unsatisfactory levels, our business could be harmed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we fail to comply with environmental, health, and safety laws and regulations, we could become subject to fines or penalties or incur
costs that could harm our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to numerous environmental, health, and safety laws and regulations, including those governing laboratory procedures and the
handling, use, storage, treatment, and disposal of hazardous materials and wastes. Our operations involve the use of hazardous materials,
including chemicals and biological materials. Our operations also produce hazardous waste products. We generally contract with third
parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials.
In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages,
and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties
for failure to comply with such laws and regulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
we maintain workers&rsquo; compensation insurance to cover us for costs and expenses, we may incur due to injuries to our employees resulting
from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain
insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal
of biological or hazardous materials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we may incur substantial costs in order to comply with current or future environmental, health, and safety laws and regulations.
These current or future laws and regulations may impair our research, development, or production efforts. Our failure to comply with
these laws and regulations also may result in substantial fines, penalties or other sanctions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
are subject to U.S. and certain foreign export and import controls, sanctions, embargoes, anti-corruption laws, and anti-money laundering
laws and regulations. Compliance with these legal standards could impair our ability to compete in domestic and international markets.
We can face criminal liability and other serious consequences for violations, which can harm our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to export control and import laws and regulations, including the U.S. Export Administration Regulations, U.S. Customs regulations,
various economic and trade sanctions regulations administered by the U.S. Treasury Department&rsquo;s Office of Foreign Assets Controls,
the FCPA, the U.S. domestic bribery statute contained in 18 U.S.C. &sect; 201, the U.S. Travel Act, the USA PATRIOT Act, and other state
and national anti-bribery and anti-money laundering laws in the countries in which we conduct activities. Anti-corruption laws are interpreted
broadly and prohibit companies and their employees, agents, contractors, and other collaborators from authorizing, promising, offering,
or providing, directly or indirectly, improper payments or anything else of value to recipients in the public or private sector.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may engage third parties to sell our current in-development products or our future product candidates outside the United States, to conduct
clinical trials, and/or to obtain necessary permits, licenses, patent registrations, and other regulatory approvals. We have direct or
indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities, and other
organizations. We can be held liable for the corrupt or other illegal activities of our employees, agents, contractors, and other collaborators,
even if we do not explicitly authorize or have actual knowledge of such activities. Any violations of the laws and regulations described
above may result in substantial civil and criminal fines and penalties, imprisonment, the loss of export or import privileges, debarment,
tax reassessments, breach of contract, and fraud litigation, reputational harm, and other consequences.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 49; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
rely, and expect to continue to rely, on third parties to conduct, supervise, and monitor our preclinical studies and clinical trials.
If those third parties do not perform satisfactorily, including failing to meet deadlines for the completion of such trials or failing
to comply with regulatory requirements, we may be unable to obtain regulatory approval for our product candidates or any other product
candidates that we may develop in the future.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
rely, and will rely, on third-party CROs, study sites and others to conduct, supervise, and monitor our preclinical studies and clinical
trials for our product candidates. We expect to continue to rely on third parties, such as CROs, clinical data management organizations,
medical institutions, and clinical investigators, to conduct our preclinical studies and clinical trials. Although we have agreements
governing their activities, we have limited influence over their actual performance and control only certain aspects of their activities.
The failure of these third parties to successfully carry out their contractual duties or meet expected deadlines could substantially
harm our business because we may be delayed in completing or unable to complete the studies required to support future approval of our
product candidates, or we may not obtain marketing approval for or commercialize our product candidates in a timely manner or at all.
Moreover, these agreements might terminate for a variety of reasons, including a failure to perform by the third parties. If we need
to enter into alternative arrangements, our product development activities would be delayed and our business, financial condition, results
of operations, stock price and prospects may be materially harmed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
reliance on these third parties for development activities will reduce our control over these activities. Nevertheless, we are responsible
for ensuring that each of our studies is conducted in accordance with the applicable protocol, legal, regulatory, and scientific standards
and our reliance on third parties does not relieve us of our regulatory responsibilities. For example, we will remain responsible for
ensuring that each of our trials is conducted in accordance with the general investigational plan and protocols for the trial. We must
also ensure that our preclinical trials are conducted in accordance with the FDA&rsquo;s Good Laboratory Practice (GLP) regulations,
as appropriate. Moreover, the FDA and comparable foreign regulatory authorities require us to comply with standards, commonly referred
to as GCP guidelines, for conducting, recording, and reporting the results of clinical trials to assure that data and reported results
are credible and accurate and that the rights, integrity, and confidentiality of trial participants are protected. Regulatory authorities
enforce these requirements through periodic inspections of trial sponsors, clinical investigators, and trial sites. If we or any of our
third parties fail to comply with applicable GCPs or other regulatory requirements, we or they may be subject to enforcement or other
legal actions. For example, the data generated in our trials may not have been appropriately collected or documented, and thereby be
deemed unreliable and the FDA or comparable foreign regulatory authorities may conclude the study findings are not adequate and require
us to perform additional studies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 50; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we will be required to report certain financial interests of our third-party investigators if these relationships exceed certain
financial thresholds or meet other criteria. The FDA or comparable foreign regulatory authorities may question the integrity of the data
from those clinical trials conducted by investigators who may have conflicts of interest.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our trials
complies with the applicable regulatory requirements. In addition, our clinical trials must be conducted with product candidates that
were produced under cGMP regulations. Failure to comply with these regulations may require us to repeat clinical trials, which would
delay the regulatory approval process. We also are required to register certain clinical trials and post the results of certain completed
clinical trials on one or more government-sponsored databases, e.g., ClinicalTrials.gov, within specified timeframes. Failure to do so
can result in enforcement actions and adverse publicity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
third parties with which we work may also have relationships with other entities, some of which may be our competitors, for whom they
may also be conducting trials or other therapeutic development activities that could harm our competitive position. In addition, such
third parties are not our employees, and except for remedies available to us under our agreements with such third parties we cannot control
whether or not they devote sufficient time and resources to our ongoing clinical, non-clinical, and preclinical programs. If these third
parties do not successfully carry out their contractual duties, meet expected deadlines or conduct our preclinical studies or clinical
trials in accordance with regulatory requirements or our stated protocols, if they need to be replaced or if the quality or accuracy
of the data they obtain is compromised due to the failure to adhere to our protocols, regulatory requirements or for other reasons, our
trials may be repeated, extended, delayed, or terminated; we may not be able to obtain, or may be delayed in obtaining, marketing approvals
for our product candidates; we may not be able to, or may be delayed in our efforts to, successfully commercialize our product candidates;
or we or they may be subject to regulatory enforcement actions. As a result, our results of operations and the commercial prospects for
our product candidates would be harmed, our costs could increase and our ability to generate revenues could be delayed. To the extent
we are unable to successfully identify and manage the performance of third-party service providers in the future, our business, financial
condition, results of operations, stock price and prospects may be materially harmed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any of our relationships with these third parties terminate, we may not be able to enter into arrangements with alternative providers
or to do so on commercially reasonable terms. Switching or adding additional third parties involves additional cost and requires management
time and focus. In addition, there is a natural transition period when a new third party commences work. As a result, delays could occur,
which could compromise our ability to meet our desired development timelines.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will also rely on other third parties to store and distribute our product candidates for the clinical trials that we conduct. Any performance
failure on the part of our distributors could delay clinical development, marketing approval, or commercialization of our product candidates,
which could result in additional losses and deprive us of potential product revenue.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
have entered into, and may in the future enter into, certain collaboration agreements and strategic alliances to maximize the potential
of our product candidates, and we may not realize the anticipated benefits of such collaborations or alliances. We expect to continue
to form collaborations in the future with respect to our product candidates, but may be unable to do so or to realize the potential benefits
of such transactions, which may cause us to alter or delay our development and commercialization plans.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may form or seek other strategic alliances, joint ventures, or collaborations, or enter into additional licensing arrangements with third
parties that we believe will complement or augment our development and commercialization efforts with respect to product candidates we
develop. These transactions can entail numerous operational and financial risks, including exposure to unknown liabilities, disruption
of our business and diversion of our management&rsquo;s time and attention in order to manage a collaboration. We also cannot be certain
that, following a strategic transaction or license, we will achieve the revenue or other anticipated benefits that led us to enter into
the arrangement. Additionally, the success of any collaboration arrangements may depend on the efforts and activities of our collaborators.
Collaborators generally have significant discretion in determining the efforts and resources that they will apply to these arrangements.
Disagreements between parties to a collaboration arrangement regarding clinical development and commercialization matters can lead to
delays in the development process or commercializing the applicable product candidate and, in some cases, termination of the collaboration
arrangement. These disagreements can be difficult to resolve if neither of the parties has final decision-making authority.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we are not able to establish future collaborations on commercially reasonable terms, we may have to alter our development and commercialization
plans for one or more of our other development programs.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
face significant competition in seeking appropriate additional collaborators. Our ability to reach a definitive agreement for any collaboration
will depend, among other things, upon our assessment of the collaborator&rsquo;s resources and expertise, the terms and conditions of
the proposed collaboration and the proposed collaborator&rsquo;s evaluation of a number of factors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are unable to reach agreements with suitable collaborators on a timely basis, on acceptable terms, or at all, we may have to curtail
the development of a product candidate, reduce or delay its development program or one or more of our other development programs, delay
its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake
development or commercialization activities at our own expense. If we elect to fund and undertake development or commercialization activities
on our own, we may need to obtain additional expertise and additional capital, which may not be available to us on acceptable terms,
or at all. If we fail to enter into collaborations and do not have sufficient funds or expertise to undertake the necessary development
and commercialization activities, we may not be able to further develop our product candidates or bring them to market or continue to
develop our product platform and our business may be materially and adversely affected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 51; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
current and any future collaborations are not a guarantee of success, and all collaborations are as risky, or riskier, than
undertaking the activities ourselves.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators
    may not perform their obligations as expected;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators
    may not pursue development and commercialization of product candidates that achieve regulatory approval or may elect not to continue
    or renew development or commercialization programs based on clinical trial results, changes in the collaborators&rsquo; strategic
    focus or available funding, or external factors, such as an acquisition, that divert resources or create competing priorities;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators
    may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product
    candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators
    could fail to make timely regulatory submissions for a product candidate;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators
    may not comply with all applicable regulatory requirements
    or may fail to report safety data in accordance with all applicable regulatory requirements, which could subject them or us to regulatory
    enforcement actions;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators
    could independently develop, or develop with third parties, products that compete directly or indirectly with our products or product
    candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized
    under terms that are more economically attractive than ours;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">product
    candidates discovered in collaboration with us may be viewed by our collaborators as competitive with their own product candidates
    or products, which may cause collaborators to cease to devote resources to the commercialization of our product candidates;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    collaborator with marketing and distribution rights to one or more of our product candidates that achieve regulatory approval may
    not commit sufficient resources to the marketing and distribution of such product candidate or product;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">disagreements
    with collaborators, including disagreements over proprietary rights, contract interpretation or the preferred course of development,
    might cause delays or termination of the research, development or commercialization of product candidates, might lead to additional
    responsibilities for us with respect to product candidates, or might result in litigation or arbitration, any of which would be time
    consuming and expensive;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators
    may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite
    litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation;
    and</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators
    may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, all of the risks relating to product development, regulatory approval and commercialization described in this prospectus also
apply to the activities of any of our current or future collaborators.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Collaborations
with biopharmaceutical companies and other third parties often are terminated or allowed to expire by the other party. Any such termination
or expiration could adversely affect us financially and could harm our business reputation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any collaborations we have entered into or might enter into do not result in the successful development and commercialization of products
or if one of our collaborators subsequently terminates its agreement with us, we may not receive any future research funding or milestone
or royalty payments under such collaboration. If we do not receive the funding we expect under the agreements, our development of our
product candidates could be delayed and we may need additional resources to develop our product candidates and our product platform.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 52; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
if any collaborator of ours is involved in a business combination, the collaborator might deemphasize or terminate development or commercialization
of any product candidate licensed to it by us. If one of our collaborators terminates its agreement with us, we may find it more difficult
to attract new collaborators and our reputation in the business and financial communities could be adversely affected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
face significant competition in seeking appropriate collaborators. Our ability to reach a definitive agreement for any collaboration
will depend, among other things, upon our assessment of the collaborator&rsquo;s resources and expertise, the terms and conditions of
the proposed collaboration and the proposed collaborator&rsquo;s evaluation of a number of factors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are unable to reach agreements with suitable collaborators on a timely basis, on acceptable terms, or at all, we may have to curtail
the development of a product candidate, reduce or delay its development program or one or more of our other development programs, delay
its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake
development or commercialization activities at our own expense. If we elect to fund and undertake development or commercialization activities
on our own, we may need to obtain additional expertise and additional capital, which may not be available to us on acceptable terms,
or at all. If we fail to enter into collaborations and do not have sufficient funds or expertise to undertake the necessary development
and commercialization activities, we may not be able to further develop our product candidates or bring them to market or continue to
develop our product platform and our business may be materially and adversely affected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Disruptions
at the FDA and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire and
retain key leadership and other personnel, or otherwise prevent new products and services from being developed or commercialized in a
timely manner, which could negatively impact our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding
levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes.
Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of other government agencies
that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disruptions
at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies,
which would adversely affect our business. For example, over the last several years, including for 35 days beginning on December 22,
2018, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical
employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA
to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Separately,
the FDA and regulatory authorities outside the United States have and may adopt restrictions or other policy measures in response to
the COVID-19 pandemic that divert resources and delay their attention to any submissions we may make. If a prolonged government shutdown
occurs, or if global health concerns continue to prevent the FDA or other regulatory authorities from conducting their regular inspections,
reviews, or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely
review and process our regulatory submissions, which could have a material adverse effect on our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to Commercialization</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>There
is no assurance that we will be able to obtain FDA approval and, even if we do, there is no assurance that either we, or our collaboration
partners, will be successful in commercializing any product candidate for which we receive regulatory approval, or experience
significant delays in doing so, our business will be materially harmed.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if we obtain FDA approval, there is no assurance that</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
we, or our collaboration partners, will be successful in obtaining marketing approval from applicable regulatory authorities for
ENV 105 or any other product candidate. Our ability to generate revenues from any such products will depend on our success in:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top">Successfully completing our Phase
    1 and Phase 2 clinical trials and obtaining FDA approval for our product candidates;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">launching
    commercial sales of such products, whether alone or in collaboration with others;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">receiving
    approved labels with claims that are necessary or desirable for successful marketing, and that do not contain safety or other limitations
    that would impede our ability to market such products;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">creating
    market demand for such products through marketing, sales and promotion activities;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">hiring,
    training, and deploying a sales force or contracting with third parties to commercialize such products in the United States;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">creating
    partnerships with, or offering licenses to, third parties to promote and sell such products in foreign markets where we receive marketing
    approval;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">manufacturing
    such products in sufficient quantities and at acceptable quality and cost to meet commercial demand at launch and thereafter;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 53; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing
    and maintaining agreements with wholesalers, distributors, and group purchasing organizations on commercially reasonable terms;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">maintaining
    patent and trade secret protection and regulatory exclusivity for such products;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">achieving
    market acceptance of such products by patients, the medical community, and third-party payors;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">achieving
    coverage and adequate reimbursement from third-party payors for such products;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">achieving
    patients&rsquo; willingness to pay out-of-pocket in the absence of such coverage and adequate reimbursement from third-party payors;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">competing
    effectively with other therapies; and</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">maintaining
    a continued acceptable safety profile of such products following launch.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the extent we are not able to do any of the foregoing, our business, financial condition, results of operations, stock price and prospects
will be materially harmed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
face significant competition from other biopharmaceutical and biotechnology companies, academic institutions, government agencies, and
other research organizations, which may result in others discovering, developing or commercializing products more quickly or marketing
them more successfully than us. If their product candidates are shown to be safer or more effective than ours, our commercial opportunity
may be reduced or eliminated.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
development and commercialization of cancer resistance products and immunotherapy products is characterized by rapidly advancing technologies,
intense competition and a strong emphasis on proprietary rights. We face competition with respect to our current product candidates,
and will face competition with respect to any product candidates that we may seek to develop or commercialize in the future, from major
biopharmaceutical companies, specialty biopharmaceutical companies, and biotechnology companies worldwide. Potential competitors also
include academic institutions, government agencies, and other public and private research organizations that conduct research, seek patent
protection, and establish collaborative arrangements for research, development, manufacturing, and commercialization.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
certain of our product candidates may be used in combination with other drugs with different mechanisms of action, if and when marketed
they will still compete with a number of drugs that are currently marketed or in development that also target cancer. To compete effectively
with these drugs, our product candidates will need to demonstrate advantages in clinical efficacy and safety compared to these competitors
when used alone or in combination with other drugs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
commercial opportunities could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective,
have fewer or less severe side effects, are easier to administer or are less expensive alone or in combination with other therapies than
any products that we may develop alone or in combination with other therapies. Our competitors also may obtain FDA or comparable foreign
regulatory authorities&rsquo; approval for their products more rapidly than we may obtain approval for ours, which could result in our
competitors establishing a strong market position before we are able to enter the market. In addition, our ability to compete may be
affected in many cases by third-party payors&rsquo; coverage and reimbursement decisions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
of the companies with which we are competing or may compete in the future have significantly greater financial resources and expertise
in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals, and marketing
approved products than we do. Mergers and acquisitions in the biopharmaceutical and biotechnology industries may result in even more
resources being concentrated among a smaller number of our competitors. Early-stage companies may also prove to be significant competitors,
particularly through collaborative arrangements with large and established companies. These third parties compete with us in recruiting
and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical
trials, as well as in developing or acquiring technologies complementary to, or necessary for, our programs. If we are unable to successfully
compete with these companies our business, financial condition, results of operations, stock price and prospects may be materially harmed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 54; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we are unable to establish effective marketing, sales and distribution capabilities or enter into agreements with third parties to market
and sell our product candidates, if they are approved, the revenues that we generate may be limited and we may never become profitable.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently do not have a commercial infrastructure for the marketing, sale, and distribution of any products that we may develop. If and
when our product candidates receive marketing approval, we intend to commercialize our product candidates on our own or in collaboration
with others and potentially with pharmaceutical or biotechnology partners in other geographies. In order to commercialize our products,
we must build our marketing, sales, and distribution capabilities or make arrangements with third parties to perform these services.
We may not be successful in doing so. Should we decide to move forward in developing our own marketing capabilities, we may incur expenses
prior to product launch or even approval in order to recruit a sales force and develop a marketing and sales infrastructure. If a commercial
launch is delayed as a result of the FDA or comparable foreign regulatory authority requirements or other reasons, we would incur these
expenses prior to being able to realize any revenue from sales of our product candidates. Even if we are able to effectively hire a sales
force and develop a marketing and sales infrastructure, our sales force and marketing teams may not be successful in commercializing
our product candidates. This may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing
personnel.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may also or alternatively decide to collaborate with third-party marketing and sales organizations to commercialize any approved product
candidates, in which event, our ability to generate product revenues may be limited. To the extent we rely on third parties to commercialize
any products for which we obtain regulatory approval, we may receive less revenues than if we commercialized these products ourselves,
which could materially harm our prospects. In addition, we would have less control over the sales efforts of any other third parties
involved in our commercialization efforts, and could be held liable if they failed to comply with applicable legal or regulatory requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have no prior experience in the marketing, sale, and distribution of biopharmaceutical products, and there are significant risks involved
in building and managing a commercial infrastructure. The establishment and development of commercial capabilities, including compliance
plans, to market any products we may develop will be expensive and time consuming and could delay any product launch, and we may not
be able to successfully develop this capability. We will have to compete with other biopharmaceutical and biotechnology companies, including
oncology-focused companies, to recruit, hire, train, manage, and retain marketing and sales personnel, which is expensive and time consuming
and could delay any product launch. Developing our sales capabilities may also divert resources and management attention away from product
development.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event we are unable to develop a marketing and sales infrastructure, we may not be able to commercialize our product candidates,
which could limit our ability to generate product revenues and materially harm our business, financial condition, results of operations,
stock price and prospects. Factors that may inhibit our efforts to commercialize our product candidates include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    inability to recruit, train, manage, and retain adequate numbers of effective sales and marketing personnel;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    inability of sales personnel to obtain access to physicians or educate adequate numbers of physicians on the benefits of prescribing
    our product candidates;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    inability to effectively oversee a geographically dispersed sales and marketing team;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs associated with training personnel, including sales and marketing personnel, on compliance matters and monitoring their actions;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
    inability to secure coverage and adequate reimbursement by third-party payors, including government and private health plans;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    unwillingness of patients to pay out-of-pocket in the absence of coverage and adequate reimbursement from third-party payors;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    clinical indications for which the products are approved and the claims that we may make for the products;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">limitations
    or warnings, including distribution or use restrictions, contained in the products&rsquo; approved labeling;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    distribution and use restrictions imposed by the FDA or comparable foreign regulatory authorities or to which we agree as part of
    a mandatory REMS or voluntary risk management plan;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">liability
    for our personnel, including sales or marketing personnel, who fail to comply with applicable law;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies
    with more extensive product lines; and</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">unforeseen
    costs and expenses associated with creating an independent sales and marketing organization or engaging a contract sales organization.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>


<!-- Field: Page; Sequence: 55; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Even
if any of our product candidates receive marketing approval, they may fail to achieve the degree of market acceptance by physicians,
patients, hospitals, cancer treatment centers, third-party payors and others in the medical community necessary for commercial success.
The revenues that we generate from their sales may be limited, and we may never become profitable.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have never commercialized a product candidate for any indication. Even if our product candidates are approved by the appropriate regulatory
authorities for marketing and sale, they may not gain acceptance among physicians, patients, third-party payors, and others in the medical
community. If any product candidates for which we obtain regulatory approval does not gain an adequate level of market acceptance, we
could be prevented from or significantly delayed in achieving profitability. Market acceptance of our product candidates by the medical
community, patients, and third-party payors will depend on a number of factors, some of which are beyond our control. For example, physicians
are often reluctant to switch their patients and patients may be reluctant to switch from existing therapies even when new and potentially
more effective or safer treatments enter the market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Efforts
to educate the medical community and third-party payors on the benefits of our product candidates may require significant resources and
may not be successful. If any of our product candidates is approved but does not achieve an adequate level of market acceptance, we could
be prevented from or significantly delayed in achieving profitability. The degree of market acceptance of any product for which we receive
marketing approval will depend on a number of factors, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    efficacy of our product, including in combination with other cancer therapies;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    commercial success of any cancer therapies with which our product may be co-administered;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    prevalence and severity of adverse events associated with our product or those products with which it is co-administered;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    clinical indications for which our product is approved and the approved claims that we may make with respect to the product;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">limitations
    or warnings contained in the FDA-approved labeling of the product or the labeling approved by comparable foreign regulatory authorities,
    including potential limitations or warnings for our product that may be more restrictive than other competitive products;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in the standard of care for the targeted indications for our product, which could reduce the marketing impact of any claims that
    we could make following FDA approval or approval by comparable foreign regulatory authorities, if obtained;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    relative convenience and ease of administration of our product and any products with which it is co-administered;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    cost of treatment compared with the economic and clinical benefit of alternative treatments or therapies;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    availability of coverage and adequate reimbursement by third-party payors, such as private insurance companies and government healthcare
    programs, including Medicare and Medicaid;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    ability to have our product placed on approved formularies;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">patients&rsquo;
    willingness to pay out-of-pocket in the absence of such coverage and adequate reimbursement from third-party payors;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    price concessions required by third-party payors to obtain coverage and adequate reimbursement;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    extent and strength of our marketing and distribution of our product;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    safety, efficacy, and other potential advantages over, and availability of, alternative treatments already used or that may later
    be approved;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">distribution
    and use restrictions imposed by the FDA or comparable foreign regulatory authorities with respect to our product or to which we agree
    as part of a REMS or voluntary risk management plan;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    timing of market introduction of our product, as well as competitive products;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to offer our product for sale at competitive prices;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    extent and strength of our raw material supplier and service provider support;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 56; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    actions of companies that market any products with which our product is co-administered;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    approval of other new products;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">adverse
    publicity about our product or any products with which it is co-administered, or favorable publicity about competitive products;
    and</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">potential
    product liability claims.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
size of the potential market for our product candidates is difficult to estimate and, if any of our assumptions are inaccurate, the actual
markets for our product candidates may be smaller than our estimates. If the market opportunities for any product candidates we develop
are smaller than we believe they are, our potential revenues may be adversely affected, and our business may suffer.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
potential market opportunities for our product candidates are difficult to estimate and will depend in large part on the drugs with which
our product candidates are co-administered and the success of competing therapies and therapeutic approaches. In particular, the market
opportunity for cancer resistance drugs is hard to estimate given that it is an emerging field. Our projections of both the number of
people who have these diseases, as well as the subset of people with these diseases who have the potential to benefit from treatment
with our product candidates, are based on estimates. Our estimates of the potential market opportunities are predicated on many assumptions,
which may include industry knowledge and publications, third-party research reports, and other surveys. Although we believe that our
internal assumptions are reasonable, these assumptions involve the exercise of significant judgment on the part of our management, are
inherently uncertain, and their reasonableness has not been assessed by an independent source. These estimates may prove to be incorrect
and new studies may change the estimated incidence or prevalence of these diseases. The number of patients in the United States, Europe,
and elsewhere may turn out to be lower than expected, and patients may not be amenable to treatment with our product. If any of the assumptions
proves to be inaccurate, the actual markets for our product candidates could be smaller than our estimates of the potential market opportunities.
Additionally, because of the potential that any product candidates we develop could cure a target disease, we may not receive recurring
revenues from patients and may deplete the patient population prevalence through curative therapy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to Government Regulation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we fail to comply with federal and state healthcare laws, including fraud and abuse laws, we could face substantial penalties and our
business, financial condition, results of operations, stock price and prospects will be materially harmed.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
current and future arrangements with healthcare providers, third-party payors, customers, and others may expose us to broadly applicable
healthcare fraud and abuse, and other healthcare laws, which may constrain the business or financial arrangements and relationships through
which we research, as well as sell, market and distribute any products for which we obtain marketing approval. The applicable federal,
state and foreign healthcare laws and regulations that may affect our ability to operate include, but are not limited to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    federal Anti-Kickback Statute, which prohibits, among other things, individuals and entities from knowingly and willfully soliciting,
    receiving, offering or paying any remuneration (including any kickback, bribe, or rebate), directly or indirectly, overtly or covertly,
    in cash or in kind, to induce, or in return for, either the referral of an individual for, or the purchase, lease, order or recommendation
    of, any good, facility, item or service for which payment may be made, in whole or in part, under a federal healthcare program, such
    as the Medicare and Medicaid programs.</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    federal civil and criminal false claims laws, including, without limitation, the civil FCA, and the federal Civil Monetary Penalties
    Law, which prohibit individuals or entities from, among other things, knowingly presenting, or causing to be presented, false or
    fraudulent claims for payment of federal funds, and knowingly making, or causing to be made, a false record or statement material
    to a false or fraudulent claim to avoid, decrease or conceal an obligation to pay money to the federal government.</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Health Insurance Portability and Accountability Act of 1996 (HIPAA), which prohibits, among other things, knowingly and willfully
    executing, or attempting to execute, a scheme or artifice to defraud any healthcare benefit program or obtain, by means of false
    or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control of,
    any healthcare benefit program, regardless of the payor (e.g., public or private), willfully obstructing a criminal investigation
    of a healthcare offense, and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact
    or making any materially false, fictitious or fraudulent statements in connection with the delivery of, or payment for, healthcare
    benefits, items or services relating to healthcare matters.</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    U.S. Federal Food, Drug and Cosmetic Act, which prohibits, among other things, the adulteration or misbranding of drugs, biological
    products and medical devices.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 57; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    federal physician payment transparency requirements, sometimes referred to as the Physician Payments Sunshine Act, created under
    the ACA and its implementing regulations, which require certain manufacturers of drugs, devices, biological products and medical
    supplies for which payment is available under Medicare, Medicaid or the Children&rsquo;s Health Insurance Program (with certain exceptions)
    to report annually to the Centers for Medicare &amp; Medicaid Services (CMS) information related to payments or other transfers of
    value made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), other healthcare professionals
    (such as physician assistants and nurse practitioners), and teaching hospitals, as well as ownership and investment interests held
    by such physicians and their immediate family members.</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Analogous
    state and foreign anti-kickback and false claims laws that may apply to sales or marketing arrangements and claims involving healthcare
    items or services reimbursed by non-governmental third-party payors, including private insurers, or that apply regardless of payor;
    state laws that require pharmaceutical companies to comply with the pharmaceutical industry&rsquo;s voluntary compliance guidelines
    and the relevant compliance guidance promulgated by the federal government; state and local laws that require drug manufacturers
    to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing
    expenditures; state laws that require the reporting of information related to drug pricing; and state and local laws requiring the
    registration of pharmaceutical sales representatives.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we or our operations are found to be in violation of any federal or state healthcare law, or any other governmental laws or regulations
that apply to us, we may be subject to penalties, including significant civil, criminal, and administrative penalties, damages, monetary
fines, disgorgement, imprisonment, suspension and debarment from government contracts, and refusal of orders under existing government
contracts, exclusion from participation in U.S. federal or state health care programs, additional reporting requirements and/or oversight
if we become subject to corporate integrity agreements or similar agreement to resolve allegations of non-compliance, contractual damages,
reputational harm, diminished profits and future earnings, and the curtailment or restructuring of our operations, any of which could
materially adversely affect our ability to operate our business and our financial results. If any of the physicians or other healthcare
providers or entities with whom we expect to do business is found not to be in compliance with applicable laws, it may be subject to
significant criminal, civil or administrative sanctions, including but not limited to, exclusions from participation in U.S. federal
or state healthcare programs, which could also materially affect our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
an effective compliance program can mitigate the risk of investigation and prosecution for violations of these laws, the risks cannot
be entirely eliminated. Moreover, achieving and sustaining compliance with such laws may prove costly. Any action against us for violation
of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&rsquo;s
attention from the operation of our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
the government or third-party payors fail to provide adequate coverage, reimbursement and payment rates for our product candidates, or
if health maintenance organizations or long-term care facilities choose to use therapies that are less expensive or considered a better
value, our revenue and prospects for profitability will be limited.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
both domestic and foreign markets, sales of our products will depend in part upon the availability of coverage and adequate reimbursement
from third-party payors or placement on approved product formularies. Such third-party payors include government health programs such
as Medicare and Medicaid, managed care providers, private health insurers, and other organizations. Coverage decisions may depend upon
clinical and economic standards that disfavor new therapeutic products when more established or lower cost therapeutic alternatives are
already available or subsequently become available, even if our products are alone in a class. Third-party payors establish reimbursement
levels. Therefore, even if coverage is provided, the approved reimbursement amount may not be high enough to allow us to establish or
maintain a market share sufficient to realize a sufficient return on our or their investments. If reimbursement is not available, or
is available only to limited levels, our product candidates may be competitively disadvantaged, and we may not be able to successfully
commercialize our product candidates. Alternatively, securing favorable reimbursement terms may require us to compromise pricing and
prevent us from realizing an adequate margin over cost. Our failure to obtain or maintain timely or adequate pricing or formulary placement
of our products, or failure to obtain such formulary placement at favorable pricing may negatively impact our revenue.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is significant uncertainty related to third-party payor coverage and reimbursement of newly approved therapeutics. Marketing approvals,
pricing, and reimbursement for new therapeutic products vary widely from country to country. Current and future legislation may significantly
change the approval requirements in ways that could involve additional costs and cause delays in obtaining approvals. Some countries
require approval of the sale price of a therapeutic before it can be marketed. In many countries, the pricing review period begins after
marketing or product licensing approval is granted. In some foreign markets, prescription biopharmaceutical pricing remains subject to
continuing governmental control even after initial approval is granted. As a result, we might obtain marketing approval for a product
in a particular country, but then be subject to price regulations that delay commercial launch of the product, possibly for lengthy time
periods, which may negatively impact the revenues we are able to generate from the sale of the product in that country. Adverse pricing
limitations may hinder our ability to recoup our investment in one or more product candidates, even if our product candidates obtain
marketing approval. Our ability to commercialize our product candidates will depend in part on the extent to which coverage and reimbursement
for these products and related treatments will be available from third-party payors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 58; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
significant trend within the healthcare industry is cost containment, both in the United States and elsewhere. Third-party payors, whether
foreign or domestic, or governmental or commercial, are developing increasingly sophisticated methods of controlling healthcare costs,
including use of formularies. Exclusion of a product from a formulary or other restrictions can significantly impact drug usage in the
patient population and beyond. Consequently, pharmaceutical companies compete to gain access to formularies for their products, typically
on the basis of unique product features, such as greater efficacy, better patient ease of use, or fewer side effects, as well as the
overall cost of the therapy. Certain third-party payors are requiring that companies provide them with predetermined discounts from list
prices, are using preferred drug lists to leverage greater discounts in competitive classes, are disregarding therapeutic differentiators
within classes, are challenging the prices charged for therapeutics, and are negotiating price concessions based on performance goals.
In addition, third-party payors are increasingly requiring higher levels of evidence of the benefits and clinical outcomes of new technologies,
benchmarking against other therapies, seeking performance-based discounts, and challenging the prices charged. We cannot be sure that
coverage will be available for any product candidate that we commercialize and, if available, that the reimbursement rates will be adequate.
If payors subject our product candidates to maximum payment amounts, or impose limitations that make it difficult to obtain reimbursement,
providers may choose to use therapies which are less expensive when compared to our product candidates. Additionally, if payors require
high copayments, beneficiaries may seek alternative therapies. We may need to conduct post-marketing studies in order to demonstrate
the cost-effectiveness of any products to the satisfaction of hospitals, other target customers and their third-party payors. Such studies
might require us to commit a significant amount of management time and financial and other resources. Our products might not ultimately
be considered cost-effective. Adequate third-party coverage and reimbursement might not be available to enable us to maintain price levels
sufficient to realize an appropriate return on investment in product development.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, in the United States, no uniform policy of coverage and reimbursement for products exists among third-party payors. Therefore,
coverage and reimbursement for products can differ significantly from payor to payor. Further, we believe that future coverage and reimbursement
will likely be subject to increased restrictions both in the United States and in international markets. Third-party coverage and reimbursement
for our products or product candidates for which we receive regulatory approval may not be available or adequate in either the United
States or international markets, which could have a negative effect on our business, financial condition, results of operations, stock
price and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
may also be delays in obtaining coverage and reimbursement for newly approved therapeutics, and coverage may be more limited than the
indications for which the product is approved by the FDA or comparable foreign regulatory authorities. Such delays have made it increasingly
common for manufacturers to provide newly approved drugs to patients experiencing coverage delays or disruption at no cost for a limited
period in order to ensure that patients are able to access the drug. Moreover, eligibility for reimbursement does not imply that any
therapeutic will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sale, and
distribution. Interim reimbursement levels for new therapeutics, if applicable, may also not be sufficient to cover our costs and may
only be temporary. Reimbursement rates may vary, by way of example, according to the use of the product and the clinical setting in which
it is used. Reimbursement rates may also be based on reimbursement levels already set for lower cost products or may be incorporated
into existing payments for other services.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
inability to promptly obtain coverage and adequate reimbursement from third-party payors for any of our product candidates for which
we obtain marketing approval could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize
products and our overall financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
are subject to new legislation, regulatory proposals and third-party payor initiatives that may increase our costs of compliance, and
adversely affect our ability to market our products, obtain collaborators, and raise capital.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes
regarding the healthcare system that could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval
activities and affect our ability to profitably sell any products for which we obtain marketing approval. We expect that current laws,
as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional
downward pressure on the price that we may receive for any approved products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
example, the ACA was passed in March 2010 and substantially changed the way healthcare is financed by both governmental and private insurers,
and continues to significantly impact the United States pharmaceutical industry.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
have been executive, judicial and congressional challenges to certain aspects of the ACA. For example, legislation enacted in 2017, informally
titled the Tax Cuts and Jobs Act of 2017 (the Tax Act), includes a provision repealing, effective January 1, 2019, the tax-based shared
responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a
year that is commonly referred to as the &ldquo;individual mandate.&rdquo; On June 17, 2021 the U.S. Supreme Court dismissed a challenge
on procedural grounds that argued the ACA is unconstitutional in its entirety because the &ldquo;individual mandate&rdquo; was repealed
by Congress. Thus, the ACA will remain in effect in its current form. Further, prior to the U.S. Supreme Court ruling, on January 28,
2021, President Biden issued an executive order that initiated a special enrollment period for purposes of obtaining health insurance
coverage through the ACA marketplace. The executive order also instructed certain governmental agencies to review and reconsider their
existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and
waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance
coverage through Medicaid or the ACA. In addition, on August 16, 2022, President Biden signed the Inflation Reduction Act of 2022 (the
IRA) into law, which among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces
through plan year 2025. The IRA also eliminates the &ldquo;donut hole&rdquo; under the Medicare Part D program beginning in 2025 by significantly
lowering the beneficiary maximum out-of-pocket cost through a newly established manufacturer discount program. It is possible that the
ACA will be subject to judicial or Congressional challenges in the future. It is unclear how any such challenges and the healthcare reform
measures of the Biden administration will impact the ACA and our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 59; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
legislative changes have been proposed and adopted in the United States since the ACA. For example, through the process created by the
Budget Control Act of 2011, there are automatic reductions of Medicare payments to providers up to 2% per fiscal year, which went into
effect in April 2013 and, following passage of the Bipartisan Budget Act of 2018 (BBA) and the Infrastructure Investment and Jobs Act,
will remain in effect until 2031 unless additional Congressional action is taken. However, COVID-19 relief support legislation suspended
the 2% Medicare sequester from May 1, 2020 through March 31, 2022. Under current legislation the actual reduction in Medicare payments
will vary from 1% in 2022 to up to 4% in the final fiscal year of this sequester.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, there have been a number of other legislative and regulatory proposals aimed at changing the biopharmaceutical industry. For
instance, the Drug Quality and Security Act of 2013 imposes obligations on manufacturers of biopharmaceutical products related to product
tracking and tracing. Further, manufacturers have product investigation, quarantine, disposition, and notification responsibilities related
to counterfeit, diverted, stolen, and intentionally adulterated products that would result in serious adverse health consequences of
death to humans, as well as products that are the subject of fraudulent transactions or which are otherwise unfit for distribution such
that they would be reasonably likely to result in serious health consequences or death.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compliance
with the federal track and trace requirements may increase our operational expenses and impose significant administrative burdens. As
a result of these and other new proposals, we may determine to change our current manner of operation, provide additional benefits or
change our contract arrangements, any of which could have a material adverse effect on our business, financial condition, results of
operations, stock price and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
has been heightened governmental scrutiny in the United States of pharmaceutical pricing practices in light of the rising cost of prescription
drugs and biological products. Such scrutiny has resulted in presidential executive orders, congressional inquiries and proposed and
enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship
between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the federal level, the Trump administration used several means to propose or implement drug pricing reform, including through federal
budget proposals, executive orders and policy initiatives. For example, on July 24, 2020 and September 13, 2020, the Trump administration
announced several executive orders related to prescription drug pricing that attempt to implement several of the administration&rsquo;s
proposals. The FDA concurrently released a final rule and guidance in September 2020, implementing a portion of the importation executive
order providing pathways for states to build and submit importation plans for drugs from Canada. Further, on November 20, 2020, the U.S.
Department of Health and Human Services (HHS) finalized a regulation removing safe harbor protection for price reductions from pharmaceutical
manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required
by law. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a new safe harbor for
certain fixed fee arrangements between pharmacy benefit managers and manufacturers. The implementation of the rule has been delayed until
2032. In July 2021, the Biden administration released an executive order, &ldquo;Promoting Competition in the American Economy,&rdquo;
with multiple provisions aimed at prescription drugs. In response to Biden&rsquo;s executive order, on September 9, 2021, HHS released
a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform and sets out a variety of potential
legislative policies that Congress could pursue as well as potential administrative actions HHS can take to advance these principles.
In addition, the IRA directs the Secretary of HHS to establish a Drug Price Negotiation Program (the Program) to lower prices for certain
single-source prescription drugs and biologics covered under Medicare Parts B and D, based on criteria established under the IRA. Under
the Program, the Secretary of HHS will publish a list of &ldquo;selected drugs,&rdquo; and will then negotiate maximum fair prices (MFP)
with their manufacturers. Beginning in 2026, the first year of the Program, the number will be limited to 10 Part D drugs and biologics.
By 2029, and in subsequent years thereafter, the number will increase to 20 drugs and biologics covered under Part D and Part B. Agreements
between HHS and manufacturers will remain in place until a drug or biologic is no longer considered a &ldquo;selected drug&rdquo; for
negotiation purposes. Manufacturers who do not comply with the negotiated prices set under the Program will be subject to an excise tax
based on a percentage of total sales of a &ldquo;selected drug&rdquo; up to 95% and the potential of civil monetary penalties. Additionally,
on March 11, 2021, President Biden signed the American Rescue Plan Act of 2021 into law, which eliminates the statutory Medicaid drug
rebate cap, currently set at 100% of a drug&rsquo;s average manufacturer price, for single source and innovator multiple source drugs,
beginning January 1, 2024.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and
biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and
marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk
purchasing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
new laws or regulations, including those that may result in additional reductions in Medicare and other healthcare funding, could have
a material adverse effect on customers for our products, if approved, and, accordingly, on our results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 60; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect that the ACA, as well as other federal and state healthcare reform measures that may be adopted in the future, may result in more
rigorous coverage criteria, increased regulatory burdens and operating costs, decreased net revenue from our biopharmaceutical products,
decreased potential returns from our development efforts, and additional downward pressure on the price that we receive for any approved
product. It is also possible that additional governmental action is taken in response to the COVID-19 pandemic. Any reduction in reimbursement
from Medicare or other government healthcare programs may result in a similar reduction in payments from private payors. The implementation
of cost containment measures or other healthcare reforms may prevent us from commercializing our products and being able to generate
revenue, and we could be prevented from or significantly delayed in achieving profitability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
are subject to the U.S. Foreign Corrupt Practices Act and other anti-corruption laws, as well as import and export control laws, customs
laws, sanctions laws and other laws governing our operations. If we fail to comply with these laws, we could be subject to civil or criminal
penalties, and other consequences, which could adversely affect our business, financial condition, results of operations, stock price
and prospects.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
operations are subject to anti-corruption laws, including the U.S. Foreign Corrupt Practices Act (FCPA) and other anti-corruption laws
that apply in countries where we do business. The FCPA and these other anti-corruption laws generally prohibit us and our employees and
intermediaries from authorizing, promising, offering, providing, soliciting, or receiving, directly or indirectly, corrupt or improper
payments or anything else of value to or from recipients in the public or private sector. We can be held liable for the corrupt or other
illegal activities of our personnel or intermediaries, even if we do not explicitly authorize or have prior knowledge of such activities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are also subject to other laws and regulations governing our international operations, including applicable import and export control
regulations, economic sanctions on countries and persons, anti-money laundering laws, customs requirements and currency exchange regulations,
collectively referred to as the trade control laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
can provide no assurance that we will be completely effective in ensuring our compliance with all applicable anti-corruption laws or
other legal requirements, including trade control laws. If we are not in compliance with applicable anti-corruption laws or trade control
laws, we may be subject to criminal and civil penalties, disgorgement and other sanctions and remedial measures, and legal expenses,
which could have an adverse impact on our business, financial condition, results of operations, stock price and prospects. In addition,
we cannot predict the nature, scope or effect of future regulatory requirements to which our international operations might be subject
or the manner in which existing laws might be administered or interpreted. An investigation of any potential violations of anti-corruption
laws or trade control laws by U.S. or other authorities could also have an adverse impact on our reputation, our business, financial
condition, results of operations, stock price and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
are subject to stringent and evolving U.S. and foreign laws, regulations, rules, contractual obligations, policies and other obligations
related to data privacy and security. Our actual or perceived failure to comply with such obligations could lead to regulatory investigations
or actions; litigation; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; loss
of customers or sales; and other adverse business consequences.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the ordinary course of business, we process, generate, use, transfer, disclose, make accessible, protect, secure, dispose of, transmit,
and share (collectively, processing) personal data and other sensitive information, including proprietary and confidential business data,
trade secrets, intellectual property, data we collect about trial participants in connection with clinical trials, sensitive third-party
data, and patient information. Our data processing activities may subject us to numerous data privacy and security obligations, such
as various laws, regulations, guidance, industry standards, external and internal privacy and security policies, contracts, and other
obligations that govern the processing of personal data by us and on our behalf.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may be subject to or affected by evolving federal, state and foreign data protection laws and regulations, such as laws and regulations
that address privacy and data security. In the United States, federal, state, and local governments have enacted numerous data privacy
and security laws, including data breach notification laws, personal data privacy laws, and consumer protection laws (e.g. Section 5
of the Federal Trade Commission Act). For example, HIPAA as amended by the Health Information Technology for Economic and Clinical Health
Act (HITECH), imposes specific requirements relating to the privacy, security, and transmission of individually identifiable health information.
We may obtain health information or other personal information from third parties, including research institutions from which we obtain
clinical trial data, that are subject to privacy and security requirements under HIPAA. While we do not believe that we are currently
acting as a covered entity or business associate under HIPAA and thus are not directly regulated under HIPAA, any person may be prosecuted
under HIPAA&rsquo;s criminal provisions if it knowingly receives individually identifiable health information from a HIPAA-covered healthcare
provider or research institution that has not satisfied HIPAA&rsquo;s requirements for disclosure of individually identifiable health
information under aiding-and-abetting or conspiracy principles.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 61; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
states have also adopted data privacy and security laws and regulations, which govern the privacy, processing and protection of health-related
and other personal information. Such laws and regulations will be subject to interpretation by various courts and other governmental
authorities, thus creating potentially complex compliance issues for us and our future customers and strategic partners. For example,
the California Consumer Privacy Act of 2018 (CCPA) imposes obligations on covered businesses. These obligations include, but are not
limited to, providing specific disclosures in privacy notices and affording California residents certain rights related to their personal
data. The CCPA allows for statutory fines for noncompliance (up to $7,500 per violation). Although the CCPA exempts some data processed
in the context of clinical trials, the CCPA may increase compliance costs and potential liability with respect to other personal data
we may maintain about California residents. In addition, it is anticipated that the California Privacy Rights Act of 2020 (CPRA), effective
January 1, 2023, would expand the CCPA. The CPRA establishes a new California Privacy Protection Agency to implement and enforce
the CPRA, which could increase the risk of enforcement. Other states have enacted data privacy laws. For example, Virginia passed the
Consumer Data Protection Act, and Colorado passed the Colorado Privacy Act, both of which became effective in 2023. In addition,
data privacy and security laws have been proposed at the federal, state, and local levels in recent years, which could further complicate
compliance efforts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outside
the United States, an increasing number of laws, regulations, and industry standards apply to data privacy and security. For example,
the European Union&rsquo;s General Data Protection Regulation (EU GDPR), the United Kingdom&rsquo;s GDPR (UK GDPR), and the Swiss Federal
Act on Data Protection impose strict requirements for processing personal data. For example, under the EU GDPR, government regulators
may impose temporary or definitive bans on data processing, as well as fines of up to 20 million euros or 4% of annual global revenue,
whichever is greater. Further, individuals or consumer protection organizations authorized at law to represent their interests may initiate
litigation related to processing of individuals&rsquo; personal data.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compliance
with U.S. and foreign data protection laws and regulations could require us to take on more onerous obligations in our contracts, in
addition to direct compliance obligations under those laws. We may be directly or contractually subject to data privacy and security
obligations, including industry standards adopted by industry groups and may become subject to new data privacy and security obligations
in the future. For example, certain privacy laws, such as the EU GDPR and the CCPA, require companies to impose specific contractual
restrictions on their service providers. Moreover, clinical trial subjects about whom we or our potential collaborators obtain information,
as well as the providers who share this information with us, may contractually limit our ability to use and disclose the information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the ordinary course of business, we may transfer personal data from Europe and other jurisdictions to the United States or other countries.
Europe and other jurisdictions have enacted laws requiring data to be localized or limiting the transfer of personal data to other countries.
In particular, Europe has significantly restricted the transfer of personal data to the United States and other countries whose privacy
laws it believes are inadequate. Other jurisdictions may adopt similarly stringent interpretations of their data localization and cross-border
data transfer laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
there are currently various mechanisms that may be used to transfer personal data from Europe to the United States in compliance with
law, such as the EU and UK&rsquo;s standard contractual clauses, these mechanisms are subject to legal challenges, and there is no assurance
that we can satisfy or rely on these measures to lawfully transfer personal data to the United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
there is no lawful manner for us to transfer personal data from Europe or other jurisdictions to the United States, or if the requirements
for a legally-compliant transfer are too onerous, we could face significant adverse consequences, including the interruption or degradation
of our operations, the need to relocate part of or all of our business or data processing activities to other jurisdictions at significant
expense, increased exposure to regulatory actions, substantial fines and penalties, the inability to transfer data and work with partners,
vendors and other third parties, which could limit our ability to conduct clinical trial activities in Europe or elsewhere, and injunctions
against our processing or transferring of personal data necessary to operate our business. Some European regulators have prevented companies
from transferring personal data out of Europe for allegedly violating the GDPR and EU&rsquo;s cross-border data transfer limitations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Obligations
related to data privacy and security are quickly changing in an increasingly stringent fashion, creating some uncertainty as to the effective
future legal framework. Additionally, these obligations may be subject to differing applications and interpretations, which may be inconsistent
or conflict among jurisdictions. Preparing for and complying with these obligations requires significant resources and may necessitate
changes to our information technologies, systems, and practices and to those of any third parties that process personal data on our behalf.
Although we endeavor to comply with all applicable data privacy and security obligations, we may at times fail (or be perceived to have
failed) to do so. We may also be bound by contractual obligations related to data privacy and security, and our efforts to comply with
such obligations may not be successful. Additionally, we publish privacy policies, self-certifications, and other documentation regarding
our collection, use and disclosure of personal information and/or other confidential information. Although we endeavor to comply with
our published policies, certifications, and documentation, we may at times fail to do so or may be perceived to have failed to do so.
Moreover, despite our efforts, our personnel or third parties upon whom we rely may fail to comply with such obligations. Such failures
can subject us to potential international, local, state and federal action if they are found to be deceptive, unfair, or misrepresentative
of our actual practices, which could negatively impact our business operations and compliance posture. For example, any failure by a
third-party processor to comply with applicable law, regulations, or contractual obligations could result in adverse effects, including
inability to or interruption in our ability to operate our business and proceedings against us by governmental entities or others. If
we fail, or are perceived to have failed, to address or comply with data privacy and security obligations, we could face significant
consequences. These consequences may include, but are not limited to, government enforcement actions (e.g., investigations, fines, penalties,
audits, inspections, and similar); litigation (including class-related claims); additional reporting requirements and/or oversight; bans
on processing personal data; orders to destroy or not use personal data; and imprisonment of company officials. Any of these events could
have a material adverse effect on our reputation, business, or financial condition, including but not limited to: loss of customers;
interruptions or stoppages in our business operations (including, as relevant, clinical trials); inability to process personal data or
to operate in certain jurisdictions; limited ability to develop or commercialize our products; expenditure of time and resources to defend
any claim or inquiry; adverse publicity; or revision or restructuring of our operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 62; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Violations
of or liabilities under environmental, health and safety laws and regulations could subject us to fines, penalties or other costs that
could have a material adverse effect on the success of our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to numerous federal, state and local environmental, health and safety laws and regulations, including those governing
laboratory procedures, the handling, use, storage, treatment and disposal of hazardous materials and wastes and the cleanup of
contaminated sites. Our operations involve the controlled production, storage, use and disposal of hazardous and flammable
materials, including chemicals and biological materials such as infectious agents and various radioactive compounds. We would incur
substantial costs as a result of violations of or liabilities under environmental requirements in connection with our operations or
property, including fines, penalties and other sanctions, investigation and cleanup costs and third-party claims. Although we
generally contract with third parties for the disposal of hazardous materials and wastes from our operations, we cannot eliminate
the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of
hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could
incur significant costs associated with civil or criminal fines and penalties, as well as our curtailment of the use of these
materials or even shutting down our facilities and operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
we maintain workers&rsquo; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting
from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. While we maintain
insurance covering our manufacturing facility only, and not our other facilities, for environmental liability or toxic tort claims that
may be asserted against us in connection with our storage or disposal of biological or hazardous materials, such insurance coverage may
not be sufficient to cover extraordinary or unanticipated events at our manufacturing facility.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to Ownership of Our Common Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
you purchase common stock in this offering, you will suffer immediate dilution of your investment.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
initial public offering price per share of our common stock is substantially higher than the pro forma as adjusted net tangible book
value per share. Therefore, if you purchase common stock in this offering, you will pay a price per share that substantially exceeds
our pro forma as adjusted net tangible book value per share after this offering. Based on an assumed initial public offering price of
$4.00 per share, you will experience immediate dilution of $3.61 per share, representing the difference between our pro forma
as adjusted net tangible book value per share after this offering and the assumed initial public offering price per share. After this
offering, we will also have outstanding options and warrants to purchase shares of our common stock, in some cases with exercise prices
lower than the initial public offering price. To the extent these outstanding options or warrants are exercised, there will be further
dilution to investors in this offering. For further information regarding the dilution resulting from this offering, see the section
titled &ldquo;Dilution&rdquo; in this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Future
sales of our common stock, or</I></B></FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I> the perception in
the public markets that these sales may occur, could cause the market price for our common stock to decline.</I></B></FONT><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
of a substantial number of shares of our common stock in the public market could occur at any time, subject to the restrictions and limitations
described below. If our stockholders sell, or the market perceives that our stockholders intend to sell, substantial amounts of our common
stock in the public market following this offering, the market price of our common stock could decline significantly.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the closing of this offering, we will have 12,761,179 outstanding shares of common stock, after giving effect to the conversion
of all $675,000 of our outstanding convertible notes into 281,250 shares of common stock, assuming no exercise of the underwriters&rsquo;
over-allotment option and no exercise of outstanding stock options. Of these shares, the shares sold in this offering will be freely
tradable and the remaining shares of common stock will be available for sale in the public market beginning after the end of the 180<SUP>th
</SUP>day after the date of this prospectus following the expiration of lock-up agreements between our stockholders and certain of the
underwriters for this offering, subject, in the case of our affiliates, to the conditions of Rule 144 under the Securities Act. The representatives,
on behalf of the underwriters, may release these stockholders from their lock-up agreements at any time and without notice, which would
allow for earlier sales of shares in the public market subject to the conditions of Rule 144 under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 63; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">We have reserved 1,650,000
shares of common stock for issuance under our 2023 equity incentive plans (the &ldquo;2023 Equity Incentive Plan&rdquo;),
of which we will issue a total of $150,000 in options to purchase shares of common stock to our independent directors upon completion
of this initial public offering. We cannot predict the effect, if any, that market sales of shares of our common stock or the availability
of shares of our common stock for sale will have on the market price of our common stock prevailing from time to time. Sales of substantial
amounts of shares of our common stock in the public market, or the perception that those sales will occur, could cause the market price
of our common stock to decline.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, promptly following the closing of this
offering, we intend to file a registration statement on Form S-8 registering the shares of common stock subject to options or other equity
awards issued or reserved for future issuance under our 2023 Equity Incentive Plan. Shares registered on Form S-8
will be available for sale in the public market subject to vesting arrangements and exercise of options, the lock-up agreements described
above and, in the case of our affiliates, the restrictions of Rule 144 under the Securities Act.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
after this offering, the holders of an aggregate of shares of our common stock, or their transferees, will have rights, subject to some
conditions, to require us to file one or more registration statements covering their shares or to include their shares in registration
statements that we may file for ourselves or other stockholders. If we were to register the resale of these shares, they could be freely
sold in the public market without limitation. If these additional shares are sold, or if it is perceived that they will be sold, in the
public market, the trading price of our common stock could decline.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Financings
could adversely affect common stock ownership interest and rights in comparison with those of other security holders.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors, in accordance with our Certificate of Incorporation and Bylaws, has the power to issue additional shares of
common stock or preferred stock without stockholder approval. If additional funds are raised through the issuance of equity or convertible
debt securities, the percentage ownership of our existing stockholders will be reduced, and these newly issued securities may have rights,
preferences or privileges senior to those of existing stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Our board of directors may establish
the rights, privileges, preferences and restrictions, including voting rights, of future series of stock and to issue such stock without
approval from our shareholders. The rights of holders of common stock may suffer as a result of the rights granted to holders of preferred
stock that may be issued in the future. In addition, we could issue preferred stock to prevent a change in control of our Company, depriving
common shareholders of an opportunity to sell their stock at a price in excess of the prevailing market price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we issue any additional common stock or securities convertible into common stock, such issuance will reduce the proportionate ownership
and voting power of each other stockholder. In addition, such stock issuances might result in a reduction of the per share book value
of our common stock and result in what is more commonly known as dilution. We may issue further shares as consideration for the cash
or assets or services out of our authorized but unissued common stock that would, upon issuance, represent a majority of the voting power
and equity of our Company. The result of such an issuance would be those new stockholders and management would control our Company, and
persons unknown could replace our management at that time. Such an occurrence would result in a greatly reduced percentage of ownership
of our Company by our current stockholders, which could present significant risks to stockholders. The Company may raise capital in the
futures in &ldquo;down rounds&rdquo; at a lower per share price than it&rsquo;s the price in this offering or the trading price for our
stock, which would be dilutive to prior investors, and there can be no assurance that future rounds will not be necessary that would
be dilutive to investors in the current round. Investors may experience dilution in any future financing conducted by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may not be able to satisfy listing requirements of NYSE American  or maintain a listing of our common stock on such exchange.</I></B></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
our common stock is listed for trading on NYSE American, we must meet certain financial and liquidity criteria
to maintain such listing. If we violate the listing requirements of such stock exchange, or if we fail to meet any of such
exchange&rsquo;s continued listing standards, our common stock may be delisted. In addition, our board of directors may determine
that the cost of maintaining our listing on a national securities exchange outweighs the benefits of such listing. A delisting of our
common stock from  NYSE American may materially impair our stockholders&rsquo; ability to buy and sell our common
stock and could have an adverse effect on the market price of, and the efficiency of the trading market for, our common stock. The delisting
of our common stock could significantly impair our ability to raise capital and the value of your investment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
our shares of common stock become subject to the penny stock rules, it would become more difficult to trade our shares.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
SEC has adopted rules that regulate broker-dealer practices in connection with transactions in penny stocks. Penny stocks are generally
equity securities with a price of less than $5.00, other than securities registered on certain national securities exchanges or authorized
for quotation on certain automated quotation systems, provided that current price and volume information with respect to transactions
in such securities is provided by the exchange or system. If we do not retain a listing on NYSE American or another national
securities exchange and if the price of our common stock is less than $5.00, our common stock could be deemed a penny stock. The penny
stock rules require a broker-dealer, before a transaction in a penny stock not otherwise exempt from those rules, to deliver a standardized
risk disclosure document containing specified information. In addition, the penny stock rules require that before effecting any transaction
in a penny stock not otherwise exempt from those rules, a broker-dealer must make a special written determination that the penny stock
is a suitable investment for the purchaser and receive (i) the purchaser&rsquo;s written acknowledgment of the receipt of a risk disclosure
statement; (ii) a written agreement to transactions involving penny stocks; and (iii) a signed and dated copy of a written suitability
statement. These disclosure requirements may have the effect of reducing the trading activity in the secondary market for our common
stock, and therefore stockholders may have difficulty selling their shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>While
we will not be a controlled company following completion of our initial public offering, our Chairman of the board of directors
presently has control over key decision making as a result of his control of a majority of our voting stock and exercises significant
voting power.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
completion of this offering, John S. Yu, our Chairman, and CEO, will be able to exercise voting rights with respect to an aggregate of
5,316,572 shares of common stock, which represents approximately 43.7% of the voting power of our outstanding capital stock. As
a result, Dr. Yu has the ability to control the outcome of matters submitted to our stockholders for approval, including the election
of directors and any merger, consolidation, or sale of all or substantially all of our assets. This concentrated control could delay,
defer, or prevent a change of control, merger, consolidation, or sale of all or substantially all of our assets that our other stockholders
support, or conversely this concentrated control could result in the consummation of such a transaction that our other stockholders do
not support. This concentrated control could also discourage a potential investor from acquiring our common stock due to the limited
voting power of such stock relative to the shares of common stock and might harm the market price of our common stock. In addition, Dr.
Yu has the ability to control the management and major strategic investments of our company as a result of his position as our CEO and
his ability to control the election or replacement of our directors. In the event of his death, the shares of our capital stock that
Dr. Yu owns will be transferred to the persons or entities that he designates. As a board member and officer, Dr. Yu owes a fiduciary
duty to our stockholders and must act in good faith in a manner he reasonably believes to be in the best interests of our stockholders.
As a stockholder, even a controlling stockholder, Dr. Yu is entitled to vote his shares in his own interests, which may not always be
in the interests of our stockholders generally.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Concentration
of ownership of our common stock among our existing executive officers, directors, and principal stockholders may prevent new investors
from influencing significant corporate decisions and matters submitted to stockholders for approval.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
completion of this offering, our executive officers, directors, and current beneficial owners of 5% or more of our capital stock and
their respective affiliates will, in the aggregate, beneficially own 71.8% of our outstanding common stock, based on the number of shares
of our capital stock outstanding as of April [&nbsp;&nbsp;], 2024, assuming no exercise of the underwriters&rsquo; over-allotment
option and no exercise of outstanding options. As a result, these persons, acting together, would be able to significantly influence
all matters requiring stockholder approval, including the election and removal of directors, any merger, consolidation, or sale of all
or substantially all of our assets, or other significant corporate transactions. In addition, these persons, acting together, may have
the ability to control the management and affairs of our company. Accordingly, this concentration of ownership may harm the market price
of our common stock by:</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">delaying,
    deferring, or preventing a change in control;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">entrenching
    our management and/or the board of directors;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">impeding
    a merger, consolidation, takeover, or other business combination involving us; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">discouraging
    a potential acquirer from making a tender offer or otherwise attempting to obtain control of us.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 64; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, some of these persons or entities may have interests different than yours. For example, because many of these stockholders
purchased their shares at prices substantially below the price at which shares are being sold in this offering and have held their shares
for a longer period, they may be more interested in selling our company to an acquirer than other investors, or they may want us to pursue
strategies that deviate from the interests of other stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Provisions
in our corporate charter documents and under Delaware law could make an acquisition of our company, which may be beneficial to our stockholders,
more difficult and may prevent attempts by our stockholders to replace or remove our current management. </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provisions
in our certificate of incorporation and our bylaws may discourage, delay or prevent a merger, acquisition, or other change in control
of our company that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your
shares. These provisions also could limit the price that investors might be willing to pay in the future for shares of our common stock,
thereby depressing the market price of our common stock. In addition, because our board of directors is responsible for appointing the
members of our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current
management by making it more difficult for stockholders to replace members of our board of directors. Among other things, these provisions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">allow
                                            the authorized number of our directors to be changed only by resolution of our board of directors;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">limit
                                            the manner in which stockholders can remove directors from the board of directors;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">establish
                                            advance notice requirements for stockholder proposals that can be acted on at stockholder
                                            meetings and nominations to our board of directors;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">require
                                            that stockholder actions must be effected at a duly called stockholder meeting and prohibit
                                            actions by our stockholders by written consent;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">limit
                                            who may call stockholder meetings;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">authorize
                                            our board of directors to issue preferred stock without stockholder approval, which could
                                            be used to institute a stockholder rights plan, or so-called &#8220;poison pill,&#8221; that
                                            would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing
                                            acquisitions that have not been approved by our board of directors; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">require
                                            the approval of the holders of at least 66 2/3% of the votes that all our stockholders would
                                            be entitled to cast to amend or repeal certain provisions of our charter or bylaws.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 38.45pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, or
the DGCL, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a
period of three years after the date of the transaction in which the person acquired more than 15% of our outstanding voting stock, unless
the merger or combination is approved in a prescribed manner. These provisions could discourage potential acquisition proposals and could
delay or prevent a change in control transaction. They could also have the effect of discouraging others from making tender offers for
our common stock, including transactions that may be in your best interests. These provisions may also prevent changes in our management
or limit the price that investors are willing to pay for our stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
certificate of incorporation provides that unless we consent in writing to the selection of an alternative forum, and except for actions
brought under the Securities Act or the Exchange Act, the Court of Chancery of the State of Delaware will be the exclusive forums
for substantially all disputes between us and our stockholders. In addition, our exclusive
forum provision may result in increased costs for investors to bring a claim.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
certificate of incorporation provides that unless we consent in writing to the selection of an alternative forum, and except for actions
brought under the Securities Act or the Exchange Act, the Court of Chancery of the State of Delaware is the exclusive forum for:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
                                            derivative action or proceeding brought on our behalf;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
                                            action asserting a breach of fiduciary duty;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
                                            action asserting a claim against us arising pursuant to any provision of the DGCL or our
                                            certificate of incorporation or bylaws;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any action or proceeding to interpret, apply, enforce, or determine the
validity of our certificate of incorporation, or our bylaws; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
                                            action asserting a claim against us or any of our directors, officers, employees, or agents
                                            that is governed by the internal-affairs doctrine.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 65; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
person purchasing or otherwise acquiring or holding any interest in shares of our capital stock is deemed to have received notice of
and consented to the foregoing provisions. These choice of forum provisions may limit a stockholder&rsquo;s ability to bring a claim
in a judicial forum that it finds more favorable for disputes with us or with our directors, officers, other employees or agents, or
our other stockholders, which may discourage such lawsuits against us and such other persons or may result in additional expense to a
stockholder seeking to bring a claim against us. Alternatively, if a court were to find this choice of forum provision inapplicable to,
or unenforceable in respect of, one or more of the specified types of actions or proceedings, we may incur additional costs associated
with resolving such matters in other jurisdictions, which could adversely affect our business, results of operations, financial condition,
and prospects. In addition, our exclusive forum provision may result in increased costs for investors to bring a claim.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
choice of forum provision in our certificate of incorporation specifically excludes actions brought under the Securities Act or Exchange
Act. Section 27 of the Exchange Act creates exclusive federal jurisdiction over all claims brought to enforce any duty or liability created
by the Exchange Act or the rules and regulations thereunder. Consequently, this forum selection provision would not apply to suits brought
to enforce a duty or liability created by the Exchange Act or any other claim for which the U.S. federal courts have exclusive jurisdiction.
Moreover, Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all claims brought to enforce
any duty or liability created by the Securities Act or the rules and regulations thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
the Delaware courts have determined that such choice of forum provisions are facially valid, a stockholder may nevertheless seek to bring
a claim in a venue other than those designated in the exclusive forum provisions, and there can be no assurance that such provisions
will be enforced by a court in those other jurisdictions. We note that investors cannot waive compliance with the federal securities
laws and the rules and regulations thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
will have broad discretion in the use of proceeds from this offering and may invest or spend the proceeds in ways with which you do not
agree and in ways that may not increase the value of your investment. </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management will have broad discretion in the application of our cash, including the net proceeds from this offering, and could spend
the proceeds in ways that do not improve our results of operations or enhance the value of our common stock. The failure by our management
to apply these funds effectively could result in financial losses that could have a negative impact on our business, cause the price
of our common stock to decline, and delay the development of our current in-development products and planned pipeline and expansion programs
as well as commercial preparedness. Pending their use, we may invest our cash, including the net proceeds from this offering, in a manner
that does not produce value or that loses value. See the section titled &ldquo;Use of Proceeds&rdquo; for additional information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
do not anticipate paying any cash dividends on our capital stock in the foreseeable future, and accordingly, stockholders must rely on
capital appreciation, if any, for any return on their investment. </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not anticipate paying any cash dividends on our common stock in the foreseeable future. Instead, we plan to retain any earnings to
maintain and expand our existing operations. In addition, any future credit facility or debt securities may contain terms prohibiting
or limiting the amount of dividends that may be declared or paid on our common stock. If we do not pay cash dividends, you could receive
a return on your investment in our common stock only if you are able to sell your shares in the future and the market price of our common
stock has increased when you sell your shares. As a result, investors seeking cash dividends should not purchase our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>General
Risk Factors </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>An
active trading market for our common stock may not develop and you may not be able to resell your shares at or above the initial offering
price, if at all. </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
offering constitutes the initial public offering of our common stock, and no public market has previously existed for our common stock.
We have applied to list our common stock on NYSE American and are awaiting determination on which
stock exchange we may qualify. Any delay in the commencement of trading of our common stock on such exchange would impair
the liquidity of the market for the shares and make it more difficult for holders to sell their shares of our common stock. If our common
stock is listed and quoted on NYSE American, there can be no assurance that an active trading market
for the shares will develop or be sustained after this offering is completed. The initial offering price will be determined by negotiations
among the lead underwriters and us. Among the factors to be considered in determining the initial public offering price are our future
prospects and the prospects of our industry in general, our financials and certain other financial and operating information in recent
periods, and the market prices of securities and certain financial and operating information of companies engaged in activities similar
to ours. However, there can be no assurance that, following the completion of this offering, the shares of our common stock will trade
at a price equal to or greater than the public offering price.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 66; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
trading price of our common stock may be volatile, and you could lose all or part of your investment. </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
trading price of our common stock following this offering is likely to be highly volatile and could be subject to wide fluctuations in
response to various factors, some of which are beyond our control, including limited trading volume. The stock market in general and
the market for biopharmaceutical companies in particular have experienced extreme volatility that has often been unrelated to the operating
performance of particular companies. As a result of this volatility, investors may not be able to sell their shares at or above the price
paid for the shares. In addition to the factors discussed in this &ldquo;Risk Factors&rdquo; section and elsewhere in this prospectus,
these factors include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            commencement, enrollment, or results of our planned and future clinical trials;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            loss of any of our key research, development, or management personnel;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
                                            or legal changes or developments in the United States and other countries or in the status
                                            of our regulatory approvals;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            success of competitive products or technologies;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            emergence of new competitors or new technologies;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            ability to develop and market new and enhanced products on a timely basis;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">adverse
                                            actions taken by regulatory agencies with respect to our clinical trials or manufacturers;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
                                            or developments in laws or regulations applicable to our current in-development products
                                            or any future product candidates;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
                                            to our relationships with collaborators, manufacturers, or suppliers;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            results of our testing and clinical trials;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">disruption
                                            to our operations or those of other sources critical to our operations;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">unanticipated
                                            safety, tolerability, or efficacy concerns;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements
                                            by us or our competitors of acquisitions, new products, significant contracts, commercial
                                            relationships or capital commitments;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">other
                                            announcements concerning our competitors or the pharmaceutical industry in general;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">actual
                                            or anticipated fluctuations in our operating results or those of our competitors;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
                                            in financial estimates or recommendations by securities analysts;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">potential
                                            acquisitions;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            results of our efforts to discover, develop, acquire, or in-license additional product candidates;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">commencement
                                            of, or our involvement in, litigation;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">dilutive
                                            issuances of our stock or the stock of our subsidiaries, or the incurrence of additional
                                            debt;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
                                            in our board of directors or management;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">adoption
                                            of new or different accounting standards;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            trading volume of our common stock on NYSE American;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">sales
                                            of our common stock by us, our executive officers and directors or our stockholders or the
                                            anticipation that such sales may occur in the future;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">general
                                            economic, political, and market conditions and overall fluctuations in the financial markets
                                            in the United States or the United Kingdom (including those relating to macroeconomic events,
                                            such as the COVID-19 pandemic and the recent outbreak of hostilities between Russia and Ukraine);</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">stock
                                            market price and volume fluctuations of comparable companies and, in particular, those that
                                            operate in the biopharmaceutical industry;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">general
                                            economic conditions and slow or negative growth of related markets; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">investors&#8217;
                                            general perception of us and our business.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
and other market and industry factors may cause the market price and demand for our common stock to fluctuate substantially,
regardless of our actual operating performance, which may limit or prevent investors from selling their shares of our common stock
at or above the price paid for the shares and may otherwise negatively affect the liquidity of our common stock. In addition, the
stock market in general, and biopharmaceutical companies in particular, have experienced extreme price and volume fluctuations that
have often been unrelated or disproportionate to the operating performance of these companies. </FONT>Some companies that have
experienced volatility in the trading price of their shares have been the subject of securities class action litigation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><B><I>Any
lawsuit to which we are a party, regardless of merit, may result in an unfavorable judgment. We also may decide to settle lawsuits
on unfavorable terms. Any such negative outcome could result in payments of substantial damages or fines, damage to our reputation or
adverse changes to our business practices.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">Any
lawsuit to which we are a party, regardless of the merit of such lawsuit, may result in an unfavorable judgment. We also may decide to
settle lawsuits on unfavorable terms. Any such negative outcome could result in payments of substantial damages or fines, damage to our
reputation or adverse changes to our business practices. Defending against litigation is costly and time-consuming and could divert
our management&rsquo;s attention and our resources. Furthermore, during the course of litigation, there could be negative public announcements
of the results of hearings, motions, or other interim proceedings or developments, which could have a negative effect on the market price
of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 67; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
equity research analysts do not publish research or reports, or publish unfavorable research or reports, about us, our business, or our
market, our stock price and trading volume could decline. </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
trading market for our common stock will be influenced by the research and reports that equity research analysts publish about us and
our business. We do not currently have and may never obtain research coverage by equity research analysts. Equity research analysts may
elect not to provide research coverage of our common stock after the completion of this offering, and such lack of research coverage
may adversely affect the market price of our common stock. In the event we do have equity research analyst coverage, we will not have
any control over the analysts or the content and opinions included in their reports. The price of our shares could decline if one or
more equity research analysts downgrade our shares or issue other unfavorable commentary or research about us. If one or more equity
research analysts ceases coverage of us or fails to publish reports on us regularly, demand for our shares could decrease, which in turn
could cause the trading price or trading volume of our common stock to decline.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
will incur significantly increased costs as a result of operating as a company whose common stock is publicly traded in the United States,
and our management will be required to devote substantial time to new compliance initiatives. </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a public company in the United States, we will incur significant legal, accounting, and other expenses that we did not incur previously.
These expenses will likely be even more significant after we no longer qualify as an emerging growth company. The Sarbanes-Oxley Act,
the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of NYSE American, and other applicable securities rules and regulations impose various requirements on public companies in the United States, including
the establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Our senior management
and other personnel will need to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations
will increase our legal and financial compliance costs and will make some activities more time-consuming and costly. For example, we
expect that these rules and regulations may make it more difficult and more expensive for us to obtain director and officer liability
insurance, which in turn could make it more difficult for us to attract and retain qualified senior management personnel or members for
our board of directors. We cannot predict or estimate the amount of additional costs we may incur or the timing of such costs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">However,
these rules and regulations are often subject to varying interpretations, in many cases due to their lack of specificity, and, as a result,
their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result
in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance
practices.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to Section 404, public companies are required to furnish a report by our senior management on our internal control over financial
reporting. However, as we are presently an emerging growth company, so long as we remain in the status, or up to five years,
we will not be required to include an attestation report on internal control over financial reporting issued by our independent registered
public accounting firm. At such time as we will be required to prepare for eventual compliance with Section 404, we will be required
to engage in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging.
In this regard, we will need to continue to dedicate internal resources, potentially engage outside consultants, and adopt a detailed
work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes
as appropriate, validate through testing that controls are functioning as documented, and implement a continuous reporting and improvement
process for internal control over financial reporting. Despite our efforts, there is a risk that we will not be able to conclude, within
the prescribed timeframe or at all, that our internal control over financial reporting is effective as required by Section 404. Identifying
material weaknesses could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our
financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Significant
disruptions of our information technology systems or data security incidents could result in significant financial, legal, regulatory,
business, and reputational harm to us. </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are increasingly dependent on information technology systems and infrastructure, including mobile technologies, to operate our business.
In the ordinary course of our business, we collect, store, process, and transmit large amounts of sensitive information, including intellectual
property, proprietary business information, personal information, and other confidential information. It is critical that we do so in
a secure manner to maintain the confidentiality, integrity, and restricted availability of such sensitive information. We have also outsourced
elements of our operations, including elements of our information technology infrastructure, to third parties and, as a result, we manage
a number of third-party vendors who may or could have access to our computer networks or our confidential information. In addition, many
of those third parties in turn subcontract or outsource some of their responsibilities to other third parties. While all information
technology operations are inherently vulnerable to inadvertent or intentional security breaches, incidents, attacks, and exposures, the
accessibility and distributed nature of our information technology systems, and the sensitive information stored on those systems, make
such systems potentially vulnerable to unintentional or malicious, internal, and external attacks on our technology environment. Potential
vulnerabilities can be exploited from inadvertent or intentional actions of our employees, third-party vendors, business partners, or
by malicious third parties. Attacks of this nature are increasing in their frequency, levels of persistence, sophistication, and intensity,
and are being conducted by sophisticated and organized groups and individuals with a wide range of motives (including industrial espionage)
and expertise, including organized criminal groups, &ldquo;hacktivists,&rdquo; nation states, and others. In addition to the extraction
of sensitive information, such attacks could include the deployment of harmful malware, ransomware, denial-of-service attacks, social
engineering, and other means to affect service reliability and threaten the confidentiality, integrity, and availability of information.
In addition, the prevalent use of mobile devices increases the risk of data security incidents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 68; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant
disruptions of our or our third-party vendors&rsquo; or business partners&rsquo; information technology systems or other similar data
security incidents could adversely affect our business operations and result in the loss, misappropriation, and unauthorized access,
use or disclosure of, or the prevention of access to, sensitive information, which could result in financial, legal, regulatory, business,
and reputational harm to us. In addition, information technology system disruptions, whether from attacks on our technology environment
or from computer viruses, natural disasters, terrorism, war, and telecommunication and electrical failures, could result in a material
disruption of our development programs and our business operations. For example, the loss of clinical trial data from ongoing, completed
or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or
reproduce the data. We cannot ensure that our data protection efforts and our investment in information technology, or the efforts or
investments of CROs, consultants or other third parties with which we work, will prevent breakdowns or breaches in our or their systems
or other cybersecurity incidents that cause loss, destruction, unavailability, alteration, dissemination of, or damage, or unauthorized
access to, our data, including personal data, assets, and other data processed or maintained on our behalf, that could have a material
adverse effect upon our reputation, business, operations, or financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
we have implemented security measures intended to protect our information technology systems and infrastructure, there can be no assurance
that such measures will successfully prevent service interruptions or security incidents. There is no way of knowing with certainty whether
we have experienced any data security incidents that have not been discovered. While we have no reason to believe this to be the case,
attackers have become very sophisticated in the way they conceal access to systems, and many companies that have been attacked are not
aware that they have been attacked. Any event that leads to unauthorized access, use, or disclosure of personal information, including
personal information regarding our patients or employees, could disrupt our business, harm our reputation, compel us to comply with applicable
federal and state breach notification laws and foreign law equivalents, subject us to time-consuming, distracting, and expensive litigation,
regulatory investigation and oversight, mandatory corrective action, require us to verify the correctness of database contents, or otherwise
subject us to liability under laws, regulations, and contractual obligations, including those that protect the privacy and security of
personal information. This could result in increased costs to us, and result in significant legal and financial exposure and reputational
harm. In addition, any failure or perceived failure by us or our vendors or business partners to comply with our privacy, confidentiality,
or data security-related legal or other obligations to third parties, or any further security incidents or other inappropriate access
events, may result in governmental investigations, enforcement actions, regulatory fines, litigation, or public statements against us
by advocacy groups or others, and could cause third parties, including clinical sites, regulators, or current and potential partners,
to lose trust in us, or we could be subject to claims by third parties that we have breached our privacy- or confidentiality-related
obligations. Moreover, data security incidents and other inappropriate access can be difficult to detect, and any delay in identifying
them may lead to increased harm of the type described above. Any of the foregoing could have a material adverse effect on our reputation,
business, operations, or financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
are an &ldquo;emerging growth company&rdquo; and as a result of the reduced disclosure and governance requirements applicable to emerging
growth companies, our common stock may be less attractive to investors. </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are an &ldquo;emerging growth company&rdquo; as defined in the JOBS Act. For so long as we remain an emerging growth company, we are
permitted by SEC rules and plan to rely on exemptions from certain disclosure requirements that are applicable to other SEC-registered
public companies that are not emerging growth companies. These exemptions include not being required to comply with the auditor attestation
requirements of Section 404, not being required to comply with the auditor requirements to communicate critical audit matters in the
auditor&rsquo;s report on the financial statements, reduced disclosure obligations regarding executive compensation, and exemptions from
the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments
not previously approved. As a result, the information we provide stockholders will be different than the information that is available
with respect to other public companies. We have taken advantage of reduced reporting burdens in this prospectus. In particular, in this
prospectus, we have provided only two years of audited financial statements and we have not included all of the executive compensation
related information that would be required if we were not an emerging growth company. We cannot predict whether investors will find our
common stock less attractive if we rely on these exemptions. If some investors find our common stock less attractive as a result, there
may be a less active trading market for our common stock, and our stock price may be more volatile.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with
new or revised accounting standards. This allows an emerging growth company to delay the adoption of certain accounting standards until
those standards would otherwise apply to private companies. We have elected to avail ourselves of this exemption and, therefore, we will
not be subject to the same requirements to adopt new or revised accounting standards as other public companies that are not &ldquo;emerging
growth companies.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 69; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
are also classified as a &ldquo;smaller reporting company&rdquo; and are exempt from certain disclosure requirements, which could make
our stock less attractive to potential investors.</I></B></FONT></P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rule
12b-2 of the Exchange Act defines a &ldquo;smaller reporting company&rdquo; as an issuer that is not an investment company, an asset-backed
issuer, or a majority-owned subsidiary of a parent that is not a smaller reporting company and that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt; text-indent: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Had
                                            a public float of less than $250 million as of the last business day of its most recently
                                            completed fiscal quarter, computed by multiplying the aggregate number of worldwide number
                                            of shares of its voting and non-voting common equity held by non-affiliates by the price
                                            at which the common equity was last sold, or the average of the bid and asked prices of common
                                            equity, in the principal market for the common equity; or</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#9679;</TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
                                            the case of an initial registration statement under the Securities Act or the Exchange Act
                                            for shares of its common equity, had a public float of less than $250 million as of a date
                                            within 30 days of the date of the filing of the registration statement, computed by multiplying
                                            the aggregate worldwide number of such shares held by non-affiliates before the registration
                                            plus, in the case of a Securities Act registration statement, the number of such shares included
                                            in the registration statement by the estimated offering price of the shares; or</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#9679;</TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
                                            the case of an issuer who had annual revenue of less than $100 million during the most recently
                                            completed fiscal year for which audit financial statements are available, had a public float
                                            as calculated under paragraph (1) or (2) of this definition that was either zero or less
                                            than $700 million.</FONT></TD></TR></TABLE>

<P STYLE="text-align: justify; text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0pt; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a &ldquo;smaller reporting company&rdquo; we are not required and may not include a Compensation Discussion and Analysis section in our
proxy statements; we provide only three years of business development information; provide fewer years of selected data; and have other
&ldquo;scaled&rdquo; disclosure requirements that are less comprehensive than issuers that are not &ldquo;smaller reporting companies&rdquo;
which could make our stock less attractive to potential investors, which could make it more difficult for you to sell your shares.</FONT></P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>As
a &ldquo;smaller reporting company,&rdquo; we may at some time in the future choose to exempt our company from certain corporate governance
requirements that could have an adverse effect on our public shareholders.</I></B></FONT></P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
NYSE American rules, a &ldquo;smaller reporting company,&rdquo; as defined in Rule 12b-2 under the Exchange Act, is
not subject to certain corporate governance requirements otherwise applicable to companies listed on NYSE American.
For example, a smaller reporting company is exempt from the requirement of having a compensation committee composed solely of directors
meeting certain enhanced independence standards, as long as the compensation committee has at least two members who do meet such standards.
Although we have determined not to avail ourselves of this or other exemptions from NYSE American requirements that
are or may be afforded to smaller reporting companies while we will seek to maintain our shares on NYSE American, in
the future we may elect to rely on any or all of these exemptions. By electing to utilize any such exemptions, our Company may be subject
to greater risks of poor corporate governance, poorer management decision-making processes, and reduced results of operations from problems
in our corporate organization. Consequently, if we were to avail ourselves of these exemptions, our stock price might suffer, and there
is no assurance that we would be able to continue to meet all continued listing requirements of NYSE American from which we would not be exempt, including minimum stock price requirements.</FONT></P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Recent
and potential future changes to U.S. and non-U.S. tax laws could materially adversely affect our company. </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Existing,
new, or future changes in tax laws, regulations, and treaties, or the interpretation thereof, in addition to tax policy initiatives and
reforms under consideration in the United States or internationally and other initiatives could have an adverse effect on the taxation
of international businesses. Furthermore, countries where we are subject to taxes, including the United States, are independently evaluating
their tax policy and we may see significant changes in legislation and regulations concerning taxation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recently
enacted U.S. tax legislation has significantly changed the U.S. federal income taxation of U.S. corporations, including by reducing the
U.S. corporate income tax rate, limiting interest deductions, and revising the rules governing NOLs. Many of these changes are effective
immediately, without any transition periods or grandfathering for existing transactions. The legislation is unclear in many respects
and could be subject to potential amendments and technical corrections, as well as interpretations and implementing regulations by the
Treasury and Internal Revenue Service, or the IRS, any of which could lessen or increase certain adverse impacts of the legislation.
In addition, it is unclear how these U.S. federal income tax changes will affect state and local taxation, which often uses federal taxable
income as a starting point for computing state and local tax liabilities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
reduction of the corporate tax rate under the legislation may cause a reduction in the economic benefit of deferred tax assets available
to us.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2023, we had federal and state net operating loss, or NOLs, carryforwards of approximately $2.0 million,
respectively. Under the Tax Cuts and Jobs Act of 2017, or the Tax Act, as modified by the Coronavirus Aid, Relief, and Economic Security
Act, or the CARES Act, our NOLs generated in tax years beginning after December 31, 2020 may be carried forward indefinitely, but the
deductibility of such federal NOLs in tax years beginning after December 31, 2020, is limited to 80% of taxable income. This change may
require us to pay federal income taxes in future years despite generating a loss for federal income tax purposes in prior years. It is
uncertain if and to what extent various states will conform to the Tax Act or the CARES Act.</FONT></P>

<P STYLE="text-align: justify; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In addition, under Sections 382 and 383 of the U.S. Internal Revenue Code of 1986, as amended,
or the Code, if a corporation undergoes an &ldquo;ownership change,&rdquo; generally defined as a greater than 50 percentage point change
(by value) in its equity ownership by certain stockholders over a three-year period, the corporation&rsquo;s ability to use its pre-change
NOLs and other pre-change tax attributes (such as research and development tax credits) to offset its post-change income or taxes may
be limited. We may have experienced ownership changes in the past and may experience ownership changes in the future as a result of this
offering and/or subsequent shifts in our stock ownership (some of which may be outside our control). As a result, our ability to use
our pre-change NOLs and tax credits to offset post-change taxable income, if any, could be subject to limitations. Similar provisions
of state tax law may also apply. In addition, at the
state level, there may be periods during which the use of NOLs is suspended or otherwise limited, which could accelerate or permanently
increase state taxes owed.</FONT></P>

<P STYLE="margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We are unable to
predict what tax reform may be proposed or enacted in the future or what effect such changes would have on our business, but such changes,
to the extent they are brought into tax legislation, regulations, policies or practices, could affect our effective tax rates in the
future in countries where we have operations and have an adverse effect on our overall tax rate in the future, along with increasing
the complexity, burden, and cost of tax compliance. While some of the changes made by the tax legislation may adversely affect us
in one or more reporting periods and prospectively, other changes may be beneficial on a going-forward basis. We intend to work with
our tax advisors and auditors to determine the full impact that the recent tax legislation as a whole will have on us.</FONT></P>
<P STYLE="margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
urge our stockholders to consult with their legal and tax advisors with respect to any such legislative changes and the potential tax
consequences of investing in or holding our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Changes
in accounting standards and subjective assumptions, estimates and judgments by management related to complex accounting matters may materially
impact reporting of our financial condition and results of operations.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounting
principles generally accepted in the United States and related accounting pronouncements, implementation guidelines, and interpretations
we apply to a wide range of matters that are relevant to our business, such as accounting for long-lived asset impairment and share-based
compensation, are complex and involve subjective assumptions, estimates and judgments by our management. Changes in these rules or their
interpretation or changes in underlying assumptions, estimates or judgments by our management could significantly change or add significant
volatility to our reported or expected financial performance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>A
potential failure to maintain effective internal control over financial reporting in accordance with Section 404 of the Sarbanes-Oxley
Act could have a material adverse effect on our business, financial condition, and results of operations.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over
financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation
of financial statements in accordance with U.S. generally accepted accounting principles, or GAAP. Under standards established by the
Public Company Accounting Oversight Board, or PCAOB, a deficiency in internal control over financial reporting exists when the design
or operation of a control does not allow management or personnel, in the normal course of performing their assigned functions, to prevent
or detect misstatements on a timely basis. The PCAOB defines a material weakness as a deficiency, or combination of deficiencies, in
internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of annual or interim
financial statements will not be prevented, or detected and corrected, on a timely basis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will be required, pursuant to Section 404 of the Sarbanes-Oxley Act, to furnish a report by management on, among other things,
regarding the effectiveness of our internal control over financial reporting starting with the second annual report filed by
the Company after completion of our IPO and in each year thereafter. Our auditors, however, will not be required to attest
to the effectiveness of our internal control over financial reporting until we are no longer deemed an Emerging Growth Company, which
will not be until after we have been a public reporting company for five fiscal years or until we have annual gross revenues of more
than $1.235 billion, whichever occurs sooner. If we are unable to assert that our internal control over financial reporting is effective,
or when required in the future, investors may lose confidence in the accuracy and completeness of
our financial reports, the market price of our common stock could be adversely affected, and we could become subject to litigation or
investigations by the stock exchange on which our common stock are listed, the SEC or other regulatory authorities, which could require
additional financial and management resources and could have a material adverse effect on our business, financial condition, and results
of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I></I></B></FONT></P>

<!-- Field: Page; Sequence: 70; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
lack of public company experience of our management team could adversely impact our ability to comply with the reporting requirements
of U.S. securities laws, which could have a materially adverse effect on our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
officers have limited public company experience, which could impair our ability to comply with legal and regulatory requirements such
as those imposed by Sarbanes-Oxley Act. Such responsibilities include complying with federal securities laws and making required disclosures
on a timely basis. Any such deficiencies, weaknesses or lack of compliance could have a materially adverse effect on our ability to comply
with the reporting requirements of the Exchange Act, which is necessary to maintain our public company status. If we were to fail to
fulfill those obligations, our ability to continue as a U.S. public company would be in jeopardy in which event you could lose your entire
investment in our Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
could be subject to securities class action litigation.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the past, when the market price of a stock has been volatile, holders of that stock sometimes have instituted securities class action
litigation against the company that issued the stock following a decline in the market price of their securities. This risk is especially
relevant for us because biotechnology companies have experienced significant share price volatility in recent years. Securities litigation
against us, regardless of the merits or outcome, could result in substantial costs and divert the time and attention of our management
from our business, which could have a material adverse effect on our business, financial condition, and results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
directors&rsquo; liability to us and stockholders is limited; claims for indemnification by our directors and officers
may reduce our available funds to satisfy successful third-party claims against us and may reduce the amount of money available to us.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
certificate of incorporation and bylaws provide that we will indemnify our directors and officers, in each case, to the fullest extent
permitted by Delaware law. Pursuant to our bylaws and the DGCL, our directors will not be liable to the Company or any stockholders for
damages for any breach of fiduciary duty, except (i) acts that breach his or her duty of loyalty to the Company or its stockholders;
(ii) acts or omissions without good faith or involving intentional misconduct or knowing violation of the law; (iii) pursuant to Section
174 of the DGCL regarding director liability for unlawful payment of a dividend or unlawful stock purchase or redemption; or (iv) for
any transaction from which the director derived an improper personal benefit. Accordingly, we will have a much more limited right of
action against our directors that otherwise would be the case. This provision does not affect the liability of any director under federal
or applicable state securities laws. In addition, we have entered into indemnification agreements with each of our executive officers
and directors. The indemnification agreements provide the executive officers and directors with contractual rights to indemnification,
expense advancement and reimbursement, to the fullest extent permitted under the DGCL. The bylaws also require us, if so requested, to
advance expenses that such director or officer incurred in defending or investigating a threatened or pending action, suit or proceeding,
provided that such person will return any such advance if it is ultimately determined that such person is not entitled to indemnification
by us. Any claims for indemnification by our directors and officers may reduce our available funds to satisfy successful third-party
claims against us and may reduce the amount of money available to us.</FONT><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Indemnity
provisions in various agreements potentially expose us to substantial liability for intellectual property infringement, data protection,
and other losses. </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
agreements with third parties may include indemnification provisions under which we agree to indemnify them for losses suffered or incurred
as a result of claims of intellectual property infringement or other liabilities relating to or arising from our contractual obligations.
Large indemnity payments could harm our business and financial condition. Although we normally contractually limit our liability with
respect to such obligations, we may still incur substantial liability. Any dispute with a third party with respect to such obligations
could have adverse effects on our relationship with that third party and relationships with other existing or new partners, harming our
business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
are currently operating in a period of economic uncertainty and capital markets disruption, which has been significantly impacted by
geopolitical instability due to the ongoing military conflict between Russia and Ukraine.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.
and global markets are experiencing volatility and disruption following the escalation of geopolitical tensions and the start of the
military conflict between Russia and Ukraine. In February 2022, Russia launched a full-scale military invasion of Ukraine. Although the
length and impact of the ongoing military conflict is highly unpredictable, the conflict in Ukraine could lead to market disruptions,
including significant volatility in commodity prices, credit and capital markets. Additionally, Russia&rsquo;s prior annexation of Crimea,
recognition of two separatist republics in the Donetsk and Luhansk regions of Ukraine, subsequent military interventions in Ukraine,
and attempted annexation of four oblasts in Ukraine have led to sanctions and other penalties being levied by the United States, European
Union and other countries against Russia, Belarus, the Crimea Region of Ukraine, the so-called Donetsk People&rsquo;s Republic, and the
so-called Luhansk People&rsquo;s Republic, including agreement to remove certain Russian financial institutions from the Society for
Worldwide Interbank Financial Telecommunication (SWIFT) payment system. Additional potential sanctions and penalties have also been proposed
and/or threatened. Russian military actions and the resulting sanctions could adversely affect the global economy and financial markets
and lead to instability and lack of liquidity in capital markets, potentially making it more difficult for us to obtain additional funds.
Any of the abovementioned factors could affect our business, prospects, financial condition, and operating results. The extent and duration
of the military action, sanctions and resulting market disruptions are impossible to predict, but could be substantial. Any such disruptions
may also magnify the impact of other risks described in this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 71; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="ak_001"></A>SPECIAL
NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus contains forward-looking statements. All statements other than statements of historical facts contained in this prospectus,
including statements regarding our future results of operations and financial position, business strategy, product candidates, planned
preclinical and nonclinical studies and clinical trials, results of preclinical and nonclinical studies, clinical trials, research and
development costs, regulatory approvals, timing and likelihood of success, as well as plans and objectives of management for future operations,
are forward-looking statements. These statements involve known and unknown risks, uncertainties, and other important factors that are
in some cases beyond our control and may cause our actual results, performance, or achievements to be materially different from any future
results, performance or achievements expressed or implied by the forward-looking statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
some cases, you can identify forward-looking statements by terms such as &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;should,&rdquo;
&ldquo;would,&rdquo; &ldquo;expect,&rdquo; &ldquo;plan,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;could,&rdquo; &ldquo;intend,&rdquo; &ldquo;target,&rdquo;
&ldquo;project,&rdquo; &ldquo;believe,&rdquo; &ldquo;estimate,&rdquo; &ldquo;predict,&rdquo; &ldquo;potential,&rdquo; or &ldquo;continue,&rdquo;
or the negative of these terms or other similar expressions. Forward-looking statements contained in this prospectus include, but are
not limited to, statements about:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            use of the net proceeds from this offering;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            initiation, timing, progress, and results of our preclinical and nonclinical studies and
                                            clinical trials, and our research and development programs, including the manufacture of
                                            clinical trial material and drug product for launch;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            ability of our planned clinical trials for are target drugs to be sufficient for regulatory
                                            approval in the United States;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            ability to retain the continued service of our key professionals and to identify, hire, and
                                            retain additional qualified professionals;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            ability to advance product candidates into, and successfully complete, clinical trials;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            timing of and our ability to obtain and maintain regulatory approvals for our product candidates;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            commercialization of our product candidates, if approved;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            ability of our current in-development products, if approved, to successfully compete with
                                            other therapies, including therapies currently in development;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            pricing, coverage, and reimbursement of our product candidates, if approved;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            implementation of our business model, strategic plans for our business, and product candidates;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            scope of protection we are able to establish and maintain for intellectual property rights
                                            covering our product candidates;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            ability to identify additional product candidates and advance them into clinical development;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            estimates regarding expenses, capital requirements, and needs for additional financing;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            financial performance; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">developments
                                            relating to our competitors and our industry.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have based these forward-looking statements largely on our current expectations and projections about our business, the industry in which
we operate and financial trends that we believe may affect our business, financial condition, results of operations, and prospects and
these forward-looking statements are not guarantees of future performance or development. These forward-looking statements speak only
as of the date of this prospectus and are subject to a number of risks, uncertainties, and assumptions described in the section titled
&ldquo;Risk Factors&rdquo; and elsewhere in this prospectus. Because forward-looking statements are inherently subject to risks and uncertainties,
some of which cannot be predicted or quantified, you should not rely on these forward-looking statements as predictions of future events.
The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ
materially from those projected in the forward-looking statements. Except as required by applicable law, we do not plan to publicly update
or revise any forward-looking statements contained herein until after we distribute this prospectus, whether as a result of any new information,
future events, or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, statements that &ldquo;we believe&rdquo; and similar statements reflect our beliefs and opinions on the relevant subject. These
statements are based upon information available to us as of the date of this prospectus, and while we believe such information forms
a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate
that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are
inherently uncertain, and you are cautioned not to unduly rely upon these statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 72; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="ak_003"></A>USE
OF PROCEEDS </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assuming
we complete an $6.2 million offering, we estimate that we will receive net proceeds from this offering of approximately $5.6
million (or approximately $6.5 million if the underwriters&rsquo; option to purchase additional shares of our common stock
is exercised in full) based on the assumed initial public offering price of $4.0 per share, after deducting underwriting discounts
and commissions and estimated offering expenses payable by us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to use the net proceeds from this offering to fund Phase 1 and Phase 2 clinical trials of our product candidate ENV 105 and preclinical
candidates including KROS 101, potential acquisition or in-licensing activities, and working capital and general corporate purposes.
The funds are expected to be used as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">approximately
                                            $1.0&nbsp;million to fund the clinical trials of our lead product candidate ENV
                                            105;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><P STYLE="margin: 0">approximately
                                            $0.7&nbsp;million to pay outstanding accounts payable; and</P></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
                                            remaining proceeds for working capital and general corporate purposes.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The use of proceeds could differ from the estimates
above if the enrollment in our clinical trials is greater than expected in the first 12 months of the trials. If that happens, we may
need to use additional proceeds to fund our clinical trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; margin: 0; font: 10pt Times New Roman, Times, Serif">In order to complete the Phase 2 trial for prostate
cancer for ENV 105 we anticipate we will need $1.7
million. The ENV 105 Phase 1 trial for non-small cell lung cancer will be completed with no additional funding as it is fully
funded by an external source. For preclinical development of KROS 101, KROS 301 and KRS 401, we estimate requiring $3.2 million. Aside
from our ongoing trials, we intend to advance one drug at a time, depending on availability of funds. There can be no guarantee that
we will be successful in completing the clinical trials or reaching the required milestones.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe, based on our current operating plan, that the net proceeds from this offering will be sufficient to fund our operations for
at least the next 12 months. </FONT>As a result, and as we will require  approximately $5.5 million in additional
funding to support our drug development efforts during months 13-24, we will be seeking to raise additional capital following
completion of the IPO.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our expected use of proceeds from this offering described above represents our current intentions
based on our present plans and business conditions. As of the date of this prospectus, we cannot predict with certainty all of the particular
uses for the proceeds to be received upon the closing of this offering or the actual amounts that we will spend on the uses set forth
above. In the case that the net proceeds from this offering not be sufficient for us to fund any/all of our current in-development products
through regulatory approval, we may need to raise additional capital to commercialize our current in-development products and to develop
any future product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
amounts and timing of our actual expenditures will depend on numerous factors, including the time and cost necessary to conduct our planned
clinical trials, the results of our planned clinical trials and other factors described in the section titled &ldquo;Risk Factors&rdquo;
in this prospectus, as well as the amount of cash used in our operations and any unforeseen cash needs. Therefore, our actual expenditures
may differ materially from the estimates described above. We may find it necessary or advisable to use the net proceeds for other purposes.
We will have broad discretion over how to use the net proceeds to us from this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 73; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="ak_004"></A><B>DIVIDEND
POLICY </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not anticipate declaring or paying, in the foreseeable future, any cash dividends on our capital stock. We intend to retain all available
funds and future earnings, if any, to fund the development and expansion of our business. Any future determination regarding the declaration
and payment of dividends, if any, will be at the discretion of our board of directors, subject to applicable laws, and will depend on
then-existing conditions, including our financial condition, operating results, contractual restrictions, capital requirements, business
prospects, and other factors our board of directors may deem relevant. In addition, our ability to pay cash dividends on our capital
stock in the future may be limited by the terms of any future debt or preferred securities we issue or any credit facilities we enter
into.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 74; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="ak_005"></A>CAPITALIZATION
</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth our cash, cash equivalents and investments and capitalization as of December 31, 2023:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">on
                                            an actual basis;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">on
                                            a pro forma basis, giving effect to (i) the automatic conversion of all of our outstanding
                                            convertible notes and accrued interest into 334,375 shares of our common stock <FONT STYLE="background-color: white">in
                                            connection with the closing of this offering, (ii) the conversion of certain accounts payable
                                            into 312,500 shares of our common stock</FONT> upon effectiveness of this registration statement;
                                            and (iii) the conversion of amounts due to related parties into 1,664 shares of our common
                                            stock upon effectiveness of this registration statement; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">on
                                            a pro forma, as adjusted basis, giving effect to (i) the pro forma adjustments set forth
                                            above and (ii) our receipt of net proceeds from the sale of 1,550,000 shares of common
                                            stock in this offering at the assumed initial public offering price of $4.00 per share,
                                            after deducting underwriting discounts and commissions and estimated offering expenses payable
                                            by us.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should read this table together with the sections titled &ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition and
Results of Operations&rdquo; and &ldquo;Description of Capital Stock,&rdquo; and our financial statements and the related notes included
elsewhere in this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> As of December 31, 2023 </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD><TD> &nbsp; </TD><TD STYLE="font-weight: bold"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center"> Pro Forma </TD><TD STYLE="font-weight: bold"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> Actual </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> Pro Forma </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> As Adjusted </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD STYLE="font-weight: bold"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center"> (Unaudited) </TD><TD STYLE="font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center"> (Unaudited) </TD><TD STYLE="font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center"> (Unaudited) </TD><TD STYLE="font-weight: bold"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD STYLE="font-weight: bold"> &nbsp; </TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: center"> (In thousands, except share amounts) </TD><TD STYLE="font-weight: bold"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD><TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 46%; padding-bottom: 2.5pt"> Cash </TD><TD STYLE="width: 2%; padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="width: 14%; border-bottom: Black 2.5pt double; text-align: right"> 93 </TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD><TD STYLE="width: 2%; padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="width: 14%; border-bottom: Black 2.5pt double; text-align: right"> 93 </TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD><TD STYLE="width: 2%; padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="width: 14%; border-bottom: Black 2.5pt double; text-align: right"> 5,693 </TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Convertible notes payable, net of debt discount of $105 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 638 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left"> Shareholders&rsquo; Equity (Deficit) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD> Common stock, par value $0.001, 100,000,000 shares authorized; 10,562,640 shares issued and outstanding; 11,211,179 shares
    issued and outstanding pro forma; 12,761,179 shares issued and outstanding pro forma as adjusted </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 11 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 11 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 13 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Additional paid-in capital </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 4,123 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 5,680 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 11,278 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt"> Accumulated deficit </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> (6,212 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> ) </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> (6,317 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> ) </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> (6,317 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> ) </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt"> Total shareholder&rsquo;s equity (deficit) </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> (2,078 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> ) </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> (626 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> ) </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 4,974 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt"> Total Capitalization </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> (1,440 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> ) </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> (626 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> ) </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> 4,974 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
pro forma, as adjusted information above is illustrative only, and our capitalization following the closing of this offering will be
adjusted based on the actual initial public offering price and other terms of this offering determined at pricing. Each $1.00 increase
or decrease in the assumed initial public offering price of $4.00 per share would increase or decrease, as applicable, each of
our pro forma as adjusted cash, additional paid-in capital, total stockholders&rsquo; deficit and total capitalization by approximately
$1.4 million, assuming the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same,
and after deducting underwriting discounts and commissions and estimated offering expenses payable by us. Similarly, each increase or
decrease of 1.0 million shares in the number of shares common stock offered by us would increase or decrease, as applicable, each of
our pro forma as adjusted cash, additional paid-in capital, total stockholders&rsquo; deficit, and total capitalization by approximately
$3.7 million, assuming the assumed initial public offering price of $4.00 per share remains the same, and after deducting
underwriting discounts and commissions and estimated offering expenses payable by us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
number of shares of our common stock to be issued and outstanding after this offering pro forma and pro forma as adjusted in the table
above is based on 10,562,640 shares of common stock outstanding as of December 31, 2023, after giving effect to the automatic
conversion of all of our outstanding convertible notes and accrued interest along with certain accounts payable into a total of 648,539
shares of common stock upon effectiveness of this registration statement, and excludes:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">150,000
                                            shares of our common stock issuable upon the exercise of outstanding warrants as of December
                                            31, 2023, with a weighted-average exercise price of $4.17 per share; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">1,650,000
                                            shares of our common stock will be reserved for future issuance under our 2023 Equity Incentive
                                            Plan, which will become effective once the registration statement of which this prospectus
                                            forms a part is declared effective, as well as any future automatic annual increases in the
                                            number of shares of common stock reserved for issuance under our 2023 Equity Incentive Plan.
                                            See the section entitled &ldquo;Equity Incentive Plans&rdquo; below.</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<!-- Field: Page; Sequence: 75; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="ak_006"></A>DILUTION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
you invest in our common stock in this offering, your interest will be diluted to the extent of the difference between the initial public
offering price per share of common stock and the pro forma as adjusted net tangible book value per share immediately after this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2023, we had a historical net tangible book value (deficit) of $(2.1) million, or $(0.20) per share
of common stock based on the 10,562,640 shares of common stock outstanding as of such date. Our historical net tangible book value
(deficit) per share represents total tangible assets less total liabilities and redeemable convertible preferred stock, which is not
included within permanent equity, divided by the number of shares of common stock outstanding as of December 31, 2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
pro forma net tangible book value as of December 31, 2023, was $(0.6) million, or $(0.06) per share. Pro forma net
tangible book value per share represents the amount of our total tangible assets less our total liabilities, divided by 11,211,179
shares of common stock outstanding as of such date, after giving effect to the automatic conversion of all of our convertible notes
payable, amounts due to related parties and certain accounts payable as of December 31, 2023 into 648,539 shares
of our common stock upon the closing of this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
giving effect to the sale by us of shares of common stock in this offering at the assumed initial public offering price of $4.00 per
share, and after deducting underwriting discounts and commissions and estimated offering expenses payable by us, our pro forma as adjusted
net tangible book value as of December 31, 2023 would have been $5.0 million, or $0.39 per share. This amount represents
an immediate increase in pro forma as adjusted net tangible book value of $0.45 per share to our existing stockholders and an immediate
dilution in pro forma as adjusted net tangible book value of $3.61 per share to investors purchasing common stock in this offering.
We determine dilution by subtracting the pro forma as adjusted net tangible book value per share after this offering from the amount
of cash paid by an investor for a share of common stock in this offering. The following table illustrates this dilution on a per share
basis:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0pt">Assumed initial public offering price per share</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4.00</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; width: 68%">Historical net tangible book value (deficit) per share as of December 31, 2023</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: right; width: 12%"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"> (0.20) </P></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left"></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left">Pro forma increase in historical net tangible book value per share attributable to the pro forma transactions described in the preceding paragraphs</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">0.14</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt">Pro forma net tangible book value per share as of December 31, 2023</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"> (0.06 </TD>
    <TD> ) </TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left">Increase in pro forma as adjusted net tangible book value per share attributable to investors purchasing shares in this offering</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">0.45</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Pro forma as adjusted net tangible book value per share after this offering</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 0.39 </TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Dilution in pro forma as adjusted net tangible book value per share to investors purchasing shares in this offering</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 3.61 </TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
dilution information discussed above is illustrative only and may change based on the actual initial public offering price and other
terms of this offering. Each $1.00 increase or decrease in the assumed initial public offering price of $4.00 per share would
increase or decrease, as applicable, our pro forma as adjusted net tangible book value per share after this offering by $0.11
per share and increase or decrease, as applicable, the dilution to investors purchasing shares in this offering by $0.11 per share,
in each case assuming the number of shares of common stock offered by us, as set forth on the cover page of this prospectus, remains
the same, and after deducting underwriting discounts and commissions and estimated offering expenses payable by us. Similarly, each increase
or decrease of 1.0 million shares in the number of shares of common stock offered by us would increase or decrease our pro forma as adjusted
net tangible book value by approximately $0.30 per share and decrease or increase, as applicable, the dilution to investors purchasing
shares in this offering by approximately $0.30 per share, in each case assuming the assumed initial public offering price of $4.00
per share remains the same, and after deducting underwriting discounts and commissions and estimated offering expenses payable by
us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the underwriters exercise their option to purchase additional shares of common stock in full, the pro forma net tangible book value per
share, as adjusted to give effect to this offering, would be $0.47 per share, and the dilution in pro forma net tangible book
value per share to investors in this offering would be $3.53 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 76; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes, as of December 31, 2023 (amounts in thousands, except share and price per share amounts): </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            total number of shares of common stock purchased from us by our existing stockholders (including
                                            convertible noteholders whose notes automatically convert following completion of this offering) and by investors purchasing shares
                                            in this offering;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            total consideration paid to us by our existing stockholders and by investors purchasing shares
                                            in this offering, assuming an initial public offering price of $4.00 per share, before
                                            deducting underwriting discounts and commissions and estimated offering expenses payable
                                            by us in connection with this offering; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            average price per share paid by existing stockholders for shares issued prior to this offering
                                            and by investors purchasing shares in this offering.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 38.45pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 38.45pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Shares Purchased</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total Consideration</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Average Price Per</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Percent</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Percent</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Share</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 30%; text-align: left">Existing stockholders</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right"> 11,211,179 </TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right"> 87.8 </TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right"> 4,394 </TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">41.5</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right"> 0.39 </TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">New investors</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,550,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 12.2 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">6,200</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">58.5</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">4.00</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> 12,761,179 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">100.0</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">%</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> 10,594 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">100.0</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">%</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 38.45pt; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">The foregoing
discussion and table above (other than the historical net tangible book value calculation) are based on 11,211,179 shares of common
stock outstanding as of December 31, 2023, after giving effect to the automatic conversion of all of our outstanding convertible
notes and accrued interest, amounts due to related parties and certain accounts payable, as of December 31, 2023, into
648,539 shares of our common stock upon the closing of this offering, and excludes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">150,000
                                            shares of our common stock issuable upon the exercise of outstanding warrants as of December
                                            31, 2023, with a weighted-average exercise price of $4.17 per share;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,650,000
                                            </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares
                                            of our common stock reserved for future issuance under our 2023 Equity Incentive Plan,
                                            which will become effective once the registration statement of which this prospectus forms
                                            a part is declared effective, as well as any future automatic annual increases in the number
                                            of shares of common stock reserved for issuance under our 2023 Equity Incentive Plan.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 38.45pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 38.45pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<!-- Field: Page; Sequence: 77; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 38.45pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="ak_007"></A>MANAGEMENT&rsquo;S
DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>The
following discussion and analysis should be read in conjunction with &ldquo;Selected Financial Data&rdquo; and our financial statements
and related notes included elsewhere in this prospectus. This discussion and analysis and other parts of this prospectus contain forward-looking
statements based upon current beliefs that involve risks, uncertainties and assumptions, such as statements regarding our plans, objectives,
expectations and intentions. Our actual results and the timing of selected events could differ materially from those described in or
implied by these forward-looking statements as a result of several factors, including those set forth under &ldquo;Risk Factors&rdquo;
and elsewhere in this prospectus. You should carefully read the &ldquo;Risk Factors&rdquo; section of this prospectus to gain an understanding
of the important factors that could cause actual results to differ materially from our forward-looking statements. Please also see the
section entitled &ldquo;Special Note Regarding Forward- Looking Statements.&rdquo;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Overview</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a clinical-stage biopharmaceutical company advancing therapeutics for cancer patients that are designed to overcome key hurdles
in immune suppression and drug resistance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">Our mission
is to advance our portfolio of innovative therapeutics to reverse key mechanisms of therapeutic resistance and immune suppression and
transform the way cancer is treated. We have leveraged molecular insights of the mechanisms of therapeutic resistance and immune suppression
to develop a new class of novel drugs that we expect will target drug resistance and checkpoints of immune suppression. As of the
date of this prospectus, our product candidates have not been approved as safe or effective by the FDA or any other comparable foreign
regulator.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
inception, our operations have focused on organizing and staffing our company, business planning, raising capital, acquiring and developing
our technology, establishing our intellectual property portfolio, identifying potential product candidates and undertaking preclinical
and clinical studies and manufacturing. We do not have any products approved for sale and have not generated any revenue from product
sales.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">Since inception,
we have incurred significant operating losses. Our net losses were $1.1 million and $1.8 million for the years ended
December 31, 2022 and 2023, respectively. As of December 31, 2023, we had an accumulated deficit of $6.2 million.
We expect to continue to incur significant and increasing expenses and operating losses for the foreseeable future, as we advance our
current and future product candidates through preclinical and clinical development, manufacture drug product and drug supply, seek regulatory
approval for our current and future product candidates, maintain and expand our intellectual property portfolio, hire additional research
and development and business personnel and operate as a public company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2020, the World Health Organization declared COVID-19 a global pandemic and the United States declared a national emergency with
respect to COVID-19. In response to the COVID-19 pandemic, a number of governmental orders and other public health guidance measures
have been implemented across much of the United States, including in the locations of our office, clinical trial sites and third parties
on whom we rely. As the COVID-19 pandemic started to spread in the first half of 2020, our clinical trial sites reported it had the most
impact on patient care as facilities were generally ill prepared to conduct business as usual; adequate clinical evaluations, physical
exams and tests were either absent or drastically reduced. Our clinical trial sites further reported that their institutions better adjusted
to pandemic conditions beginning in the second half of 2020. As our corporate operations presently take place entirely virtually, COVID-19
has had no material impact on our operations to date. As we begin our clinical trials, we will continue to monitor the impact
COVID-19 may have on the operations of our trials. We have taken measures to secure our research and development project activities,
and work in laboratories has been organized to reduce the risk of COVID-19 transmission. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will not generate revenue from product sales unless and until we successfully complete clinical development and obtain regulatory approval
for our product candidates. In addition, if we obtain regulatory approval for our product candidates and do not enter into a third-party
commercialization partnership, we will likely incur significant expenses related to developing our commercialization capability
to support product sales, marketing, manufacturing, and distribution activities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result, we will need substantial additional funding to support our continuing operations and pursue our growth strategy. Until we can
generate significant revenue from product sales, if ever, we expect to finance our operations through a combination of public or private
equity offerings and debt financings or other sources, such as potential collaboration agreements, strategic alliances and licensing
arrangements. We may be unable to raise additional funds or enter into such other agreements or arrangements when needed on acceptable
terms, or at all. Our failure to raise capital or enter into such agreements as, and when needed, could have a material adverse effect
on our business, results of operations and financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
report of our independent registered public accounting firm on our financial statements for the years ended December 31, 2022 and 2023
included an explanatory paragraph indicating that there was substantial doubt about our ability to continue as a going concern. See
Note 1 to our annual financial statements appearing at the end of this prospectus for additional information on our assessment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern, contemplating
the realization of assets and the settlement of liabilities and commitments in the normal course of business. As reflected in the accompanying
consolidated financial statements, the Company incurred a net loss of $1.8 million during the year ended December 31,
2023, and had a shareholders&rsquo; deficit of $2.1 million as of December 31, 2023. These factors raise substantial
doubt, as defined under GAAP, about the Company&rsquo;s ability to continue as a going concern for the next 12 months. Management&rsquo;s
plan to continue as a going concern is dependent upon the Company&rsquo;s ability to raise additional funds and implement its strategies.
The financial statements do not include any adjustments related to the recoverability and classification of assets or the amounts and
classification of liabilities that might be necessary if the Company is unable to continue as a going concern.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 78; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2023, the Company had cash on hand in the amount of $0.1 million. The ability to continue as a going concern is dependent
on the Company attaining and maintaining profitable operations in the future and raising additional capital to meet its obligations and
repay its liabilities arising from normal business operations when they come due. Since inception, the Company has funded its operations
primarily through equity and debt financings and it expects to continue to rely on these sources of capital in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
assurance can be given that any future financing will be available or, if available, that it will be on terms that are satisfactory to
the Company. Even if the Company is able to obtain additional financing, it may contain undue restrictions on our operations, in the
case of debt financing, or cause substantial dilution for our stockholders, in case of equity financing.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Share
Exchange between Kairos and Enviro</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2021, Enviro and Kairos completed the Enviro-Kairos share exchange, whereby the Enviro shareholders exchanged 100% of the
issued and outstanding shares of Enviro (on a fully diluted basis) for 6,000,000 shares of newly issued restricted common stock of Kairos.
After the closing, Enviro became a wholly owned subsidiary of Kairos.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Critical Accounting Policies and Significant
Judgments and Estimates</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">This Management&rsquo;s Discussion and Analysis
of Financial Condition and Results of Operations is based on our financial statements, which have been prepared in accordance with accounting
principles generally accepted in the United States, or GAAP. The preparation of these financial statements requires us to make estimates,
judgments and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities
as of the date of the balance sheets and the reported amounts of expenses during the reporting periods. In accordance with GAAP, we base
our estimates on historical experience and on various other assumptions that we believe are reasonable under the circumstances at the
time such estimates are made. Actual results may differ materially from our estimates and judgments under different assumptions or conditions.
We periodically review our estimates in light of changes in circumstances, facts and experience. The effects of material revisions in
estimates are reflected in our financial statements prospectively from the date of the change in estimate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We define our critical accounting policies as
those accounting principles that require us to make subjective estimates and judgments about matters that are uncertain and are likely
to have a material impact on our financial condition and results of operations, as well as the specific manner in which we apply those
principles. While our significant accounting policies are more fully described in Note 2 to our audited financial statements appearing
elsewhere in this prospectus, we believe the following are the critical accounting policies used in the preparation of our financial
statements that require significant estimates and judgments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Research and Development Expenses</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Research and development expenses consist primarily
of costs incurred in connection with the development of our product candidates. We expense research and development costs as incurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At the end of each reporting period, we compare payments
made to third-party service providers to the estimated progress toward completion of the applicable research or development objectives.
Such estimates are subject to change as additional information becomes available. Depending on the timing of payments to the service
providers and the progress that we estimate has been made as a result of the service provided, we may record net prepaid or accrued expenses
relating to these costs. As of December 31, 2022 and 2023, we have not made any material adjustments to our prior
estimates of accrued research and development expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Off-Balance Sheet Arrangements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the years ended December 31, 2022 and 2023, we did not have, and we do not currently have, any off-balance sheet arrangements (as defined
under SEC rules).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Quantitative and Qualitative Disclosures about
Market Risk</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our cash is held on deposit in demand accounts
at a large financial institution in amounts, at times, in excess of the Federal Deposit Insurance Corporation, or FDIC, insurance coverage
limit of $250,000 per depositor, per FDIC-insured bank, per ownership category. We have reviewed the consolidated financial statements
of this institution and believe it has sufficient assets and liquidity to conduct its operations in the ordinary course of business with
little or no credit risk to us. Financial instruments that potentially subject us to concentrations of credit risk principally consist
of cash equivalents. We limit our credit risk associated with cash equivalents by placing investments in highly rated money market funds.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Inflation generally affects us by increasing our
cost of labor. We do not believe that inflation had a material effect on our business, financial condition or results of operations during
the years ended December 31, 2022 or 2023. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Recent Accounting Pronouncements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For a description of recently issued accounting
standards that may have a material impact on our financial statements or will otherwise apply to our operations, please see Note 2 to
our audited financial statements appearing elsewhere in this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Components
of Results of Operations</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Net
Sales</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">We
have not generated any sales to date. There was no revenue recorded from any sources during the years ended December 31, 2022 and 2023. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Operating
Expenses</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
operating expenses consist of (i) research and development expenses and (ii) general and administrative expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Research
and Development Expenses</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Ramachandran Murali is our Vice President of Research and Development. Dr. Murali is a doctor and scientist at Cedars-Sinai Medical
Center, and is the inventor, with others, of three of the patent technologies that are subject to the Kairos-Cedars license agreements,
described above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are engaged in rolling out Phase 1 and Phase 2 clinical trials for <B>ENV-105</B> and a Phase 1 trial for <B>KROS-201</B>.
In addition, we are continuously performing preclinical research including animal models of disease, medicinal chemistry laboratory studies,
formulation, and toxicology and biodistribution studies. Our clinical development costs may vary significantly based on factors such
as: per patient trial costs; the number of trials required for approval; the number of sites included in the trials; the location where
the trials are conducted; the length of time required to enroll eligible patients; the number of patients that participate in the trials;
the number of doses that patients receive; the drop-out or discontinuation rates of patients; potential additional safety monitoring
requested by regulatory agencies; the duration of patient participation in the trials and follow-up; the cost and timing of manufacturing
our product candidates; the phase of development of our product candidates; and the efficacy and safety profile of our product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
successful development and commercialization of product candidates is highly uncertain. This is due to the numerous risks and uncertainties
associated with product development and commercialization, including the following: the timing and progress of nonclinical and clinical
development activities; the number and scope of nonclinical and clinical programs we decide to pursue; raising necessary additional funds;
the progress of the development efforts of parties with whom we may enter into collaboration arrangements; our ability to maintain our
current development program and to establish new ones; our ability to establish new licensing or collaboration arrangements; the successful
initiation and completion of clinical trials with safety, tolerability and efficacy profiles that are satisfactory to the FDA or any
comparable foreign regulatory authority; the receipt and related terms of regulatory approvals from applicable regulatory authorities;
the availability of drug substance and drug product for use in production of our product candidate; establishing and maintaining agreements
with third-party manufacturers for clinical supply for our clinical trials and commercial manufacturing, if our product candidates are
approved; our ability to obtain and maintain patents, trade secret protection and regulatory exclusivity, both in the United States and
internationally; our ability to protect our rights in our intellectual property portfolio; the commercialization of our product candidates,
if and when approved; obtaining and maintaining third-party insurance coverage and adequate reimbursement; the acceptance of our product
candidate, if approved, by patients, the medical community and third-party payors; competition with other products; the impact of any
business interruptions to our operations, including the timing and enrollment of patients in our planned clinical trials, or to those
of our manufacturers, suppliers, or other vendors resulting from the COVID-19 pandemic or similar public health crisis; and a continued
acceptable safety profile of our therapies following approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 79; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
change in the outcome of any of these variables with respect to the development of our product candidates could significantly change
the costs and timing associated with the development of that product candidate. We may never succeed in obtaining regulatory approval
for any of our product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>General
and administrative expenses</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses consist primarily of salaries and related costs for personnel in executive, finance, corporate and business
development, as well as administrative functions. General and administrative expenses also include legal fees relating to patent,
corporate and IPO-related matters; professional fees for accounting, auditing, tax and administrative consulting services;
insurance costs; administrative travel expenses; marketing expenses and other operating costs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
anticipate that our general and administrative expenses will increase in the future as we increase our headcount to support our business
operations. We also anticipate that we will incur increased accounting, audit, legal, regulatory, compliance and director and officer
insurance costs, as well as investor and public relations expenses associated with being a public company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Results
of Operations</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>For
the Years Ended December 31, 2022 and 2023 </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes our results of operations for the years ended December 31, 2022 and 2023 (in thousands):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid">Operating Expenses:</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">December 31, <BR> 2022</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">December 31,
    <BR> 2023 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 60%; text-align: left">Research and development</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">87</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"> 82 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">General and administrative</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">484</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> 1,632 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">Total operating expenses</TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">571</TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"> 1,714 </TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Loss from operations</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">(571</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> (1,714 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> Other expenses: </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Interest expense</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(51</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> (42 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Debt discount amortization</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(408</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> (56 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"> Financing costs </TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"> (20 </TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> ) </TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; text-align: left; padding-bottom: 1.5pt"> Total other
    expenses </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> (479 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> (98 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; text-align: left; padding-bottom: 1.5pt">Net loss</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> (1,050 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> (1,812 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Research
and Development Expenses</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below summarizes our research and development expenses for the years ended December 31, 2022 and 2023 (in thousands):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid">Research and Development Expenses:</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">December 31, <BR> 2022</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">December 31,
    <BR> 2023 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt; width: 60%">Clinical and related expenses</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left; width: 1%"> $ </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right; width: 16%">87</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left; width: 1%">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left; width: 1%"> $ </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right; width: 16%"> 82 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left; width: 1%">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Total research and development expenses</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">87</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"> 82 </P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses were $0.1 million and $0.1 million for the years ended December 31, 2022 and 2023, respectively.
There were no significant changes between periods.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -15pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>General
and Administrative Expenses</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below summarizes our general and administrative expenses for the years ended December 31, 2022 and 2023 (in thousands):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">General and Administrative Expenses:</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">December 31, <BR> 2022</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">December 31, <BR> 2023</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 60%; text-align: left; padding-left: 10pt">Patent related expenses</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 16%; text-align: right">110</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 16%; text-align: right"> 45 </TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Fair value of common stock issued to shareholders </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">913</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Legal fees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 89 </TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Accounting fees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">28</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 154 </TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Other professional fees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">45</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 42 </TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Fees relating to license agreements</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">112</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 176 </TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Insurance expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">20</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 29 </TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Amortization expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">160</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 160 </TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Other expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">7</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 24 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Total general and administrative expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">484</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 1,632 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses were $0.5 million and $1.6 million for the years ended December 31, 2022 and 2023, respectively,
an increase of $1.1 million. Significant changes between periods are as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    $0.9 million increase in the fair value of common shares issued in 2023 to shareholders, as no common shares were
    issued in 2022. </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -15pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Other
Expenses</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
expenses were $0.5 million and $0.1 million for the years ended December 31, 2022 and 2023. The decrease of $0.4
million in 2023 was primarily due to decreased debt discount amortization in 2023. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 80; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Liquidity
and Capital Resources</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Going
Concern</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets
and the settlement of liabilities and commitments in the normal course of business. As reflected in the accompanying consolidated financial
statements, we have not yet generated revenues and have incurred recurring net losses since our inception. During the year ended
December 31, 2023, we incurred a net loss of $1.8 million and had a shareholders&rsquo; deficit of $2.1 million
as of December 31, 2023. These factors raise substantial doubt about our ability to continue as a going concern. Our ability to
continue as a going concern is dependent upon our ability to raise additional funds and implement our strategies. The financial statements
do not include any adjustments that might be necessary if we are unable to continue as a going concern.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2023, we had cash on hand in the amount of $0.1 million. The ability to continue as a going concern is dependent
on us raising additional capital and attaining and maintaining profitable operations in the future to meet our obligations and repay
our liabilities arising from normal business operations when they come due. Since inception, we have funded our operations primarily
through equity and debt financings and we expect to continue to rely on these sources of capital in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
assurance can be given that any future financing will be available or, if available, that it will be on terms that are satisfactory to
us. Even if we are able to obtain additional financing, it may contain undue restrictions on our operations, in the case of debt financing,
or cause substantial dilution for our stockholders, in the case of equity financing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Cash
Flows for the Years Ended December 31, 2022 and 2023 </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below summarizes our cash flow activities for the years ended December 31, 2022 and 2023 (in thousands):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Years Ended December 31,</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid">Net cash provided by (used in):</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">2022</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"> 2023 </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left">Operating activities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">(353</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"> 81 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Investing activities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> - </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Financing activities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">717</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> (425 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> ) </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Net increase (decrease) in cash</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">364</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> (344 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> ) </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Operating
Activities</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2022, we used cash from operating activities of $0.4 million, compared to $0.08 million provided
during the year ended December 31, 2023. During the year ended December 31, 2022, we incurred a net loss of $1.1 million and
had non-cash expenses of $0.6 million, compared to a net loss of $1.8 million and non-cash expenses of $1.1 million during
the year ended December 31, 2023. Non-cash expenses during 2022 included amortization expense of $0.2 million and amortization
of debt discount of $0.4 million. Non-cash expenses during 2023 included amortization expense of $0.2 million, amortization
of debt discount of $0.06 million and the fair value of common stock issued to shareholders of $0.9 million. The net change
in assets and liabilities during the year ended December 31, 2022 provided cash of $0.1 million, compared to $0.8 million provided
during the year ended December 31, 2023. The primary source of cash for both years resulted from the increase in
accounts payable and accrued expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Investing
Activities</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
was no cash used in investing activities for the years ended December 31, 2022 and 2023. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Financing
Activities</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash provided by (used in) financing activities for the years ended December 31, 2022 and 2023 was $0.7 million and $(0.4)
million, respectively. For the year ended December 31, 2022, cash provided by financing activities consisted of proceeds from the
issuance of convertible notes payable of $0.9 million. Cash used in financing activities during the year ended December 31, 2022 related
to the repayment of a note payable of $0.03 million, the repayment of an advance from a related party of $0.01 million and the payments
of deferred offering costs of $0.06 million and debt issuance costs of $0.1 million. For the year ended December 31, 2023, there was
no cash provided by financing activities. Cash used in financing activities in 2023 consisted of the payment of deferred
offering costs of $0.4 million.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Debt
Agreements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Advances
from Related Parties </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">During the year ended December
31, 2021, shareholders of the Company, and a company whose principal stockholder is also a stockholder of the Company, advanced the Company
$0.01 million, which was all outstanding at December 31, 2021. The advances accrue no interest, are unsecured and are due on demand.
As of December 31, 2021, $0.01 million was owed on the advances. During the year ended December 31, 2022, the Company repaid $0.01 million
of the advances, and as of December 31, 2022 and 2023, a total of $0.004 million remained outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Convertible
Notes Payable</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">During the year ended December
31, 2022, the Company entered into several convertible note payable agreements with certain investors in the aggregate total of $0.7
million. The convertible notes accrue interest at 6% per annum, are unsecured and are due by April 2025. If the Company does not close
an IPO transaction within 12 months following the date of issuance of the notes, the Company will have the choice of paying off the principal
plus all accrued and unpaid interest, or the note&rsquo;s principal balance will increase to 110% of its original balance. The notes
are convertible at the option of the noteholders into shares of the Company&rsquo;s common stock at a price per share as defined in the
agreement or will automatically be converted into shares of the Company&rsquo;s common stock at 60% of the IPO price per share upon the
closing of an IPO transaction. The net proceeds relating to the agreements, net of expenses, were $0.6 million. The convertible note
offerings were completed pursuant to an exemption from registration under Rule 506(b) of the Securities Act of 1933, as amended (the
&ldquo;Securities Act&rdquo;). Boustead Securities, LLC acted as placement agent in each of the June and September 2022 private placements
and received $0.09 million and $0.02 million cash compensation, respectively, and five-year warrants to purchase shares
of common stock equal to 7.0% of the number of the Conversion Shares at an exercise price equal to the conversion price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> During the year ended
December 31, 2023, as we did not close our IPO transaction within 12 months of the date of the notes, the notes&rsquo; principal balance
increased to 110% of their original balance, or an increase of $0.07 million. As of December 31, 2023, $0.7 million of principal was outstanding on the
notes and $0.06 million of accrued and unpaid interest. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <B>Conversion of Accounts
Payable</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> Subsequent to December
31, 2023, we entered into agreements with Cedars-Sinai Medical Center (&ldquo;Cedars&rdquo;) under which Cedars agreed to convert $0.8 million of the total
accounts payable due to them of $0.9 million into 312,500 shares of our common stock upon the closing of the Company&rsquo;s IPO. The conversion
price of the shares will be equal to 60% of the IPO closing price. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <B>Conversion of Amounts
Due to Related Parties</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> Subsequent to December
31, 2023, two officers and shareholders agreed to convert the $0.004 million due to them into 1,664 shares of the Company&rsquo;s common stock, effective
upon the closing of the Company&rsquo;s IPO. The conversion price of the shares will be equal to 60% of the IPO closing price. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <B>Loans from Related
Parties</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> Subsequent to December
31, 2023, the Company borrowed $0.07 million from three of its officers. The loans accrue interest at 7.5% per annum, are unsecured,
and are due in April 2025. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 81; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Funding
Requirements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect our expenses to increase substantially in connection with our ongoing research activities, particularly as we pursue the
advancement of our product candidates through clinical trials. In addition, we expect to incur additional costs associated with operating
as a public company. The timing and amount of our operating expenditures will depend on numerous variables, including:
the initiation, progress, timing, costs and results of the clinical trials for our product candidates or any future product
candidates we may develop; the initiation, progress, timing, costs and results of nonclinical studies for our product candidates or any
future product candidates we may develop; our ability to maintain our relationships with key collaborators; the outcome, timing and cost
of seeking and obtaining regulatory approvals from the FDA and comparable foreign regulatory authorities, including the potential for
such authorities to require that we perform more nonclinical studies or clinical trials than those that we currently expect or change
their requirements on studies that had previously been agreed to; the cost to establish, maintain, expand, enforce and defend the scope
of our intellectual property portfolio, including the amount and timing of any payments we may be required to make, or that we may receive,
in connection with licensing, preparing, filing, prosecuting, defending and enforcing any patents or other intellectual property rights;
the effect of competing technological and market developments; the costs of continuing to grow our business, including hiring key personnel
and maintain or acquiring operating space; market acceptance of any approved product candidates, including product pricing, as well as
product coverage and the adequacy of reimbursement by third-party payors; the cost of acquiring, licensing or investing in additional
businesses, products, product candidates and technologies; the cost and timing of selecting, auditing and potentially validating a manufacturing
site for commercial-scale manufacturing; the cost of establishing sales, marketing and distribution capabilities for any product candidates
for which we may receive regulatory approval and that we determine to commercialize; and our need to implement additional internal systems
and infrastructure, including financial and reporting systems.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that our existing cash, plus the net proceeds from this offering, will enable us to fund our operating expenses and capital expenditure
requirements for at least the next 12 months. We have based this estimate on assumptions that may prove to be wrong, and we could exhaust
our available capital resources sooner than we expect. We expect that we will require additional funding to complete the clinical development
and commercialize our product candidates, if we receive regulatory approval, and pursue in-licenses or acquisitions of other product
candidates. If we receive regulatory approval for our product candidates, we expect to incur significant commercialization expenses related
to product manufacturing, sales, marketing and distribution, depending on where we choose to commercialize ourselves.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Until
such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity
and debt financings, collaborations, strategic alliances, and marketing, distribution or licensing arrangements with third parties. To
the extent that we raise additional capital through the sale of equity or convertible debt securities, ownership interest may be materially
diluted, and the terms of such securities could include liquidation or other preferences that adversely affect your rights as a common
stockholder. Debt financing and preferred equity financing, if available, may involve agreements that include restrictive covenants that
limit our ability to take specified actions, such as incurring additional debt, making capital expenditures or declaring dividends. If
we raise funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we
may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant
licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings or other
arrangements when needed, we may be required to delay, reduce or eliminate our product development or future commercialization efforts,
or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Contractual
Obligations and Commitments</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Exclusive
License Agreements with Cedars-Sinai Medical Center (&ldquo;Cedars&rdquo;)</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> entered into four Exclusive License Agreements
with Cedars which grants us licensing rights with respect to certain patent rights owned by Cedars as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Methods
                                            of use of compounds that bind to RelA of NFkB;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Composition
                                            and methods for treating fibrosis;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compositions
                                            and methods for treating cancer and autoimmune diseases; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Method
                                            of generating activated T cells for cancer therapy.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 82; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 2, 2021, our wholly owned subsidiary, Enviro Therapeutics, Inc. (&ldquo;Enviro&rdquo;), entered into two Exclusive License
Agreements with Cedars, which granted Enviro exclusive licensing rights (which include the right to sublicense) with respect to certain
patent rights owned by Cedars, as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
                                            Exclusive License Agreement (the &#8220;Enviro-Cedars License Agreement (Mitochondrial DNA)&#8221;)
                                            for Enviro to develop, manufacture, use and sell products utilized or derived from patent
                                            rights worldwide related to the &#8220;Compositions and Methods for Treating Diseases and
                                            Conditions by Depletion of Mitochondrial DNA from Circulation and for Detection of Mitochondrial
                                            DNA&#8221; invented by Dr. Neil Bhowmick and others; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
                                            Exclusive License Agreement, (the &#8220;Enviro-Cedars License Agreement (Endoglin Antagonism)&#8221;
                                            and, collectively with the Enviro-Cedars License Agreement (Mitochondrial DNA), the &#8220;Enviro-Cedars
                                            License Agreements&#8221;) for Enviro to develop, manufacture, use and sell products utilized
                                            or derived from the patent rights and technical information worldwide related to the &#8220;Sensitization
                                            of Tumors to Therapies Through Endoglin Antagonism&#8221; invented by Dr. Neil Bhowmick and
                                            others.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>License
Agreement with Tracon Pharmaceutical, Inc.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 21, 2021, Enviro entered into a License Agreement with Tracon Pharmaceutical, Inc. (&ldquo;Tracon&rdquo;). Pursuant to the Tracon
License Agreement, Tracon granted Enviro access to inactive IND filings for &ldquo;TRC105&rdquo; in the United States; ownership of &ldquo;TRC105&rdquo;
stored vials of drug product manufactured to GMP standards stored at Fisher Clinical or their designee; and assignment of Tracon&rsquo;s
patent rights to its &ldquo;CD105 technologies&rdquo; (all as defined or described in the Tracon License Agreement).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Agreement
with former Chief Financial Officer</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have an agreement with our former Chief Financial Officer that requires us to pay $0.05 million upon the completion of raising more than
$0.9 million in a debt or an equity financing. No amount was owed at December 31, 2022 or 2023. In addition, on
September 27, 2023, we have entered into an employment agreement with our Chief Financial Officer, which will become effective
upon completion of this initial public offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<!-- Field: Page; Sequence: 83; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="ak_008"></A>BUSINESS
</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Overview</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a clinical-stage biopharmaceutical company advancing therapeutics for cancer patients that are designed to overcome key hurdles in immune
suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung
cancer, breast cancer, and glioblastoma. <FONT STYLE="background-color: white">We are driven by innovative science to develop novel and
transformative drug therapies to treat cancer. </FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white">Our
mission is to advance our portfolio of innovative therapeutics to target key mechanisms of therapeutic resistance and immune suppression
and transform the way cancer is treated. We have leveraged molecular insights of the mechanisms of therapeutic resistance and immune
suppression to develop a new class of novel drugs that we expect will target drug resistance and checkpoints of immune suppression.
Our seven-drug portfolio offers diversification and mitigates the overall exposure to many of the inherent risks of drug development.
Our proprietary technologies are licensed from Cedars-Sinai Medical Center, the largest academic medical center in the Western U.S. and
ranked number one in California and number two in the nation in U.S. News &amp; World Report&rsquo;s Best Hospitals Honor
Roll for 2022-2023. As of the date of this prospectus, our product candidates have not been approved as safe or effective by the FDA
or any other comparable foreign regulator.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
product portfolio currently consists of:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Five
                                            pre-clinical or clinical-trial stage drug candidates developed by us and designed to target
                                            immune response.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Two
                                            therapeutic agents developed by our Enviro Therapeutics, Inc. subsidiary and designed to
                                            increase anti-tumor response in conjunction with cancer therapies by addressing resistance
                                            to these agents.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
                                            variety of technologies licensed by our Enviro Therapeutics, Inc. subsidiary and consisting
                                            of compositions and methods for treating diseases and conditions by targeting CD105 and depleting
                                            mitochondrial DNA from the circulation.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Our
Science</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The human immune system can tell the difference between
normal cells in the body and those it sees as &ldquo;foreign,&rdquo; which allows it to focus an attack on the foreign cells while leaving
the normal cells alone. To do this, our immune system uses &ldquo;checkpoints&rdquo; &ndash; molecules on certain immune cells that need
to be activated (or inactivated) to start an immune response. Cancer cells can find ways to use these checkpoints to avoid being attacked
by the immune system.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">We are developing small molecules that we believe
can specifically target these central checkpoints. In addition, we are developing an activated T cell therapy designed to target
cancer stem cells.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white">In June of 2021, we announced
the acquisition of Enviro Therapeutics, Inc. to incorporate their advanced pipeline of drug candidates in Phase 1 and Phase 2 trials.
The pipeline includes two therapeutic agents addressing what we believe to be significant unmet needs in prostate and lung cancer markets
and that we believe can help address cancer progression, in particular, in those cancers that develop resistance to standard therapies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white">As a result, we have a pipeline
of seven drugs. We have filed an Investigational New Drug, or IND, application with the FDA that has become effective for <B>ENV 105</B>.
As a result, we began a Phase 1 trial for non-small cell lung cancer in September 2023 and in September 2023 opened
a randomized Phase 2 trial for prostate cancer. We believe that the mechanism of action for <B>ENV 105</B> may addresses the resistance
mechanism of tumor dormancy. This was only possible because <B>ENV 105 </B>targets both the cancer cells as well as its supportive non-cancer
environment. The advantage of targeting the unique environment supporting the tumor cells is that their capacity to adapt and evade therapy
is significantly lower than that of the cancer itself. As such, <B>ENV 105</B> is designed to address resistance to chemotherapy, radiation
therapy, androgen targeted therapy, EGFR inhibitors, or checkpoint inhibition when given in combination. Interestingly, since the target
of <B>ENV 105</B>, endoglin, is upregulated by the tumor and supporting cells in response to androgen targeted therapy and EGFR inhibitors
as a proven mechanism of resistance, we believe the co-administration of <B>ENV 105</B> specifically targets this mechanism of resistance.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Through
the Enviro Therapeutics, Inc. acquisition, we also obtained <B>ENV 205</B>, a pre-clinical therapeutic for treating diseases and conditions
by depletion of mitochondrial DNA from circulation and for detection of mitochondrial DNA. We intend to use this antibody technology
to treat chemotherapy resistance and for cachexia, a common problem in the cancer patient population.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>Our
Pipeline</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">We
have sought to develop a broad </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">portfolio of <FONT STYLE="background-color: white">novel
and transformative drug therapies to treat cancer. Our current portfolio consists of seven drug therapies consisting of </FONT>peptide
and small molecule cancer immunotherapeutics <FONT STYLE="background-color: white"><B>KROS 101</B>, <B>102</B>, <B>201</B>, <B>301</B>,
and <B>401</B> and </FONT>therapeutic agents <FONT STYLE="background-color: white"><B>ENV 105</B> and <B>205</B>. We started three
clinical trials in the fall of 2023 for <B>KROS 201</B> and <B>ENV 105</B>. </FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 84; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">KROS
101 is a small molecule that targets the GITR ligand, a signal for T cell growth to remove a checkpoint barrier to fight a host of cancers.
Our second drug, <B>KROS 201</B>, is a T cell therapy activated by dendritic cells to </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">treat
glioblastoma, a deadly and common brain cancer. Our <B>ENV 105</B> drug seeks to address unmet medical needs in large markets of prostate
and lung cancers. For example, the global prostate cancer therapeutics market size was valued at USD 7.9 billion and at USD 1.7 billion
for EGFR mutant non-small cell lung cancer. Our <B>ENV 105</B> biologic drug targets endoglin and addresses resistance to androgen targeted
drugs and EGFR inhibitors. A Phase 2 trial involving a heavily pre-treated population suffering from prostate cancer was initiated
at Cedars-Sinai Medical Center. The primary objective of the study was to measure the proportion of patients at two months who had either
disease stabilization or regression (i.e. complete or partial response), referred to as the clinical benefit rate. A clinical benefit
rate of 62% was observed. This Phase 2 trial involved the use of enzalutamide (Xtandi&reg;, Pfizer) and abiraterone (ZYTIGA&reg;,
Janssen), two forms of hormone therapy that blocks the androgen receptor and its target ligand, testosterone, respectively. These two
agents are considered standard of care for nearly all recurrent prostate cancer patients.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white">The trial accrued patients
that were resistant to the very androgen targeted therapy (enzalutamide or abiraterone) that was given in the trial in addition to ENV105.
Importantly, ENV105 administration alone has no clinical benefit, based on pre-clinical findings (conducted by us) and previous clinical
findings (through trials performed by the National Cancer Institute). However, two agents that apparently have no clinical effect,
when combined result in halting tumor progression. The finding is well justified by numerous publications demonstrating hormone
therapy resistance develops through the induction of CD105, the target of ENV 105 [Placencio-Hickok et al. (2020) Endocrine Related
Cancer 27:1; Kato et al. (2020) Oncogene 38: 716; Smith et. al. (2023) Molecular Therapy 31: 78; Thiruvalluvanet. al. (2023) Cancers
14: 2491]. All the patients in the trial were not only resistant to the two hormone therapy agents, but the patients had all had
at least one other intervention after surgical or radiation progression. For some they had failed to respond to five other drugs. The
responders to the combination therapy were patients that had exceedingly few other options for survival. The study enrolled 11 patients
prior to closure, each of whom were enrolled in one of two arms (or specific treatments) in the clinical trial. Three patients were enrolled
in the abiraterone acetate arm and eight in the enzalutamide arm. Of these patients only two and six patients on each arm were considered
assessable, respectively (i.e. completed at least two months of therapy with imaging). Of the 11 patients enrolled in the trials, nine
were evaluable. This investigator-initiated trial closed to accrual prior to its planned enrollment of 40 patients due to limitation
of the drug supply from the manufacturer. The drug supply has since been expanded and obtained by Kairos Pharma. The primary objective
of the study was to measure the proportion of patients at two months who had either disease stabilization or regression (i.e., complete
or partial response), referred to as the clinical benefit rate. Disease status assessments were made by RECIST 1.1 or PCWG3 criteria.
One of the two patients on the abiraterone arm experienced a &lt;50% decline in his serum PSA concentration with disease stabilization
by scans. Four of the six patients on the enzalutamide arm experienced clinical benefit by three showing stabilization of disease, and
one showing decline in his serum PSA concentration and scan improvement. Grade 3 side effects consisting of hyponatremia, urinary retention,
and cellulitis were noted on the abiraterone arm. None of these grade 3 events were attributed to the use of ENV105. No grade 3 events
were noted on the enzalutamide arm. The most frequent grade 1-2 events occurring in at least two patients included anemia, nausea, and
gingival bleeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white">A three-gene panel was identified
to serve as a companion biomarker for patient selection. There are no approved companion diagnostic tests for ENV105. However, candidate
biomarkers revealed in the previous Phase 2 trial will be verified in the new Phase 2 trial to better predict patients that would best
respond to the ENV105. Our Enviro Therapeutics, Inc. subsidiary will strive to co-develop companion biomarkers with all drugs in
its portfolio, enabling identification of potential drug responders prior to therapy. As of the date of this prospectus, our companion
diagnostics are in development and have not been approved by the FDA. There is no guarantee that these companion diagnostics will be
approved by the FDA or comparable foreign regulatory agencies.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>KROS 101</B> is a small molecule that induces
trimerization of the GITR ligand and is the culmination of the pioneering work of Dr. Ramachandran Murali, our Vice President of Research
and Development, in 3D crystallography. <B>KROS 201</B> consists of potent T cells that are stimulated by dendritic cells in the test
tube to target cancer stem cells. Our initial focus of <B>KROS 201</B> is to treat glioblastoma. Dr. Yu runs a lab that is known
for its pioneering work in dendritic cell immunotherapy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>ENV 105 </B>demonstrated an ability to target
CD105 which is elevated in drug resistance in prostate cancer. Androgen therapy resistance in prostate cancer is being targeted
in the Phase 2 trial. EGFR antagonist resistance in lung cancer is being targeted in a Phase 1 trial. The <B>ENV 105</B> Phase
2 trial in prostate cancer with apalutamide (Janssen) is a multicenter trial being conducted at Cedars-Sinai, University of Utah, and
City of Hope. The Phase 1 trial in lung cancer with Tagrisso (AstraZeneca) is being conducted at Cedars-Sinai.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are also developing <B>KROS 102</B>, <B>KROS 301</B>, and <B>KROS 401</B>. <B>KROS 102</B> is a GITR ligand antagonist designed to increase
inhibitory Treg functions while hampering T effector cell numbers and function. <B>KROS 301</B> is a tumor targeting small molecule and
checkpoint inhibitor with two distinct mechanisms of action resulting from blocking intranuclear localization of RelA, a key component
of the NF-KB pathway. <B>KROS 401</B> is a tumor microenvironment immune modulator and cyclic peptide inhibitor of IL-4 and IL-13 reversing
tumor associated macrophage inhibition. Both therapies reverse the mechanism of immune suppression at the tumor site.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Finally, we are developing <B>ENV 205</B>, what we
believe to be a first-of-its-kind biologic that targets prostate cancers that have become otherwise resistant to chemotherapy. As of
the date of this prospectus, <B>ENV 205</B> has not been approved by the FDA or any other comparable foreign regulator. <B>ENV 205</B>
targets the excretion of mitochondrial DNA found elevated in circulation when patients are on chemotherapy. Higher blood levels of mitochondrial
DNA are not only associated with chemotherapy resistance, but more widely recognized as a mediator of cardiac toxicity and other systemic
inflammatory events contributing to the negative side effects of chemotherapy use. Thus, depleting mitochondrial DNA with the
administration of <B>ENV 205 </B>restores chemotherapy sensitivity with reduced toxic side effects.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Addressing these critical targets strike cancer at
what we believe to be its most vulnerable point. The group of founding scientists generating our initial drugs have combined their pioneering
contributions in structural, biology, immunology, and cancer therapy to bring to unmet medical needs what we believe are life changing
therapeutics. As of the date of this prospectus, aside from the clinical trials, which are conducted off-site at third party facilities,
our operations are all conducted virtually as we aim to be efficient in our deployment of capital and leverage our history with premier
academic medical centers to efficiently enroll and execute clinical trials.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 85; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Our
Development Pipeline and Programs</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
drug development programs for <B>KROS 101</B>, <B>102</B>, <B>201</B>, <B>301</B>, and <B>401</B> as well as therapeutic agents <B>ENV
105</B> and <B>ENV 205</B> are summarized in the following table.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><IMG SRC="chart_002.jpg" ALT=""><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Kairos-Developed
Products</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kairos&rsquo;
products consist of five pre-clinical or clinical-trial stage drug candidates developed by Kairos and designed to target immune response.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>KROS
101</B> is an orally available GITR (glucocorticoid-induced tumor necrosis factor receptor) ligand small-molecule antagonist designed
to deplete regulatory T cells (Tregs) and activate effector T cells to augment the antitumor immune response for the treatment of patients
with cancer. We are developing <B>KROS 101</B> as a systemic immune modulator to address immunosuppressive activity of solid cancers
and we are currently working towards completing IND-enabling pharmacokinetic, toxicity and safety studies in 2024. <B>KROS 101
</B>stabilizes the GITR ligand to signal GITR to impact cancer therapy. GITR is a powerful checkpoint that suppresses the immune response
against cancer. This checkpoint is a central switch that promotes &ldquo;killer&rdquo; effector T cell functions and hampers inhibitory
regulatory T cell (Treg) functions. Due to its central role in regulating Treg, GITR receptor complex is considered an optimal therapeutic
target for treating cancer. This may be the optimal complement to add to current checkpoint inhibitors as it shows a dose dependent effective
response in increasing the immune response. As a competitive antagonist, <B>KROS 101</B> could be dosed to avoid the typical common side
effects of checkpoint inhibitors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe our GITR targeting small molecule has the potential to be a significant improvement over existing antibody treatments that have
been tested in clinical trials. When GITRL binds to the GITR on the surface of Treg cells, the suppressive activity of Treg cells against
effector T cells is reduced. While on the effector T cell, GITR-GITRL binding induces the proliferation of effector T cells. This receptor
is central to the regulation of the immune system.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Whereas
previous competitor therapeutics targeting GITR were antibodies that bind the receptor, our small molecule drug fits into the GITR ligand
stabilizing the three-pronged trimer structure. This structure enables the amplification of the GITR receptor trimer, leading to physiologic
signaling for T cell proliferation. The analogy is a digital signal rather than a limited analog signal. This powerful physiologic signal
can lead to exponential signaling of T cells to proliferate against cancer cells. In addition, the small molecule half-life enables reversibility,
allows for fine tuning to limit side effects. Having both agonist and antagonist molecules can reverse potential untoward effects. In
addition, this small molecule may also be given orally as a medication. The discovery of KROS 101 was the culmination of transformative
structural biology based on exclusive proprietary 3D crystallography first used to model GITR ligand by Kairos&rsquo; scientists.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white">KROS 101 is currently
in pre-IND studies in development for a Phase 1 trial.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 86; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">KROS
102 is a GITR antagonist designed to increase the inhibitory regulatory T cell (Treg) functions, while hampering T effector cell numbers
and function. KROS 102 has been shown to decrease T effector cells and increase Treg cells in a dose dependent fashion to treat autoimmune
diseases. We are developing a novel GITR inhibitor that can impact the abnormal immune responses against one&rsquo;s own body.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
to its central role in regulating Treg, the GITR receptor complex is an optimal therapeutic target to treat autoimmunity. By potently
and specifically inhibiting an immune response, this strategy may impact autoimmune diseases such as Crohn&rsquo;s disease, multiple
sclerosis, and rheumatoid arthritis. KROS 102 has been shown to decrease T effector cells and increase Treg cells in a dose dependent
fashion. KROS 102 is currently in preclinical studies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">KROS
201 is a proprietary technology for the production of activated T cells. Activated T cells (ATC) are killer T cells that are made from
a patient&rsquo;s white blood cells in a cell culture by activating with cytokines or T cell activating signals and by priming dendritic
cells loaded with glioblastoma cancer stem cell specific antigens. Kairos generates activated T cells that will be infused intravenously
into patients with recurrent glioblastoma.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">KROS
201 begins with the activation of T cells using dendritic cells for the treatment of patients with glioblastoma. Activated T cells (ATC)
are killer T cells that are made from a patient&rsquo;s white blood cells in a cell culture by activating with cytokines or T cell activating
signals and by priming dendritic cells loaded with glioblastoma cancer stem cell specific antigens. Cytotoxic and helper T cells are
generated in a cell manufacturing center and infused into patients with recurrent glioblastoma.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe KROS 201 has the potential to become a novel T cell therapy that allows a &ldquo;plug and play&rdquo; scenario where a patient&rsquo;s
specific tumor can be addressed as well as the improvement of cancer treatment by stimulating patients&rsquo; immune systems to generate
a long-term population of cytotoxic T cells &amp; helper T cells directed against the tumor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
completed IND-enabling pharmacology and toxicology studies and submitted an IND application.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">KROS 301
is a tumor-targeting small molecule and checkpoint inhibitor with two distinct mechanisms of action resulting from blocking intranuclear
localization of RelA, a key component of the NF-KB pathway. NF-KB is a key component for cancer growth and drug resistance. KROS 301
targets tumor cells in in RelA/p65 biomarker positive solid tumors. The use of this biomarker enables choosing patients that will
respond to the drug enabling efficient clinical trials that are more likely to succeed. KROS 301 is in active pre-clinical development.
Separate approval will be required for the development and approval of a companion diagnostic. This approval may be delayed or not
issued by the FDA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">KROS
401 is a tumor microenvironment immune modulator and cyclic peptide inhibitor of IL-4 and IL-13 reversing tumor associated macrophage
inhibition. KROS 401 reduced the M2 macrophage population and limits fibrosis of the pancreas due to anti-inflammatory process (Xue,
Nature Com. 2015). Other indications may include pulmonary fibrosis, Crohn&rsquo;s disease, and other inflammatory conditions. KROS 401
blocks the IL4/IL13 cytokine immune receptors for triple negative breast cancer and in addition, it increases anti-tumor response in
conjunction with radiation therapy in an animal model.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recently,
it became clear that macrophages in tumors are altered by the Th2 cytokines IL-4 and IL-13, inducing alternatively activated macrophages
or M2. Breast cancer associated tumor associated macrophages are mainly activated M2 macrophages. Thus, shifting the balance toward M1
macrophages will prevent tumor growth and enable T cell activation and killing, which is dependent on Th1 cytokines. We will target a
key Th2 cytokine pathway, IL-4, and IL-13 to block macrophage immunosuppression with KROS 401, thereby allowing T cells to access tumors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe there are significant advantages to KROS 401 as our peptide binds to IL13R alpha1 and IL4R alpha1 (type I) receptor complex and
blocks both IL-4 and IL-13 mediated signaling. The implication is that targeting IL-4Ralpha is predominantly for indications such as
asthma or eczema, while the type I is for macrophages/tumor growth (esp IL13R). KROS 401 is in preclinical development.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 87; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Enviro
and Enviro-Licensed or -Acquired Products</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enviro&rsquo;s
product portfolio includes two therapeutic agents at different stages of clinical development.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">ENV
105 is a Phase 2 clinical stage therapeutic agent designed to address cancer progression. ENV 105 is an antibody therapeutic
designed for use by prostate cancer patients resistant to androgen-targeted therapy, which is being tested in a Phase 2
clinical trial. We began accruing patients for the trial in September 2023. This  multicenter randomized Phase 2 trial
involving Cedars-Sinai Medical Center and City of Hope in Los Angeles California and Huntsman Cancer Center in Utah is
testing the combination of a third-generation androgen targeted therapy, apalutamide (Janssen), with or without ENV 105
for prostate cancer patients that have developed resistance to at least one other androgen targeted inhibitor (NCT05534646). Dr.
Edwin Posadas is the principal investigator of this multi-institutional trial. <FONT STYLE="background-color: white">Dr. Posadas is
Director of the Experimental Therapeutics Program and the Medical Director of the Urologic Oncology Program at the Samuel Oschin
Comprehensive Cancer Institute at Cedars-Sinai Medical Center. </FONT>Companion biomarkers for efficient selection of patients to
potentially respond to the drug will be evaluated in this trial. The genetic biomarker potentially identifies responsive patients to
ENV 105 prior to therapy for a future Phase 3 trial. The companion biomarker would require a separate approval by the FDA. Prostate
cancer is the most common, non-cutaneous cancer affecting men in the United States and 1.2 million new cases registered worldwide.
It is also the second leading cause of cancer death in American males. Androgen targeted therapy accounts for USD 15 billion in
sales in 8 primary markets. Since nearly all patients eventually develop resistance to androgen targeted therapy, addressing this
population with a drug targeting endoglin (ENV 105) is of high value for this single indication. In clinical trials, ENV 105 has
been shown to be reasonably well-tolerated in patients as an adjunct to contemporary androgen targeted inhibitors (NCT03418324). Grade
3 hyponatremia, urinary retention, and cellulitis were noted on the abiraterone arm. None of these were attributed to the use of
ENV105. No grade 3 events were noted on the enzalutamide arm. The most frequent grade 1-2 events occurring in at least two patients
(listed as abiraterone, enzalutamide) included anemia, nausea, and gingival bleeding. Careful mechanism-of-action studies have
revealed that ENV 105 impacts a more ubiquitous means of cancer drug resistance, cancer dormancy, the growth potential for this drug
alone can be large. A Phase 1 EGFR antagonist resistant non-small cell lung cancer targeted therapy combination of Tagrisso
(osimertinib, AstraZeneca) and ENV 105 is at Cedars-Sinai Medical Center. The principal investigator of this clinical trial is Dr.
Karen L. Reckamp, <FONT STYLE="background-color: white">Professor in Medicine, Director of the Division of Medical Oncology at
Cedars-Sinai Medical Center</FONT>. We also expect targeted therapies to contribute to the growth of the prostate and EGFR-dependent
non-small cell lung cancer market, as immune therapies have not shown efficacy for these two cancer types.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">ENV
205, an antibody fragment targeting mitochondrial DNA was shown to limit chemotherapy resistant prostate cancer in
preclinical studies. Mitochondrial DNA depletion limit inflammation-induced pro-tumorigenic activity and sensitizes prostate
cancer to docetaxel. This biologic is a first of its kind strategy of chemotherapy sensitization. The development of chemotherapy
resistance is an unfortunate eventuality for patients with solid tumors. The projected market share of $74.3 billion by 2027 for
chemotherapy alone, support an effectively large market share for ENV205, as the only biologic reported to restore
chemotherapy sensitivity in preclinical studies.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
Market Opportunity</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Global
cancer drug spending is expected to reach $311.2 billion by 2026 driven largely by the growth of immuno-oncology (EvaluatePharma World
Preview 2020). Global immunotherapy market estimates show significant compound growth with sales expectations ranging from $94.7-$126.9
billion by 2026, exhibiting a CAGR of up to 20.2% from 2020 (Grand View Res.). Increasing patient pool and higher mortality rates are
augmenting the need for cancer immunotherapy globally. We are uniquely positioned to advance our immunotherapies that may have the potential
to transform the way cancer is treated using antibodies that target CD105 to reverse drug resistance to prostate and lung cancer and
activated T cells that target cancer stem cells that are the root of glioblastoma. Our pipeline of immunotherapeutic agents that signals
growth of effector T cells against cancer, and reverse immunosuppression at the cancer site are being rapidly advanced to address large
unmet needs in cancer immunotherapy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ENV
105 </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
broad application of ENV 105 as a complementary drug to support standard of care cancer therapy for many cancer types has revealed numerous
potential therapeutic strategies that have not been exhaustively explored in pre-clinical models. This is based on the identification
that ENV 105 acts on both the cancer cells and cancer associated fibroblastic cells, thus it complements many cancer epithelia-directed
therapies. However, we have focused on three indications in pre-clinical studies, two of which have matured to clinical trials: prostate
cancer (Phase 2 with androgen signaling inhibitors), lung cancer (Phase 1 with EGFR antagonist), and head and neck cancer (preclinical
with radiation or chemotherapy).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Prostate
cancer</U>: There are 300,000 castrate resistant prostate cancer patients in the U.S. eligible to be given combination therapy of ENV
105 + androgen signaling inhibitors for $5,000 per month (based on comparable neutralizing antibodies). This would suggest a potential
US$9 billion gross sales for ENV 105 for a six-month dose in the U.S. for this single indication. As a point of reference, androgen signaling
inhibitors on their own make up $10 billion market inclusive of Sanofi; Johnson and Johnson Services, Inc.; Pfizer, Inc.; Astellas Pharma,
Inc.; and Bayer AG &ndash; predicted to grow to $15 billion global market by 2027 of castrate resistant prostate cancer patients.
None have been approved to extend efficacy apart from chemotherapy (docetaxel and cabazitaxel) with undesirable toxicity profiles.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 88; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Lung
cancer</U>: There are approximately 30,466 patients with an EGFR driven non-small cell lung cancer annually in the U.S. The incidence
of EGFR driven NSCLC is most prevalent in non-smokers and those of east Asian descent, 35-40% of NSCLC &ndash; 341,633 patients annually
in Asia (China, India, Japan, S. Korea, Thailand, Philippines). To determine lung cancer market share for ENV 105, the current market
share for Tagrisso (US$3 billion annual sales for AstraZeneca) can be used as point of reference. Accordingly, ENV 105 could have a $1
billion market share in the U.S. as a combination therapy with EGFR antagonists to improve or extend its efficacy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Head
and neck cancer</U>: The capacity for ENV105 to complement both radiation and chemotherapy would suggest future clinical application
in many solid tumor types. For head and neck cancer, the World Health Organization estimates over 550,000 new cases of and around 300,000
deaths per year. The rising consumption of alcohol and tobacco is a major factor behind estimated 7.9% increase in the head and neck
cancer by 2030. The global head &amp; neck cancer drug market is estimated at $1.51 billion in 2021. Chemotherapy is the standard of
care alone or in combination with radiation therapy, where toxicity is the greatest limitation. Administration of ENV 105 enables lower
radiation dosing to improve quality of life.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>KROS
101 and KROS 102</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Checkpoint
inhibitors are immunotherapeutic agents that block proteins that suppress a potent immune response of the body against cancers and other
&ldquo;foreign&rdquo; agents. KROS 101 and 102 are checkpoint inhibitors and agonists that enable T cells to expand and contract respectively.
The global immune checkpoint inhibitor market size was $31.4 billion in 2021 and anticipated to be $148 billion in 2020 with a CAGR of
18.81% from 2022 to 2030 (Precedence Research).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>KROS
201</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>KROS
201</B> is an activated T cell therapy that targets glioblastoma. T cell therapy market size is expected to be around $20.8 billion by
2030 from its value of $4.9 billion in 2021 with a CAGR of 20.4% during the forecast period 2022-2030 (Vision Research Reports).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>KROS
301</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
global small-molecule cancer therapies market size was valued at $175.3 billion in 2021 and is expected to have a CAGR of 5.44% from
2022 to 2030 (Grandview Research). KROS 301 is a small molecule that targets the NF-kB pathway in cancer to prevent cancer growth and
block checkpoint inhibitor expression of PD-L1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>KROS
401</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
global peptide therapeutics market size was estimated at $39.3 billion in 2021 and is expected to reach $42.1 billion in 2022 (Grandview
Research). KROS 401 is a cyclic peptide that blocks IL-4 and IL-13 receptors on tumor associated macrophage to reverse immune suppression
at the tumor site.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ENV
205</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cachexia
is debilitating disease of muscle wasting not treatable by nutrition supplementation associated with the death of 30% of all cancer,
20% of AIDS, and 30% of COPD patients. Cachexia is an unfortunate underrecognized consequence of many chronic diseases. We believe ENV
205 is a molecule found to limit the process of muscle wasting through the capture and excretion of mitochondrial DNA in circulation.
Cachexia is considered an orphan disease in the U.S. and Europe, increasing hospitalization costs and length of stay in several disease
types. The cancer cachexia therapeutics market is estimated to reach above $1 billion in the U.S. alone. The application of ENV 105 as
cachexia therapeutic is further supported by the demonstrated restoration of docetaxel therapy sensitivity in resistant prostate cancer
models. Taxane-based therapy, inclusive of docetaxel, paclitaxel, and cabazataxel, is standard of care for majority of solid tumors (inclusive
of breast cancer, non-small cell lung cancer, advanced stomach cancer, head and neck cancer and metastatic prostate cancer). Strong preclinical
data suggest ENV 205 chemotherapy sensitization in a combination therapy setting and limit the development of cachexia as a single agent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 89; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will aggressively pursue ENV 105 and ENV 205 in pre-clinical and clinical trials. Future therapeutic targets will be developed
based on the overriding mission to complement traditional cancer-targeted drugs with those that address the tumor microenvironment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Our
Strategy</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
goal is to unlock the power of the immune system on the two most pervasive problems in cancer treatment: (i) resistance to therapy
and (ii) immune suppression by cancer. We believe this road will lead to major improvement in the quality of life of cancer patients
and will transform the outcomes of patients. We seek to develop cutting-edge therapeutics for cancer patients that reverse the inhibitory
effects of cancer on the immune system. To this end, our strategy involves rapidly and efficiently advancing our existing portfolio of
innovative products through clinical development and leveraging our current industry-leading team. The strategy consists of the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
                                            multi-pronged toolkit of potent and life changing therapeutics with differing modalities,
                                            targets, and stages of development. Their commonality is targeting key mechanisms of drug
                                            resistance and immune suppression by cancer.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leverage
                                            our academic research and clinical connections with our industry collaborations.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Complete
                                            enrollment of</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
                                            prostate patients in a randomized multi-institutional Phase 2 trial of ENV 105.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Complete
                                            enrollment</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
                                            in a Phase 1 trial of ENV105 for patients with non-small lung cancer on Tagrisso.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Initiate
                                            a Phase 1 trial of activated T cell therapy for KROS 201 in patients with glioblastoma.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Complete
                                            pre-IND studies for the checkpoint inhibitor KROS 101.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Continue
                                            to advance our pipeline of immunotherapeutics for clinical trials.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maintain
                                            a portfolio of innovative therapeutics to mitigate risk.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leverage
                                            virtual infrastructure for efficient execution of collaborative clinical and translational
                                            research.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Utilize
                                            internal development capabilities to leverage close academic partnerships.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
particular, we intend to deploy an aggressive, three-pronged, growth strategy that we believe will help us develop our clinical pipeline
and maximize our success, consisting of strategic partnerships, commercial development, and portfolio optimization.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Strategic
                                            Partnerships</I></B> &#8211; We will focus on expanding our existing pipeline through establishing
                                            strategic partnerships with companies that have interesting products and technologies. We
                                            intend to focus on novel, early-stage and preclinical assets in a variety of therapeutic
                                            areas.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Commercial
                                            Development</I></B> &#8211; We expect to participate and assist in the commercial development
                                            activities of its assets with our strategic partners. Commercial development activities may
                                            include, but are not limited to, clinical development, market research, healthcare economics,
                                            market access, sales/marketing, and commercial launch strategies.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Portfolio
                                            Optimization</I></B> &#8211; We will continue to evaluate, prioritize, optimize, and make
                                            appropriate changes in our pipeline portfolio as market development dynamics and/or product
                                            opportunities change.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="chart_022.jpg" ALT=""><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I></I></B></FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
Team </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
company is led by our CEO and Chairman, Dr. John S. Yu., our Chief Scientific Officer, Dr. Neil Bhowmick, our Vice President
of Research and Development, Dr. Ramachandran Murali, and our Chief Financial Officer, and Mr. Doug Samuelson.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 90; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Yu is a Professor and Clinical Chief in the Department of Neurosurgery and Director of the Brain Tumor Center at Cedars-Sinai Medical
Center in Los Angeles, California. Dr. Bhowmick is a Professor of the Department of Medicine and Director of the Cancer Biology Program
at Cedars-Sinai Medical Center. Dr. Murali is a structural biologist at Cedars-Sinai Medical Center, and the inventor, with others, of
three of the patent technologies licensed to Kairos.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Intellectual
Property </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Overview</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Yu, Dr. Bhowmick, and Dr. Murali have developed certain proprietary technology, and identified other proprietary technology developed
by researchers and Cedars, that the Company will pursue for commercialization. Proprietary technology invented and developed by doctors
and scientists and Cedars are owned by Cedars, and then optioned and/or licensed to such doctors and scientists, or other third parties,
for commercialization in partnership with Cedars. Kairos and its subsidiary Enviro have multiple such options and/or license agreements
with Cedars regarding proprietary technology that the Company is pursuing for commercialization, as described below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
of our patent rights are subject to the license agreements between the patent owner and the Company, described below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Kairos
Intellectual Property Agreements with Cedars-Sinai Medical Center</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kairos
has entered into four Exclusive License Agreements with Cedars-Sinai Medical Center, which are sometimes referred to as the Kairos-Cedars
license agreements, which grant Kairos exclusive licensing rights (which include the right to sublicense) with respect to certain
patent rights owned by Cedars to the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Method
                                            of generating activated T cells for cancer therapy, invented by Dr. John S. Yu and others.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Methods
                                            of use of compounds that bind to RelA of NFkB, invented by Dr. Ramanchandran Murali and others.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Composition
                                            and methods for treating fibrosis, invented by Dr. Ramanchandran Murali and others.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compositions
                                            and methods for treating cancer and autoimmune diseases, invented by Dr. Ramanchandran Murali
                                            and others.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the exclusive license agreement in item 1 above, Kairos is required to pay (i) an initial license fee in the mid five-figures
upon the raising of $500,000 in capital, (ii) an annual maintenance fee in the low five-figures, (iii) royalties based
on low single-digit percentage of patent product sales and less than one percent of other sales and (iv) other non-royalty sublicense
fees ranging from a mid-single-digit to low double-digit percentage of such revenues shall be due and payable to Cedars, depending on
the stage of FDA authorization at the time the sublicense revenue is generated. Non-royalty sublicense revenue would be between 5%
and 35% depending on the phase of FDA testing of the product during which the sublicense agreement is signed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, Kairos is required to the Cedars based on the following milestones: (i) successful completing of Phase 1 clinical trial; (ii)
the successful completing of Phase 2 clinical trial and receipt of U.S. Food and Drug Administration, or FDA, or equivalent regulatory
agency in another jurisdiction approval for a Phase 3 clinical trial; (iii) receipt of FDA approval; and (iv) cumulative net sales exceeding
$50,000,000. If all of these milestones are met, the required milestone payments will total $4,400,000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
each of the exclusive license agreement in items 2, 3 and 4, Kairos is required to (i) pay an initial license fee of
$15,000 in total, (ii) reimburse Cedars for patent protection costs ranging from the high four-figures to the mid-five-figures, (iii) pay
an annual maintenance fee in the low five-figures and (iv) pay royalties based on a low single-digit percentage of net sales. The
royalty obligations as to each product shall terminate on a country-by-country basis concurrently with the expiration of the last to
expire of a valid claim within the patent rights that covers such product, including any term extensions thereof. There are no
non-royalty expiration dates. Patent expiration dates and specific jurisdictions of foreign patents that we in-license from Cedars-Sinai
are listed in the Patent Table at page 90 below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Enviro
Intellectual Property Agreements with Cedars-Sinai Medical Center</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 16, 2020, Enviro entered into two Exclusive Option Agreements with Cedars-Sinai Medical Center that give Enviro options
to enter into an Exclusive Agreement with Cedars which would grant Enviro exclusive licensing rights (which include the right
to sublicense) to certain patent rights owned by Cedars with respect to (1) compositions and methods for treating diseases and conditions
by depletion of mitochondrial DNA from circulation for detection of mitochondrial DNA, and (2) sensitization of tumors to therapies through
endoglin antagonism.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 91; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<!-- Field: Split-Segment; Name: Split_01 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
consideration of these agreements, Enviro agreed to pay option fees of $2,000 and $3,000, respectively. Enviro&rsquo;s options expire
nine months from the effective date. On January 9, 2021 and January 11, 2021, the parties agreed to extend both nine-month
option periods for an additional six months. In consideration of these extensions, Enviro agreed to pay an extension fee of $500, and
$1,000, respectively. Enviro entered into two Exclusive License Agreements with Cedars-Sinai Medical Center on June 2, 2021. Enviro and
Cedars entered into:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
                                            Exclusive License Agreement for Enviro to develop, manufacture, use and sell products utilized
                                            or derived from patent rights worldwide, which include one patent application in the United
                                            States related to the &ldquo;Compositions and Methods for Treating Diseases and Conditions
                                            by Depletion of Mitochondrial DNA from Circulation and for Detection of Mitochondrial DNA&rdquo;
                                            invented by Dr. Neil Bhowmick and others; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
                                            Exclusive License Agreement for Enviro to develop, manufacture, use and sell products utilized
                                            or derived from the patent rights and technical information worldwide, which include six
                                            patent applications in the United States, Australia, Canada, China, Europe and Japan related
                                            to the &ldquo;Sensitization of Tumors to Therapies Through Endoglin Antagonism&rdquo; invented
                                            by Dr. Neil Bhowmick and others.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
milestones agreed to were as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Completion of preclinical studies within two years of the effective date,
as stipulated in the agreement thereof (the &ldquo;Effective Date&rdquo;);</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Completion
                                            of toxicology studies within two and a half years of the Effective Date; </FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Obtaining
                                            IND within three years of the Effective Date; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beginning
                                            Phase 1 trial within four years of the Effective Date.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this prospectus, we have completed milestones 1, 2 and 3.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Exclusive License Agreement between Enviro and Cedars was made effective on June 2, 2021.</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
Pursuant to the two Enviro-Cedars license agreements, Enviro must meet certain milestones relating commercialization, and, if not
met or extended, Cedars may convert the exclusive licenses into non-exclusive licenses or to co-exclusive licenses, or terminate the
licenses. In exchange for each of the licenses, Enviro shall pay an upfront license fee, plus an additional fee when Enviro has
raised at least $250,00,00 in capital company-wide for any program or purpose; provided, however, will only have to pay such fee
once between both Enviro-Cedars license agreements. Enviro shall also reimburse Cedars for the costs incurred in the prosecution of
the patent rights subject to the Enviro-Cedars license agreements prior to the date of execution of such agreements. The
aggregate potential fees that Enviro may have to pay in exchange for the licenses is $464,749.33 as of April 28,2023. Cedars
shall also receive royalty payments of a mid-single-digit percentage of net sales of products associated with the licensed patent
right and less than one percent of net sales of other products derived from Cedars&rsquo; technical information, with a minimum
royalty year in the low five-digits due beginning on the third anniversary of the effective date of the license. To the extent
Enviro derives non-royalty sublicensing revenues, a high single-digit to low double-digit percentage of such revenues shall be due
and payable to Cedars, depending on the stage of FDA authorization at the time the sublicense revenue is generated. Non-royalty
sublicense revenue would be between 5% and 35% depending on the phase of FDA testing of the product during which the sublicense
agreement is signed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enviro
shall pay Cedars in connection with achieving certain milestones relating to products derived from the patent rights: (i) successful
completion of Phase 1 clinical trial; (ii) successful completion of Phase 2 clinical trial, receipt of FDA approval, and approval
for a Phase 3 clinical trial; (iii) FDA approval of a new drug application or biologics license applications; and (iv)
cumulative net sales exceeding $100,000,000. The maximum aggregate milestone payment for ENV 105 will be $7,150,000 when cumulative net sales have exceeded $100,000,000. The last-to-expire of licensed patents is scheduled to expire on June 14, 2037. Patent
expiration dates, specific jurisdictions of foreign patents are listed in the Patent Table above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Enviro-Cedars license agreements will, unless sooner terminated, continue in effect on a country-by-country basis until the last to expire
of the patents covering the patent rights or future patent rights. Under the terms of the Enviro-Cedars license agreements, unless waived
by Cedars, the agreement shall automatically terminate: (a) if Enviro ceases, dissolves or winds up its business operations; (b) if performance
by either party jeopardizes the licensure, accreditation or tax exempt status of Cedars or the agreement is deemed illegal by a governmental
body; (c) within 30 days for non-payment of royalties or if of Enviro fails to undertake commercially reasonable efforts to exploit the
patent rights or future patent rights; (d) within 60 days of Enviro&rsquo;s failure to cure any breach or default of a material obligation
under the agreements (e) within 90 days of Enviro&rsquo;s failure to cure any breach or default of a material obligation under the agreements;
or (f) upon mutual written agreement of the parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Enviro
License and Supply Agreement with Tracon Pharmaceuticals, Inc.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">On May
21, 2021, Enviro entered into an Enviro-Tracon license agreement with Tracon. Pursuant to the Enviro-Tracon license agreement,
Tracon grants to Enviro access to inactive IND filings for &ldquo;TRC105&rdquo; in the United States, ownership of &ldquo;TRC105&rdquo;
stored vials of drug product manufactured to GMP standards stored at Fisher Clinical or their designee, and assignment of Tracon&rsquo;s
patent rights to its &ldquo;CD105 technologies.&rdquo; Dr. Bhowmick, our Chief Scientific and Enviro&rsquo;s CEO, is a consultant
at Tracon Pharmaceuticals, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 92; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Enviro-Tracon license agreement, Enviro paid Tracon an upfront fee of $100,000, and is obligated to pay Tracon an additional $500,000
upon its or its successor&rsquo;s completion of one or more financings through the sale of equity (or debt convertible to equity) in
an amount of $10,000,000, and an additional $500,000 within 10 days of its or its successor&rsquo;s completion of one or more financings
through the sale of equity (or debt convertible to equity) in an amount of $22,000,000. In addition, Enviro is obligated to pay Tracon
a royalty of 3% of net sales on a country-by-country basis of the products subject to the agreement, and non-royalty payments of 3% of
consideration for sublicensing fees. The royalty payments would terminate upon the completion of use of the TRC105 product. The non-royalty
payments would terminate upon payment of $500,000 after the financing of an aggregate amount of $22,000,0000 to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enviro issued Tracon equity ownership in Enviro equal to a number of shares
of restricted common stock of Enviro equal to 7% on a fully diluted and converted basis of all common and preferred shares of Enviro.
In connection with the Enviro-Kairos share exchange, the parties agreed that Tracon would receive, in exchange for its Enviro common stock,
280,000 shares of the restricted common stock of Kairos (which is equal to 1.41229% of the issued and outstanding shares of Kairos on
a fully diluted and converted basis). Until such time as Tracon has received all of the cash consideration (as described above), Enviro
or its successor in interest, shall issue to Tracon, without further consideration, any additional common stock of Enviro, or such successor
in interest, necessary so that Tracon maintains ownership of shares of Enviro, or such successor in interest, equal to the Tracon-Enviro
Equity on a fully diluted and converted basis of all stock in Enviro (or its successor). Notwithstanding the foregoing, if Tracon receives
the full cash consideration within six months of the effective date of the Enviro-Tracon license agreement, then Tracon shall automatically
return to Enviro (or any successor entity, if applicable) a number of shares of the restricted common stock of Enviro (or its successor)
such that upon such return of shares Tracon shall possess an amount of shares in Enviro (or its successor) equal to 2% on a fully-diluted
and converted basis relative to the other Enviro shareholders who exchanged their shares in the Enviro-Kairos share exchange. The returned
portion of the Tracon-Enviro equity shall automatically be terminated, cancelled and of no further force and effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Enviro-Tracon license agreement, we have exclusive licensing rights (which include the right to sublicense) to eight issued
U.S. patents, four U.S. Utility or provisional patent applications, 24 issued patents and 24 patent applications in foreign jurisdictions.
Patent expiration dates, specific jurisdictions of foreign patents are listed in the Patent Table below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>PATENT TABLE</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 9pt">Name
    of the Patent</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 9pt">Patent
    No./Application No.</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt"><B>Status</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt"><B>(Patent
                                            granted or Patent application) </B></FONT></P></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 9pt">Products
    or Technologies to which the Patents or Patent Applications Relate</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 9pt">Type
    of Patent Protection</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 9pt">Expiration
    Date</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 9pt">Jurisdiction</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 16%; text-align: left"><FONT STYLE="font-size: 9pt">ENDOGLIN ANTIBODIES</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left; width: 1%"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 10%; text-align: left"><FONT STYLE="font-size: 9pt">8,221,753</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left; width: 14%"><FONT STYLE="font-size: 9pt">GRANTED</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left; width: 1%"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left; width: 13%"><FONT STYLE="font-size: 9pt">ENV 105</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left; width: 1%"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left; width: 15%"><FONT STYLE="font-size: 9pt">Product</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left; width: 1%"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; width: 12%"><FONT STYLE="font-size: 9pt">2030-03-31</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left; width: 1%"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 14%; text-align: left"><FONT STYLE="font-size: 9pt">United States of America</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">ENDOGLIN ANTIBODIES</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">9,150,652</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">APPLICATION</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">ENV 105</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">Method of treatment</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 9pt">2029-09-30</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">United States of America</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">ENDOGLIN ANTIBODIES</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">9,944,714&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">GRANTED</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">ENV 105</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">Composition of matter</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 9pt">2030-03-31</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">United States of America</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">ANTIBODY FORMULATIONS AND USES THEREOF</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">201810659773.9</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">APPLICATION&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">ENV 105</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">Both a Product and a Method of Treatment Patent</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 9pt">2033-09-05</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">China (People&rsquo;s Republic)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">ANTIBODY FORMULATIONS AND USES THEREOF</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">1538/DELNP/2015&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">APPLICATION</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">ENV 105</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">Both a Product and a Method of Treatment Patent</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 9pt">2033-09-05</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">India</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">ANTIBODY FORMULATIONS AND USES THEREOF</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">6445671</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">GRANTED</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">ENV 105</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">Both a Product and a Method of Treatment Patent</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 9pt">2033-09-05</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">Japan</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">ANTIBODY FORMULATIONS AND USES THEREOF</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">6602446</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">GRANTED</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">ENV 105</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">Both a Product and a Method of Treatment Patent</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 9pt">2033-09-05</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">Japan</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">ANTIBODY FORMULATIONS AND USES THEREOF</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">368996</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">GRANTED</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">ENV 105</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">Both a Product and a Method of Treatment Patent</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 9pt">2033-09-05</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">Mexico</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">ANTIBODY FORMULATIONS AND USES THEREOF</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">10,195,281</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">GRANTED</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">ENV 105</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">Product and Formulation</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 9pt">2034-12-25</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">United States of America</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">ANTIBODY FORMULATIONS AND USES THEREOF</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">1501001224</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">APPLICATION</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">ENV 105</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">Both a Product and a Method of Treatment Patent</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 9pt">2033-09-05</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">Thailand</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">ANTIBODY FORMULATIONS AND USES THEREOF</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">MY-180157-A</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">GRANTED</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">ENV 105</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">Both a Product and a Method of Treatment Patent</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 9pt">2033-09-05</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">Malaysia</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">METHODS AND USE OF COMPOUNDS THAT BIND TO RELA
    OF NF-KB</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">16804352.9</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">APPLICATION</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">KROS 301</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">Both a Product and a Method of Treatment Patent</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 9pt">2036-06-01</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">European Patent</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">METHODS AND USE OF COMPOUNDS THAT BIND TO RELA
    OF NF-KB</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">10,881,641</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">GRANTED</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">KROS 301</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">Method of treatment</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 9pt">2037-11-30</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">United States of America</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">COMPOSITIONS AND METHODS FOR TREATING FIBROSIS</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">3194446</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">GRANTED</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">KROS 401</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">Both a Product and a Method of Treatment Patent</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 9pt">2035-09-18</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">European Patent</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">COMPOSITIONS AND METHODS FOR TREATING FIBROSIS</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">7095990</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">GRANTED</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">KROS 401</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">Both a Product and a Method of Treatment Patent</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 9pt">2035-09-18</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">Japan</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">COMPOSITIONS AND METHODS FOR TREATING FIBROSIS</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">10,245,298</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">GRANTED</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">KROS 401</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">Pharmaceutical composition</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 9pt">2035-09-18</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">United States of America</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">COMPOSITIONS AND METHODS FOR TREATING FIBROSIS</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">11,547,738</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">GRANTED</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">KROS 401</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">Method of treatment</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 9pt">2035-09-18</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">United States of America</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">COMPOSITIONS AND METHODS FOR TREATING FIBROSIS</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">18/093,667</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">APPLICATION</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">KROS 401</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">Both a Product and a Method of Treatment Patent</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 9pt">2035-09-18</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">United States of America</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">COMPOSITIONS AND METHODS FOR TREATING CANCER
    AND AUTOIMMUNE DISEASES</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">3,108,796</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">APPLICATION</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">KROS 101 and KROS 102</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">Both a Product and a Method of Treatment Patent</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 9pt">2039-08-08</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">Canada</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 93; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 9pt">Name
    of the Patent</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 9pt">Patent
    No./Application No.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt"><B>Status</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt"><B>(Patent
                                            granted or Patent application) </B></FONT></P></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 9pt">Products
    or Technologies to which the Patents or Patent Applications Relate</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 9pt">Type
    of Patent Protection</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 9pt">Expiration
    Date</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 9pt">Jurisdiction</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left; width: 16%"><FONT STYLE="font-size: 9pt">COMPOSITIONS AND METHODS FOR TREATING
    CANCER AND AUTOIMMUNE DISEASES</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left; width: 1%"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left; width: 10%"><FONT STYLE="font-size: 9pt">201980062092.7</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left; width: 1%"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left; width: 14%"><FONT STYLE="font-size: 9pt">APPLICATION</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left; width: 1%"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left; width: 13%"><FONT STYLE="font-size: 9pt">KROS 101 and KROS 102</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left; width: 1%"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left; width: 15%"><FONT STYLE="font-size: 9pt">Both a Product and a Method of Treatment
    Patent</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left; width: 1%"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; width: 12%"><FONT STYLE="font-size: 9pt">2039-08-08</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left; width: 1%"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left; width: 14%"><FONT STYLE="font-size: 9pt">China</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">COMPOSITIONS AND METHODS FOR TREATING CANCER
    AND AUTOIMMUNE DESEASES</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">19848154.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">APPLICATION</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">KROS 101 and KROS 102</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">Both a Product and a Method of Treatment Patent</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 9pt">2039-08-08</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">European Patent</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">COMPOSITIONS AND METHODS FOR TREATING CANCER
    AND AUTOIMMUNE</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">2021-506687</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">APPLICATION</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">KROS 101 and KROS 102</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">Both a Product and a Method of Treatment Patent</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 9pt">2039-08-08</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">Japan</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">COMPOSITIONS AND METHODS FOR TREATING CANCER
    AND AUTOIMMUNE DISEASES</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">10-2021-7006602</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">APPLICATION</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">KROS 101 and KROS 102</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">Both a Product and a Method of Treatment Patent</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 9pt">2039-08-08</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">Korea, Republic of (KR)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">COMPOSITIONS AND METHODS FOR TREATING CANCER
    AND AUTOIMMUNE DISEASES</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">17/266,488</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">APPLICATION</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">KROS 101 and KROS 102</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">Both a Product and a Method of Treatment Patent</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 9pt">2039-08-08</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">United States of America</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">METHOD OF GENERATING ACTIVATED T CELLS FOR CANCER
    THERAPY</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">3,150,273</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">APPLICATION</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">KROS 201</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">Both a Product and a Method of Treatment Patent</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 9pt">2040-08-10</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">Canada</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">METHOD OF GENERATING ACTIVATED T CELLS FOR CANCER
    THERAPY</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">20850517.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">APPLICATION</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">KROS 201</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">Both a Product and a Method of Treatment Patent</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 9pt">2040-08-10</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">European Patent</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">METHOD OF GENERATING ACTIVATED T CELLS FOR CANCER
    THERAPY</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">17/633,505</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">APPLICATION</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">KROS 201</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">Both a Product and a Method of Treatment Patent</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 9pt">2040-08-10</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">United States of America</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">SENSITIZATION OF TUMORS TO THERAPIES THROUGH
    ENDOGLIN ANTAGONISM</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">2017286561</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">APPLICATION</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">ENV 105</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">Both a Product and a Method of Treatment Patent</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 9pt">2037-06-14</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">Australia</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">SENSITIZATION OF TUMORS TO THERAPIES THROUGH
    ENDOGLIN ANTAGONISM</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">3026066</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">APPLICATION</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">ENV 105</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">Both a Product and a Method of Treatment Patent</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 9pt">2037-06-14</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">Canada</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">SENSITIZATION OF TUMORS TO THERAPIES THROUGH
    ENDOGLIN ANTAGONISM</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">201780050000.4</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">APPLICATION</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">ENV 105</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">Both a Product and a Method of Treatment Patent</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 9pt">2037-06-14</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">China</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">SENSITIZATION OF TUMORS TO THERAPIES THROUGH
    ENDOGLIN ANTAGONISM</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">17814046.3</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">APPLICATION</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">ENV 105</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">Both a Product and a Method of Treatment Patent</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 9pt">2037-06-14</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">European Patent</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 94; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 9pt">Name
    of the Patent</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 9pt">Patent
    No./Application No.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt"><B>Status</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt"><B>(Patent
                                            granted or Patent application) </B></FONT></P></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 9pt">Products
    or Technologies to which the Patents or Patent Applications Relate</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 9pt">Type
    of Patent Protection</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 9pt">Expiration
    Date</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 9pt">Jurisdiction</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left; width: 16%"><FONT STYLE="font-size: 9pt">SENSITIZATION OF TUMORS TO THERAPIES
    THROUGH ENDOGLIN ANTAGONISM</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left; width: 1%"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left; width: 10%"><FONT STYLE="font-size: 9pt">7092684</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left; width: 1%"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left; width: 14%"><FONT STYLE="font-size: 9pt">GRANTED</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left; width: 1%"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left; width: 13%"><FONT STYLE="font-size: 9pt">ENV 105</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left; width: 1%"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left; width: 15%"><FONT STYLE="font-size: 9pt">Both a Product and a Method of Treatment
    Patent</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left; width: 1%"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; width: 12%"><FONT STYLE="font-size: 9pt">2037-06-14</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left; width: 1%"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left; width: 14%"><FONT STYLE="font-size: 9pt">Japan</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">SENSITIZATION OF TUMORS TO THERAPIES THROUGH
    ENDOGLIN ANTAGONISM</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">17/685,040</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">APPLICATION</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">ENV 105</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">Both a Product and a Method of Treatment Patent</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 9pt">2037-06-14</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">United States of America</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">COMPOSITIONS AND METHODS FOR TREATING DISEASES
    AND CONDITIONS BY DEPLETION OF MITOCHONDRIAL OR GENOMIC DNA FROM CIRCULATION</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">3162518</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">APPLICATION</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">ENV 205</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">Both a Product and a Method of Treatment Patent</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 9pt">2040-11-25</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">Canada</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">COMPOSITIONS AND METHODS FOR TREATING DISEASES
    AND <BR>CONDITIONS BY DEPLETION OF MITOCHONDRIAL OR GENOMIC DNA <BR>FROM CIRCULATION</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">20893032.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">APPLICATION</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">ENV 205</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">Both a Product and a Method of Treatment Patent</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 9pt">2040-11-25</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">European Patent</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">COMPOSITIONS AND METHODS FOR TREATING DISEASES
    AND CONDITIONS BY DEPLETION OF MITOCHONDRIAL OR GENOMIC DNA FROM CIRCULATION</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">2022-530781</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">APPLICATION</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">ENV 205</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">Both a Product and a Method of Treatment Patent</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 9pt">2040-11-25</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">Japan</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">COMPOSITIONS AND METHODS FOR TREATING DISEASES
    AND CONDITIONS BY DEPLETION OF MITOCHONDRIAL OR <BR>GENOMIC DNA FROM CIRCULATION</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">17/779,716</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">APPLICATION</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">ENV 205</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">Both a Product and a Method of Treatment Patent</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 9pt">2040-11-25</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 9pt">United States of America</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Pursuant
to the Kairos-Cedars license agreements, we have exclusive licensing rights (which include the right to sublicense) to four issued U.S.
patents and three patent applications in foreign jurisdictions.</FONT> <FONT STYLE="font-family: TimesNewRomanPSMT,serif">Maximum aggregate
milestone payment is $2,150,000 when each product exceeds $5,000,000 in cumulative net sales.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 95; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 9pt">Name
    of the Patent</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 9pt">Patent
    No./Application No.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt"><B>Status</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt"><B>(Patent
                                            granted or Patent application) </B></FONT></P></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 9pt">Products
    or Technologies to which the Patents or Patent Applications Relate</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 9pt">Type
    of Patent Protection</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 9pt">Expiration
    Date</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 9pt">Jurisdiction</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 16%; color: #111734; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">COMPOSITIONS
    AND METHODS FOR TREATING CANCER AND AUTOIMMUNE DESEASES</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%; color: #111734; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 10%; color: #111734; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">19848154.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%; color: #111734; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 14%; color: #111734; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">APPLICATION</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%; color: #111734; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 13%; color: #111734; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">KROS
    101 and KROS 102</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%; color: #111734; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 15%; color: #111734; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">Both
    a Product and a Method of Treatment Patent</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%; color: #111734; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 12%; color: #111734; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">2039-08-08</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%; color: #111734; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 14%; color: #111734; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">European
    Patent</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; color: #111734; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">COMPOSITIONS
    AND METHODS FOR TREATING CANCER AND AUTOIMMUNE</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; color: #111734; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; color: #111734; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">2021-506687</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; color: #111734; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; color: #111734; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">APPLICATION&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; color: #111734; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; color: #111734; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">KROS
    101 and KROS 102</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; color: #111734; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; color: #111734; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">Both
    a Product and a Method of Treatment Patent</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; color: #111734; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; color: #111734; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">2039-08-08</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; color: #111734; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; color: #111734; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">Japan</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; color: #111734; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">COMPOSITIONS
    AND METHODS FOR TREATING CANCER AND AUTOIMMUNE DISEASES</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; color: #111734; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; color: #111734; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">10-2021-7006602</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; color: #111734; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; color: #111734; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">APPLICATION</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; color: #111734; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; color: #111734; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">KROS
    101 and KROS 102</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; color: #111734; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; color: #111734; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">Both
    a Product and a Method of Treatment Patent</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; color: #111734; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; color: #111734; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">2039-08-08</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; color: #111734; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; color: #111734; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">Korea,
    Republic of (KR)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; color: #111734; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">COMPOSITIONS
    AND METHODS FOR TREATING CANCER AND AUTOIMMUNE DISEASES</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">17/266,488</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; color: #111734; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; color: #111734; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">APPLICATION</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; color: #111734; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; color: #111734; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">KROS
    101 and KROS 102</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; color: #111734; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; color: #111734; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">Both
    a Product and a Method of Treatment Patent</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; color: #111734; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; color: #111734; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">2039-08-08</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; color: #111734; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; color: #111734; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">United
    States of America</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; color: #111734; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">METHOD
    OF GENERATING ACTIVATED T CELLS FOR CANCER THERAPY</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; color: #111734; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; color: #111734; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">3,150,273</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; color: #111734; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; color: #111734; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">APPLICATION</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; color: #111734; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; color: #111734; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">KROS
    201</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; color: #111734; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; color: #111734; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">Both
    a Product and a Method of Treatment Patent</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; color: #111734; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; color: #111734; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">2040-08-10</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; color: #111734; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; color: #111734; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">Canada</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; color: #111734; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">METHOD
    OF GENERATING ACTIVATED T CELLS FOR CANCER THERAPY</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; color: #111734; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; color: #111734; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">20850517.2</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; color: #111734; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; color: #111734; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">APPLICATION</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; color: #111734; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; color: #111734; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">KROS
    201</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; color: #111734; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; color: #111734; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">Both
    a Product and a Method of Treatment Patent</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; color: #111734; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; color: #111734; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">2040-08-10</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; color: #111734; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; color: #111734; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">European
    Patent</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; color: #111734; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">METHOD
    OF GENERATING ACTIVATED T CELLS FOR CANCER THERAPY</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">17/633,505</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; color: #111734; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; color: #111734; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">APPLICATION</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; color: #111734; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; color: #111734; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">KROS
    201</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; color: #111734; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; color: #111734; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">Both
    a Product and a Method of Treatment Patent</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; color: #111734; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; color: #111734; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">2040-08-10</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; color: #111734; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; color: #111734; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">United
    States of America</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; color: #111734; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">SENSITIZATION
    OF TUMORS TO THERAPIES THROUGH ENDOGLIN ANTAGONISM</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; color: #111734; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; color: #111734; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">2017286561</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; color: #111734; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; color: #111734; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">APPLICATION</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; color: #111734; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; color: #111734; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">ENV
    105</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; color: #111734; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; color: #111734; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">Both
    a Product and a Method of Treatment Patent</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; color: #111734; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; color: #111734; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">2037-06-14</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; color: #111734; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; color: #111734; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">Australia</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; color: #111734; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">SENSITIZATION
    OF TUMORS TO THERAPIES THROUGH ENDOGLIN ANTAGONISM</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; color: #111734; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; color: #111734; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">3026066</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; color: #111734; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; color: #111734; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">APPLICATION</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; color: #111734; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; color: #111734; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">ENV
    105</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; color: #111734; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; color: #111734; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">Both
    a Product and a Method of Treatment Patent</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; color: #111734; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; color: #111734; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">2037-06-14</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; color: #111734; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; color: #111734; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">Canada</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; color: #111734; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">SENSITIZATION
    OF TUMORS TO THERAPIES THROUGH ENDOGLIN ANTAGONISM</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; color: #111734; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; color: #111734; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">201780050000.4</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; color: #111734; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; color: #111734; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">APPLICATION</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; color: #111734; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; color: #111734; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">ENV
    105</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; color: #111734; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; color: #111734; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">Both
    a Product and a Method of Treatment Patent</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; color: #111734; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; color: #111734; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">2037-06-14</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; color: #111734; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; color: #111734; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">China</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; color: #111734; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">SENSITIZATION
    OF TUMORS TO THERAPIES THROUGH ENDOGLIN ANTAGONISM</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; color: #111734; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; color: #111734; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">17814046.3</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; color: #111734; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; color: #111734; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">APPLICATION</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; color: #111734; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; color: #111734; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">ENV
    105</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; color: #111734; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; color: #111734; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">Both
    a Product and a Method of Treatment Patent</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; color: #111734; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; color: #111734; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">2037-06-14</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; color: #111734; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; color: #111734; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">European
    Patent</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; color: #111734; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">SENSITIZATION
    OF TUMORS TO THERAPIES THROUGH ENDOGLIN ANTAGONISM</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; color: #111734; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; color: #111734; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">7092684</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; color: #111734; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; color: #111734; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">GRANTED</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; color: #111734; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; color: #111734; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">ENV
    105</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; color: #111734; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; color: #111734; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">Both
    a Product and a Method of Treatment Patent</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; color: #111734; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; color: #111734; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">2037-06-14</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; color: #111734; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; color: #111734; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">Japan</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; color: #111734; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">SENSITIZATION
    OF TUMORS TO THERAPIES THROUGH ENDOGLIN ANTAGONISM</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; color: #111734; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; color: #111734; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">17/685,040</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; color: #111734; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; color: #111734; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">APPLICATION</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; color: #111734; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; color: #111734; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">ENV
    105</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; color: #111734; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; color: #111734; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">Both
    a Product and a Method of Treatment Patent</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; color: #111734; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; color: #111734; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">2037-06-14</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; color: #111734; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; color: #111734; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">United
    States of America</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 96; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">Name of the Patent</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">Patent
    No./Application No.</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Status</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Patent
                                            granted or Patent application) </B></FONT></P></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">Products or Technologies
    to which the Patents or Patent Applications Relate</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">Type of Patent Protection</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">Expiration Date</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">Jurisdiction</TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; color: #111734; text-align: left; width: 16%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS
    AND METHODS FOR TREATING DISEASES AND CONDITIONS BY DEPLETION OF MITOCHONDRIAL OR GENOMIC DNA FROM CIRCULATION</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; color: #111734; vertical-align: bottom; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; color: #111734; text-align: left; width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3162518</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; color: #111734; text-align: left; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; color: #111734; text-align: left; width: 14%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">APPLICATION</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; color: #111734; vertical-align: bottom; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; color: #111734; vertical-align: bottom; width: 13%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ENV
    205</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; color: #111734; vertical-align: bottom; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; color: #111734; text-align: left; width: 15%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Both
    a Product and a Method of Treatment Patent</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; color: #111734; text-align: left; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; color: #111734; text-align: center; width: 12%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2040-11-25</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; color: #111734; vertical-align: bottom; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; color: #111734; vertical-align: bottom; width: 14%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Canada</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; color: #111734; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS
    AND METHODS FOR TREATING DISEASES AND CONDITIONS BY DEPLETION OF MITOCHONDRIAL OR GENOMIC DNA FROM CIRCULATION</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; color: #111734; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; color: #111734; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20893032.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; color: #111734; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; color: #111734; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">APPLICATION</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; color: #111734; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; color: #111734; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ENV
    205</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; color: #111734; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; color: #111734; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Both
    a Product and a Method of Treatment Patent</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; color: #111734; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; color: #111734; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2040-11-25</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; color: #111734; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; color: #111734; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">European
    Patent</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; color: #111734; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS
    AND METHODS FOR TREATING DISEASES AND CONDITIONS BY DEPLETION OF MITOCHONDRIAL OR GENOMIC DNA FROM CIRCULATION</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; color: #111734; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; color: #111734; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022-530781</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; color: #111734; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; color: #111734; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">APPLICATION</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; color: #111734; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; color: #111734; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ENV
    205</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; color: #111734; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; color: #111734; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Both
    a Product and a Method of Treatment Patent</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; color: #111734; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; color: #111734; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2040-11-25</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; color: #111734; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; color: #111734; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Japan</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; color: #111734; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPOSITIONS
    AND METHODS FOR TREATING DISEASES AND CONDITIONS BY DEPLETION OF MITOCHONDRIAL OR &nbsp;GENOMIC DNA FROM CIRCULATION</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; color: #111734; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; color: #111734; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17/779,716</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; color: #111734; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; color: #111734; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">APPLICATION</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; color: #111734; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; color: #111734; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ENV
    205</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; color: #111734; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; color: #111734; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Both
    a Product and a Method of Treatment Patent</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; color: #111734; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; color: #111734; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2040-11-25</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; color: #111734; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; color: #111734; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">United
    States of America</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Protecting
Our Intellectual Property Rights</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
strive to protect our proprietary technology, inventions, and know-how to enhance improvements that are commercially important
to the development of our business, including seeking, maintaining, and defending patent rights. We also rely on trade secrets and know-how
relating to our proprietary technology platform, on continuing technological innovation and on in-licensing opportunities to develop,
strengthen and maintain the strength of our position in the field of immune therapeutics and cell therapy that may be important for the
development of our business. We additionally may rely on regulatory protection afforded through data exclusivity, market exclusivity
and patent term extensions where available.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
commercial success depends in part on our ability to: obtain and maintain patent and other protections for commercially important technology,
inventions and know-how related to our business; defend and enforce our patents; preserve the confidentiality of our trade secrets; and
operate without infringing the valid enforceable patents and intellectual property rights of third parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to stop third parties from making, using, selling, offering to sell, or importing our products depends in large part on the extent
to which we have rights under valid and enforceable licenses, patents, or trade secrets that cover these activities. In some cases, these
rights may need to be enforced by third party licensors. With respect to Company-licensed intellectual property, we cannot be sure that
patents will be granted with respect to any of the pending patent applications or with respect to any patent applications filed in the
future, nor can we be sure that any of the existing patents or any patents that may be granted to us in the future will be commercially
useful in protecting our commercial products and methods of manufacturing the same. For more information, please see &ldquo;Risk Factors&mdash;Risks
Related to Our Intellectual Property.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with our licensing partners, we seek to protect our proprietary position by, among other things, filing patent applications
in the United States and internationally in certain jurisdictions where it is available. For example, in coordination with our licensing
partners, we file U.S. and selected foreign patent applications related to proprietary technology, inventions, and improvements that
are important to the development of our business. We also intend to seek patent protection, or rely upon trade secret rights, to protect
other technologies that may be used to discover and validate targets and that may be used to identify and develop novel products or improvements
thereof. We seek protection, in part, through confidentiality and proprietary information agreements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 97; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
term of individual patents depends upon the legal term of the patents in the countries in which they are obtained. In most countries
in which we file, the patent term is 20 years from the earliest date of filing a non-provisional application which matures into a granted
patent. A U.S. patent also may be accorded a patent term adjustment, or PTA, under certain circumstances to compensate for delays in
obtaining the patent caused by the U.S. Patent and Trademark Office. In some instances, such a PTA may result in a U.S. patent term extending
beyond 20 years from the earliest date of filing a non-provisional patent application. In addition, in the U.S., the term of a U.S. patent
that covers an FDA approved drug may also be eligible for patent term extension, which permits patent term restoration as compensation
for the patent term lost during the FDA regulatory review process. The Hatch Waxman Act permits a patent term extension of up to five
years beyond the expiration of the patent. The length of the patent term extension is related to the length of time the drug is under
regulatory review. Patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product
approval and only one patent applicable to an approved drug may be extended. Similar provisions are available in Europe and other foreign
jurisdictions to extend the term of a patent that covers an approved drug. In the future, if and when our products receive FDA approval,
we expect to apply for patent term extensions on patents covering those products. We plan to seek patent term extensions to any of our
issued patents in any jurisdiction where these are available; however, there is no guarantee that the applicable authorities, including
the FDA in the U.S., will agree with our assessment of whether such extensions should be granted, and if granted, the length of such
extensions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Trademark
Protection</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not yet filed any trademark applications for its wordmarks; however, we intend to file applications for trademark protection in
the United States for goods and services, and potentially other relevant jurisdictions, but no assurance can be given as to whether such
applications will be granted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Corporate
Reorganizations</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Kairos
Pharma, Ltd. was originally incorporated on June 17, 2013 in the state of California as NanoGB13, Inc. The Company changed its name to
&ldquo;Kairos Pharma, Ltd.&rdquo; on July 15, 2016. On May 10, 2023, we filed a certificate of conversion with the Secretary of State
of the State of California, and on the same date, we also filed with the Delaware Secretary of State a certificate of conversion converting
the Company from a non-Delaware corporation to a Delaware corporation pursuant to section 265 of the Delaware General Corporation Law
t. In addition, on May 10, 2023, we filed a certificate of incorporation with the Secretary of State of the State of Delaware, thus completing
our conversion into a Delaware corporation. In conjunction with the Company&rsquo;s conversion into a Delaware corporation, on May 10, 2023, the Company conducted
a 1-for-2.5 Reverse Stock Split. After the Reverse Stock Split, as of June 5, 2023, there were 10,334,357 shares of our common stock
outstanding.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 13, 2019, Kairos entered into an Agreement of Merger with AcTcell Biopharma, Inc., or AcTcell, whereby the Company issued 5,045,000
shares of its common stock for all the issued and outstanding shares of AcTcell common stock. AcTcell was a California corporation that
was incorporated on July 22, 2019. AcTcell&rsquo;s only asset at the merger date an Exclusive License Agreement dated August 30, 2019
between AcTcell and Cedars-Sinai Medical Center. AcTcell had no liabilities at the merger date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">John
Yu, the Company&rsquo;s Chairman, Chief Executive Officer and majority shareholder, was the sole owner of AcTcell. The acquisition of
AcTcell by Kairos was treated as a transaction between entities under common control resulting in the historical costs basis of AcTcell&rsquo;s
assets and liabilities being recognized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 98; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s Enviro Therapeutics, Inc. subsidiary, or Enviro, was incorporated on November 15, 2019 under the law of the state of
California and is an early-stage company that is focused on the development of therapeutics targeting the tumor microenvironment to complement
conventional and targeted therapies designed against the cancer cells. Kairos&rsquo; Chairman, Chief Executive officer and majority shareholder,
Dr. Yu, was also a founder and shareholder of Enviro.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 3, 2021, Kairos and Enviro entered into a share exchange whereby Kairos acquired of all of the common stock of Enviro in exchange
for stock in Kairos. In the Enviro-Kairos share exchange, the Enviro shareholders exchanged 100% of the issued and outstanding shares
of Enviro (on a fully diluted basis) for 6,000,000 shares of newly issued restricted common stock of Kairos, which, as of the
closing of the Enviro-Kairos share exchange: (i) represented approximately twenty percent (20%) of the outstanding shares of capital
stock of the Company on a fully diluted basis, including all issued and outstanding convertible promissory notes, preferred stock, SAFEs,
other securities convertible into capital stock, stock options and warrants, and after giving effect to the issuance of the shares in
the Enviros-Kairos share exchange, and (ii) have voting power approximately equal to twenty percent (20%) of all shares eligible to vote
on matters by the shareholders of Kairos. At the closing of the Enviro-Kairos share exchange, Kairos issued each of Dr. Yu and Dr. Neil
Bhowmick (the other co-founder of Enviro) 1,860,000 of Kairos&rsquo; restricted common stock in exchange for their shares of Enviro.
Kairos also issued Tracon Pharmaceutical, Inc., an unaffiliated third party, 280,000 shares of Kairos&rsquo; restricted common stock
in exchange from their shares of Enviro, which Tracon had received pursuant to a license and supply agreement between Enviro and Tracon,
pursuant to which Enviro had acquired certain licensing rights from Tracon, described further below under &ldquo;Business&ndash;Intellectual
Property.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the closing of the Enviro-Kairos share exchange, prior to our 1-for-2.5 reverse split conducted in 2023 and including the newly
issued shares in that transaction, Kairos had approximately 19,825,957 shares of common stock issued and outstanding on a fully diluted
basis (including 18,825,957 outstanding shares of common stock, and 1,000,000 warrants exercisable into 1,000,000 shares of common stock).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Manufacturing</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not currently own or operate manufacturing facilities for the production of clinical or commercial quantities of our product candidates.
When we begin manufacturing, we intend to use vendors that are compliant with current &ldquo;Good Manufacturing Practices&rdquo; or cGMP,
in pharmaceutical production. We expect that commercial quantities of any compound and materials for our product candidates, if approved,
will be manufactured in facilities and by processes that comply with FDA and other regulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Competition
</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
biopharmaceutical industry is characterized by intense competition and rapid innovation. Our potential competitors include large pharmaceutical
and biotechnology companies, specialty pharmaceutical companies and generic drug companies. Many of our potential competitors have greater
financial and technical human resources than we do, as well as greater experience in the discovery and development of product candidates,
obtaining FDA and other regulatory approvals of products, and the commercialization of those products. Accordingly, our potential competitors
may be more successful than us in obtaining FDA-approved drugs and achieving widespread market acceptance. We anticipate that we will
face intense and increasing competition as new drugs enter the market and advanced technologies become available. Finally, the development
of new treatment methods for the diseases we are targeting could render our product candidates non-competitive or obsolete.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
immunotherapy field is characterized by the rapid evolution of technologies and products and by fierce competition based on the development
of compounds, often with similar mechanisms of action. Clinical development plans are further compounded by the possibility of overlapping
intellectual property. A wide variety of commercial players, large pharmaceutical companies, established and emerging biotechnology companies,
and several not-for-profit entities are actively developing potentially competitive products in immunotherapy and in our lead indications.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
respect to KROS-101, it faces potential competition from several GITR focused monoclonal antibody products that are currently under development,
including multiple candidates from large pharmaceutical companies, all of which are either Phase 1 or Phase 2 clinical trial. Another
product candidate was discontinued after a completed Phase 1 in 2018.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 99; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the area of targeted immunotherapy, Kairos&rsquo; KROS-102 candidate will, if successful compete, with several monoclonal antibody-based
products that target PD-1 or PD-L1 proteins. Such PD-1 or PD-L1 inhibitors activate the immune system to attack tumors and are used to
treat certain types of cancer. Currently, there are multiple marketed drugs targeting these same proteins produced by large pharmaceutical
companies. In contrast to currently marketed drugs from these large pharmaceutical companies, KROS-101 is a small molecule which is expected
to be significantly less expensive to manufacture than a monoclonal antibody-based product.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the area of cell therapy only two products produced by large pharmaceutical companies have been approved for marketing in the United
States, but we estimate that more than 150 clinical trials are currently in progress. One such product is a treatment for B-cell lymphoma,
and another is a treatment for large B-cell lymphoma. Both of these therapies are based on CAR T technology where specially altered T
cells are used to fight cancer. A sample of a patient&rsquo;s T cells are collected from the blood, then modified to produce
special structures called chimeric antigen receptors (CARs) on their surface. While CAR T therapies have proven to be effective in the
above products the manufacturing process is complex and very costly leading to extremely high pricing. As an alternative, some companies
are pursuing T Cell Receptor (TCR) technology. Unlike CAR T cells that recognize proteins expressed on the surface of a cell, TCRs can
recognize tumor-specific proteins on the inside of cells.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe the key competitive factors that will affect the development and commercial success of our initial product candidate, ENV 105,
if approved, will be other agents that in the future may address resistance mechanisms of therapeutics used for prostate cancer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Government
Regulation and Product Approval </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Government
authorities in the United States, at the federal, state, and local level, and other countries extensively regulate, among other things,
the research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion,
advertising, distribution, marketing, and export and import of drug products. A new drug must be approved by the FDA through the New
Drug Application, or NDA, process before it may be legally marketed in the United States. We, along with any third-party contractors,
will be required to navigate the various preclinical, clinical and commercial approval requirements of the governing regulatory agencies
of the countries in which we wish to conduct studies or seek approval of our products and product candidates. The process of obtaining
regulatory approvals and the subsequent compliance with applicable federal, state, local, and foreign statutes and regulations require
the expenditure of substantial time and financial resources.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>U.S.
Drug Development Process </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States, the FDA regulates drugs under the federal Food, Drug, and Cosmetic Act, or FD&amp;C Act, and its implementing regulations.
The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local, and foreign statutes
and regulations require the expenditure of substantial time and financial resources. The process required by the FDA before a drug may
be marketed in the United States generally involves the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">completion
                                            of preclinical laboratory tests, animal studies, and formulation studies in accordance with
                                            FDA&#8217;s Good Laboratory Practice requirements and other applicable regulations;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">submission
                                            to the FDA of an IND application, which must become effective before human clinical trials
                                            may begin;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">approval
                                            by an independent Institutional Review Board, or IRB, or ethics committee at each clinical
                                            site before each trial may be initiated;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">performance
                                            of adequate and well-controlled human clinical trials in accordance with good clinical practices,
                                            or GCPs, to establish the safety and efficacy of the proposed drug for its intended use;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">preparation
                                            of and submission to the FDA of an NDA after completion of all pivotal trials;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
                                            determination by the FDA within 60 days of its receipt of an NDA to file the application
                                            for review;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">satisfactory
                                            completion of an FDA advisory committee review, if applicable;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">satisfactory
                                            completion of an FDA inspection of the manufacturing facility or facilities at which the
                                            drug is produced to assess compliance with current Good Manufacturing Practice, or cGMP,
                                            requirements to assure that the facilities, methods and controls are adequate to preserve
                                            the drug&#8217;s identity, strength, quality and purity, and of selected clinical investigation
                                            sites to assess compliance with GCPs; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
                                            review and approval of the NDA to permit commercial marketing of the product for particular
                                            indications for use in the United States.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 100; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to beginning the first clinical trial with a product candidate in the United States, a sponsor must submit an IND to the FDA. An IND
is a request for authorization from the FDA to administer an investigational new drug product to humans. The central focus of an IND
submission is on the general investigational plan and the protocol(s) for clinical studies. The IND also includes results of animal and
in vitro studies assessing the toxicology, pharmacokinetics, pharmacology, and pharmacodynamic characteristics of the product; chemistry,
manufacturing, and controls information; and any available human data or literature to support the use of the investigational product.
An IND must become effective before human clinical trials may begin. The IND automatically becomes effective 30 days after receipt by
the FDA, unless the FDA, within the 30-day time period, raises safety concerns or questions about the proposed clinical trial. In such
a case, the IND may be placed on clinical hold and the IND sponsor, and the FDA must resolve any outstanding concerns or questions before
the clinical trial can begin. Submission of an IND therefore may or may not result in FDA authorization to begin a clinical trial.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators in
accordance with GCPs, which include the requirement that all research subjects provide their informed consent for their participation
in any clinical study. Clinical trials are conducted under protocols detailing, among other things, the objectives of the study, the
parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated. A separate submission to the existing IND
must be made for each successive clinical trial conducted during product development and for any subsequent protocol amendments. Furthermore,
an independent IRB for each site proposing to conduct the clinical trial must review and approve the plan for any clinical trial and
its informed consent form before the clinical trial begins at that site and must monitor the study until completed. Some studies also
include oversight by an independent group of qualified experts organized by the clinical study sponsor, known as a data safety monitoring
board, which provides authorization for whether or not a study may move forward at designated check points based on access to certain
data from the study and may halt the clinical trial if it determines that there is an unacceptable safety risk for subjects or other
grounds, such as no demonstration of efficacy. Depending on its charter, this group may determine whether a trial may move forward at
designated check points based on access to certain data from the trial. The FDA or the sponsor may suspend a clinical trial at any time
on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly,
an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance
with the IRB&rsquo;s requirements or if the drug has been associated with unexpected serious harm to patients. There are also requirements
governing the reporting of ongoing clinical studies and clinical study results to public registries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Human
clinical trials are typically conducted in three sequential phases that may overlap or be combined:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Phase
                                            1</I></B><I>:</I> The product candidate is initially introduced into healthy human subjects
                                            or patients with the target disease or condition. These studies are designed to test the
                                            safety, dosage tolerance, absorption, metabolism and distribution of the investigational
                                            product in humans, the side effects associated with increasing doses, and, if possible, to
                                            gain early evidence on effectiveness.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Phase
                                            2</I></B><I>:</I> The product candidate is administered to a limited patient population with
                                            a specified disease or condition to evaluate the preliminary efficacy, optimal dosages, and
                                            dosing schedule and to identify possible adverse side effects and safety risks. Multiple
                                            Phase 2 clinical trials may be conducted to obtain information prior to beginning larger
                                            and more expensive Phase 3 clinical trials.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Phase
                                            3</I></B><I>:</I> The product candidate is administered to an expanded patient population
                                            to further evaluate dosage, to provide statistically significant evidence of clinical efficacy,
                                            and to further test for safety, generally at multiple geographically dispersed clinical trial
                                            sites. These clinical trials are intended to establish the overall risk/benefit ratio of
                                            the investigational product and to provide an adequate basis for product approval.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
some cases, the FDA may require, or companies may voluntarily pursue, additional clinical trials after a product is approved to gain
more information about the product. These so-called Phase 4 studies may be conducted after initial marketing approval and may be used
to gain additional experience from the treatment of patients in the intended therapeutic indication. In certain instances, the FDA may
mandate the performance of Phase 4 clinical trials as a condition of approval of an NDA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Concurrent
with clinical trials, companies usually complete additional animal studies and must also develop additional information about the chemistry
and physical characteristics of the drug and finalize a process for manufacturing the product in commercial quantities in accordance
with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate
and, among other things, the manufacturer must develop methods for testing the identity, strength, quality, and purity of the final drug.
In addition, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the product
candidate does not undergo unacceptable deterioration over its shelf life.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
the IND is active and before approval, progress reports summarizing the results of the clinical trials and nonclinical studies performed
since the last progress report must be submitted at least annually to the FDA, and written IND safety reports must be submitted to the
FDA and investigators for serious and unexpected suspected adverse events, findings from other studies suggesting a significant risk
to humans exposed to the same or similar drugs, findings from animal or in vitro testing suggesting a significant risk to humans, and
any clinically important increased incidence of a serious suspected adverse reaction compared to that listed in the protocol or investigator
brochure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 101; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, during the development of a new drug, sponsors are given opportunities to meet with the FDA at certain points. These points
may be prior to submission of an IND, at the end of Phase 2, and before an NDA is submitted. Meetings at other times may be requested.
These meetings can provide an opportunity for the sponsor to share information about the data gathered to date, for the FDA to provide
advice, and for the sponsor and the FDA to reach agreement on the next phase of development. Sponsors typically use the meetings at the
end of the Phase 2 trial to discuss Phase 2 clinical results and present plans for the pivotal Phase 3 clinical trials that they believe
will support approval of the new drug.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>U.S.
Review and Approval Process </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assuming
successful completion of all required testing in accordance with all applicable regulatory requirements, the results of product development,
preclinical, and other nonclinical studies and clinical trials, along with descriptions of the manufacturing process, analytical tests
conducted on the chemistry of the drug, proposed labeling, and other relevant information are submitted to the FDA as part of an NDA
requesting approval to market the product. Data can come from company-sponsored clinical studies intended to test the safety and effectiveness
of a use of the product, or from a number of alternative sources, including studies initiated by independent investigators. The submission
of an NDA is subject to the payment of substantial user fees; a waiver of such fees may be obtained under certain limited circumstances.
Additionally, no user fees are assessed on NDAs for products designated as orphan drugs, unless the product also includes a non-orphan
indication.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA conducts a preliminary review of all NDAs within the first 60 days after submission, before accepting them for filing, to determine
whether they are sufficiently complete to permit substantive review, The FDA may request additional information rather than accept an
NDA for filing. In this event, the NDA must be resubmitted with the additional information. The resubmitted application also is subject
to review before the FDA accepts it for filing. Once filed, the FDA reviews an NDA to determine, among other things, whether a product
is safe and effective for its intended use and whether its manufacturing is cGMP-compliant to assure and preserve the product&rsquo;s
identity, strength, quality, and purity. Under the Prescription Drug User Fee Act, or PDUFA, guidelines that are currently in effect,
the FDA has a goal of ten months from the filing date to complete a standard review of an NDA for a drug that is a new molecular entity,
and of ten months from the date of NDA receipt to complete a standard review of an NDA for a drug that is not a new molecular entity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA may refer an application for a novel drug to an advisory committee. An advisory committee is a panel of independent experts, including
clinicians and other scientific experts, that reviews, evaluates, and provides a recommendation as to whether the application should
be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations
carefully when making decisions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
approving an NDA, the FDA will typically inspect the facility or facilities where the product is manufactured. The FDA will not approve
an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP and adequate to assure
consistent production of the product within required specifications. Additionally, before approving an NDA, the FDA will typically inspect
one or more clinical sites to assure compliance with GCPs. If the FDA determines that the application, manufacturing process or manufacturing
facilities are not acceptable, it will outline the deficiencies in the submission and often will request additional testing or information.
Notwithstanding the submission of any requested additional information, the FDA ultimately may decide that the application does not satisfy
the regulatory criteria for approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
the FDA evaluates an NDA and conducts inspections of manufacturing facilities where the investigational product and/or its drug substance
will be produced, the FDA may issue an approval letter or a Complete Response Letter, or CRL. An approval letter authorizes commercial
marketing of the product with specific prescribing information for specific indications. A CRL will describe all of the deficiencies
that the FDA has identified in the NDA, except that where the FDA determines that the data supporting the application are inadequate
to support approval, the FDA may issue the CRL without first conducting required inspections and/or reviewing proposed labeling. In issuing
the CRL, the FDA may recommend actions that the applicant might take to place the NDA in condition for approval, including requests for
additional information or clarification. The FDA may delay or refuse approval of an NDA if applicable regulatory criteria are not satisfied,
require additional testing or information and/or require post-marketing testing and surveillance to monitor safety or efficacy of a product.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 102; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->99<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
regulatory approval of a product is granted, such approval will be granted for particular indications and may entail limitations on the
indicated uses for which such product may be marketed. For example, the FDA may approve the NDA with a Risk Evaluation and Mitigation
Strategy, or REMS, to ensure the benefits of the product outweigh its risks. A REMS is a safety strategy to manage a known or potential
serious risk associated with a medicine and to enable patients to have continued access to such medicines by managing their safe use,
and could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods,
patient registries, and other risk minimization tools. The FDA also may condition approval on, among other things, changes to proposed
labeling or the development of adequate controls and specifications. The FDA may also require one or more Phase 4 post-market studies
and surveillance to further assess and monitor the product&rsquo;s safety and effectiveness after commercialization and may limit further
marketing of the product based on the results of these post-marketing studies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the Pediatric Research Equity Act, or PREA, requires a sponsor to conduct pediatric clinical trials for most drugs, for a new
active ingredient, new indication, new dosage form, new dosing regimen, or new route of administration. Under PREA, original NDAs and
supplements must contain a pediatric assessment unless the sponsor has received a deferral or waiver. The required assessment must evaluate
the safety and effectiveness of the product for the claimed indications in all relevant pediatric subpopulations and support dosing and
administration for each pediatric subpopulation for which the product is safe and effective. The sponsor or FDA may request a deferral
of pediatric clinical trials for some or all of the pediatric subpopulations. A deferral may be granted for several reasons, including
a finding that the drug is ready for approval for use in adults before pediatric clinical trials are complete or that additional safety
or effectiveness data needs to be collected before the pediatric clinical trials begin. The FDA must send a non-compliance letter to
any sponsor that fails to submit the required assessment, keep a deferral current, or fails to submit a request for approval of a pediatric
formulation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Expedited
Development and Review Programs </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA offers several expedited development and review programs for qualifying product candidates. For example, the Fast Track
program is intended to expedite or facilitate the process for reviewing new products that are intended to treat a serious or life-threatening
disease or condition and demonstrate the potential to address unmet medical needs for the disease or condition. Fast Track designation
applies to the combination of the product and the specific indication for which it is being studied. The sponsor of a Fast Track designated
product has opportunities for more frequent interactions with the applicable FDA review team during product development and, once an
NDA is submitted, the product candidate may be eligible for priority review. A Fast Track designated product may also be eligible for
rolling review, where the FDA may consider for review sections of the NDA on a rolling basis before the complete application is submitted,
if the sponsor provides a schedule for the submission of the sections of the NDA, the FDA agrees to accept sections of the NDA and determines
that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the NDA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
product candidate intended to treat a serious or life-threatening disease or condition may also be eligible for Breakthrough Therapy
designation to expedite its development and review. A product candidate can receive Breakthrough Therapy designation if preliminary clinical
evidence indicates that the product candidate, alone or in combination with one or more other drugs or biologics, may demonstrate substantial
improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early
in clinical development. The designation includes all of the Fast Track program features, as well as more intensive FDA interaction and
guidance beginning as early as Phase 1 and an organizational commitment to expedite the development and review of the product candidate,
including involvement of senior managers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
marketing application for a drug submitted to the FDA for approval, including a product candidate with a Fast Track designation and/or
Breakthrough Therapy designation, may be eligible for other types of FDA programs intended to expedite the FDA review and approval process,
such as priority review. A product candidate is eligible for priority review if it is designed to treat a serious or life-threatening
disease or condition, and if approved, would provide a significant improvement in safety or effectiveness compared to available alternatives
for such disease or condition. For new-molecular-entity NDAs, priority review designation means the FDA&rsquo;s goal is to take action
on the marketing application within six months of the 60-day filing date, or with respect to non-new-molecular-entity NDAs, within six
months of the NDA receipt date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 103; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->100<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
product candidates studied for their safety and effectiveness in treating serious or life-threatening diseases or conditions may utilize
an accelerated approval pathway upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely
to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is
reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity,
rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of accelerated approval,
the FDA will generally require the sponsor to perform adequate and well-controlled post-marketing clinical studies to verify and describe
the anticipated effect on irreversible morbidity or mortality or other clinical benefit. Products receiving accelerated approval may
be subject to expedited withdrawal procedures if the sponsor fails to conduct the required post-marketing studies or if such studies
fail to verify the predicted clinical benefit. In addition, the FDA currently requires as a condition for accelerated approval pre-approval
of promotional materials, which could adversely impact the timing of the commercial launch of the product.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fast
Track designation, Breakthrough Therapy designation, priority review designation, and the accelerated approval pathway do not change
the standards for approval, but may expedite the development or approval process. Even if a product candidate qualifies for one or more
of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time
period for FDA review or approval will not be shortened.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Exclusivity</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA provides periods of non-patent regulatory exclusivity, which provides the holder of an approved NDA limited protection from new competition
in the marketplace for the innovation represented by its approved drug for a period of three or five years following the FDA&rsquo;s
approval of the NDA. Five years of exclusivity are available to new chemical entities, or NCEs. An NCE is a drug that contains no active
moiety that has been approved by the FDA in any other NDA. An active moiety is the molecule or ion, excluding those appended portions
of the molecule that cause the drug to be an ester, salt, including a salt with hydrogen or coordination bonds, or other noncovalent,
or not involving the sharing of electron pairs between atoms, derivatives, such as a complex (<I>i.e.</I>, formed by the chemical interaction
of two compounds), chelate (<I>i.e.</I>, a chemical compound), or clathrate (<I>i.e.</I>, a polymer framework that traps molecules),
of the molecule, responsible for the therapeutic activity of the drug substance. During the exclusivity period, the FDA may not accept
for review or approve an Abbreviated New Drug Application, or ANDA, or a 505(b)(2) NDA submitted by another company that contains the
previously approved active moiety. An ANDA or 505(b)(2) application, however, may be submitted one year before NCE exclusivity expires
if a Paragraph IV certification is filed. Five-year and three-year exclusivity will not delay the submission or approval of a 505(b)(1)
NDA; however, an applicant submitting a 505(b)(1) NDA would be required to conduct or obtain a right of reference to all of the preclinical
studies and adequate and well-controlled clinical trials necessary to demonstrate safety and efficacy. In addition, under the Generating
Antibiotic Incentives Now, or GAIN, Act, the FDA may designate a product as a Qualified Infectious Disease Product, or QIDP. In order
to receive this designation, a drug must qualify as an antibiotic or antifungal drug for human use intended to treat serious or life-threatening
infections, including those caused by either (1) an antibiotic or antifungal resistant pathogen, including novel or emerging infectious
pathogens, or (2) a so-called &lsquo;&lsquo;qualifying pathogen&rsquo;&rsquo; found on a list of potentially dangerous, drug-resistant
organisms to established and maintained by the FDA. A sponsor must request such designation before submitting a marketing application.
Upon approving a marketing application for a QIDP-designated product, the FDA will extend by an additional five years any non-patent
marketing exclusivity period awarded. This extension is in addition to any pediatric exclusivity extension awarded, and the extension
will be awarded only to a drug first approved on or after the date of enactment of the GAIN Act. The GAIN Act prohibits the grant of
an exclusivity extension where the application is a supplement to an application for which an extension is in effect or has expired,
is a subsequent application for a specified change to an approved product or is an application for a product that does not meet the definition
of QIDP based on the uses for which it is ultimately approved.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Post-approval
Requirements </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Drug
products manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including,
among other things, requirements relating to record-keeping, reporting of adverse experiences, periodic reporting, product sampling and
distribution, and advertising and promotion of the product. After approval, most changes to the approved product, such as adding new
indications or other labeling claims, are subject to prior FDA review and approval. There also are continuing, annual program fees for
any marketed products. Drug manufacturers and their subcontractors are required to register their establishments with the FDA and certain
state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP, which
impose certain procedural and documentation requirements upon us and our third-party manufacturers. Changes to the manufacturing process
are strictly regulated, and, depending on the significance of the change, may require prior FDA approval before being implemented. FDA
regulations also require investigation and correction of any deviations from cGMP and impose reporting requirements. Accordingly, manufacturers
must continue to expend time, money, and effort in the area of production and quality control to maintain compliance with cGMP and other
aspects of regulatory compliance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 104; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->101<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA may withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product
reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity
or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved
labeling to add new safety information; imposition of post-market studies or clinical studies to assess new safety risks; or imposition
of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions
                                            on the marketing or manufacturing of the product, complete withdrawal of the product from
                                            the market or product recalls;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">fines,
                                            warning letters, or untitled letters;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">clinical
                                            holds on clinical studies;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusal
                                            of the FDA to approve pending applications or supplements to approved applications, or suspension
                                            or revocation of product approvals;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">product
                                            seizure or detention, or refusal to permit the import or export of products;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">consent
                                            decrees, corporate integrity agreements, debarment, or exclusion from federal healthcare
                                            programs;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">mandated
                                            modification of promotional materials and labeling and the issuance of corrective information;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            issuance of safety alerts, Dear Healthcare Provider letters, press releases, and other communications
                                            containing warnings or other safety information about the product; or</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">injunctions
                                            or the imposition of civil or criminal penalties.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA closely regulates the marketing, labeling, advertising, and promotion of drug products. A company can make only those claims relating
to safety and efficacy, purity, and potency that are approved by the FDA and in accordance with the provisions of the approved label.
The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses. Failure to comply with
these requirements can result in, among other things, adverse publicity, warning letters, corrective advertising, and potential civil
and criminal penalties. Physicians may prescribe, in their independent professional medical judgment, legally available products for
uses that are not described in the product&rsquo;s labeling and that differ from those tested by us and approved by the FDA. Physicians
may believe that such off-label uses are the best treatment for many patients in varied circumstances. The FDA does not regulate the
behavior of physicians in their choice of treatments. The FDA does, however, restrict manufacturer&rsquo;s communications regarding the label use of their products. However, companies may share truthful and not misleading information that is otherwise consistent
with a product&rsquo;s FDA-approved labelling.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Other
Healthcare Laws </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States, we are subject to a number of federal and state healthcare regulatory laws that restrict business practices in the
healthcare industry. These laws include, but are not limited to, federal and state anti-kickback, false claims, and other healthcare
fraud and abuse laws, as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
U.S. federal Anti-Kickback Statute prohibits, among other things, any person or entity from knowingly and willfully offering, paying,
soliciting, receiving, or providing any remuneration, directly or indirectly, overtly or covertly, to induce or in return for purchasing,
leasing, ordering, or arranging for, or recommending the purchase, lease, or order of any good, facility, item or service reimbursable,
in whole or in part, under Medicare, Medicaid, or other federal healthcare programs. A person or entity does not need to have actual
knowledge of the statute or specific intent to violate it to have committed a violation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
federal false claims, including the civil False Claims Act, prohibit, among other things, any person or entity from knowingly presenting,
or causing to be presented, a false, fictitious or fraudulent claim for payment to, or approval by, the federal government, knowingly
making, using, or causing to be made or used a false record or statement material to a false or fraudulent claim to the federal government,
or knowingly making a false statement to avoid, decrease, or conceal an obligation to pay money to the U.S. federal government. A claim
includes &ldquo;any request or demand&rdquo; for money or property presented to the U.S. government. Actions under the civil False Claims
Act may be brought by the Attorney General or as a qui tam action by a private individual in the name of the government. Moreover, a
claim including items or services resulting from a violation of the U.S. federal Anti-Kickback Statute constitutes a false or fraudulent
claim for purposes of the federal civil False Claims Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 105; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->102<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the civil monetary penalties statute, subject to certain exceptions, prohibits, among other things, the offer or transfer of
remuneration, including waivers of copayments and deductible amounts (or any part thereof), to a Medicare or state healthcare program
beneficiary if the person knows or should know it is likely to influence the beneficiary&rsquo;s selection of a particular provider,
practitioner or supplier of services reimbursable by Medicare or a state healthcare program. HIPAA created additional federal criminal
statutes that prohibit, among other actions, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare
benefit program, including private third-party payors, knowingly and willfully embezzling or stealing from a healthcare benefit program,
willfully obstructing a criminal investigation of a healthcare offense, and knowingly and willfully falsifying, concealing or covering
up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for
healthcare benefits, items or services. Similar to the U.S. federal Anti-Kickback Statute, a person or entity does not need to have actual
knowledge of the statute or specific intent to violate it in order to have committed a violation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HIPAA,
as amended by HITECH, and their respective implementing regulations, which impose obligations on &ldquo;covered entities,&rdquo; including
certain healthcare providers, health plans, and healthcare clearinghouses, as well as their respective &ldquo;business associates&rdquo;
and their respective subcontractors that create, receive, maintain, or transmit individually identifiable health information for or on
behalf of a covered entity, with respect to safeguarding the privacy, security, and transmission of individually identifiable health
information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
federal Physician Payments Sunshine Act requires certain manufacturers of drugs, devices, biologics, and medical supplies for which payment
is available under Medicare, Medicaid, or the Children&rsquo;s Health Insurance Program, with specific exceptions, to report annually
to the Centers for Medicare &amp; Medicaid Services, or CMMS, information related to payments or other transfers of value made to physicians
(defined to include doctors, dentists, optometrists, podiatrists, and chiropractors), certain other healthcare professionals including
physician assistants and nurse practitioners beginning in 2022, and teaching hospitals, and applicable manufacturers and applicable group
purchasing organizations to report annually to CMMS ownership and investment interests held by physicians and their immediate family
members.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Similar
state and local laws and regulations may also restrict business practices in the pharmaceutical industry, such as state anti-kickback
and false claims laws, which may apply to business practices, including but not limited to, research, distribution, sales, and marketing
arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers,
or by patients themselves; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&rsquo;s voluntary
compliance guidelines and the relevant compliance guidance promulgated by the federal government, or otherwise restrict payments that
may be made to healthcare providers and other potential referral sources; state laws and regulations that require drug manufacturers
to file reports relating to pricing information and marketing expenditures or which require tracking gifts and other remuneration and
items of value provided to physicians, other healthcare providers and entities; and state and local laws that require the registration
of pharmaceutical sales representatives.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Violations
of any of these laws and other applicable healthcare fraud and abuse laws may be punishable by criminal and civil sanctions, including
fines and civil monetary penalties, the possibility of exclusion from federal healthcare programs (including Medicare and Medicaid),
disgorgement and corporate integrity agreements, which impose, among other things, rigorous operational and monitoring requirements on
companies. Similar sanctions and penalties, as well as imprisonment, also can be imposed upon executive officers and employees of such
companies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Coverage
and Reimbursement </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
of any pharmaceutical product depend, in part, on the extent to which such product will be covered by third-party payors, such as federal,
state, and foreign government healthcare programs, commercial insurance and managed healthcare organizations, and the level of reimbursement
for such product by third-party payors. In the United States, no uniform policy exists for coverage and reimbursement for pharmaceutical
products among third-party payors. Therefore, decisions regarding the extent of coverage and amount of reimbursement to be provided are
made on a plan-by-plan basis. The process for determining whether a third-party payor will provide coverage for a product typically is
separate from the process for setting the price of such product or for establishing the reimbursement rate that the payor will pay for
the product once coverage is approved.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third-party
payors may limit coverage to specific products on an approved list, also known as a formulary, which might not include all of the FDA-approved
products for a particular indication, or place products at certain formulary levels that result in lower reimbursement levels and higher
cost-sharing obligation imposed on patients. One third-party payor&rsquo;s decision to cover a particular medical product or service
does not ensure that other payors will also provide coverage for the medical product or service and the level of coverage and reimbursement
can differ significantly from payor to payor. As a result, the coverage determination process will often require us to provide scientific
and clinical support for the use of our products to each payor separately and can be a time-consuming process, with no assurance that
coverage and adequate reimbursement will be applied consistently or obtained in the first instance. Additionally, a third-party payor&rsquo;s
decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 106; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->103<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
as a condition of participating in, and having products covered under, certain federal healthcare programs, such as Medicare and Medicaid,
we are subject to federal laws and regulations that require pharmaceutical manufacturers to calculate and report certain price reporting
metrics to the government, such as Medicaid Average Manufacturer Price, or AMP, and Best Price, Medicare Average Sales Price, the 340B
Ceiling Price, and Non-Federal AMP reported to the Department of Veteran Affairs, and with respect to Medicaid, pay statutory rebates
on utilization of manufacturers&rsquo; products by Medicaid beneficiaries. Compliance with such laws and regulations require significant
resources and any findings of non-compliance may have a material adverse effect on our revenues.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Healthcare
Reform </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States and certain foreign jurisdictions, there have been, and we expect there will continue to be, a number of legislative
and regulatory changes to the healthcare system. In the United States, by way of example, in March 2010, the ACA was signed into law,
which substantially changed the way healthcare is financed by both governmental and private insurers in the United States and significantly
affected the pharmaceutical industry. The ACA, among other things, increased the minimum level of Medicaid rebates payable by manufacturers
of brand name drugs; required collection of rebates for drugs paid by Medicaid managed care organizations; required manufacturers to
participate in a coverage gap discount program, under which they must agree to offer point-of-sale discounts (increased to 70 percent,
effective as of January 1, 2019) off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap
period, as a condition for the manufacturer&rsquo;s outpatient drugs to be covered under Medicare Part D; imposed a non-deductible annual
fee on pharmaceutical manufacturers or importers who sell certain &ldquo;branded prescription drugs&rdquo; to specified federal government
programs; implemented a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated
for drugs that are inhaled, infused, instilled, implanted, or injected expanded the types of entities eligible for the 340B drug discount
program; expanded eligibility criteria for Medicaid programs; created a new Patient-Centered Outcomes Research Institute to oversee,
identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; and established
a Center for Medicare Innovation at CMMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending,
potentially including prescription drug spending.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
its enactment, there have been judicial, administrative, executive, and Congressional legislative challenges to certain aspects of the
ACA. For example, on June 17, 2021, the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the ACA is unconstitutional
in its entirety because the &ldquo;individual mandate&rdquo; was repealed by Congress. Thus, the ACA will remain in effect in its current
form. Further, prior to the U.S. Supreme Court ruling, President Biden issued an executive order that initiated a special enrollment
period from February 15, 2021, through August 15, 2021, for purposes of obtaining health insurance coverage through the ACA marketplace.
The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit
access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements,
and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. It is possible
that the Affordable Care Act will be subject to judicial or Congressional challenges in the future. It is unclear how such challenges
and the healthcare reform measures of the Biden administration will impact the ACA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
legislative changes have been proposed and adopted since the ACA was enacted, including aggregate reductions of Medicare payments to
providers of 2% per fiscal year, which was temporarily suspended from May 1, 2020 through December 31, 2021, and reduced payments to
several types of Medicare providers. Moreover, there has recently been heightened governmental scrutiny over the manner in which manufacturers
set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted legislation designed,
among other things, to bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs
and reform government program reimbursement methodologies for pharmaceutical products. By way of example, the American Taxpayer Relief
Act of 2021, effective January 1, 2024, would eliminate the statutory cap on rebate amounts owed by drug manufacturers under the Medicaid
Drug Rebate Program, or MDRP, which is currently capped at 100% of the AMP for a covered outpatient drug. Further, based on a recent
executive order, the Biden administration expressed its intent to pursue certain policy initiatives to reduce drug prices.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Individual
states in the United States have also become increasingly active in implementing regulations designed to control pharmaceutical product
pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure
and transparency measures and, in some cases, mechanisms to encourage importation from other countries and bulk purchasing. In addition,
regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine which drugs and suppliers
will be included in their healthcare programs. Furthermore, there has been increased interest by third-party payors and governmental
authorities in reference pricing systems and publication of discounts and list prices.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 107; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->104<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect additional state and federal healthcare reform measures to be adopted in the future, any of which could limit the amounts that
federal and state governments will pay for healthcare products and services, which could result in reduced demand for our products or
additional pricing pressure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Data
Privacy and Security Laws </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Numerous
state, federal and foreign laws, including consumer protection laws and regulations, govern the collection, dissemination, use, access
to, confidentiality, and security of personal information, including health-related information. In the United States, numerous federal
and state laws and regulations, including data breach notification laws, health information privacy and security laws, including Health
Insurance Portability and Accountability Act, or HIPAA, and federal and state consumer protection laws and regulations (<I>e.g.</I>,
Section 5 of the Federal Trade Commission Act) that govern the collection, use, disclosure, and protection of health-related and other
personal information could apply to our operations or the operations of our partners. In addition, certain state and non-U.S. laws, such
as the California Consumer Privacy Act, or CCPA, the California Privacy Rights Act, or CPRA, and the General Data Protection Regulation,
or GDPR, govern the privacy and security of personal information, including health-related information in certain circumstances, some
of which are more stringent than HIPAA and many of which differ from each other in significant ways and may not have the same effect,
thus complicating compliance efforts. Failure to comply with these laws, where applicable, can result in the imposition of significant
civil and/or criminal penalties and private litigation. Privacy and security laws, regulations, and other obligations are constantly
evolving, may conflict with each other to make compliance efforts more challenging, and can result in investigations, proceedings, or
actions that lead to significant penalties and restrictions on data processing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Regulation
and Procedures Governing Approval of Medicinal Products in the EU </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to regulations in the United States, we will be subject to a variety of foreign regulations governing clinical trials and commercial
sales and distribution of our product candidates to the extent we choose to sell any of our product candidates outside of the United
States. Whether or not we obtain FDA approval for a product, we must obtain approval of a product by equivalent competent authorities
in foreign jurisdictions before we can commence clinical trials or marketing of the product in those countries. The approval process
varies from country to country and the time may be longer or shorter than that required for FDA approval. The requirements governing
the conduct of clinical trials, product licensing, pricing, and reimbursement vary greatly from country to country. As in the United
States, post-approval regulatory requirements, such as those regarding product manufacture, marketing, or distribution would apply to
any product that is approved outside the United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
process governing the marketing authorization, or MA, of medicinal products in the EU entails satisfactory completion of preclinical
studies and adequate and well-controlled clinical trials to establish the safety, quality, and efficacy of the medicinal product for
each proposed therapeutic indication.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
also requires the submission to the relevant competent authorities of a marketing authorization application, or MAA and granting of an
MA by these authorities before the product can be marketed and sold in the EU.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
aforementioned EU rules are generally applicable in the European Economic Area, or EEA, which consists of the 27 EU member states, as
well as Norway, Liechtenstein and Iceland.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Failure
to comply with EU and member state laws that apply to the conduct of clinical trials, manufacturing approval, MA of medicinal products
and marketing of such products, both before and after grant of the MA, or with other applicable regulatory requirements may result in
administrative, civil, or criminal penalties. These penalties could include delays or refusal to authorize the conduct of clinical trials,
or to grant MA, product withdrawals and recalls, product seizures, suspension, withdrawal, or variation of the MA, total or partial suspension
of production, distribution, manufacturing or clinical trials, operating restrictions, injunctions, suspension of licenses, fines, and
criminal penalties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Non-Clinical
Studies and Clinical Trials </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Similar
to the United States, the various phases of non-clinical research in the EU are subject to significant regulatory controls.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 108; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->105<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-clinical
studies are performed to demonstrate the health or environmental safety of new chemical or biological substances. Non-clinical studies
must be conducted in compliance with the principles of good laboratory practice, or GLP, as set forth in Directive 2004/10/EC. In particular,
non-clinical studies, both in vitro and in vivo, must be planned, performed, monitored, recorded, reported and archived in accordance
with the GLP principles, which define a set of rules and criteria for a quality system for the organizational process and the conditions
for non-clinical studies. These GLP standards reflect the Organization for Economic Co-operation and Development requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Clinical Trials Directive 2001/20/EC, the Directive 2005/28/EC on GCP and the related national implementing provisions of the individual
EU member states govern the system for the approval of clinical trials in the EU.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
trials of medicinal products in the EU must be conducted in accordance with EU and national regulations and the International Conference
on International Conference on Harmonization, or ICH, guidelines on GCP, as well as the applicable regulatory requirements and the ethical
principles that have their origin in the Declaration of Helsinki. If the sponsor of the clinical trial is not established within the
EU, it must appoint an EU entity to act as its legal representative. The sponsor must take out a clinical trial insurance policy, and
in most EU member states, the sponsor is liable to provide &lsquo;no fault&rsquo; compensation to any study subject injured in the clinical
trial.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the applicable regulatory system, an applicant must obtain prior approval from the competent national authority of the EU member states
in which the clinical trial is to be conducted. Furthermore, the applicant may only start a clinical trial at a specific study site after
the competent ethics committee has issued a related favorable opinion. The application for authorization of a clinical trial must be
accompanied by, among other documents, a copy of the trial protocol and an investigational medicinal product dossier containing information
about the manufacture and quality of the medicinal product under investigation as prescribed by Directive 2001/20/EC, Directive 2005/28/EC,
where relevant the related implementing national provisions of the individual EU member states, and further detailed in applicable guidance
documents. Any substantial changes to the trial protocol or to other information submitted with the clinical trial application must be
notified to or approved by the relevant competent national authorities and ethics committees. Medicinal products used in clinical trials
must be manufactured in accordance with GMP.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
April 2014, the new Clinical Trials Regulation, (EU) No 536/2014, or Clinical Trials Regulation, was adopted. The Regulation is anticipated
to enter into force on January 31, 2022. The Clinical Trials Regulation will be directly applicable in all of the EU member states, repealing
the current Clinical Trials Directive 2001/20/EC. Conduct of all clinical trials performed in the EU will continue to be bound by currently
applicable provisions until the new Clinical Trials Regulation becomes applicable. The extent to which on-going clinical trials will
be governed by the Clinical Trials Regulation will depend on the duration of the individual clinical trial. If a clinical trial continues
for more than three years from the day on which the Clinical Trials Regulation becomes applicable, the Clinical Trials Regulation will
at that time begin to apply to the clinical trial.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
new Clinical Trials Regulation aims to simplify and streamline the approval of clinical trials in the EU. The main characteristics of
the regulation include: a streamlined application procedure via a single-entry point, the &ldquo;EU portal;&rdquo; a single set of documents
to be prepared and submitted for the application, as well as simplified reporting procedures for clinical trial sponsors; and a harmonized
procedure for the assessment of applications for clinical trials, which is divided in two parts. Part I is assessed by the competent
authorities of all EU member states in which an application for authorization of a clinical trial has been submitted (member states concerned).
Part II is assessed separately by each member state concerned. Strict deadlines have been established for the assessment of clinical
trial applications. The role of the relevant ethics committees in the assessment procedure will continue to be governed by the national
law of the concerned EU member state. However, overall related timelines will be defined by the Clinical Trials Regulation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Marketing
Authorizations </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
obtain an MA for a product in the EU, an applicant must submit an MAA either under a centralized procedure administered by the EMA or
one of the procedures administered by competent authorities in the EU member states (decentralized procedure, national procedure, or
mutual recognition procedure). An MA may be granted only to an applicant established in the EU.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
centralized procedure provides for the grant of a single MA by the European Commission that is valid for all EU member states. Pursuant
to Regulation (EC) No 726/2004, the centralized procedure is compulsory for specific products, including for (i) medicinal products derived
from biotechnological processes, (ii) products designated as orphan medicinal products, (iii) advanced therapy medicinal products, or
ATMPs, and (iv) products with a new active substance indicated for the treatment of HIV/AIDS, cancer, neurodegenerative diseases, diabetes,
autoimmune, and other immune dysfunctions and viral diseases. For products with a new active substance indicated for the treatment of
other diseases and products that are highly innovative or for which a centralized process is in the interest of patients, the centralized
procedure may be optional.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 109; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->106<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the centralized procedure, the EMA&rsquo;s Committee for Medicinal Products for Human Use, or CHMP, is responsible for conducting the
initial assessment of a product. The CHMP is also responsible for several post-authorization and maintenance activities, such as the
assessment of modifications or extensions to an existing MA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the centralized procedure in the EU, the maximum timeframe for the evaluation of an MAA is 210 days, excluding clock stops when additional
information or written or oral explanation is to be provided by the applicant in response to questions of the CHMP. Accelerated assessment
may be granted by the CHMP in exceptional cases, when a medicinal product targeting an unmet medical need is expected to be of major
interest from the point of view of public health and in particular from the viewpoint of therapeutic innovation. If the CHMP accepts
a request for accelerated assessment, the time limit of 210 days will be reduced to 150 days (not including clock stops). The CHMP can,
however, revert to the standard time limit for the centralized procedure if it considers that it is no longer appropriate to conduct
an accelerated assessment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unlike
the centralized authorization procedure, the decentralized MA procedure requires a separate application to, and leads to separate approval
by, the competent authorities of each EU member state in which the product is to be marketed. This application is identical to the application
that would be submitted to the EMA for authorization through the centralized procedure. The reference EU member state prepares a draft
assessment and drafts of the related materials within 120 days after receipt of a valid application. The resulting assessment report
is submitted to the concerned EU member states who, within 90 days of receipt, must decide whether to approve the assessment report and
related materials. If a concerned EU member state cannot approve the assessment report and related materials due to concerns relating
to a potential serious risk to public health, disputed elements may be referred to the Heads of Medicines Agencies&rsquo; Coordination
Group for Mutual Recognition and Decentralised Procedures&mdash;Human (CMDh) for review. The subsequent decision of the European Commission
is binding on all EU member states.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
mutual recognition procedure allows companies that have a medicinal product already authorized in one EU member state to apply for this
authorization to be recognized by the competent authorities in other EU member states. Like the decentralized procedure, the mutual recognition
procedure is based on the acceptance by the competent authorities of the EU member states of the MA of a medicinal product by the competent
authorities of other EU member states. The holder of a national MA may submit an application to the competent authority of an EU member
state requesting that this authority recognize the MA delivered by the competent authority of another EU member state. In principle,
an MA has an initial validity of five years. The MA may be renewed after five years on the basis of a re-evaluation of the risk-benefit
balance by the EMA or by the competent authority of the EU member state in which the original MA was granted. To support the application,
the MA holder must provide the EMA or the competent authority with a consolidated version of the Common Technical Document, or eCTD,
providing up-to-date data concerning the quality, safety and efficacy of the product, including all variations introduced since the MA
was granted, at least nine months before the MA ceases to be valid. The European Commission or the competent authorities of the EU member
states may decide, on justified grounds relating to pharmacovigilance, to proceed with one further five-year renewal period for the MA.
Once subsequently definitively renewed, the MA shall be valid for an unlimited period. Any authorization which is not followed by the
actual placing of the medicinal product on the EU market (in case of centralized procedure) or on the market of the authorizing EU member
state within three years after authorization ceases to be valid (the so-called sunset clause).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Innovative
products that target an unmet medical need and are expected to be of major public health interest may be eligible for a number of expedited
development and review programs, such as the Priority Medicines, or PRIME, scheme, which provides incentives similar to the breakthrough
therapy designation in the United States. PRIME is a voluntary scheme aimed at enhancing the EMA&rsquo;s support for the development
of medicinal products that target unmet medical needs. It permits increased interaction and early dialogue with companies developing
promising medicinal products, to optimize their product development plans and speed up their evaluation to help the product reach patients
earlier than normal. Product developers that benefit from PRIME designation are potentially eligible for accelerated assessment of their
MAA although this is not guaranteed. Benefits accrue to sponsors of product candidates with PRIME designation, including but not limited
to, early and proactive regulatory dialogue with the EMA, frequent discussions on clinical trial designs and other development program
elements, and potentially accelerated MAA assessment once a dossier has been submitted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the EU, a &ldquo;conditional&rdquo; MA may be granted in cases where all the required safety and efficacy data are not yet available.
The conditional MA is subject to conditions to be fulfilled for generating the missing data or ensuring increased safety measures. It
is valid for one year and must be renewed annually until all related conditions have been fulfilled. Once any pending studies are provided,
the conditional MA can be converted into a traditional MA. However, if the conditions are not fulfilled within the timeframe set by the
EMA, the MA will cease to be renewed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 110; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->107<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
MA may also be granted &ldquo;under exceptional circumstances&rdquo; where the applicant can show that it is unable to provide comprehensive
data on the efficacy and safety under normal conditions of use even after the product has been authorized and subject to specific procedures
being introduced. These circumstances may arise in particular when the intended indications are very rare and, in the state of scientific
knowledge at that time, it is not possible to provide comprehensive information, or when generating data may be contrary to generally
accepted ethical principles. Like a conditional MA, an MA granted in exceptional circumstances is reserved to medicinal products intended
to be authorized for treatment of rare diseases or unmet medical needs for which the applicant does not hold a complete data set that
is required for the grant of a standard MA. However, unlike the conditional MA, an applicant for authorization in exceptional circumstances
is not subsequently required to provide the missing data. Although the MA &ldquo;under exceptional circumstances&rdquo; is granted definitively,
the risk-benefit balance of the medicinal product is reviewed annually and the MA is withdrawn in case the risk-benefit ratio is no longer
favorable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to an MA, various other requirements apply to the manufacturing and placing on the EU market of medicinal products.
Manufacture of medicinal products in the EU requires a manufacturing authorization, and import of medicinal products into the EU
requires a manufacturing authorization allowing for import. The manufacturing authorization holder must comply with various
requirements set out in the applicable EU laws, regulations and guidance. These requirements include compliance with EU GMP
standards when manufacturing medicinal products and APIs, including the manufacture of APIs outside of the EU with the intention to
import the APIs into the EU. Similarly, the distribution of medicinal products within the EU is subject to compliance with the
applicable EU laws, regulations and guidelines, including the requirement to hold appropriate authorizations for distribution
granted by the competent authorities of the EU member states. MA holders, manufacturing and import authorization (MIA) holders, or
distribution authorization holders may be subject to civil, criminal or administrative sanctions, including suspension of
manufacturing authorization, in case of non-compliance with the EU or EU member states&rsquo; requirements applicable to the
manufacturing of medicinal products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Data
and Market Exclusivity </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
EU provides opportunities for data and market exclusivity related to MAs. Upon receiving an MA, innovative medicinal products are generally
entitled to receive eight years of data exclusivity and ten years of market exclusivity. Data exclusivity, if granted, prevents regulatory
authorities in the EU from referencing the innovator&rsquo;s data to assess a generic application or biosimilar application for eight
years from the date of authorization of the innovative product, after which a generic or biosimilar MAA can be submitted, and the innovator&rsquo;s
data may be referenced. The market exclusivity period prevents a successful generic or biosimilar applicant from commercializing its
product in the EU until ten years have elapsed from the initial MA of the reference product in the EU. The overall ten-year period may,
occasionally, be extended for a further year to a maximum of 11 years if, during the first eight years of those ten years, the MA holder
obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization,
are held to bring a significant clinical benefit in comparison with existing therapies. However, there is no guarantee that a product
will be considered by the EU&rsquo;s regulatory authorities to be a new chemical/biological entity, and products may not qualify for
data exclusivity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the EU, there is a special regime for biosimilars, or biological medicinal products that are similar to a reference medicinal product
but that do not meet the definition of a generic medicinal product. For such products, the results of appropriate preclinical or clinical
trials must be provided in support of an application for MA. Guidelines from the EMA detail the type of quantity of supplementary data
to be provided for different types of biological product.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Pediatric
Development </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the EU, Regulation (EC) No 1901/2006 provides that all MAAs for new medicinal products have to include the results of trials conducted
in the pediatric population, in compliance with a pediatric investigation plan, or PIP, agreed with the EMA&rsquo;s Pediatric Committee,
or PDCO. The PIP sets out the timing and measures proposed to generate data to support a pediatric indication of the medicinal product
for which MA is being sought. The PDCO can grant a deferral of the obligation to implement some or all of the measures provided in the
PIP until there are sufficient data to demonstrate the efficacy and safety of the product in adults. Further, the obligation to provide
pediatric clinical trial data can be waived by the PDCO when these data are not needed or appropriate because the product is likely to
be ineffective or unsafe in children, the disease or condition for which the product is intended occurs only in adult populations, or
when the product does not represent a significant therapeutic benefit over existing treatments for pediatric patients. Once the MA is
obtained in all EU member states and study results are included in the product information, even when negative, the product is eligible
for a six-month extension to the Supplementary Protection Certificate, or SPC, if any is in effect at the time of authorization or, in
the case of orphan medicinal products, a two-year extension of orphan market exclusivity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 111; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->108<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Post-Approval
Requirements </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Where
an MA is granted in relation to a medicinal product in the EU, the holder of the MA is required to comply with a range of regulatory
requirements applicable to the manufacturing, marketing, promotion, and sale of medicinal products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Similar
to the United States, both MA holders and manufacturers of medicinal products are subject to comprehensive regulatory oversight by the
EMA, the European Commission, or the competent regulatory authorities of the individual EU member states. The holder of an MA must establish
and maintain a pharmacovigilance system and appoint an individual qualified person for pharmacovigilance who is responsible for oversight
of that system. Key obligations include expedited reporting of suspected serious adverse reactions and submission of periodic safety
update reports, or PSURs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
new MAAs must include a risk management plan describing the risk management system that the company will put in place and documenting
measures to prevent or minimize the risks associated with the product. The regulatory authorities may also impose specific obligations
as a condition of the MA. Such risk-minimization measures or post-authorization obligations may include additional safety monitoring,
more frequent submission of PSURs, or the conduct of additional clinical trials or post-authorization safety studies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the EU, the advertising and promotion of medicinal products are subject to both EU and EU member states&rsquo; laws governing promotion
of medicinal products, interactions with physicians and other healthcare professionals, misleading and comparative advertising and unfair
commercial practices. Although general requirements for advertising and promotion of medicinal products are established under EU directives,
the details are governed by regulations in each member state and can differ from one country to another. For example, applicable laws
require that promotional materials and advertising in relation to medicinal products comply with the product&rsquo;s Summary of Product
Characteristics, or SmPC, as approved by the competent authorities in connection with an MA. The SmPC is the document that provides information
to physicians concerning the safe and effective use of the product. Promotional activity that does not comply with the SmPC is considered
off-label and is prohibited in the EU. Direct-to-consumer advertising of prescription medicinal products is also prohibited in the EU.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Japanese
Drug Regulation </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Being
a member of the ICH, Japan has pharmaceutical regulations fundamentally similar to those of the United States and the EU. Clinical trials
of medicinal products in Japan must be conducted in accordance with Japanese regulations based on ICH guidelines governing GCP. If the
sponsor of the clinical trial is not established within Japan, it must appoint an entity within the country to act as its caretaker who
should be authorized to act on the sponsor&rsquo;s behalf. The sponsor must take out a clinical trial insurance policy, and, according
to the industry agreement, should put in place a common compensation policy for the injuries from the trial. Prior to the commencement
of human clinical studies, the sponsor must complete an evaluation of the safety of the investigative product and submit a clinical trial
notification and clinical trial protocol to the authorities in advance, upon agreement of the IRB of the participating institutions.
When the authorities do not comment on the notification, the sponsor may proceed with the clinical trial. Any substantial changes to
the trial protocol or other information submitted must be cleared by the IRB and notified to the authorities. Medicines used in clinical
trials must be manufactured in accordance with GMP.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
market a medicinal product in Japan, we must obtain regulatory approval. To obtain regulatory approval of an investigational medicinal
product, we must submit a new drug application. If the product is designed for treating certain &ldquo;difficult diseases&rdquo; or those
whose patient size is limited, we may be able to obtain designation as an orphan drug product if it demonstrates unique therapeutic value.
Separately, the latest amendment to the law introduced separate pathways for (i) truly innovative products with a unique mode of action
and (ii) those which will satisfy unmet medical needs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
evaluation of new drug applications is based on an assessment of the risk-benefit balance of the product on the basis of scientific criteria
concerning its quality, safety, and efficacy. Once the review organization completes its review, the matter is considered by the advisory
committee of experts, and the government grants approval upon positive recommendation from the committee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 112; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->109<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
volume and quality of the clinical data are key determinants of the approval decision. Clinical trial data generated overseas is accepted
as part of the data package consistent with the ICH recommendation. Typically, a limited dose response clinical trial for Japanese subjects
is required to ensure that data are extrapolatable for the Japanese population.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Separate
from the approval requirement, it is also mandatory to possess a distribution license of an appropriate class for the manufacturer to
commercially distribute the product in Japan. Non-Japanese companies who possess only the product approval may designate an appropriate
license holder in Japan to commercially distribute the product, rather than distributing it on its own. The license is valid for five
years.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Employees
and Human Capital Resources </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of February 14, 2024, we had three employees (including our executive officers), each of whom is a part-time employee primarily
engaged in research and development activities, and all hold M.D. or Ph.D. degrees. Our Chief Financial Officer is currently a part-time
contractor, although he will serve on a full-time basis upon the effectiveness of this registration statement. All officers and directors
of the Company worked approximately 20 hours per week under their appropriate responsibility. We had no full-time employees. We consider
our relationship with our employees to be good. None of our employees is subject to a collective bargaining agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
recognize that our continued ability to attract, retain, and motivate exceptional employees is vital to ensuring our long-term competitive
advantage. Our employees are critical to our long-term success and are essential to helping us meet our goals. Among other things, we
support and incentivize our employees in the following ways:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Talent
                                            development, compensation, and retention:</I></B> We strive to provide our employees with
                                            a rewarding work environment, including the opportunity for growth, success, and professional
                                            development. We provide a competitive compensation and benefits package, including bonus
                                            and equity incentive plans, a 401(k) plan&#8212;all designed to attract and retain a skilled
                                            and diverse workforce.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Health
                                            and safety:</I></B> We support the health and safety of our employees by providing comprehensive
                                            insurance benefits, an employee assistance program, company-paid holidays, a personal time-off
                                            program, and other additional benefits which are intended to assist employees to manage their
                                            well-being.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Inclusion
                                            and diversity:</I></B> We are committed to efforts to increase diversity and foster an inclusive
                                            work environment that supports our workforce.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Properties
</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
corporate address is 2355 Westwood Blvd. #139, Los Angeles, CA. 90064. This is the address of our registered agent. We
currently do not lease any properties, but if required, we believe that suitable additional or alternative space would be available
in the future on commercially reasonable terms. As of the date of this prospectus, all of our operations are conducted
virtually.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Legal
Proceedings </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, we may become involved in material legal proceedings or be subject to claims arising in the ordinary course of our business.
Regardless of outcome, such proceedings or claims can have an adverse impact on us because of defense and settlement costs, diversion
of resources, and other factors, and there can be no assurances that favorable outcomes will be obtained. We are not presently party to
any legal proceedings material to our operations or of which any of our property is the subject, nor are we aware of any such proceedings
that are contemplated by a government authority.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 113; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->110<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><A NAME="ak_009"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>MANAGEMENT
</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Executive
Officers, Management, and Directors </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are led by an industry leading senior management team and board of directors with extensive capabilities in immuno-oncology and
with a wealth of experience in drug development, commercialization and successful business exits. Collectively, our team possesses a
strong record of success, as demonstrated by more than 50 patents held, 12 accepted INDs and approved new drug applications, or NDAs,
or biologics license applications, or BLAs, and significant experience at leading life sciences companies including Amgen Inc., Genexine
Inc. and Pfizer Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth information regarding our executive officers and directors as of the date of this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Age
    </B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 46%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Position(s)</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">John
    S. Yu, M.D.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">59</P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CEO
    and Chairman of the Board of Directors</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neil
    Bhowmick, Ph.D.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">53</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Scientific Officer</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ramachandran
    Murali. Ph.D.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">64</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vice
    President of Research and Development</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Doug
    Samuelson</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">64</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hyun
    W. Bae, M.D.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">54</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rosemary
    Mazanet M.D., Ph.D.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">67</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director
    Designate*</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hansoo
    Michael Keyoung, M.D., Ph.D.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">49</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director
    Designate*</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 25%"><DIV STYLE="margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid; margin-bottom: 0pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">* Each director designate will become a member of
our board of directors upon effectiveness of this offering.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Executive
Officers </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>John
S. Yu, M.D., CEO and Chairman of the Board of Directors</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Dr. <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yu,
our co-founder, Chairman and Chief Executive Officer, is a medical clinician and investigator. Since 2019, Dr. Yu has also served as
the Chief Financial Officer and a director of our wholly owned subsidiary, Enviro. Dr. Yu is committed to advancing Kairos&rsquo;s
pipeline to tackle the most unmet needs in cancer: resistance to cancer therapeutics and the suppressed immune response in cancer.
As the Professor of Neurosurgery and Director of Surgical Neuro-Oncology at Cedars-Sinai Medical Center, where he has worked since
January 1998 until present, he has dedicated his medical career to the development of immunotherapy for cancer and glioblastoma. Dr.
Yu is the co-inventor of the GITR and activated T cell technology. Dr. Yu earned his bachelor&rsquo;s degree from Stanford
University in 1985 and spent a year at the Sorbonne in Paris studying French literature while completing a fellowship in immunology
at the Institut Pasteur in Paris, and earned his medical degree from Harvard Medical School in 1990 and a master&rsquo;s degree from
the Harvard University Department of Genetics in 1990, before pursuing a neurosurgical residency at Massachusetts General Hospital
in Boston. His portfolio has included 26 research grants, 10 patents, seven FDA-approved investigational drugs and 17 IRB approved
clinical trials. </FONT>We believe Dr. Yu, with his substantial experience in the field, is qualified to serve on our board of
directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><I><U>Neil Bhowmick, Ph.D., Chief Scientific Officer
</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white">Dr.
Bhowmick, our Chief Scientific Officer, has more than 20 years of broad biochemistry experience filing and prosecuting patents in
therapeutics and devices, published in peer-reviewed journals (110 publications) leading foundational and pre-clinical cancer
studies, obtaining regulatory approvals, and conducting clinical trials. Dr. Bhowmick discovered the role of fibroblasts in cancer
therapy resistance and has used this finding to extend the time of cancer remission in multiple cancer types in preclinical and
clinical examples as a founder and CEO of Enviro Therapeutics Inc. He trained at Vanderbilt University and is the Professor of
Medicine at Cedars-Sinai Medical Center and Director of the Cancer Biology Program at Cedars-Sinai Cancer. He is on the Editorial
Board of four scientific journals and charter member of a NIH grant study section. Dr. Bhowmick was a Consultant at Celgene
(currently Bristol Myers Squibb, a New York Stock Exchange-listed company) in 2009, Xencor Inc., a Nasdaq-listed company, from 2019
to 2020 and at Tracon, a Nasdaq-listed company, from 2014 to 2019. He currently serves on the Scientific Advisory Board of
FibroBiologics. Dr. Bhowmick has received NCI/NIH funding for over 15 years, has been cited over 15,000 times, and holds six patents
for biomarker detection platforms and stromal targeted therapeutics (inclusive of ENV 105 and ENV 205<B>).</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
<!-- Field: Page; Sequence: 114; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->111<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><I><U>Ramachandran Murali, Ph.D., Vice President
of Research and Development </U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Dr. Murali, our Vice President of Research and
Development, is an established structural biologist with expertise in macromolecular crystallography, computational biology, drug discovery,
immunology, and cancer biology. Using these skills, Dr. Murali advanced a unique technology for creating small peptidomimetics and small
molecule drugs that target protein-protein/DNA interactions for diagnostic and therapeutic applications in areas like cancer biology,
immunotherapy, and autoimmune pathologies. Dr. Murali co-founded three biotech startup companies, including Xcyte Therapeutics, a cancer
immunotherapy company founded in Seattle, WA in 1996, Ception Therapeutics, Inc, an immunotherapeutic pharmaceutical company founded
in Philadelphia, PA in 2003 and Nidus, CA, a immunotherapeutic company founded in Los Angeles, CA in 2005. Dr. Murali&rsquo;s accomplishments
also include developing small molecule agonist/antagonists for numerous cell surface receptor complexes, including members of the TNFR
super family. Recently, he targeted various transcription factors, such as Onecut-2, for cancer therapy. Dr. Murali has over 10 years
of experience in collaborating with several biotech companies and is a co-inventor of more than 10 patents. Dr. Murali obtained his doctoral
degree in Biophysics from the University of Madras, one of the pioneering institutes for structural biology in India. Upon graduation,
he completed his post-doctoral training at Columbia University and the Wistar Institute (Philadelphia, PA). Later, he joined the University
of Pennsylvania as a faculty member and rose to the position of Associate Professor. He is currently a Professor in the Department of
Biomedical Sciences, Research Division of Immunology at Cedars-Sinai Medical Center (Los Angeles, CA).</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Doug
Samuelson, Chief Financial Officer </U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Samuelson has served as our external Chief Financial Officer since 2019. Mr. Samuelson is a finance and accounting professional with
over 25 years of experience. From 2016 to 2022, Mr. Samuelson  served as the Chief Financial Officer of Wellness Center
USA, Inc. in Tucson, Arizona. From 2016 to March 2020, Mr. Samuelson served as the Director of Accounting of Second Sight Medical Products,
Inc., and in this position, managed all accounting functions, including all general ledger close functions, tax reporting, external audit
responsibilities, banking and technical accounting issues. From 2018 to 2019, Mr. Samuelson served as the Chief Financial Officer of
AdvaVet, Inc., in Los Angeles, California, the U.S. subsidiary of Swedish pharmaceutical company, Oasmia Pharmaceutical AB (NASDAQ: OASM).
From 2016 to 2018, Mr. Samuelson was the Chief Financial Officer of Solis Tek, Inc. (OTC: GNAL), where he handled all financial reporting
with the SEC. Mr. Samuelson obtained a Bachelor of Science in Accounting from University of Utah, College of Business and obtained a
Master of Science in Computer Science from California State University, Northridge, School of Engineering. He is also a Certified Public
Accountant in the State of California.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Non-Employee
Directors </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Hyun
W. Bae, M.D., Independent Director</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Hyun W. Bae has served on our board of directors as an independent director since September 9, 2020. Dr. Bae is currently a Professor
in Orthopaedic Surgery at Cedars-Sinai Medical Center, the Director of Cedars&rsquo; Education and Fellowship program, and a clinical
partner of the Orthopaedic Stem Cell and Tissue Engineering Laboratory. Since 2010, Dr. Bae has served as the Chief Medical Officer and
a director of Prosidyan, a company that develops proprietary fiber-based bioactive glass products. Dr. Bae has served as a Scientific
Advisory Board Member of Mesoblast since 2008, Engage Surgical since 2018, and Spine Biopharma since 2019. He also served as a Scientific
Advisory Board Member of Tissuegene from 2008 to 2015. Dr. Bae is a 20-year veteran of the drug development industry and is a renowned
researcher and inventor. He was principal investigator for four FDA-approved randomized clinical trials and has completed
30 clinical studies throughout his career. Dr. Bae also has authored 60 published scientific papers, written five review articles and
holds 30 patents. Dr. Bae obtained a Biomechanics degree from Columbia University and a Doctor of Medicine degree, cum laude, from Yale
University and is a former NIH Howard Hughes Research Fellow in Bethesda, Maryland. We believe that Dr. Bae is qualified to serve on
our board of directors because of his industry and technical experience, including his operational experience in drug discovery
and development, and service on multiple company boards.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 115; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->112<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Rosemary
Mazanet M.D., Ph.D., Independent Director</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Rosemary Mazanet has agreed to serve on our board of directors as an independent director upon completion of this offering.
Since June 2015, Dr. Mazanet has served as the Chair of the Scientific Advisory Board and since September 2017 as Chief Science Officer
for Columbia Care, Inc. She is a Director at Oncternal Therapeutics, a Nasdaq-listed company, since January 2021, and private company
Angiochem. She has served as Clinical Advisor and interim C-suite management to many companies and funds through her consultancy business,
R Mazanet LLC, which she has managed as President since May 2004. Dr. Mazanet also has experience in public equity markets as a Managing
Partner at Apelles Investment, LLC from 2007 to 2014, and as the Head of Research at Oracle Partners LP from 1998 to 2004. Prior to her
public equity work, Dr. Mazanet worked at Amgen, Inc., where she led Clinical Development teams that conducted successful development
programs leading to product approvals. Dr. Mazanet served as a director and member of the audit committee of GTx, Inc., a Nasdaq-listed
company, from January 2002 to June 2010 and an independent Director of MasterCell from 2019 to 2020. Both companies were subsequently
acquired. Dr. Mazanet has served as a Trustee at the University of Pennsylvania Health System since July 2002, and as the Chair, Executive
Advisory Board for the Wharton Leonard Davis Institute since December 2020. Dr. Mazanet holds a B.A. in biology from the University of
Virginia, and a Doctor of Medicine degree and a Doctor of Philosophy degree from the University of Pennsylvania. Dr. Mazanet is trained
as an internist and oncologist with privileges at the Harvard Hospitals. We believe that Dr. Mazanet is qualified to serve on our board
of directors because of her extensive experience managing and advising public and private companies in medical technology fields,
her experience in public equity markets, her development team experience in drug discovery and development, and service on multiple company
boards.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Hansoo
Michael Keyoung, M.D., Ph.D., Independent Director</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Hansoo Michael Keyoung has agreed to serve on our board of directors as an independent director upon completion of this
offering. For over 20 years, Dr. Keyoung has led a successful career as a physician, healthcare executive, and investor in the United
States, Europe and Asia. Since 2017, Dr. Keyoung has served as the head of North America for CBC Group, a healthcare-dedicated private
equity firm with over $4 billion in assets under management. He has served as Board Chair of AffaMed Therapeutics since 2019, a director
of Graybug Vision, a Nasdaq-listed company, since 2019, and a director of InxMed since 2019. From 2015 to 2017, Dr. Keyoung also served
as the Chief Executive Officer of Genexine, a KOSDAQ-listed biotech company with a $1 billion plus market cap focused on developing innovative
biologic drugs for cancer and rare diseases. During his tenure as Chief Executive Officer of Genexine, he successfully helped lead clinical
development in Europe and Asia, raised $100 million in equity, and set up partnerships with Merck, Fosun Pharma, Tasly Pharma, and Kalbe
Pharma. From 2013 to 2015, he also served as President of Catalyst Biosciences, a Nasdaq-listed company and a clinical-stage hemophilia
and ophthalmology company that partnered with Pfizer, MedImmune, and Isu Abxis. Additionally, he has experience advising Eli Lilly, Bausch
&amp; Lomb, and Samsung Electronics/Biologics on Asian expansion, global drug development and commercial partnership strategies. Dr.
Keyoung has a Doctor of Medicine degree and a Doctor of Philosophy degree in neuroscience and neurology from Cornell University Weill
Medical College and Memorial Sloan Kettering. He was also a Biomedical Fellow at Rockefeller University and Memorial Sloan Kettering.
We believe that Dr. Keyoung is qualified to serve on our board of directors because of his extensive experience serving in management
and on boards of directors of public company, his experience in private equity investing in healthcare companies, and his extensive advisory
work to industry-leading healthcare companies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><B>Family Relationships</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white">There are no other family
relationships among our directors and executive officers.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Composition
of Our Board of Directors </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Our business and affairs are organized under the
direction of our board of directors, which currently consists of two members and at the completion of our IPO will consist of four members,
each of whom are elected to serve for one year <FONT STYLE="background-color: white">terms to hold office until the next annual meeting
of our stockholders and until a successor is appointed and qualified, or until their removal, resignation, or death</FONT>. The primary
responsibilities of our board of directors are to provide oversight, strategic guidance, counseling, and direction to our management.
Our board of directors meets on a regular basis and additionally as required.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Director
Independence and Diversity </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the NYSE American Listing Rules independent directors must comprise a majority of our board of directors as a listed
company within one year of the listing date. NYSE American Rules also require that boards of directors of five
or more members have at least two diverse directors (including at least one woman and at least one member of an underrepresented community)
or that boards of directors of four or fewer members have at least one diverse director or, each case, explain why the company has not
appointed such diverse directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors has undertaken a review of the independence and diversity of each director. Based on information provided by each
director concerning her or his background, employment and affiliations, including family relationships, our board of directors has determined
that three of our four directors, each of Dr. Bae, Mazanet, and Keyoung, are independent directors and that our board of directors
meets the diversity requirements imposed by Nasdaq.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Committees
of Our Board of Directors </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors has established an audit committee, a compensation committee, and a nominating and corporate governance committee,
each of which is made up of independent directors, in compliance with the NYSE American Listing Rules. The composition
and responsibilities of each of the committees of our board of directors are described below. Members serve on these committees until
their resignation or until otherwise determined by our board of directors. Each committee intends to adopt a written charter that satisfies
the application rules and regulation of the SEC and the NYSE American Listing Rules, which we will post to our website
at https://kairospharma.com upon the closing of this offering. Our board of directors may establish other committees as it deems necessary
or appropriate from time to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 116; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->113<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Audit
Committee </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
completion of this offering, our audit committee will consist of Dr. Michael Keyoung, Dr. Hyun W. Bae, and Dr. Rosemary Mazanet, each
of whom our board of directors has determined satisfies the independence requirements under the NYSE American Listing
Rules and Rule 10A-3(b)(1) of the Exchange Act. The chair of our audit committee will be Dr. Michael Keyoung, whom our board of directors
has determined is an &ldquo;audit committee financial expert&rdquo; within the meaning of SEC regulations. Each member of our audit committee
can read and understand fundamental financial statements in accordance with applicable requirements. In arriving at these determinations,
the board of directors has examined each audit committee member&rsquo;s scope of experience and the nature of their employment in the
corporate finance sector.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
primary purpose of the audit committee is to discharge the responsibilities of our board of directors with respect to our corporate accounting
and financial reporting processes, systems of internal control and financial-statement audits, and to oversee our independent registered
accounting firm. Specific responsibilities of our audit committee include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">helping
                                            our board of directors oversee our corporate accounting and financial reporting processes;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">managing
                                            the selection, engagement, qualifications, independence and performance of a qualified firm
                                            to serve as the independent registered public accounting firm to audit our financial statements;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">discussing
                                            the scope and results of the audit with the independent registered public accounting firm,
                                            and reviewing, with management and the independent accountants, our interim and year-end
                                            operating results;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">developing
                                            procedures for employees to submit concerns anonymously about questionable accounting or
                                            audit matters;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
                                            related person transactions;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining
                                            and reviewing a report by the independent registered public accounting firm at least annually,
                                            that describes our internal quality control procedures, any material issues with such procedures,
                                            and any steps taken to deal with such issues when required by applicable law; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">approving
                                            or, as permitted, pre-approving, audit and permissible non-audit services to be performed
                                            by the independent registered public accounting firm.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Compensation
Committee </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
completion of this offering, our compensation committee will consist of Dr, Rosemary Mazanet, Dr. Hansoo Michael Keyoung, and Dr. Hyun
Bae. The chair of our compensation committee will be Dr. Rosemary Mazanet. Our board of directors has determined that each member of
our compensation committee is independent under the NYSE American Listing Rules and as a &ldquo;non-employee director&rdquo;
as defined in Rule 16b-3 promulgated under the Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
primary purpose of our compensation committee is to discharge the responsibilities of our board of directors in overseeing our compensation
policies, plans and programs, and to review and determine the compensation to be paid to our executive officers, directors and other
senior management, as appropriate. Specific responsibilities of our compensation committee include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
                                            and approving the compensation of our chief executive officer, other executive officers,
                                            and senior management;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
                                            and recommending to our board of directors the compensation paid to our directors;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
                                            and approving the compensation arrangements with our executive officers and other senior
                                            management;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">administering
                                            our equity incentive plans and other benefit programs;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing,
                                            adopting, amending, and terminating, incentive compensation and equity plans, severance agreements,
                                            profit sharing plans, bonus plans, change-of-control protections, and any other compensatory
                                            arrangements for our executive officers and other senior management;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing,
                                            evaluating, and recommending to our board of directors&#8217; succession plans for our executive
                                            officers; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
                                            and establishing general policies relating to compensation and benefits of our employees,
                                            including our overall compensation strategy, including base salary, incentive compensation,
                                            and equity-based grants, to assure that it promotes stockholder interests and supports our
                                            strategic and tactical objectives, and that it provides for appropriate rewards and incentives
                                            for our management and employees.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 117; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->114<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Nominating
and Corporate Governance Committee </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
completion of this offering, our nominating and corporate governance committee will consist of Dr. Rosemary Mazanet, Dr. Hyun Bae,
and Dr. Michael Keyoung. The chair of our nominating and corporate governance committee will be Dr. Rosemary Mazanet. Our board of
directors has determined that each member of the nominating and corporate governance committee is independent under the NYSE
American Listing Rules, a non-employee director, and free from any relationship that would interfere with the exercise of his or her
independent judgment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Specific
responsibilities of our nominating and corporate governance committee include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">identifying
                                            and evaluating candidates, including the nomination of incumbent directors for reelection
                                            and nominees recommended by stockholders, to serve on our board of directors;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">considering
                                            and making recommendations to our board of directors regarding the composition and chairmanship
                                            of the committees of our board of directors;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">instituting
                                            plans or programs for the continuing education of our board of directors and orientation
                                            of new directors;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">developing
                                            and making recommendations to our board of directors regarding corporate governance guidelines
                                            and matters; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">overseeing
                                            periodic evaluations of the board of directors&#8217; performance, including committees of
                                            the board of directors and management.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Code
of Business Conduct and Ethics </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with this offering, we intend to adopt a written Code of Business Conduct and Ethics that applies to all our employees,
officers, and directors. This includes our principal executive officer, principal financial officer, and principal accounting
officer or controller, or persons performing similar functions. The full text of our Code of Business Conduct and Ethics will be
posted on our website at www.kairospharma.com. We intend to disclose on our website any future amendments of our Code of
Business Conduct and Ethics or waivers that exempt any principal executive officer, principal financial officer, principal
accounting officer or controller, persons performing similar functions, or our directors from provisions in the Code of Business
Conduct and Ethics. Information contained on, or accessible through, our website is not a part of this prospectus, and the inclusion
of our website address in this prospectus is only an inactive textual reference.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Compensation
Committee Interlocks and Insider Participation </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">None
of the members of the compensation committee is currently, or has been at any time, one of our executive officers or employees. None
of our executive officers currently serves, or has served during the last calendar year, as a member of the board of directors or compensation
committee of any entity that has one or more executive officers serving as a member of our board of directors or compensation committee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Non-Employee
Director Compensation </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the fiscal years ended December 31, 2023 and 2022, Hyun W. Bae, M.D. served on our board of directors as a non-employee
director. No compensation was awarded to or earned by or paid to Dr. Bae for the fiscal years ended December 31, 2023 and 2022. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">We will enter into director
agreements with each of our directors in advance of effectiveness of this registration statement. Such agreements will provide for annual
cash compensation of $50,000, payable in quarterly installments in arrears, plus an additional $10,000 cash compensation for the chair
of the audit committee. In addition, our policy provides that, upon initial election or appointment to our board of directors,
each new non-employee director will be granted a one-time grant, or Director Initial Grant, of 10,000 restricted stock units (&ldquo;RSUs&rdquo;)
that will vest in substantially equal annual installments over a period of three years. The Director Initial Grant is subject to
full acceleration vesting upon the sale of our Company, in accordance with the terms of our 2023 Equity Incentive Plan.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will reimburse all reasonable out-of-pocket expenses incurred by directors for their attendance at meetings of our board of directors
or any committee thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employee
directors will receive no additional compensation for their service as a director.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Our
certificate of incorporation contains provisions limiting the liability of directors, and our bylaws provide that we will indemnify each
of our directors and officers to the fullest extent permitted under Delaware law. Our certificate of incorporation and bylaws will also
provide our board of directors with discretion to indemnify our employees and other agents when determined appropriate by the board of
directors. In addition, we intend to enter into an indemnification agreement with each of our directors and executive officers, which
will require us to indemnify them. For more information regarding these agreements, see the section titled &ldquo;Executive Compensation
&mdash; Limitations on Liability and Indemnification.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 118; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->115<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="ak_010"></A>EXECUTIVE
COMPENSATION </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
named executive officers for the year ended December 31, 2023 and 2022 were Dr. Yu, Dr. Bhowmick, Dr. Murali, and Mr. Samuelson.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Summary
Compensation Table </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">None
of our named officers were paid a salary, were granted options, or received any compensation of any type during the fiscal years ended
December 31, 2023 and 2022. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>Employment Agreements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have entered into employment agreements with each of our executive officers which will become effective concurrently with the consummation
of this initial public offering (&ldquo;IPO&rdquo;). At such time, our executive officers will receive compensation on an annual basis
in cash, payable in monthly installments, as well as options to purchase common stock subject to achieving certain key performance indicators.
The terms of the employment agreements are as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Employment
Agreement with John Yu, MD</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 27, 2023, we entered enter into an employment agreement with our Chief Executive Officer and Chairman of the Board, John Yu,
M.D. Dr. Yu&rsquo;s employment agreement will become effective upon consummation of our IPO. Under the terms of his employment
agreement, Dr. Yu will receive base compensation of $175,000 per year. Dr. Yu will also receive 14,000 restricted stock units
(&ldquo;RSUs&rdquo;), which RSUs will vest annually in substantially equal installments over a period of three years. In addition,
Dr. Yu will be entitled to receive an annual cash or stock bonus, as may be determined by the compensation committee of the board of
directors. Should Dr. Yu terminate his employment for &ldquo;Good Reason,&rdquo; as defined in the agreement, he will be entitled to
his then applicable base salary for period of six months, subject to his continued compliance with certain requirements of his
employment agreement. Dr. Yu will also be entitled to standard benefits that may be offered by the Company from time to time,
including 30 days&rsquo; paid vacation. Prior to completion of our IPO, Dr. Yu has received no salary from the
Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Employment
Agreement with Doug Samuelson</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
presently have an at will agreement with our Chief Financial Officer, Doug Samuelson, pursuant to which Mr. Samuelson is paid $90.00
per hour, is eligible to receive an annual discretionary bonus, as may be determined by the board of directors, and pursuant to which
Mr. Samuelson is eligible to participate in the Company&rsquo;s standard medical, retirement and insurance benefit plans, and is subject
to standard non-disclosure and confidentiality provisions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 27, 2023, we entered into an employment agreement with Mr. Samuelson, which employment agreement will become effective
upon consummation of our IPO. Under the employment agreement, Mr. Samuelson will be entitled to receive (i) a base salary equal to
$50,000 per year, payable in monthly installments; (ii) an annual grant of 50,000 RSUs, which RSUs will be issued each year on the
anniversary date of our IPO, with each grant becoming fully vested after 12 months; and (iii) such number of RSUs equal to 1.2 times
the amount of outstanding invoices then owed to Mr. Samuelson according to his current consulting agreement, with such number of
RSUs to be calculated at our IPO per share purchase price. In addition, in the event of &ldquo;Change of Control,&rdquo; as such
term is defined in his employment agreement, Mr. Samuelson will be entitled to receive 250,000 RSUs, which number shall include all
RSUs Mr. Samuelson has received up until the date of the Change of Control, and which shall all vest immediately upon issuance. Mr.
Samuelson will also be entitled to receive an annual cash or stock bonus, as may be determined by the compensation committee of the
board of directors and will be entitled to standard benefits that may be offered by the Company from time to time, including 30
days&rsquo; paid vacation and six months&rsquo; severance in the event his employment is terminated without cause.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Employment
Agreement with Neil Bhowmick, MD</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 27, 2023, we entered into an employment agreement with our Chief Scientific Officer, Neil Bhowmick, M.D., which employment
agreement will become effective upon the consummation of our IPO. Under Dr. Bhowmick&rsquo;s employment agreement,
Dr. Bhowmick will receive a base salary equal to $100,000 per year, payable in monthly installments, and 14,000 RSUs, which RSUs will
vest annually over a period of three years. In addition, Dr. Bhowmick will be entitled to receive an annual cash or stock bonus, as may
be determined by the board of directors or a committee thereof. Dr. Bhowmick will also be entitled to standard benefits that may be offered
by the Company from time to time, including 30 days&rsquo; paid vacation and six months&rsquo; severance in the event his employment
is terminated without &ldquo;Good Cause&rdquo; in accordance with the terms of his employment agreement. Prior to completion of our IPO,
Dr. Bhowmick received no salary from the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Employment
Agreement with Ramachandran Murali, MD</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 27, 2023, we entered into an employment agreement with our Vice President of Research and Development, Ramachandran
Murali, MD, which will become effective upon consummation of our IPO. Under Dr. Murali&rsquo;s employment agreement, Dr. Murali will receive base compensation of $80,000 per year and will receive
an initial grant of 14,0000 RSUs, which RSUs will vest annually in substantially equal installments over a period of three years. In
addition, Dr. Murali will be entitled to receive an annual cash or stock bonus, as may be determined by the board of directors or a committee
thereof. Dr. Murali will also be entitled to standard benefits that may be offered by the Company from time to time, including 30 days&rsquo;
paid vacation and six months&rsquo; severance in the event his employment is terminated without &ldquo;Good Cause&rdquo; in accordance
with the terms of his employment agreement. Prior to completion of our IPO, Dr. Murali received no salary from the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Equity-Based
Incentive Awards</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
equity-based incentive awards are designed to align our interests and those of our stockholders with those of our employees and consultants,
including our executive officers. Our board of directors or an authorized committee thereof is responsible for approving equity grants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
did not grant any equity awards to our named executive officers during the fiscal years ended December 31, 2023 and 2022.
Following the completion of this offering, we may grant additional equity awards to our executive officers pursuant to our 2023 Equity
Incentive Plan, the terms of which are described below under &ldquo;&mdash;Employee Benefit and Stock Plans&mdash;2023 Equity Incentive
Plan.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Outstanding
Equity Awards as of December 31, 2022 and 2021</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July 2023, we adopted our 2023 Equity Incentive Plan, which reserves 1,650,000 shares of common stock for issuance under the plan. As
we only recently adopted our 2023 Equity Incentive Plan, and as we are waiting to complete our initial public offering before we grant
any incentive awards, none of our named officers had been granted options, or received any other type of equity compensation, during
the fiscal years ended December 31, 2023 and 2022. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Emerging
Growth Company Status</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are an &ldquo;emerging growth company,&rdquo; as defined in the JOBS Act. As an emerging growth company we will be exempt from certain
requirements related to executive compensation, including the requirements to hold a nonbinding advisory vote on executive compensation
and to provide information relating to the ratio of total compensation of our chief executive officer to the median of the annual total
compensation of all of our employees, each as required by the Investor Protection and Securities Reform Act of 2010, which is part of
the Dodd-Frank Wall Street Reform and Consumer Protection Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 119; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->116<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Pension
Benefits </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
named executive officers did not participate in, or otherwise receive any benefits under, any pension or retirement plan sponsored by
us during the fiscal years ended December 31, 2023 and 2022. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Nonqualified
Deferred Compensation </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
named executive officers did not participate in, or earn any benefits under, a non-qualified deferred compensation plan sponsored by
us during the fiscal years ended December 31, 2023 and 2022. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Other
Compensation and Benefits </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
of our current named executive officers are eligible to participate in our employee benefit plans, including our medical, dental, and
vision plans, in each case on the same basis as all of our other employees. We pay the premiums for the medical, disability, and accidental
death and dismemberment insurance for all of our employees, including our named executive officers. We generally do not provide perquisites
or personal benefits to our named executive officers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Equity
Benefit Plans </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that our ability to grant equity-based awards is a valuable and necessary compensation tool that aligns the long-term financial
interests of our employees, consultants, and directors with the financial interests of our stockholders. In addition, we believe that
our ability to grant options and other equity-based awards helps us to attract, retain, and motivate employees, consultants, and directors,
and encourages them to devote their best efforts to our business and financial success. As a result, we adopted the 2023 Equity
Incentive Plan in July 2023 in advance of this offering. The 2023 Equity Incentive Plan includes the features
set forth below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>2023
</I></B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Equity Incentive Plan </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Tax
Limitations on Options. </I></B>Each option will be designated in an award agreement as either an Incentive Stock Option
(&ldquo;ISO&rdquo;) or a Nonstatutory Stock Option (&ldquo;NSO&rdquo;). However, notwithstanding such designation, to the extent that
the aggregate fair market value of the shares with respect to which ISOs are exercisable for the first time by the participant
during any calendar year exceeds $100,000, such options will be treated as NSOs. The fair market value of the shares will be
determined as of the time the option with respect to such shares is granted. The administrator will determine the term of each
option in its sole discretion; provided, however, that the term will be no more than ten (10) years from the date of grant in the
case of ISOs. Moreover, in the event an ISO is granted to a participant who, at the time of grant, owns stock representing more than
10% of the total combined voting power of all classes of stock of the Company, the term of the ISO will be five (5) years from the
date of grant or such shorter term as may be provided in the award agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Restricted
Stock Unit Awards</I>.</B> Restricted stock units (&ldquo;RSUs&rdquo;) may be granted at any time and from time to time as
determined by the administrator of the 2023 Equity Incentive Plan. Each RSU grant will be evidenced by an award agreement that will
specify such other terms and conditions as the administrator, in its sole discretion, will determine in accordance with the terms
and conditions of the 2023 Equity Incentive Plan. The administrator, in its discretion, may accelerate the time at which any
restrictions will lapse or be removed, subject to the prohibition on acceleration of the timing of distribution of deferred
compensation subject to Section 409A of the Code, to the extent applicable to the award. On the date set forth in the award
agreement, all unearned RSUs will be forfeited to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Restricted
Stock Awards</I>.</B> Each restricted stock award will be evidenced by an award agreement that will specify the period of restriction,
the number of shares granted, and such other terms and conditions as the administrator will determine. During the period of restriction,
service providers holding shares of restricted stocks granted hereunder may exercise full voting rights with respect to those shares,
unless the administrator determines otherwise in a manner not prohibited by the award agreement. During the period of restriction, service
providers holding shares of restricted stocks will be entitled to receive all dividends and other distributions paid with respect to
such shares unless otherwise provided in the award agreement. If any such dividends or distributions are paid in shares, the shares will
be subject to the same restrictions on transferability and provisions for forfeiture as the shares of restricted stocks with respect
to which they were paid. On the date set forth in the award agreement, the restricted stocks for which restrictions have not lapsed will
revert to the Company and again will become available for grant under the 2023 Equity Incentive Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Stock
Appreciation Rights</I>.</B> Stock appreciation rights will be granted in accordance with stock appreciation rights agreements,
in the form adopted by the administrator. The exercise price of stock appreciation rights will be not less than 100% of the fair
market value of a share on the date of grant. Each stock appreciation right grant will be evidenced by an award agreement that will
specify the exercise price, the number of shares with respect to which the award is granted, the term of the stock appreciation
right, the conditions of exercise, and such other terms and conditions as the administrator, in its sole discretion, will determine.
Stock appreciation right granted under the 2023 Equity Incentive Plan will expire upon the date determined by the administrator and
set forth in the award agreement; provided, however, that the term will be no more than ten (10) years from the date of grant
thereof. Upon exercise of a stock appreciation right, a participant will be entitled to receive payment from the Company in an
amount determined by multiplying: (i) the difference between the fair market value of a share on the date of exercise over the
&ldquo;stock appreciation right exercise price,&rdquo; as defined under Treasury Regulation Section 1.409A-1(b)(i)(B)(2), i.e., the
fair market value of a share on the date of grant of the stock appreciation right; times (ii) the number of shares with respect to
which the stock appreciation right is exercised. At the discretion of the administrator, the payment upon stock appreciation right
exercise may be in cash, in shares of equivalent value, or in some combination thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 120; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->117<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Performance
Awards</I>.</B> Performance units and performance shares may be granted to service providers at any time and from time to time, as
will be determined by the administrator, in its sole discretion. Each performance unit will have an initial value that is established
by the administrator on or before the date of grant. Each performance share will have an initial value equal to the fair market value
of a share on the date of grant. The administrator will set performance objectives or other vesting provisions. The administrator may
set vesting criteria based upon the achievement of Company-wide, business unit, or individual goals (including, but not limited to, continued
employment), or any other basis determined by the administrator in its discretion. Each award of performance units/shares will be evidenced
by an award agreement that will specify the performance period, and such other terms and conditions as the administrator, in its sole
discretion, will determine. After the applicable performance period has ended, the holder of performance units/shares will be entitled
to receive a payout of the number of performance units/shares earned by the participant over the performance period, to be determined
as a function of the extent to which the corresponding performance objectives or other vesting provisions have been achieved. Payment
of earned performance units/shares will be made as soon as practicable after the expiration of the applicable performance period or,
if earlier, after the date on which a participant&rsquo;s interest in such performance units/shares is no longer subject to a substantial
risk of forfeiture, provided however, that in no event shall such payment be made after the later to occur of (i) December 31 of the
year in which such risk of forfeiture lapses or (ii) two and one-half months after such risk of forfeiture lapses. The administrator,
in its sole discretion, may pay earned performance units/shares in the form of cash, in shares (which have an aggregate fair market value
equal to the value of the earned performance units/shares at the close of the applicable performance period) or in a combination thereof.
On the date set forth in the award agreement, all unearned or unvested performance units/shares will be forfeited to the Company, and
again will be available for grant under the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Other
Stock Awards</I>.</B> The administrator may grant other awards based in whole or in part by reference to our common stock. The administrator
will set the number of shares under the stock award (or cash equivalent) and all other terms and conditions of such awards.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Adjustments</I>.
</B>In the event that any dividend or other distribution (whether in the form of cash, shares, other securities, or other property),
recapitalization, stock split, reverse stock split, reorganization, merger, consolidation, split-up, spin-off, combination, repurchase,
or exchange of shares or other securities of the Company, or other change in the corporate structure of the Company affecting the shares
occurs, the administrator, in order to prevent diminution or enlargement of the benefits or potential benefits intended to be made available
under the 2023 Equity Incentive Plan, will adjust the number and class of shares that may be delivered under the 2023 Equity Incentive Plan and/or the number, class, and
price of shares covered by each outstanding award, and the numerical share limits set forth thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Dissolution
or Liquidation.</I></B> In the event of the proposed dissolution or liquidation of the Company, any corporate separation or division,
including, but not limited to, a split-up, a split-off or a spin-off; a reverse merger in which the Company is the surviving entity,
but the shares of Company stock outstanding immediately preceding the merger are converted by virtue of the merger into other property,
whether in the form of securities, cash or otherwise; or the transfer of more than fifty percent (50%) of the then outstanding voting
stock of the Company to another person or entity, the administrator will notify each participant as soon as practicable prior to the
effective date of such proposed transaction. The Company, to the extent permitted by applicable law but otherwise in its sole discretion
may provide for: (i) the continuation awards by the Company (if the Company is surviving entity or its parent; (ii) the assumption of
the 2023 Equity Incentive Plan and such outstanding awards by the surviving entity or its parent; (iii) the substitution by the surviving entity or its
parent of rights with substantially the same terms for such outstanding awards; or (iv) the cancellation of such outstanding rights without
payment of any consideration provided that in the case of this clause (iv), the administrator will provide notice of its intention to
cancel award and offer a reasonable opportunity to exercise vested awards.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Change
in Control</I>.</B> In the event of a merger or change in control, as defined in the 2023 Equity Incentive Plan, each outstanding award will be treated
as the administrator determines, including, without limitation, that each award will be assumed or an equivalent option or right substituted
by the successor corporation or a parent or subsidiary of the successor corporation. The administrator will not be required to treat
all awards similarly in the transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Plan
Amendment or Termination</I>.</B> The administrator may at any time amend, alter, suspend, or terminate the 2023 Equity Incentive Plan. The Company
will obtain stockholder approval to any amendment to the 2023 Equity Incentive Plan to the extent necessary or desirable to comply with applicable rules
and regulations. No amendment, alteration, suspension, or termination of the 2023 Equity Incentive Plan will impair the rights of any participant, unless
mutually agreed otherwise between the participant and the administrator, which agreement must be in writing and signed by the participant
and the Company. Termination of the 2023 Equity Incentive Plan will not affect the administrator&rsquo;s ability to exercise the powers granted to it
thereunder with respect to awards granted under the 2023 Equity Incentive Plan prior to the date of such termination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 121; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->118<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="ak_011"></A>CERTAIN
RELATIONSHIPS AND RELATED PERSON TRANSACTIONS </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following includes a summary of transactions since January 1, 2021 to which we have been a party in which the amount involved exceeded
or will exceed the lesser of $120,000 as of December 31, 2023, and in which any of our directors, executive officers or, to our
knowledge, beneficial owners of more than 5% of our capital stock or any member of the immediate family of any of the foregoing persons
had or will have a direct or indirect material interest, other than equity and other compensation, termination, change in control and
other arrangements, which are described under &ldquo;Executive Compensation.&rdquo; We also describe below certain other transactions
with our directors, executive officers and stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <B>Loans and <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advances
from Related Parties</FONT></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: #1D2228"> <FONT>On
April 26, 2024, the Company borrowed $0.07 million from three of its officers. The loans accrue interest at 7.5% per annum, are unsecured,
and are due in April 2025. </FONT> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2021, shareholders of the Company, and a company whose principal stockholder is also a stockholder of the
Company, advanced the Company $0.01 million, which was all outstanding at December 31, 2021. The advances accrue no interest, are unsecured
and are due on demand. As of December 31, 2021, $0.01 million was owed on the advances. During the year ended December 31, 2022, the
Company repaid $0.01 million of the advances, and as of December 31, 2022 and September 30, 2023, a total of $0.004 was outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Policies
and Procedures for Transactions with Related Persons </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to effectiveness of this offering, we intend to adopt a written policy that our executive officers, directors, nominees for election
as a director, beneficial owners of more than 5% of any class of our common stock, and any members of the immediate family of any of
the foregoing persons are not permitted to enter into a related person transaction with us without the approval or ratification of our
board of directors or our audit committee. Any request for us to enter into a transaction with an executive officer, director, nominee
for election as a director, beneficial owner of more than 5% of any class of our common stock, or any member of the immediate family
of any of the foregoing persons, in which the amount involved exceeds $120,000 (or, if less, 1% of the average of our total assets in
a fiscal year) and such person would have a direct or indirect interest, must be presented to our board of directors or our audit committee
for review, consideration and approval. In approving or rejecting any such proposal, our board of directors or our audit committee is
to consider the material facts of the transaction, including whether the transaction is on terms no less favorable than terms generally
available to an unaffiliated third party under the same or similar circumstances and the extent of the related person&rsquo;s interest
in the transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 122; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->119<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="ak_012"></A>PRINCIPAL
STOCKHOLDERS </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth information regarding beneficial ownership of our capital stock as of the date of this prospectus by:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">each
                                            person, or group of affiliated persons, known by us to beneficially own more than 5% of our
                                            common stock;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">each
                                            of our directors and named executive officers; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">all
                                            of our current executive officers and directors as a group.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have determined beneficial ownership in accordance with the rules and regulations of the SEC, and the information is not necessarily
indicative of beneficial ownership for any other purpose. Except as indicated by the footnotes below, we believe, based on information
furnished to us, that the persons and entities named in the table below have sole voting and sole investment power with respect to all
shares that they beneficially own, subject to applicable community property laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Applicable
percentage ownership before the offering is based on 10,562,640 shares of our common stock outstanding as of April 30,
2024.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Applicable
percentage ownership after the offering is based on shares of common stock outstanding immediately after the closing of this offering,
after giving effect to the issuance of 334,375 shares of common stock upon conversion of convertible notes, conversion
of amounts due to related parties into 1,664 shares of common stock and 312,500 shares of common stock upon conversion of certain
accounts payable, in connection with the closing of this offering. In computing the number of shares beneficially owned by a person and
the percentage ownership of such person, we deemed to be outstanding all shares subject to options held by the person that are currently
exercisable, or exercisable within 60 days of the date of this prospectus. However, except as described above, we did not deem such shares
outstanding for the purpose of computing the percentage ownership of any other person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
otherwise indicated, the address for each beneficial owner listed in the table below is 2355 Westwood Blvd. #139, Los Angeles,
California 90064.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number
                                                                      of Shares</B></FONT></P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center">Percentage of Shares<BR>
 Beneficially Owned</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">Name of Beneficial Owner</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><B></B> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Beneficially<BR>

                                            Owned (#)</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Before<BR>
 Offering (%)</B> &nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>After
                                            <BR>
                                            Offering (%)* </B></FONT></P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 50%; text-align: left">Greater than 5% Holders:</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Technomedics Management and Systems, Inc.<SUP>(1)</SUP></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,173,572</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 11.1 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 9.2 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Belmet Therapeutics, LLC<SUP>(2)</SUP></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">997,750</P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"> 9.4 </P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 7.8 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Directors and Named Executive Officers:</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">John S. Yu, M.D.</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">5,316,572</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 50.3 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 41.7 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Ramachandran Murali, Ph.D.</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">132,857</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1.3</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1.1</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Neil Bhowmick, Ph.D.</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,116,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 10.6 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 8.7 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Douglas Samuelson</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Hyun W. Bae, M.D</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">44,286</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> *<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> ** </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Rosemary Mazanet, M.D.</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Hansoo Michael Keyoung, M.D.</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">All directors and executive officers as a group (7
    persons)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">6,609,715</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 62.6 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 51.8 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> *Calculated assuming
12,761,179 shares outstanding after the offering, assuming 1,550,000 shares sold in the offering not including the underwriters&rsquo;
overallotment option. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> ** Represents beneficial
ownership of less than 1%.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
Manfred Mosk exercises voting and investment power of all shares held by Technomedics Management and Systems, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(2) Judith Buchmiller is the beneficial owner
of, and exercises voting control and investment power over, all shares held in the name of Belmet Therapeutics, LLC.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 123; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->120<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="ak_013"></A>DESCRIPTION
OF CAPITAL STOCK </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>General
</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following description of our capital stock and certain provisions of our certificate of incorporation and bylaws are summaries and are
qualified by reference to the certificate of incorporation and the bylaws. Copies of these documents have been filed with the SEC as
exhibits to our registration statement, of which this prospectus forms a part.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">authorized capital stock consists of 100,000,000
shares of common stock, par value $0.001 per share and 20,000,000 shares of preferred stock, par value $0.001 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this prospectus, prior to giving effect to the issuance of 1,550,000 shares of common stock being sold in this offering
and 334,375 shares of common stock issuable upon conversion of convertible notes and 312,500 shares of common stock issuable upon
conversion of certain accounts payable upon effectiveness of this offering, there were 10,562,640 shares of common stock outstanding
and held of record by 27 stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common
Stock </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Voting
Rights </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Each
holder of common stock is entitled to one vote for each share owned on all matters voted upon by shareholders, and a majority vote is
required for all actions to be taken by shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Economic
Rights </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as otherwise expressly provided in our certificate of incorporation or required by applicable law, all shares of
our common stock will have the same rights and privileges and rank equally, share ratably and be identical in all respects for all matters,
including those described below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Dividends</I>.
</B>Subject to preferences that may apply to any shares of preferred stock outstanding at the time, the holders of our common stock are
entitled to receive dividends out of funds legally available if our board of directors, in its discretion, determines to issue dividends
and then only at the times and in the amounts that our board of directors may determine. See the section titled &ldquo;Dividend Policy&rdquo;
for further information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Liquidation
Rights</I>.</B> On our liquidation, dissolution, or winding-up, the holders of our stock will be entitled to share equally, identically,
and ratably in all assets remaining after the payment of any liabilities, liquidation preferences, and accrued or declared but unpaid
dividends, if any, with respect to any outstanding preferred stock, unless a different treatment is approved by the affirmative vote
of the holders of a majority of the outstanding shares of such affected class, voting separately as a class.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>No
Preemptive or Similar Rights </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
holders of shares of our common stock are not entitled to preemptive rights, and are not subject to conversion, redemption, or sinking
fund provisions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Fully
Paid and Non-Assessable </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with this offering, our legal counsel will opine that the shares of our common stock to be issued under this offering will
be fully paid and non-assessable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 124; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->121<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Preferred
Stock </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
our certificate of incorporation, our board of directors will have the authority, without further action by the stockholders,
to issue up to 20,000,000 shares of preferred stock, par value $0.001 per share, in one or more series, to establish from
time to time the number of shares to be included in each such series, to fix the rights, preferences and privileges of the shares of
each wholly unissued series and any qualifications, limitations or restrictions thereon and to increase or decrease the number of shares
of any such series, but not below the number of shares of such series then outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors may authorize the issuance of preferred stock with voting or conversion rights that could adversely affect the voting
power or other rights of the holders of the common stock. The issuance of preferred stock, while providing flexibility in connection
with possible acquisitions and other corporate purposes, could, among other things, have the effect of delaying, deferring or preventing
a change in our control that may otherwise benefit holders of our common stock and may adversely affect the market price of the common
stock and the voting and other rights of the holders of our common stock. We have no current plans to issue any shares of preferred stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Registration
Rights </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the closing of this offering and subject to the lock-up agreements entered into in connection with this offering and federal securities
laws, certain holders of shares of our common stock, including those shares of our common stock that will be issued upon the conversion
of convertible notes in connection with this offering, will initially be entitled to certain rights with respect to registration
of such shares under the Securities Act. These shares are referred to as registrable securities. The holders of these registrable securities
possess registration rights pursuant to the terms of our investors&rsquo; rights and lock-up agreement and
are described in additional detail below. The registration of shares of our common stock pursuant to the exercise of the registration
rights described below would enable the holders to trade these shares without restriction under the Securities Act when the applicable
registration statement is declared effective. We will pay the registration expenses, other than underwriting discounts, selling commissions
and stock transfer taxes, of the shares registered pursuant to the demand, piggyback, and Form S-3 registrations described below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Generally,
in an underwritten offering, the managing underwriter, if any, has the right, subject to specified conditions and limitations, to limit
the number of shares the holders may include. The demand, piggyback and Form S-3 registration rights described below will expire no
later than three years after the closing of this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Demand
Registration Rights </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the closing of this offering, holders of an aggregate of 281,250 shares of our common stock, following conversion of convertible
notes, will be entitled to certain demand registration rights. At any time beginning 180 days after the closing of this offering,
the holders of a majority of these shares may request that we register all or a portion of their shares. We are not required to
effect more than registration statements which are declared or ordered effective. Such request for registration must cover shares with
an anticipated aggregate offering price of at least $5 million. With certain exceptions, we are not required to effect the filing of
a registration statement during the period starting with the date of the filing of, and ending on a date 180 days following the effective
date of the registration statement for this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Piggyback
Registration Rights </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with this offering, the holders of an aggregate of 431,250 shares of our common stock, consisting of 281,250 shares
of common stock issuable upon conversion of convertible notes and exercise of warrants to purchase 150,000 shares of common stock, will
be entitled to piggy back registration rights, and the necessary percentage of holders waived, their rights to notice of this
offering and to include their shares of registrable securities in this offering. After this offering, in the event that we propose to
register any of our securities under the Securities Act, either for our own account or for the account of other security holders, the
holders of these shares will be entitled to certain piggyback registration rights allowing the holder to include their shares in such
registration, subject to certain marketing and other limitations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 125; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->122<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Anti-Takeover
Provisions </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The provisions of Delaware law, our certificate of incorporation, and our
bylaws, which are summarized below, may have the effect of delaying, deferring, or discouraging another person from acquiring control
of our company. They are also designed, in part, to encourage persons seeking to acquire control of us to negotiate first with our board
of directors. We believe that the benefits of increased protection of our potential ability to negotiate with an unfriendly or unsolicited
acquirer outweigh the disadvantages of discouraging a proposal to acquire us because negotiation of these proposals could result in an
improvement of their terms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Certificate
of Incorporation and Bylaws</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
our stockholders do not have cumulative voting rights, stockholders holding
a majority of the voting power of our shares of common stock will be able to elect all of our directors. Our certificate of incorporation
and our bylaws provide for stockholder actions at a duly called meeting of stockholders or by written consent, subject to relevant proxy
rules. A special meeting of stockholders may be called by a majority of our board of directors, the chair of our board of directors, or
our chief executive officer or president. Our bylaws establish an advance notice procedure for stockholder proposals to be brought before
an annual meeting of our stockholders, including proposed nominations of persons for election to our board of directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">authorization of undesignated preferred stock makes
it possible for our board of directors to issue preferred stock with voting or other rights or preferences that could impede the success
of any attempt to change our control.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
provisions are designed to reduce our vulnerability to an unsolicited acquisition proposal and to discourage certain tactics that may
be used in proxy fights. However, such provisions could have the effect of discouraging others from making tender offers for our shares
and may have the effect of deterring hostile takeovers or delaying changes in our control or management. As a consequence, these provisions
may also inhibit fluctuations in the market price of our stock that could result from actual or rumored takeover attempts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Section
203 of the Delaware General Corporation Law </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
we have a class of voting stock that is either listed on a national securities exchange or held of record by more than 2,000 stockholders,
we will be subject to Section 203 of the DGCL which prohibits a Delaware corporation from engaging in any business combination with any
interested stockholder for a period of three years after the date that such stockholder became an interested stockholder, subject to
certain exceptions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Choice
of Forum </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
certificate of incorporation provides that unless we consent in writing to the selection of an alternative forum, and except for
any actions brought under the Securities Act or the Exchange Act (which actions are specifically excluded from the exclusive jurisdiction clause in our certificate of incorporation), the Court of Chancery of the State of Delaware is the sole
and exclusive forum for the following claims or causes of action under the Delaware statutory or common law: (i) any derivative
claim or cause of action brought on our behalf; (ii) any claim or cause of action for a breach of fiduciary duty owed by any of our
current or former directors, officers, other employees to us or our stockholders; (iii) any action asserting a claim against us
arising pursuant to any provision of the DGCL or our certificate of incorporation or bylaws; (iv) any claim or cause of action
seeking to interpret, apply, enforce or determine the validity of our certificate of incorporation or our bylaws (as each may be
amended from time to time, including any right, obligation, or remedy thereunder); and (v) any action asserting a claim against us
governed by the internal affairs doctrine.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note
that Section 27 of the Exchange Act creates exclusive federal jurisdiction over all claims brought to enforce any duty or liability created
by the Exchange Act or the rules and regulations thereunder. Consequently, this forum selection provision would not apply to suits brought
to enforce a duty or liability created by the Exchange Act or any other claim for which the U.S. federal courts have exclusive jurisdiction.
Moreover, Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all claims brought to enforce
any duty or liability created by the Securities Act or the rules and regulations thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the avoidance of doubt, these provisions are intended to benefit and may be enforced by us, our officers and directors, the underwriters
to any offering giving rise to such complaint, and any other professional entity whose profession gives authority to a statement made
by that person or entity and who has prepared or certified any part of the documents underlying the offering. While the Delaware courts
have determined that such choice of forum provisions are facially valid, a stockholder may nevertheless seek to bring a claim in a venue
other than those designated in the exclusive forum provisions, and there can be no assurance that such provisions will be enforced by
a court in those other jurisdictions. We note that investors cannot waive compliance with the federal securities laws and the rules and
regulations thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
our certificate of incorporation provides that any person or entity holding, owning or otherwise acquiring any interest in any
of our securities shall be deemed to have notice of and consented to these provisions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 126; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->123<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Limitations
on Liability and Indemnification </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
DGCL authorizes corporations to limit or eliminate the personal liability of directors of corporations and their stockholders for monetary
damages for breaches of directors&rsquo; fiduciary duties, subject to certain exceptions. The Company&rsquo;s certificate of incorporation
includes a provision that eliminates the personal liability of directors for damages for any breach of fiduciary duty as a director where,
in civil proceedings, the person acted in good faith and in a manner that person reasonably believed to be in or not opposed to the best
interests of the Company or, in criminal proceedings, where the person had no reasonable cause to believe that his or her conduct was
unlawful.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s bylaws provide that the Company must indemnify and advance expenses to its directors and officers to the fullest extent
authorized by the DGCL. The Company also is expressly authorized to carry directors&rsquo; and officers&rsquo; liability insurance providing
indemnification for its directors, officers, and certain employees for some liabilities. The Company believes that these indemnification
and advancement provisions and insurance are useful to attract and retain qualified directors and executive officers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
limitation of liability, advancement and indemnification provisions in the certificate of incorporation and bylaws may discourage stockholders
from bringing lawsuit against directors for breach of their fiduciary duty. These provisions also may have the effect of reducing the
likelihood of derivative litigation against directors and officers, even though such an action, if successful, might otherwise benefit
the Company and its stockholders. In addition, your investment may be adversely affected to the extent the Company pays the costs of
settlement and damage awards against directors and officer pursuant to these indemnification provisions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is currently no pending material litigation or proceeding involving any of the Company&rsquo;s directors, officers, or employees for
which indemnification is sought.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Corporate
Opportunities</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
certificate of incorporation provides for the renouncement by the Company of any interest or expectancy of the Company in, or being offered
an opportunity to participate in any matter, transaction, or interest that is presented to, or acquired, created, or developed by, or
which otherwise comes into possession of, any director of the Company who is not an employee or officer of the Company or any of its
subsidiaries, unless such matter, transaction, or interest is presenting to, or acquired, created, or developed by, or otherwise comes
into the possession of a director of the Company expressly and solely in that director&rsquo;s capacity as a director of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Dissenters&rsquo;
Rights of Appraisal and Payment</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the DGCL, with certain exceptions, the Company&rsquo;s stockholders will have appraisal rights in connection with a merger or consolidation
of the Company. Pursuant to the DGCL, stockholders who properly request and perfect appraisal rights in connection with such merger or
consolidation will have the right to receive payment of the fair value of their shares as determined by the Delaware Court of Chancery.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Stockholders&rsquo;
Derivative Actions</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the DGCL, any of the Company&rsquo;s stockholders may bring an action in the Company&rsquo;s name to procure a judgment in the Company&rsquo;s
favor, also known as a derivative action, provided that the stockholder bringing the action is a holder of the Company&rsquo;s shares
at the time of the transaction to which the action relates or such stockholder&rsquo;s stock thereafter devolved by operation of law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exchange
Listing </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock is not currently listed on any securities exchange. We are seeking to have our common stock listed for trading on the NYSE
American LLC, or NYSE American, under the symbol &ldquo;KAPA.&rdquo; The closing of this offering is contingent on obtaining approval
of our listing application from the NYSE American and there is no assurance that our common stock will be approved for listing
on such exchange.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Transfer
Agent and Registrar </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
transfer agent for our capital stock is VStock Transfer LLC, located in Woodmere, NY. The phone number of our transfer
agent is (212) 828-8436. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 127; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->124<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><A NAME="ak_014"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SHARES
ELIGIBLE FOR FUTURE SALE </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
the closing of this offering, there was no public market for our common stock. Future sales of substantial amounts of our
common stock, including shares issued on the exercise of outstanding options, in the public market after this offering, or the possibility
of these sales or issuances occurring, could adversely affect the prevailing market price for our common stock or impair our ability
to raise equity capital.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on 10,562,640 shares outstanding as of April 30, 2024, upon the closing of this offering, a total of 12,761,179
shares of common stock will be outstanding (and 12,993,679 shares of common stock outstanding if the underwriters exercise their
overallotment option), assuming the automatic conversion upon the closing of this offering of all convertible notes outstanding into
334,375 shares of our common stock, conversion of amounts due to related parties into 1,664 shares of common stock, and
conversion of $750,000 in accounts payable into 312,500 shares of common stock. Of these shares, all of the common stock sold in this
offering by us, plus any shares sold by us on exercise of the underwriters&rsquo; option to purchase additional common stock, will be
freely tradable in the public market without restriction or further registration under the Securities Act, unless these shares are held
by &ldquo;affiliates,&rdquo; as that term is defined in Rule 144 under the Securities Act, or Rule 144.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
remaining shares of common stock, as well as, upon issuance, the shares of common stock subject to stock options, will be &ldquo;restricted
securities,&rdquo; as that term is defined in Rule 144. These restricted securities are eligible for public sale only if they are registered
under the Securities Act or if they qualify for an exemption from registration under Rules 144 or 701 under the Securities Act, which
are summarized below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to the lock-up agreements described below and the provisions of Rule 144 or Rule 701 under the Securities Act, as well as our insider
trading policy, these restricted securities will be available for sale in the public market after the date of this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Rule
144 </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
general, under Rule 144 as currently in effect, once we have been subject to public company reporting requirements of Section 13 or Section
15(d) of the Exchange Act for at least 90 days, an eligible stockholder is entitled to sell such shares without complying with the manner
of sale, volume limitation, or notice provisions of Rule 144, subject to compliance with the public information requirements of Rule
144. To be an eligible stockholder under Rule 144, such stockholder must not be deemed to have been one of our affiliates for purposes
of the Securities Act at any time during the 90 days preceding a sale and must have beneficially owned the shares proposed to be sold
for at least six months, including the holding period of any prior owner other than our affiliates. If such a person has beneficially
owned the shares proposed to be sold for at least one year, including the holding period of any prior owner other than our affiliates,
then such person is entitled to sell such shares without complying with any of the requirements of Rule 144, subject to the expiration
of the lock-up agreements described below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 128; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->125<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
general, under Rule 144, as currently in effect, our affiliates, or persons selling shares on behalf of our affiliates are entitled to
sell shares on expiration of the lock-up agreements described below. Beginning 90 days after the date of this prospectus, within any
three-month period, such stockholders may sell a number of shares that does not exceed the greater of:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1%
                                            of the number of shares of common stock then outstanding, which will equal approximately
                                            shares immediately after this offering, assuming no exercise of the underwriters&#8217; option
                                            to purchase additional shares of common stock from us; or</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                                                                                                                                                                                                                          average weekly trading volume of our common stock on NYSE American during the four calendar weeks preceding the filing of a notice
                                                                                                                                                                                                                                          on Form 144 with respect to such sale.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
under Rule 144 by our affiliates or persons selling shares on behalf of our affiliates are also subject to certain manner of sale provisions
and notice requirements and to the availability of current public information about us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Rule
701 </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rule
701 of the Securities Act (Rule 701) generally allows a stockholder who was issued shares under a written compensatory plan or contract
and who is not deemed to have been an affiliate of our company during the immediately preceding 90 days, to sell these shares in reliance
on Rule 144, but without being required to comply with the public information, holding period, volume limitation, or notice provisions
of Rule 144. Rule 701 also permits affiliates of our company to sell their Rule 701 shares under Rule 144 without complying with the
holding period requirements of Rule 144. All holders of Rule 701 shares, however, are required by that rule to wait until 90 days after
the date of this prospectus before selling those shares under Rule 701, subject to the expiration of the lock-up agreements described
below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Form
S-8 Registration Statements </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
the effectiveness of this registration statement, we</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
intend to file with the SEC a registration statement on Form S-8 under the Securities Act to register the offer and sale of shares
of our common stock that are issuable under our equity incentive plan. This registration statement will become effective immediately
upon filing. Shares covered by the registration statement on Form S-8 will then be eligible for sale in the public markets,
subject to vesting restrictions, any applicable lock-up agreements described below, and Rule 144 limitations applicable to affiliates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Lock-up
Arrangements </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We,
and all of our directors, executive officers, and the holders of substantially all of our common stock and securities exercisable for
or convertible into our common stock outstanding immediately on the closing of this offering, have agreed with the underwriters that,
until 360 days for officers and directors and 180 days for all other holders after the date of the underwriting agreement
related to this offering, we and they will not (and will not cause or direct any affiliate to), without the prior written consent of
the representatives of the underwriters, subject to certain exceptions, directly or indirectly, offer, pledge, sell, contract to sell,
assign, transfer, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right, or warrant
to purchase, lend or otherwise transfer or dispose of, or announce the intention to otherwise dispose of, any of our shares of common
stock, or any securities convertible into or exercisable or exchangeable for shares of our common stock, or enter into, or announce the
intention to enter into, any hedging, swap, or similar agreement or arrangement that transfers, is designed to transfer or reasonably
could be expected to transfer, in whole or in part, directly or indirectly, the economic consequence of ownership of the securities,
whether any such swap or transaction is to be settled by delivery of our common stock or other securities, in cash or otherwise. These
agreements are described in the section entitled &ldquo;Underwriting.&rdquo; The representatives of the underwriters, however, may,
in their sole discretion, release any of the securities subject to these lock-up agreements at any time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the restrictions contained in the lock-up agreements described above, we have entered into agreements with certain security
holders, including the amended and restated investors&rsquo; rights agreement, our standard form of option agreement and our standard
form of restricted stock agreement, that contain market stand-off provisions or incorporate market stand-off provisions from our equity
incentive plan imposing restrictions on the ability of such security holders to offer, sell, or transfer our equity securities for a
period of 180 days following the date of this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Registration
Rights </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the closing of this offering, subject to the lock-up provisions set forth above and pursuant to our amended and restated investors&rsquo; rights agreement, the holders of shares
of our common stock, or their transferees, will be entitled to certain rights with respect to the registration of the offer and sale
of their shares under the Securities Act, subject to the terms of the lock-up agreements described under the section titled &ldquo;&mdash;Lock-up
Arrangements&rdquo; above. Registration of these shares under the Securities Act would result in the shares becoming freely tradable
without restriction under the Securities Act immediately on the effectiveness of the registration. Any sales of securities by these stockholders
could have a material adverse effect on the trading price of our common stock. See the section titled &ldquo;Description of Capital Stock&mdash;Registration
Rights&rdquo; for additional information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 129; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->126<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="ak_015"></A>CERTAIN
MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO NON-U.S. HOLDERS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of certain material U.S. federal income tax consequences to non-U.S. holders (as defined below) of the purchase,
ownership and disposition of our common stock issued pursuant to this offering. This discussion is not a complete analysis of all potential
U.S. federal income tax consequences relating thereto, does not address the potential application of the Medicare contribution tax on
net investment income, and does not address any estate or gift tax consequences or any tax consequences arising under any state, local,
or foreign tax laws, or any other U.S. federal tax laws. This discussion is based on the Code, Treasury Regulations promulgated thereunder,
judicial decisions and published rulings and administrative pronouncements of the IRS, all as in effect on the date of this prospectus.
These authorities are subject to differing interpretations and may change, possibly retroactively, resulting in U.S. federal income tax
consequences different from those discussed below. We have not requested a ruling from the IRS with respect to the statements made and
the conclusions reached in the following summary, and there can be no assurance that the IRS or a court will agree with such statements
and conclusions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
discussion is limited to non-U.S. holders who purchase our common stock pursuant to this offering and who hold our common stock as a
&ldquo;capital asset&rdquo; within the meaning of Section 1221 of the Code (generally, property held for investment). This discussion
does not address all of the U.S. federal income tax consequences that may be relevant to a non-U.S. holder in light of such non-U.S.
holder&rsquo;s particular circumstances. This discussion also does not consider any specific facts or circumstances that may be relevant
to non-U.S. holders subject to special rules under the U.S. federal income tax laws, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">certain
                                            former citizens or long-term residents of the United States;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">partnerships
                                            or other pass-through entities (and investors therein);</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;controlled
                                            foreign corporations;&#8221;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;passive
                                            foreign investment companies;&#8221;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">corporations
                                            that accumulate earnings to avoid U.S. federal income tax;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">banks,
                                            financial institutions, investment funds, insurance companies, brokers, dealers, or traders
                                            in securities;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">tax-exempt
                                            organizations and governmental organizations;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">tax-qualified
                                            retirement plans;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">persons
                                            who acquire our common stock through the exercise of an option or otherwise as compensation;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">qualified
                                            foreign pension funds as defined in Section 897(l)(2) of the Code and entities all of the
                                            interests of which are held by qualified foreign pension funds;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">persons
                                            subject to the alternative minimum tax;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">persons
                                            subject to special tax accounting rules under Section 451(b) of the Code;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">persons
                                            that own or have owned, actually or constructively, more than 5% of our common stock;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">persons who have elected to mark securities to market; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">persons
                                            holding our common stock as part of a hedging or conversion transaction or straddle, or a
                                            constructive sale, or other risk reduction strategy or integrated investment.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an entity or arrangement that is classified as a partnership for U.S. federal income tax purposes holds our common stock, the U.S. federal
income tax treatment of a partner in the partnership will generally depend on the status of the partner, the activities of the partnership
and certain determinations made at the partner level. Partnerships holding our common stock and the partners in such partnerships are
urged to consult their tax advisors about the particular U.S. federal income tax consequences to them of holding and disposing of our
common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>THIS
DISCUSSION IS NOT TAX ADVICE. PROSPECTIVE INVESTORS SHOULD CONSULT THEIR TAX ADVISORS REGARDING THE PARTICULAR U.S. FEDERAL INCOME TAX
CONSEQUENCES TO THEM OF ACQUIRING, OWNING, AND DISPOSING OF OUR COMMON STOCK, AS WELL AS ANY TAX CONSEQUENCES ARISING UNDER ANY
STATE, LOCAL OR FOREIGN TAX LAWS AND ANY OTHER U.S. FEDERAL TAX LAWS. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Definition
of Non-U.S. Holder </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
purposes of this discussion, a non-U.S. holder is any beneficial owner of our common stock that is not a &ldquo;U.S. person&rdquo; or
a partnership (including any entity or arrangement treated as a partnership) for U.S. federal income tax purposes. A U.S. person is any
person that, for U.S. federal income tax purposes, is or is treated as any of the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
                                            individual who is a citizen or resident of the United States;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 130; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->127<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
                                            corporation created or organized under the laws of the United States, any state thereof or
                                            the District of Columbia;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
                                            estate, the income of which is subject to U.S. federal income tax regardless of its source;
                                            or</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
                                            trust (i) whose administration is subject to the primary supervision of a U.S. court and
                                            which has one or more U.S. persons who have the authority to control all substantial decisions
                                            of the trust, or (ii) that has a valid election in effect under applicable Treasury Regulations
                                            to be treated as a U.S. person.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Distributions
on Our Common Stock </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
described in the section titled &ldquo;Dividend Policy,&rdquo; we do not anticipate declaring or paying, in the foreseeable future, any
cash dividends on our capital stock. However, if we distribute cash or other property on our common stock, such distributions will constitute
dividends for U.S. federal income tax purposes to the extent paid from our current or accumulated earnings and profits, as determined
under U.S. federal income tax principles. Amounts not treated as dividends for U.S. federal income tax purposes will constitute a return
of capital and will first be applied against and reduce a holder&rsquo;s tax basis in our common stock, but not below zero. Any excess
will be treated as gain realized on the sale or other disposition of our common stock and will be treated as described under &ldquo;&ndash;Gain
on Disposition of Our Common Stock&rdquo; below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to the discussion below regarding effectively connected income, backup withholding and FATCA (as defined below), dividends paid to a
non-U.S. holder of our common stock generally will be subject to U.S. federal withholding tax at a rate of 30% of the gross amount of
the dividends or such lower rate specified by an applicable income tax treaty. To receive the benefit of a reduced treaty rate, a non-U.S.
holder must furnish us or our withholding agent with a valid IRS Form W-8BEN (in the case of individuals) or IRS Form W-8BEN-E (in the
case of entities), or other appropriate form, certifying such holder&rsquo;s qualification for the reduced rate. This certification must
be provided to us or our withholding agent before the payment of dividends and must be updated periodically. In the case of a non-U.S.
holder that is an entity, Treasury Regulations and the relevant tax treaty provide rules to determine whether, for purposes of determining
the applicability of the tax treaty, dividends will be treated as paid to the entity or to those holding an interest in the entity. If
the non-U.S. holder holds our common stock through a financial institution or other agent acting on the non-U.S. holder&rsquo;s behalf,
the non-U.S. holder will be required to provide appropriate documentation to the agent, which then will be required to provide certification
to us or our withholding agent, either directly or through other intermediaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a non-U.S. holder holds our common stock in connection with the conduct of a trade or business in the United States, and dividends paid
on our common stock are effectively connected with such holder&rsquo;s U.S. trade or business (and are attributable to such holder&rsquo;s
permanent establishment or fixed base in the United States if required by an applicable tax treaty), the non-U.S. holder will be exempt
from U.S. federal withholding tax. To claim the exemption, the non-U.S. holder must generally furnish a valid IRS Form W-8ECI (or applicable
successor form) to the applicable withholding agent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">However,
any such effectively connected dividends paid on our common stock generally will be subject to U.S. federal income tax on a net income
basis at the regular U.S. federal income tax rates in the same manner as if such holder were a resident of the United States. A non-U.S.
holder that is a foreign corporation also may be subject to an additional branch profits tax equal to 30% (or such lower rate specified
by an applicable income tax treaty) of its effectively connected earnings and profits for the taxable year, as adjusted for certain items.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-U.S.
holders that do not provide the required certification on a timely basis, but that qualify for a reduced treaty rate, may obtain a refund
of any excess amounts withheld by timely filing an appropriate claim for refund with the IRS. Non-U.S. holders should consult their tax
advisors regarding any applicable income tax treaties that may provide for different rules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Gain
on Disposition of Our Common Stock </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to the discussion below regarding backup withholding and FATCA (as defined below), a non-U.S. holder generally will not be subject to
U.S. federal income tax on any gain realized on the sale or other disposition of our common stock, unless:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            gain is effectively connected with the non-U.S. holder&#8217;s conduct of a trade or business
                                            in the United States and, if required by an applicable income tax treaty, is attributable
                                            to a permanent establishment or fixed base maintained by the non-U.S. holder in the United
                                            States;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            non-U.S. holder is a nonresident alien individual present in the United States for 183 days
                                            or more during the taxable year of the disposition, and certain other requirements are met;
                                            or</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
                                            are or become a United States real property holding corporation, or a USRPHC, for U.S. federal
                                            income tax purposes at any time within the shorter of the five-year period preceding the
                                            disposition or the non-U.S. holder&#8217;s holding period for our common stock, and our common
                                            stock is not regularly traded on an established securities market during the calendar year
                                            in which the sale or other disposition occurs.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 131; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->128<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Determining
whether we are a USRPHC depends on the fair market value of our U.S. real property interests relative to the fair market value of our
other trade or business assets and our foreign real property interests. We believe that we are not currently and we do not anticipate
becoming a USRPHC for U.S. federal income tax purposes, although there can be no assurance we will not in the future become a USRPHC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gain
described in the first bullet point above generally will be subject to U.S. federal income tax on a net income basis at the regular U.S.
federal income tax rates in the same manner as if such holder were a resident of the United States. A non-U.S. holder that is a foreign
corporation also may be subject to an additional branch profits tax equal to 30% (or such lower rate specified by an applicable income
tax treaty) of its effectively connected earnings and profits for the taxable year, as adjusted for certain items. A non-U.S. holder
described in the second bullet point above will be subject to U.S. federal income tax at a flat 30% rate (or such lower rate specified
by an applicable income tax treaty), on gain realized upon the sale or other taxable disposition of our common stock which may be offset
by certain U.S.-source capital losses (even though the individual is not considered a resident of the United States), provided that the
non-U.S. holder has timely filed U.S. federal income tax returns with respect to such losses. If we are or become a United States real
property holding corporation during the period described in the third bullet point above and our common stock is not regularly traded
for purposes of the relevant rules, gain arising from the sale or other taxable disposition of our common stock by a non-U.S. holder
will generally be subject to U.S. federal income tax in the same manner as gain that is effectively connected with the conduct of a U.S.
trade or business, except that the branch profits tax generally will not apply.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-U.S.
holders should consult their tax advisors regarding any applicable income tax treaties that may provide for different rules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Information
Reporting and Backup Withholding </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Annual
reports are required to be filed with the IRS and provided to each non-U.S. holder indicating the amount of distributions on our common
stock paid to such holder and the amount of any tax withheld with respect to those distributions. These information reporting requirements
apply even if no withholding was required because the distributions were effectively connected with the holder&rsquo;s conduct of a U.S.
trade or business, or withholding was reduced or eliminated by an applicable income tax treaty. This information also may be made available
under a specific treaty or agreement with the tax authorities in the country in which the non-U.S. holder resides or is established.
Backup withholding, generally will not apply to payments to a non-U.S. holder of dividends on or the gross proceeds of a disposition
of our common stock provided the non-U.S. holder furnishes the required certification for its non-U.S. status, such as by providing a
valid IRS Form W-8BEN, IRS Form W-8BEN-E, or IRS Form W-8ECI, or certain other requirements are met, and if the payor does not have actual
knowledge, or reason to know, that the holder is a U.S. person who is not an exempt recipient.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Backup
withholding is not an additional tax. If any amount is withheld under the backup withholding rules, the non-U.S. holder should consult
with a U.S. tax advisor regarding the possibility of and procedure for obtaining a refund or a credit against the non-U.S. holder&rsquo;s
U.S. federal income tax liability, if any.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Withholding
on Payment to Certain Foreign Accounts or Entities </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sections
1471 through 1474 of the Code (commonly referred to as FATCA), impose a U.S. federal withholding tax of 30% on certain payments made
to a &ldquo;foreign financial institution&rdquo; (as specially defined under these rules) unless such institution enters into an agreement
with the U.S. government to withhold on certain payments and to collect and provide to the U.S. tax authorities substantial information
regarding certain U.S. account holders of such institution (which includes certain equity and debt holders of such institution, as well
as certain account holders that are foreign entities with U.S. owners) or an exemption applies. FATCA also generally will impose a U.S.
federal withholding tax of 30% on certain payments made to a non-financial foreign entity unless such entity provides the withholding
agent a certification identifying certain direct and indirect U.S. owners of the entity or an exemption applies. An intergovernmental
agreement between the United States and an applicable foreign country may modify these requirements. Under certain circumstances, a non-U.S.
holder might be eligible for refunds or credits of such taxes. FATCA currently applies to dividends paid on our common stock and would
have applied also to payments of gross proceeds from the sale or other disposition of our common stock. The U.S. Treasury Department
has released proposed regulations under FATCA providing for the elimination of the federal withholding tax of 30% applicable to gross
proceeds of a sale or other disposition of our common stock. Under these proposed Treasury Regulations (which may be relied upon by taxpayers
prior to finalization), FATCA will not apply to gross proceeds from sales or other dispositions of our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prospective
investors are encouraged to consult with their own tax advisors regarding the possible implications of FATCA on their investment in our
common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 132; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->129<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="ak_016"></A>UNDERWRITING</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with this offering, we will enter into an underwriting agreement with Boustead Securities, LLC to serve as lead book-running
manager of the offering and as representative of the several underwriters (if any) named below. Subject to the terms and conditions of
the underwriting agreement, each underwriter will severally agree to purchase the number of shares of common stock set forth opposite
its name below at the initial public offering price less underwriting discounts and commissions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid">Underwriter</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number of</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Shares
                                                                                                                                                                                                                                                                                                                    of</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common
Stock</B></FONT></P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 82%; text-align: left">Boustead Securities, LLC</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; width: 14%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; padding-left: 10pt">Total</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to the terms and conditions set forth under the underwriting agreement, the underwriters have agreed to purchase ________ shares of common
stock offered by this prospectus (other than those covered by the over-allotment option described below, if any are purchased).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
underwriters are offering the shares of common stock subject to various conditions and may reject all or part of any order. The representative
of the underwriters has advised us that the underwriters propose initially to offer the shares of common stock to the public at the public
offering price set forth on the cover page of this prospectus and to dealers at a price less a concession not in excess of $[&nbsp;&nbsp;&nbsp;]
per share of common stock. After the shares of common stock are released for sale to the public, the representative may change the offering
price, the concession, and other selling terms at various times.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>Discounts and Commissions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table provides information regarding the amount of the discounts and commissions to be paid to the underwriters by us, before
expenses. The information assumes either no exercise or full exercise of the over-allotment option we granted to the representative of
the underwriters:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Per <BR> Share of <BR> Common
    Stock</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Total<BR> Without<BR> Over-Allotment
    <BR> Option</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Total <BR> With <BR> Over-Allotment
    <BR> Option</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 46%; text-align: justify">Initial public offering price</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">4.00</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">6,200,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">7,130,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Underwriting discounts and commission (7%)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.28</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">434,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">499,100</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Non-accountable expense allowance (1%)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.04</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">62,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">71,300</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Proceeds, before expenses, to us</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3.68</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">5,704,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">6,559,600</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">We have agreed to pay the representative the reasonable out-of-pocket
expenses incurred by the representative in connection with this offering up to $280,000. The representative&rsquo;s reimbursable out-of-pocket
expenses include: (i) reasonable fees of representative&rsquo;s legal counsel up to $125,000, (ii) due diligence and other expenses incurred
prior to completion of this offering up to $75,000, (iii) road show, travel, platform on-boarding fees, and other reasonable out-of-pocket
accountable expenses up to $75,000, and (iv) $5,000 for background check on our officers, directors and major shareholders. As of the
date of this prospectus, we have paid the representative advances of $_____ for its anticipated out-of-pocket costs. Such advance payments
will be returned to us to the extent such out-of-pocket expenses are not actually incurred in accordance with FINRA Rule 5110(g)(4)(A).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
estimate that our total expenses of the offering, excluding the estimated underwriting discounts and commissions and excluding the non-accountable
expense allowance, will be approximately $______.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>Representative&rsquo;s
Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have also agreed to issue to the representative of the underwriters warrants to purchase a number of shares of common stock equal to
an aggregate of 7% of the aggregate number of the shares sold in this offering. The warrants will be exercisable on a cashless basis
at an exercise price equal to 120% of the offering price of the shares sold in this offering. The warrants are exercisable commencing
six months after the date of effectiveness of the registration statement of which this prospectus forms a part, and the warrants will
be exercisable for a period of five years from the effective date of the registration statement of which this prospectus forms a part.
We have agreed to a one-time demand registration of the shares of common stock underlying the underwriter&rsquo;s warrants for a period
of five years from the effective date of the registration statement. The underwriter&rsquo;s warrants also provide for immediate &ldquo;piggyback&rdquo;
registration rights with respect to the underlying shares of common stock during the five-year period commencing from the effective
date of the registration statement related to this offering. Such piggyback rights shall expire on a date which shall be five
years from the date of commencement of sales of the share offered hereby. The warrants are not redeemable by us. The warrants and the
shares of common stock issuable upon exercise of the warrants have been included on the registration statement of which this prospectus
forms a part. Pursuant to applicable FINRA rules, and in particular Rule 5110, the warrants (and underlying shares) issued to the underwriters
may not be sold, transferred, assigned, pledged, or hypothecated, or the subject of any hedging, short sale, derivative, put or call
transaction that would result in the effective disposition of the securities by any person for a period of 180 days after the effective
date of the registration statement related to this offering; provided, however, that the warrants (and the underlying shares) may be
transferred to the underwriters&rsquo; officers, partners, registered persons or affiliates as long as the warrants (and the underlying
shares) remain subject to the lockup.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have agreed to indemnify the underwriters against certain liabilities, including liabilities under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Right
of First Refusal</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have agreed to provide</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> the representative of the
underwriters the right of first refusal for one year from the date of commencement of sales of this public offering to act as financial
advisor or to act as joint financial advisor on at least equal economic terms on any public or private financing (debt or equity), merger,
business combination, recapitalization or sale of some or all of the equity or assets of our company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Company
and Shareholder Lock-Ups</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have agreed to a 12-month &ldquo;lock-up&rdquo; from the closing of this offering, during which, without the prior written consent of
Boustead Securities, LLC, we will not issue, sell or register with the SEC (other than on Form S-8 or on any successor form) with respect
to any of our equity securities (or any securities convertible into, exercisable for or exchangeable for any of our equity securities),
except for (i) the issuance of the shares of common stock offered pursuant to this prospectus; and (ii) the issuance of shares of common
stock pursuant to our existing equity incentive or bonus plan as described in the registration statement of which this prospectus forms
a part.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 133; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->130<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
executive officers, directors and certain of our significant stockholders have also agreed to a 12-month &ldquo;lock-up,&rdquo; during
which, without the prior written consent of Boustead Securities, LLC, they will not, directly or indirectly, (i) offer, pledge, assign,
encumber, announce the intention to sell, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract
to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, any shares of common stock or any securities
convertible into or exercisable or exchangeable for common stock, owned either of record or beneficially (as defined in the Exchange
Act) by any signatory of the lock-up agreement on the date of the prospectus or thereafter acquired; (ii) enter into any swap
or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of the common stock or any securities
convertible into or exercisable or exchangeable for common stock, whether any such transaction described in clauses (i) or (ii) above
is to be settled by delivery of common stock or such other securities, in cash or otherwise, or publicly announce an intention to do
any of the foregoing; and (iii) make any demand for or exercise any right with respect to, the registration of any shares of common stock
or any security convertible into or exercisable or exchangeable for common stock. The foregoing shall not apply to (i) common stock to
be transferred as a gift or gifts (provided that (a) any donee shall execute and deliver to Boustead Securities, LLC, acting on behalf
of the underwriters, not later than one business day prior to such transfer, a lock-up agreement to Boustead Securities, LLC and (b)
if the lock-up signatory is required to file a report under Section 16(a) of the Exchange Act, reporting a reduction in beneficial ownership
of shares of common stock or beneficially owned shares or any securities convertible into or exercisable or exchangeable for common stock
or beneficially owned shares during the 15-month &ldquo;lock-up,&rdquo; the lock-up signatory shall include a statement in such report
to the effect that such transfer is being made as a gift), and (ii) the sale of the shares of common stock to be sold pursuant to this
prospectus<I>.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rules
of the SEC may limit the ability of the underwriters to bid for or purchase shares of our common stock before the distribution of the
shares is completed. However, the underwriters may engage in the following activities in accordance with the rules:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stabilizing
                                            transactions &#8212; the representative may make bids or purchases for the purpose of pegging,
                                            fixing or maintaining the price of the common stock, so long as stabilizing bids do not exceed
                                            a specified maximum.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Over-allotments
                                            and syndicate covering transactions &#8212; the underwriters may sell more shares of common
                                            stock in connection with this offering than the number of shares that they have committed
                                            to purchase. This over-allotment creates a short position for the underwriters. This short
                                            sales position may involve either &#8220;covered&#8221; short sales or &#8220;naked&#8221;
                                            short sales. Covered short sales are short sales made in an amount not greater than the underwriter&#8217;s
                                            over-allotment option to purchase additional shares in this offering described above. The
                                            underwriters may close out any covered short position either by exercising their over-allotment
                                            option or by purchasing shares in the open market. To determine how they will close the covered
                                            short position, the underwriters will consider, among other things, the price of shares available
                                            for purchase in the open market, as compared to the price at which they may purchase shares
                                            through the over-allotment option. Naked short sales are short sales in excess of the over-allotment
                                            option. The underwriters must close out any naked short position by purchasing shares in
                                            the open market. A naked short position is more likely to be created if the underwriters
                                            are concerned that, in the open market after pricing, there may be downward pressure on the
                                            price of the shares that could adversely affect investors who purchase shares in this offering.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Penalty
                                            bids &#8212; if the representative purchases shares of common stock in the open market in
                                            a stabilizing transaction or syndicate covering transaction, it may reclaim a selling concession
                                            from the underwriters and selling group members who sold those shares of common stock as
                                            part of this offering.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Passive
                                            market making &#8212; market makers in the common stock who are underwriters or prospective
                                            underwriters may make bids for or purchases of shares of common stock, subject to limitations,
                                            until the time, if ever, at which a stabilizing bid is made.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Similar
to other purchase transactions, the underwriters&rsquo; purchases to cover the syndicate short sales or to stabilize the market price
of our common stock may have the effect of raising or maintaining the market price of our common stock or preventing or mitigating a
decline in the market price of our common stock. As a result, the price of our common stock may be higher than the price that might otherwise
exist in the open market. The imposition of a penalty bid might also have an effect on the price of the common stock if it discourages
resales of our shares of common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neither
we nor the underwriters make any representation or prediction as to the effect that the transactions described above may have on the
price of our common stock. These transactions may occur on  NYSE American or otherwise. If such
transactions are commenced, they may be discontinued without notice at any time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>Prior
Relationship with Boustead Securities, LLC</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">In June and September 2022<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
we completed a $450,000 convertible note offering and a $225,000 convertible note offering, respectively, to certain accredited investors,
which notes are convertible into shares of common stock (the &ldquo;Conversion Shares&rdquo;) at a conversion price equal to 60% of the
per share of common stock sold in this offering. The convertible note offering was completed pursuant to an exemption from registration
under Rule 506(b) of the Securities Act. Boustead Securities, LLC acted as placement agent in each of the June and September 2022
private placements and received $86,893 and $19,315 cash compensation, respectively, and five-year warrants to purchase shares of common
stock equal to 7.0% of the number of the Conversion Shares at an exercise price equal to the conversion price.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
warrants received in connection with the June and September 2022 private placements (the &ldquo;Private Placement Warrants&rdquo;) (and
underlying shares) will not be exercisable or convertible more than five years from the commencement of this public offering. Pursuant
to applicable FINRA rules and, in particular, Rule 5110(e)(1), the Private Placement Warrants (and underlying shares) may not
be sold, transferred, assigned, pledged or hypothecated, or be the subject of any hedging, short sale, derivative, put or call transaction
that would result in the effective economic disposition of the securities for a period of 180 days beginning on the date of commencement
of sales of this public offering; provided, however, the Private Placement Warrants (and underlying shares) may be transferred
to the underwriter&rsquo;s officers, partners, registered persons or affiliates as long as the warrants remain subject to the lock-up
restriction&nbsp;above.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 134; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->131<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Electronic
Delivery of Prospectus: A prospectus in electronic format may be delivered to potential investors by one or more of the underwriters
participating in this offering. The prospectus in electronic format will be identical to the paper version of such prospectus. Other
than the prospectus in electronic format, the information on any underwriter&rsquo;s website and any information contained in any other
website maintained by an underwriter is not part of this prospectus or the registration statement of which this prospectus forms a part.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Determination
of Offering Price</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to the offering there has not been a public market for our shares of common stock. As a result, the public offering price for our shares
of common stock has been determined by negotiations between us and the representative of the underwriters. Among the factors to be considered
in these negotiations were the prevailing market conditions, our financial information, market valuations of other companies that we
and the representative believe to be comparable to us, estimates of our business potential, the present states of our development and
other factors deemed relevant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 33.75pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
offer no assurance that the public offering price will correspond to the price at which the shares of common stock will trade in the
public market subsequent to the offering or that an active trading market for the shares of common stock will develop and continue after
the offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Selling
Restrictions </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Canada</I>.
</B>The common stock may be sold only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors,
as defined in National Instrument 45-106 <I>Prospectus Exemptions</I> or subsection 73.3(1) of the <I>Securities Act </I>(Ontario), and
are permitted clients, as defined in National Instrument 31-103 <I>Registration Requirements, Exemptions and Ongoing Registrant Obligations</I>.
Any resale of the common stock must be made in accordance with an exemption from, or in a transaction not subject to, the prospectus
requirements of applicable securities laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if this prospectus
(including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by
the purchaser within the time limit prescribed by the securities legislation of the purchaser&rsquo;s province or territory. The purchaser
should refer to any applicable provisions of the securities legislation of the purchaser&rsquo;s province or territory for particulars
of these rights or consult with a legal advisor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to section 3A.3 of National Instrument 33-105 <I>Underwriting Conflicts </I>(NI 33-105), the underwriters are not required to comply
with the disclosure requirements of NI 33-105 regarding underwriter conflicts of interest in connection with this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>European
Economic Area</I>.</B> In relation to each Member State of the European Economic Area (each, a Relevant State), no shares of common stock
have been offered or will be offered pursuant to the offering to the public in that Relevant State prior to the publication of a prospectus
in relation to the shares of common stock which has been approved by the competent authority in that Relevant State or, where appropriate,
approved in another Relevant State and notified to the competent authority in that Relevant State, all in accordance with the Prospectus
Regulation, except that offers of shares of common stock may be made to the public in that Relevant State at any time under the following
exemptions under the Prospectus Regulation:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
                                            any legal entity which is a qualified investor as defined under Article 2 of the Prospectus
                                            Regulation;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
                                            fewer than 150 natural or legal persons (other than qualified investors as defined under
                                            Article 2 of the Prospectus Regulation), subject to obtaining the prior consent of the representatives
                                            of the underwriters for any such offer; or</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
                                            any other circumstances falling within Article 1(4) of the Prospectus Regulation,</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">provided
that no such offer of shares of common stock shall require our company or any underwriter to publish a prospectus pursuant to Article
3 of the Prospectus Regulation or supplement a prospectus pursuant to Article 23 of the Prospectus Regulation and each person who initially
acquires any shares of common stock or to whom any offer is made will be deemed to have represented, acknowledged, and agreed to and
with each of the underwriters and our company that it is a &ldquo;qualified investor&rdquo; within the meaning of Article 2(e) of the
Prospectus Regulation. In the case of any shares of common stock being offered to a financial intermediary as that term is used in the
Prospectus Regulation, each such financial intermediary will be deemed to have represented, acknowledged, and agreed that the shares
of common stock acquired by it in the offer have not been acquired on a non-discretionary basis on behalf of, nor have they been acquired
with a view to their offer or resale to, persons in circumstances which may give rise to an offer of any shares of common stock to the
public other than their offer or resale in a Relevant State to qualified investors as so defined or in circumstances in which the prior
consent of the underwriters has been obtained to each such proposed offer or resale.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the purposes of this provision, the expression an &ldquo;offer to the public&rdquo; in relation to the shares of common stock in any
Relevant State means the communication in any form and by any means of sufficient information on the terms of the offer and any shares
of common stock to be offered so as to enable an investor to decide to purchase or subscribe for any shares of common stock, and the
expression &ldquo;Prospectus Regulation&rdquo; means Regulation (EU) 2017/1129.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 135; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->132<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>United
Kingdom</I>.</B> No shares of common stock have been offered or will be offered pursuant to the offering to the public in the United
Kingdom prior to the publication of a prospectus in relation to the shares of common stock which has been approved by the Financial Conduct
Authority, except that the shares of common stock may be offered to the public in the United Kingdom at any time:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
                                            any legal entity which is a qualified investor as defined under Article 2 of the U.K. Prospectus
                                            Regulation;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
                                            fewer than 150 natural or legal persons (other than qualified investors as defined under
                                            Article 2 of the U.K. Prospectus Regulation), subject to obtaining the prior consent of the
                                            representatives of the underwriters for any such offer; or</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
                                            any other circumstances falling within Section 86 of the FSMA,</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">provided
that no such offer of the shares of common stock shall require our company or any underwriter to publish a prospectus pursuant to Section
85 of the FSMA or supplement a prospectus pursuant to Article 23 of the U.K. Prospectus Regulation. For the purposes of this provision,
the expression an &ldquo;offer to the public&rdquo; in relation to the shares of common stock in the United Kingdom means the communication
in any form and by any means of sufficient information on the terms of the offer and any shares of common stock to be offered so as to
enable an investor to decide to purchase or subscribe for any shares of common stock and the expression &ldquo;U.K. Prospectus Regulation&rdquo;
means Regulation (EU) 2017/1129 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018. In addition,
in the United Kingdom, this document is being distributed only to, and is directed only at, and any offer subsequently made may only
be directed at persons who are &ldquo;qualified investors&rdquo; (as defined in the U.K. Prospectus Regulation) (i) who have professional
experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial
Promotion) Order 2005, as amended, or the &ldquo;Order,&rdquo; and/or (ii) who are high net worth companies (or persons to whom it may
otherwise be lawfully communicated) falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to
as relevant persons). In the United Kingdom, any investment or investment activity to which this document relates is only available to,
and will be engaged in with, relevant persons. Any person in the United Kingdom who is not a relevant person must not act on or rely
upon this document or any of its contents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Switzerland</I>.
</B>The securities will not be offered, directly or indirectly, to the public in Switzerland and this prospectus does not constitute
a public offering prospectus as that term is understood pursuant to article 652a or 1156 of the Swiss Federal Code of Obligations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Israel</I>.
</B>In the State of Israel this prospectus shall not be regarded as an offer to the public to purchase shares of common stock under the
Israeli Securities Law, 5728&ndash;1968, which requires a prospectus to be published and authorized by the Israel Securities Authority,
if it complies with certain provisions of Section 15 of the Israeli Securities Law, 5728&ndash;1968, including, inter alia, if: (i) the
offer is made, distributed, or directed to not more than 35 investors, subject to certain conditions (Addressed Investors); or (ii) the
offer is made, distributed, or directed to certain qualified investors defined in the First Addendum of the Israeli Securities Law, 5728&ndash;1968,
subject to certain conditions (Qualified Investors). The Qualified Investors shall not be taken into account in the count of the Addressed
Investors and may be offered to purchase securities in addition to the 35 Addressed Investors. Our company has not and will not take
any action that would require it to publish a prospectus in accordance with and subject to the Israeli Securities Law, 5728&ndash;1968.
We have not and will not distribute this prospectus or make, distribute, or direct an offer to subscribe for our common stock to any
person within the State of Israel, other than to Qualified Investors and up to 35 Addressed Investors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Qualified
Investors may have to submit written evidence that they meet the definitions set out in of the First Addendum to the Israeli Securities
Law, 5728&ndash;1968. In particular, we may request, as a condition to be offered common stock, that Qualified Investors will each represent,
warrant and certify to us and/or to anyone acting on our behalf: (i) that it is an investor falling within one of the categories listed
in the First Addendum to the Israeli Securities Law, 5728&ndash;1968; (ii) which of the categories listed in the First Addendum to the
Israeli Securities Law, 5728&ndash;1968 regarding Qualified Investors is applicable to it; (iii) that it will abide by all provisions
set forth in the Israeli Securities Law, 5728&ndash;1968 and the regulations promulgated thereunder in connection with the offer to be
issued common stock; (iv) that the shares of common stock that it will be issued are, subject to exemptions available under the Israeli
Securities Law, 5728&ndash;1968: (a) for its own account; (b) for investment purposes only; and (c) not issued with a view to resale
within the State of Israel, other than in accordance with the provisions of the Israeli Securities Law, 5728&ndash;1968; and (v) that
it is willing to provide further evidence of its Qualified Investor status. Addressed Investors may have to submit written evidence in
respect of their identity and may have to sign and submit a declaration containing, inter alia, the Addressed Investor&rsquo;s name,
address and passport number or Israeli identification number.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not authorized and do not authorize the making of any offer of securities through any financial intermediary on our behalf, other
than offers made by the underwriters and their respective affiliates, with a view to the final placement of the securities as contemplated
in this document. Accordingly, no purchaser of the shares, other than the underwriters, is authorized to make any further offer of shares
on our behalf or on behalf of the underwriters.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 136; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->133<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><A NAME="ak_017"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>LEGAL
MATTERS </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
validity of the securities being offered by this prospectus will be passed upon for us by Dorsey &amp; Whitney LLP, New York,
New York. Olshan Frome Wolosky LLP, New York, New York, is acting as counsel for the underwriters.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="ak_018"></A>EXPERTS
</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
audited consolidated financial statements of Kairos Pharma, Ltd. as of December 31, 2023, and 2022 and for each of the
years then ended included in this prospectus have been so included in reliance on the report of Marcum LLP, an independent registered
public accounting firm, which includes an explanatory paragraph as to our company&rsquo;s ability to continue as a going concern, given
upon their authority as experts in auditing and accounting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="ak_019"></A>WHERE
YOU CAN FIND ADDITIONAL INFORMATION </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have filed with the SEC a registration statement on Form S-1 under the Securities Act with respect to the shares of common stock offered
by this prospectus. This prospectus, which constitutes a part of the registration statement, does not contain all the information set
forth in the registration statement, some of which is contained in exhibits to the registration statement as permitted by the rules and
regulations of the SEC. For further information with respect to us and our common stock, we refer you to the registration statement,
including the exhibits filed as a part of the registration statement. Statements contained in this prospectus concerning the contents
of any contract or any other document are not necessarily complete. If a contract or document has been filed as an exhibit to the registration
statement, please see the copy of the contract or document that has been filed. Each statement in this prospectus relating to a contract
or document filed as an exhibit is qualified in all respects by the filed exhibit. The SEC also maintains an internet website that contains
reports and other information about issuers, like us, that file electronically with the SEC. The address of that website is www.sec.gov.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
the closing of this offering, we will be subject to the information reporting requirements of the Exchange Act, and we will file reports,
proxy statements, and other information with the SEC. These reports, proxy statements, and other information will be available for inspection
and copying at the public reference room and website of the SEC referred to above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also maintain a website at https://kairospharma.com. Information contained in, or accessible through, our website is not a part of this
prospectus, and the inclusion of our website address in this prospectus is only as an inactive textual reference.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 137; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->134<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Kairos
Pharma, Ltd.</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U><A NAME="a_001"></A>Index
to the Consolidated Financial Statements</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page</B></FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Audited
    Consolidated Financial Statements</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ap_001">Report of Independent Registered Public Accounting Firm</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">F-2</TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#loa_001">Consolidated
    Balance Sheets at December 31, 2022 and 2023 </A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-3</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#loa_002">Consolidated
    Statements of Operations for the Years Ended December 31, 2022 and 2023 </A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-4</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#loa_003">Consolidated
    Statements of Shareholders&rsquo; Deficit for the Years Ended December 31, 2022 and 2023 </A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-5</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#loa_004">Consolidated
    Statements of Cash Flows for the Years Ended December 31, 2022 and 2023 </A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-6</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#loa_005">Notes to the Consolidated Financial Statements</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-7</FONT></TD>
    </TR>
</TABLE>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 138; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="ap_001"></A>Report of
Independent Registered Public Accounting Firm</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the Shareholders and Board of Directors of</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kairos
Pharma, Ltd.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Opinion
on the Consolidated Financial Statements</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have audited the accompanying consolidated balance sheets of Kairos Pharma, Ltd. and Subsidiary (the &ldquo;Company&rdquo;) as of December
31, 2023 and 2022, the related consolidated statements of operations, shareholders&rsquo; deficit and cash flows for each of the two
years in the period ended December 31, 2023, and the related notes (collectively referred to as the &ldquo;financial statements&rdquo;).
In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December
31, 2023 and 2022, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2023,
in conformity with accounting principles generally accepted in the United States of America.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Explanatory
Paragraph &ndash; Going Concern</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As more fully described
in Note 1, the Company has a significant working capital deficiency, has incurred significant losses and needs to raise additional funds
to meet its obligations and sustain its operations. These conditions raise substantial doubt about the Company&rsquo;s ability to continue
as a going concern. Management&rsquo;s plans in regard to these matters are also described in Note 1. The financial statements do not
include any adjustments that might result from the outcome of this uncertainty.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Basis
for Opinion</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
financial statements are the responsibility of the Company&rsquo;s management. Our responsibility is to express an opinion on the Company&rsquo;s
financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board
(United States) (&ldquo;PCAOB&rdquo;) and are required to be independent with respect to the Company in accordance with the U.S. federal
securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
conducted our audits in accordance with the standards of the PCAOB and in accordance with auditing standards generally accepted in the
United States of America. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the
financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were
we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an
understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the
Company&rsquo;s internal control over financial reporting. Accordingly, we express no such opinion.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error
or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding
the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant
estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit<B>s
</B>provide a reasonable basis for our opinion.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marcum
<FONT STYLE="font-variant: small-caps">llp</FONT></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have served as the Company&rsquo;s auditor since 2021.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Los
Angeles, California</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
30, 2023</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 139; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Kairos
Pharma, Ltd.</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"> <A NAME="loa_001"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Consolidated
Balance Sheets</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(In
thousands, except for share amounts and par value data)</FONT> </P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD><TD> &nbsp; </TD><TD STYLE="font-weight: bold"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center"> Pro Forma </TD><TD STYLE="font-weight: bold"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> December 31, </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> December 31, </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> 2022 </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> 2023 </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> 2023 </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: center"> ASSETS </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD><TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left"> Current Assets </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 46%"> Cash </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 14%; text-align: right"> 437 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 14%; text-align: right"> 93 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 14%; text-align: right"> 93 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt"> Prepaid expenses </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 8 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 8 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt"> Total Current Assets </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 437 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 101 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 101 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Deferred offering costs </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 57 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 482 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 482 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt"> Intangible assets, net </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 542 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 382 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 382 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt"> Total Other Assets </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 599 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 864 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 864 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt"> TOTAL ASSETS </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> 1,036 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> 965 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> 965 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: center"> LIABILITIES AND SHAREHOLDERS&rsquo; DEFICIT </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left"> Current Liabilities </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Accounts payable and accrued expenses </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 1,629 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 2,401 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 1,591 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt"> Due to related parties </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 4 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 4 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt"> Total Current Liabilities </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 1,633 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 2,405 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 1,591 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt"> Convertible notes payable, net of debt discount of $93 and $105 at December
    31, 2022 and 2023, respectively </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 582 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 638 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt"> Total Liabilities </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 2,215 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 3,043 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 1,591 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left"> Shareholders&rsquo; Deficit </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Preferred stock, par value $0.001, 20,000,000 shares authorized; no shares issued and outstanding,
    respectively; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Common stock, par value $0.001, 100,000,000 shares authorized; 10,334,357 and 10,562,640 shares
    issued and outstanding, respectively; 11,211,179 shares issued and outstanding pro forma (unaudited) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 10 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 11 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 11 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Additional paid-in capital </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 3,211 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 4,123 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 5,680 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt"> Accumulated deficit </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> (4,400 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> ) </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> (6,212 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> ) </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> (6,317 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> ) </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt"> Total Shareholders&rsquo; Deficit </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> (1,179 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> ) </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> (2,078 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> ) </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> (626 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> ) </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt"> TOTAL LIABILITIES AND SHAREHOLDERS&rsquo; DEFICIT </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> 1,036 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> 965 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> 965 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD></TR>
  </TABLE>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated financial statements.</FONT> </P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>


<!-- Field: Page; Sequence: 140; Options: NewSection; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Kairos
Pharma, Ltd.</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="loa_002"></A><B>Consolidated
Statements of Operations</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(in
thousands, except for share amounts and per share data)</FONT> </P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD STYLE="font-weight: bold"> &nbsp; </TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center"> Years Ended </TD><TD STYLE="font-weight: bold"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> December 31, </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> 2022 </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> 2023 </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD><TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt"> Revenues </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Operating expenses: </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; width: 60%; text-align: left"> Research and development </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 16%; text-align: right"> 87 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 16%; text-align: right"> 82 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"> General and administrative </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 484 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 1,632 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt"> Total operating expenses </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 571 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 1,714 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt"> Loss from operations </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> (571 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> ) </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> (1,714 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> ) </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Other expenses: </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left"> Interest expense </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (51 </TD><TD STYLE="text-align: left"> ) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (42 </TD><TD STYLE="text-align: left"> ) </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left"> Debt discount amortization </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (408 </TD><TD STYLE="text-align: left"> ) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (56 </TD><TD STYLE="text-align: left"> ) </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"> Financing costs </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> (20 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> ) </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt"> Total other expenses </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> (479 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> ) </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> (98 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> ) </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt"> NET LOSS </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> (1,050 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> ) </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> (1,812 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> ) </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt"> BASIC AND DILUTED LOSS PER COMMON SHARE </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> (0.10 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> ) </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> (0.17 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> ) </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> WEIGHTED-AVERAGE COMMON SHARES OUTSTANDING </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"> BASIC AND DILUTED </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> 10,236,764 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> 10,382,515 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt"> PRO FORMA BASIC AND DILUTED LOSS PER COMMON SHARE </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> (0.10 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> ) </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> (0.16 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> ) </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD> PRO FORMA WEIGHTED-AVERAGE COMMON SHARES </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"> OUTSTANDING BASIC AND DILUTED </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> 10,839,452 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> 11,031,054 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD></TR>
  </TABLE>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated financial statements.</FONT> </P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>


<!-- Field: Page; Sequence: 141; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Kairos
Pharma, Ltd.</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="loa_003"></A>Consolidated
Statements of Shareholders&rsquo; Deficit (Unaudited)</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(in
thousands, except share amounts)</FONT> </P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="text-align: center; font-weight: bold"> &nbsp; </TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> Common Stock </TD><TD STYLE="text-align: center; font-weight: bold"> &nbsp; </TD><TD STYLE="text-align: center; font-weight: bold"> &nbsp; </TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> Common Stock to be Issued </TD><TD STYLE="text-align: center; font-weight: bold"> &nbsp; </TD><TD STYLE="text-align: center; font-weight: bold"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center"> Additional Paid-in </TD><TD STYLE="text-align: center; font-weight: bold"> &nbsp; </TD><TD STYLE="text-align: center; font-weight: bold"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center"> Accumulated </TD><TD STYLE="text-align: center; font-weight: bold"> &nbsp; </TD><TD STYLE="text-align: center"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> &nbsp; </TD><TD STYLE="text-align: center"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="text-align: center; font-weight: bold"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> Shares </TD><TD STYLE="text-align: center; font-weight: bold"> &nbsp; </TD><TD STYLE="text-align: center; font-weight: bold"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> Amount </TD><TD STYLE="text-align: center; font-weight: bold"> &nbsp; </TD><TD STYLE="text-align: center; font-weight: bold"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> Shares </TD><TD STYLE="text-align: center; font-weight: bold"> &nbsp; </TD><TD STYLE="text-align: center; font-weight: bold"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> Amount </TD><TD STYLE="text-align: center; font-weight: bold"> &nbsp; </TD><TD STYLE="text-align: center; font-weight: bold"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> Capital </TD><TD STYLE="text-align: center; font-weight: bold"> &nbsp; </TD><TD STYLE="text-align: center; font-weight: bold"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> Deficit </TD><TD STYLE="text-align: center; font-weight: bold"> &nbsp; </TD><TD STYLE="text-align: center; font-weight: bold"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> Total </TD><TD STYLE="text-align: center; font-weight: bold"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD><TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 37%; font-weight: bold"> Balance, December 31, 2021 </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 5%; text-align: right"> 8,055,575 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 5%; text-align: right"> 8 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 5%; text-align: right"> 2,124,000 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 5%; text-align: right"> 2 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 5%; text-align: right"> 2,173 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 5%; text-align: right"> (3,350 </TD><TD STYLE="width: 1%; text-align: left"> ) </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 5%; text-align: right"> (1,167 </TD><TD STYLE="width: 1%; text-align: left"> ) </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Shares issued from common stock to be issued </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 2,124,000 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 2 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (2,124,000 </TD><TD STYLE="text-align: left"> ) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (2 </TD><TD STYLE="text-align: left"> ) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Shares issued upon conversion of convertible notes payable and accrued interest </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 154,782 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 648 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 648 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Fair value of stock warrant issued in connection with convertible note payable </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 390 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 390 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt"> Net loss </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> (1,050 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> ) </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> (1,050 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> ) </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold"> Balance, December 31, 2022 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 10,334,357 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 10 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 3,211 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> (4,400 </TD><TD STYLE="text-align: left"> ) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> (1,179 </TD><TD STYLE="text-align: left"> ) </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Fair value of shares issued in connection with shareholder dispute </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 228,283 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 1 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 912 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 913 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Net loss </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (1,812 </TD><TD STYLE="text-align: left"> ) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (1,812 </TD><TD STYLE="text-align: left"> ) </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt"> Balance, December 31, 2023 </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> 10,562,640 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> 11 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> - </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> - </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> 4,123 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> (6,212 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> ) </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> (2,078 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> ) </TD></TR>
  </TABLE>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated financial statements.</FONT> </P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>


<!-- Field: Page; Sequence: 142; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Kairos
Pharma, Ltd.</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="loa_004"></A>Consolidated
Statements of Cash Flows</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(In
thousands)</FONT> </P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD STYLE="font-weight: bold"> &nbsp; </TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center"> Years Ended </TD><TD STYLE="font-weight: bold"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> December 31, </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> 2022 </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> 2023 </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-decoration: underline; text-align: left"> Cash Flows from Operating Activities </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 60%; text-align: left"> Net loss </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 16%; text-align: right"> (1,050 </TD><TD STYLE="width: 1%; text-align: left"> ) </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 16%; text-align: right"> (1,812 </TD><TD STYLE="width: 1%; text-align: left"> ) </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Adjustments to reconcile net loss to net cash provided by (used in) operating activities: </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left"> Amortization expense </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 160 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 160 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left"> Amortization of debt discount </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 408 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 56 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left"> Fair value of common stock issued in connection with shareholder dispute </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 913 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left"> Changes in operating assets and liabilities: </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left"> (Increase) Decrease in: </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left"> Prepaid expenses </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (8 </TD><TD STYLE="text-align: left"> ) </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left"> (Decrease) Increase in: </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"> Accounts payable and accrued expenses </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 129 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 772 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt"> Net cash provided by (used in) operating activities </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> (353 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> ) </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 81 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-decoration: underline; text-align: left"> Cash Flows from Financing Activities </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Proceeds from convertible notes payable </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 925 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Repayment of note payable </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (30 </TD><TD STYLE="text-align: left"> ) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Repayment of advance from related party </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (10 </TD><TD STYLE="text-align: left"> ) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Payment of debt isuance costs </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (111 </TD><TD STYLE="text-align: left"> ) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt"> Payment of deferred offering costs </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> (57 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> ) </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> (425 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> ) </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt"> Net cash provided by (used in) financing activities </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 717 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> (425 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> ) </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Net increase (decrease) in cash </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 364 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (344 </TD><TD STYLE="text-align: left"> ) </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt"> Cash beginning of year </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 73 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 437 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt"> Cash end of year </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> 437 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> 93 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-decoration: underline; text-align: left"> Supplemental cash flows disclosures: </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt"> Interest paid </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> - </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> - </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt"> Taxes paid </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> - </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> - </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-decoration: underline; text-align: left"> Supplemental non-cash financing disclosures: </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt"> Issuance of convertible notes payable recorded as debt discount </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> - </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> 68 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt"> Conversion of convertible notes payable and accrued interest </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> 648 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> - </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt"> Fair value of warrant recorded as debt discount on issuance of convertible
    note payable </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> 390 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> - </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD></TR>
  </TABLE>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated financial statements.</FONT> </P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>


<!-- Field: Page; Sequence: 143; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>KAIROS
PHARMA, LTD.</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="loa_005"></A>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FOR
THE YEARS ENDED DECEMBER 31, 2022 and 2023</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(In
thousands, except for share amounts and per share data)</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
1 &ndash; BASIS OF PRESENTATION</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Organization
and Operations</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kairos
Pharma, Ltd. (the &ldquo;Company&rdquo; or &ldquo;Kairos&rdquo;) was incorporated on June 17, 2013 under the laws of the state of California
as NanoGB13, Inc. The Company changed its name to Kairos Pharma, Ltd. on July 15, 2016 and subsequently converted into a Delaware corporation
under the same name, Kairos Pharm, Ltd., on May 10, 2023. The Company is an early-stage biotechnology company, which is focused on the
development of immunotherapy and cell therapy treatments for oncology.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Going
Concern</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the
realization of assets and the settlement of liabilities and commitments in the normal course of business. As reflected in the accompanying
consolidated financial statements, the Company incurred a net loss of $1,812 during the year ended
December 31, 2023, and had a shareholders&rsquo; deficit of $2,078 as of December 31, 2023. These factors raise substantial doubt, as
defined under GAAP, about the Company&rsquo;s ability to continue as a going concern for the twelve months following the issuance of
these consolidated financial statements. Management&rsquo;s plan to continue as a going concern is dependent upon the Company&rsquo;s
ability to raise additional funds and implement its strategies. The financial statements do not include any adjustments related to the
recoverability and classification of assets or the amounts and classification of liabilities that might be necessary if the Company is
unable to continue as a going concern.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2023, the Company had cash on hand in the amount of $93. The ability to continue as a going concern is dependent on the
Company attaining and maintaining profitable operations in the future and raising additional capital to meet its obligations and repay
its liabilities arising from normal business operations when they come due. Since inception, the Company has funded its operations primarily
through equity and debt financings and it expects to continue to rely on these sources of capital in the future.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
assurance can be given that any future financing will be available or, if available, that it will be on terms that are satisfactory to
the Company. Even if the Company is able to obtain additional financing, it may contain undue restrictions on our operations, in the
case of debt financing, or cause substantial dilution for our stockholders, in the case of equity financing.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Stock
Split</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 28, 2022, the Company effected a 1.5-for-1 stock split of its common stock. The par value and the authorized shares of the Company&rsquo;s
common stock were not adjusted as a result of the stock split. The accompanying consolidated financial statements and notes to the financial
statements give retroactive effect to the stock split for all periods presented.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Reverse
Stock Split</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 10, 2023, the Company effected a 1-for-2.5 reverse stock split of its common stock. The par value and the authorized shares of the
Company&rsquo;s common stock were not adjusted as a result of the reverse stock split. The accompanying consolidated financial statements
and notes to the financial statements give retroactive effect to the reverse stock split for all periods presented.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>


<!-- Field: Page; Sequence: 144; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Reincorporation</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s Certificate of Incorporation, as filed with the State of Delaware on May 10, 2023, following the Company&rsquo;s conversion
from a California corporation into a Delaware corporation, authorizes the Company to issue up to 120,000,000 shares, consisting of 100,000,000
shares of common stock, par value of $0.001 per share, and 20,000,000 shares of preferred stock, par value $0.001 per share. The accompanying
consolidated financial statements and notes to the financial statements give retroactive effect to the reincorporation for all periods
presented.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>NOTE
2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>Basis
of Consolidation</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements and accompanying notes have been prepared in accordance with accounting principles generally
accepted in the United States of America (&ldquo;U.S. GAAP&rdquo;). The accompanying consolidated financial statements include the accounts
of the Company and its wholly owned subsidiary, Enviro Therapeutics, Inc. All intercompany balances and transactions have been eliminated
in consolidation.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Use
of Estimates</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect
the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial
statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and
assumptions. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it
believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values
of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results
experienced by the Company may differ materially and adversely from the Company&rsquo;s estimates. To the extent there are material differences
between the estimates and the actual results, future results of operations will be affected. Significant estimates in the accompanying consolidated financial statements include the valuation allowance on deferred tax assets and impairment analysis and useful
life for intangible assets.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Cash</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the purpose of the statement of cash flows, cash includes currency on hand with banks and financial institutions.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Concentration
of Credit Risk</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.2pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments, which potentially subject the Company to concentration of credit risk, consist primarily of cash deposits. Accounts at each
financial institution are insured by the Federal Deposit Insurance Corporation (&ldquo;FDIC&rdquo;) up to certain limits. The Company
does not maintain deposits in excess of federally insured limits.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Intangible
Assets</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s intangible assets are stated at fair value as of the date acquired, less accumulated amortization. Amortization is calculated
based on the estimated useful lives of the assets, which were determined to be five years, using the straight-line method. The intangible
asset consists of a licensing agreement that the Company acquired through its acquisition of Enviro Therapeutics, Inc. during the year
ended December 31, 2021, with an acquisition cost of $800 (see Note 3). Amortization expense relating to the intangible asset during
the years ended December 31, 2022 and 2023 was $160, respectively, with an unamortized balance of $542 and $382 at December 31, 2022
and 2023, respectively.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Impairment
of Long-Lived Assets</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company applies the provisions of ASC Topic 360, <I>Property, Plant, and Equipment</I>, which addresses financial accounting and reporting
for the impairment of long-lived assets. A long-lived asset that is held and used should be tested for recoverability whenever events
or changes in circumstances indicate that the carrying amount of the asset group may not be recoverable regardless of whether such carrying
amount is zero or negative. If the estimated undiscounted future cash flows are less than the carrying value, an impairment determination
is required. In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair value of the long-lived
assets. No impairment was recorded relating to the Company&rsquo;s intangible asset during the years ended December 31, 2022 and 2023.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT> </P>


<!-- Field: Page; Sequence: 145; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Net
Loss Per Share</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
loss per share is calculated in accordance with ASC Topic 260, <I>Earnings Per Share</I>. Basic earnings per share (&ldquo;EPS&rdquo;)
is based on the weighted average number of common shares outstanding. Diluted EPS is based on the assumption that all dilutive securities
are converted. When options or warrants are outstanding, dilution is computed by applying the treasury stock method. Under this method,
options and warrants are assumed to be exercised at the beginning of the period (or at the time of issuance, if later), and funds obtained
thereby are assumed to be used to purchase common stock at the average market price during the period. For the years ended December 31,
2022 and 2023, the basic and diluted shares outstanding were the same, as potentially dilutive shares were considered anti-dilutive.
At December 31, 2022 and 2023, the potentially dilutive securities consisted of 180,000 and 150,000 shares relating to outstanding stock
warrants, respectively.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Deferred
Offering Costs</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company capitalizes certain legal, professional, accounting and other third-party fees that are directly associated with in-process equity
issuances as deferred offering costs until such equity issuances are consummated. After consummation of the equity issuance, these costs
are recorded as a reduction in the capitalized amount associated with the equity issuance. Should the equity issuance be delayed or abandoned,
the deferred offering costs will be expensed immediately as a charge to operating expenses in the Statement of Operations. As of December
31, 2022 and 2023, the Company had incurred $57 and $482 of deferred offering costs related to the Company&rsquo;s initial public offering
of its common stock (&ldquo;IPO&rdquo;).</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Fair
Value Measurements</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.2pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company determines the fair value of its assets and liabilities based on the exchange price in U.S. dollars that would be received to
sell an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability
in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value maximize
the use of observable inputs and minimize the use of unobservable inputs. The Company uses a fair value hierarchy with three levels of
inputs, of which the first two are considered observable and the last unobservable, to measure fair value:</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Level
    1 &mdash;</I> Quoted prices in active markets for identical assets or liabilities.</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Level
    2 &mdash;</I> Inputs, other than Level 1, that are observable, either directly or indirectly, such as quoted prices for similar assets
    or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable
    market data for substantially the full term of the assets or liabilities.</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Level
    3 &mdash;</I> Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of
    the assets or liabilities.</FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying amounts of financial instruments such as cash, and accounts payable and accrued liabilities, approximate the related fair values
due to the short-term maturities of these instruments. The carrying amounts of the Company&rsquo;s convertible notes payable approximate
their fair values as the interest rates of the notes are based on prevailing market rates.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Income
Taxes</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income
tax expense is based on pretax financial accounting income. Deferred tax assets and liabilities are recognized for the expected tax consequences
of temporary differences between the tax bases of assets and liabilities and their reported amounts. Valuation allowances are recorded
to reduce deferred tax assets to the amount that will more likely than not be realized. The Company recorded a 100% valuation allowance
against its deferred tax assets as of December 31, 2022 and 2023.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>


<!-- Field: Page; Sequence: 146; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for uncertainty in income taxes using a two-step approach to recognizing and measuring uncertain tax positions. The
first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more
likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any.
The second step is to measure the tax benefit as the largest amount that is more than 50 percent likely of being realized upon settlement.
The Company classifies the liability for unrecognized tax benefits as current to the extent that the Company anticipates payment (or
receipt) of cash within one year. Interest and penalties related to uncertain tax positions are recognized in the provision for income
taxes.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Patents
and Patent Application Costs</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
the Company believes that its patents and underlying technology have continuing value, the amount of future benefits to be derived from
the patents is uncertain. Patent costs are therefore expensed as incurred and are included in General and administrative expenses on
the accompanying consolidated Statements of Operations. Patent expenses were $110 and $45 during the years ended December 31, 2022 and
2023.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Research
and Development Costs</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company expenses its research and development costs as incurred. Research and developments costs for the years ended December 31, 2022
and 2023 were $87 and $82, respectively.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Pro
Forma Financial Information (unaudited)</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the closing of a qualified public offering (as defined in the Company&rsquo;s Certificate of Incorporation), all of the Company&rsquo;s
convertible notes payable, including accrued interest, and certain accounts payable will automatically convert into shares of common
stock. The accompanying unaudited pro forma balance sheet as of December 31, 2023 has been prepared to give effect to (i) the automatic
conversion of all of the convertible notes payable and accrued interest into an aggregate of 334,375 shares of common stock as if the
Company&rsquo;s proposed public offering had occurred on December 31, 2023, (ii) the issuance of 312,500 shares of common stock upon
the conversion of certain accounts payable as of December 31, 2023 and (iii) the issuance of 1,664 shares of common stock upon the conversion
of certain amounts due to related parties as of December 31, 2023, each in connection with the closing of this offering. The shares of
common stock issuable and the proceeds expected to be received in the proposed public offering are excluded from such pro forma financial
information.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
unaudited pro forma basic and diluted net loss per share in the accompanying statements of operations for the year ended December 31,
2023 have been computed to give effect to the automatic conversion of all convertible notes payable, amounts due to related parties,
and certain accounts payable into shares of common stock. The unaudited pro forma basic and diluted net loss per share for the year ended
December 31, 2023 was computed using the weighted average number of shares of common stock outstanding, including the pro forma effect
of the conversion of all convertible notes payable and the related accrued interest, and certain accounts payable and amounts due to
related parties, as if the Company&rsquo;s proposed public offering had occurred on January 1, 2023. The unaudited pro forma net loss
per share does not include the shares expected to be sold or related proceeds to be received in the proposed public offering.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>


<!-- Field: Page; Sequence: 147; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the Company&rsquo;s unaudited pro forma net loss per share (in thousands except for share amounts and per share data):</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
  <TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"> Year Ended<BR> December 31, 2023 </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD> Numerator: </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 78%; text-align: left; padding-bottom: 2.5pt; padding-left: 10pt"> Net loss </TD><TD STYLE="width: 2%; padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="width: 18%; border-bottom: Black 2.5pt double; text-align: right"> (1,812 </TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; text-align: left"> ) </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD> Denominator: </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt"> Weighted average number of common shares outstanding </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 10,382,515 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt"> Pro forma weighted average shares outstanding after giving
    effect to the conversion of convertible notes payable and certain accounts payable </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 648,539 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt; padding-left: 10pt"> Pro forma weighted average common shares outstanding </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> 11,031,054 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt"> Pro forma net loss per share, basic and diluted </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> (0.16 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> ) </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Recent
Accounting Pronouncements</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2019, the Financial Accounting Standards Board (&ldquo;FASB&rdquo;) issued Accounting Standards Update (&ldquo;ASU&rdquo;) 2019-12,
<I>Simplifying the Accounting for Income Taxes</I> which amends ASC 740 <I>Income Taxes</I> (ASC 740). This update is intended to simplify
accounting for income taxes by removing certain exceptions to the general principles in ASC 740 and amending existing guidance to improve
consistent application of ASC 740. This update is effective for fiscal years beginning after December 15, 2021. The guidance in this
update has various elements, some of which are applied on a prospective basis and others on a retrospective basis with earlier application
permitted. The Company is currently evaluating the effect of this ASU on the Company&rsquo;s financial statements and related disclosures.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">In
August 2020, the FASB issued ASU No. 2020-06 (&ldquo;ASU 2020-06&rdquo;) &ldquo;<I>Debt&mdash;Debt with Conversion and Other Options
(Subtopic 470-20) and Derivatives and Hedging&mdash;Contracts in Entity&rsquo;s Own Equity (Subtopic 815-40)</I>.&rdquo; ASU 2020-06
reduces the number of accounting models for convertible debt instruments by eliminating the cash conversion and beneficial conversion
accounting models. As a result, the Company&rsquo;s convertible debt instruments will be accounted for as a single liability measured
at its amortized cost as long as no other features require bifurcation and recognition as derivatives. For contracts in an entity&rsquo;s
own equity, the type of contracts primarily affected by this update are freestanding and embedded features that are accounted for as
derivatives under the current guidance due to a failure to meet the settlement conditions of the derivative scope exception. The Company
adopted ASU No. 2020-06 effective January 1, 2021 using the modified retrospective approach.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounted for convertible notes payable (when it has determined that the embedded conversion options should not be bifurcated
from their host instruments) in accordance with ASC 470-20, <I>Debt with Conversion and Other Options </I>up through December 31, 2020.
Accordingly, the Company recorded, when necessary, discounts to convertible notes payable for the intrinsic value of conversion options
embedded in debt instruments based upon the differences between the fair value of the underlying common stock at the commitment date
of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements were amortized
over the term of the related debt to their earliest date of redemption. The Company determined that the embedded conversion options in
its issued convertible notes payable do not meet the definition of a derivative liability.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2021, the FASB issued ASU 2021-04, <I>Earnings Per Share (Topic 260), Debt&mdash;Modifications and Extinguishments (Subtopic 470-50),
Compensation&mdash;Stock Compensation (Topic 718), and Derivatives and Hedging&mdash;Contracts in Entity&rsquo;s Own Equity (Subtopic
815-40): Issuer&rsquo;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options</I>.
ASU 2021-04 provides clarification and reduces diversity in an issuer&rsquo;s accounting for modifications or exchanges of freestanding
equity-classified written call options (such as warrants) that remain equity classified after modification or exchange. An issuer measures
the effect of a modification or exchange as the difference between the fair value of the modified or exchanged warrant and the fair value
of that warrant immediately before modification or exchange. ASU 2021-04 introduces a recognition model that comprises four categories
of transactions and the corresponding accounting treatment for each category (equity issuance, debt origination, debt modification, and
modifications unrelated to equity issuance and debt origination or modification). ASU 2021-04 is effective for all entities for fiscal
years beginning after December 15, 2021, including interim periods within those fiscal years. An entity should apply the guidance provided
in ASU 2021-04 prospectively to modifications or exchanges occurring on or after the effective date. Early adoption is permitted for
all entities, including adoption in an interim period. If an entity elects to early adopt ASU 2021-04 in an interim period, the guidance
should be applied as of the beginning of the fiscal year that includes that interim period. The adoption of ASU 2021-04 is not expected
to have a material impact on the Company&rsquo;s financial statements or disclosures.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>


<!-- Field: Page; Sequence: 148; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public
Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company&rsquo;s
present or future consolidated financial statements.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
3 &ndash; ACQUISITION OF ENVIRO THERAPEUTICS, INC.</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 3, 2021, the Company and Enviro Therapeutics, Inc. (&ldquo;Enviro&rdquo;) entered into a share exchange agreement, whereby the Company
acquired all of the common stock of Enviro in exchange for shares of the Company&rsquo;s common stock (the &ldquo;Enviro-Kairos Share
Exchange&rdquo;). Pursuant to the Enviro-Kairos Share Exchange, the Enviro shareholders exchanged 100% of the issued and outstanding
shares of Enviro (on a fully diluted basis) for 2,400,000 restricted shares of the Company&rsquo;s common stock.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s Chairman, Chief Executive Officer and majority shareholder, was also a shareholder of Enviro who exercised control over
Enviro. The acquisition of Enviro by the Company is being treated as a transaction between entities under common control resulting in
the historical cost basis of Enviro&rsquo;s assets and liabilities being recognized, rather than the asset and liabilities being recorded
at fair value as would be the case in a business combination between entities not under common control. The historical cost basis of
Enviro&rsquo;s asset and liabilities is as follows:</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 78%"> Cash </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 18%; text-align: right"> 6 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Intangible assets </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 800 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Accounts payable </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (51 </TD><TD STYLE="text-align: left"> ) </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt"> Advances from related parties </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> (129 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> ) </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> 627 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
4 &ndash; ADVANCES FROM RELATED PARTIES</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2021, shareholders of the Company, and a company whose principal stockholder is also a stockholder of the
Company, advanced the Company $14, which was all outstanding at December 31, 2021. The advances accrue no interest, are unsecured and
are due on demand. As of December 31, 2021, $14 was owed on the advances. During the year ended December 31, 2022, the Company repaid
$10 of the advances, and as of December 31, 2022 and 2023, a total of $4 was outstanding.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
5 &ndash; NOTE PAYABLE</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July 2020, the Company entered into a note payable agreement with another company under which the Company borrowed $50. The note accrues
interest at 1% per annum, is unsecured and is due in July 2021. As of December 31, 2020, $50 was outstanding on the note. During the
year ended December 31, 2021, the Company repaid $20 on the note, and as of December 31, 2021, $30 was outstanding on the note. During
the year ended December 31, 2022, the Company repaid $30 on the note, and as of December 31, 2022, no amount was outstanding on the note.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
6 &ndash; CONVERTIBLE NOTES PAYABLE</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Convertible
notes payable consisted of the following as of December&nbsp;31, 2022 and 2023:</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="margin-left: 0.5in; border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"> December&nbsp;31,<BR> 2022 </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"> December&nbsp;31,<BR> 2023 </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"> Convertible note payable (a) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"> Convertible note payable (b) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; width: 64%; text-align: justify"> Convertible notes payable (c) </TD><TD STYLE="padding-bottom: 1.5pt; width: 2%"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"> 675 </TD><TD STYLE="padding-bottom: 1.5pt; width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt; width: 2%"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"> 743 </TD><TD STYLE="padding-bottom: 1.5pt; width: 1%; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 675 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 743 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt"> Less: current portion </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 2.5pt"> Convertible notes payable &ndash; long - term portion </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> 675 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> 743 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 0.25in">&nbsp;</TD>
  <TD STYLE="text-align: justify; width: 0.25in"> (a) </TD>
  <TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In August 2021, the
  Company entered into a convertible note payable agreement with an individual in the amount of $350. The note accrued interest at 10%
  per annum, was unsecured and was due the latter of August 2021 or the closing of a proposed merger by the Company. The note was
  convertible at the option of the noteholder to convert into shares of the Company&rsquo;s common stock at $4.17 per share. At
  December 31, 2021, principal of $350 and accrued and unpaid interest of $14, was owed on the note. During the year ended December
  31, 2022, the note accrued interest of $23. In 2022, all the principal plus accrued and unpaid interest converted into 92,000 shares
  of the Company&rsquo;s common stock based on the principal and accrued interest due on the date of conversion. As of December 31, 2022 and 2023, no principal or accrued interest was outstanding on the note.</FONT> </TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>


<!-- Field: Page; Sequence: 149; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
  <TD STYLE="text-align: justify; width: 0.25in"> (b) </TD>
  <TD STYLE="text-align: justify"> During <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the year ended
  December 31, 2022, the Company entered into a convertible note payable agreement with the same individual in the amount of $250. The
  note accrued interest at 10% per annum, was unsecured and was due upon the closing of a proposed IPO transaction by the Company, or
  by July 2022, if the IPO transaction has not occurred by that date. The note included an original issue discount (OID) of 8.0%. The
  note was convertible at the option of the noteholder to convert into shares of the Company&rsquo;s common stock at $4.17 per share
  or will be automatically converted into shares of the Company&rsquo;s common stock at $4.17 per share upon the closing of an IPO
  transaction. The net proceeds received relating to the agreement were $230.</FONT> </TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the convertible note payable, the Company issued the noteholder a warrant to purchase 150,000 shares of the Company&rsquo;s
common stock for $4.17 per share. The warrant expires in March 2025. The Company calculated the relative fair value of the warrant issued
to the noteholder to be $390 using a Black Scholes option pricing model and recognized a debt discount at the date of issuance in the
same amount. The note discount is being amortized over the term of the note and the unamortized portion is recognized as a reduction
to the carrying amount of the note. As the note matured during the year ended December 31, 2022, the Company amortized the entire amount
of the debt discount, leaving no unamortized balance at December 31, 2022. As of December 31, 2022 and 2023, no principal or accrued interest was outstanding on the note.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
2022, all of the principal plus accrued and unpaid interest from both convertible notes payable above totaling $600 of principal,
plus accrued and unpaid interest of $48, converted into 154,782 shares of the Company&rsquo;s common stock based on the principal
and accrued interest due on the date of conversion. As of December 31, 2022 and 2023, no principal or accrued interest was
outstanding on the two notes.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="width: 0.25in"> (c) </TD>
  <TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended
  December 31, 2022, the Company entered into several convertible note payable agreements with individuals and an entity in the
  aggregate total of $675. The notes accrue interest at 6% per annum, are unsecured and are due by April 2025. If the Company does not
  close an IPO transaction within 12 months of the date of the note, the Company will have the choice of paying off the principal plus
  all accrued and unpaid interest, or the note&rsquo;s principal balance will increase to 110% of its original balance. The notes are
  convertible at the option of the noteholders to convert into shares of the Company&rsquo;s common stock at a price per share as
  defined in the agreement or will automatically be converted into shares of the Company&rsquo;s common stock at 60% of the IPO price
  per share upon the closing of an IPO transaction. The net proceeds relating to the agreements, net of expenses, were $564. As of
  December 31, 2022, $675 of principal was outstanding on the notes, and $17 of accrued and unpaid interest.</FONT> </TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2023, no principal or interest payments were made on the notes and the notes accrued interest of $43. As the Company did not close its IPO transaction within 12 months of the
date of the notes, the notes&rsquo; principal balance increased to 110% of their original balance, or an increase of $68. As of December 31, 2023, $743 of principal was outstanding on the notes and $60 of accrued and unpaid interest.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"> The Company accounted for the
$68 increase in the principal balance as a debt discount. During the year ended December 31, 2023, the Company amortized $16 of debt
discount, leaving an unamortized balance of $52 at December 31, 2023. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Also
in connection with the convertible note agreements, the Company incurred debt issuance costs of $111, which the Company recorded as a
debt discount during the year ended December 31, 2022. During the year ended December 31, 2022, the Company amortized $18 of debt discount,
leaving an unamortized balance of $93 at December 31, 2022. During the year ended December 31, 2023, the Company amortized $40 of debt
discount, leaving an unamortized balance of $53 at December 31, 2023. As of December 31, 2023, there was a total unamortized balance
of $105.</FONT> </P>

<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"> <FONT STYLE="background-color: white">In
the event the Company closes its IPO, then the principal amount of $743, plus the accrued and unpaid interest of $60, will automatically
convert into 334,375 shares of the Company&rsquo;s common stock based on the principal and accrued interest due as of December 31,
2023.</FONT> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
7 &ndash; SHAREHOLDERS&rsquo; EQUITY</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Common
Stock</U></B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I><U>Authorized
Shares</U></I></B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s Certificate of Incorporation, as filed with the State of Delaware on May 10, 2023, following the Company&rsquo;s conversion
from a California corporation into a Delaware corporation, authorizes the Company to issue up to 120,000,000 shares, consisting of 100,000,000
shares of common stock, par value of $0.001 per share, and 20,000,000 shares of preferred stock, par value $0.001 per share. Holders
of shares of common stock have full voting rights, one vote for each share held of record. Shareholders are entitled to receive dividends
as may be declared by the board of directors out of funds legally available and share pro rata in any distributions with shareholders
upon liquidation. Shareholders have no conversion, pre-emptive or subscription rights. All outstanding shares of common stock are fully
paid and non-assessable. As of December 31, 2022 and 2023, there were 10,334,357 and 10,562,640 shares of common stock issued and outstanding,
respectively, and no shares of preferred stock outstanding, respectively.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>


<!-- Field: Page; Sequence: 150; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I><U>Common
Stock to be Issued for Services</U></I></B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
September 2020, the Company entered into a verbal agreement with a consulting firm to provide certain business development services to
the Company. The agreement was formally executed in April 2021 but contained the same terms as the verbal agreement. The term of the
agreement was from September 1, 2020 to January 31, 2021, which is the defined service period for the services to be performed and provided
for the issuance of 2,100,000 restricted shares of the Company&rsquo;s common stock to the consulting firm. The shares vested over the
term of the agreement and had a fair value on the date of the verbal agreement of $1,000. The shares were not issued to the consulting
firm until 2022 and thus are categorized as Common Stock to be Issued on the accompanying December 31, 2021 consolidated Statement of
Shareholders&rsquo; Deficit.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <B><I><U>Common Shares Issued in Connection with
a Shareholder Dispute</U></I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <B><I>&nbsp;</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> During the year ended December 31, 2023, the Company
issued 228,284 shares of its common stock to two shareholders relating to the settlement of a dispute. The Company valued the shares
on the date of grant to be $913. The value of the shares was recorded in general and administrative expenses during the year ended December
31, 2023. Upon the issuance of the shares, the shareholders entered into agreements with the Company under which they agreed to the final settlement
of the dispute. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I><U>Stock
Warrants</U></I></B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below summarizes the Company&rsquo;s warrant activities for years ended December 31, 2022 and 2023:</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.5in">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"> &nbsp; </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"> Number of<BR>
 Warrant Shares </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"> Exercise Price<BR>
 Range Per Share </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"> Weighted Average<BR>
 Exercise Price </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 46%"> Balance, December 31, 2021 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"> 120,000 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> $ </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.17
                                            - 8.33</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> $ </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"> 5.23 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> Granted </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 150,000 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 4.17 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 4.17 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> Cancelled </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> &ndash; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> &ndash; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> &ndash; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> Exercised </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> &ndash; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> &ndash; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> &ndash; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> Forfeited/Expired </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> (90,000 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> ) </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> 4.17 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> 4.17 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> Balance, December 31, 2022 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 180,000 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.17
                                            - 8.33</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 4.86 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> Granted </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> &ndash; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> &ndash; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> &ndash; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> Cancelled </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> &ndash; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> &ndash; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> &ndash; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> Exercised </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> &ndash; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> &ndash; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> &ndash; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> Forfeited/Expired </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> (30,000 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> ) </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> 8.33 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> 8.33 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> Balance, December 31, 2023 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> 150,000 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"> $ </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> 4.17 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"> $ </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> 4.17 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> Vested and exercisable, December 31, 2023 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> 150,000 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"> $ </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> 4.17 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"> $ </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> 4.17 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>


<!-- Field: Page; Sequence: 151; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes information concerning outstanding and exercisable warrants as of December 31, 2023:</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="10" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"> Warrants Outstanding </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="10" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"> Warrants Exercisable </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Range
                                            of</B></FONT> </P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exercise</B></FONT> </P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Prices</B></FONT> </P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number</B></FONT> </P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Outstanding</B></FONT> </P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Average</B></FONT> </P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Remaining</B></FONT> </P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Contractual</B></FONT> </P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Life</B></FONT> </P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(in
                                            years)</B></FONT> </P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Weighted</B></FONT> </P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Average</B></FONT> </P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exercise
                                            Price</B></FONT> </P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number</B></FONT> </P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exercisable</B></FONT> </P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Average</B></FONT> </P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Remaining</B></FONT> </P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Contractual</B></FONT> </P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Life</B></FONT> </P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(in
                                            years)</B></FONT> </P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Weighted</B></FONT> </P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Average</B></FONT> </P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exercise</B></FONT> </P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Price</B></FONT> </P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left; width: 1%"> $ </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right; width: 10%"> 4.17 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left; width: 1%"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 2%"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right; width: 1%"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right; width: 11%"> 150,000 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 2%"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left; width: 1%"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right; width: 11%"> 1.17 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left; width: 1%"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 2%"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left; width: 1%"> $ </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right; width: 11%"> 4.17 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left; width: 1%"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 2%"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right; width: 1%"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right; width: 11%"> 150,000 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 2%"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left; width: 1%"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right; width: 11%"> 1.17 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left; width: 1%"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 2%"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left; width: 1%"> $ </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right; width: 11%"> 4.17 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left; width: 1%"> &nbsp; </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2022, the Company entered into a convertible note payable agreement with an individual in the amount of $250.
In connection with that agreement, the Company granted a warrant to the lender to purchase up to 150,000 shares of the Company&rsquo;s
common stock with an exercise price of $4.17 per share. The warrant expires in March 2025.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2021, the Company entered into a convertible note payable agreement with an individual in the amount of $350
(see Note 6). In connection with that agreement, the Company granted a warrant to the lender to purchase up to 90,000 shares of the Company&rsquo;s
common stock with an exercise price of $4.17 per share. The warrant expired in August 2022. Also in 2021, the Company sold 60,000 shares
of its common stock for net proceeds of $250. In connection with the sale, the Company issued a stock warrant to the shareholder to purchase
30,000 shares of the Company&rsquo;s common stock with an exercise price of $8.33 per share. The warrant expired in April 2023.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Also
in 2022, the Company granted the underwriters for their IPO, two stock warrants in connection with bridge loans they assisted the Company
in obtaining <FONT STYLE="background-color: white">(see Note 6)</FONT>. The underwriters <FONT STYLE="background-color: white">will be
entitled to receive the number of warrant shares equal to 7% of the conversion shares that will be issued to the lenders at the time
of the IPO. The warrants will be good for five years from the date of the IPO. However, the underwriters may not sell the shares underlying
the warrants for a period of six months following the IPO. The exercise price for the warrants will be equal to 60% of the per share
price of the Company&rsquo;s common stock sold in the IPO.</FONT></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
was no intrinsic value for warrant shares outstanding at December 31, 2023.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
8 &ndash; INCOME TAXES</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial
reporting purposes and the amounts used for income tax purposes. A full valuation allowance is established against all net deferred tax
assets as of December 31, 2022 and 2023 based on estimates of recoverability. While the Company has optimistic plans for its business
strategy, it determined that such a valuation allowance was necessary given the current and expected near term losses and the uncertainty
with respect to its ability to generate sufficient profits from its business model. Because of the impacts of the valuation allowance,
there was no income tax expense or benefit for the years ended December 31, 2022 and 2023.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>


<!-- Field: Page; Sequence: 152; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
reconciliation of the differences between the effective and statutory income tax rates for the years ended December 31, 2022 and 2023
is shown below:</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"> 2022 </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"> 2023 </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"> Amount </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"> Percent </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"> Amount </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"> Percent </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 38%; text-align: left"> Federal statutory rates </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> $ </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"> (221 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> ) </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"> 21.0 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: left"> % </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> $ </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"> (381 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> ) </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"> 21.0 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: left"> % </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> State income taxes </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> (84 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> ) </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 8.0 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> % </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> (145 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> ) </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 8.0 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> % </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> Permanent differences </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 18 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> (0.2 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> )% </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> - </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> - </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> % </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"> Valuation allowance against net deferred tax assets </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> 287 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> (28.8 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> )% </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> 526 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> (29.0 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> )% </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"> Effective rate </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"> - </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"> - </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> % </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"> - </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"> - </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> % </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2022 and 2023, the significant components of the deferred tax assets and liabilities are summarized below:</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"> 2022 </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"> 2023 </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> Deferred income tax assets: </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left; padding-left: 10pt"> Net operating loss carryforwards </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> $ </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"> 604 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> $ </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"> 857 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"> Amortization of intangibles </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 37 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 37 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; padding-left: 10pt"> Accrued expenses </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> 463 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> 687 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 20pt"> Total deferred income tax assets </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 1,104 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 1,581 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; padding-left: 10pt"> Less: valuation allowance </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> (1,104 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> ) </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"> (1,581 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> ) </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"> Total deferred income tax assets </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"> - </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"> $ </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"> - </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> &nbsp; </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
valuation allowance increased by $218 and $477 in 2022 and 2023, respectively, as a result of the Company generating additional net operating
losses.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has recorded as of December 31, 2022 and 2023 a valuation allowance of $1,104 and $1,581, respectively, as it believes that it
is more likely than not that the deferred tax assets will not be realized in future years. Management has based its assessment on the
Company&rsquo;s lack of profitable operating history.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company conducts an analysis of its tax positions and has concluded that it has no uncertain tax positions as of December 31, 2022 and
2023.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has net operating loss (&ldquo;NOL&rdquo;) carryforwards of approximately $2,000 and are subject to IRS code section 382 limitations.
Approximately $9 of the net operating loss carry-forwards begin to expire in 2031 and approximately $2,000 may be carried forward indefinitely.
NOL carryforwards may be subject to limitation under Sections 382 of the Internal Revenue Code, and similar state provisions which limit
the amount carryforwards that can be utilized to offset future taxable income. In general, an ownership change, as defined by Sections
382, results from transactions increasing ownership of certain stockholders in the stock of the corporation by more than 50 percentage
points over a three-year period. The Company does not anticipate performing a complete analysis of the limitation on the annual use of
the net operating loss carryforwards until the time that it anticipates it will be able to utilize these tax attributes. This could impose
an annual limit or reduction on the Company&rsquo;s ability to utilize net operating loss carryforwards and could cause U.S. federal
income taxes to be paid earlier than otherwise would be paid if such limitations were not in effect. The U.S. federal net operating loss
carryforwards are stated before any such anticipated limitations. If a change in ownership were to have occurred, the Company&rsquo;s
NOL carryforwards could be eliminated or restricted.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2021, 2022 and 2023 tax years are still subject to audit.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Coronavirus Aid, Relief, and Economic Security (CARES) Act was enacted on March 27, 2020. Among the business provisions, the CARES Act
provided for various payroll tax incentives, changes to net operating loss carryback and carryforward rules, business interest expense
limitation increases, and bonus depreciation on qualified improvement property. Additionally, the Consolidated Appropriations Act of
2021 was signed on December 27, 2020 which provided additional COVID relief provisions for businesses. The Company has evaluated the
impact of both the Acts and has determined that any impact is not material to its financial statements.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>


<!-- Field: Page; Sequence: 153; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
9 &ndash; COMMITMENTS</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I><U>Kairos
Exclusive License Agreements with Cedars-Sinai Medical Center (Cedars)</U></I></B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has entered into four Exclusive License Agreements with Cedars which grants the Company licensing rights with respect to certain
patent rights owned by Cedars as follows:</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.22in; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Methods
    of use of compounds that bind to RelA of NFkB;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Composition
    and methods for treating fibrosis;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compositions
    and methods for treating cancer and autoimmune diseases; and</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Method
    of generating activated T cells for cancer therapy.</FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
each of the exclusive license agreement in items 1, 2 and 3, the Company was required to pay an initial license fee of $5, reimburse
Cedars for patent protection costs ranging from approximately $9 to $61, pay an annual maintenance fee of $10, and pay royalties based
on 3.75% of net sales and pay other non-royalty sublicense fees ranging from 5% to 35% of sales of products. In addition, for items 1,
2 and 3, the Company is required to pay Cedars based on the following milestones:</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.22in; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$150
    upon the successful completing of Phase I clinical trial;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$250
    (for items 1 and 2) and $500,000 (for item 3) upon the successful completing of Phase II clinical trial for a product and receipt
    of Food and Drug Administration (&ldquo;FDA&rdquo;) approval for a Phase III clinical trial;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$1,500
    upon receipt of FDA approval of a new drug application or equivalent foreign regulatory approval in a non-United States major commercial
    market; and</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$250
    upon cumulative net sales exceeding $5,000.</FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
exclusive license agreement in item 4, the Company is required to pay an initial license fee of $50 upon the raising of $500 in capital,
pay an annual maintenance fee of $10, pay royalties based on 4.25% of patent product sales and 0.5% of other sales and pay other non-royalty
sublicense fees ranging from 5% to 35%. In addition, the Company is required to pay Cedars based on the following milestones:</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.22in; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$150
    upon the successful completing of Phase I clinical trial;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$250
    upon the successful completing of Phase II clinical trial and receipt of Food and Drug Administration (&ldquo;FDA&rdquo;) or equivalent
    regulatory agency in another jurisdiction approval for a Phase III clinical trial;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$1,500
    upon receipt of FDA approval of a new drug application; and</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$2,500
    upon cumulative net sales exceeding $50,000.</FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I><U>Enviro
Therapeutics</U></I></B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 2, 2021, the Company&rsquo;s wholly owned subsidiary, Enviro Therapeutics, Inc. (Enviro), entered into two Exclusive License Agreements
with Cedars, which granted Enviro exclusive licensing rights (which include the right to sublicense) with respect to certain patent rights
owned by Cedars, as follows:</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.22in; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
    Exclusive License Agreement (the &ldquo;Enviro-Cedars License Agreement (Mitochondrial DNA)&rdquo;) for Enviro to develop, manufacture,
    use and sell products utilized or derived from patent rights worldwide related to the &ldquo;Compositions and Methods for Treating
    Diseases and Conditions by Depletion of Mitochondrial DNA from Circulation and for Detection of Mitochondrial DNA&rdquo; invented
    by Dr. Neil Bhowmick and others; and</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
    Exclusive License Agreement, (the &ldquo;Enviro-Cedars License Agreement (Endoglin Antagonism)&rdquo; and, collectively with the
    Enviro-Cedars License Agreement (Mitochondrial DNA), the &ldquo;Enviro-Cedars License Agreements&rdquo;) for Enviro to develop, manufacture,
    use and sell products utilized or derived from the patent rights and technical information worldwide related to the &ldquo;Sensitization
    of Tumors to Therapies Through Endoglin Antagonism&rdquo; invented by Dr. Neil Bhowmick and others.</FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>


<!-- Field: Page; Sequence: 154; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
exchange for each of the licenses, Enviro is required to pay an upfront license fee in the mid four-figures and low-five figures, respectively.
Enviro is also required to reimburse Cedars for the costs in the mid-to-high six figures incurred in the prosecution of the patent rights
subject to the Enviro-Cedars License Agreements prior to the date of execution of such agreements, and certain costs and fees then outstanding
aggregating in the low-six figures owed by Kairos pursuant to the Kairos-Cedars License Agreements. Pursuant to the Enviro-Cedars License
Agreements, Cedars shall also receive royalty payments of a mid-single-digit percentage of net sales of products associated with the
licensed patent right and less than one percent of net sales of other products derived from Cedars&rsquo; technical information, with
a minimum annual royalty fee in the low five-digits due beginning on the third anniversary of the effective date of the Enviro-Cedars
License Agreements. To the extent Enviro derives non-royalty sublicensing revenues, a high single-digit to low double-digit percentage
of such revenues would be due and payable to Cedars, with the actual percentage of such revenues dependent on the stage of FDA authorization
at the time the sublicense revenue is generated.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enviro
is also required to pay Cedars in connection with achieving the following Payment Milestones relating to products derived from the patent
rights: successful completion of a Phase I clinical trial; successful completion of a Phase II clinical trial, receipt of FDA approval,
and approval for a Phase III clinical trial; FDA approval of an NDA or BLA; cumulative net sales exceeding $50,000; and cumulative net
sales exceeding $100,000. If all of these payment milestones are met among both of the Enviro-Cedars License Agreements, the required
milestone payments would total in the mid-to-high seven-figures.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Enviro-Cedars License Agreements, Enviro is obligated to meet the following Commercialization Milestones. Pursuant to the Enviro-Cedars
License Agreement (Endoglin Antagonism), Enviro is obligated to (1) obtain an IND for a patent product within 1 year of the effective
date of the agreement, (2) commence a Phase II trial within 2 years of the effective date of the agreement, and (3) submit an NDA or
BLA to the FDA or equivalent regulatory agency in another jurisdiction within 7 years of the effective date of the agreement. Pursuant
to the Enviro-Cedars License Agreement (Mitochondrial DNA), Enviro is obligated to (1) complete preclinical studies of a patent product
within 2 years of the effective date of the agreement, (2) complete toxicology studies within 2.5 years of the effective date of the
agreement, (3) obtain IND within 3 years of the effective date of the agreement, (4) begin a Phase I trial within 4 years of the effective
date of the agreement, and (5) submit an NDA or BLA to the FDA or equivalent regulatory agency in another jurisdiction within 7 years
of the effective date of the agreement. If the Commercialization Milestones are not met or extended, Cedars may convert the exclusive
licenses into non-exclusive licenses or to a co-exclusive licenses or terminate the licenses.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Enviro-Cedars License Agreements will, unless sooner terminated, continue in effect on a country-by-country basis until the last of the
patents covering the patent rights or future patent rights expires. Under the terms of the Enviro-Cedars License Agreements, unless waived
by Cedars, the agreements would automatically terminate: (a) if Enviro ceases, dissolves or winds up its business operations; (b) if
performance by either party jeopardizes the licensure, accreditation or tax exempt status of Cedars or the agreement is deemed illegal
by a governmental body; (c) within 30 days for non-payment of royalties or if Enviro fails to undertake commercially reasonable efforts
to exploit the patent rights or future patent rights; (d) within 60 days of Cedars&rsquo; failure to cure any breach or default of a
material obligation under the agreements; (e) within 90 days of Enviro&rsquo;s failure to cure any breach or default of a material obligation
under the agreements; or (f) upon mutual written agreement of the parties.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I><U>License
Agreement with Tracon Pharmaceutical, Inc.</U></I></B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 21, 2021, Enviro entered into a License Agreement with Tracon Pharmaceutical, Inc. (&ldquo;Tracon&rdquo;). Pursuant to the Tracon
License Agreement, Tracon granted Enviro access to inactive IND filings for &ldquo;TRC105&rdquo; in the United States; ownership of &ldquo;TRC105&rdquo;
stored vials of drug product manufactured to GMP standards stored at Fisher Clinical or their designee; and assignment of Tracon&rsquo;s
patent rights to its &ldquo;CD105 technologies&rdquo; (all as defined or described in the Tracon License Agreement).</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>


<!-- Field: Page; Sequence: 155; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Tracon License Agreement, Enviro paid Tracon an upfront fee of $100, and will pay Tracon an additional $500 upon its or its successor&rsquo;s
completion of one or more financings through the sale of equity (or debt convertible to equity) in an amount of $10,000, and an additional
$500 within 10 days of its or its successor&rsquo;s completion of one or more financings through the sale of equity (or debt convertible
to equity) in an amount of $22,000 (the payment of the $100 and the two payments of $500 are referred to in the aggregate as the &ldquo;Cash
Consideration&rdquo;). In addition, Enviro will pay Tracon a royalty of 3% of net sales on a country-by-country basis of the products
subject to the Tracon License Agreement, and non-royalty payments of 3% of sublicensing fees.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enviro
issued Tracon equity ownership in Enviro equal to a number of shares of restricted common stock of Enviro equal to seven percent (7%)
on a fully-diluted and converted basis of all common and preferred shares of Enviro (the &ldquo;Tracon-Enviro Equity&rdquo;). In connection
with the Enviro-Kairos Share Exchange, the parties agreed that Tracon would receive, in exchange for its Enviro common stock, 420,000
restricted shares of Kairos Common Stock (which is equal to 1.41229% of the issued and outstanding shares of Kairos on a fully-diluted
and converted basis) as the Tracon-Enviro Equity. Until such time as Tracon has received all of the Cash Consideration (as defined in
the Tracon License Agreement), Enviro or its successor in interest, will issue to Tracon, without further consideration, any additional
shares of common stock of Enviro, or such successor in interest, necessary so that Tracon maintains ownership of shares of Enviro, or
such successor in interest, equal to the Tracon-Enviro Equity on a fully-diluted and converted basis of all stock in Enviro (or its successor).
Notwithstanding the foregoing, if Tracon receives the full Cash Consideration within six (6) months of the effective date of the Tracon
License Agreement, then Tracon will automatically return to Enviro (or any successor entity, if applicable) a number of restricted shares
of the common stock of Enviro (or its successor) such that upon such return of shares Tracon will possess an amount of shares in Enviro
(or its successor) equal to two percent (2%) on a fully-diluted and converted basis relative to the other Enviro shareholders who exchanged
their shares in the Enviro-Kairos Share Exchange. The returned portion of the Tracon-Enviro Equity will automatically be terminated,
cancelled and of no further force and effect.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I><U>Agreement
with former Chief Financial Officer</U></I></B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has an agreement with its former Chief Financial Officer that requires the Company to pay $50 upon the completion of raising
more than $850 in debt or equity financing. No amount was owed at December 31, 2022 and 2023.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <B>NOTE 10 &ndash; SUBSEQUENT EVENTS</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> Subsequent to December 31, 2023, the Company
entered into agreements with Cedars-Sinai Medical Center (Cedars) under which Cedars agreed to convert $750 of the total accounts
payable due to them of $942 into 312,500 shares of the Company&rsquo;s common stock upon the closing of the Company&rsquo;s IPO. The
conversion price of the shares will be equal to 60% of the IPO closing price. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> Subsequent to December 31, 2023, two officers
and shareholders agreed to convert the $4 due to them into 1,664 shares of the Company&rsquo;s common stock, effective upon the closing
of the Company&rsquo;s IPO. The conversion price of the shares will be equal to 60% of the IPO closing price. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> Subsequent to December 31, 2023, the Company borrowed $72 from three of its officers. The loans accrue interest
at 7.5%, are due in April 2025 and are unsecured. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>


<!-- Field: Page; Sequence: 156; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font: 10pt Times New Roman, Times, Serif; border-top: Black 4pt solid; border-bottom: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 14pt"><B>1,550,000
</B></FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 14pt"><B>Shares </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="logo_001.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 14pt"><B>Common
Stock </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="border-top: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>PROSPECTUS
</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="border-top: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 14pt"><B>Boustead
Securities,</B></FONT><FONT STYLE="font-size: 14pt"><B> LLC</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Through
and including&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , 2024 (the 25th day after
the date of this prospectus), all dealers effecting transactions in these securities, whether or not participating in this offering,
may be required to deliver a prospectus. This is in addition to a dealer&rsquo;s obligation to deliver a prospectus when acting as an
underwriter and with respect to an unsold allotment or subscription.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font: 10pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid; border-bottom: Black 4pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>




<!-- Field: Page; Sequence: 157 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PART
II </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>INFORMATION
NOT REQUIRED IN PROSPECTUS </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
otherwise indicated, all references to &ldquo;Kairos,&rdquo; the &ldquo;company,&rdquo; &ldquo;we,&rdquo; &ldquo;our,&rdquo; &ldquo;us,&rdquo;
or similar terms refer to Kairos Pharma, Ltd.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
13. Other Expenses of Issuance and Distribution. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth all expenses to be paid by us, other than underwriting discounts and commissions, in connection with this
offering. All amounts shown are estimates except for the Securities and Exchange Commission, or the SEC, registration fee, the Financial
Industry Regulatory Authority, Inc., or FINRA, filing fee, and either the NYSE American listing fee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><B>Amount Paid<BR>
 or to Be Paid</B></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 82%; text-align: left">SEC registration fee</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"> 1,141 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">FINRA filing fee</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 2,750 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">NYSE American listing fee</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 60,000 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Printing and engraving expenses</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*
</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Legal fees and expenses</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">* </FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Accounting fees and expenses</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">* </FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Custodian transfer agent and registrar fees</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">* </FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">Miscellaneous expenses</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">* </FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; padding-left: 10pt">Total</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;* </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 25%"><DIV STYLE="border-top: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To be provided by amendment. </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
14. Indemnification of Directors and Executive Officers. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 145 of the DGCL authorizes a court to award, or a corporation&rsquo;s
board of directors to grant, indemnity to directors and executive officers in terms sufficiently broad to permit such indemnification
under certain circumstances for liabilities, including reimbursement for expenses incurred, arising under the Securities Act of 1933,
as amended, or the Securities Act. Our certificate of incorporation permits indemnification of our directors, officers, employees and
other agents to the maximum extent permitted by the DGCL, and our bylaws provide that we will indemnify our directors and executive officers
and permit us to indemnify our employees and other agents, in each case to the maximum extent permitted by the DGCL.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have entered into indemnification agreements with our directors and executive officers, whereby we have agreed to indemnify our directors
and executive officers to the fullest extent permitted by law, including indemnification against expenses and liabilities incurred in
legal proceedings to which the director or executive officer was, or is threatened to be made, a party by reason of the fact that such
director or executive officer is or was a director, executive officer, employee, or agent of Kairos, provided that such director or executive
officer acted in good faith and in a manner that the director or executive officer reasonably believed to be in, or not opposed to, the
best interest of the company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
present, there is no pending litigation or proceeding involving a director or executive officer of the company regarding which indemnification
is sought, nor is the registrant aware of any threatened litigation that may result in claims for indemnification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
maintain insurance policies that indemnify our directors and officers against various liabilities arising under the Securities Act and
the Securities Exchange Act of 1934, as amended, that might be incurred by any director or officer in his capacity as such.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
underwriters are obligated, under certain circumstances, under the underwriting agreement to be filed as Exhibit 1.1 to this Registration
Statement, to indemnify us and our officers and directors against liabilities under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 158; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
15. Recent Sales of Unregistered Securities. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Set
forth below is information regarding unregistered securities issued by us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">On August 5, 2021, the Company issued
a $350,000 convertible note, bearing interest at a rate of 10% per annum, to a certain accredited investor. All of the principal plus
accrued and unpaid interest converted into 230,000 shares of the Company&rsquo;s common stock based on the principal and accrued interest
due on the date of conversion. The issuance was made in accordance with an exemption from registration in accordance Section 4(a)(2)
of the Securities Act.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white">On June 3,
2021, the Company issued a total of 6,000,000 shares of common stock to the shareholders of Enviro Therapeutics, Inc. in conjunction
with the Company&rsquo;s acquisition of Enviro pursuant to the terms of a share exchange agreement. The issuance was exempt from registration
pursuant to Section 4(a)(2) of the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white">During the
year ended December 31, 2021, the Company issued a total of 5,310,000 shares of common stock to certain bona fide consulting firms pursuant
to an exemption from registration under Rule 701 promulgated under the Securities Act as transactions under contracts relating to compensation,
or under Section 4(a)(2) of the Securities Act as a transaction by an issuer not involving a public offering. The recipients of such
securities were bona fide consulting firms. Appropriate legends were affixed to the securities issued in these transactions. Each of
the recipients of securities in these transactions had adequate access, through employment, business, or other relationships, to information
about us.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-size: 10pt">In March
2022</FONT><FONT STYLE="font-size: 8pt"></FONT><FONT STYLE="font-size: 10pt">, the Company entered into a convertible note payable
agreement with an individual in the amount of $250,000. The note accrues interest at 10% per annum, is unsecured and is due upon the
closing of a proposed IPO transaction by the Company, or by July 2022, if the IPO transaction has not occurred by that date. The note
includes an original issue discount (OID) of 8.0%. The note is convertible at the option of the noteholder to convert into shares of
the Company&rsquo;s common stock at $1.67 per share, or will be automatically converted into shares of the Company&rsquo;s common stock
at $1.67 per share upon the closing of an IPO transaction. In connection with the convertible note payable, the Company issued the noteholder
a warrant to purchase 250,000 shares of the Company&rsquo;s common stock for $1.67 per share. The convertible note and warrant offering
were made pursuant to an exemption from registration under Section 4(a)(2) of the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-size: 10pt">In
June and September 2022</FONT><FONT STYLE="font-size: 8pt"></FONT><FONT STYLE="font-size: 10pt">, the Company entered into
several convertible note payable agreements with individuals and an entity in the aggregate total of $675,000 (the &ldquo;Convertible Note Offering&rdquo;). The notes accrue
interest at 6% per annum, are unsecured and are due by April 2025. If the Company does not close an IPO transaction within 12 months
of the date of the note, the Company will have the choice of paying off the principal plus all accrued and unpaid interest, or the
note&rsquo;s principal balance will increase to 110% of its original balance. The notes are convertible at the option of the
noteholders to convert into shares of the Company&rsquo;s common stock at a price per share as defined in the agreement, or will be
automatically be converted into shares of the Company&rsquo;s common stock at 60% of the IPO price per share upon the closing of the
IPO.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Boustead Securities acted
as placement agent for the Convertible Note Offering and received a commission equal to 7.0% of the gross proceeds from the offering
and five-year warrants to purchase the equivalent of 7.0% of the shares issuable upon conversion of the convertible notes sold in the
offering, which warrants will be exercisable at 60% of the IPO per share offering price. This offering was made pursuant to an exemption
from registration under Rule 506(b) of Regulation D under the Securities Act.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
16. Exhibits and Financial Statement Schedules. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>(a)
Exhibits. </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap; width: 0.65in"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit&nbsp;</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number</B></FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt; width: 0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ex1-1.htm">Form of Underwriting Agreement by and between Kairos Pharma, Ltd. and Boustead Securities, LLC, as representative of the underwriters.</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1962011/000149315223034915/ex2-1.htm" STYLE="-sec-extract: exhibit">Agreement
    of Merger between Kairos Pharma, Ltd. and AcTcell Biopharma, Inc., dated November 13, 2019.</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2</FONT>*</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1962011/000149315223034915/ex2-2.htm" STYLE="-sec-extract: exhibit">Share
    Exchange Agreement between Kairos Pharma, Ltd. and Enviro Therapeutics, Inc,. dated June 3, 2021.</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap; vertical-align: top">3.1*</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><A HREF="https://www.sec.gov/Archives/edgar/data/1962011/000149315223034915/ex3-1.htm" STYLE="-sec-extract: exhibit">Certificate of Amendment of Article of Incorporation, field with Secretary of State of the State of California, dated July 15, 2016.</A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1962011/000149315223034915/ex3-2.htm" STYLE="-sec-extract: exhibit">Amended
    and Restated Articles of Incorporation of Kairos Pharma, Ltd., dated November 12, 2019 (California). </A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1962011/000149315223034915/ex3-3.htm" STYLE="-sec-extract: exhibit">Certificate of Conversion filed with the Secretary of State of the State of California, dated May 10, 2023.</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1962011/000149315223034915/ex3-4.htm" STYLE="-sec-extract: exhibit">Certificate of Conversion from a non-Delaware corporation to a Delaware corporation pursuant to section 265 of the Delaware General Corporation Law filed with the Secretary of State of the State of Delaware, dated May 10, 2023.</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.5*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1962011/000149315223034915/ex3-5.htm" STYLE="-sec-extract: exhibit">Certificate of Incorporation of Kairos Pharma, Ltd. filed with the Secretary of State of the State of Delaware, dated May 10, 2023.</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.6</FONT>*</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1962011/000149315223034915/ex3-6.htm" STYLE="-sec-extract: exhibit">Bylaws of Kairos Pharma, Ltd. (Delaware).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap; vertical-align: top"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ex4-1.htm">Form of Representative&rsquo;s Warrant</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><A HREF="ex5-1.htm">Legal Opinion of Dorsey &amp; Whitney LLP</A></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1962011/000149315223034915/ex10-1.htm" STYLE="-sec-extract: exhibit">Exclusive
    Option Agreement, dated March 16, 2020, between Cedars-Sinai Medical Center and Enviro Therapeutics, Inc. (re Depletion of Mitochondrial DNA).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1962011/000149315223034915/ex10-2.htm" STYLE="-sec-extract: exhibit">Amendment
    to Exclusive Option Agreement, dated January 11, 2021, between Cedars-Sinai Medical Center and Enviro Therapeutics, Inc. (re Depletion of Mitochondrial DNA).</A></FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 159; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap; vertical-align: top; width: 0.65in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom; width: 0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1962011/000149315223034915/ex10-3.htm" STYLE="-sec-extract: exhibit">Exclusive
    Option Agreement, dated March 16, 202, between Cedars-Sinai Medical Center and Enviro Therapeutics, Inc. (re Sensitization of Solid Tumors).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4</FONT>*</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1962011/000149315223034915/ex10-4.htm" STYLE="-sec-extract: exhibit">Amendment
    to Exclusive Option Agreement, dated January 9, 2021, between Cedars-Sinai Medical Center and Enviro Therapeutics, Inc. (re Sensitization of Solid Tumors).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1962011/000149315223034915/ex10-5.htm" STYLE="-sec-extract: exhibit">Exclusive
    License Agreement, dated June 21, 2021, between Cedars-Sinai Medical Center and Enviro Therapeutics, Inc. (re Compositions and Methods for Treating Diseases and Conditions by Depletion of Mitochondrial or Genomic DNA from Circulation and
    for Detection of Mitochondrial or Genomic DNA).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6</FONT>*</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1962011/000149315223034915/ex10-6.htm" STYLE="-sec-extract: exhibit">Exclusive
    License Agreement, dated June 2, 2021, between Cedars-Sinai Medical Center and Enviro Therapeutics, Inc. (re Sensitization of Tumors to Therapies Through Endoglin Antagonism).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7</FONT>*</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1962011/000149315223034915/ex10-7.htm" STYLE="-sec-extract: exhibit">Exclusive
    License Agreement, dated August 30, 2019, between Cedars-Sinai Medical Center and Kairos Pharma, Ltd. (as successor to AcTcell
    Biopharma, Inc.) (re Methods of generating activated T cells for cancer therapy).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8</FONT>*</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1962011/000149315223034915/ex10-8.htm" STYLE="-sec-extract: exhibit">Amendment
    to Exclusive License Agreement, dated June 17, 2021, between Cedars-Sinai Medical Center and Kairos Pharma, Ltd. (re Methods of generating activated T cells for cancer therapy).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9</FONT>*</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1962011/000149315223034915/ex10-9.htm" STYLE="-sec-extract: exhibit">Exclusive
    License Agreement, dated October 1, 2017, between Cedars-Sinai Medical Center and Kairos Pharma, Ltd. (re Methods of use of compounds that bind to RelA of NFkB).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.11</FONT>*</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1962011/000149315223034915/ex10-11.htm" STYLE="-sec-extract: exhibit">Amendment
    to Exclusive License Agreement, dated June 17, 2021, between Cedars-Sinai Medical Center and Kairos Pharma, Ltd. (re Methods of use of compounds that bind to RelA of NFkB).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.12*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1962011/000149315223034915/ex10-12.htm" STYLE="-sec-extract: exhibit">Exclusive
    License Agreement, dated October 1, 2017, between Cedars-Sinai Medical Center and Kairos Pharma, Ltd. (re Composition and Methods for Treating Fibrosis).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.13</FONT>*</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1962011/000149315223034915/ex10-13.htm" STYLE="-sec-extract: exhibit">Amendment
    to Exclusive License Agreement, dated June 17, 2021, between Cedars-Sinai Medical Center and Kairos Pharma, Ltd. (re Composition and Methods for Treating Fibrosis).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.14</FONT>*</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1962011/000149315223034915/ex10-14.htm" STYLE="-sec-extract: exhibit">Exclusive
    License Agreement, dated March 12, 2019, between Cedars-Sinai Medical Center and Kairos Pharma, Ltd. (re Composition and Methods for Treating Cancer and Autoimmune Diseases).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.15</FONT>*</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1962011/000149315223034915/ex10-15.htm" STYLE="-sec-extract: exhibit">Amendment
    to Exclusive License Agreement, dated June 17, 2021, between Cedars-Sinai Medical Center and Kairos Pharma, Ltd. (re Composition and Methods for Treating Cancer and Autoimmune Diseases).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.16</FONT>*</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1962011/000149315223034915/ex10-16.htm" STYLE="-sec-extract: exhibit">License
    and Supply Agreement, dated May 21, 2021, between Tracon Pharmaceuticals, Inc., Enviro Therapeutics, Inc., and Kairos Pharma,
    Ltd.</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap; vertical-align: top">10.17*</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><A HREF="https://www.sec.gov/Archives/edgar/data/1962011/000149315223034915/ex10-17.htm" STYLE="-sec-extract: exhibit">First
    Amendment to Exclusive License Agreement, dated April 18, 2021, between Cedars-Sinai Medical Center and Enviro Therapeutics,
    Inc. (re Methods for Treating Diseases and Conditions by Depletion of Mitochondrial or Genomic DNA). </A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap; vertical-align: top"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">10.18*</P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><A HREF="https://www.sec.gov/Archives/edgar/data/1962011/000149315223034915/ex10-18.htm" STYLE="-sec-extract: exhibit">Second
    Amendment to Exclusive License Agreement, dated October 11, 2022, between Cedars-Sinai Medical Center and Enviro Therapeutics,
    Inc. (re Sensitization of Tumors to Therapies Through Endoglin Antagonism). </A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.20</FONT>*</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1962011/000149315223034915/ex10-20.htm" STYLE="-sec-extract: exhibit">Form of Subscription Agreement for 6% Convertible Notes</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.21*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1962011/000149315223034915/ex10-21.htm" STYLE="-sec-extract: exhibit">Form of 6% Convertible Note</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.22</FONT>*</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1962011/000149315223034915/ex10-22.htm" STYLE="-sec-extract: exhibit">Form of Investor Rights and Lock-Up Agreement for 6% Convertible Notes</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap; vertical-align: top">10.23*</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><A HREF="https://www.sec.gov/Archives/edgar/data/1962011/000149315223034915/ex10-23.htm" STYLE="-sec-extract: exhibit">Kairos Pharma, Ltd. 2023 Equity Incentive Plan.</A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap; vertical-align: top">10.24*</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><A HREF="https://www.sec.gov/Archives/edgar/data/1962011/000149315223034915/ex10-24.htm" STYLE="-sec-extract: exhibit">Form of Director Offer Letter</A></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify; width: 0.65in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.25*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify; width: 0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1962011/000149315223034915/ex10-25.htm" STYLE="-sec-extract: exhibit">Form of Employment Agreement for John Yu</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.26*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1962011/000149315223034915/ex10-26.htm" STYLE="-sec-extract: exhibit">Form of Employment Agreement with Doug Samuelson</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.27*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1962011/000149315223034915/ex10-27.htm" STYLE="-sec-extract: exhibit">Form of Employment Agreement for Neil Bhowmick</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.28*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1962011/000149315223034915/ex10-28.htm" STYLE="-sec-extract: exhibit">Form of Employment Agreement for Ramachandran Murali</A></FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap; vertical-align: top; width: 0.65in">10.29*</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom; width: 0.1in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><A HREF="https://www.sec.gov/Archives/edgar/data/1962011/000149315223034915/ex10-29.htm" STYLE="-sec-extract: exhibit">Form of Indemnification Agreement between Kairos Pharma, Ltd. and each of its directors.</A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap; vertical-align: top"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.30</FONT> </P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ex10-30.htm">Conversion Agreement, dated March 7, 2024, between Cedars-Sinai Medical Center, Kairos Pharma, Ltd. and Enviro Therapeutics, Inc.</A></FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap; vertical-align: top"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.31</FONT> </P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ex10-31.htm">Second Amendment to the Exclusive License Agreement to Methods and Use of Compounds that Bind to RelA of NF-kB, dated March 7, 2024, between Kairos Pharma Ltd. and Cedars-Sinai Medical Center.</A></FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap; vertical-align: top"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.32</FONT> </P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ex10-32.htm">Second Amendment to the Exclusive License Agreement to Composition and Methods for Treating Fibrosis with Kairos Pharma Ltd, dated March 7, 2024, between Kairos Pharma, Ltd. and Cedars-Sinai Medical Center.</A></FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap; vertical-align: top"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.33</FONT> </P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ex10-33.htm">Second Amendment to the Exclusive License Agreement to Compositions and Methods for Treating Cancer and Autoimmune Diseases, dated March 7, 2024, between Kairos Pharma, Ltd. and Cedars-Sinai Medical Center.</A></FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap; vertical-align: top"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.34</FONT> </P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ex10-34.htm">Third Amendment to Exclusive License to Compositions and Methods for Treating Diseases and Conditions by Depletion of Mitochondrial or Genomic DNA, dated March 7, 2024, between Enviro Therapeutics, Inc. and Cedars-Sinai Medical Center.</A></FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap; vertical-align: top"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.35</FONT> </P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ex10-35.htm">Third Amendment to the Exclusive License Agreement to Sensitization of Tumors to Therapies Through Endoglin Antoganism, dated March 7, 2024, between Enviro Therapeutics, Inc. and Cedars-Sinai Medical Center.</A></FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap; vertical-align: top"> 10.36 </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"> <A HREF="ex10-36.htm">Form of Loan Agreement, dated April 26, 2024, between the Company and Certain Officers.</A> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.1</FONT>*</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1962011/000149315223034915/ex21-1.htm" STYLE="-sec-extract: exhibit">List of subsidiaries of Kairos Pharma, Ltd.</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ex23-1.htm">Consent of Marcum LLP, independent registered public accounting firm.</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.2</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><A HREF="ex5-1.htm">Consent of Dorsey &amp; Whitney LLP (included in Exhibit 5.1)</A></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24.1*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1962011/000149315223034915/forms-1.htm#a_002" STYLE="-sec-extract: exhibit">Power of Attorney (included on signature page).</A> </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap; vertical-align: top">99.1*</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><A HREF="https://www.sec.gov/Archives/edgar/data/1962011/000149315223034915/ex99-1.htm" STYLE="-sec-extract: exhibit">Consent of Rosemary Mazanet M.D., Ph.D.</A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap; vertical-align: top">99.2*</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><A HREF="https://www.sec.gov/Archives/edgar/data/1962011/000149315223034915/ex99-2.htm" STYLE="-sec-extract: exhibit">Consent of Hansoo Michael Keyoung, M.D., Ph.D.</A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap; vertical-align: top"> 107* </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1962011/000149315224006764/ex107.htm" STYLE="-sec-extract: exhibit">Filing
                                            Fee Table </A></P></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Previously
    filed.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Unless otherwise indicated, filed herewith.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 160; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>(b)
Financial Statement Schedules. </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
financial statement schedules are omitted because the information required to be set forth therein is not applicable or is shown in the
financial statements or the notes thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
17. Undertakings. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
The undersigned registrant hereby undertakes to provide to the underwriters at the closing specified in the underwriting agreement certificates
in such denominations and registered in such names as required by the underwriters to permit prompt delivery to each purchaser.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons
of the registrant under the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the U.S. Securities
and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable.
In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred
or paid by a director, officer, or controlling person of the registrant in the successful defense of any action, suit, or proceeding)
is asserted by such director, officer, or controlling person in connection with the securities being registered, the registrant will,
unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction
the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the
final adjudication of such issue.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
The undersigned registrant hereby undertakes that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For purposes of determining
    any liability under the Securities Act, the information omitted from the form of prospectus filed as part of this registration statement
    in reliance on Rule 430A and contained in a form of prospectus filed by the registrant under Rule 424(b)(1) or (4) or 497(h) under
    the Securities Act will be deemed to be part of this registration statement as of the time it was declared effective. </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the purpose of determining
    any liability under the Securities Act of 1933, as amended, each post-effective amendment that contains a form of prospectus will
    be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that
    time will be deemed to be the initial bona fide offering thereof. </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 161; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SIGNATURES
</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Act of 1933, as amended, the registrant has duly caused this registration statement to be signed
on its behalf by the undersigned, thereunto duly authorized, in the City of Los Angeles, State of California on April 30,
2024.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">KAIROS
    PHARMA, LTD.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By
    </FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>/s/ John S. Yu</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">John
    S. Yu</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer and Chairman of the Board of Directors</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_002"></A>POWER
OF ATTORNEY </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in
the capacities and on the dates indicated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 34%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Signature</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 42%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Position</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Date</B></FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>/s/
    John S. Yu</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer and Chairman of the Board of Directors (principal executive officer)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif">April 30,
    </FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">2024</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">John
    S. Yu</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>/s/
    Doug Samuelson</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Chief
    Financial Officer (principal financial and accounting officer)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif">April 30,
    </FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">2024</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Doug Samuelson</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>/s/
    *</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"> April 30,
    2024</TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hyun
    W. Bae</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
  </TABLE>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; width: 3%">*By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 30%"><I>/s/ John S. Yu</I></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 67%">&nbsp;</TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">John S. Yu, M.D.</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Attorney-in-Fact</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    </TR>
  </TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 162; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>ex1-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
1.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNDERWRITING
AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">__________,
202__</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Boustead
Securities, LLC</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6
Venture, Suite 395</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Irvine,
CA 92618</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>As
Representative of the several Underwriters</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>named
on Schedule 1 attached hereto</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ladies
and Gentlemen:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned, Kairos Pharma, Ltd., a Delaware corporation (the &ldquo;<B>Company</B>&rdquo;), hereby confirms its agreement (this &ldquo;<B>Agreement</B>&rdquo;)
with Boustead Securities, LLC (hereinafter referred to as &ldquo;you&rdquo; (including its correlatives) or the &ldquo;<B>Representative</B>&rdquo;)
and with the other underwriters named on <U>Schedule 1</U> hereto for which the Representative is acting as representative (the Representative
and such other underwriters being collectively called the &ldquo;<B>Underwriters</B>&rdquo; or, individually, an &ldquo;<B>Underwriter</B>&rdquo;)
as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
<U>Purchase and Sale of Shares</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1
<I><U>Firm Shares</U>.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1.1.
<U>Nature and Purchase of Firm Shares</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
On the basis of the representations and warranties herein contained, but subject to the terms and conditions herein set forth, the Company
agrees to sell in the aggregate [&#9679;] shares of common stock of the Company, par value $0.001 per share (&ldquo;<B>Common Stock</B>&rdquo;),
and each Underwriter agrees to purchase, severally and not jointly, on the Closing Date (as defined below), an aggregate of [&#9679;]
shares (&ldquo;<B>Firm Shares</B>&rdquo; or &ldquo;<B>Shares</B>&rdquo;) of Common Stock. The offering and sale of the Shares is herein
referred to as the &ldquo;<B>Offering</B>.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
The Firm Shares are to be offered together to the public at the offering price per one Firm Share as set forth on <U>Schedule 2-A</U>
hereto (the &ldquo;<B>Purchase Price</B>&rdquo;). The Underwriters, severally and not jointly, agree to purchase from the Company the
number of Firm Shares set forth opposite their respective names on <U>Schedule 1</U> attached hereto and made a part hereof at the purchase
price for one Firm Share of $[&#9679;] (or 93% of the Purchase Price).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1.2.
<U>Firm Shares Payment and Delivery</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
Delivery and payment for the Firm Shares shall be made at 10:00 a.m., Eastern time, on the second (2<SUP>nd</SUP>) Business Day following
the effective date (the &ldquo;<B>Effective Date</B>&rdquo;) of the Registration Statement (as defined in <U>Section 2.1.1</U> below)
(or the third (3<SUP>rd</SUP>) Business Day following the Effective Date if the Registration Statement is declared effective after 4:01
p.m., Eastern time) or at such earlier time as shall be agreed upon by the Representative and the Company, at the offices of Olshan Frome
Wolosky LLP, 1325 Avenue of the Americas, 15th Floor, New York, New York 10019 (&ldquo;<B>Representative&rsquo;s Counsel</B>&rdquo;),
or at such other place (or remotely by facsimile or other electronic transmission) as shall be agreed upon by the Representative and
the Company. The hour and date of delivery and payment for the Firm Shares is called the &ldquo;<B>Closing Date</B>.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
Payment for the Firm Shares shall be made on the Closing Date by wire transfer in Federal (same day) funds, payable to the order of the
Company upon delivery of the certificates (in form and substance satisfactory to the Underwriters) representing the Firm Shares (or through
the facilities of the Depository Trust Company (&ldquo;<B>DTC</B>&rdquo;)) for the account of the Underwriters. The Firm Shares shall
be registered in such name or names and in such authorized denominations as the Representative may request in writing prior to the Closing
Date. The Company shall not be obligated to sell or deliver the Firm Shares except upon tender of payment by the Representative for all
of the Firm Shares. The term &ldquo;<B>Business Day</B>&rdquo; means any day other than a Saturday, a Sunday or a legal holiday or a
day on which banking institutions are authorized or obligated by law to close in New York, New York.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.2
<I><U>Over-allotment Option</U></I>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.2.1.
<U>Option Shares</U>. For the purposes of covering any over-allotments in connection with the distribution and sale of the Firm Shares,
the Company hereby grants to the Underwriters an option to purchase up to [&#9679;] additional Shares, representing fifteen percent (15%)
of the Firm Shares sold in the offering, from the Company (the &ldquo;<B>Over-allotment Option</B>&rdquo;). Such [&#9679;] additional
Shares, the net proceeds of which will be deposited with the Company&rsquo;s account, are hereinafter referred to as &ldquo;<B>Option
Shares</B>.&rdquo; The purchase price to be paid per Option Share shall be equal to the price per Firm Share set forth in <U>Section
1.1.1</U> hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.2.2.
<U>Exercise of Option</U>. The Over-allotment Option granted pursuant to <U>Section 1.2.1</U> hereof may be exercised by the Representative
as to all (at any time) or any part (from time to time) of the Option Shares within 45 days after the Effective Date. The purchase price
to be paid per Option Share shall be equal to the Firm Share purchase price. The Underwriters shall not be under any obligation to purchase
any Option Shares prior to the exercise of the Over-allotment Option. The Over-allotment Option granted hereby may be exercised by giving
oral notice to the Company from the Representative, which must be confirmed in writing by overnight mail or facsimile or other electronic
transmission setting forth the number of Option Shares to be purchased and the date and time for delivery of and payment for the Option
Shares (the &ldquo;<B>Option Closing Date</B>&rdquo;), which shall not be later than five (5) full Business Days after the date of the
notice or such other time as shall be agreed upon by the Company and the Representative, at the offices of Representative Counsel, or
at such other place (including remotely by facsimile or other electronic transmission) as shall be agreed upon by the Company and the
Representative. If such delivery and payment for the Option Shares does not occur on the Closing Date, the Option Closing Date will be
as set forth in the notice. Upon exercise of the Over-allotment Option with respect to all or any portion of the Option Shares, subject
to the terms and conditions set forth herein, (i) the Company shall become obligated to sell to the Underwriters the number of Option
Shares specified in such notice and (ii) each of the Underwriters, acting severally and not jointly, shall purchase that portion of the
total number of Option Shares then being purchased that the number of Firm Shares as set forth on Schedule 1 opposite the name of such
Underwriter bears to the total number of Firm Shares (except as otherwise agreed to by the Underwriters).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.2.3.
<U>Option Shares Payment and Delivery</U>. Payment for the Option Shares shall be made on the Option Closing Date by wire transfer in
Federal (same day) funds, payable to the order of the Company upon delivery to you of certificates (in form and substance satisfactory
to the Underwriters) representing the Option Shares (or through the facilities of DTC) for the account of the Underwriters. The Option
Shares shall be registered in such name or names and in such authorized denominations as the Representative may request in writing at
least two (2) full Business Days prior to the Option Closing Date. The Company shall not be obligated to sell or deliver the Option Shares
except upon tender of payment by the Representative for applicable Option Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.3
<I><U>Representative&rsquo;s Warrants</U></I>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.3.1.
<U>Purchase Warrants</U>. The Company hereby agrees to issue and sell to the Representative (and/or its designees) on the Closing Date,
or Option Closing Date, as applicable (&ldquo;<B>Representative&rsquo;s Warrants</B>&rdquo;), five-year warrants for the purchase of
a number of shares of Common Stock equal to 7.0% of the number of the Firm Shares issued in the Offering, pursuant to a warrant in the
form attached hereto as <B><U>Exhibit A</U></B>, at an initial exercise price of $[&#9679;] (or 120% of the public offering price per
Firm Share). The Representative&rsquo;s Warrants and the shares of Common Stock issuable upon exercise thereof are hereinafter referred
to together as the &ldquo;<B>Representative&rsquo;s Securities</B>.&rdquo; The Representative understands and agrees that there are significant
restrictions pursuant to FINRA Rule 5110 against transferring the Representative&rsquo;s Warrants and the underlying shares of Common
Stock during the one hundred eighty (180) days after the Effective Date and by its acceptance thereof shall agree that it will not sell,
transfer, assign, pledge or hypothecate the Representative&rsquo;s Warrants, or any portion thereof, or be the subject of any hedging,
short sale, derivative, put or call transaction that would result in the effective economic disposition of such securities for a period
of one hundred eighty (180) days following the Effective Date to anyone other than (i) an Underwriter or a selected dealer in connection
with the Offering, or (ii) an officer, partner, registered person or affiliate of the Representative or of any such Underwriter or selected
dealer; and only if any such transferee agrees to the foregoing lock-up restrictions. The Representative understands and agrees that
the Representative&rsquo;s Warrants are exercisable or convertible commencing upon the Closing Date and will not be exercisable or convertible
for more than five years from the commencement of sales of the Offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.3.2.
<U>Delivery</U>. Delivery of the Representative&rsquo;s Warrants shall be made on the Closing Date and shall be issued in the name or
names and in such authorized denominations as the Representative may request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
<U>Representations and Warranties of the Company</U>. The Company represents and warrants to the Underwriters as of the Applicable Time
(as defined below), as of the Closing Date and as of the Option Closing Date, if any, as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>2.1.
<U>Filing of Registration Statement</U>.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1.1.
<U>Pursuant to the Securities Act</U>. The Company has filed with the U.S. Securities and Exchange Commission (the &ldquo;<B>Commission</B>&rdquo;)
a registration statement, and an amendment or amendments thereto, on Form S-1 (File No. 333-274805), including any related prospectus
or prospectuses, for the registration of the Shares and the Representative&rsquo;s Securities under the Securities Act of 1933, as amended
(the &ldquo;<B>Securities Act</B>&rdquo;), which registration statement and amendment or amendments have been prepared by the Company
in all material respects in conformity with the requirements of the Securities Act and the rules and regulations of the Commission under
the Securities Act (the &ldquo;<B>Securities Act Regulations</B>&rdquo;) and will contain all material statements that are required to
be stated therein in accordance with the Securities Act and the Securities Act Regulations. Except as the context may otherwise require,
such registration statement, as amended, on file with the Commission at the time the registration statement became effective (including
the Preliminary Prospectus (as hereinafter defined) included in the registration statement, financial statements, schedules, exhibits
and all other documents filed as a part thereof and all information deemed to be a part thereof as of the Effective Date pursuant to
paragraph (b) of Rule 430A of the Securities Act Regulations (the &ldquo;<B>Rule 430A Information</B>&rdquo;)), is referred to herein
as the &ldquo;<B>Registration Statement</B>.&rdquo; If the Company files any registration statement pursuant to Rule 462(b) of the Securities
Act Regulations, then after such filing, the term &ldquo;<B>Registration Statement</B>&rdquo; shall include such registration statement
filed pursuant to Rule 462(b). The Registration Statement has been declared effective by the Commission on the date hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
prospectus used prior to the effectiveness of the Registration Statement, and each prospectus that omitted the Rule 430A Information
that was used after such effectiveness and prior to the execution and delivery of this Agreement, is herein called a &ldquo;<B>Preliminary
Prospectus</B>.&rdquo; The Preliminary Prospectus, subject to completion, dated __________, 202__, that was included in the Registration
Statement immediately prior to the Applicable Time is hereinafter called the &ldquo;<B>Pricing Prospectus</B>.&rdquo; The final prospectus
in the form first furnished to the Underwriters for use in the Offering is hereinafter called the &ldquo;<B>Prospectus</B>.&rdquo; Any
reference to the &ldquo;<B>most recent Preliminary Prospectus</B>&rdquo; shall be deemed to refer to the latest Preliminary Prospectus
included in the Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Applicable
Time</B>&rdquo; means [&#9679;] p.m., Eastern time, on the date of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Issuer
Free Writing Prospectus</B>&rdquo; means any &ldquo;issuer free writing prospectus,&rdquo; as defined in Rule 433 of the Securities Act
Regulations (&ldquo;<B>Rule 433</B>&rdquo;), including without limitation any &ldquo;free writing prospectus&rdquo; (as defined in Rule
405 of the Securities Act Regulations) relating to the Shares that is (i) required to be filed with the Commission by the Company, (ii)
a &ldquo;road show that is a written communication&rdquo; within the meaning of Rule 433(d)(8)(i), whether or not required to be filed
with the Commission, or (iii) exempt from filing with the Commission pursuant to Rule 433(d)(5)(i) because it contains a description
of the Shares or of the Offering that does not reflect the final terms, in each case in the form filed or required to be filed with the
Commission or, if not required to be filed, in the form retained in the Company&rsquo;s records pursuant to Rule 433(g).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Issuer
General Use Free Writing Prospectus</B>&rdquo; means any Issuer Free Writing Prospectus that is intended for general distribution to
prospective investors (other than a &ldquo;<I>bona fide</I> electronic road show,&rdquo; as defined in Rule 433 (the &ldquo;<B>Bona Fide
Electronic Road Show</B>&rdquo;)), as evidenced by its being specified in <U>Schedule 2-B</U> hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Issuer
Limited Use Free Writing Prospectus</B>&rdquo; means any Issuer Free Writing Prospectus that is not an Issuer General Use Free Writing
Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Pricing
Disclosure Package</B>&rdquo; means any Issuer General Use Free Writing Prospectus issued at or prior to the Applicable Time, the Pricing
Prospectus and the information included on <U>Schedule 2-A</U> hereto, all considered together.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1.2.
<U>Pursuant to the Exchange Act</U>. The Company has filed with the Commission a Form 8-A (File Number 001-_____), dated ___________,
202__, providing for the registration pursuant to Section 12(b) under the Securities Exchange Act of 1934, as amended (the &ldquo;<B>Exchange
Act</B>&rdquo;), of the Common Stock. The registration of the Common Stock under the Exchange Act has become effective on or prior to
the date hereof. The Company has taken no action designed to, or likely to have the effect of, terminating the registration of the Common
Stock under the Exchange Act, nor has the Company received any notification that the Commission is contemplating terminating such registration.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>2.2.
<U>Stock Exchange Listing</U>. </I>The Shares and the shares of Common Stock underlying the Representative&rsquo;s Warrants have been
approved for listing on NYSE American LLC (the &ldquo;<B>Exchange</B>&rdquo;), and the Company has taken no action designed to, or likely
to have the effect of, delisting of the Shares or the shares of Common Stock underlying the Representative&rsquo;s Warrants from the
Exchange, nor has the Company received any written notification that the Exchange is contemplating terminating such listing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>2.3.
<U>No Stop Orders, etc</U>. </I>Neither the Commission nor, to the Company&rsquo;s knowledge, any state regulatory authority has issued
any written order preventing or suspending the use of the Registration Statement, any Preliminary Prospectus or the Prospectus or has
instituted or, to the Company&rsquo;s knowledge, threatened to institute, any proceedings with respect to such an order. The Company
has complied with each request (if any) from the Commission for additional information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>2.4.
<U>Disclosures in Registration Statement</U>.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.4.1.
<U>Compliance with Securities Act and 10b-5 Representation</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
Each of the Registration Statement and any post-effective amendment thereto, at the time it became effective, complied in all material
respects with the requirements of the Securities Act and the Securities Act Regulations. Each Preliminary Prospectus, including the prospectus
filed as part of the Registration Statement as originally filed or as part of any amendment or supplement thereto, and the Prospectus,
at the time each was filed with the Commission, complied in all material respects with the requirements of the Securities Act and the
Securities Act Regulations. Each Preliminary Prospectus delivered to the Underwriters for use in connection with this Offering and the
Prospectus was or will be identical to the electronically transmitted copies thereof filed with the Commission pursuant to EDGAR, except
to the extent permitted by Regulation S-T.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
Neither the Registration Statement nor any amendment thereto, at its effective time, as of the Applicable Time, at the Closing Date,
contained, contains, or will contain an untrue statement of a material fact or omitted, omits or will omit to state a material fact required
to be stated therein or necessary to make the statements therein not misleading; <I>provided, however</I>, that this representation and
warranty shall not apply to statements made in reliance upon and in conformity with written information furnished to the Company in writing
with respect to the Underwriters by the Representative expressly for use in the Registration Statement, the Pricing Prospectus or the
Prospectus or any amendment thereof or supplement thereto. The parties acknowledge and agree that such information provided by or on
behalf of any Underwriter consists solely of the information in the table set forth in the second paragraph of the &ldquo;Underwriting&rdquo;
section and the disclosure contained in the &ldquo;Underwriting&rdquo; subsections &ldquo;&mdash;Discounts and Commissions&rdquo; and
&ldquo;Representative&rsquo;s Warrants&rdquo; of the Prospectus (the &ldquo;<B>Underwriters&rsquo; Information</B>&rdquo;). The Pricing
Disclosure Package, as of the Applicable Time, at the Closing Date, did not, does not and will not include an untrue statement of a material
fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which
they were made, not misleading; and each Issuer Limited Use Free Writing Prospectus hereto does not conflict with the information contained
in the Registration Statement, any Preliminary Prospectus, the Pricing Prospectus or the Prospectus, and each such Issuer Limited Use
Free Writing Prospectus, as supplemented by and taken together with the Pricing Prospectus as of the Applicable Time, did not include
an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in light of
the circumstances under which they were made, not misleading; <I>provided</I>, <I>however</I>, that this representation and warranty
shall not apply to the Underwriters&rsquo; Information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
Neither the Prospectus nor any amendment or supplement thereto (including any prospectus wrapper), as of its issue date, at the time
of any filing with the Commission pursuant to Rule 424(b), at the Closing Date, included, includes or will include an untrue statement
of a material fact or omitted, omits or will omit to state a material fact necessary in order to make the statements therein, in the
light of the circumstances under which they were made, not misleading; <I>provided</I>, <I>however</I>, that this representation and
warranty shall not apply to the Underwriters&rsquo; Information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.4.2.
<U>Disclosure of Agreements</U>. The agreements and documents described in the Registration Statement, the Pricing Disclosure Package
and the Prospectus conform in all material respects to the descriptions thereof contained therein and there are no agreements or other
documents required by the Securities Act and the Securities Act Regulations to be described in the Registration Statement, the Pricing
Disclosure Package and the Prospectus or to be filed with the Commission as exhibits to the Registration Statement, that have not been
so described or filed. Each agreement or other instrument (however characterized or described) to which the Company is a party or by
which it is or may be bound or affected and (i) that is referred to in the Registration Statement, the Pricing Disclosure Package and
the Prospectus, or (ii) is material to the Company&rsquo;s business, has been duly authorized and validly executed by the Company, is
in full force and effect in all material respects and is enforceable against the Company and, to the Company&rsquo;s knowledge, the other
parties thereto, in accordance with its terms, except (x) as such enforceability may be limited by bankruptcy, insolvency, reorganization
or similar laws affecting creditors&rsquo; rights generally, (y) as enforceability of any indemnification or contribution provision may
be limited under the federal and state securities laws, and (z) that the remedy of specific performance and injunctive and other forms
of equitable relief may be subject to the equitable defenses and to the discretion of the court before which any proceeding therefor
may be brought. Except as disclosed in the Registration Statement, the Pricing Disclosure Package or the Prospectus, none of such agreements
or instruments has been assigned by the Company, and neither the Company nor, to the Company&rsquo;s knowledge, any other party is in
default thereunder and, to the Company&rsquo;s knowledge, no event has occurred that, with the lapse of time or the giving of notice,
or both, would constitute a default thereunder, except for any default or event which would not reasonably be expected to result in a
Material Adverse Change (as defined below). To the Company&rsquo;s knowledge, performance by the Company of the material provisions of
such agreements or instruments will not result in a violation of any existing applicable law, rule, regulation, judgment, order or decree
of any governmental agency or court, domestic or foreign, having jurisdiction over the Company or any of its assets or businesses (each,
a &ldquo;<B>Governmental Entity</B>&rdquo;), including, without limitation, those relating to environmental laws and regulations, except
for any violation which would not reasonably be expected to result in a Material Adverse Change (as defined below).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.4.3.
<U>Prior Securities Transactions</U>. During the past three (3) years prior to the date of this Agreement, no securities of the Company
have been sold by the Company or by or on behalf of, or for the benefit of, any person or persons controlling, controlled by or under
common control with the Company, except as disclosed in the Registration Statement, the Pricing Disclosure Package and any Preliminary
Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.4.4.
<U>Regulations</U>. The disclosures in the Registration Statement, the Pricing Disclosure Package and the Prospectus concerning the effects
of federal, state, local and all foreign regulation on the Offering and regulations applicable to the Company&rsquo;s business as currently
contemplated are correct in all material respects and no other such regulations are required to be disclosed in the Registration Statement,
the Pricing Disclosure Package and the Prospectus which are not so disclosed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>2.5.
<U>Changes after Dates in Registration Statement</U>.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.5.1.
<U>No Material Adverse Change</U>. Since the respective dates as of which information is given in the Registration Statement, the Pricing
Disclosure Package and the Prospectus, except as otherwise specifically stated therein: (i) there has been no material adverse change
in the financial position or results of operations of the Company or its Subsidiaries taken as a whole, nor any change or development
that, singularly or in the aggregate, would involve a material adverse change in or affecting the condition (financial or otherwise),
results of operations, business, or assets of the Company or its Subsidiaries taken as a whole (a &ldquo;<B>Material Adverse Change</B>&rdquo;);
(ii) there have been no material transactions entered into by the Company or its Subsidiaries, other than as contemplated pursuant to
this Agreement; and (iii) no officer or director of the Company has resigned from any position with the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.5.2.
<U>Recent Securities Transactions, etc</U>. Subsequent to the respective dates as of which information is given in the Registration Statement,
the Pricing Disclosure Package and the Prospectus, and except as may otherwise be indicated or contemplated herein or disclosed in the
Registration Statement, the Pricing Disclosure Package and the Prospectus, the Company has not: (i) issued any securities or incurred
any liability or obligation, direct or contingent, for borrowed money; or (ii) declared or paid any dividend or made any other distribution
on or in respect to its capital stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>2.6.
<U>Independent Accountants</U></I>. To the knowledge of the Company, Marcum LLP (&ldquo;<B>Auditor</B>&rdquo;), whose report is filed
with the Commission as part of the Registration Statement, the Pricing Disclosure Package and the Prospectus, is an independent registered
public accounting firm as required by the Securities Act and the Securities Act Regulations and the Public Company Accounting Oversight
Board. The Auditor has not, during the periods covered by the financial statements included in the Registration Statement, the Pricing
Disclosure Package and the Prospectus, provided to the Company any non-audit services, as such term is used in Section 10A(g) of the
Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>2.7.
<U>Financial Statements, etc</U>.</I> The financial statements, including the notes thereto and supporting schedules, if any, included
in the Registration Statement, the Pricing Disclosure Package and the Prospectus, fairly present in all material respects the financial
position and the results of operations of the Company at the dates and for the periods to which they apply; and such financial statements
have been prepared in conformity with U.S. generally accepted accounting principles (&ldquo;<B>GAAP</B>&rdquo;), consistently applied
throughout the periods involved (provided that unaudited interim financial statements are subject to year-end audit adjustments that
are not expected to be material in the aggregate and do not contain all footnotes required by GAAP); and any supporting schedules included
in the Registration Statement present fairly in all material respects the information required to be stated therein. Except as included
therein, no historical or pro forma financial statements are required to be included in the Registration Statement, the Pricing Disclosure
Package or the Prospectus under the Securities Act or the Securities Act Regulations. The pro forma and pro forma as adjusted financial
information and the related notes, if any, included in the Registration Statement, the Pricing Disclosure Package and the Prospectus
have been properly compiled and prepared in all material respects in accordance with the applicable requirements of the Securities Act
and the Securities Act Regulations and present fairly in all material respects the information shown therein, and the assumptions used
in the preparation thereof are reasonable and the adjustments used therein are appropriate to give effect to the transactions and circumstances
referred to therein. All disclosures contained in the Registration Statement, the Pricing Disclosure Package or the Prospectus regarding
&ldquo;non-GAAP financial measures&rdquo; (as such term is defined by the rules and regulations of the Commission), if any, comply with
Regulation G of the Exchange Act and Item 10 of Regulation S-K of the Securities Act, to the extent applicable. Each of the Registration
Statement, the Pricing Disclosure Package and the Prospectus discloses all material off-balance sheet transactions, arrangements, obligations
(including contingent obligations), and other relationships of the Company with unconsolidated entities or other persons that may have
a material current or future effect on the Company&rsquo;s financial condition, changes in financial condition, results of operations,
liquidity, capital expenditures, capital resources, or significant components of revenues or expenses. Except as disclosed in the Registration
Statement, the Pricing Disclosure Package and the Prospectus, (a) neither the Company nor any of its subsidiaries listed in Exhibit 21.1
to the Registration Statement (each, a &ldquo;<B>Subsidiary</B>&rdquo; and, collectively, the &ldquo;<B>Subsidiaries</B>&rdquo;), has
incurred any material liabilities or obligations, direct or contingent, or entered into any material transactions other than in the ordinary
course of business, (b) the Company has not declared or paid any dividends or made any distribution of any kind with respect to its Common
Stock or preferred stock (c) there has not been any change in the capital of the Company or any of its Subsidiaries, or, other than in
the course of business, any grants under any stock compensation plan, and (d) there has not been any Material Adverse Change in the Company&rsquo;s
long-term or short-term debt. The Company represents that it has no direct or indirect subsidiaries other than those listed in Exhibit
21.1 to the Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>2.8.
<U>Authorized Capital; Options, etc</U></I>. The Company had, at the date or dates indicated in the Registration Statement, the Pricing
Disclosure Package and the Prospectus, the duly authorized, issued and outstanding capitalization as set forth therein. Based on the
assumptions stated in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the Company will have on the Closing
Date the adjusted capitalization set forth therein. Except as set forth in, or contemplated by, the Registration Statement, the Pricing
Disclosure Package and the Prospectus, on the Effective Date, as of the Applicable Time and on the Closing Date and any Option Closing
Date, there will be no options, warrants, or other rights to purchase or otherwise acquire any authorized, but unissued Common Stock
or any security convertible or exercisable into Common Stock, or any contracts or commitments to issue or sell Common Stock or any such
options, warrants, rights or convertible securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>2.9.
<U>Valid Issuance of Securities, etc.</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.9.1.
<U>Outstanding Securities</U>. All issued and outstanding securities of the Company issued prior to the transactions contemplated by
this Agreement have been duly authorized and validly issued and are fully paid and nonassessable; the holders thereof have no rights
of rescission with respect thereto, and are not subject to personal liability by reason of being such holders; and none of such securities
were issued in violation of the preemptive rights of any holders of any security of the Company or similar contractual rights granted
by the Company. The Common Stock, preferred stock, and any other securities outstanding or to be outstanding upon consummation of the
Offering conform in all material respects to all statements relating thereto contained in the Registration Statement, the Pricing Disclosure
Package and the Prospectus. The offers and sales of the outstanding Common Stock were at all relevant times either registered under the
Securities Act and the applicable state securities or &ldquo;blue sky&rdquo; laws or, based in part on the representations and warranties
of the purchasers of such shares, exempt from such registration requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.9.2.
<U>Securities Sold Pursuant to this Agreement</U>. The Shares and Representative&rsquo;s Warrants have been duly authorized for issuance
and sale and, when issued and paid for, will be validly issued, fully paid and non-assessable; the holders thereof are not and will not
be subject to personal liability by reason of being such holders; the Shares and Representative&rsquo;s Warrants are not and will not
be subject to the preemptive rights of any holders of any security of the Company or similar contractual rights granted by the Company;
and all corporate action required to be taken for the authorization, issuance and sale of the Shares and Representative&rsquo;s Warrants
has been duly and validly taken; the Common Stock issuable upon exercise of the Representative&rsquo;s Warrants have been duly authorized
and reserved for issuance by all necessary corporate action on the part of the Company and when issued in accordance with such Representative&rsquo;s
Warrants, as the case may be, such Common Stock will be validly issued, fully paid and non-assessable. The Shares and the Representative&rsquo;s
Warrants conform in all material respects to all statements with respect thereto contained in the Registration Statement, the Pricing
Disclosure Package and the Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>2.10.
<U>Registration Rights of Third Parties</U></I>. Except as set forth in the Registration Statement, the Pricing Disclosure Package and
the Prospectus, no holders of any securities of the Company or any rights exercisable for or convertible or exchangeable into securities
of the Company have the right to require the Company to register any such securities of the Company under the Securities Act or to include
any such securities in a registration statement to be filed by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>2.11.
<U>Validity and Binding Effect of Agreements</U>.</I> This Agreement and the Representative&rsquo;s Warrants have been duly and validly
authorized by the Company, and, when executed and delivered, will constitute, the valid and binding agreements of the Company, enforceable
against the Company in accordance with their respective terms, except: (i) as such enforceability may be limited by bankruptcy, insolvency,
reorganization or similar laws affecting creditors&rsquo; rights generally; (ii) as enforceability of any indemnification or contribution
provision may be limited under the federal and state securities laws; and (iii) that the remedy of specific performance and injunctive
and other forms of equitable relief may be subject to the equitable defenses and to the discretion of the court before which any proceeding
therefor may be brought.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>2.12.
<U>No Conflicts, etc</U>.</I> The execution, delivery and performance by the Company of this Agreement and all ancillary documents, the
consummation by the Company of the transactions herein and therein contemplated and the compliance by the Company with the terms hereof
and thereof do not and will not, with or without the giving of notice or the lapse of time or both: (i) result in a material breach of,
or conflict with any of the terms and provisions of, or constitute a material default under, or result in the creation, modification,
termination or imposition of any lien, charge or encumbrance upon any property or assets of the Company pursuant to the terms of any
agreement or instrument to which the Company is a party; (ii) result in any violation of the provisions of the Company&rsquo;s Certificate
of Incorporation (as the same may be amended or restated from time to time, the &ldquo;<B>Charter</B>&rdquo;) or the by-laws of the Company;
or (iii) violate any existing applicable law, rule, regulation, judgment, order or decree of any Governmental Entity as of the date hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>2.13.
<U>No Defaults; Violations</U>.</I> No material default exists in the due performance and observance of any term, covenant or condition
of any material license, contract, indenture, mortgage, deed of trust, note, loan or credit agreement, or any other agreement or instrument
evidencing an obligation for borrowed money, or any other material agreement or instrument to which the Company is a party or by which
the Company may be bound or to which any of the properties or assets of the Company is subject. The Company is not (i) in violation of
any term or provision of its Charter or by-laws, or (ii) in violation of any franchise, license, permit, applicable law, rule, regulation,
judgment or decree of any Governmental Entity, except in the cases of clause (ii) for such violations which would not reasonably be expected
to cause a Material Adverse Change.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>2.14.
<U>Corporate Power; Licenses; Consents</U>.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.14.1.
<U>Conduct of Business</U>. Except as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the
Company has all requisite corporate power and authority, and has all necessary authorizations, approvals, orders, licenses, certificates
and permits of and from all governmental regulatory officials and bodies that it needs as of the date hereof to conduct its business
purpose as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, except for the absence of which
would not reasonably be expected to result in a Material Adverse Change.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.14.2.
<U>Transactions Contemplated Herein</U>. The Company has all corporate power and authority to enter into this Agreement and to carry
out the provisions and conditions hereof, and all consents, authorizations, approvals and orders required in connection therewith have
been obtained. No consent, authorization or order of, and no filing with, any court, government agency, the Exchange or other body is
required for the valid issuance, sale and delivery of the Shares and the consummation of the transactions and agreements contemplated
by this Agreement and the delivery of the Representative&rsquo;s Warrants and as contemplated by the Registration Statement, the Pricing
Disclosure Package and the Prospectus, except with respect to applicable Securities Act Regulations, state securities laws and the rules
and regulations of the Financial Industry Regulatory Authority, Inc. (&ldquo;<B>FINRA</B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>2.15.
<U>Directors &amp; Officers Questionnaires</U>.</I> All information contained in the questionnaires (the &ldquo;<B>Questionnaires</B>&rdquo;)
completed by each of the Company&rsquo;s directors and executive officers immediately prior to the Offering (the &ldquo;<B>Insiders</B>&rdquo;)
as supplemented by all information concerning the Company&rsquo;s directors, executive officers and principal shareholders as described
in the Registration Statement, the Pricing Disclosure Package and the Prospectus, as well as in the Lock-Up Agreements (as defined in
<U>Section 2.24</U> below), provided to the Underwriters, is true and correct in all material respects and the Company has not become
aware of any information which would cause the information disclosed in the Questionnaires to become materially inaccurate and incorrect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>2.16.
<U>Litigation; Governmental Proceedings</U>.</I> There is no action, suit, proceeding, inquiry, arbitration, investigation, litigation
or governmental proceeding pending or, to the Company&rsquo;s knowledge, threatened against, or involving the Company or, to the Company&rsquo;s
knowledge, any executive officer or director that is required to be disclosed in the Registration Statement, the Pricing Disclosure Package
and the Prospectus which has not been disclosed<I>.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>2.17.
<U>Good Standing</U>. </I>The Company has been duly organized and is validly existing as a corporation and is in good standing under
the laws of the State of Delaware as of the date hereof, and is duly qualified to do business and is in good standing in each other jurisdiction
in which its ownership or lease of property or the conduct of business requires such qualification, except where the failure to qualify,
singularly or in the aggregate, would not have or reasonably be expected to result in a Material Adverse Change.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>2.18.
<U>Insurance</U>.</I> The Company has obtained the benefits of insurance, (including, without limitation, as to directors and officers
insurance coverage), with reputable insurers, in such amounts and covering such risks which the Company believes are adequate, and all
such insurance is in full force and effect. The Company has no reason to believe that it will not be able to obtain comparable coverage
from similar institutions as may be necessary or appropriate to conduct its business as now conducted and at a cost that would not result
in a Material Adverse Change.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>2.19.
<U>Transactions Affecting Disclosure to FINRA</U>.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.19.1.
<U>Finder&rsquo;s Fees</U>. Except as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, there
are no claims, payments, arrangements, agreements or understandings relating to the payment of a finder&rsquo;s, consulting or origination
fee by the Company or any Insider with respect to the sale of the Shares hereunder or any other arrangements, agreements or understandings
of the Company or, to the Company&rsquo;s knowledge, any of its shareholders that may affect the Underwriters&rsquo; compensation, as
determined by FINRA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.19.2.
<U>Payments within Six Months</U>. Except as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus,
the Company has not made any direct or indirect payments (in cash, securities or otherwise) to: (i) any person, as a finder&rsquo;s fee,
consulting fee or otherwise, in consideration of such person raising capital for the Company or introducing to the Company persons who
raised or provided capital to the Company; (ii) any FINRA member; or (iii) any person or entity that has any direct or indirect affiliation
or association with any FINRA member, within the six (6) months immediately prior to the original filing of the Registration Statement,
other than the payment to the Underwriters as provided hereunder in connection with the Offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.19.3.
<U>Use of Proceeds</U>. None of the net proceeds of the Offering will be paid by the Company to any participating FINRA member or its
affiliates, except as specifically authorized herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.19.4.
<U>FINRA Affiliation</U>. To the Company&rsquo;s knowledge, and except as may otherwise be disclosed in FINRA questionnaires provided
to the Representative&rsquo;s Counsel, there is no (i) officer or director of the Company, (ii) beneficial owner of 5% or more of any
class of the Company&rsquo;s securities or (iii) beneficial owner of the Company&rsquo;s unregistered equity securities which were acquired
during the 180-day period immediately preceding the filing of the Registration Statement that is an affiliate or associated person of
a FINRA member participating in the Offering (as determined in accordance with the rules and regulations of FINRA).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.19.5.
<U>Information</U>. All information provided by the Company in its FINRA questionnaire to Representative&rsquo;s Counsel specifically
for use by Representative&rsquo;s Counsel in connection with its Public Offering System filings (and related disclosure) with FINRA is
true, correct and complete in all material respects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>2.20.
<U>Foreign Corrupt Practices Act</U>.</I> None of the Company and its Subsidiaries or, to the Company&rsquo;s knowledge, any director,
officer, agent, employee or affiliate of the Company and its Subsidiaries or any other person acting on behalf of the Company and its
Subsidiaries, has, directly or indirectly, given or agreed to give any money, gift or similar benefit (other than legal price concessions
to customers in the ordinary course of business) to any customer, supplier, employee or agent of a customer or supplier, or official
or employee of any governmental agency or instrumentality of any government (domestic or foreign) or any political party or candidate
for office (domestic or foreign) or other person who was, is, or may be in a position to help or hinder the business of the Company (or
assist it in connection with any actual or proposed transaction) that (i) might subject the Company to any damage or penalty in any civil,
criminal or governmental litigation or proceeding, (ii) if not given in the past, might have had a Material Adverse Change or (iii) if
not continued in the future, might adversely affect the assets, business, operations or prospects of the Company. The Company has taken
reasonable steps to ensure that its accounting controls and procedures are sufficient to cause the Company to comply in all material
respects with the Foreign Corrupt Practices Act of 1977, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>2.21.
<U>Compliance with OFAC</U>.</I> None of the Company and its Subsidiaries or, to the Company&rsquo;s knowledge, any director, officer,
agent, employee or affiliate of the Company and its Subsidiaries or any other person acting on behalf of the Company and its Subsidiaries,
is currently subject to any U.S. sanctions administered by the Office of Foreign Assets Control of the U.S. Department of the Treasury
(&ldquo;<B>OFAC</B>&rdquo;), and the Company will not, directly or indirectly, use the proceeds of the Offering hereunder, or lend, contribute
or otherwise make available such proceeds to any subsidiary, joint venture partner or other person or entity, for the purpose of financing
the activities of any person currently subject to any U.S. sanctions administered by OFAC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>2.22.
<U>Money Laundering Laws</U>. </I>The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance
with applicable financial recordkeeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as
amended, the money laundering statutes of all jurisdictions, the rules and regulations thereunder and any related or similar rules, regulations
or guidelines, issued, administered or enforced by any Governmental Entity (collectively, the &ldquo;<B>Money Laundering Laws</B>&rdquo;);
and no action, suit or proceeding by or before any Governmental Entity involving the Company with respect to the Money Laundering Laws
is pending or, to the best knowledge of the Company, threatened.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>2.23.
<U>Officers&rsquo; Certificate</U>.</I> Any certificate signed by any duly authorized officer of the Company and delivered to you or
to Representative&rsquo;s Counsel shall be deemed a representation and warranty by the Company to the Underwriters as to the matters
covered thereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>2.24.
<U>Lock-Up Agreements</U></I><U>.</U> The Company has caused each of its officers, directors and owners of 1% or more of the Company&rsquo;s
outstanding Common Stock (or securities convertible or exercisable into Common Stock) (collectively, the &ldquo;<B>Lock-Up Parties</B>&rdquo;)
to deliver to the Representative an executed Lock-Up Agreement, in forms substantially similar to those attached hereto as <U>Exhibit
B-1</U> for executive officers, directors and owners of 5% or greater of the Company&rsquo;s outstanding Common Stock after giving effect
to the Offering and <U>Exhibit B-2</U> for owners of 1% to 4.99% of the Company&rsquo;s outstanding Common Stock after giving effect
to the Offering (together, the &ldquo;<B>Lock-Up Agreements</B>&rdquo;), prior to the execution of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>2.25.
<U>Subsidiaries</U></I>. All Subsidiaries of the Company are duly organized and in good standing under the laws of the place of organization
or incorporation, and each Subsidiary is in good standing in each jurisdiction in which its ownership or lease of property or the conduct
of business requires such qualification, except where the failure to qualify would not have a Material Adverse Change. The Company&rsquo;s
ownership and control of each Subsidiary is as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>2.26.
<U>Related Party Transactions</U>.</I> There are no business relationships or related party transactions involving the Company or any
other person required to be described in the Registration Statement, the Pricing Disclosure Package and the Prospectus that have not
been described as required by the Securities Act Regulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>2.27.
<U>Board of Directors</U>. </I>The Board of Directors of the Company is comprised of the persons set forth under the heading of the Pricing
Prospectus and the Prospectus captioned &ldquo;Management.&rdquo; The qualifications of the persons serving as board members and the
overall composition of the board comply with the Exchange Act, the Exchange Act Regulations, the Sarbanes-Oxley Act of 2002 and the rules
promulgated thereunder (the &ldquo;<B>Sarbanes-Oxley Act</B>&rdquo;) applicable to the Company and the listing rules of the Exchange.
At least one member of the Audit Committee of the Board of Directors of the Company qualifies as an &ldquo;audit committee financial
expert,&rdquo; as such term is defined under Regulation S-K and the listing rules of the Exchange. In addition, at least a majority of
the persons serving on the Board of Directors qualify as &ldquo;independent,&rdquo; as defined under the listing rules of the Exchange.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>2.28.
<U>Sarbanes-Oxley Compliance</U>.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.28.1.
<U>Disclosure Controls</U>. Except as disclosed in the Registration Statement, Pricing Disclosure Package and the Prospectus, the Company
has developed and currently maintains disclosure controls and procedures that will comply with Rule 13a-15 or 15d-15 under the Exchange
Act Regulations, and such controls and procedures are effective to ensure that all material information concerning the Company will be
made known on a timely basis to the individuals responsible for the preparation of the Company&rsquo;s Exchange Act filings and other
public disclosure documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.28.2.
<U>Compliance</U>. The Company is, or at the Applicable Time and on the Closing Date or the Option Closing Date will be, in material
compliance with the provisions of the Sarbanes-Oxley Act applicable to it, and has implemented or will implement such programs and has
taken reasonable steps to ensure the Company&rsquo;s future compliance (not later than the relevant statutory and regulatory deadlines
therefor) with all of the material provisions of the Sarbanes-Oxley Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>2.29.
</I><U>Accounting Controls</U>. Except as disclosed in the Registration Statement, Pricing Disclosure Package and the Prospectus, the
Company maintains systems of &ldquo;internal control over financial reporting&rdquo; (as defined under Rules 13a-15 and 15d-15 under
the Exchange Act Regulations) that comply in all material respects with the requirements of the Exchange Act and have been designed by,
or under the supervision of, its respective principal executive and principal financial officers, or persons performing similar functions,
to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external
purposes in accordance with GAAP, including, but not limited to, internal accounting controls sufficient to provide reasonable assurance
that (i) transactions are executed in accordance with management&rsquo;s general or specific authorizations; (ii) transactions are recorded
as necessary to permit preparation of financial statements in conformity with GAAP and to maintain asset accountability; (iii) access
to assets is permitted only in accordance with management&rsquo;s general or specific authorization; and (iv) the recorded accountability
for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences.
Except as disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the Company is not aware of any
material weaknesses in its internal control over financial reporting, and, if applicable, with respect to such remedial actions disclosed
in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the Company represents that it has taken all remedial
actions set forth in such disclosure. The Company&rsquo;s auditors and the Audit Committee of the Board of Directors of the Company have
been advised of: (i) all significant deficiencies and material weaknesses in the design or operation of internal controls over financial
reporting which are known to the Company&rsquo;s management and that have adversely affected or are reasonably likely to adversely affect
the Company&rsquo; ability to record, process, summarize and report financial information; and (ii) any fraud known to the Company&rsquo;s
management, whether or not material, that involves management or other employees who have a significant role in the Company&rsquo;s internal
controls over financial reporting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>2.30.
<U>No Investment Company Status</U></I>. The Company is not and, after giving effect to the Offering and the application of the proceeds
thereof as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, will not be, required to register
as an &ldquo;investment company,&rdquo; as defined in the Investment Company Act of 1940, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>2.31.
<U>No Labor Disputes</U>.</I> No labor dispute with the employees of the Company or any of its Subsidiaries exists or, to the knowledge
of the Company, is imminent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>2.32.
<U>Intellectual Property Rights</U></I>. To the Company&rsquo;s knowledge, the Company and each of its Subsidiaries owns or possesses
or has valid rights to use all patents, patent applications, trademarks, service marks, trade names, trademark registrations, service
mark registrations, copyrights, licenses, inventions, trade secrets and similar rights (&ldquo;<B>Intellectual Property Rights</B>&rdquo;)
necessary for the conduct of the business of the Company and its Subsidiaries as currently carried on and as described in the Registration
Statement, the Pricing Disclosure Package and the Prospectus. To the knowledge of the Company, no action or use by the Company or any
of its Subsidiaries necessary for the conduct of its business as currently carried on and as described in the Registration Statement
and the Prospectus will involve or give rise to any infringement of, or license or similar fees for, any Intellectual Property Rights
of others. Neither the Company nor any of its Subsidiaries has received any written notice alleging any such infringement, fee or conflict
with asserted Intellectual Property Rights of others. Except as would not reasonably be expected to result, individually or in the aggregate,
in a Material Adverse Change (A) to the knowledge of the Company, there is no infringement, misappropriation or violation by third parties
of any of the Intellectual Property Rights owned by the Company; (B) there is no pending or, to the knowledge of the Company, threatened
action, suit, proceeding or claim by others challenging the rights of the Company in or to any such Intellectual Property Rights, and
the Company is unaware of any facts which would form a reasonable basis for any such claim, that would, individually or in the aggregate,
together with any other claims in this <U>Section 2.32</U>, reasonably be expected to result in a Material Adverse Change; (C) the Intellectual
Property Rights owned by the Company and, to the knowledge of the Company, the Intellectual Property Rights licensed to the Company have
not been adjudged by a court of competent jurisdiction invalid or unenforceable, in whole or in part, and there is no pending or, to
the Company&rsquo;s knowledge, threatened action, suit, proceeding or claim by others challenging the validity or scope of any such Intellectual
Property Rights, and the Company is unaware of any facts which would form a reasonable basis for any such claim that would, individually
or in the aggregate, together with any other claims in this <U>Section 2.32</U>, reasonably be expected to result in a Material Adverse
Change; (D) there is no pending or, to the Company&rsquo;s knowledge, threatened action, suit, proceeding or claim by others that the
Company infringes, misappropriates or otherwise violates any Intellectual Property Rights or other proprietary rights of others, the
Company has not received any written notice of such claim and the Company is unaware of any other facts which would form a reasonable
basis for any such claim that would, individually or in the aggregate, together with any other claims in this <U>Section 2.32</U>, reasonably
be expected to result in a Material Adverse Change; and (E) to the Company&rsquo;s knowledge, no employee of the Company is in or has
ever been in violation in any material respect of any term of any employment contract, patent disclosure agreement, invention assignment
agreement, non-competition agreement, non-solicitation agreement, nondisclosure agreement or any restrictive covenant to or with a former
employer where the basis of such violation relates to such employee&rsquo;s employment with the Company, or actions undertaken by the
employee while employed with the Company and could reasonably be expected to result, individually or in the aggregate, in a Material
Adverse Change. To the Company&rsquo;s knowledge, all material technical information developed by and belonging to the Company which
has not been patented has been kept confidential. The Company is not a party to or bound by any options, licenses or agreements with
respect to the Intellectual Property Rights of any other person or entity that are required to be set forth in the Registration Statement,
the Pricing Disclosure Package and the Prospectus and are not described therein. The Registration Statement, the Pricing Disclosure Package
and the Prospectus contain in all material respects the same description of the matters set forth in the preceding sentence. None of
the technology employed by the Company has been obtained or is being used by the Company in violation of any contractual obligation binding
on the Company or, to the Company&rsquo;s knowledge, any of its officers, directors or employees, or otherwise in violation of the rights
of any persons.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>2.33.
<U>Taxes</U></I>. Each of the Company and its Subsidiaries has filed all returns (as hereinafter defined) required to be filed with taxing
authorities prior to the date hereof or has duly obtained extensions of time for the filing thereof, except in any case in which the
failure so to file would not reasonably be expected to cause a Material Adverse Change. Each of the Company and its Subsidiaries has
paid all taxes (as hereinafter defined) shown as due on such returns that were filed and has paid all taxes imposed on or assessed against
the Company or such respective Subsidiary, except for any such taxes that are currently being contested in good faith or as would not
reasonably be expected to cause a Material Adverse Change. The provisions for taxes payable, if any, shown on the financial statements
filed with or as part of the Registration Statement are sufficient for all accrued and unpaid taxes, whether or not disputed, and for
all periods to and including the dates of such consolidated financial statements. Except as disclosed in writing to the Underwriters,
(i) no issues have been raised (and are currently pending) by any taxing authority in connection with any of the returns or taxes asserted
as due from the Company or its Subsidiaries, and (ii) no waivers of statutes of limitation with respect to the returns or collection
of taxes have been given by or requested from the Company or its Subsidiaries. The term &ldquo;taxes&rdquo; means all federal, state,
local, foreign and other net income, gross income, gross receipts, sales, use, ad valorem, transfer, franchise, profits, license, lease,
service, service use, withholding, payroll, employment, excise, severance, stamp, occupation, premium, property, windfall profits, customs,
duties or other taxes, fees, assessments or charges of any kind whatever, together with any interest and any penalties, additions to
tax or additional amounts with respect thereto. The term &ldquo;returns&rdquo; means all returns, declarations, reports, statements and
other documents required to be filed in respect to taxes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>2.34.
<U>ERISA Compliance</U>.</I> The Company is not subject to the Employee Retirement Income Security Act of 1974, as amended, or the regulations
and published interpretations thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>2.35.
<U>Compliance with Laws</U></I>. Except as otherwise disclosed in the Registration Statement, Pricing Disclosure Package and Prospectus
and as could not, individually or in the aggregate, be expected to result in a Material Adverse Change, each of the Company and each
Subsidiary, the Company: (A) is and at all times has been in compliance with all statutes, rules, or regulations applicable to the products
and services provided by the Company (&ldquo;<B>Applicable Laws</B>&rdquo;), except as could not, individually or in the aggregate, reasonably
be expected to have a Material Adverse Change; (B) has not received any warning letter, untitled letter or other correspondence or notice
from any other governmental authority alleging or asserting noncompliance with any Applicable Laws or any licenses, certificates, approvals,
clearances, authorizations, permits and supplements or amendments thereto required by any such Applicable Laws (&ldquo;<B>Authorizations</B>&rdquo;);
(C) possesses all material Authorizations and such material Authorizations are valid and in full force and effect and are not in material
violation of any term of any such Authorizations; (D) has not received written notice of any claim, action, suit, proceeding, hearing,
enforcement, investigation, arbitration or other action from any governmental authority or third party alleging that any product operation
or activity is in violation of any Applicable Laws or Authorizations and has no knowledge that any such governmental authority or third
party is considering any such claim, litigation, arbitration, action, suit, investigation or proceeding that if brought would result
in a Material Adverse Change; (E) has not received written notice that any Governmental Entity has taken, is taking or intends to take
action to limit, suspend, modify or revoke any Authorizations and has no knowledge that any such Governmental Entity is considering such
action; (F) has filed, obtained, maintained or submitted all material reports, documents, forms, notices, applications, records, claims,
submissions and supplements or amendments as required by any Applicable Laws or Authorizations and that all such reports, documents,
forms, notices, applications, records, claims, submissions and supplements or amendments were complete and correct in all material respects
on the date filed (or were corrected or supplemented by a subsequent submission); and (G) has not, either voluntarily or involuntarily,
initiated, conducted, or issued or caused to be initiated, conducted or issued, any recall, market withdrawal or replacement, safety
alert, post-sale warning, or other notice or action relating to the alleged lack of safety of any product or any alleged product defect
or violation and, to the Company&rsquo;s knowledge, no third party has initiated, conducted or intends to initiate any such notice or
action.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>2.36.
<U>Ineligible Issuer</U>.</I> At the time of filing the Registration Statement and any post-effective amendment thereto, at the time
of effectiveness of the Registration Statement and any amendment thereto, at the earliest time thereafter that the Company or another
offering participant made a bona fide offer (within the meaning of Rule 164(h)(2) of the Securities Act Regulations) of the Shares and
at the date hereof, the Company was not and is not an &ldquo;ineligible issuer,&rdquo; as defined in Rule 405, without taking account
of any determination by the Commission pursuant to Rule 405 that it is not necessary that the Company be considered an ineligible issuer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>2.37.
<U>Real Property</U>.</I> Except as set forth in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the Company
and its Subsidiaries have good and marketable title in fee simple to, or have valid rights to lease or otherwise use, all items of real
or personal property which are material to the business of the Company and its Subsidiaries taken as a whole, in each case free and clear
of all liens, encumbrances, security interests, claims and defects that do not, singly or in the aggregate, materially affect the value
of such property and do not interfere with the use made and proposed to be made of such property by the Company or its Subsidiaries;
and all of the leases and subleases material to the business of the Company and its Subsidiaries, considered as one enterprise, and under
which the Company or any of its Subsidiaries holds properties described in the Registration Statement, the Pricing Disclosure Package
and the Prospectus, are in full force and effect, and neither the Company nor any Subsidiary has received any written notice of any material
claim of any sort that has been asserted by anyone adverse to the rights of the Company or any Subsidiary under any of the leases or
subleases mentioned above, or affecting or questioning the rights of the Company or such Subsidiary to the continued possession of the
leased or subleased premises under any such lease or sublease, which would result in a Material Adverse Change.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>2.38.
<U>Contracts Affecting Capital</U></I>. There are no transactions, arrangements or other relationships between and/or among the Company,
any of its affiliates (as such term is defined in Rule 405 of the Securities Act Regulations) and any unconsolidated entity, including,
but not limited to, any structured finance, special purpose or limited purpose entity that could reasonably be expected to materially
affect the Company&rsquo;s or its Subsidiaries&rsquo; liquidity or the availability of or requirements for their capital resources required
to be described or incorporated by reference in the Registration Statement, the Pricing Disclosure Package and the Prospectus which have
not been described or incorporated by reference as required.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>2.39.
<U>Loans to Directors or Officers</U>.</I> There are no outstanding loans, advances (except normal advances for business expenses in
the ordinary course of business) or guarantees or indebtedness by the Company or its Subsidiaries to or for the benefit of any of the
officers or directors of the Company, its Subsidiaries or any of their respective family members, except as disclosed in the Registration
Statement, the Pricing Disclosure Package and the Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>2.40.
<U>Industry Data; Forward-looking Statements</U>.</I> The statistical and market-related data included in each of the Registration Statement,
the Pricing Disclosure Package and the Prospectus are based on or derived from sources that the Company reasonably and in good faith
believes are reliable and accurate or represent the Company&rsquo;s good faith estimates that are made on the basis of data derived from
such sources. No forward-looking statement (within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act)
contained in the Prospectus has been made or reaffirmed without a reasonable basis or has been disclosed other than in good faith.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>2.41.
<U>Testing-the-Waters Communications</U></I>. The Company has not (i) alone engaged in any Testing-the-Waters Communications and (ii)
authorized anyone to engage in Testing-the-Waters Communications. The Company confirms that the Representative has been authorized to
act on its behalf in undertaking Testing-the-Waters Communications. The Company has not distributed any Written Testing-the-Waters Communications
other than those listed on <U>Schedule 2-C</U> hereto. &ldquo;Written Testing-the-Waters Communication&rdquo; means any Testing-the-Waters
Communication that is a written communication within the meaning of Rule 405 under the Securities Act; &ldquo;Testing-the-Waters Communication&rdquo;
means any oral or written communication with potential investors undertaken in reliance on Section 5(d) of the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>2.42.
<U>Emerging Growth Company</U>. </I>The Company is an &ldquo;emerging growth company,&rdquo; as defined in Section 2(a) of the Securities
Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>2.43.
<U>Electronic Road Show</U>.</I> The Company has made available a Bona Fide Electronic Road Show in compliance with Rule 433(d)(8)(ii)
of the Securities Act Regulations such that no filing of any &ldquo;road show&rdquo; (as defined in Rule 433(h) of the Securities Act
Regulations) is required in connection with the Offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>2.44.
<U>Margin Securities</U>.</I> The Company owns no &ldquo;margin securities&rdquo; as that term is defined in Regulation U of the Board
of Governors of the Federal Reserve System (the &ldquo;<B>Federal Reserve Board</B>&rdquo;), and none of the proceeds of Offering will
be used, directly or indirectly, for the purpose of purchasing or carrying any margin security, for the purpose of reducing or retiring
any indebtedness which was originally incurred to purchase or carry any margin security or for any other purpose which might cause any
of the Common Stock to be considered a &ldquo;purpose credit&rdquo; within the meanings of Regulation T, U or X of the Federal Reserve
Board<I>. </I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>2.45.
<U>Dividends and Distributions</U></I>. Except as disclosed in the Pricing Disclosure Package, Registration Statement and the Prospectus,
no Subsidiary of the Company is currently prohibited or restricted, directly or indirectly, from paying any dividends to the Company,
from making any other distribution on such Subsidiary&rsquo;s capital stock, from repaying to the Company any loans or advances to such
Subsidiary from the Company or from transferring any of such Subsidiary&rsquo;s property or assets to the Company or any other Subsidiary
of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>2.46.
<U>Lending Relationships</U></I>. Except as disclosed in the Pricing Disclosure Package, Registration Statement and the Prospectus, the
Company (i) does not have any material lending or other relationship with any bank or lending affiliate of the Underwriters and (ii)
does not intend to use any of the proceeds from the sale of the Securities hereunder to repay any outstanding debt owed to any affiliate
of the Underwriters.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>2.47.
<U>Regulatory Compliance</U></I>. Except as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus,
the Company (A) has not received any unresolved FDA Form 483, notice of observations, warning letter, untitled letter or other written
correspondence from the U.S. Food and Drug Administration (&ldquo;<B>FDA</B>&rdquo;), or any other court or arbitrator or federal, state,
local or foreign governmental or regulatory authority, alleging or asserting noncompliance with the Federal Food, Drug and Cosmetic Act
(21 U.S.C. &sect; 301 et seq.); (B) possesses all material licenses, certificates, registrations, approvals, clearances, authorizations,
permits and supplements or amendments thereto, and has made all declarations and filings with, the appropriate federal, state, local
or foreign governmental or regulatory authorities (including, without limitation, state or other food and drug regulatory authorities)
that are necessary for the ownership or lease of its properties or the conduct of its business as described in the Registration Statement,
the Pricing Disclosure Package and the Prospectus, and such Authorizations are valid and in full force and effect and the Company is
not in material violation of any term of any such Authorizations; (C) has not received written notice of any ongoing claim, action, suit,
proceeding, hearing, enforcement, investigation, arbitration or other action from any Governmental Entity or third party alleging that
any product, operation or activity is in material violation of any FDA regulation or Authorizations and has no knowledge that any such
Governmental Entity or third party is considering any such claim, litigation, arbitration, action, suit, investigation or proceeding;
(D) has not received written notice that any Governmental Entity has taken, is taking or intends to take action to suspend, revoke or
restrict any Authorizations and has no knowledge that any such Governmental Entity is considering such action; (E) has filed, obtained,
maintained or submitted all material reports, schedules, statements, filings, registrations, documents, forms, notices, applications,
records, claims, submissions and supplements or amendments thereto as required by any FDA regulation or Authorizations and that all such
reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments were complete and correct
on the date filed (or were corrected or supplemented by a subsequent submission); (F) has not, either voluntarily or involuntarily, initiated,
conducted, or issued or caused to be initiated, conducted or issued, any recall, or market withdrawal or other notice or action relating
to any alleged product defect or violation and, to the Company&rsquo;s knowledge, no third party has initiated or conducted any such
notice or action; (G) is not party to any corporate integrity agreement, deferred prosecution agreement, monitoring agreement, consent
decree, settlement order, or similar agreements, or have any reporting obligations pursuant to any such agreement, plan or correction
or other remedial measure entered into with any Governmental Entity; and (H) has not been convicted of any criminal offense relating
to the delivery of any item or service reimbursable under a federal or state food and drug program.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>2.48.
<U>Clinical Trials</U></I>. The clinical trials conducted by or on behalf of or sponsored by the Company or in which the Company or its
product candidates have participated have been and, if still pending, are being conducted (i) in material compliance with all statutes,
rules, regulations and guidance applicable thereto and (ii) in all material respects in accordance with medical and scientific research
procedures that the Company reasonably believes are appropriate. The Company has not received any notices or other correspondence from
the FDA or any other Governmental Entity requiring the termination, suspension or material modification of any clinical trials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>2.49.
<U>No Affiliation with Non-U.S. Persons</U></I>. The Company and its Subsidiaries are not, are not controlled by, and do not have substantial
ties with, a &ldquo;foreign person&rdquo; as such term is defined under rules and regulations of the Committee on Foreign Investment
in the United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
<U>Covenants of the Company</U>. The Company covenants and agrees as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>3.1.
<U>Amendments to Registration Statement</U>.</I> The Company shall deliver to the Representative, prior to filing, any amendment or supplement
to the Registration Statement or Prospectus proposed to be filed after the Effective Date and not file any such amendment or supplement
to which the Representative shall reasonably object in writing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>3.2.
<U>Federal Securities Laws</U>.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2.1.
<U>Compliance</U>. The Company, subject to <U>Section 3.2.2</U>, shall comply with the requirements of Rule 430A of the Securities Act
Regulations, and will notify the Representative promptly, and confirm the notice in writing, (i) when any post-effective amendment to
the Registration Statement shall become effective or any amendment or supplement to the Prospectus shall have been filed; (ii) of the
receipt of any comments from the Commission; (iii) of any request by the Commission for any amendment to the Registration Statement or
any amendment or supplement to the Prospectus or for additional information; (iv) of the issuance by the Commission of any stop order
suspending the effectiveness of the Registration Statement or any post-effective amendment or of any order preventing or suspending the
use of any Preliminary Prospectus or the Prospectus, or of the suspension of the qualification of the Shares and the Representative&rsquo;s
Warrants for offering or sale in any jurisdiction, or of the initiation or threatening of any proceedings for any of such purposes or
of any examination pursuant to Section 8(d) or 8(e) of the Securities Act concerning the Registration Statement and (v) if the Company
becomes the subject of a proceeding under Section 8A of the Securities Act in connection with the Offering of the Shares and Representative&rsquo;s
Warrants. The Company shall effect all filings required under Rule 424(b) of the Securities Act Regulations, in the manner and within
the time period required by Rule 424(b) (without reliance on Rule 424(b)(8)), and shall take such steps as it deems necessary to ascertain
promptly whether the form of prospectus transmitted for filing under Rule 424(b) was received for filing by the Commission and, in the
event that it was not, it will promptly file such prospectus. The Company shall use its reasonable best efforts to prevent the issuance
of any stop order, prevention or suspension and, if any such order is issued, to obtain the lifting thereof at the earliest possible
moment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2.2.
<U>Continued Compliance</U>. The Company shall comply with the Securities Act, the Securities Act Regulations, the Exchange Act and the
Exchange Act Regulations so as to permit the completion of the distribution of the Shares as contemplated in this Agreement and in the
Registration Statement, the Pricing Disclosure Package and the Prospectus. If at any time when a prospectus relating to the Shares is
(or, but for the exception afforded by Rule 172 of the Securities Act Regulations (&ldquo;<B>Rule 172</B>&rdquo;), would be) required
by the Securities Act to be delivered in connection with sales of the Shares, any event shall occur or condition shall exist as a result
of which it is necessary, in the opinion of counsel for the Underwriters or for the Company, to (i) amend the Registration Statement
in order that the Registration Statement will not include an untrue statement of a material fact or omit to state a material fact required
to be stated therein or necessary to make the statements therein not misleading; (ii) amend or supplement the Pricing Disclosure Package
or the Prospectus in order that the Pricing Disclosure Package or the Prospectus, as the case may be, will not include any untrue statement
of a material fact or omit to state a material fact necessary in order to make the statements therein not misleading in the light of
the circumstances existing at the time it is delivered to a purchaser or (iii) amend the Registration Statement or amend or supplement
the Pricing Disclosure Package or the Prospectus, as the case may be, in order to comply with the requirements of the Securities Act
or the Securities Act Regulations, the Company will promptly (A) give the Representative notice of such event; (B) prepare any amendment
or supplement as may be necessary to correct such statement or omission or to make the Registration Statement, the Pricing Disclosure
Package or the Prospectus comply with such requirements and, a reasonable amount of time prior to any proposed filing or use, furnish
the Representative with copies of any such amendment or supplement and (C) file with the Commission any such amendment or supplement;
<I>provided </I>that the Company shall not file or use any such amendment or supplement to which the Representative or Representative&rsquo;s
Counsel shall reasonably object. The Company will furnish to the Underwriters such number of copies of such amendment or supplement as
the Underwriters may reasonably request. The Company has given the Representative notice of any filings made pursuant to the Exchange
Act or the Exchange Act Regulations within forty-eight (48) hours prior to the Applicable Time. The Company shall give the Representative
notice of its intention to make any such filing from the Applicable Time until the Closing Date and the exercise in full or expiration
of the Over-allotment Option specified in <U>Section 1.2</U> hereof and will furnish the Representative with copies of the related document(s)
a reasonable amount of time prior to such proposed filing, as the case may be, and will not file or use any such document to which the
Representative or counsel for the Underwriters shall reasonably object.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2.3.
<U>Exchange Act Registration</U>. Until three (3) years after the date of this Agreement, the Company shall use its commercially reasonable
efforts to maintain the registration of the Common Stock under the Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2.4.
<U>Free Writing Prospectuses</U>. The Company agrees that, unless it obtains the prior consent of the Representative, it shall not make
any offer relating to the Shares that would constitute an Issuer Free Writing Prospectus or that would otherwise constitute a &ldquo;free
writing prospectus,&rdquo; or a portion thereof, required to be filed by the Company with the Commission or retained by the Company under
Rule 433; <I>provided</I> that the Representative shall be deemed to have consented to each Issuer General Use Free Writing Prospectus
set forth in <U>Schedule 2-B</U>. The Company represents that it has treated or agrees that it will treat each such free writing prospectus
consented to, or deemed consented to, by the Underwriters as an &ldquo;issuer free writing prospectus,&rdquo; as defined in Rule 433,
and that it has complied and will comply with the applicable requirements of Rule 433 with respect thereto, including timely filing with
the Commission where required, legending and record keeping. If at any time following issuance of an Issuer Free Writing Prospectus there
occurred or occurs an event or development as a result of which such Issuer Free Writing Prospectus conflicted or would conflict with
the information contained in the Registration Statement or included or would include an untrue statement of a material fact or omitted
or would omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances existing
at that subsequent time, not misleading, the Company will promptly notify the Underwriters and will promptly amend or supplement, at
its own expense, such Issuer Free Writing Prospectus to eliminate or correct such conflict, untrue statement or omission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2.5.
<U>Testing-the-Waters Communications</U>. If at any time following the distribution of any Written Testing-the-Waters Communication there
occurred or occurs an event or development as a result of which such Written Testing-the-Waters Communication included or would include
an untrue statement of a material fact or omitted or would omit to state a material fact necessary in order to make the statements therein,
in the light of the circumstances existing at that subsequent time, not misleading, the Company shall promptly notify the Representative
and shall promptly amend or supplement, at its own expense, such Written Testing-the-Waters Communication to eliminate or correct such
untrue statement or omission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>3.3.
<U>Delivery to the Underwriters of Registration Statements</U></I>. The Company has delivered or made available or shall deliver or make
available to the Representative and Representative&rsquo;s Counsel, without charge, signed copies of the Registration Statement as originally
filed and each amendment thereto (including exhibits filed therewith) and signed copies of all consents and certificates of experts,
and upon request will also deliver to the Underwriters, without charge, a conformed copy of the Registration Statement as originally
filed and each amendment thereto (without exhibits) for each of the Underwriters. The copies of the Registration Statement and each amendment
thereto furnished to the Underwriters will be identical to the electronically transmitted copies thereof filed with the Commission pursuant
to EDGAR, except to the extent permitted by Regulation S-T.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>3.4.
<U>Delivery to the Underwriters of Prospectuses</U>.</I> The Company has delivered or made available or will deliver or make available
to each Underwriter, without charge, as many copies of each Preliminary Prospectus as such Underwriter reasonably requested, and the
Company hereby consents to the use of such copies for purposes permitted by the Securities Act. The Company will furnish to each Underwriter,
without charge, during the period when a prospectus relating to the Shares is (or, but for the exception afforded by Rule 172, would
be) required to be delivered under the Securities Act, such number of copies of the Prospectus (as amended or supplemented) as such Underwriter
may reasonably request. The Prospectus and any amendments or supplements thereto furnished to the Underwriters will be identical to the
electronically transmitted copies thereof filed with the Commission pursuant to EDGAR, except to the extent permitted by Regulation S-T.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>3.5.
<U>Effectiveness and Events Requiring Notice to the Representative</U>.</I> The Company shall use its commercially reasonable efforts
to cause the Registration Statement covering the issuance of the shares of Common Stock underlying the Representative&rsquo;s Warrants
to remain effective with a current prospectus for at least nine (9) months after the Applicable Time, and shall notify the Representative
immediately and confirm the notice in writing: (i) of the cessation of the effectiveness of the Registration Statement and any amendment
thereto; (ii) of the issuance by the Commission of any stop order or of the initiation, or the threatening, of any proceeding for that
purpose; (iii) of the issuance by any state securities commission of any proceedings for the suspension of the qualification of the shares
of Common Stock underlying the Representative&rsquo;s Warrants for offering or sale in any jurisdiction or of the initiation, or the
threatening, of any proceeding for that purpose; (iv) of the mailing and delivery to the Commission for filing of any amendment or supplement
to the Registration Statement or Prospectus; (v) of the receipt of any comments or request for any additional information from the Commission;
and (vi) of the happening of any event during the period described in this <U>Section 3.5</U> that, in the judgment of the Company, makes
any statement of a material fact made in the Registration Statement, the Pricing Disclosure Package or the Prospectus untrue or that
requires the making of any changes in (a) the Registration Statement in order to make the statements therein not misleading, or (b) in
the Pricing Disclosure Package or the Prospectus in order to make the statements therein, in light of the circumstances under which they
were made, not misleading. If the Commission or any state securities commission shall enter a stop order or suspend such qualification
at any time, the Company shall make every reasonable effort to obtain promptly the lifting of such order.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>3.6.
<U>Review of Financial Statements.</U></I> For a period of three (3) years after the date of this Agreement, the Company, at its expense,
shall cause its regularly engaged independent registered public accounting firm to review (but not audit) the Company&rsquo;s financial
statements for each of the three fiscal quarters immediately preceding the announcement of any quarterly financial information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>3.7.
<U>Listing</U>.</I> The Company shall use its commercially reasonable efforts to maintain the listing of the Shares and the shares of
Common Stock underlying the Representative&rsquo;s Warrant on the Exchange for at least three (3) years following the date of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>3.8.
<U>Financial Public Relations Firm</U></I>. As of the Effective Date, or promptly thereafter, the Company shall have retained a financial
public relations firm reasonably acceptable to the Representative and the Company, which shall initially be _______________, which firm
shall be experienced in assisting issuers in initial public offerings of securities and in their relations with their security holders,
and shall retain such firm or another firm reasonably acceptable to the Representative for a period of not less than two (2) years after
the Effective Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>3.9.
<U>Reports to the Representative</U>.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.9.1.
<U>Periodic Reports, etc</U>. For a period of three (3) years after the date of this Agreement, the Company shall furnish or make available
to the Representative copies of such financial statements and other periodic and special reports as the Company from time to time furnishes
generally to holders of any class of its securities and also furnish or make available to the Representative: (i) a copy of each periodic
report the Company shall be required to file with the Commission under the Exchange Act and the Exchange Act Regulations; (ii) a copy
of every press release and every news item and article with respect to the Company or its affairs which was released by the Company;
(iii) a copy of each Form 8-K prepared and filed by the Company; (iv) a copy of each registration statement filed by the Company under
the Securities Act; and (v) such additional documents and information with respect to the Company and the affairs of any future subsidiaries
of the Company as the Representative may from time to time reasonably request; <I>provided</I> the Representative shall sign, if requested
by the Company, a Regulation FD compliant confidentiality agreement which is reasonably acceptable to the Representative and Representative&rsquo;s
Counsel in connection with the Representative&rsquo;s receipt of such information. Documents filed with the Commission pursuant to its
EDGAR system shall be deemed to have been delivered to the Representative pursuant to this <U>Section 3.9.1</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.9.2.
<U>Transfer Agent; Transfer Sheets</U>. For a period of three (3) years after the date of this Agreement, the Company shall retain a
transfer agent and registrar acceptable to the Representative (the &ldquo;<B>Transfer Agent</B>&rdquo;) and shall furnish to the Representative
at the Company&rsquo;s sole cost and expense such transfer sheets of the Company&rsquo;s securities as the Representative may reasonably
request, including the daily and monthly consolidated transfer sheets of the Transfer Agent and DTC. VStock Transfer, LLC is acceptable
to the Representative to act as Transfer Agent for the Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.9.3.
<U>Trading Reports</U>. For a period of six (6) months after the date hereof, during such time as the Shares are listed on the Exchange,
the Company shall provide to the Representative, at the Company&rsquo;s expense, such reports published by the Exchange relating to price
trading of the Shares, as the Representative shall reasonably request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>3.10.
<U>Payment of Expenses</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.10.1.
<U>General Expenses Related to the Offering</U>. The Company hereby agrees to pay on each of the Closing Date and the Option Closing
Date, if any, to the extent not paid at the Closing Date, all expenses incident to the performance of the obligations of the Company
under this Agreement, including, but not limited to: (a) all filing fees and communication expenses relating to the registration of the
Shares to be sold in the Offering (including the Over-allotment Option) with the Commission; (b) all Public Filing System filing fees
associated with the review of the Offering by FINRA; (c) all fees, expenses and disbursements relating to the registration, qualification
or exemption of the Shares under the securities laws of such foreign jurisdictions as the Representative may reasonably designate; (d)
all fees, expenses and disbursements relating to background checks of the Company&rsquo;s officers and directors and other due diligence
expenses; (e) the costs associated with receiving commemorative mementos and lucite tombstones; (f) fees and expenses of the Representative&rsquo;s
Counsel; (g) the Underwriters&rsquo; due diligence expenses; and (h) the Underwriters&rsquo; &ldquo;road show&rdquo; expenses for the
Offering, with all of the Underwriters&rsquo; actual out-of-pocket expenses under subsections <U>3.10.1(d)-(h)</U> not to exceed $280,000,
of which $[&#9679;] has previously been paid. The Representative may deduct from the net proceeds of the Offering payable to the Company
on the Closing Date, or the Option Closing Date, if any, the expenses set forth herein to be paid by the Company to the Underwriters;
<I>provided</I>, <I>however</I>, that in the event that the Offering is terminated, the Company agrees to reimburse the Underwriters
pursuant to <U>Section 8.3</U> hereof. Notwithstanding the foregoing, any advance received by the Representative will be reimbursed to
the Company to the extent not actually incurred in compliance with FINRA Rule 5110(g)(4)(A).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.10.2.
<U>Non-accountable Expenses</U>. The Company further agrees that, in addition to the expenses payable pursuant to <U>Section 3.10.1</U>,
on the Closing Date it shall pay to the Representative, by deduction from the net proceeds of the Offering contemplated herein, a non-accountable
expense allowance equal to one percent (1.0%) of the gross proceeds received by the Company from the sale of the Firm Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>3.11.
<U>Application of Net Proceeds</U>. </I>The Company shall apply the net proceeds from the Offering received by it in a manner consistent
with the application thereof described under the caption &ldquo;Use of Proceeds&rdquo; in the Registration Statement, the Pricing Disclosure
Package and the Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>3.12.
<U>Delivery of Earnings Statements to Security Holders</U></I>. The Company will timely file such reports pursuant to the Exchange Act
as are necessary in order to make generally available to its security holders as soon as practicable, an earnings statement (which need
not be certified by independent registered public accounting firm unless required by the Securities Act or the Securities Act Regulations,
but which shall satisfy the provisions of Rule 158(a) under Section 11(a) of the Securities Act) covering a period of at least twelve
(12) consecutive months beginning after the date of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>3.13.
<U>Stabilization</U>.</I> Neither the Company nor, to its knowledge, any of its employees, directors or shareholders has taken or shall
take, directly or indirectly, any action designed to or that has constituted or that might reasonably be expected to cause or result
in, under Regulation M of the Exchange Act, or otherwise, stabilization or manipulation of the price of any security of the Company to
facilitate the sale or resale of the Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>3.14.
<U>Internal Controls</U></I>. Except to the extent disclosed in the Registration Statement, Pricing Disclosure Package and Prospectus,
the Company shall maintain a system of internal accounting controls sufficient to provide reasonable assurances that: (i) transactions
are executed in accordance with management&rsquo;s general or specific authorization; (ii) transactions are recorded as necessary in
order to permit preparation of financial statements in accordance with GAAP and to maintain accountability for assets; (iii) access to
assets is permitted only in accordance with management&rsquo;s general or specific authorization; and (iv) the recorded accountability
for assets is compared with existing assets at reasonable intervals and appropriate action is taken with respect to any differences.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>3.15.
<U>Accountants</U></I>. As of the date of this Agreement, the Company has retained an independent registered public accounting firm reasonably
acceptable to the Representative, and the Company shall continue to retain a nationally recognized independent registered public accounting
firm for a period of at least three (3) years after the date of this Agreement. The Representative acknowledges that the Auditor is acceptable
to the Representative.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>3.16.
<U>FINRA</U></I>. For a period of ninety (90) days after the later of the Closing Date or the Option Closing Date, the Company shall
advise the Representative (who shall make an appropriate filing with FINRA) if it is or becomes aware that (i) any officer or director
of the Company, (ii) any beneficial owner of 5% or more of any class of the Company&rsquo;s securities or (iii) any beneficial owner
of the Company&rsquo;s unregistered equity securities which were acquired during the one hundred eighty (180) days immediately preceding
the filing of the original Registration Statement is or becomes an affiliate or associated person of a FINRA member participating in
the Offering (as determined in accordance with the rules and regulations of FINRA).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>3.17.
<U>No Fiduciary Duties</U></I>. The Company acknowledges and agrees that the Underwriters&rsquo; responsibility to the Company is solely
contractual in nature and that none of the Underwriters or their affiliates or any selling agent shall be deemed to be acting in a fiduciary
capacity, or otherwise owes any fiduciary duty to the Company or any of its affiliates in connection with the Offering and the other
transactions contemplated by this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>3.18.
<U>Company, Executive Officers, Directors and Holders of At Least 1% Lock-Up</U></I>. The Company, on behalf of itself and any successor
entity, and the Company&rsquo;s executive officers, directors and holders of 5% or greater of the outstanding shares of Common Stock
after giving effect to the Offering agree, without the prior written consent of the Representative, to be locked up for a period of three
hundred sixty five (365) days after the date of this Agreement. Holders of 1% to 4.99% of the outstanding shares of Common Stock after
giving effect to the Offering agree to be locked up for a period of one hundred eighty (180) days after the date of this Agreement, <I>provided
</I>that if the aggregate of such holder&rsquo;s shares were to equal or exceed 20% of the issued and outstanding shares of Common Stock
on a fully-diluted basis prior to the completion of the Offering, then such holder&rsquo;s lock-up period shall be for a period of three
hundred sixty five (365) days after the date of this Agreement. The respective three hundred sixty five (365) or one hundred eighty (180)
day period that the Company, executive officers, directors, and/or shareholders agree to be locked up are each hereinafter referred to
as the &ldquo;<B>Lock-Up Period</B>.&rdquo; Holders of less than 1% of the outstanding shares of Common Stock after giving effect to
the Offering are not subject to any lock-up period, <I>provided </I>that if the aggregate of such holder&rsquo;s shares of Common Stock
were to equal or exceed 5% of the issued and outstanding shares of Common Stock on a fully-diluted basis prior to the completion of the
Offering, then such holder&rsquo;s Lock-Up Period shall be for a period of one hundred eighty (180) days after the date of this Agreement.
During the Lock-Up Period, as applicable, the Company and each of the Company&rsquo;s executive officers, directors and holders of Common
Stock who are subject to a Lock-Up Period shall not, directly or indirectly, without the prior written consent of the Representative,
(i) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant or
amend the terms of any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any shares
of capital stock of the Company or any securities convertible into or exercisable or exchangeable for shares of capital stock of the
Company; (ii) file or cause to be filed any registration statement with the Commission relating to the offering of any shares of capital
stock of the Company or any securities convertible into or exercisable or exchangeable for shares of capital stock of the Company (other
than pursuant to a registration statement on Form S-8 for employee benefit plans); or (iii) enter into any swap or other arrangement
that transfers to another, in whole or in part, any of the economic consequences of ownership of capital stock of the Company, whether
any such transaction described in clause (i), (ii) or (iii) above is to be settled by delivery of shares of capital stock of the Company
or such other securities, in cash or otherwise. The restrictions contained in this section shall not apply to (i) the Shares and the
Representative&rsquo;s Warrants and shares underlying the Representative&rsquo;s Warrants to be sold hereunder; (ii) the issuance by
the Company of Common Stock upon the exercise of an outstanding option or warrant or the conversion of a security outstanding on the
date hereof or disclosed in the Registration Statement and the Pricing Disclosure Package; and (iii) the issuance of Common Stock pursuant
to the Company&rsquo;s existing stock option, equity incentive or bonus plans as disclosed in the Registration Statement and the Pricing
Disclosure Package. The Company agrees not to accelerate the vesting of any option or warrant or the lapse of any repurchase right prior
to the expiration of any applicable Lock-Up Period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>3.19.
<U>Release of D&amp;O Lock-up Period</U></I>. If the Representative, in its sole discretion, agrees to release or waive the restrictions
set forth in the Lock-Up Agreements described in <U>Section 2.24</U> hereof for an executive officer or director of the Company and provides
the Company with notice of the impending release or waiver at least three (3) Business Days before the effective date of the release
or waiver, the Company agrees to announce the impending release or waiver by a press release through a major news service at least two
(2) Business Days before the effective date of the release or waiver.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>3.20.
<U>Blue Sky Qualifications</U>.</I> The Company shall use its reasonable best efforts, in cooperation with the Underwriters, if necessary,
to qualify the Shares for offering and sale under the applicable securities laws of such states and other jurisdictions (domestic or
foreign) as the Representative may designate and to maintain such qualifications in effect so long as required to complete the distribution
of the Shares; <I>provided</I>, <I>however</I>, that the Company shall not be obligated to file any general consent to service of process
or to qualify as a foreign corporation or as a dealer in securities in any jurisdiction in which it is not so qualified or to subject
itself to taxation in respect of doing business in any jurisdiction in which it is not otherwise so subject.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>3.21.
<U>Reporting Requirements</U>.</I> The Company, during the period when a prospectus relating to the Shares is (or, but for the exception
afforded by Rule 172, would be) required to be delivered under the Securities Act, will file all documents required to be filed with
the Commission pursuant to the Exchange Act within the time periods required by the Exchange Act and Exchange Act Regulations. Additionally,
the Company shall report the use of proceeds from the issuance of the Shares as may be required under Rule 463 under the Securities Act
Regulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
<U>Conditions of Underwriters&rsquo; Obligations</U>. The obligations of the Underwriters to purchase and pay for the Shares, as provided
herein, shall be subject to (i) the continuing accuracy of the representations and warranties of the Company as of the date hereof and
as of each of the Closing Date and the Option Closing Date, if any; (ii) the accuracy of the statements of officers of the Company made
pursuant to the provisions hereof; (iii) the performance by the Company of its obligations hereunder; and (iv) the following conditions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>4.1.
<U>Regulatory Matters</U>.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1.1.
<U>Effectiveness of Registration Statement; Rule 430A Information</U>. The Registration Statement has become effective not later than
5:00 p.m., Eastern time, on the date of this Agreement or such later date and time as shall be consented to in writing by you, and, at
each of the Closing Date and any Option Closing Date, no stop order suspending the effectiveness of the Registration Statement or any
post-effective amendment thereto has been issued under the Securities Act, no order preventing or suspending the use of any Preliminary
Prospectus or the Prospectus has been issued and no proceedings for any of those purposes have been instituted or are pending or, to
the Company&rsquo;s knowledge, contemplated by the Commission. The Company has complied with each request (if any) from the Commission
for additional information. The Prospectus containing the Rule 430A Information shall have been filed with the Commission in the manner
and within the time frame required by Rule 424(b) (without reliance on Rule 424(b)(8)) or a post-effective amendment providing such information
shall have been filed with, and declared effective by, the Commission in accordance with the requirements of Rule 430A.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1.2.
<U>FINRA Clearance</U>. On or before the date of this Agreement, the Representative shall have received clearance from FINRA as to the
amount of compensation allowable or payable to the Underwriters as described in the Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1.3.
<U>Stock Exchange Listing Clearance</U>. On the Closing Date, the Firm Shares shall have been approved for listing on the Exchange, subject
only to official notice of issuance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>4.2.
<U>Company Counsel Matters</U>.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2.1.
<U>Closing Date Opinion of Counsel</U>. On the Closing Date, the Representative shall have received the favorable opinion of Dorsey &amp;
Whitney LLP, counsel to the Company, including a written statement providing certain &ldquo;10b-5&rdquo; negative assurances, dated the
Closing Date, in form and substance reasonably satisfactory to Representative&rsquo;s Counsel addressed to the Representative and stating
that such opinion may be relied upon by Representative&rsquo;s Counsel.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2.2.
<U>Opinion of Company&rsquo;s Intellectual Property Counsel</U>. On the Closing Date, the Representative shall have received the favorable
opinion of ____________, regulatory counsel to the Company, dated the Closing Date, in form and substance reasonably satisfactory to
Representative&rsquo;s Counsel addressed to the Representative and stating that such opinion may be relied upon by Representative&rsquo;s
Counsel.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2.3.
<U>Option Closing Date Opinions of Counsel</U>. On the Option Closing Date, if any, the Representative shall have received the favorable
opinions of each counsel listed in <U>Sections 4.2.1</U> and <U>4.2.2</U>, dated the Option Closing Date, in form and substance reasonably
satisfactory to Representative&rsquo;s Counsel addressed to the Representative and confirming as of the Option Closing Date the statements
made by such counsels in their respective opinions delivered on the Closing Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2.4.
<U>Reliance</U>. In rendering such opinions, such counsel may rely: (i) as to matters involving the application of laws other than the
laws of the United States and jurisdictions in which they are admitted, to the extent such counsel deems proper and to the extent specified
in such opinion, if at all, upon an opinion or opinions (in form and substance reasonably satisfactory to the Representative) of other
counsel reasonably acceptable to the Representative, familiar with the applicable laws; and (ii) as to matters of fact, to the extent
they deem proper, on certificates or other written statements of officers of the Company and officers of departments of various jurisdictions
having custody of documents respecting the corporate existence or good standing of the Company, <I>provided </I>that copies of any such
statements or certificates shall be delivered to Representative&rsquo;s Counsel if requested.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>4.3.
<U>Comfort Letters</U>.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3.1.
<U>Cold Comfort Letter</U>. At the time this Agreement is executed you shall have received a cold comfort letter containing statements
and information of the type customarily included in accountants&rsquo; comfort letters with respect to the financial statements and certain
financial information contained in the Registration Statement, the Pricing Disclosure Package and the Prospectus, addressed to the Representative
and in form and substance satisfactory in all respects to you and to the Auditor, dated as of the date of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3.2.
<U>Bring-down Comfort Letter</U>. At each of the Closing Date and Option Closing Date, if any, the Representative shall have received
from the Auditor a letter, dated as of the Closing Date or the Option Closing Date, as applicable, to the effect that the Auditor reaffirms
the statements made in the letter furnished pursuant to <U>Section 4.3.1</U>, except that the specified date referred to shall be a date
not more than three (3) Business Days prior to the Closing Date or the Option Closing Date, as applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>4.4.
<U>Officers&rsquo; Certificates</U>.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4.1.
<U>Officers&rsquo; Certificate</U>. The Company shall have furnished to the Representative a certificate, dated the Closing Date and
any Option Closing Date (if such date is other than the Closing Date), of its Chief Executive Officer and its Chief Financial Officer
stating that (i) such officers have carefully examined the Registration Statement, the Pricing Disclosure Package, any Issuer Free Writing
Prospectus and the Prospectus and, in their opinion, the Registration Statement and each amendment thereto, as of the Applicable Time
and as of the Closing Date (or any Option Closing Date if such date is other than the Closing Date) did not include any untrue statement
of a material fact and did not omit to state a material fact required to be stated therein or necessary to make the statements therein
not misleading, and the Pricing Disclosure Package, as of the Applicable Time and as of the Closing Date (or any Option Closing Date
if such date is other than the Closing Date), any Issuer Free Writing Prospectus as of its date and as of the Closing Date (or any Option
Closing Date if such date is other than the Closing Date), the Prospectus and each amendment or supplement thereto, as of the respective
date thereof and as of the Closing Date, did not include any untrue statement of a material fact and did not omit to state a material
fact necessary in order to make the statements therein, in the light of the circumstances in which they were made, not misleading, (ii)
since the effective date of the Registration Statement, no event has occurred which should have been set forth in a supplement or amendment
to the Registration Statement, the Pricing Disclosure Package or the Prospectus, (iii) as of the Closing Date (or any Option Closing
Date if such date is other than the Closing Date), the representations and warranties of the Company in this Agreement are true and correct
in all material respects (except for those representations and warranties qualified as to materiality, which shall be true and correct
in all respects and except for those representations and warranties which refer to facts existing at a specific date, which shall be
true and correct as of such date) and the Company has complied with all agreements and satisfied all conditions on its part to be performed
or satisfied hereunder at or prior to the Closing Date (or any Option Closing Date if such date is other than the Closing Date), and
(iv) there has not been, subsequent to the date of the most recent audited financial statements included or incorporated by reference
in the Pricing Disclosure Package, a Material Adverse Change.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4.2.
<U>Secretary&rsquo;s Certificate</U>. At each of the Closing Date and the Option Closing Date, if any, the Representative shall have
received a certificate of the Company signed by the Secretary of the Company, dated the Closing Date or the Option Closing Date, as the
case may be, respectively, certifying: (i) that each of the Charter and Bylaws is true and complete, has not been modified and is in
full force and effect; (ii) that the resolutions of the Company&rsquo;s Board of Directors (and any pricing committee thereof) relating
to the Offering are in full force and effect and have not been modified; and (iii) as to the incumbency of the officers of the Company.
The documents referred to in such certificate shall be attached to such certificate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>4.5.
<U>No Material Changes</U></I>. Prior to and on each of the Closing Date and the Option Closing Date, if any: (i) there shall have been
no Material Adverse Change in the condition or prospects or the business activities, financial or otherwise, of the Company from the
latest dates as of which such condition is set forth in the Registration Statement, the Pricing Disclosure Package and the Prospectus;
(ii) no action, suit or proceeding, at law or in equity, shall have been pending or threatened against the Company or any Insider before
or by any court or federal or state commission, board or other administrative agency wherein an unfavorable decision, ruling or finding
may reasonably be expected to cause a Material Adverse Change, except as set forth in the Registration Statement, the Pricing Disclosure
Package and the Prospectus; (iii) no stop order shall have been issued under the Securities Act and no proceedings therefor shall have
been initiated or threatened by the Commission; and (iv) the Registration Statement, the Pricing Disclosure Package and the Prospectus
and any amendments or supplements thereto shall contain all material statements which are required to be stated therein in accordance
with the Securities Act and the Securities Act Regulations and shall conform in all material respects to the requirements of the Securities
Act and the Securities Act Regulations, and neither the Registration Statement, the Pricing Disclosure Package nor the Prospectus nor
any amendment or supplement thereto shall contain any untrue statement of a material fact or omit to state any material fact required
to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>4.6.
<U>Delivery of Agreements</U>.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6.1.
<U>Lock-Up Agreements</U>. On or before the date of this Agreement, the Company shall have delivered to the Representative executed copies
of the Lock-Up Agreements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6.2.
<U>Representative&rsquo;s Warrants</U>. On the Closing Date and on each Option Closing Date (if any), the Company shall have delivered
to the Representative executed Representative&rsquo;s Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>4.7.
<U>Additional Documents</U></I>. At the Closing Date and at each Option Closing Date, if any, Representative&rsquo;s Counsel shall have
been furnished with such documents and opinions as they may require for the purpose of enabling Representative&rsquo;s Counsel to deliver
an opinion to the Underwriters, or in order to evidence the accuracy of any of the representations or warranties, or the fulfillment
of any of the conditions, herein contained; and all proceedings taken by the Company in connection with the issuance and sale of the
Shares and the Representative&rsquo;s Warrants as herein contemplated shall be satisfactory in form and substance to the Representative
and Representative&rsquo;s Counsel.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
<U>Indemnification</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>5.1.
<U>Indemnification of the Underwriters</U>.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1.1.
<U>General</U>. Subject to the conditions set forth below, the Company agrees to indemnify and hold harmless each Underwriter, its affiliates
and each of its and their respective directors, officers, members, employees, representatives, partners, shareholders, affiliates, counsel,
and agents and each person, if any, who controls any such Underwriter within the meaning of Section 15 of the Securities Act or Section
20 of the Exchange Act (collectively, the &ldquo;<B>Underwriter Indemnified Parties</B>&rdquo; and each, an &ldquo;<B>Underwriter Indemnified
Party</B>&rdquo;), against any and all loss, liability, claim, damage and expense whatsoever (including but not limited to any and all
legal or other expenses reasonably incurred in investigating, preparing or defending against any litigation, commenced or threatened,
or any claim whatsoever, whether arising out of any action between any of the Underwriter Indemnified Parties and the Company or between
any of the Underwriter Indemnified Parties and any third party, or otherwise) to which they or any of them may become subject under the
Securities Act, the Exchange Act or any other statute or at common law or otherwise or under the laws of foreign countries (a &ldquo;<B>Claim</B>&rdquo;),
arising out of or based upon any untrue statement or alleged untrue statement of a material fact contained, or the omission or alleged
omission therefrom of a material fact required to be stated therein or necessary to make the statements therein, in the light of the
circumstances under which they were made, not misleading, in (A) the Registration Statement, the Pricing Disclosure Package, any Preliminary
Prospectus, the Prospectus, or in any Issuer Free Writing Prospectus or in any Written Testing-the-Waters Communication (as from time
to time each may be amended and supplemented); (B) any materials or information provided to investors by, or with the approval of, the
Company in connection with the marketing of the Offering, including any &ldquo;road show&rdquo; or investor presentations made to investors
by the Company (whether in person or electronically); or (C) any application or other document or written communication (in this <U>Section
5</U>, collectively called &ldquo;application&rdquo;) executed by the Company or based upon written information furnished by the Company
in any jurisdiction in order to qualify the Shares and Representative&rsquo;s Warrants under the securities laws thereof or filed with
the Commission, any state securities commission or agency, the Exchange or any other national securities exchange; <I>unless</I>, with
respect to each subsection (A) through (C), such statement or omission was made in reliance upon, and in conformity with, the Underwriters&rsquo;
Information. With respect to any untrue statement or omission or alleged untrue statement or omission made in the Registration Statement,
Pricing Disclosure Package or Prospectus, the indemnity agreement contained in this <U>Section 5.1.1</U> shall not inure to the benefit
of any Underwriter Indemnified Party to the extent that any loss, liability, claim, damage or expense of such Underwriter Indemnified
Party results from the fact that a copy of the Prospectus was not given or sent to the person asserting any such loss, liability, claim
or damage at or prior to the written confirmation of sale of the Shares to such person as required by the Securities Act and the Securities
Act Regulations, and if the untrue statement or omission has been corrected in the Prospectus, unless such failure to deliver the Prospectus
was a result of non-compliance by the Company with its obligations under <U>Section 3.3</U> hereof. The Company also agrees that it will
reimburse each Underwriter Indemnified Party for all reasonable fees and expenses (including but not limited to any and all legal or
other expenses reasonably incurred in investigating, preparing or defending against any litigation, commenced or threatened, or any claim
whatsoever, whether arising out of any action between any of the Underwriter Indemnified Parties and the Company or between any of the
Underwriter Indemnified Parties and any third party, or otherwise) (collectively, the &ldquo;<B>Expenses</B>&rdquo;), and further agrees
wherever and whenever possible to advance payment of Expenses as they are incurred by an Underwriter Indemnified Party in investigating,
preparing, pursuing or defending any Claim.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1.2.
<U>Procedure</U>. If any action is brought against an Underwriter Indemnified Party in respect of which indemnity may be sought against
the Company pursuant to <U>Section 5.1.1</U>, such Underwriter Indemnified Party shall promptly notify the Company in writing of the
institution of such action and the Company shall assume the defense of such action, including the employment and fees of counsel (subject
to the approval of such Underwriter Indemnified Party (which approval shall not be unreasonably withheld)) and payment of actual expenses
if an Underwriter Indemnified Party requests that the Company do so. Such Underwriter Indemnified Party shall have the right to employ
its or their own counsel in any such case, and the fees and expenses of such counsel shall be at the expense of the Company and shall
be advanced by the Company; <I>provided</I>, <I>however</I>, that the Company shall not be obligated to bear the reasonable fees and
expenses of more than one firm of attorneys selected by the Underwriter Indemnified Party (in addition to local counsel). Notwithstanding
anything to the contrary contained herein, and provided that the Company has timely honored its obligations under <U>Section 5</U>, the
Underwriter Indemnified Party shall not enter into any settlement without the prior written consent (which shall not be unreasonably
withheld) of the terms of any settlement by the Company. The Company shall not be liable for any settlement of any action effected without
its prior written consent (which shall not be unreasonably delayed or withheld). In addition, the Company shall not, without the prior
written consent of the Underwriters (which consent shall not be unreasonably withheld), settle, compromise or consent to the entry of
any judgment in or otherwise seek to terminate any pending or threatened action in respect of which advancement, reimbursement, indemnification
or contribution may be sought hereunder (whether or not such Underwriter Indemnified Party is a party thereto) unless such settlement,
compromise, consent or termination (i) includes an unconditional release of each Underwriter Indemnified Party, acceptable to such Underwriter
Indemnified Party, from all liabilities, expenses and claims arising out of such action for which indemnification or contribution may
be sought and (ii) does not include a statement as to or an admission of fault, culpability or a failure to act, by or on behalf of any
Underwriter Indemnified Party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>5.2.
<U>Indemnification of the Company</U></I>. Each Underwriter, severally and not jointly, agrees to indemnify and hold harmless the Company,
its directors, its officers who signed the Registration Statement and persons who control the Company within the meaning of Section 15
of the Securities Act or Section 20 of the Exchange Act against any and all loss, liability, claim, damage and expense described in the
foregoing indemnity from the Company to the several Underwriters, as incurred, but only with respect to such losses, liabilities, claims,
damages and expenses (or actions in respect thereof) which arise out of or are based upon untrue statements or omissions, or alleged
untrue statements or omissions made in the Registration Statement, any Preliminary Prospectus, the Pricing Disclosure Package or Prospectus
or any amendment or supplement thereto or in any application, in reliance upon, and in conformity with, the Underwriters&rsquo; Information.
In case any action shall be brought against the Company or any other person so indemnified based on any Preliminary Prospectus, the Registration
Statement, the Pricing Disclosure Package or Prospectus or any amendment or supplement thereto or any application, and in respect of
which indemnity may be sought against any Underwriter, such Underwriter shall have the rights and duties given to the Company, and the
Company and each other person so indemnified shall have the rights and duties given to the several Underwriters by the provisions of
<U>Section 5.1.2</U>. The Company agrees promptly to notify the Representative of the commencement of any litigation or proceedings against
the Company or any of its officers, directors or any person, if any, who controls the Company within the meaning of Section 15 of the
Securities Act or Section 20 of the Exchange Act, in connection with the issuance and sale of the Shares or in connection with the Registration
Statement, the Pricing Disclosure Package, the Prospectus, or any Issuer Free Writing Prospectus or any Written Testing-the-Waters Communication.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>5.3.
<U>Contribution</U>.</I> If the indemnification provided for in this <U>Section 5</U> shall for any reason be unavailable to or insufficient
to hold harmless an indemnified party under <U>Section 5.1</U> or <U>Section 5.2</U> in respect of any liabilities and Expenses referred
to therein, then each indemnifying party shall, in lieu of indemnifying such indemnified party, contribute to the amount paid or payable
by such indemnified party as a result of such liabilities and Expenses, (i) in such proportion as shall be appropriate to reflect the
relative benefits received by the Company, on the one hand, and each of the Underwriters, on the other hand, from the Offering, or (ii)
if the allocation provided by clause (i) above is not permitted by applicable law, in such proportion as is appropriate to reflect not
only the relative benefits referred to in clause (i) above but also the relative fault of the Company, on the one hand, and the Underwriters,
on the other hand, in connection with the matters as to which such liabilities or Expenses relate, as well as any other relevant equitable
considerations. The relative benefits received by the Company, on the one hand, and the Underwriters, on the other, with respect to such
Offering shall be deemed to be in the same proportion as the total net proceeds actually received by the Company from the Offering of
the Shares purchased under this Agreement (before deducting expenses) received by the Company bear to the total underwriting discounts
and commissions actually received by the Underwriters in connection with the Offering, in each case as set forth in the table on the
cover page of the Prospectus. The relative fault of the Company, on the one hand, and the Underwriters, on the other, shall be determined
by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission
to state a material fact relates to information supplied by the Company, on the one hand, or the Underwriters, on the other, and the
parties&rsquo; relative intent, knowledge, access to information and opportunity to correct or prevent such untrue statement, omission,
act or failure to act; <I>provided</I> that the parties hereto agree that the written information furnished to the Company through the
Representative by or on behalf of any Underwriter for use in any Preliminary Prospectus, any Registration Statement or the Prospectus,
or in any amendment or supplement thereto, consists solely of the Underwriters&rsquo; Information. The Company and the Underwriters agree
that it would not be just and equitable if contributions pursuant to this <U>Section 5.3</U> were determined by pro rata allocation (even
if the Underwriters were treated as one entity for such purpose) or by any other method of allocation which does not take into account
the equitable considerations referred to above in this <U>Section 5.3</U>. Notwithstanding the above, the Underwriters shall not be required
to contribute any amount in excess of the underwriting discount applicable to the Firm Shares and Option Shares purchased by the Underwriters
hereby. No person guilty of fraudulent misrepresentation within the meaning of Section 11(f) of the Securities Act shall be entitled
to contribution from a party who was not guilty of such fraudulent misrepresentation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>5.4.
</I><U>Limitation</U>. The Company also agrees that no Underwriter Indemnified Party shall have any liability (whether direct or indirect,
in contract or tort or otherwise) to the Company for or in connection with advice or services rendered or to be rendered by any Underwriter
Indemnified Party pursuant to this Agreement, the transactions contemplated thereby or any Underwriter Indemnified Party&rsquo;s actions
or inactions in connection with any such advice, services or transactions, except to the extent that a court of competent jurisdiction
has made a finding that liabilities (and related Expenses) of the Company have resulted from such Underwriter Indemnified Party&rsquo;s
fraud, bad faith, gross negligence or willful misconduct in connection with any such advice, actions, inactions or services or such Underwriter
Indemnified Party&rsquo;s breach of this Agreement or any obligations of confidentiality owed to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>5.5.
</I><U>Survival and Third-Party Beneficiaries</U>. The advancement, reimbursement, indemnity and contribution obligations set forth in
this <U>Section 5</U> shall remain in full force and effect regardless of any termination of, or the completion of any Underwriter Indemnified
Party&rsquo;s services under or in connection with, this Agreement. Each Underwriter Indemnified Party is an intended third-party beneficiary
of this <U>Section 5</U>, and has the right to enforce the provisions of <U>Section 5</U>, as if the Underwriter Indemnified Party was
a party to this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.
<U>Default by an Underwriter</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>6.1.
<U>Default Not Exceeding 10% of Firm Shares or Option Shares</U>.</I> If any Underwriter or Underwriters shall default in its or their
obligations to purchase the Firm Shares or the Option Shares, if the Over-allotment Options is exercised hereunder, and if the number
of the Firm Shares or Option Shares with respect to which such default relates does not exceed in the aggregate 10% of the number of
Firm Shares or Option Shares that all Underwriters have agreed to purchase hereunder, then such Firm Shares or Option Shares to which
the default relates shall be purchased by the non-defaulting Underwriters in proportion to their respective commitments hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>6.2.
<U>Default Exceeding 10% of Firm Shares or Option Shares</U></I>. In the event that the default addressed in <U>Section 6.1</U> relates
to more than 10% of the Firm Shares or Option Shares, you may in your discretion arrange for yourself or for another party or parties
to purchase such Firm Shares or Option Shares to which such default relates on the terms contained herein. If, within one (1) Business
Day after such default relating to more than 10% of the Firm Shares or Option Shares, you do not arrange for the purchase of such Firm
Shares or Option Shares, then the Company shall be entitled to a further period of one (1) Business Day within which to procure another
party or parties satisfactory to you to purchase said Firm Shares or Option Shares on such terms. In the event that neither you nor the
Company arrange for the purchase of the Firm Shares or Option Shares to which a default relates as provided in this <U>Section 6</U>,
this Agreement will automatically be terminated by you or the Company without liability on the part of the Company (except as provided
in <U>Section 5</U> and <U>Section 8.3</U> hereof) or the several Underwriters (except as provided in <U>Section 5</U> hereof); <I>provided</I>,
<I>however</I>, that if such default occurs with respect to the Option Shares, this Agreement will not terminate as to the Firm Shares;
and <I>provided, further</I>, that nothing herein shall relieve a defaulting Underwriter of its liability, if any, to the other Underwriters
and to the Company for damages occasioned by its default hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>6.3.
<U>Postponement of Closing Date</U></I>. In the event that the Firm Shares or Option Shares to which the default relates are to be purchased
by the non-defaulting Underwriters, or are to be purchased by another party or parties as aforesaid, you or the Company shall have the
right to postpone the Closing Date or Option Closing Date for a reasonable period, but not in any event exceeding five (5) Business Days,
in order to effect whatever changes may thereby be made necessary in the Registration Statement, the Pricing Disclosure Package or the
Prospectus or in any other documents and arrangements, and the Company agrees to file promptly any amendment to the Registration Statement,
the Pricing Disclosure Package or the Prospectus that in the opinion of counsel for the Underwriter may thereby be made necessary. The
term &ldquo;Underwriter&rdquo; as used in this Agreement shall include any party substituted under this <U>Section 6</U> with like effect
as if it had originally been a party to this Agreement with respect to such Firm Shares or Option Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.
<U>Additional Covenants</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>7.1.
<U>Right of First Refusal</U></I>. During the period ending twelve (12) months after the Closing Date, provided that the closing of the
purchase of the Firm Shares hereunder actually occurs, the Company grants the Representative the right of first refusal to act as financial
advisor or to act as joint financial advisor, on at least equal economic terms on any public or private financing (debt or equity), merger,
business combination, recapitalization or sale of some or all of the equity or assets of the Company (collectively, &ldquo;<B>Future
Services</B>&rdquo;). In the event the Company notifies the Representative of its intention to pursue an activity that would enable the
Representative to exercise its right of first refusal to provide Future Services, the Representative shall notify the Company of its
election to provide such Future Services, including notification of the compensation and other terms to which the Representative shall
be entitled, within thirty (30) days after written notice by the Company. In the event the Company engages the Representative to provide
such Future Services, the Representative will be compensated consistent with the compensation in this Agreement, unless mutually agreed
otherwise by the Company and the Representative.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.
<U>Effective Date of this Agreement and Termination Thereof</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>8.1.
<U>Effective Date</U></I>. This Agreement shall become effective when both the Company and the Representative have executed the same
and delivered counterparts of such signatures to the other party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>8.2.
<U>Termination</U>.</I> The Representative shall have the right to terminate this Agreement at any time prior to any Closing Date, (i)
if any domestic or international event or act or occurrence has materially disrupted, or in your opinion will in the immediate future
materially disrupt, general securities markets in the United States; or (ii) if (a) the Common Stock has not been approved for listing
on the Exchange, (b) the Company has taken any action designed to, or likely to have the effect of, delisting the Common Stock from the
Exchange, or (c) the Company has received any notification that the Exchange is contemplating terminating such listing; or (iii) if trading
on the New York Stock Exchange or the Nasdaq Stock Market LLC shall have been suspended or materially limited, or minimum or maximum
prices for trading shall have been fixed, or maximum ranges for prices for securities shall have been required by FINRA or by order of
the Commission or any other government authority having jurisdiction; or (iv) if the United States shall have become involved in a new
war or an increase in major hostilities; or (v) if a banking moratorium has been declared by a New York State or federal authority; or
(vi) if a moratorium on foreign exchange trading has been declared which materially adversely impacts the United States securities markets;
or (vii) if the Company shall have sustained a material loss by fire, flood, accident, hurricane, earthquake, theft, sabotage or other
calamity or malicious act which, whether or not such loss shall have been insured, will, in your opinion, make it inadvisable to proceed
with the delivery of the Firm Shares; or (viii) if the Company is in material breach of any of its representations, warranties or covenants
hereunder; or (ix) if the Representative shall have become aware after the date hereof of such a Material Adverse Change, or such adverse
material change in general market conditions as in the Representative&rsquo;s judgment would make it impracticable to proceed with the
offering, sale and/or delivery of the Shares or to enforce contracts made by the Underwriters for the sale of the Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>8.3.
<U>Expenses</U>.</I> Notwithstanding anything to the contrary in this Agreement, except in the case of a default by the Underwriters,
pursuant to <U>Section 6.2</U> above, in the event that this Agreement shall not be carried out for any reason whatsoever, within the
time specified herein or any extensions thereof pursuant to the terms herein, the Company shall be obligated to pay to the Underwriters
their actual and accountable out-of-pocket expenses related to the transactions contemplated herein then due and payable up to the amounts
set forth in <U>Section 3.10.1</U> and upon demand the Company shall pay such amount thereof to the Representative on behalf of the Underwriters;
<I>provided</I>, <I>however</I>, that such expense cap in no way limits or impairs the indemnification and contribution provisions of
this Agreement. Notwithstanding the foregoing, any advance received by the Representative will be reimbursed to the Company to the extent
not actually incurred in compliance with FINRA Rule 5110(g)(4)(A).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>8.4.
<U>Indemnification</U></I>. Notwithstanding any contrary provision contained in this Agreement, any election hereunder or any termination
of this Agreement, and whether or not this Agreement is otherwise carried out, the provisions of <U>Section 5</U> shall remain in full
force and effect and shall not be in any way affected by, such election or termination or failure to carry out the terms of this Agreement
or any part hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>8.5.
<U>Representations, Warranties, Agreements to Survive</U></I>. All representations, warranties and agreements contained in this Agreement
or in certificates of officers of the Company submitted pursuant hereto, shall remain operative and in full force and effect regardless
of (i) any investigation made by or on behalf of any Underwriter or its Affiliates or selling agents, any person controlling any Underwriter,
its officers or directors or any person controlling the Company or (ii) delivery of and payment for the Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.
<U>Miscellaneous</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>9.1.
<U>Notices</U>. </I>All communications hereunder, except as herein otherwise specifically provided, shall be in writing and shall be
mailed (registered or certified mail, return receipt requested), emailed, personally delivered, or sent by facsimile transmission and
confirmed and shall be deemed given when so delivered or faxed and confirmed or if mailed, two (2) days after such mailing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
to the Representative:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Boustead
Securities, LLC</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6
Venture, Suite 395</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Irvine,
California 92618</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn:
Mr. Keith Moore, Chief Executive Officer</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:
keith@boustead1828.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>With
a copy (which shall not constitute notice) to:</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Olshan
Frome Wolosky LLP</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1325
Avenue of the Americas, 15th Floor</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
York, New York 10019</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn:
Spencer G. Feldman, Esq.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:
sfeldman@olshanlaw.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
to the Company:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Kairos
Pharma, Ltd.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2355
Westwood Blvd., #139</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Los
Angeles, California 90064</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn:
Dr. John S. Yu, M.D., Chief Executive Officer</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:
john.yu@cshs.org</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>With
a copy (which shall not constitute notice) to</I>:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Dorsey
&amp; Whitney LLP</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">51
West 52nd Street</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
York, New York 10019</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn:
Megan Penick, Esq.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:
penick.megan@dorsey.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>9.2.
<U>Headings</U>.</I> The headings contained herein are for the sole purpose of convenience of reference, and shall not in any way limit
or affect the meaning or interpretation of any of the terms or provisions of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>9.3.
<U>Amendment</U>.</I> This Agreement may only be amended by a written instrument executed by each of the parties hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>9.4.
<U>Entire Agreement</U>.</I> This Agreement (together with the other agreements and documents being delivered pursuant to or in connection
with this Agreement) constitutes the entire agreement of the parties hereto with respect to the subject matter hereof and thereof, and
supersedes all prior agreements and understandings of the parties, oral and written, with respect to the subject matter hereof. Notwithstanding
anything to the contrary set forth herein, it is understood and agreed by the parties hereto that all other terms and conditions of that
certain engagement letter between the Company and the Representative, dated as of March 28, 2022 (the &ldquo;<B>Engagement Letter</B>&rdquo;),
shall remain in full force and effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>9.5.
<U>Binding Effect</U>.</I> This Agreement shall inure solely to the benefit of and shall be binding upon the Representative, the Underwriters,
the Company and the controlling persons, directors and officers referred to in <U>Section 5</U> hereof, and their respective successors,
legal representatives, heirs and assigns, and no other person shall have or be construed to have any legal or equitable right, remedy
or claim under or in respect of or by virtue of this Agreement or any provisions herein contained. The term &ldquo;successors and assigns&rdquo;
shall not include a purchaser, in its capacity as such, of securities from any of the Underwriters.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>9.6.
<U>Governing Law; Consent to Jurisdiction; Trial by Jury</U>.</I> This Agreement shall be governed by and construed and enforced in accordance
with the laws of the State of New York, without giving effect to conflict of laws principles thereof. The Company hereby agrees that
any action, proceeding or claim against it arising out of, or relating in any way to this Agreement shall be brought and enforced in
the New York Supreme Court, County of New York, or in the United States District Court for the Southern District of New York, and irrevocably
submits to such jurisdiction, which jurisdiction shall be exclusive. The Company hereby waives any objection to such exclusive jurisdiction
and that such courts represent an inconvenient forum. Any such process or summons to be served upon the Company may be served by transmitting
a copy thereof by registered or certified mail, return receipt requested, postage prepaid, addressed to it at the address set forth in
<U>Section 9.1</U> hereof. Such mailing shall be deemed personal service and shall be legal and binding upon the Company in any action,
proceeding or claim. The Company agrees that the prevailing party(ies) in any such action shall be entitled to recover from the other
party(ies) all of its reasonable attorneys&rsquo; fees and expenses relating to such action or proceeding and/or incurred in connection
with the preparation therefor. The Company (on its behalf and, to the extent permitted by applicable law, on behalf of its shareholders
and affiliates) and each of the Underwriters hereby irrevocably waives, to the fullest extent permitted by applicable law, any and all
right to trial by jury in any legal proceeding arising out of or relating to this Agreement or the transactions contemplated hereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>9.7.
<U>Execution in Counterparts</U>.</I> This Agreement may be executed in one or more counterparts, and by the different parties hereto
in separate counterparts, each of which shall be deemed to be an original, but all of which taken together shall constitute one and the
same agreement, and shall become effective when one or more counterparts has been signed by each of the parties hereto and delivered
to each of the other parties hereto. Delivery of a signed counterpart of this Agreement by facsimile or email/pdf transmission shall
constitute valid and sufficient delivery thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>9.8.
<U>Waiver, etc</U></I>. The failure of any of the parties hereto to at any time enforce any of the provisions of this Agreement shall
not be deemed or construed to be a waiver of any such provision, nor to in any way effect the validity of this Agreement or any provision
hereof or the right of any of the parties hereto to thereafter enforce each and every provision of this Agreement. No waiver of any breach,
non-compliance or non-fulfillment of any of the provisions of this Agreement shall be effective unless set forth in a written instrument
executed by the party or parties against whom or which enforcement of such waiver is sought; and no waiver of any such breach, non-compliance
or non-fulfillment shall be construed or deemed to be a waiver of any other or subsequent breach, non-compliance or non-fulfillment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>9.9.
<U>Exclusive Financial Advisor</U></I>. Under the Engagement Letter, the Representative has been engaged as the exclusive financial advisor
for a term that will expire upon the later to occur of (i) eighteen (18) months after the date of the Engagement Letter, (ii) twelve
(12) months after the Closing Date of the Offering or (iii) the mutual written agreement of the Company and the Representative to terminate
such role. This term may be extended for additional six (6) month periods under the same terms and conditions as described in the Engagement
Letter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>[Signature
Page Follows]</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the foregoing correctly sets forth the understanding between the Underwriters and the Company, please so indicate in the space provided
below for that purpose, whereupon this letter shall constitute a binding agreement between us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very
    truly yours,</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>KAIROS
    PHARMA, LTD.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confirmed
as of the date first written above mentioned, on behalf of itself and as Representative of the several Underwriters named on <U>Schedule
1</U> hereto:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BOUSTEAD
    SECURITIES, LLC</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>[Signature
Page to Underwriting Agreement]</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 30 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>SCHEDULE
1</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 49%; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Underwriter</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center; width: 2%; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 49%; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total
    Number of</B> F<B>irm Shares</B> t<B>o be Purchased</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Boustead
    Securities, LLC</B></FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TOTAL</B></FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 31 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>SCHEDULE
2-A</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Pricing
Information</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number
of Firm Shares: _____</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Public
Offering Price per Firm Share: $_____</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Underwriting
Discount per Firm Share: $____</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-Accountable
Expense Allowance per Firm Share: $____</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 32 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>SCHEDULE
2-B</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Issuer
General Use Free Writing Prospectuses</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 33 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>SCHEDULE
2-C</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Written
Testing-the-Waters Communications</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 34 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>EXHIBIT
A</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Form
of Representative&rsquo;s Warrant</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 35 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>EXHIBIT
B-1</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Form
of Lock-Up Agreement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Executive
Officers, Directors and 5% Holders)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">__________,
2024</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Boustead
Securities, LLC</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6
Venture, Suite 395</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Irvine,
CA 92618</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ladies
and Gentlemen:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Lock-Up Agreement (this &ldquo;<B>Agreement</B>&rdquo;) is being delivered to Boustead Securities, LLC (the &ldquo;<B>Underwriter</B>&rdquo;)
in connection with the proposed Underwriting Agreement (the &ldquo;<B>Underwriting Agreement</B>&rdquo;) between Kairos Pharma, Ltd.,
a Delaware corporation (the &ldquo;<B>Company</B>&rdquo;), and the Underwriter, relating to the proposed public offering (the &ldquo;<B>Offering</B>&rdquo;)
of common stock, par value $0.001 per share (the &ldquo;<B>Common Stock</B>&rdquo;), of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to induce the Underwriter to continue its efforts in connection with the Offering, and in light of the benefits that the offering
of the shares of Common Stock will confer upon the undersigned in the capacity as an executive officer, director and/or 5% or greater
shareholder of the Company, and for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the
undersigned agrees with the Underwriter that, during the period beginning on and including the date of this Agreement through and including
the date that is the 365<SUP>th</SUP> day after the commencement date of the trading of the Common Stock (the &ldquo;<B>Lock-Up Period</B>&rdquo;),
the undersigned will not, without the prior written consent of the Underwriter, directly or indirectly, (i) offer, sell, assign, transfer,
pledge, contract to sell, or otherwise dispose of, or announce the intention to otherwise dispose of, any shares of Common Stock now
owned or hereafter acquired by the undersigned or with respect to which the undersigned has or hereafter acquires the power of disposition
(including, without limitation, the Common Stock which may be deemed to be beneficially owned by the undersigned in accordance with the
rules and regulations promulgated under the Securities Act of 1933, as amended, and as the same may be amended or supplemented on or
after the date hereof from time to time (the &ldquo;<B>Securities Act</B>&rdquo;) (such shares, the &ldquo;<B>Beneficially Owned Shares</B>&rdquo;)
or securities convertible into or exercisable or exchangeable for shares of Common Stock, (ii) enter into any swap, hedge or similar
agreement or arrangement that transfers in whole or in part, the economic risk of ownership of the Shares or securities convertible into
or exercisable or exchangeable for shares of Common Stock, whether now owned or hereafter acquired by the undersigned or with respect
to which the undersigned has or hereafter acquires the power of disposition, or (iii) engage in any short selling of the shares of Common
Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
(i) during the last 17 days of the Lock-Up Period, the Company issues an earnings release or material news or a material event relating
to the Company occurs, or (ii) prior to the expiration of the Lock-Up Period, the Company announces that it will release earnings results
or becomes aware that material news or a material event will occur during the 16-day period beginning on the last day of the Lock-Up
Period, the restrictions imposed by this Agreement shall continue to apply until the expiration of the 18-day period beginning on the
issuance of the earnings release or the occurrence of such material news or material event, as applicable, unless the Underwriter waives,
in writing, such extension.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the undersigned is an executive officer or director of the Company, (i) the Underwriter agrees that, at least three (3) business days
before the effective date of any release or waiver of the foregoing restrictions in connection with a transfer of shares of Common Stock,
the Underwriter will notify the Company of the impending release or waiver, and (ii) the Company has agreed in the Underwriting Agreement
to announce the impending release or waiver by press release through a major news service at least two (2) business days before the effective
date of the release or waiver. Any release or waiver granted by the Underwriter hereunder to any such executive officer or director shall
only be effective two (2) business days after the publication date of such press release; <U>provided</U> that such press release is
not a condition to the release of the aforementioned lock-up provisions due to the expiration of the Lock-Up Period. The provisions of
this paragraph will also not apply if (a) the release or waiver is effected solely to permit a transfer not for consideration and (b)
the transferee has agreed in writing to be bound by the same terms described in this Agreement to the extent and for the duration that
such terms remain in effect at the time of such transfer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 36 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
restrictions set forth in the immediately preceding paragraph shall not apply to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    the undersigned is a natural person, any transfers made by the undersigned (a) as a bona fide gift to any member of the immediate
    family (as defined below) of the undersigned or to a trust the beneficiaries of which are exclusively the undersigned or members
    of the undersigned&rsquo;s immediate family, (b) by will or intestate succession upon the death of the undersigned, (c) as a bona
    fide gift to a charity or educational institution, or (d) if the undersigned is or was an executive officer, director or employee
    of the Company, to the Company pursuant to the Company&rsquo;s right of repurchase upon termination of the undersigned&rsquo;s service
    with the Company;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    the undersigned is a corporation, partnership, limited liability company or other business entity, any transfers to any shareholder,
    partner or member of, or owner of a similar equity interest in, the undersigned, as the case may be, if, in any such case, such transfer
    is not for value;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    the undersigned is a corporation, partnership, limited liability company or other business entity, any transfer made by the undersigned
    (a) in connection with the sale or other bona fide transfer in a single transaction of all or substantially all of the undersigned&rsquo;s
    capital stock, partnership interests, membership interests or other similar equity interests, as the case may be, or all or substantially
    all of the undersigned&rsquo;s assets, in any such case not undertaken for the purpose of avoiding the restrictions imposed by this
    Agreement, or (b) to another corporation, partnership, limited liability company or other business entity so long as the transferee
    is an affiliate (as defined below) of the undersigned and such transfer is not for value;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    exercise by the undersigned of any stock option(s) issued pursuant to the Company&rsquo;s existing stock option plans, including
    any exercise effected by the delivery of shares of Common Stock of the Company held by the undersigned; <U>provided</U> that the
    shares of Common Stock received upon such exercise shall remain subject to the restrictions provided for in this Agreement;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    exercise by the undersigned of any warrant(s) issued by the Company prior to the date of this Agreement, including any exercise effected
    by the delivery of shares of Common Stock of the Company held by the undersigned; <U>provided</U> that the shares of Common Stock
    received upon such exercise shall remain subject to the restrictions provided for in this Agreement;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    occurrence after the date hereof of any of (a) an acquisition by an individual or legal entity or &ldquo;group&rdquo; (as described
    in Rule 13d-5(b)(1) promulgated under the Securities Exchange Act of 1934, as amended (the &ldquo;<B>Exchange Act</B>&rdquo;)), of
    effective control (whether through legal or beneficial ownership of capital stock of the Company, by contract or otherwise) of 100%
    of the voting securities of the Company, (b) the Company merges into or consolidates with any other entity, or any entity merges
    into or consolidates with the Company, (c) the Company sells or transfers all or substantially all of its assets to another person,
    or (d) <U>provided</U> that the shares of Common Stock received upon any of the events set forth in clauses (a) through (c) above
    shall remain subject to the restrictions provided for in this Agreement;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    Offering; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8)
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">transfers
    consented to in writing by the Underwriter;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>provided</U>,
<U>however</U>, that in the case of any transfer described in clause (1), (2) or (3) above, it shall be a condition to the transfer that
the transferee executes and delivers to the Underwriter, acting on behalf of the Underwriter, not later than one (1) business day prior
to such transfer, a written agreement, in substantially the form of this Agreement (it being understood that any references to &ldquo;immediate
family&rdquo; in the agreement executed by such transferee shall expressly refer only to the immediate family of the undersigned and
not to the immediate family of the transferee) and otherwise satisfactory in form and substance to the Underwriter. In addition, the
restrictions set forth herein shall not prevent the undersigned from entering into a sales plan pursuant to Rule 10b5-1 under the Exchange
Act after the date hereof; <U>provided</U> that (i) a copy of such plan is provided to the Underwriter promptly upon entering into the
same and (ii) no sales or transfers may be made under such plan until the Lock-Up Period ends or this Agreement is terminated in accordance
with its terms. For purposes of this paragraph, &ldquo;immediate family&rdquo; shall mean a spouse, child, grandchild or other lineal
descendant (including by adoption), father, mother, brother or sister of the undersigned, and &ldquo;affiliate&rdquo; shall have the
meaning set forth in Rule 405 under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned further agrees that (i) it shall not, during the Lock-Up Period, make any demand or request for or exercise any right with
respect to the registration under the Securities Act of any shares of Common Stock or other Beneficially Owned Shares or any securities
convertible into or exercisable or exchangeable for shares of Common Stock or other Beneficially Owned Shares, and (ii) the Company may,
with respect to any shares of Common Stock or other Beneficially Owned Shares or any securities convertible into or exercisable or exchangeable
for shares of Common Stock or other Beneficially Owned Shares owned or held (of record or beneficially) by the undersigned, cause the
transfer agent or other registrar to enter stop transfer instructions and implement stop transfer procedures with respect to such securities
during the Lock-Up Period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned hereby represents and warrants that the undersigned has full power and authority to enter into this Agreement and that this
Agreement has been duly authorized (if the undersigned is not a natural person), executed and delivered by the undersigned and is a valid
and binding agreement of the undersigned. This Agreement and all authority herein conferred are irrevocable and shall survive the death
or incapacity of the undersigned (if a natural person) and shall be binding upon the heirs, personal representatives, successors and
assigns of the undersigned.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Agreement shall automatically terminate upon the earliest to occur, if any, of (1) either the Underwriter, on the one hand, or the Company,
on the other hand, advising the other in writing they have determined not to proceed with the Offering, (2) termination of the Underwriting
Agreement before the sale of any shares of Common Stock, or (3) the withdrawal of the Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[<I>Signature
Page Follows</I>]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 37 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Agreement shall be governed by and construed in accordance with the laws of the State of New York, without regard to the conflict of
laws principles thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very
    truly yours,</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Name
    - Please Print)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Signature)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Name
    of Signatory, in the case of entities - Please Print)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Title
    of Signatory, in the case of entities - Please Print)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 38 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>EXHIBIT
B-2</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Form
of Lock-Up Agreement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1%
to 4.99% Holders)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">__________,
2024</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Boustead
Securities, LLC</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6
Venture, Suite 395</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Irvine,
CA 92618</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ladies
and Gentlemen:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Lock-Up Agreement (this &ldquo;<B>Agreement</B>&rdquo;) is being delivered to Boustead Securities, LLC (the &ldquo;<B>Underwriter</B>&rdquo;)
in connection with the proposed Underwriting Agreement (the &ldquo;<B>Underwriting Agreement</B>&rdquo;) between Kairos Pharma, Ltd.,
a Delaware corporation (the &ldquo;<B>Company</B>&rdquo;), and the Underwriter, relating to the proposed public offering (the &ldquo;<B>Offering</B>&rdquo;)
of common stock, par value $0.001 per share (the &ldquo;<B>Common Stock</B>&rdquo;), of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to induce the Underwriter to continue its efforts in connection with the Offering, and in light of the benefits that the offering
of the shares of Common Stock will confer upon the undersigned in the capacity as a shareholder of the Company, and for good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the undersigned agrees with the Underwriter that, during
the period beginning on and including the date of this Agreement through and including the date that is the 180<SUP>th</SUP> day after
the commencement date of the trading of the Common Stock (the &ldquo;<B>Lock-Up Period</B>&rdquo;), the undersigned will not, without
the prior written consent of the Underwriter, directly or indirectly, (i) offer, sell, assign, transfer, pledge, contract to sell, or
otherwise dispose of, or announce the intention to otherwise dispose of, any shares of Common Stock now owned or hereafter acquired by
the undersigned or with respect to which the undersigned has or hereafter acquires the power of disposition (including, without limitation,
the Common Stock which may be deemed to be beneficially owned by the undersigned in accordance with the rules and regulations promulgated
under the Securities Act of 1933, as amended, and as the same may be amended or supplemented on or after the date hereof from time to
time (the &ldquo;<B>Securities Act</B>&rdquo;) (such shares, the &ldquo;<B>Beneficially Owned Shares</B>&rdquo;) or securities convertible
into or exercisable or exchangeable for shares of Common Stock, (ii) enter into any swap, hedge or similar agreement or arrangement that
transfers in whole or in part, the economic risk of ownership of the Shares or securities convertible into or exercisable or exchangeable
for shares of Common Stock, whether now owned or hereafter acquired by the undersigned or with respect to which the undersigned has or
hereafter acquires the power of disposition, or (iii) engage in any short selling of the shares of Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
(i) during the last 17 days of the Lock-Up Period, the Company issues an earnings release or material news or a material event relating
to the Company occurs, or (ii) prior to the expiration of the Lock-Up Period, the Company announces that it will release earnings results
or becomes aware that material news or a material event will occur during the 16-day period beginning on the last day of the Lock-Up
Period, the restrictions imposed by this Agreement shall continue to apply until the expiration of the 18-day period beginning on the
issuance of the earnings release or the occurrence of such material news or material event, as applicable, unless the Underwriter waives,
in writing, such extension.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the undersigned is an executive officer or director of the Company, (i) the Underwriter agrees that, at least three (3) business days
before the effective date of any release or waiver of the foregoing restrictions in connection with a transfer of shares of Common Stock,
the Underwriter will notify the Company of the impending release or waiver, and (ii) the Company has agreed in the Underwriting Agreement
to announce the impending release or waiver by press release through a major news service at least two (2) business days before the effective
date of the release or waiver. Any release or waiver granted by the Underwriter hereunder to any such executive officer or director shall
only be effective two (2) business days after the publication date of such press release; <U>provided</U> that such press release is
not a condition to the release of the aforementioned lock-up provisions due to the expiration of the Lock-Up Period. The provisions of
this paragraph will also not apply if (a) the release or waiver is effected solely to permit a transfer not for consideration and (b)
the transferee has agreed in writing to be bound by the same terms described in this Agreement to the extent and for the duration that
such terms remain in effect at the time of such transfer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 39 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
restrictions set forth in the immediately preceding paragraph shall not apply to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    the undersigned is a natural person, any transfers made by the undersigned (a) as a bona fide gift to any member of the immediate
    family (as defined below) of the undersigned or to a trust the beneficiaries of which are exclusively the undersigned or members
    of the undersigned&rsquo;s immediate family, (b) by will or intestate succession upon the death of the undersigned, (c) as a bona
    fide gift to a charity or educational institution, or (d) if the undersigned is or was an executive officer, director or employee
    of the Company, to the Company pursuant to the Company&rsquo;s right of repurchase upon termination of the undersigned&rsquo;s service
    with the Company;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    the undersigned is a corporation, partnership, limited liability company or other business entity, any transfers to any shareholder,
    partner or member of, or owner of a similar equity interest in, the undersigned, as the case may be, if, in any such case, such transfer
    is not for value;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    the undersigned is a corporation, partnership, limited liability company or other business entity, any transfer made by the undersigned
    (a) in connection with the sale or other bona fide transfer in a single transaction of all or substantially all of the undersigned&rsquo;s
    capital stock, partnership interests, membership interests or other similar equity interests, as the case may be, or all or substantially
    all of the undersigned&rsquo;s assets, in any such case not undertaken for the purpose of avoiding the restrictions imposed by this
    Agreement, or (b) to another corporation, partnership, limited liability company or other business entity so long as the transferee
    is an affiliate (as defined below) of the undersigned and such transfer is not for value;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    exercise by the undersigned of any stock option(s) issued pursuant to the Company&rsquo;s existing stock option plans, including
    any exercise effected by the delivery of shares of Common Stock of the Company held by the undersigned; <U>provided</U> that the
    shares of Common Stock received upon such exercise shall remain subject to the restrictions provided for in this Agreement;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    exercise by the undersigned of any warrant(s) issued by the Company prior to the date of this Agreement, including any exercise effected
    by the delivery of shares of Common Stock of the Company held by the undersigned; <U>provided</U> that the shares of Common Stock
    received upon such exercise shall remain subject to the restrictions provided for in this Agreement;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    occurrence after the date hereof of any of (a) an acquisition by an individual or legal entity or &ldquo;group&rdquo; (as described
    in Rule 13d-5(b)(1) promulgated under the Securities Exchange Act of 1934, as amended (the &ldquo;<B>Exchange Act</B>&rdquo;)), of
    effective control (whether through legal or beneficial ownership of capital stock of the Company, by contract or otherwise) of 100%
    of the voting securities of the Company, (b) the Company merges into or consolidates with any other entity, or any entity merges
    into or consolidates with the Company, (c) the Company sells or transfers all or substantially all of its assets to another person,
    or (d) <U>provided</U> that the shares of Common Stock received upon any of the events set forth in clauses (a) through (c) above
    shall remain subject to the restrictions provided for in this Agreement;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    Offering; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8)
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">transfers
    consented to in writing by the Underwriter;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>provided</U>,
<U>however</U>, that in the case of any transfer described in clause (1), (2) or (3) above, it shall be a condition to the transfer that
the transferee executes and delivers to the Underwriter, acting on behalf of the Underwriter, not later than one (1) business day prior
to such transfer, a written agreement, in substantially the form of this Agreement (it being understood that any references to &ldquo;immediate
family&rdquo; in the agreement executed by such transferee shall expressly refer only to the immediate family of the undersigned and
not to the immediate family of the transferee) and otherwise satisfactory in form and substance to the Underwriter. In addition, the
restrictions set forth herein shall not prevent the undersigned from entering into a sales plan pursuant to Rule 10b5-1 under the Exchange
Act after the date hereof; <U>provided</U> that (i) a copy of such plan is provided to the Underwriter promptly upon entering into the
same and (ii) no sales or transfers may be made under such plan until the Lock-Up Period ends or this Agreement is terminated in accordance
with its terms. For purposes of this paragraph, &ldquo;immediate family&rdquo; shall mean a spouse, child, grandchild or other lineal
descendant (including by adoption), father, mother, brother or sister of the undersigned, and &ldquo;affiliate&rdquo; shall have the
meaning set forth in Rule 405 under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned further agrees that (i) if the aggregate of the undersigned&rsquo;s shares of Common Stock were to equal or exceed 20% of
the Company&rsquo;s outstanding shares of Common Stock on a fully-diluted basis prior to the completion of the Offering, then the Lock-Up
Period shall be for a period beginning on and including the date of this Agreement through and including the date that is the 365<SUP>th
</SUP>day after the commencement date of the trading of the Common Stock, (ii) it shall not, during the Lock-Up Period, make any demand
or request for or exercise any right with respect to the registration under the Securities Act of any shares of Common Stock or other
Beneficially Owned Shares or any securities convertible into or exercisable or exchangeable for shares of Common Stock or other Beneficially
Owned Shares, and (iii) the Company may, with respect to any shares of Common Stock or other Beneficially Owned Shares or any securities
convertible into or exercisable or exchangeable for shares of Common Stock or other Beneficially Owned Shares owned or held (of record
or beneficially) by the undersigned, cause the transfer agent or other registrar to enter stop transfer instructions and implement stop
transfer procedures with respect to such securities during the Lock-Up Period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned hereby represents and warrants that the undersigned has full power and authority to enter into this Agreement and that this
Agreement has been duly authorized (if the undersigned is not a natural person), executed and delivered by the undersigned and is a valid
and binding agreement of the undersigned. This Agreement and all authority herein conferred are irrevocable and shall survive the death
or incapacity of the undersigned (if a natural person) and shall be binding upon the heirs, personal representatives, successors and
assigns of the undersigned.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Agreement shall automatically terminate upon the earliest to occur, if any, of (1) either the Underwriter, on the one hand, or the Company,
on the other hand, advising the other in writing they have determined not to proceed with the Offering, (2) termination of the Underwriting
Agreement before the sale of any shares of Common Stock, or (3) the withdrawal of the Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[<I>Signature
Page Follows</I>]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 40 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Agreement shall be governed by and construed in accordance with the laws of the State of New York, without regard to the conflict of
laws principles thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very
    truly yours,</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Name
    - Please Print)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Signature)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Name
    of Signatory, in the case of entities - Please Print)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Title
    of Signatory, in the case of entities - Please Print)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 41; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>3
<FILENAME>ex4-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right; text-indent: 0.2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
4.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THE
REGISTERED HOLDER OF THIS PURCHASE WARRANT AGREES, BY ITS ACCEPTANCE HEREOF, THAT SUCH HOLDER WILL NOT FOR A PERIOD OF ONE HUNDRED EIGHTY
(180) DAYS FOLLOWING [&#9679;], 202[&#9679;] (THE &ldquo;<B>EFFECTIVE DATE</B>&rdquo;), WHICH IS THE COMMENCEMENT OF SALES OF COMMON
STOCK IN THE OFFERING FOR WHICH THIS PURCHASE WARRANT WAS ISSUED TO THE REPRESENTATIVE OF THE UNDERWRITERS AS CONSIDERATION (THE &ldquo;<B>OFFERING</B>&rdquo;):
(A) SELL, TRANSFER, ASSIGN, PLEDGE OR HYPOTHECATE THIS PURCHASE WARRANT TO ANYONE OTHER THAN OFFICERS, PARTNERS, REGISTERED PERSONS OR
AFFILIATES OF BOUSTEAD SECURITIES, LLC, EACH OF WHICH SHALL HAVE AGREED TO THE RESTRICTIONS CONTAINED HEREIN, IN ACCORDANCE WITH FINANCIAL
INDUSTRY REGULATORY AUTHORITY (&ldquo;<B>FINRA</B>&rdquo;) RULE 5110(E)(1), OR (B) CAUSE THIS PURCHASE WARRANT OR THE SECURITIES ISSUABLE
HEREUNDER TO BE THE SUBJECT OF ANY HEDGING, SHORT SALE, DERIVATIVE, PUT OR CALL TRANSACTION THAT WOULD RESULT IN THE EFFECTIVE ECONOMIC
DISPOSITION OF THIS PURCHASE WARRANT OR THE SECURITIES HEREUNDER, EXCEPT AS PROVIDED FOR IN FINRA RULE 5110(E)(2).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>COMMON
STOCK PURCHASE WARRANT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the Purchase of [&#9679;]<SUP>1</SUP> Shares of Common Stock</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">of</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kairos
Pharma, Ltd.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
<U>Purchase Warrant</U>. THIS CERTIFIES THAT, in consideration of funds duly paid by or on behalf of [&#9679;] (&ldquo;<B>Holder</B>&rdquo;),
as registered owner of this Purchase Warrant, to Kairos Pharma, Ltd., a Delaware corporation (the &ldquo;<B>Company</B>&rdquo;), Holder
is entitled, at any time or from time to time beginning the Effective Date, and at or before 5:00 p.m., Eastern time, [&#9679;], 202[&#9679;]<SUP>2
</SUP>(the &ldquo;<B>Expiration Date</B>&rdquo;), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up
to [&#9679;] shares (the &ldquo;<B>Shares</B>&rdquo;) of common stock of the Company, par value $0.001 per share (&ldquo;<B>Common Stock</B>&rdquo;),
subject to adjustment as provided in <U>Section 6</U> hereof. If the Expiration Date is a day on which banking institutions are authorized
by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the
terms herein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate this Purchase
Warrant. This Purchase Warrant is initially exercisable at $[&#9679;]<SUP>3</SUP> per Share; <U>provided</U>, <U>however</U>, that
upon the occurrence of any of the events specified in <U>Section 6</U> hereof, the rights granted by this Purchase Warrant, including
the exercise price per Share and the Shares to be received upon such exercise, shall be adjusted as therein specified. The term &ldquo;<B>Exercise
Price</B>&rdquo; shall mean the initial exercise price or the adjusted exercise price, depending on the context.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
<U>Exercise</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1
<U>Exercise Form</U>. In order to exercise this Purchase Warrant, the exercise form attached hereto must be duly executed and completed
and delivered to the Company, together with this Purchase Warrant and payment of the Exercise Price for the Shares being purchased payable
in cash by wire transfer of immediately available funds to an account designated by the Company or by certified check or official bank
check. If the subscription rights represented hereby shall not be exercised at or before 5:00 p.m., Eastern time, on the Expiration Date,
this Purchase Warrant shall become and be void without further force or effect, and all rights represented hereby shall cease and expire.
Each exercise hereof shall be irrevocable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2
<U>Cashless Exercise</U>. In lieu of exercising this Purchase Warrant by payment of cash or check payable to the order of the Company
pursuant to <U>Section 2.1</U> above, this Purchase Warrant may also be exercised, in whole or in part, at such time by means of a &ldquo;cashless
exercise&rdquo; in which the Holder shall be entitled to receive a number of shares of Common Stock equal to the quotient obtained by
dividing [(A-B) (X)] by (A), where:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(A)
= the FMV of one share of Common Stock;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 30%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP>1
                                            </SUP>To be equal to 7% of the aggregate number of shares of Common Stock sold by the Company
                                            in the offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>2
</SUP>To be five years from the commencement of sales in the offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>3
</SUP>To be 120% of the initial public offering price per Share.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(B)
= the Exercise Price of this Purchase Warrant, as adjusted hereunder; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(X)
= the number of shares of Common Stock underlying the Purchase Warrant that would be issuable upon exercise of this Purchase Warrant
in accordance with the terms of this Purchase Warrant if such exercise were by means of a cash exercise rather than a cashless exercise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the Securities
Act of 1933, as amended (the &ldquo;<B>Act</B>&rdquo;), the Shares shall take on the registered characteristics of the Purchase Warrants
being exercised. The Company agrees not to take any position contrary to this <U>Section 2.2</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
anything herein to the contrary, on the Expiration Date, this Purchase Warrant shall be automatically exercised via cashless exercise
pursuant to this <U>Section 2.2</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>FMV</B>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed
or quoted on a Trading Market, the value shall be deemed to be the highest intra-day or closing price on any trading day on such Trading
Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a trading day from 9:30 a.m. (Eastern
time) to 4:02 p.m. (Eastern time)) during the five trading days preceding the exercise, (b) if OTCQB or OTCQX is not a Trading Market,
the value shall be deemed to be the highest intra-day or closing price on any trading day on the OTCQB or OTCQX on which the Common Stock
is then quoted as reported by Bloomberg L.P. (based on a trading day from 9:30 a.m. (Eastern time) to 4:02 p.m. (Eastern time)) during
the five trading days preceding the exercise, as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB
or OTCQX and if prices for the Common Stock are then reported on the Pink Open Market operated by OTC Markets Group, Inc. (or a similar
organization or agency succeeding to its functions of reporting prices), the &ldquo;OTC Markets Group,&rdquo; the value shall be deemed
to be the highest intra-day or closing price on any trading day on the Pink Sheets on which the Common Stock is then quoted as reported
by OTC Markets Group (based on a trading day from 9:30 a.m. (Eastern time) to 4:02 p.m. (Eastern time)) during the five trading days
preceding the exercise, or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser
selected in good faith by the Holder and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Trading
Market</B>&rdquo; means The Nasdaq Capital Market, or any of the following other markets or exchanges on which the Common Stock is listed
or quoted for trading on the date in question: the NYSE American, The Nasdaq Global Market, The Nasdaq Global Select Market or the New
York Stock Exchange (or any successors to any of the foregoing).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3
<U>Legend</U>. Each certificate for the securities purchased under this Purchase Warrant shall bear a legend as follows unless such securities
have been registered under the Act:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;The
securities represented by this certificate have not been registered under the Securities Act of 1933, as amended (the &ldquo;Act&rdquo;),
or applicable state law. Neither the securities nor any interest therein may be offered for sale, sold or otherwise transferred except
pursuant to an effective registration statement under the Act, or pursuant to an exemption from registration under the Act and applicable
state law which, in the opinion of counsel to the Company, is available.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.4
<U>Resale of Shares</U>. Holder and the Company acknowledge that as of the date hereof the Staff of the Division of Corporation Finance
of the Securities and Exchange Commission (the &ldquo;<B>Commission</B>&rdquo;) has published Compliance &amp; Disclosure Interpretation
528.04 in the Securities Act Rules section thereof, stating that the holder of securities issued in connection with a public offering
may not rely upon Rule 144 promulgated under the Act to establish an exemption from registration requirements under Section 4(a)(1) under
the Act, but may nonetheless apply Rule 144 constructively for the resale of such shares in the following manner: (a) provided that six
months has elapsed since the last sale under the registration statement, an underwriter or finder may resell the securities in accordance
with the provisions of Rule 144(c), (e), and (f), except for the notice requirement; (b) a purchaser of the shares from an underwriter
receives restricted securities unless the sale is made with an appropriate, current prospectus, or unless the sale is made pursuant to
the conditions contained in (a) above; (c) a purchaser of the shares from an underwriter who receives restricted securities may include
the underwriter&rsquo;s holding period, provided that the underwriter or finder is not an affiliate of the issuer; and (d) if an underwriter
transfers the shares to its employees, the employees may tack the firm&rsquo;s holding period for purposes of Rule 144(d), but they must
aggregate sales of the distributed shares with those of other employees, as well as those of the underwriter or finder, for a six-month
period from the date of the transfer to the employees. Holder and the Company also acknowledge that the Staff of the Division of Corporation
Finance of the Commission has advised in various no-action letters that the holding period associated with securities issued without
registration to a service provider commences upon the completion of the services, which the Company agrees and acknowledges shall be
the final closing of the Offering, and that Rule 144(d)(3)(ii) provides that securities acquired from the issuer solely in exchange for
other securities of the same issuer shall be deemed to have been acquired at the same time as the securities surrendered for conversion
(which the Company agrees is the date of the initial issuance of this Purchase Warrant). In the event that following a reasonably-timed
written request by Holder to transfer the Shares in accordance with Compliance &amp; Disclosure Interpretation 528.04 counsel for the
Company in good faith concludes that Compliance &amp; Disclosure Interpretation 528.04 no longer may be relied upon as a result of changes
in applicable laws, regulations, or interpretations of the Commission&rsquo;s Division of Corporation Finance, or as a result of judicial
interpretations not known by the Company or its counsel on the date hereof, then the Company shall promptly, and in any event within
five (5) business days following the request, provide written notice to Holder of such determination. As a condition to giving such notice,
the parties shall negotiate in good faith a single demand registration right pursuant to an agreement in customary form reasonably acceptable
to the parties; <U>provided</U> that notwithstanding anything to the contrary, the obligations of the Company pursuant to this <U>Section
2</U> shall terminate on the fifth (5th) anniversary of the Effective Date. In the absence of such conclusion by counsel for the Company,
the Company shall, upon such a request of Holder given no earlier than six (6) months after the final closing of the Offering, instruct
its transfer agent to permit the transfer of such shares in accordance with Compliance &amp; Disclosure Interpretation 528.04; <U>provided
</U>that Holder has provided such documentation as shall be reasonably be requested by the Company to establish compliance with the conditions
of Compliance &amp; Disclosure Interpretation 528.04. Notwithstanding anything to the contrary, pursuant to FINRA Rule 5110(g)(8)(B)-(D),
the Holder shall not be entitled to more than one (1) demand registration right hereunder and the duration of the registration rights
hereunder shall not exceed five (5) years from the Effective Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
<U>Transfer</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1
<U>General Restrictions</U>. The registered Holder of this Purchase Warrant agrees by his, her or its acceptance hereof, that such Holder
will not: (a) sell, transfer, assign, pledge or hypothecate this Purchase Warrant for a period of one hundred eighty (180) days following
the Effective Date to anyone other than: (i) Boustead Securities, LLC (&ldquo;<B>Boustead</B>&rdquo;) or an underwriter, placement agent,
or a selected dealer participating in the Offering, or (ii) a bona fide officer, partner, registered person or affiliate of Boustead
or of any such underwriter, placement agent or selected dealer, in each case in accordance with FINRA Rule 5110(e)(1), or (b) cause this
Purchase Warrant or the securities issuable hereunder to be the subject of any hedging, short sale, derivative, put or call transaction
for a period of one hundred eighty (180) days following the Effective Date that would result in the effective economic disposition of
this Purchase Warrant or the securities hereunder, except as provided for in FINRA Rule 5110(e)(2). After one hundred eighty (180) days
after the Effective Date, transfers to others may be made subject to compliance with or exemptions from applicable securities laws. In
order to make any permitted assignment, the Holder must deliver to the Company the assignment form attached hereto duly executed and
completed, together with the Purchase Warrant and payment of all transfer taxes, if any, payable in connection therewith. The Company
shall within five (5) business days transfer this Purchase Warrant on the books of the Company and shall execute and deliver a new Purchase
Warrant or Purchase Warrants of like tenor to the appropriate assignee(s) expressly evidencing the right to purchase the aggregate number
of shares of Common Stock purchasable hereunder or such portion of such number as shall be contemplated by any such assignment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2
<U>Restrictions Imposed by the Act</U>. The securities evidenced by this Purchase Warrant shall not be transferred unless and until:
(i) if required by applicable law, the Company has received the opinion of counsel for the Company that the securities may be transferred
pursuant to an exemption from registration under the Act and applicable state securities laws, or (ii) a registration statement or a
post-effective amendment to the Registration Statement relating to the offer and sale of such securities has been filed by the Company
and declared effective by the Commission and compliance with applicable state securities law has been established.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
<U>Piggyback Registration Rights</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1
<U>Grant of Right</U>. Whenever the Company proposes to register any shares of Common Stock under the Act (other than (i) a registration
effected solely to implement an employee benefit plan or a transaction to which Rule 145 of the Act is applicable, or (ii) a registration
statement on Form S-4, S-8 or any successor form thereto or another form not available for registering the Shares issuable upon exercise
of this Purchase Warrant for sale to the public), whether for its own account or for the account of one or more stockholders of the Company
(a &ldquo;<B>Piggyback Registration</B>&rdquo;), the Company shall give prompt written notice (in any event no later than ten (10) business
days prior to the filing of such registration statement) to the Holder of the Company&rsquo;s intention to effect such a registration
and, subject to the remaining provisions of this <U>Section 4.1</U>, shall include in such registration the Shares underlying this Purchase
Warrant (the &ldquo;<B>Registrable Securities</B>&rdquo;) that the Holders have (within ten (10) business days of the respective Holder&rsquo;s
receipt of such notice) requested in writing (including such number) to be included within such registration. If a Piggyback Registration
is an underwritten offering and the managing underwriter advises the Company that it has determined in good faith that marketing factors
require a limit on the number of shares of Common Stock to be included in such registration, including all Shares issuable upon exercise
of this Purchase Warrant (if the Holder has elected to include such shares in such Piggyback Registration) and all other shares of Common
Stock proposed to be included in such underwritten offering, the Company shall include in such registration (i) first, the number of
shares of Common Stock that the Company proposes to sell and (ii) second, the number of shares of Common Stock, if any, requested to
be included therein by selling stockholders (including the Holder) allocated pro rata among all such persons on the basis of the number
of shares of Common Stock then owned by each such person. If any Piggyback Registration is initiated as a primary underwritten offering
on behalf of the Company, the Company shall select the investment banking firm or firms to act as the managing underwriter or underwriters
in connection with such offering. Notwithstanding anything to the contrary, the obligations of the Company pursuant to this <U>Section
4.1</U> shall terminate on the earlier of (i) the fifth (5th) anniversary of the Effective Date and (ii) the date that Rule 144 would
allow the Holder to sell its Registrable Securities during any ninety (90) day period. The duration of the Piggyback Registration rights
granted in this <U>Section 4.1</U> shall not exceed more than five (5) years from the Effective Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2
<U>Indemnification</U>. The Company shall indemnify the Holder(s) of the Registrable Securities to be sold pursuant to any registration
statement hereunder and each person, if any, who controls such Holders within the meaning of Section 15 of the Act or Section 20(a) of
the Securities Exchange Act of 1934, as amended (the &ldquo;<B>Exchange Act</B>&rdquo;), against all loss, claim, damage, expense or
liability (including all reasonable attorneys&rsquo; fees and other out-of-pocket expenses reasonably incurred in investigating, preparing
or defending against any claim whatsoever) to which any of them may become subject under the Act, the Exchange Act or otherwise, arising
from such registration statement but only to the same extent and with the same effect as the provisions pursuant to which the Company
has agreed to indemnify Boustead contained in the Underwriting Agreement between Boustead and the Company, dated as of [&#9679;], 202[&#9679;]
(the &ldquo;<B>Underwriting Agreement</B>&rdquo;). The Holder(s) of the Registrable Securities to be sold pursuant to such registration
statement, and their successors and assigns, shall severally, and not jointly, indemnify the Company, against all loss, claim, damage,
expense or liability (including all reasonable attorneys&rsquo; fees and other expenses reasonably incurred in investigating, preparing
or defending against any claim whatsoever) to which they may become subject under the Act, the Exchange Act or otherwise, arising from
information furnished by or on behalf of such Holders, or their successors or assigns, in writing, for specific inclusion in such registration
statement to the same extent and with the same effect as the provisions contained in the Underwriting Agreement pursuant to which Boustead
has agreed to indemnify the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3
<U>Exercise of Purchase Warrants</U>. Nothing contained in this Purchase Warrant shall be construed as requiring the Holder(s) to exercise
their Purchase Warrants prior to or after the initial filing of any registration statement or the effectiveness thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4
<U>Documents Delivered to Holders</U>. The Company shall deliver promptly to each Holder participating in the offering requesting the
correspondence and memoranda described below, copies of all correspondence between the Commission and the Company, its counsel or auditors
and all memoranda relating to discussions with the Commission or its staff with respect to the registration statement and permit each
Holder and underwriter to do such investigation, upon reasonable advance notice, with respect to information contained in or omitted
from the registration statement as it deems reasonably necessary to comply with applicable securities laws or rules of FINRA. Such investigation
shall include access to books, records and properties and opportunities to discuss the business of the Company with its officers and
independent auditors, all to such reasonable extent and at such reasonable times, during normal business hours, as any such Holder shall
reasonably request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5
<U>Underwriting Agreement</U>. The Holders shall be parties to any underwriting agreement relating to a Piggyback Registration. Such
Holders shall not be required to make any representations or warranties to or agreements with the Company or the underwriters except
as they may relate to such Holders, their shares of Common Stock and the amount and nature of their ownership thereof and their intended
methods of distribution.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6
<U>Documents to be Delivered by Holder(s)</U>. Each of the Holder(s) participating in any of the foregoing offerings shall furnish to
the Company a completed and executed questionnaire provided by the Company requesting information customarily sought of selling security
holders and customary selling security holder confirmations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.7
<U>Damages</U>. Should the Company fail to comply with such provisions, the Holder(s) shall, in addition to any other legal or other
relief available to the Holder(s), be entitled to obtain specific performance or other equitable (including injunctive) relief against
the threatened breach of such provisions or the continuation of any such breach, without the necessity of proving actual damages and
without the necessity of posting bond or other security.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
<U>New Purchase Warrants to be Issued</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1
<U>Partial Exercise or Transfer</U>. Subject to the restrictions in <U>Section 3</U> hereof, this Purchase Warrant may be exercised or
assigned in whole or in part. In the event of the exercise or assignment hereof in part only, upon surrender of this Purchase Warrant
for cancellation, together with the duly executed exercise or assignment form and funds sufficient to pay any Exercise Price and/or transfer
tax if exercised pursuant to <U>Section 2.1</U> hereto, the Company shall cause to be delivered to the Holder without charge a new Purchase
Warrant of like tenor to this Purchase Warrant in the name of the Holder evidencing the right of the Holder to purchase the number of
shares of Common Stock purchasable hereunder as to which this Purchase Warrant has not been exercised or assigned.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.2
<U>Lost Certificate</U>. Upon receipt by the Company of evidence satisfactory to it of the loss, theft, destruction or mutilation of
this Purchase Warrant and of reasonably satisfactory indemnification or the posting of a bond, determined in the sole discretion of the
Company, the Company shall execute and deliver a new Purchase Warrant of like tenor and date. Any such new Purchase Warrant executed
and delivered as a result of such loss, theft, mutilation or destruction shall constitute a substitute contractual obligation on the
part of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.
<U>Adjustments</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.1
<U>Adjustments to Exercise Price and Number of Securities</U>. The Exercise Price and the number of shares of Common Stock underlying
the Purchase Warrant shall be subject to adjustment from time to time as hereinafter set forth:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.1.1
<U>Share Dividends; Split Ups</U>. If, after the date hereof, and subject to the provisions of <U>Section 6.3</U> below, the number of
outstanding shares of Common Stock is increased by a stock dividend payable in shares of Common Stock or by a split up of shares of Common
Stock or other similar event, then, on the effective day thereof, the number of Shares purchasable hereunder shall be increased in proportion
to such increase in outstanding shares of Common Stock, and the Exercise Price shall be proportionately decreased.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.1.2
<U>Aggregation of Shares</U>. If, after the date hereof, and subject to the provisions of <U>Section 6.3</U> below, the number of outstanding
shares of Common Stock is decreased by a consolidation, combination or reclassification of Common Stock or other similar event, then,
on the effective date thereof, the Shares purchasable hereunder shall be decreased in proportion to such decrease in outstanding shares
of Common Stock, and the Exercise Price shall be proportionately increased.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.1.3
<U>Replacement of Securities upon Reorganization, etc</U>. In case of any reclassification or reorganization of the outstanding shares
of Common Stock other than a change covered by <U>Section 6.1.1</U> or <U>6.1.2</U> hereof or that solely affects the par value of such
shares, or in the case of any share reconstruction or amalgamation or consolidation or merger of the Company with or into another corporation
(other than a consolidation or share reconstruction or amalgamation or merger in which the Company is the continuing corporation and
that does not result in any reclassification or reorganization of the outstanding shares of Common Stock), or in the case of any sale
or conveyance to another corporation or entity of the property of the Company as an entirety or substantially as an entirety in connection
with which the Company is dissolved, the Holder of this Purchase Warrant shall have the right thereafter (until the expiration of the
right of exercise of this Purchase Warrant) to receive upon the exercise hereof, for the same aggregate Exercise Price payable hereunder
immediately prior to such event, the kind and amount of shares of stock or other securities or property (including cash) receivable upon
such reclassification, reorganization, share reconstruction or amalgamation, or consolidation, or upon a dissolution following any such
sale or transfer, by a Holder of the number of Shares obtainable upon exercise of this Purchase Warrant immediately prior to such event;
and if any reclassification also results in a change in the Shares covered by <U>Section 6.1.1</U> or <U>6.1.2</U>, then such adjustment
shall be made pursuant to <U>Sections 6.1.1</U>, <U>6.1.2</U> and this <U>Section 6.1.3</U>. The provisions of this <U>Section 6.1.3
</U>shall similarly apply to successive reclassifications, reorganizations, share reconstructions or amalgamations, or consolidations,
sales or other transfers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.1.4
<U>Changes in Form of Purchase Warrant.</U> This form of Purchase Warrant need not be changed because of any change pursuant to this
<U>Section 6.1</U>, and Purchase Warrants issued after such change may state the same Exercise Price and the same number of Shares as
are stated in the Purchase Warrants initially issued pursuant to this Agreement. The acceptance by any Holder of the issuance of new
Purchase Warrants reflecting a required or permissive change shall not be deemed to waive any rights to an adjustment occurring after
the Effective Date or the computation thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.2
<U>Substitute Purchase Warrant</U>. In case of any consolidation of the Company with, or share reconstruction or amalgamation or merger
of the Company with or into, another corporation (other than a consolidation or share reconstruction or amalgamation or merger which
does not result in any reclassification or change of the outstanding shares of Common Stock), the corporation formed by such consolidation
or share reconstruction or amalgamation shall execute and deliver to the Holder a supplemental Purchase Warrant providing that the holder
of each Purchase Warrant then outstanding or to be outstanding shall have the right thereafter (until the stated expiration of such Purchase
Warrant) to receive, upon exercise of such Purchase Warrant, the kind and amount of shares of stock and other securities and property
receivable upon such consolidation or share reconstruction or amalgamation, by a holder of the number of Shares for which such Purchase
Warrant might have been exercised immediately prior to such consolidation, share reconstruction or amalgamation or merger, sale or transfer.
Such supplemental Purchase Warrant shall provide for adjustments which shall be identical to the adjustments provided for in this <U>Section
6</U>. The above provision of this <U>Section 6.2</U> shall similarly apply to successive consolidations or share reconstructions or
amalgamations or mergers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.3
<U>Elimination of Fractional Interests</U>. The Company shall not be required to issue certificates representing fractions of shares
of Common Stock upon the exercise of the Purchase Warrant, nor shall it be required to issue scrip or pay cash in lieu of any fractional
interests, it being the intent of the parties that all fractional interests shall be eliminated by rounding any fraction up or down,
as the case may be, to the nearest whole number of shares of Common Stock or other securities, properties or rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.
<U>Reservation</U>. The Company shall at all times reserve and keep available out of its authorized shares of Common Stock, solely for
the purpose of issuance upon exercise of the Purchase Warrants, such number of shares of Common Stock or other securities, properties
or rights as shall be issuable upon the exercise thereof. The Company covenants and agrees that, upon exercise of the Purchase Warrants
and payment of the Exercise Price therefor, in accordance with the terms hereby, all of the Shares and other securities issuable upon
such exercise shall be duly and validly issued, fully paid and non-assessable and not subject to preemptive rights of any shareholder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.
<U>Certain Notice Requirements</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.1
<U>Holder&rsquo;s Right to Receive Notice</U>. Nothing herein shall be construed as conferring upon the Holders the right to vote or
consent or to receive notice as a shareholder for the election of directors or any other matter, or as having any rights whatsoever as
a shareholder of the Company. If, however, at any time prior to the expiration of the Purchase Warrants and their exercise, any of the
events described in <U>Section 8.2</U> shall occur, then, in one or more of said events, the Company shall deliver to each Holder a copy
of each notice relating to such events given to the other shareholders of the Company at the same time and in the same manner that such
notice is given to the shareholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.2
<U>Events Requiring Notice</U>. The Company shall be required to give the notice described in this <U>Section 8</U> upon one or more
of the following events: (i) if the Company takes a record of the holders of shares of Common Stock for the purpose of entitling them
to receive a dividend or distribution payable otherwise than in cash, or a cash dividend or distribution payable otherwise than out of
retained earnings, as indicated by the accounting treatment of such dividend or distribution on the books of the Company, or (ii) the
Company offers to all the holders of shares of Common Stock any additional shares of capital stock of the Company or securities convertible
into or exchangeable for shares of capital stock of the Company, or any option, right or warrant to subscribe therefor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.3
<U>Notice of Change in Exercise Price</U>. The Company shall, promptly after an event requiring a change in the Exercise Price pursuant
to <U>Section 6</U> hereof, send notice to the Holders of such event and change (&ldquo;<B>Price Notice</B>&rdquo;). The Price Notice
shall describe the event causing the change and the method of calculating same.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.4
<U>Transmittal of Notices</U>. All notices, requests, consents and other communications under this Purchase Warrant shall be in writing
and shall be deemed to have been duly made when hand delivered, or mailed by express mail or private courier service: (i) if to the registered
Holder of the Purchase Warrant, to the address of such Holder as shown on the books of the Company, or (ii) if to the Company, to following
address or to such other address as the Company may designate by notice to the Holders:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
to the Representative:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Boustead
Securities, LLC</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6
Venture, Suite 395</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Irvine,
California 92618</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn:
Mr. Keith Moore, CEO</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:
keith@boustead1828.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>With
a copy (which shall not constitute notice) to:</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Olshan
Frome Wolosky LLP</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1325
Avenue of the Americas, 15th Floor</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
York, New York 10019</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn:
Spencer G. Feldman, Esq.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:
sfeldman@olshanlaw.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
to the Company:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Kairos
Pharma, Ltd.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2355
Westwood Blvd., #139</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Los
Angeles, California 90064</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn:
Dr. John S. Yu, M.D., CEO</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:
john.yu@cshs.org</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>With
a copy (which shall not constitute notice) to</I>:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Dorsey
&amp; Whitney LLP</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">51
West 52nd Street</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
York, New York 10019</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn:
Megan J. Penick, Esq.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:
penick.megan@dorsey.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.
<U>Miscellaneous</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.1
<U>Amendments</U>. The Company and Boustead may from time to time supplement or amend this Purchase Warrant without the approval of any
of the Holders in order to cure any ambiguity, to correct or supplement any provision contained herein that may be defective or inconsistent
with any other provisions herein, or to make any other provisions in regard to matters or questions arising hereunder that the Company
and Boustead may deem necessary or desirable and that the Company and Boustead deem shall not adversely affect the interest of the Holders.
All other modifications or amendments shall require the written consent of and be signed by (i) the Company and (ii) the Holder(s) of
Purchase Warrants then-exercisable for at least a majority of the Shares then-exercisable pursuant to all then-outstanding Purchase Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.2
<U>Headings</U>. The headings contained herein are for the sole purpose of convenience of reference, and shall not in any way limit or
affect the meaning or interpretation of any of the terms or provisions of this Purchase Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.3.
<U>Entire Agreement</U>. This Purchase Warrant (together with the other agreements and documents being delivered pursuant to or in connection
with this Purchase Warrant) constitutes the entire agreement of the parties hereto with respect to the subject matter hereof, and supersedes
all prior agreements and understandings of the parties, oral and written, with respect to the subject matter hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.4
<U>Binding Effect</U>. This Purchase Warrant shall inure solely to the benefit of and shall be binding upon, the Holder and the Company
and their permitted assignees, respective successors, legal representative and assigns, and no other person shall have or be construed
to have any legal or equitable right, remedy or claim under or in respect of or by virtue of this Purchase Warrant or any provisions
herein contained.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.5
<U>Governing Law; Submission to Jurisdiction; Trial by Jury</U>. This Purchase Warrant shall be governed by and construed and enforced
in accordance with the laws of the State of New York, without giving effect to conflict of laws principles thereof. The Company hereby
agrees that any action, proceeding or claim against it arising out of, or relating in any way to this Purchase Warrant shall be brought
and enforced in the New York Supreme Court, County of New York, or in the United States District Court for the Southern District of New
York, and irrevocably submits to such jurisdiction, which jurisdiction shall be exclusive. The Company hereby waives any objection to
such exclusive jurisdiction and that such courts represent an inconvenient forum. Any process or summons to be served upon the Company
may be served by transmitting a copy thereof by registered or certified mail, return receipt requested, postage prepaid, addressed to
it at the address set forth in <U>Section 8</U> hereof. Such mailing shall be deemed personal service and shall be legal and binding
upon the Company in any action, proceeding or claim. The Company and the Holder agree that the prevailing party(ies) in any such action
shall be entitled to recover from the other party(ies) all of its reasonable attorneys&rsquo; fees and expenses relating to such action
or proceeding and/or incurred in connection with the preparation therefor. The Company (on its behalf and, to the extent permitted by
applicable law, on behalf of its stockholders and affiliates) and the Holder hereby irrevocably waive, to the fullest extent permitted
by applicable law, any and all right to trial by jury in any legal proceeding arising out of or relating to this Agreement or the transactions
contemplated hereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.6
<U>Waiver, etc</U>. The failure of the Company or the Holder to at any time enforce any of the provisions of this Purchase Warrant shall
not be deemed or construed to be a waiver of any such provision, nor to in any way affect the validity of this Purchase Warrant or any
provision hereof or the right of the Company or any Holder to thereafter enforce each and every provision of this Purchase Warrant. No
waiver of any breach, non-compliance or non-fulfillment of any of the provisions of this Purchase Warrant shall be effective unless set
forth in a written instrument executed by the party or parties against whom or which enforcement of such waiver is sought; and no waiver
of any such breach, non-compliance or non-fulfillment shall be construed or deemed to be a waiver of any other or subsequent breach,
non-compliance or non-fulfillment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.7
<U>Exchange Agreement</U>. As a condition of the Holder&rsquo;s receipt and acceptance of this Purchase Warrant, Holder agrees that,
at any time prior to the complete exercise of this Purchase Warrant by Holder, if the Company and Boustead enter into an agreement (&ldquo;<B>Exchange
Agreement</B>&rdquo;) pursuant to which they agree that all outstanding Purchase Warrants will be exchanged for securities or cash or
a combination of both, then Holder shall agree to such exchange and become a party to the Exchange Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>[Signature
Page Follows]</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the Company has caused this Purchase Warrant to be signed by its duly authorized officer as of the _____ day of _______
202__.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>KAIROS
    PHARMA, LTD.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>[Signature
Page to Common Stock Purchase Warrant]</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>[Form
to be used to exercise Purchase Warrant]</I></FONT></P>

<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
__________, 20___</FONT></P>

<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned hereby elects irrevocably to exercise the Purchase Warrant for ______ shares of common stock, par value $0.001 per share
(the &ldquo;<B>Shares</B>&rdquo;), of Kairos Pharma, Ltd., a Delaware corporation (the &ldquo;<B>Company</B>&rdquo;), and hereby makes
payment of $____ (at the rate of $____ per Share) in payment of the Exercise Price pursuant thereto. Please issue the Shares as to which
this Purchase Warrant is exercised in accordance with the instructions given below and, if applicable, a new Purchase Warrant representing
the number of Shares for which this Purchase Warrant has not been exercised.</FONT></P>

<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">or</FONT></P>

<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned hereby elects irrevocably to convert its right to purchase ___ Shares of the Company under the Purchase Warrant for ______
Shares, as determined in accordance with the following formula:</FONT></P>

<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">dividing
[(A-B) (X)] by (A), where:</FONT></P>

<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 0.35in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(A) =</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the FMV;</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 0.35in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(B) =</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the Exercise Price of this
Purchase Warrant, as adjusted hereunder; and</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 0.35in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(X)</FONT> =</TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> the number of shares of Common Stock underlying the Purchase
Warrant that would be issuable upon exercise of this Purchase Warrant in accordance with the terms of this Purchase Warrant if such exercise
were by means of a cash exercise rather than a cashless exercise.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned agrees and acknowledges that the calculation set forth above is subject to confirmation by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Please
issue the Shares as to which this Purchase Warrant is exercised in accordance with the instructions given below and, if applicable, a
new Purchase Warrant representing the number of Shares for which this Purchase Warrant has not been converted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature ________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature
Guaranteed _______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">INSTRUCTIONS
FOR REGISTRATION OF SECURITIES</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
  <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">(Print in Block Letters)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 8%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:</FONT></TD>
  <TD STYLE="border-bottom: Black 1.5pt solid; width: 42%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 45pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTICE:
The signature to this form must correspond with the name as written upon the face of the Purchase Warrant without alteration or enlargement
or any change whatsoever, and must be guaranteed by a bank, other than a savings bank, or by a trust company or by a firm having membership
on a registered national securities exchange.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>[Form
to be used to assign Purchase Warrant]</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASSIGNMENT</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(To
be executed by the registered Holder to effect a transfer of the within Purchase Warrant):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FOR
VALUE RECEIVED, __________________ does hereby sell, assign and transfer unto _________________________ the right to purchase shares
of common stock, par value $0.001 per share, of Kairos Pharma, Ltd., a Delaware corporation (the &ldquo;<B>Company</B>&rdquo;), evidenced
by the Purchase Warrant and does hereby authorize the Company to transfer such right on the books of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:
__________, 20___</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature __________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature
Guaranteed _________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTICE:
The signature to this form must correspond with the name as written upon the face of the within Purchase Warrant without alteration or
enlargement or any change whatsoever, and must be guaranteed by a bank, other than a savings bank, or by a trust company or by a firm
having membership on a registered national securities exchange.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>4
<FILENAME>ex5-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
5.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex5-1_001.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
30, 2024</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kairos
Pharma, Ltd.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2355
Westwood Blvd., #139</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Los
Angeles, CA 90064</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Re:
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Registration
    Statement on Form S-1 (File No. 333-274805)</U></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 4.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ladies
and Gentlemen:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have acted as counsel to Kairos Pharma, Ltd., a Delaware corporation (the &ldquo;Company&rdquo;), in connection with a Registration Statement
on Form S-1 (the &ldquo;Registration Statement&rdquo;) filed by the Company with the Securities and Exchange Commission (the &ldquo;Commission&rdquo;)
under the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;), relating to the offer and sale by the Company of up
to 1,782,500 shares of common stock, par value $0.001 per share, of the Company, including 232,500 shares to be subject to the underwriter&rsquo;s
over-allotment option (the &ldquo;Shares&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have examined such documents and have reviewed such questions of law as we have considered necessary or appropriate for the purposes
of our opinions set forth below. In rendering our opinions set forth below, we have assumed the authenticity of all documents submitted
to us as originals, the genuineness of all signatures and the conformity to authentic originals of all documents submitted to us as copies.
We have also assumed the legal capacity for all purposes relevant hereto of all natural persons. As to questions of fact material to
our opinions, we have relied upon certificates or comparable documents of officers and other representatives of the Company and of public
officials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on the foregoing, we are of the opinion that the Shares, when issued, delivered and paid for as described in the Registration Statement,
will be validly issued, fully paid and non-assessable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
opinions expressed above are limited to the Delaware General Corporation Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
hereby consent to the filing of this opinion as an exhibit to the Registration Statement, and to the reference to our firm under the
heading &ldquo;Legal Matters&rdquo; in the prospectus constituting part of the Registration Statement. In giving this consent, we do
not admit that we are within the category of persons whose consent is required under Section 7 of the Securities Act or the rules and
regulations of the Commission thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very
    truly yours,</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DORSEY
    &amp; WHITNEY LLP</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Dorsey &amp; Whitney LLP</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MJP:dm</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dorsey
&amp; Whitney LLP | 51 West 52nd Street | New York, NY | 10019-6119 | <B>T </B>212.415.9200 | <B>F </B>212.953.7201 | dorsey.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.30
<SEQUENCE>5
<FILENAME>ex10-30.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
10.30</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FINAL</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONVERSION
AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
CONVERSION AGREEMENT (this &ldquo;<B>Agreement</B>&rdquo;) is made and entered into as of March 7, 2024, by and between Cedars-Sinai
Medical Center, a California nonprofit public benefit corporation (&ldquo;<B>Cedars-Sinai</B>&rdquo;), on the one hand, and Kairos Pharma,
Ltd., a Delaware corporation (&ldquo;<B>Kairos</B>&rdquo;), and Enviro Therapeutics, Inc., a California corporation and wholly-owned
subsidiary of Kairos (&ldquo;<B>Enviro</B>&rdquo; and together with Kairos, the &ldquo;<B>Company</B>&rdquo;), on the other hand.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>RECITALS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
Cedars-Sinai is a party to those certain license agreements with the Company, and amendments thereto, set forth on <U>Schedule A</U>
hereto, pursuant to which the Company owes Cedars-Sinai an aggregate of $948,049.38 in unpaid license fees and related fees, costs and
expenses as of March 1, 2024 (the &ldquo;<B>Total Liabilities</B>&rdquo;); and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
Cedars-Sinai and the Company desire to convert an aggregate of $750,000 of the Total Liabilities (the &ldquo;<B>Converted Liabilities</B>&rdquo;)
into shares of common stock of Kairos, par value $0.001 per share (&ldquo;<B>Common Stock</B>&rdquo;), upon the terms and subject to
the conditions set forth herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOW,
THEREFORE</B>, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereto hereby
agree as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
<B>Conversion of Liabilities</B>. Subject to and conditioned upon the occurrence of, and effective immediately prior to, the closing
(the &ldquo;<B>Effective Time</B>&rdquo;) of a firm-commitment underwritten initial public offering by the Company of its Common Stock
pursuant to an effective registration statement under the Securities Act of 1933, as amended (the &ldquo;<B>Securities Act</B>&rdquo;),
resulting in at least $5,700,000 of proceeds, net of any underwriting discounts and commissions, to Kairos (the &ldquo;<B>IPO</B>&rdquo;),
and without further action by Cedars-Sinai or the Company, the Converted Liabilities shall be converted into a number of shares of Common
Stock equal to the quotient obtained by dividing (a) the Converted Liabilities by (b) an amount equal to 60% of the initial public offering
price of Common Stock in the IPO (the &ldquo;<B>Conversion Shares</B>&rdquo;). The parties agree that the Conversion Shares shall be
issued to Cedars Sinai Intellectual Property Company, a California nonprofit public benefit corporation and wholly-owned subsidiary of
Cedars-Sinai (&ldquo;<B>CSIPC</B>&rdquo;), as Cedars-Sinai&rsquo;s designee hereunder. No fractional shares of Common Stock will be issued
upon conversion of the Converted Liabilities. In lieu of any fractional share of Common Stock to which CSIPC would otherwise be entitled,
the Company will pay to CSIPC in cash the amount of the Converted Liabilities that would otherwise be converted into such fractional
share. Cedars-Sinai hereby acknowledges and agrees that upon the issuance of the Conversion Shares to CSIPC in accordance with this <B>Section
1</B>, the Company shall have fully and completely satisfied all of its obligations with respect to the Converted Liabilities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
<B>Repayment</B>. The Company hereby agrees to pay to Cedars-Sinai (or its designee), as promptly as practicable, but in no event later
than three (3) months, following the Effective Time, an amount in cash equal to the difference between the Total Liabilities and the
Converted Liabilities (the &ldquo;<B>Excess Liabilities</B>&rdquo;). Beginning on the effective date of this Agreement and continuing
until paid in full, the Excess Liabilities, or any balance thereof remaining after the Company&rsquo;s payment of any portion of the
Excess Liabilities, shall incur interest at a rate of two percent (2%) per month, computed as simple interest on the basis of a month
of 30 days for the actual number of days elapsed. The interest paid or agreed to be paid under this Section 2 shall not exceed the maximum
interest rate permitted by applicable law (the &ldquo;<B>Maximum Rate</B>&rdquo;). If Cedars-Sinai receives interest in an amount that
exceeds the Maximum Rate, the excess interest shall be applied to the outstanding Excess Liabilities remaining owed. All accrued but
unpaid interest hereunder shall be due and payable as promptly as practicable, but in no event later than three (3) months following
the Effective Time. Cedars-Sinai hereby acknowledges and agrees that upon payment in full in accordance with this Section 2 of the unpaid
Excess Liabilities and all interest accrued thereon, the Company shall have fully and completely satisfied all of its obligations with
respect to the Excess Liabilities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
<B>Legal Fees</B>. Within five business days after its receipt of a summary invoice therefor, the Company shall pay to Cedars-Sinai (or
its designee) the reasonable fees and expenses, not to exceed $25,000, of Nixon Peabody, LLP, counsel for Cedars-Sinai, incurred solely
with respect to the matters set forth herein (including, but limited to, drafting and negotiating this Agreement and drafting and negotiating
amendments to the applicable license agreements).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
<B>Representations and Warranties of the Company</B>. The Company hereby represents and warrants to Cedars-Sinai as of the date of this
Agreement and as of the Effective Time as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<U>Organization, Good Standing, Corporate Power and Qualification</U>. Each of Kairos and Enviro is a corporation duly organized, validly
existing and in good standing under the laws of the jurisdiction of its incorporation and has all requisite corporate power and authority
to carry on its business as presently conducted. Each of Kairos and Enviro is duly qualified to transact business and is in good standing
in each jurisdiction in which the failure to so qualify would have a material adverse effect on their respective business, assets (including
intangible assets), liabilities, financial condition, property or results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<U>Authorization</U>. All corporate action required to be taken by the boards of directors and stockholders of each of Kairos and Enviro
in order to authorize them to enter into this Agreement and to issue the Conversion Shares at the Effective Time has been taken or will
be taken at or prior to the Effective Time. All action on the part of the officers of each of Kairos and Enviro necessary for the execution
and delivery of this Agreement, the performance of all of their respective obligations under this Agreement to be performed as of the
Effective Time, and the issuance and delivery of the Conversion Shares has been taken or will be taken prior to the Effective Time. This
Agreement, when executed and delivered by each of Kairos and Enviro, shall constitute valid and legally binding obligations of each of
Kairos and Enviro, enforceable against them in accordance with its terms except (a) as limited by applicable bankruptcy, insolvency,
reorganization, moratorium, fraudulent conveyance, or other laws of general application relating to or affecting the enforcement of creditors&rsquo;
rights generally, or (b) as limited by laws relating to the availability of specific performance, injunctive relief, or other equitable
remedies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<U>Valid Issuance of Conversion Shares</U>. The Conversion Shares, when issued and delivered in accordance with the terms set forth in
this Agreement, will be validly issued, fully paid and nonassessable and free of restrictions on transfer other than restrictions on
transfer under applicable state and federal securities laws. In addition, the Conversion Shares, upon issuance, shall bear a restrictive
legend in substantially the form: &ldquo;THESE SHARES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS MENDED, OR THE SECURITIES
LAWS OF ANY STATE AND MAY NOT BE SOLD OR OFFERED FOR SALE IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT REGISTERING THE SHARES
OR AN OPINION OF COUNSEL OR OTHER EVIDENCE ACEPTABLE TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
<B>Representations and Warranties of Cedars-Sinai</B>. Cedars-Sinai hereby represents and warrants to the Company as of the date of this
Agreement and as of the Effective Time as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<U>Organization, Good Standing, Corporate Power and Qualification</U>. Cedars-Sinai is a corporation duly organized, validly existing
and in good standing under the laws of the jurisdiction of its incorporation and has all requisite corporate power and authority to carry
on its business as presently conducted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<U>Authorization</U>. Cedars-Sinai has full power and authority to enter into this Agreement. All corporate action required to be taken
by the boards of directors and stockholders of Cedars-Sinai necessary for the authorization, execution and delivery of this Agreement,
and the performance of all obligations of Cedars-Sinai hereunder has been taken or will be taken at or prior to the Effective Time. This
Agreement, when executed and delivered by Cedars-Sinai, shall constitute valid and legally binding obligations of Cedars-Sinai, enforceable
against it in accordance with its terms except (a) as limited by applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent
conveyance, or other laws of general application relating to or affecting the enforcement of creditors&rsquo; rights generally, or (b)
as limited by laws relating to the availability of specific performance, injunctive relief, or other equitable remedies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<U>Acquiring Securities Entirely for Own Account</U>. The Conversion Shares will be acquired for investment for Cedars-Sinai&rsquo;s
own account, not as a nominee or agent, and not with a view to the resale or distribution of any part thereof, and Cedars-Sinai has no
present intention of selling or otherwise distributing the same. Cedars-Sinai does not have any contract, undertaking, agreement or arrangement
with any person to sell, transfer or grant participations to such person or to any third person, with respect to the Conversion Shares.
</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
<U>Accredited Investor.</U> Cedars-Sinai is an &ldquo;accredited investor&rdquo; within the meaning of Rule 501 of Regulation D promulgated
pursuant to the Securities Act. Cedars-Sinai is able to fend for itself, can bear the economic risk of its investment, and has such knowledge
and experience in financial or business matters that it is capable of evaluating the merits and risks of the investment in the Conversion
Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
<U>Restricted Securities</U>. Cedars-Sinai understands that the Conversion Shares are &ldquo;restricted securities&rdquo; under the federal
and applicable state securities laws and that, pursuant to these laws, Cedars-Sinai must hold the Conversion Shares indefinitely unless
they are registered under the Securities Act and applicable state securities laws or unless an exemption from such registration requirements
is available. Cedars-Sinai will not, directly or indirectly, offer, sell, pledge, transfer or otherwise dispose of (or solicit any offers
to buy, purchase or otherwise acquire or take a pledge of) any of the Conversion Shares except in compliance with applicable federal
and state securities laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.
<B>Further Assurances</B>. Each party shall execute and deliver such further documents, instruments and certificates, and take such additional
action, as may be reasonably requested by any other party to carry out the terms, provisions and purposes of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.
<B>Entire Agreement; Modification; Governing Law</B>. This Agreement represents the entire agreement of the parties hereto relative to
the subject matter hereof and supersedes any prior agreement with respect hereto and may not be amended or modified except in writing
signed by the parties hereto. This Agreement, its construction and the determination of any rights, duties or remedies of the parties
arising out of or relating to this Agreement, shall be governed by and construed under and in accordance with the laws of the State of
California without respect to any conflict of law provision or rule that would cause the application of the laws of any other jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.
<B>Binding</B>. This Agreement shall be binding on, and inure to the benefit of, the parties to it and their respective legal representatives,
successors and permitted assigns. No party may assign or delegate any of its rights or obligations under this Agreement without the prior
written consent of the other parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.
<B>Counterparts</B>. This Agreement may be executed simultaneously in multiple counterparts, each of which shall be deemed an original,
but all of which together shall constitute one and the same instrument. Execution of this Agreement by facsimile or other electronic
means (including without limitation portable document format (pdf)) shall be deemed effective and signatures received by facsimile or
other electronic means shall be effective as original signatures.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[Signature
Page Follows.]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IN
WITNESS WHEREOF</B>, the parties hereto have executed this Agreement as of the date first written above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Cedars-Sinai
    Medical Center</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:
    </FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:
    </FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:
    </FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Kairos
    Pharma, Ltd.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">John
    Yu, M.D.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Enviro
    Therapeutics, Inc.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:
    </FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:
    </FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">John
    Yu, M.D.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:
    </FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[Signature
Page to Conversion Agreement]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Schedule
A</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>License
Agreements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exclusive
    License Agreement to Methods and Use of Compounds that Bind to RelA of NF-&kappa;B with Kairos Pharma Ltd. f/k/a NanoGB12, Inc.,
    dated October 1, 2017, as amended by the Letter Amendment dated June 17, 2021, and by the Second Amendment dated March 5, 2024.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exclusive
    License Agreement to Composition and Methods for Treating Fibrosis with Kairos Pharma Ltd. dated October 1, 2017, as amended by the
    Letter Amendment dated June 17, 2021, and by the Second Amendment dated March 5, 2024.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exclusive
    License Agreement to Compositions and Methods for Treating Cancer and Autoimmune Diseases with Kairos Pharma Ltd. dated March 12,
    2019, as amended by the Letter Amendment dated June 17, 2021, and by the Second Amendment dated March 5, 2024.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exclusive
    License Agreement to Compositions and Methods for Treating Diseases and Conditions by Depletion of Mitochondrial or Genomic DNA from
    Circulation and for Detection of Mitochondrial or Genomic DNA with Enviro Therapeutics, Inc. dated June 2, 2021, as amended by the
    First Amendment dated April 18, 2022, by the Second Amendment dated October 10, 2022, and by the Third Amendment dated March 5, 2024.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exclusive
    License Agreement to Sensitization of Tumors to Therapies Through Endoglin Antagonism with Enviro Therapeutics, Inc. dated June 2,
    2021, as amended by the First Amendment dated April 18, 2022, by the Second Amendment dated October 11, 2022, and by the Third Amendment
    dated March 5, 2024.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule
A</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.31
<SEQUENCE>6
<FILENAME>ex10-31.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
10.31</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>SECOND
AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THIS
SECOND AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT (this &ldquo;<B>Amendment</B>&rdquo;) is made and entered into as of March 7, 2024 by
and between <B>CEDARS-SINAI MEDICAL CENTER</B>, a California nonprofit public benefit corporation (&ldquo;<B>CSMC</B>&rdquo;) and <B>KAIROS
PHARMA, LTD.</B>, a California corporation (&ldquo;<B>Licensee</B>&rdquo;), under the following circumstances:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CSMC
    and Licensee entered into an Exclusive License Agreement dated October 1, 2017, as amended by the First Amendment dated June 17,
    2021 (collectively, the &ldquo;<B>License Agreement</B>&rdquo;). </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CSMC
    and Licensee are entering into a Conversion Agreement, of even date herewith (the &ldquo;<B>Conversion Agreement</B>&rdquo;), pursuant
    to which (i) the parties shall convert an aggregate of $750,000 of Licensee&rsquo;s unpaid fees, costs, and expenses under several
    license agreements, including this License Agreement, into shares of Common Stock (as defined in the Conversion Agreement) of Licensee,
    and (ii) Licensee shall pay CSMC the Excess Liabilities, with interest (as defined in, and subject to the terms of, the Conversion
    Agreement).</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Licensee
    owes $141,638.58 under the License Agreement in unpaid reimbursement of patent costs, annual maintenance fees, and late fees under
    &sect;&sect; 4.3 (Patent Costs), 4.4 (Annual License Maintenance Fee), and 4.5(h)(vi) (Late Charges), respectively, of the License
    Agreement as of March 1, 2024 (&ldquo;<B>Discharge Date</B>&rdquo;) (past-due amounts, collectively, &ldquo;<B>Liabilities</B>&rdquo;).
    The Liabilities represent 14.94% of the Total Liabilities (as defined in the Conversion Agreement). For clarity, Liabilities do not
    include owed amounts accruing and due under the License after the Discharge Date. </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    parties desire to amend the License Agreement as further described herein.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOW,
THEREFORE, in consideration of the mutual promises and covenants contained herein, in the License Agreement, in the Conversion Agreement,
and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereby agree
as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1. &nbsp;<I><U>Defined Terms</U></I></B>. Terms not otherwise defined herein shall have the meaning
ascribed to them in the License Agreement and Conversion Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2. <I><U>Amendment
to the License Agreement</U></I></B><I>.</I> The parties agree that the Liabilities shall be discharged subject to and conditioned upon
(i) the execution, delivery, and performance by Licensee of the Conversion Agreement, (ii) the closing of Licensee&rsquo;s initial public
offering (&ldquo;<B>IPO</B>&rdquo;) resulting in at least $5,700,000 of proceeds, net of any underwriting discounts and commissions,
to Licensee, and (iii) Licensee&rsquo;s payment to CSMC of the Excess Liabilities. The following shall be added to the end of &sect;
4 (Consideration):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0pt 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4.6</B> <B>Payment
of Past Due Amounts</B>. In full satisfaction of the Liabilities, and subject to the Conversion Agreement, (i) [14.94%] of the Conversion
Shares issued to Cedars Sinai Intellectual Property Company, a California nonprofit public benefit corporation and wholly-owned subsidiary
of CSMC (&ldquo;<B>CSIPC</B>&rdquo;), shall be allocated by CSMC to satisfaction of the Liabilities, and (ii) [14.94%] of the Excess
Liabilities paid to CSMC under the Conversion Agreement (including any interest due as set forth therein), shall be allocated by CSMC
to satisfaction of the Liabilities. Any material breach by Licensee of the Conversion Agreement shall be deemed a breach of the License.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3. <I><U>Other
Provisions</U></I></B>. This Amendment is a revision to the License Agreement only; it is not a novation thereof. Except as otherwise
provided herein, the terms and conditions of the License Agreement shall remain in full force and effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4. <I><U>Further
Assurances</U></I></B>. Each of the parties hereto shall execute such further documents and instruments and do all such further acts
as may be necessary or required in order to effectuate the intent and accomplish the purposes of this Amendment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5. <I><U>Counterparts</U></I></B>.
This Amendment may be executed in any number of counterparts, each of which shall be deemed an original, but all of which taken together
shall constitute one and the same instrument.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Signature
Page Follows</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the parties have executed this Amendment as of the day and year first above written.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 8.2pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Cedars-Sinai
    Medical Center</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Kairos
    Pharma, Ltd.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.32
<SEQUENCE>7
<FILENAME>ex10-32.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
10.32</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>THIRD
AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THIS
THIRD AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT (this &ldquo;<B>Amendment</B>&rdquo;) is made and entered into as of March 7, 2024 by
and between <B>CEDARS-SINAI MEDICAL CENTER</B>, a California nonprofit public benefit corporation (&ldquo;<B>CSMC</B>&rdquo;) and <B>ENVIRO
THERAPEUTICS, INC.</B>, a California corporation (&ldquo;<B>Licensee</B>&rdquo;), under the following circumstances:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CSMC
    and Licensee entered into an Exclusive License Agreement dated June 2, 2021, as amended by the First Amendment dated April 18, 2022,
    and the Second Amendment dated October 11, 2022 (collectively, the &ldquo;<B>License Agreement</B>&rdquo;). </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Licensee
    is a wholly-owned subsidiary of Kairos Pharma, Ltd. (&ldquo;<B>Kairos</B>&rdquo;).</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CSMC
    and Kairos are entering into a Conversion Agreement, of even date herewith (the &ldquo;<B>Conversion Agreement</B>&rdquo;), pursuant
    to which (i) the parties shall convert an aggregate of $750,000 of Licensee&rsquo;s unpaid fees, costs, and expenses under several
    license agreements, including this License Agreement, into shares of Common Stock (as defined in the Conversion Agreement) of Kairos,
    and (ii) Kairos shall pay CSMC the Excess Liabilities, with interest (as defined in, and subject to the terms of, the Conversion
    Agreement).</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Licensee
    owes $604,476.28 under the License Agreement in unpaid upfront fees, patent cost reimbursement, reimbursement of other fees and costs,
    and late fees under &sect;&sect; 4.1(a) (Upfront fee), 4.1(b) (Patent Cost Reimbursement), 4.1(c) (Reimbursement of Other Fees and
    Costs), and 4.2(h)(i)vi) (Late Charges), respectively, of the License Agreement as of March 1, 2024 (&ldquo;<B>Discharge Date</B>&rdquo;)
    (past-due amounts, collectively, &ldquo;<B>Liabilities</B>&rdquo;). The Liabilities represent 63.76% of the Total Liabilities (as
    defined in the Conversion Agreement). For clarity, Liabilities do not include owed amounts accruing and due under the License after
    the Discharge Date. </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">E.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    parties desire to amend the License Agreement as further described herein.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOW,
THEREFORE, in consideration of the mutual promises and covenants contained herein, in the License Agreement, in the Conversion Agreement,
and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereby agree
as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.
<I><U>Defined Terms</U></I></B>. Terms not otherwise defined herein shall have the meaning ascribed to them in the License Agreement
and Conversion Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2. <I><U>Amendment
to the License Agreement</U></I></B><I>.</I> The parties agree that the Liabilities shall be discharged subject to and conditioned upon
(i) the execution, delivery, and performance by Licensee of the Conversion Agreement, (ii) the closing of Kairos&rsquo;s initial public
offering (&ldquo;<B>IPO</B>&rdquo;) resulting in at least $5,700,000 of proceeds, net of any underwriting discounts and commissions,
to Kairos, and (iii) Licensee&rsquo;s payment to CSMC of the Excess Liabilities. The following shall be added to the end of &sect; 4
(Consideration):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0pt 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4.3</B> <B>Payment
of Past Due Amounts</B>. In full satisfaction of the Liabilities, and subject to the Conversion Agreement, (i) [63.77%] of the Conversion
Shares issued to Cedars Sinai Intellectual Property Company, a California nonprofit public benefit corporation and wholly-owned subsidiary
of CSMC (&ldquo;<B>CSIPC</B>&rdquo;), shall be allocated by CSMC to satisfaction of the Liabilities, and (ii) [63.77%] of the Excess
Liabilities paid to CSMC under the Conversion Agreement (including any interest due as set forth therein), shall be allocated by CSMC
to satisfaction of the Liabilities. Any material breach by Licensee of the Conversion Agreement shall be deemed a breach of the License.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3. <I><U>Other
Provisions</U></I></B>. This Amendment is a revision to the License Agreement only; it is not a novation thereof. Except as otherwise
provided herein, the terms and conditions of the License Agreement shall remain in full force and effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4. <I><U>Further
Assurances</U></I></B>. Each of the parties hereto shall execute such further documents and instruments and do all such further acts
as may be necessary or required in order to effectuate the intent and accomplish the purposes of this Amendment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5. <I><U>Counterparts</U></I></B>.
This Amendment may be executed in any number of counterparts, each of which shall be deemed an original, but all of which taken together
shall constitute one and the same instrument.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Signature
Page Follows</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the parties have executed this Amendment as of the day and year first above written.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 8.2pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Cedars-Sinai
    Medical Center</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Kairos
    Pharma, Ltd.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Enviro
    Therapeutics, Inc.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.33
<SEQUENCE>8
<FILENAME>ex10-33.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
10.33</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>SECOND
AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THIS
SECOND AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT (this &ldquo;<B>Amendment</B>&rdquo;) is made and entered into as of March 7, 2024 by
and between <B>CEDARS-SINAI MEDICAL CENTER</B>, a California nonprofit public benefit corporation (&ldquo;<B>CSMC</B>&rdquo;) and <B>KAIROS
PHARMA, LTD.</B>, a California corporation (&ldquo;<B>Licensee</B>&rdquo;), under the following circumstances:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CSMC
    and Licensee entered into an Exclusive License Agreement dated October 1, 2017, as amended by the First Amendment dated June 17,
    2021 (collectively, the &ldquo;<B>License Agreement</B>&rdquo;).</FONT></TD>
    <TD STYLE="width: 0.5in">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CSMC
    and Licensee are entering into a Conversion Agreement, of even date herewith (the &ldquo;<B>Conversion Agreement</B>&rdquo;), pursuant
    to which (i) the parties shall convert an aggregate of $750,000 of Licensee&rsquo;s unpaid fees, costs, and expenses under several
    license agreements, including this License Agreement, into shares of Common Stock (as defined in the Conversion Agreement) of Licensee,
    and (ii) Licensee shall pay CSMC the Excess Liabilities, with interest (as defined in, and subject to the terms of, the Conversion
    Agreement).</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Licensee
    owes $93,288.06 under the License Agreement in unpaid reimbursement of patent costs, annual maintenance fees, and late fees under
    &sect;&sect; 4.2 (Patent Costs), 4.3 (Annual License Maintenance Fee), and 4.4(h)(vi) (Late Charges), respectively, of the License
    Agreement as of March 1, 2024 (&ldquo;<B>Discharge Date</B>&rdquo;) (past-due amounts, collectively, &ldquo;<B>Liabilities</B>&rdquo;).
    The Liabilities represent 9.84% of the Total Liabilities (as defined in the Conversion Agreement). For clarity, Liabilities do not
    include owed amounts accruing and due under the License after the Discharge Date.</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    parties desire to amend the License Agreement as further described herein.</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOW,
THEREFORE, in consideration of the mutual promises and covenants contained herein, in the License Agreement, in the Conversion Agreement,
and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereby agree
as follows:</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1. <I><U>Defined
Terms</U></I></B>. Terms not otherwise defined herein shall have the meaning ascribed to them in the License Agreement and
Conversion Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2. <I><U>Amendment
to the License Agreement</U></I></B><I>.</I> The parties agree that the Liabilities shall be discharged subject to and conditioned
upon (i) the execution, delivery, and performance by Licensee of the Conversion Agreement, (ii) the closing of Licensee&rsquo;s
initial public offering (&ldquo;<B>IPO</B>&rdquo;) resulting in at least $5,700,000 of proceeds, net of any underwriting discounts
and commissions, to Licensee, and (iii) Licensee&rsquo;s payment to CSMC of the Excess Liabilities. The following shall be added to
the end of &sect; 4 (Consideration):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4.5</B> <B>Payment
of Past Due Amounts</B>. In full satisfaction of the Liabilities, and subject to the Conversion Agreement, (i) [9.84%] of the
Conversion Shares issued to Cedars Sinai Intellectual Property Company, a California nonprofit public benefit corporation and
wholly-owned subsidiary of CSMC (&ldquo;<B>CSIPC</B>&rdquo;), shall be allocated by CSMC to satisfaction of the Liabilities, and
(ii) [9.84%] of the Excess Liabilities paid to CSMC under the Conversion Agreement (including any interest due as set forth
therein), shall be allocated by CSMC to satisfaction of the Liabilities. Any material breach by Licensee of the Conversion Agreement
shall be deemed a breach of the License.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3. <I><U>Other
Provisions</U></I></B>. This Amendment is a revision to the License Agreement only; it is not a novation thereof. Except as
otherwise provided herein, the terms and conditions of the License Agreement shall remain in full force and effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4. <I><U>Further
Assurances</U></I></B>. Each of the parties hereto shall execute such further documents and instruments and do all such further acts
as may be necessary or required in order to effectuate the intent and accomplish the purposes of this Amendment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5. <I><U>Counterparts</U></I></B>.
This Amendment may be executed in any number of counterparts, each of which shall be deemed an original, but all of which taken
together shall constitute one and the same instrument.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Signature
Page Follows</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>


<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the parties have executed this Amendment as of the day and year first above written.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Cedars-Sinai
    Medical Center</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Kairos
    Pharma, Ltd.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.34
<SEQUENCE>9
<FILENAME>ex10-34.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
10.34</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>THIRD
AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THIS
THIRD AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT (this &ldquo;<B>Amendment</B>&rdquo;) is made and entered into as of March 7, 2024 by
and between <B>CEDARS-SINAI MEDICAL CENTER</B>, a California nonprofit public benefit corporation (&ldquo;<B>CSMC</B>&rdquo;) and <B>ENVIRO
THERAPEUTICS, INC.</B>, a California corporation (&ldquo;<B>Licensee</B>&rdquo;), under the following circumstances:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CSMC
    and Licensee entered into an Exclusive License Agreement dated June 2, 2021, as amended by the First Amendment dated April 18, 2022,
    and the Second Amendment dated October 10, 2022 (collectively, the &ldquo;<B>License Agreement</B>&rdquo;).</FONT></TD>
    <TD STYLE="width: 0.5in">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Licensee
    is a wholly-owned subsidiary of Kairos Pharma, Ltd. (&ldquo;<B>Kairos</B>&rdquo;).</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CSMC
    and Kairos are entering into a Conversion Agreement, of even date herewith (the &ldquo;<B>Conversion Agreement</B>&rdquo;), pursuant
    to which (i) the parties shall convert an aggregate of $750,000 of Licensee&rsquo;s unpaid fees, costs, and expenses under several
    license agreements, including this License Agreement, into shares of Common Stock (as defined in the Conversion Agreement) of Kairos,
    and (ii) Kairos shall pay CSMC the Excess Liabilities, with interest (as defined in, and subject to the terms of, the Conversion
    Agreement).</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Licensee
    owes $81,911.46 under the License Agreement in unpaid upfront fees, patent cost reimbursement, and late fees under &sect;&sect; 4.1(a)
    (Upfront Fee), 4.1(b) (Patent Cost Reimbursement). and 4.2(i)(vi) (Late Charges), respectively, of the License Agreement as of March
    1, 2024 (&ldquo;<B>Discharge Date</B>&rdquo;) (past-due amounts, collectively, &ldquo;<B>Liabilities</B>&rdquo;). The Liabilities
    represent 8.64% of the Total Liabilities (as defined in the Conversion Agreement). For clarity, Liabilities do not include owed amounts
    accruing and due under the License after the Discharge Date.</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">E.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    parties desire to amend the License Agreement as further described herein.</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOW,
THEREFORE, in consideration of the mutual promises and covenants contained herein, in the License Agreement, in the Conversion Agreement,
and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereby agree
as follows:</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1. <I><U>Defined
Terms</U></I></B>. Terms not otherwise defined herein shall have the meaning ascribed to them in the License Agreement and
Conversion Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2. <I><U>Amendment
to the License Agreement</U></I></B><I>.</I> The parties agree that the Liabilities shall be discharged subject to and conditioned
upon (i) the execution, delivery, and performance by Licensee of the Conversion Agreement, (ii) the closing of Kairos&rsquo;s
initial public offering (&ldquo;<B>IPO</B>&rdquo;) resulting in at least $5,700,000 of proceeds, net of any underwriting discounts
and commissions, to Kairos, and (iii) Licensee&rsquo;s payment to CSMC of the Excess Liabilities. The following shall be added to
the end of &sect; 4 (Consideration):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4.3</B> <B>Payment
of Past Due Amounts</B>. In full satisfaction of the Liabilities, and subject to the Conversion Agreement, (i) [8.64%] of the
Conversion Shares issued to Cedars Sinai Intellectual Property Company, a California nonprofit public benefit corporation and
wholly-owned subsidiary of CSMC (&ldquo;<B>CSIPC</B>&rdquo;), shall be allocated by CSMC to satisfaction of the Liabilities, and
(ii) [8.64%] of the Excess Liabilities paid to CSMC under the Conversion Agreement (including any interest due as set forth
therein), shall be allocated by CSMC to satisfaction of the Liabilities. Any material breach by Licensee of the Conversion Agreement
shall be deemed a breach of the License.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3. <I><U>Other
Provisions</U></I></B>. This Amendment is a revision to the License Agreement only; it is not a novation thereof. Except as
otherwise provided herein, the terms and conditions of the License Agreement shall remain in full force and effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4. <I><U>Further
Assurances</U></I></B>. Each of the parties hereto shall execute such further documents and instruments and do all such further acts
as may be necessary or required in order to effectuate the intent and accomplish the purposes of this Amendment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5. <I><U>Counterparts</U></I></B>.
This Amendment may be executed in any number of counterparts, each of which shall be deemed an original, but all of which taken
together shall constitute one and the same instrument.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Signature
Page Follows</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I></I></B></FONT></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B><BR STYLE="clear: both"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the parties have executed this Amendment as of the day and year first above written.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt; text-align: justify; text-indent: -32.3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Cedars-Sinai
    Medical Center</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Kairos
    Pharma, Ltd.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Enviro
    Therapeutics, Inc.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.35
<SEQUENCE>10
<FILENAME>ex10-35.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
10.35</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>SECOND
AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THIS
SECOND AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT (this &ldquo;<B>Amendment</B>&rdquo;) is made and entered into as of March 7, 2024 by
and between <B>CEDARS-SINAI MEDICAL CENTER</B>, a California nonprofit public benefit corporation (&ldquo;<B>CSMC</B>&rdquo;) and <B>KAIROS
PHARMA, LTD.</B>, a California corporation (&ldquo;<B>Licensee</B>&rdquo;), under the following circumstances:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CSMC
    and Licensee entered into an Exclusive License Agreement dated March 12, 2019, as amended by the First Amendment dated June 17, 2021
    (collectively, the &ldquo;<B>License Agreement</B>&rdquo;).</FONT></TD>
    <TD STYLE="width: 0.5in">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CSMC
    and Licensee are entering into a Conversion Agreement, of even date herewith (the &ldquo;<B>Conversion Agreement</B>&rdquo;), pursuant
    to which (i) the parties shall convert an aggregate of $750,000 of Licensee&rsquo;s unpaid fees, costs, and expenses under several
    license agreements, including this License Agreement, into shares of Common Stock (as defined in the Conversion Agreement) of Licensee,
    and (ii) Licensee shall pay CSMC the Excess Liabilities, with interest (as defined in, and subject to the terms of, the Conversion
    Agreement).</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Licensee
    owes $26,735.00 under the License Agreement in unpaid annual license maintenance fees, reimbursement of patent costs, and late fees
    under &sect;&sect; 4.2 (Patent Costs), 4.3 (Annual License Maintence Fee), and 4.4(h)(vi) (Late Charges), respectively, of the License
    Agreement as of March 1, 2024 (&ldquo;<B>Discharge Date</B>&rdquo;) (past-due amounts, collectively, &ldquo;<B>Liabilities</B>&rdquo;).
    The Liabilities represent 2.82% of the Total Liabilities (as defined in the Conversion Agreement). For clarity, Liabilities do not
    include owed amounts accruing and due under the License after the Discharge Date.</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    parties desire to amend the License Agreement as further described herein.</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOW,
THEREFORE, in consideration of the mutual promises and covenants contained herein, in the License Agreement, in the Conversion Agreement,
and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereby agree
as follows:</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.
<I><U>Defined Terms</U></I></B>. Terms not otherwise defined herein shall have the meaning ascribed to them in the License Agreement
and Conversion Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>


<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.
<I><U>Amendment to the License Agreement</U></I></B><I>.</I> The parties agree that the Liabilities shall be discharged subject to and
conditioned upon (i) the execution, delivery, and performance by Licensee of the Conversion Agreement, (ii) the closing of Licensee&rsquo;s
initial public offering (&ldquo;<B>IPO</B>&rdquo;) resulting in at least $5,700,000 of proceeds, net of any underwriting discounts and
commissions, to Licensee, and (iii) Licensee&rsquo;s payment to CSMC of the Excess Liabilities. The following shall be added to the end
of &sect; 4 (Consideration):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4.5
Payment of Past Due Amounts</B>. In full satisfaction of the Liabilities, and subject to the Conversion Agreement, (i) [2.82%] of the
Conversion Shares issued to Cedars Sinai Intellectual Property Company, a California nonprofit public benefit corporation and wholly-owned
subsidiary of CSMC (&ldquo;<B>CSIPC</B>&rdquo;), shall be allocated by CSMC to satisfaction of the Liabilities, and (ii) [2.82%] of the
Excess Liabilities paid to CSMC under the Conversion Agreement (including any interest due as set forth therein), shall be allocated
by CSMC to satisfaction of the Liabilities. Any material breach by Licensee of the Conversion Agreement shall be deemed a breach of the
License.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.
<I><U>Other Provisions</U></I></B>. This Amendment is a revision to the License Agreement only; it is not a novation thereof. Except
as otherwise provided herein, the terms and conditions of the License Agreement shall remain in full force and effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4.
<I><U>Further Assurances</U></I></B>. Each of the parties hereto shall execute such further documents and instruments and do all such
further acts as may be necessary or required in order to effectuate the intent and accomplish the purposes of this Amendment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.
<I><U>Counterparts</U></I></B>. This Amendment may be executed in any number of counterparts, each of which shall be deemed an original,
but all of which taken together shall constitute one and the same instrument.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Signature
Page Follows</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;<BR STYLE="clear: both"></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the parties have executed this Amendment as of the day and year first above written.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt; text-align: justify; text-indent: -32.3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Cedars-Sinai
    Medical Center</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Kairos
    Pharma, Ltd.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.36
<SEQUENCE>11
<FILENAME>ex10-36.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
10.36</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THE
SECURITIES REFERENCED HEREIN HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND HAVE BEEN ACQUIRED FOR INVESTMENT
AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH SALE OR DISTRIBUTION MAY BE EFFECTED WITHOUT
AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL IN A FORM SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION
IS NOT REQUIRED UNDER THE SECURITIES ACT OF 1933.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>PROMISSORY
NOTE</U></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$[&nbsp;&nbsp;&nbsp;&nbsp;
]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
[ &nbsp;&nbsp;&nbsp;&nbsp;], 2024<BR>
California, United States</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
value received, Kairos Pharma, Ltd., a Delaware company (the &ldquo;<U>Company</U>&rdquo;), promises to pay to Neil Bhowmick (the &ldquo;<U>Holder</U>&rdquo;),
the principal sum of $[ ] (the &ldquo;<U>Principa</U>l&rdquo;). Interest shall accrue from the date of this Promissory Note (this &ldquo;<U>Note</U>&rdquo;)
on the unpaid principal amount at a rate equal to 7.5% per annum, computed as simple interest on the basis of a year of 365 days.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1. <B><U>Basic
Terms</U>.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) <B><U>Maturity</U>.
</B>Principal, and all interest accrued under this Note, shall be due and payable on April 30, 2025 (the &ldquo;<U>Maturity Date</U>&rdquo;).
Notwithstanding the foregoing, the entire unpaid principal sum of this Note, together with accrued and unpaid interest thereon, shall
become immediately due and payable within ten (10) business days upon: (i) the commission of any act of bankruptcy by the Company, (ii)
the execution by the Company of a general assignment for the benefit of creditors, (iii) the filing by or against the Company of a petition
in bankruptcy or any petition for relief under the federal bankruptcy act or the continuation of such petition without dismissal for
a period of 90 days or more, or (iv) the appointment of a receiver or trustee to take possession of the property or assets of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) <B><U>Payment</U>.
</B>All payments shall be made in lawful money of the United States of America at such place as the Holder hereof may from time to time
designate in writing to the Company. Payment shall be credited first to the accrued interest then due and payable and the remainder shall
be applied to principal.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) <B><U>Default</U>.
</B>In the event the Company fails to repay the Note in full on the Maturity Date, the Note shall accrue interest at default interest
rate of 10% per annum (the &ldquo;Default Interest&rdquo;). Such Default Interest shall accrue until such time as the Loan and all interest
thereon is paid in full.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2. <B><U>Action
to Collect on Note</U>.</B> If action is instituted to collect on this Note, the Company promises to pay all of the Holder&rsquo;s costs
and expenses, including reasonable attorney&rsquo;s fees, incurred in connection with such action.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3. <B><U>Loss
of Note</U>.</B> Upon receipt by the Company of evidence satisfactory to it of the loss, theft, destruction or mutilation of this Note
or any Note exchanged for it, and indemnity satisfactory to the Company (in case of loss, theft or destruction) or surrender and cancellation
of such Note (in the case of mutilation), the Company will make and deliver in lieu of such Note a new Note of like tenor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4. <B><U>Miscellaneous</U>.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) <B><U>Governing
Law</U>.</B> The validity, interpretation, construction and performance of this Note, and all acts and transactions pursuant hereto and
the rights and obligations of the Company and Holder shall be governed, construed and interpreted in accordance with the laws of the
State of California, without giving effect to principles of conflicts of law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) <B><U>Entire
Agreement</U>.</B> This Note constitutes the entire agreement and understanding between the Company and the Holder relating to the subject
matter herein and supersedes all prior or contemporaneous discussions, understandings and agreements, whether oral or written between
them relating to the subject matter hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) <B><U>Amendments
and Waivers</U>.</B> Any term of this Note may be amended only with the written consent of the Company and the Holder. Any amendment
or waiver effected in accordance with this Section 4(c) shall be binding upon the Company, the Holder and each transferee of this Note.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d) <B><U>Successors
and Assigns</U>.</B> The terms and conditions of this Note shall inure to the benefit of and be binding upon the respective successors
and assigns of the Company and the Holder. Notwithstanding the foregoing, the Holder may not assign, pledge, or otherwise transfer this
Note without the prior written consent of the Company. Subject to the preceding sentence, this Note may be transferred only upon surrender
of the original Note for registration of transfer, duly endorsed, or accompanied by a duly executed written instrument of transfer in
form satisfactory to the Company. Thereupon, a new note for the same principal amount and interest will be issued to, and registered
in the name of, the transferee. Interest and principal are payable only to the registered holder of this Note.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>[Signature
Page Follows]</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the Company has executed this Promissory Note as of the date first set forth above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>the
    company:</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">KAIROS
    PHARMA, LTD.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">John
    S. Yu, M.D.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>12
<FILENAME>ex23-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Exhibit
23.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center; text-indent: -0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><U>Independent
Registered Public Accounting Firm&rsquo;s Consent</U></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
consent to the inclusion in this Registration Statement of Kairos Pharma, Ltd. on Form S-1 Amendment No. 3 (File No. 333-274805) of our
report dated April 30, 2024, which includes an explanatory paragraph as the Company&rsquo;s ability to continue as a going concern, with
respect to our audits of the consolidated financial statements of Kairos Pharma, Ltd as of December 31, 2023 and 2022 and for the years
ended December 31, 2023 and 2022, which report appears in the Prospectus, which is part of this Registration Statement. We also consent
to the reference to our Firm under the heading &ldquo;Experts&rdquo; in such Prospectus.</FONT> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
Marcum <FONT STYLE="font-variant: small-caps">llp</FONT></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marcum
<FONT STYLE="font-variant: small-caps">llp</FONT></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Los
Angeles, CA</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
30, 2024</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>logo_003.jpg
<TEXT>
begin 644 logo_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !% )T# 2(  A$! Q$!_\0
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MXS\,>'=3L_AM\/\ _2&U2Z@VM>NK>;M3_:9D153_ (%63I>]*+C^[_F#F_\
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MQAX'AM)?B_\  #5/#G@R^D6WEU#S1<1)G^^C)M;_ ':]#TS]HWP_)^UIX?\
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M6I&GRJ3L85*-.4[N)Z5@>E+116)N%%%% !1110 4444 %%%% !1110 4444
#?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>chart_002.jpg
<TEXT>
begin 644 chart_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" '6 X0# 2(  A$! Q$!_\0
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MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#Y'_X+ _\
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MT'QWXEA\):S9ZQJ5IX=OKR'2%6XL]3N;6^MWMZ^&KC_@L-X'^.J^+[#]J+X
MZQ\3_!OQ]_9;^ GP!_:!TCPA\?E^'-OXG\6?LN^//%/COX=_%7X)Q6G@O4=
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MNHVWB>_\<Z+XF75]2M[FQLSX8;2[C1+Y-4-W:>S?$W_@M%X:_:D\+^.?A?\
MMK?LN^(?CG\*/B_\(?@#H?Q1M/#/Q]O/AY\1F^/OP&^('QA\=6GQC\!^,AX"
MURPT3PSXLL_B\_A"^^&GB#1/$L>AZ'X2T!-'\1[3=6S?%8_ 9U#,<72P7"G#
M\LKA5J+#X[^S,EK8J=!4\ DX8*M5PCJ5X5/KU6E&K.C3KIQI2E3]@IU?7H5L
M$Z%&>)S3'4ZTDO;4UB,5&$'S5EK-0FX1DG1NVI*-I24GSJWT5X1B_P"#EC7/
M%'Q&\&7_ .U)\;O"GBGX7?%[1/@3XBT/XD_M5_ +X<7FK_%+Q3X-M?B%X/\
M"WP^;QKXAT:U^)<OC7P7=+XD\&WG@>YUNS\3Z;!J#Z5-</INH):\%HW[3/\
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M91GS)>B:7\</^"W(^(_C/X4:E^UI\:+;QI\//V??^&IO&5IJ/QW^&MAI&B_
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M2>]^'6O6^AZ+KV@WD>M0?0LG[!?[$'B#PKH5]\)[W]J+1M?\<?\ !+CXO_\
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M5&>-C.>&A7<(NO2A52C5I5.2-.?,OD/_ (;J_;%)R?V@_'?&/^77PAQU[_\
M"+\]#WQSV(R%_P"&[/VQL_\ )P?CKGK_ *+X0P,#G _X1@'@]?H?6NT^)_P"
M^#_P?\!Z3/X@'QN\9>/OB/IGQ5U[P%>> [+PS-X#\+6W@OQCJWA;PQH_C.[U
M"(W^HZA=K86L_CR:Q6";PQ--?1V>GWQBMEE]QO\ _@G;:^'O'O[+WAGQ%J?C
M>WTGXF:SJ'@#XR7K::--;P[\18/AI_PL?3_^$'N;W2UM]1\,7<37GAV;4BVI
MVR:WH&H6,%W+>&Y@L=)YSX-TL/AL56X9R##T,>LVEET\1P=DM)YC2R7 UL;C
MJ^$@Z52LZ2>&Q&!PSQ-' U,5F=)X*A1DYT\145/)O%^M6Q%"CQ!Q!6K8)92L
MPA2XNSN:R^IG6*I87 4\;452%"$Y0Q.'QN(^KXC'T\+EM2.+Q%6'+4H0^6O^
M&Z_VQLC'[0GCOCKFU\'^N.?^*7/?'YX^G1>$O^"A'[77A7Q-H?B*^^+NM^-;
M+2;^*YO/"7BJS\/+H/B&U 9;G3=2ETOP_:ZA:QW,+,([RRN%GLKA8;J-)?*,
M,GQ>BW"A/M,,]O*T88PSPRP2IOP1\DR1N,[B0Q4 @JXX;%!!X]=RGD$C)!SD
M>O/U-??/@7@;$4I1EP?PK.CB*-I>SR#**;G2KTHW<*V'P<*M-NG7BX5:->%6
MG)J=.I3J0C*/PL>-N-L-7C.'%O%%.OAJR:Y\^SBK&-:A5G95*.(QE2G4A&IA
MWS4ZM&<*L8RC4IU*=249?TK^+/V@M>_:A^ 5I\0?V<_B-XA^&6K6#0Q^)3I<
M.DZAXI^&WBB..1I-&\;^'[G3M2B\0>$+O+H]]HJVEU<:0\7BGPS=:A>:;-X:
MU/\ '?Q9^U_^W)X%\0ZEX5\4_'7QYI>NZ3)";FW6W\&SVMS;7<?GV&J:7?1^
M&#!J>BZI:XN-*U6U:2VO;=BR,LD4\<7AOP/^-_CS]GWQ]9>/? =^HF5!I_B3
MPU?/*WAOQOX=E<FZ\.^)+&-BMQ%N_P!)TR_B3^T="U)([[3I4S=VUY^K?Q)^
M&'PN_;+^"EE\9OA?:WNB6-O)K5ALO--EEU_X1^,[8Q7?B;P[J5O:(S:_\/I=
M4OH-2UVQT!KN,+>3^-?"%K+XHO-7T77?P>MPYDW@_G<:>?\ #^4\1^&N?X[V
M>"SS,<ARO,<VX1S*O*2IX',,55P6(Q6,R^5&G4J>TFZKK4</+%X94\7ALPP.
M+_>Z.?YMXRY(YY!GV:</>)_#^ ]IC<AR_/,SRW*>,\LPRA[3'9;AL-C</AL%
MFM*56$9Q4:&'6(K+"5I8C!ULMS'+_P ]?^&Z_P!L7_HX3QWSG&;7PAZCC'_"
M+CIGUSG(ST-(/VZ_VQN_[0GCOL<?9?!_7H?^97R.3Z]N>>*^<?$_AG7/!GB3
M6?"?B>S33]?\/:A-IFJVD5S#>0174#?,]O>6Q,-U;3(Z7%K<)L\ZWDC=XX92
M\2<RM[9$H$N[9B65,+<1DM(P?8J_-\S,$?:JD[MK 9VG'[S2X+X&Q%&EB,/P
MEPE7H5Z5.O1KT>',DJ4JM&M3C5I5*=2.6.,J=2C.%:$]I4YPFG9Z?@-;C'C/
M#U:E&OQ5Q71K49U*56C5XCSN%6G6I3E1JTIP>8\T9TZU.=&<&KQJ0E!ZI.7U
ME)^W?^V%%')+)^T+X\"1QO(_^B>$&(1/F?"CPL2<*&('5L$8YKZC3Q'_ ,%2
M)7\*P6WQ9UN]G\7WOA>PTNVL/''P3O+VRG\;^'-1\5^$#XEL+>"6^\*V_B/1
M=)OY])N_$%MI]M>30I:1R"YGAA?\IIIK:42VQNH$DE#6H431[UFEC/[O9O#&
M3:5;RQA]I+8QC/W8?V]?&T_Q2^"GBIC?M\-O@U8>!GA^$%MK^A6>GZ]KW@7P
M1J'@VX\17_B&Q\+P:K<O<W&HR:E;66OGQ!9>'I?,AT]896>XKY7BC@R%-X&/
M"/ W -=^SSFMF"S/A?)*O/\ 5LOY\JP>$C"EA:L<9CLQG&E2G)/"VIS6+J8>
MA[T_J.%^+I5/KW^MG&W'E!>TR2EE_P#9G$^=4^6.(S'ESC%XR56MB:,\)@LN
MISK5(QG#$J4Z<L'2Q%7W:?6:!\<O^"C'BD_"E?#OQA\:ZJ_QL\3^-_!_PV2V
MU#X:O)K6O?#G5)=(\9PWB?V+NT.TT:Z@FDEU'619V$]BDE];3RVREQMV'Q1_
MX*17:?$VXN_C7K/ABW^$?BF7P+XXU#QMXL^$7@[3K?QG#:3:B?"^CZAK^G6=
MCXAU>73(5U."#2)[B.;3[O3KJ.5H]1L_.XO3_P#@H)KLGAWPW>>-/#%K\3OB
M-X)\/_&[PSHOC[QIXFMWTB*R^-7B#2+J5-3T#0=(T>:8>'O!-G/X*LS;ZY97
M5Y9WRWWVB%HVMY^BM_V]/#3Z_P".?%NH?!J\N_%GQ#\&:)I'C_PU%\28I_@]
MXYU[2_"E]X/77?&'PJUGP?J]O>6UU ^G:@\T6IV_BB=],33Y_%<]A*]M7R>)
MR'B6,L3"EX0\#<M.U*A6H9#POC%5K_VY2K3GAJ>(K9=*6!EPW4>$I8W'4Z<H
M9O&MC,3EOL%2HKZG#YWP[.%!R\5N.I56Y5*U/$9YQ-A(T,,\BJTJ?UFI@XY@
MH8S_ %DIO%5,+@9R4LH=/!4,P^L^VF4/'WQ__P""@/PQ\->&_%/C/]H.^T^Q
M\66'AS5-&TNR\9_!W6?%ATKQ;X?NO$WA_5M2\&:397?BC1M*O]'LI9O[1U;2
M[.SBN'MK*25+JZAA=OQ.^/G_  46^#-OX-F^)WQ:^('A%_'NB3>(?#5A>O\
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M7X=JY5E\\AXEP-.[G@JN63I1P-+,W1E4IX>O"C0>*7[NM7H8JG@<5+]2\/\
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M*OLZU*7$N=3C.$XQK8?$T:L,Q4:V%Q>'J4L3AJT(Q52C47-"E4IUJ&'^J?\
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ML-$3P_HVLRRZDE[J44DL=XEI;B!7=)VD41-X'B#Q;PSFOB;PCG&6YW@,9E6
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MA\KG3I0PU&O'R?\ ;'UKPAXA_:F^-6M_#_6/#7B+P3?:WX5;PYKG@R[TF_\
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MC%=?$_Q-97MU\.?A8^H(VK:Q>2(EMJ'Q'^)=]:+YSPM-%%!J.IMLABM;;3_
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M- ?&A@75M3DA\$@-XC]-^!G_  3\U:^\=6%SXCENO%UK9-#-8Z1?>"]7\/\
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M&F#6VE:8C@/=7C(D4NM:]=C^T-<U --(MK81:?I>G>*KU_ \GJ1P<]>G)QZ
M8[<?= _8/\:YQ_PE6H?4_"SQIZY//G<Y//US^"G]A#QJ/^9JU \8X^%OC4\#
MI_RV]Z_8,N\6/![*<#A,MRSB;*,OP&"H4\/A,'AL!G%.C0I4XV48I9-S3D]9
M5:]5U*^(J.5:O4J59RDOQK,O"/QFS?'XO,LSX3SO,,PQU>>(Q>,Q.,RBI6KU
M9MMRDY9TU"*34*=&FJ=##THPHT*5.E",3X8/0_0UV?A'XF_$7X?J8_ _C3Q#
MX5B.O:5XI*Z'=1VP/B/0[.^L-)UD[HI";VPM-4U"UA#9@,-W(DT,P*X^L_\
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MI;_]^5_PH_L;2O\ GTM_^_*_X5L44<K_ )I?>_\ Y(=_3[C(&BZ81D6EN?\
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MC/\ =_GS]*7[%;\?Z,G.?^62<<]_E_+V]JOH,*O3IVZ4ZOUB[_FE_P"!3_\
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M0_ROC&+2:4;;*R35DVE9J-I1LO=DM)QY9+22,S[';_\ /L/^_2_X4HL[?/\
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M8^G54:U2?,Z2WBDP6B5R5ZLH;CC YSZ9(Z<5#]BM\D"W7ZF)?\/Z\UH_Y_\
MU45]+>724DNRE)+\)K\OO/REQ3Z+YI-W_P# 7J^NNO4S/L<'_/LN?^N"8_+'
M]:46=O@_Z.HX[PKS_P".\GT[\\$5I447E_/+_P "E_\ )BY%VC_X"O\ Y$S!
M9P9_X]U_[\K^N0>/_P!=!LX.OV9>_6%3Z>PX]/TQ6G11[W\TO_ I?_)AR+^6
M/_@*_P#D3--G;_\ /NN0?^>*X(Y] /;KU]*/L< Q_HR'Z0IG\?EXZ].?K6E1
M1>2^U+_P*7_R8<B[1_\  5_\B9WV* =;=..>(D(/7/!7 / XY//7 IOV.WX_
MT9>/^F*_X>OKGT]ZTZ*+R_GG_P"!2_\ DPY%VC_X"O\ Y$S?L<'/^C)_WY3Z
M<<<_AC-'V.#G_1TR ?\ EBF#CTX__7_+2HH][^:7_@4O_DQ\J[1_\!7_ ,B4
MXK>-,[(EC(P.(U7()!/IGIW]>2>*;):0,^XP*6/\10-[G)(/<GGODYR.*O44
MK.]^9WZ.[NOGS7_'[M;G*K6M&W:RM]UK?A\S,^QV_/\ HR_]^E/_ ++_ "-.
M^QV^!FW3J!_JD].,_*>!T.2>:T:*=Y?SR_\  I?_ "8N1=H_^ K_ .1,[[%;
M\_Z,G7_GDGKV^7I^F*3[';\_Z,IY[0IC\/E[X_$=<UI447E_/+_P*7_R8<B[
M1_\  5_\B9HL[?\ Y]EY/>%/_B>!]*!9V_\ S[+U'6)/_B>GK6E11[W\\O\
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MF?QYQQ]<'\N<^F#1GC(Y^E "T4@((!['D9XX/0X.#S1D?YS_ )QSR>@YST-
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M"V^('@&^\71:CI_[3VJ^(/#^W7M%'@_QMX%\)^(%.MP_:M-4#?\ K^OZ[;K
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M^(_[/?Q1_:+^%'[/FM_'#X?>)?"WA?7/B/XH\(:?<P/>0I9_V]IOA/Q-XO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?V@_\1D7Q _Z1N>#O_$RM?\ _H4:/^(R+X@?](W/!W_B96O_ /T*-?Q@;O\
M=_[Z_P#K4;O]W_OK_P"M7J?\0VX-_P"A56_\.>8?_)G+_K#FO_/VE_X3T?\
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MG[&'[%_QG7Q7J7PR\0:1>?"_]G+X3?LO^'?#_P"TM\.]:TW5O$MA''\4+O\
M:#L_@IX#\*6^KVMGKWA;P;^T)XKUF?P]K=]\&S)J7ZCZ-^W_ /LM:UK_ ,4O
M#\'CO5=/N/A#X:_: \7^*]6UWP!X^T#PUJ'A[]E#XCO\(_VE=0\%^)=7\-V>
MC>/$^"7Q&?3?"?CQ/"5YJ[Z7JGB'PXD2W,6LVDK_  Y\6OV@/$W[/W@S]E[]
ML75OA%\-? ?[4?[>?B/P5\&_'\OQ9\?_ !:\3^!O@%X$TK]F?]HK]J?0O <,
M7A/1/$VJQ3:8WPAM?!/B^'X?>$-&TCQ!\2O%.J_$#4+74=/TFSLI@#RKX[_M
M2_M%_ #X^_MN^&]4^/'C>QTS6_C=^RYI?P7\/:I\%O"5WX=^#OP;^)/P0M9-
M=^)NA_$/QYK^@^!=(\&:Q\5O WC/X5KXU\2V?Q!T6V^,SVG@R3X>ZWXT^(&@
MQ0G@S]M[_@H;\1/AOKWQ4\/_  \TFUU+X=_L%?LL?&Z_^$MM^S1\5M1\0>-/
MCM\>?CG^UE\(_B?J\W@ZY\6VOQ5O?"GP"\ ? [P_\;;_ /93\#6-G\=/'NL7
M6F?#O3?B?H%QK5G;^(/<?A5_P5D;Q_XN_P""=MEK?P=T?PQX!_;J^&_Q(U[5
M?'FC?$@>+O#_ ,+?B!H?BO0_!WPHT:VU.Y\)^$;CQ/X)^-/B&ZO]"\)^)M9T
M+P3XGMO$>M?#_P +^(O V@>*_$\N@6'S;\2/^"J-S\=OA1X_T.Y^%WPE\%_#
M/QE^W'\0?V/_  YXN^,OQ1^+'A?PYXL^#OA[]D/PC^U7X+^,4>L?!GPM=_$#
MP[K_ ,4HO$-C9^$+/PY/ ^@:5/I?B2'7[Z[6*VN0"GX@_P""AO[36D>#?BO:
M>!OB;HWQA\">!/VH_@-\)=:_:H;X 3?"74_AG\!OB9^S;XE^+?B#XM>(M&\?
M:EIGPJUFYF^*ECX.^$.A?%V[T/0_@GX63XB66O\ B+PSK1\&>((=6Y>__:._
M;#\63V?B_P",6OZ7KD7Q._8X_92^(/A3]G"Q^#'Q#L?A3XR\3V_[;T_@WQO\
M8_!]MJ<NA?$WPUXBM_A;?_#7XK^*_ACJ>O:_=_#=O'GA;0]9\3^/?"7A.T\3
M>)_N;X"?M"_"C]FOX ?LM_$/Q%^SM^T)X!\<?MY?%_P9X3\1>'M0N/BA\?\
MXB:/\3?$_A^]T?1_$?Q/^(WQ*ATGXC77P_MO"W@K28/!-[XK\,^$?%=IX'G\
M/17GPK\&:C;^(?#FB?9?PI_;2_9U^-/Q(F^%WP[\97^K^([O2O'7B#PCJ-UX
M0\6Z-X.^*?A_X6^+='\ ?$WQ#\(O'&KZ+9>%/BAH?@#QGKV@^'O$NK>#=6U>
MRMYM8TC4;.:]T+4K#5;@ _,+Q!^V%_P4+\+Z-\8?B)H7A3PM\5;G4M(_X*TV
M7P9^".G_ +/GCX7_ (7UG]A/]J#Q)\(_V<M7O;_PQX[G\8_%N^^,'@.VD\8^
M*?!.CVOAS5/BS#8^'-'^"4'A35Y]1U+Q;]*?L _M0?$KXT_'+]IKX4^*OC#H
MGQY\ _"3X7_LM^-OAQ\3X/V=/&?[.'B;7;SXS:C^T3:^.[;7=$\6:K-8>-]-
MTG5OA7I^G>'?&'@?P]X9\+Z<EOJ?P[U6+7/B1X#^('B'4>=/[<WP^\8_"?XW
M:?\ M?/\,/"/P676O^"D'P_^)MYI&O?%O0_%:_!;]FC]K3Q'^RAINI:?X>\)
M^&?$=U??VYX/NM(E^('B[2OBKX*\3:1XPU6TF\ >!+K3;ZXG\)7?V:_VC?V%
M?AOJ/Q6\'_ >[\?P?%+Q/KOQ"O?B%K'Q^M/VACXB\1?&7X'?#+3M0UCX4_$G
MXN_%C0/&?BZQ\6_#OX1:3X9UV+P%$FMWOAGX97-OXK\-^%-3;5[H:J ?K317
MQ3^RI^VUX(_:D\0_$/P/H/AGQ+IOB?X3Z!\%]5\7>);'1O$^H?!;Q-/\9/@C
M\,_C9ID_PE^)GB#PQX-O_&&@VND_$S3;"VF\4>"OA]XNU"&S?6[CP3I>G7=O
M7VM0 444AQW]1CZGC^OY4 +17R7\%_VV?V?_ (\^,I? 7@+7?%,?B2XT_P ;
M:UX8M_%GP]\;^"M/^(7A_P"''C*/P!X]\0_#76_$VAZ;HWCW1_"?BZYL=)UR
MY\-WU_)8-J6FWD\(L+^VNI/K#S1W60?6-OS/' ]ST'7% $E%8FH^(]!T:[T#
M3]8UK2M)U#Q9J\_A[PK8:GJ%I87GB;7[;0M<\4SZ'X>MKN6&?6M7A\,>&?$7
MB.73M.CN+R+0= UK5Y($L=+OY[?7\P<C;)D '_5MSGT.,$^H!X[\T 245B:3
MXE\/:^VK)H.MZ3K<F@:Q=>'M=32-1L]2?1-?L8+6YO=#U9;.:9M.UBSM[ZRF
MNM,NQ#>V\5W;O-"BS1EMI6# $9Y]1@@@X(([$$$'WH 6OBK]L3X6_$CQWKO[
M)'CWX;>!O#_Q-NOV>OVC_%/Q7\4> =>\2:9X57Q1X5\5?L>?M9?LXO8:=J^L
MZ?J6DI<0^(OCUX<O]5AO[=DF\+V?B$6\=[?"UTR^^U#R"!WX_/Z5E:S=ZC9Z
M;>W.DZ=%JVHQ6DTMEILUZ--BOYXU+1VK:@]O=1V9F)V+-+;R1*[+YA1-SA.2
MBI/5VC*5HQ<I6BFW:,4W)Z.T4FY.R2;:N)7:5XJ]E[TE&*U6LI-J,8]Y2:45
M>3:2;7X=R?L-_MH_#CX0:WX6^$/BSPIH.N75_I?C/P?X$^'OC[Q5\/OA9X/\
M0^*OV@_VZ?C1K_P9U+4?#;?#3XGZG^SG\--*_:+^#'@30[CX:>-?@SXQDLOA
M/I7C'PAX;T>ST$_![Q3Z7K/[/?[:KVNM)J=Y\0O&TT'Q:\2>(/'BZ%^V3\0_
MAB?C_P"#]6M?CFGPX@^'4^@+:-^S%;_"[4/&/PINO%6D^#%T.+QK%X2DMY;/
MQ%%X*\,P^)>U^,W_  4K\0_L\W<]O\4/V+_VA-.TVV+M)XGT+5_A=XK\*F)3
MAIVUS0?%UW!9PH-IE?4UL/*^ZX5P4'S@G_!>KX)21K-%\ /C5)$R965-6^&C
M*PP""&7Q:P((]"??&.?S_,?%/@+)\5/!9MQ%1RO&0<E+#9C@,YP5:+C>_N5\
MFA%JR<KPJ5$U:47*+C)_L&1^ /C%Q-EU+-N'.!L?GV65DG3S#)\SX;S+!RND
M^5U\)Q)65.HDTI4JU/#UH-J,Z<)WB>@ZG^RU_P %-G\.:_8ZU^U7;>,=4\/_
M  \^!D=AJ6AZUK?A*3XU>//$&L?!S6_VSH-<\/Z.W@FU^&.ES_\ "DM0TG]E
MO_A!_&?AF7P7HO[1/QFT37M7L;<>&M2T7G?'OP=_;E^#?P>M_'.F?&/XU^/O
MVCX-._9<^'OP0\-0>)?'_P 1?!M_XJGE\6Z)\8_#'Q<T#PWHFJ>";3P]?>$?
M%]SIMU^T-\5;?4$T?Q/X!^'OQ2\;^-=2\1:-(WBK!_X?U?!/./\ AGSXUY'4
M?VG\-\CMC!\6=>:3_A_3\$VS_P 8^?&O '/_ !-/AKWR".?%?3'7V/0C..%>
M,_A?_P!%IE%KV^''_P#SKO\ @>P_HP^/Z3OX7<1;7_BY+]__ "/FOQ?8_;KP
M/X>O?"/@SPIX5U#Q#JWBS4/#?AS1-"O_ !7K]S+<ZYXGO=)TRUL;SQ#K$\]Q
M<RR:GK5S!+J-ZSW$O[^Y=0[  GJPS#^Z?J1G^=?@Y_P_G^"G_1OWQKSW_P")
MK\,\8[?\S;]<\=A^!_P_G^"W/_&/GQL_\&GPUY(SQ_R-?X?SQ1_Q&?PN?_-9
MY3_X#F/_ ,[#/_B6/Q]_Z-?Q%WUJ9*OSSY'[Q98G.0.1_$,?EFGY'<KZ\<=L
M>ISQ7X)G_@O=\%!C/[/?QMYZ?\33X:<Y_P"YKS_7VI__  _K^"O_ $;W\;?_
M  :?#7_YJJK_ (C%X8NS7&.5>5HYA^N6A_Q+'X^+?PQXA7K5R3[_ /D?,_>@
MX)P&QC]<\]<__JIIR.CY_P"!8_K7X+'_ (+W_!)<AOV?/C<"!DC^T_AJ3TSV
M\58S^-0_\/\ 3X)?]&]?&T=.NJ_#0=>W_(U]?I37C#X9MI+C'+'K:W)F&OW9
M8V0_HT>/*=O^(9<0+_N+DO\ \_C][OF_O?\ CP_QH^;^]_X\/\:_!'_A_G\$
M_P#HWGXW?^#7X9__ #64A_X+Z_!,9_XQX^-YQDD#5?AGD8&3U\6 <#DX.<=
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M+!-3NTN%FMHHI_S>UK]EW_@IGJ6@^--&\"?'R^^%WQ%U6RN;!_C-X@^+^O\
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M3ZT_Z!U[^=O_ /'J ._HK@/^$^M/^@=>_G;_ /QZC_A/K3_H'7OYV_\ \>H
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M0;W]C?W'@_X:^%;Z:5G\/?#?PS9Z=?S6K',%IJGCC4X[_P 87BPH%A==(O\
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M-#9OI[_6VYR2B[.\9;/[$^UOY'IT(6!+RG(XD88P/;IGH.>!^'>H0,<<C@<
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MT<.DY*RC:[NER_S1\^GW'CXN_P"];3VCNI77PKJK_E>_F4)E 7GKAR,DXR
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M6/\ ;'BSPMH]MXN^".E>)&^+'P8&J0^"+KQ/X#@^(/@30?#?COX8:UX/\9>
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M>\.;6_Y(GA[\KV/XE!_P33_:1Q\VG6&1T!L];XZGM9KQSWSGCGTC/_!-+]I
MC!TVP&>1_H&ML,YQR%LAZD9SUK^V_P#LK3O^?.W_ ._,?_Q-']E:=_SYV_\
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M'7<Y("X'^A'@!01@=21T%?W(?V5IW_/G;_\ ?F/_ .)H_LK3O^?.W_[\Q_\
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MQ5:3_@DS^U"X"A=&!7.,Z;XAQWX^:R( ZXPH!]>]?W=_V5IW_/G;_P#?J/\
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M>F%(J2?\$@?VJI<C=X<&<\C3?$I)W8()Q8X&, ,..O !Q7][W]E:=_SYV_\
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M7^R_%N#UP,?V7DCU^;/IC  _T&/[*T[O:6_XQ1_0#E?P _ 4?V5IW_/G;_\
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M/^$&U+_G]M?^^)O_ (W7JE% 'E?_  @VI?\ /[:_]\3?_&Z/^$&U+_G]M?\
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M'F$8QU?!]_\ 'H?ZBB@".*)(HUC1$15 &U%5%R.I"J !D\]*D P,#H.!110
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M_94[?_YCZ:?^"]\P/'[,,A Q_P U6M@>@SQ_PA_')QW_ ,?(7CGX8/;B6_\
MW2L[O]SRQ?D?0OZ)WT@5OX?5O_$AX4_^?[/Z-_,]OU_^M2>8?08_SW_^M7\Y
M)_X+X3#.?V8)C]/BI"1CWQX-_D?0]*3_ (?XR]_V7YQ]/BG%SQT /@T\Y_R:
MI>.'AB_^:FBO\669S&_I?+E<A_12\?EOX?UE97TS_A;\UGUOD?T;[SZ#]?\
M&C>?0?K_ (U_."W_  7WF#!1^R[<'(R#_P +5@'&<8)_X0TCK[<<$U'_ ,/^
MIN,_LN3#D=?BO;D=>W_%&=<=/SSVIKQO\,?^BHIV_P"Q?F_ZY>B7]%3Q\6_
M%7_Q(>%?_G_^=C^D+>WH/U_QHWGT%?S<O_P7]G7!'[+<[9W X^*UOP5.,9'@
MS!Z^W7@'DA@_X. +CO\ LM2CI@GXKPCJ<8/_ !19'?C'IZ\5I_Q&OPST?^L]
M/6UO^$_-NOE_9]S)_1:\>(WOP)-..Z_UAX6;7JEGC_R/Z2=Y]!^O^-&\^@_7
M_&OYKV_X.!Y5_P";6IN!N.?BO!R._/\ PAG;U%1G_@X,E&/^,692<]!\5X^F
M1G/_ !11./I51\9_#:35N)J3OM_L&;?_ #O\OEU,W]%_QSBFWP-4TW_X7^&;
M+;_J=^9_2KYGM^O_ -:D\P]P/Y?XU_-,W_!PA(K ?\,KS<\_\E:@'''.#X)S
MW_/BH#_P<*RA6+?LJR<*QY^+D&#@9[>"0>?3!_/@Z1\8_#EWMQ'2^> S9?<W
MEZ3^5R']&7QP5V^!ZB2UO_;O#5OPSL_IBW].G3DX. ?3'?\ .D\SV_6OYEV_
MX.'95P/^&4ISP.5^+<&WZ<^""<_D.#TQS5?_ (.)I4VC_ADV9MQ(_P"2O0=,
M<'_D2.IZ=,9/:M(^+OA]+6/$$6M;/^S\VLTNJ_X3U?U6G0R?T:_&N/Q<%35N
M^>\-ZV[?\+6OG\C^G'>?0?K_ (T;S[?K_C7\Q$G_  <621E5/[)=P6.2!_PM
M^#( .">? WY\9Y[57;_@XU=64']DFX.2<?\ %W[<9 !SC/@8G/3)P#SWS73#
MQ6X"G&\<]3]U/_D79MU[/^S]?+<PE]'/QEA=SX.DDDWKG?#FRU?_ #.^B[M)
M]]';^H$OSQ@CK_/(_P /ZYIN\^@_G_7]>]?R\/\ \''TB8/_  R+<,"2#_Q>
M*U'3G//@(<@=>PZ]CBJ__!R04.W_ (9#N"?3_A<=KD'JP/\ Q0>.!Z''T K2
M/BAP-+X<\4M+W>7YJMW_ -@"_+_,YY?1^\7()N7"35DVV\\X;:26K;MGFFG]
M:G]2.\^@_P _C2AR<YQP,]#]!W]37\L4G_!RB\8S_P ,@3GJ3GXS6J$ $YZ^
M CG &3@GOT/%5G_X.660X'['MPPP""/C/:\@\]#X!Y['DXQSGM6L?$K@F?PY
MU&^EO]@S-=5U>!_0YWX$^*BO?A=72N[9UP^_P6<MOT2;\N_]4N\^@_7_ !HW
MGT'Z_P"-?RH2_P#!R^R%Q_PQS<,5 )_XO/:#&0&^9?\ A 2?7\N<$D53D_X.
M;'B7<?V-;ENXQ\:[102V,#GX?'D@Y)(QGW(SK'Q$X.E>V;Q=M[8+,VUK;;ZC
MJC&?@?XI05Y<+5+72NLRR>2UMLXYFT]]_D?U=[SZ#]?\:7>?0=/7\O\ ZXZ_
M3%?R;2_\'.YC.#^QE<L=H(_XO=9\9_A+'X>Y!R2!TY]P0*;_ /!T&ZG _8OG
M/7.?CA:C!!(Q@?#IB>AY (X.,@9K:/'W"4[6S7JK?[#F2OZWP*ML<L_!OQ)I
MWY^&:RMO_M^5.SLGTS+S1_6J7/' Z<]_\_\ UZ?G\L9S^7^/X5_(T_\ P='L
M@RW[%5UWP?\ A>-IAL'&1GX<@XQDY('3WXKR?\'3+H0I_8FN6X;!7XZV?\/7
M _X5MSG'J1UQZ'>/&G#,TG#,7)/JL'C[?C@TO^&.6IX5<?4/XO#]2.K5GC\J
MOHKO3^T>WX-']=U%?R!R?\'4\B#<?V(;@\L%_P"+[V@ P >3_P *UST/)VD9
M'8YJG)_P=:&)CG]AVZ)(R"/CS9C\.?AICCCGIGWXK6/%>0S^''7_ .Y7&K=V
MZX5>74YI^''&E/XLEFNG^^Y8];7MIF';[C^PCU[_ .>E(<]NV>/7TY[5_'7+
M_P '8+1AR?V&+ML%EP/C[8\X.#DGX9\'&.!QR3GI5"3_ (.RV0''["EV0N0#
M_P +^LP5.>A(^&+<]^ <8QCIG2/$N2RVQJ7^*C7CMIKSTHR3VW2OTN<D^!>*
MJ=^?*G&R<G?&9?LKW?\ OVEK/SLKZH_LC!Y_7'ITX_\ KYY].* >V>>?R!(_
MI7\P/[.'_!T?^R%\1)K;1OVB?AE\0_V:]<N)/+?7@TOQ8^&Z@N,3SZWX1T>#
MQA80!68RM/X$E9-@90T4@=/WA^#7[6GP4_:)\,#QM\ _B5\,_C3X2$HMY]>^
M&'Q \/>,[/3KIHA/_9^M)HD]U>>'M7BA8/=:'X@MM+UJQ.4O=/MW5E'IX;'8
M3&7^K8FC5=D^6-2*FM/Y9N$KM6:23=K/J>#CLIS++)<N.P6(PZ=G&<H.5.2?
M\M6DZM*2U5FIZ];.Z7T]17G'_"P >FF$_2Z!!XSP1"0>#DX)QD'N*7_A/_\
MJ%M_X$__ &FNLX#T:BO.?^$__P"H6W_@3_\ ::/^$_\ ^H6W_@3_ /:: /1J
M*\Y_X3__ *A;?^!/_P!IH_X3_P#ZA;?^!/\ ]IH ]&HKSG_A/_\ J%M_X$__
M &FC_A/_ /J%M_X$_P#VF@#T:BO.?^$__P"H6W_@3_\ ::/^$_\ ^H6W_@3_
M /:: /1J*\Y_X3__ *A;?^!/_P!IH_X3_P#ZA;?^!/\ ]IH ]&HKSG_A/_\
MJ%M_X$__ &FC_A/_ /J%M_X$_P#VF@#T:BO.?^$__P"H6W_@3_\ ::/^$_\
M^H6W_@3_ /:: /1J*\Y_X3__ *A;?^!/_P!IH_X3_P#ZA;?^!/\ ]IH ]&HK
MSG_A/_\ J%M_X$__ &FC_A/_ /J%M_X$_P#VF@#T:BO.?^$__P"H6W_@3_\
M::/^$_\ ^H6W_@3_ /:: /1J*\Y_X3__ *A;?^!/_P!IH_X3_P#ZA;?^!/\
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MXK_ #X7^!-<^->B_MP?$GQ%\'_&MQ^U3J_C.SUW]C#XX?!7PC\+/A+X4U?\
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M.3UQ[<8KIC)V7OO;^>7I_.CS<1'X_=VYK>[LKQVLNGIZ]S/D7"R$'.(R.O\
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M#?Y'Y7F/^_XS_L)K_P#IP?1117L'&%%%% !12$X_P_S^E .?\Y'X'O\ XYH
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M?#W]FWX%V/C/4O NE>-VMOBEX'UGQ7IG6_LY0_'S]HOXCR^#_AWXO_;)\/\
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MT"71/C=^T5^VC\3OC)^QU\8/%.H^./B+X3T+PYH&H?#[7[C4['QM'J&L:EX
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M  1>^-#%?^*@N\J3R=!L\G(P?^8D/<CH0>^.*_LN^SP?\\8_^^%_PH^SP?\
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MM'_Z"VG?^!]E_P#':_U3/^%B_P#!);_H^G]DS_Q)3X2__-G1_P +%_X)+?\
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M4:S_ ,)&MJ&,^90W]AD+$?(VLP\^DMK3Q$NISS7NKZ/<:0S3FTL;70;VSU*
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M>0722K!$ ;U%8,D'B :H)4U/2!HI90;#^P;UM4(\L#Y=9_X2-;12)07W'0V
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M&W>QO='ATA3#]IMKS2M0N=2DQ,_VI;?4(=7M;2 /$(Q;M+IMP(I SR+.I"
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M_H0?\&N__)FO@C_L,?%3_P!6IXQK^LD=/Q;^9K^3;_@UW_Y,U\$?]ACXJ?\
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MBU&]VFDP5KKF;4;KF<8N;4;J[4$XN;2;:BI1<FE%2BWS*]]H7<,2# QD;@0
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M_:17+Q+Q\1=0^7(]?* .>O0=2#G K!N?^"H?_!2!%F*_MQ_M*@K,R#'Q'O\
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M)I4]G+^XG<O]X#('!/O_ #YP?P'I2!UZEE'&,;@1U_G7X]_LP?\ !7+]B/\
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M_>7_ +Z'^-&]/[R_]]#_ !KPO^V=8_Z"M]_W_/\ A1_;.L?]!6^_[_G_  H
M]TWI_>7_ +Z'^-&]/[R_]]#_ !KPO^V=8_Z"M]_W_/\ A1_;.L?]!6^_[_G_
M  H ]TWI_>7_ +Z'^-&]/[R_]]#_ !KPO^V=8_Z"M]_W_/\ A1_;.L?]!6^_
M[_G_  H ]TWI_>7_ +Z'^-&]/[R_]]#_ !KPO^V=8_Z"M]_W_/\ A1_;.L?]
M!6^_[_G_  H ]TWI_>7_ +Z'^-&]/[R_]]#_ !KPO^V=8_Z"M]_W_/\ A1_;
M.L?]!6^_[_G_  H ]TWI_>7_ +Z'^-&]/[R_]]#_ !KPO^V=8_Z"M]_W_/\
MA1_;.L?]!6^_[_G_  H ]TWI_>7_ +Z'^-&]/[R_]]#_ !KPO^V=8_Z"M]_W
M_/\ A1_;.L?]!6^_[_G_  H ]TWI_>7_ +Z'^-&]/[R_]]#_ !KPO^V=8_Z"
MM]_W_/\ A1_;.L?]!6^_[_G_  H ]TWI_>7_ +Z'^-&]/[R_]]#_ !KPO^V=
M8_Z"M]_W_/\ A1_;.L?]!6^_[_G_  H ]TWI_>7_ +Z'^-&]/[R_]]#_ !KP
MO^V=8_Z"M]_W_/\ A1_;.L?]!6^_[_G_  H ]TWI_>7_ +Z'^-&]/[R_]]#_
M !KPO^V=8_Z"M]_W_/\ A1_;.L?]!6^_[_G_  H ]TWI_>7_ +Z'^-&]/[R_
M]]#_ !KPO^V=8_Z"M]_W_/\ A1_;.L?]!6^_[_G_  H ]TWI_>7_ +Z'^-&]
M/[R_]]#_ !KPO^V=8_Z"M]_W_/\ A1_;.L?]!6^_[_G_  H ]TWI_>7_ +Z'
M^-&]/[R_]]#_ !KPO^V=8_Z"M]_W_/\ A1_;.L?]!6^_[_G_  H ]TWI_>7_
M +Z'^-&]/[R_]]#_ !KPO^V=8_Z"M]_W_/\ A1_;.L?]!6^_[_G_  H ]TWI
M_>7_ +Z'^-&]/[R_]]#_ !KPO^V=8_Z"M]_W_/\ A1_;.L?]!6^_[_G_  H
M]TWI_>7_ +Z'^-&]/[R_]]#_ !KPO^V=8_Z"M]_W_/\ A1_;.L?]!6^_[_G_
M  H ]TW*>C*>W4=3T'6G5X4FN:TC*ZZI>%TSC?(KH2>N4='5A@#&Y6 R05;!
M!Z.R\=7D05-1LX[A5"AIK5_)E.",L87#Q/GDD))#U "@8P >I45SVG^)]'U%
ME2*[2*1AD077^CRY.T;5\S$;L#G*H[,>H7 -;X=2<9YP#CIP3@=?4\#U[=*
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MX=\#?LL>)F^(&H^&/V>_V8OB7^T3X'^-EK8>'OB!!-XR^(/BSQ-\-;KX:_\
M""^&8/"_@7Q_9>*_"^D>$3X7\:VD^L>(_P!S/)C#%@H!+%V()!9RJIO8@@EP
MBA0QY  &>!2^3$2"4!(^Z3DE1N5L*<Y4;E5B%P"RJ3RH( /R\_X)D_M5?%[]
MIG2/CK;_ !4N8O$-K\-_%_P_M?!/CU?#?@_P[/XLT;Q[\+_#GCK5;>Y7X9>-
M?B/\*]2_X13Q'JNJ>'K:;P'X[\6VVDVUM'X7\0^)?$GBG0-8\1:M^H]1)%'%
MGRT"\8"@D*!G(55R%50>0%  R<<DYCFG\IHU"AC(2%&>X!/8$G@<@ ]^PS2;
M25WT_K^M5;=M*[1_7]?U\F[)S2(K@A@".I!Z' (Y]L$@GTKC/$?@KPMXE@DB
MUC2;&[1E(W2PJ7!)/S9V]3NQCL".V17A7QM_;4_9G_9[2[7XJ?%WPCH.HP1R
ME/#6GWLGB7QG=2Q#YK6T\(^&8M7U^2XW,J$2:?#%$SJT\L41\T?CS\;O^"Z]
ME(+O2_V>/@S?W(*RQ)XP^,=W::;&7"O%]HT[P/X5U+59Y+8L8KFUGUCQ-87#
M+F.]T.W8[3\-Q'XF<#<*<T<YXERVEBH6E_9V#Q5/'YG*\N5)8+ U<1.FVG*S
MQ%;"65^:T6[_ *IP1X&^*WB1&$N%>!<[Q>6XB3IRSO,L#7R?AQ7LN:IFV;8?
M"X;$TM5S+ T,UE*-^6E5NHO[^^-__!-+]G_XP?:;N?PY966N2[BNJ64!L]7W
MGH\FH64D%Y,$R %N7N(]H("JS9K^=;]KC]DGX-?L_:EJ=GX:_::\$:]KEG=W
M-N?AW',?&&OV]S;2M#+9W.I^$!J)T6:%HY+>6'7K)Y[>X0+?7-N-Y3ROXW?M
ML_M3_M"B>S^)GQF\53>&[CS5?P+X1O9/ G@2:&4YDMM1\->&)["'Q);(0K1Q
M^+KCQ"('426WE.2U?)VV.$D1!%4$?*H4<E?[P(XSGW!&!P37\H>(GBQP/Q<J
MM/+> LMGC*EXQXCS7$4\NS2#3G:K3H<.XC"UJLKJ+4<UQ^*C[-*-2C/D:7^B
MW@E]'?Q7\.%A*V?^,>=4<OI.,Y<#<.87$Y[D$E>E*6&KXOC/"9A@L-2;C4A5
M_P!7\GRVI.+;HXB'-"=)LF2C>A(/)'&5<MR"00,=<\]?05"/XO\ ??\ ]#:I
MF<,F 0.2-HY(X*DXSUP><D9X&3BJF\J&^Z/G? )/]YCSQW[?GT.:_#X5:<FK
M5*;UM_%I?R[_ ,36^MWOZV;/ZSJTZC3M2K=;_P"SXE6U7_4.K=DDK+9:)$%U
MU'_7*7^:U7D[?3_V>.I+EB2O0Y1E. 2!N(SSZC;TP#[8YJ!WR&.0-JDCG[WS
M+@9P1GC)'89ZC)'7"45]J&MK?O*7_P M/.Q-*HH->RK-KFO:AB>CBO\ H'\B
MC+]X_P#78_\ HHU4E^\W^XG_ *&]3RN!N8G@2DY.,<H57N.H&>!W!'<53ED.
M<_*254$!AV9\<GCH03@]>G%=]"<%9N4+67_+REYO_G[YGDU:57EO[*OM+_F'
MQ';M]7O^! _4?3^IK%DZR_2Y_E#6H\H+?P@X& 6Z9Z@D C/X\>OID2,/G).,
M^?UP,A@F .3DG;A< YYY/0]]*I"Z?/#7;]Y2[W_Y^>3/&Q<)\TG[.JDZ=E>A
MB$[J6J:>'NMUNK:^MJ+_ 'S_ +P_]%BL9_NS?]<#_P"@&M:1P&.2 >">XZ;>
M#E2>!QQR3QFL>1@!(#WB*]LYV,,<D?-G  QSG/2O6P\HOF?/"TN6W[RE_>_Z
M>'B8BG45.2=.JFY+_EQB?7IAWIIN[(S+[_5C\?\ T"2L>;_7'_=3^4E:EY(I
M7&1P0,8)/.]3STS@].QZD]*R9VQ-GC& "=PQ\H;&._)8XXR?08->OAI1L_>C
MM':47U;WBY+\5V5SYO'4JB;;IU$GSM7I5D[<L>CI*7R<4_+:^->=6_WY?_1+
MUB2?ZE/]X?\ H4%;-VZDL1R-TA&.<YC9<=."<]#C!(!(ZG%F($:J"IPP[],F
M,@D,5.#MZ?7DXS7LX><.1+GC>RZVW;TU2_"Y\YCH3=.;5.I9R27[JM_=_P"G
M1BW/W!_N/_Z$*PI_O3?[K?REK<NCA0>,8*^G!;@]^I!X)'48YR!@W!^:7H 0
MPYSGD-@@ '.2Q 'J.]>SA)P4+.4$VXOXX?SRZ<U[Z]4CX_,H2YI/DFK0BG>G
M5O>[7_/IF#=?ZX?[P_\ 08ZP;S[B_P"]+_*6MNZ?Y]QP!OQD[L<*H],=1@^_
M3OC#NSG:H*_>D((.>"'QD<8^\.N.>"..?H,'))WO%IQ@DU*#3M4<G9J?;RUV
M1\AF$)W<G":24$VZ=56:;;O^[TLGK\SG[K[[?]=8/_037.7?^KN/^OB3_P!
M-=)=@*SDGC=&W!!R54G''0=CG'/3-<S=MQ,IP-TS-R5X!7!;.>5&3VS@$].G
MT.&DN9.Z2?)9N4+:2U_Y>=+'QV-3C)7C):3?PRVNW>UN;;^[=]$^N)=]9O\
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MM9MM66C2?*WJK*R4U%-WKZ_H?\*-Z^OZ'_"M#(=13=Z^OZ'_  HWKZ_H?\*
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MK*EWY<LRU-^MLO5_G<E\1<1-IOB+B%M=7G^>MZ[ZO.F]?4_&C_AS7^S'P/\
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M^-4?V%HG_0(TS_P!M?\ XU6K10!E?V%HG_0(TS_P!M?_ (U1_86B?] C3/\
MP!M?_C5:M% &5_86B?\ 0(TS_P  ;7_XU1_86B?] C3/_ &U_P#C5:M% &5_
M86B?] C3/_ &U_\ C5']A:)_T"-,_P# &U_^-5JT4 97]A:)_P! C3/_  !M
M?_C5']A:)_T"-,_\ ;7_ .-5JT4 97]A:)_T"-,_\ ;7_P"-4?V%HG_0(TS_
M , ;7_XU6K10!E?V%HG_ $"-,_\  &U_^-4?V%HG_0(TS_P!M?\ XU6K10!E
M?V%HG_0(TS_P!M?_ (U1_86B?] C3/\ P!M?_C5:M% &5_86B?\ 0(TS_P
M;7_XU1_86B?] C3/_ &U_P#C5:M% &5_86B?] C3/_ &U_\ C5']A:)_T"-,
M_P# &U_^-5JT4 97]A:)_P! C3/_  !M?_C5']A:)_T"-,_\ ;7_ .-5JT4
M97]A:)_T"-,_\ ;7_P"-4?V%HG_0(TS_ , ;7_XU6K10!E?V%HG_ $"-,_\
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M(98P01@8/4=B*T@ .@P,  #H .@ Z #T%+10 F!G/?I]?KZX[9Z<XZFEHHH
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M"$A$)3S+@LN8XF23:=P%']MJ-3&F'2]:R2!]O_LZ0Z6,QF3)O@VP 8V$[?\
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M=DR5*T66NQ7TEU&FFZW;&UC:0O?:3=V<<^TL/+M7F11<2$J2J1;BP*D9# T
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M0R7EG#?>?]BFNK97,UO%>?9;G[+),B)<?9Y_*+^3)MJ_VYHHUK_A&SK&E?\
M"0G3#K8T'^T+3^VCHHNUT\ZO_97F_;CI8OV%D=0\C[(+LBV,OG'90!JXS_GW
M!!^HQQZ4444 %%%% !4;N%XR >0 <\G' X![U(?;FL;6]%T_7].N](U>RM-3
MTS4;6XL]1TZ^@BN;*^M+B,QS6UU;S(Z30NIP\;#:V.0:F?-RRY$G/EDX*3<8
MN23LI2C&3BF[)M1DU>ZB[68K=;I75^5)NU];)M)NVUW%7MS2C&\EH12.P8LI
MSG ^20 #H3\Z+D9 SM],@<YI?,DWD;3MSP=DG([<A"/;DCZBOQI_:3_X)7>
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MY_"CS9O^>T__ '_E_P#BZ!GT*!C/7DYY.?\ (]NW:BOGKS9O^>T__?\ E_\
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MLW_/:?\ [_R__%T ?0N!UQR>I]<=**^>O-F_Y[3_ /?^7_XNCS9O^>T__?\
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MLW_/:?\ [_R__%T>;-_SVG_[_P O_P 70!]"_P"?\_YX[45\]>;-_P ]I_\
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MCH?W<H&>^.O&!CC\SD^_'TH _GL^'?C+_@JAID/PO\4^,?BU^T/XQ%A\/?\
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M.!T/\)Y)Q6)?:/I6I(\5]96]U')\I$\:/D'YB!O5PQP 3D'DD]#BOB#XV?\
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M]\]<^;'ZG@)(1CZGJ,],_6N1U2"WNHIH+F"*XMVWJT4\230.%E. Z2JT; #
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M/S8O[Z_G1YL7]]?SH DHJ/S8O[Z_G1YL7]]?SH DHJ/S8O[Z_G1YL7]]?SH
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M36X]1GN+K5[>ZTY_.^SZ;'I:VTMOODC: OJ O)6G\B-9(V'V:/SFD#DILVL
M:'V*T_Y]K?\ [\0__&Z/L5I_S[6__?B'_P"-UGV-IK<+W;7^M6]\DD96U2+2
M5M#:R%G(=V%[<&Y 5D785BW;,YRQ CM;+7XK2]BN]=MKN[FBVV-W'HZ6L=E+
MY;J)9;47TWVQ?,9)#&9X!MBV!@7+J :GV*T_Y]K?_OQ#_P#&Z/L5I_S[6_\
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M+_5?$NDZ )I8I=3UK3K%;B\A_%K2?^"2WC_P5INB6/AKQ!^S]XJ_X1?X4?L
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M3'XS,,;@Z2<IYEDV79-G&"C"*;E.I4P.3/%8:$8KFE+&9=0C'5.I[LI+^O\
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M1_PGMW_T"X?_  ,;_P"1:X6B@#NO^$]O/^@7#_X&-_\ (M'_  GMY_T"X?\
MP,;_ .1:X6B@#NO^$]O/^@7#_P"!C?\ R+1_PGMY_P! N'_P,;_Y%KA:* .Z
M_P"$]N_^@7#_ .!C?_(M'_">WG_0+A_\#&_^1:X6B@#NO^$]N_\ H%P_^!C?
M_(M'_">WG_0+A_\  QO_ )%KA:* .Z_X3V[_ .@7#_X&-_\ (M'_  GMW_T"
MX?\ P,;_ .1:X6B@#NO^$]N_^@7#_P"!C?\ R+1_PGMY_P! N'_P,;_Y%KA:
M* .Z_P"$]O/^@7#_ .!C?_(M'_">WG_0+A_\#&_^1:X6B@#NO^$]O/\ H%P_
M^!C?_(M'_">WG_0+A_\  QO_ )%KA:* .Z_X3V[_ .@7#_X&-_\ (M'_  GM
MY_T"X?\ P,;_ .1:X6B@#NO^$]O/^@7#_P"!C?\ R+1_PGMW_P! N'_P,;_Y
M%KA:* .Z_P"$]O/^@7#_ .!C?_(M'_">W?\ T"X?_ QO_D6N%HH [K_A/;S_
M *!</_@8W_R+1_PGMW_T"X?_  ,;_P"1:X6B@#NO^$]O/^@7#_X&-_\ (M'_
M  GMY_T"X?\ P,;_ .1:X6B@#NO^$]O/^@7#_P"!C?\ R+1_PGMW_P! N'_P
M,;_Y%KA:* .Z_P"$]O/^@7#_ .!C?_(M'_">WG_0+A_\#&_^1:X6B@#NO^$]
MN_\ H%P_^!C?_(M'_">WG_0+A_\  QO_ )%KA:* .Z_X3V\_Z!</_@8W_P B
MT?\ ">WG_0+A_P# QO\ Y%KA:* .Z_X3V[_Z!</_ (&-_P#(M'_">WG_ $"X
M?_ QO_D6N%HH [K_ (3V\_Z!</\ X&-_\BT?\)[>?] N'_P,;_Y%KA:* .Z_
MX3V[_P"@7#_X&-_\BT?\)[>?] N'_P #&_\ D6N%HH [K_A/;S_H%P_^!C?_
M "+1_P )[>?] N'_ ,#&_P#D6N%HH [K_A/;S_H%P_\ @8W_ ,BT?\)[=_\
M0+A_\#&_^1:X6B@#NO\ A/;S_H%P_P#@8W_R+1_PGMY_T"X?_ QO_D6N%HH
M[V/Q].)%$VEKY1'S>5<EI =P V[X$0\9^4D$DC!&#72V'BO1KY0@NA;3D#,-
MX5MV9B0&597)@8[B5"I*7X("# KQVFE001ZC';\!R#QCCIT)ZDYH ^B RE0V
M1@@'.1CG@<].O'N:<"#R#D>HKP&TU+4=. -G>W$2 AO)W>9!\ISS#)YB'IC
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M^&(+NPTA?!>@7GC#PYX2OM#T/Q-J>CZAX]\7/^"5_P '?%?@#Q"O[.&N:_\
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M<T_P_P""M,\,ZU87<5IHGBA(+WP_8Z1HGQSIW@;]O[6?!OP2_9[M/V>_BO\
M!;PK\(_V8/B9^SU\8[;3OB7^QYKW[&?QCM-"_9R\=_#GX;:K\$'M/'6H?M7V
M.MZY\3I/AS>^&?\ A8/PT^"6A>'O =OK-AXSM[34-.A7Q$ >T_#CQO\ \$XO
M G[27P9T[X:?%3Q_9_&J+2/C5=^"/#&C:9\;]6T3XG>"_P!KGXM^'/CAXOUC
M6/\ BA;_ ,,>,_ %G\5OBCX3U_POXPAU2+P[\.=3\9:+H<FO6$&K1:;-]P?
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M&'_QZ@#SNBO1/^$ 3_H*2?\ @,/_ (]1_P ( G_04D_\!A_\>H \[HKT3_A
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M/^$ 3_H*2?\ @,/_ (]1_P ( G_04D_\!A_\>H \[HKT3_A $_Z"DG_@,/\
MX]1_P@"?]!23_P !A_\ 'J /.Z*]$_X0!/\ H*2?^ P_^/4?\( G_04D_P#
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MQ$GV3^S;#2+D/#F]^V:A=6WDSDH0ML(M/N//B&9!OD,+ *GR$LVW=8X&<9Y
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M2M6@T[Q1<>&O%?BDRZI.E\L$%I:V7A*_M[F.*2>\CO+BQ1K9(S,P /:+:3Q
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M[O[+UKQQ_P E6<'@D'_F2R,$@\\$\<<8J&3_ (+YZPI _P"&7;8Y'&?BQ*"
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M 'O[UC&YY-=&G12IHVC/JAF(FL7U:=;..#,F)DOQHYDDD*A#Y36,:@NX\TA
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M\Y]2;3(Q"X!E;R1:29\M5,F9,1\I_P )_+_T"C_X%#_Y'H_X3Z7_ *!1_P#
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M"$WB[XJ?%GXFZYX0\/\ @Z]U>VU&W7PO_P $N_B7X<^&5A/'\%OV0[G6]/\
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MF5?N@]P/;TI]>*_LV^*M3\=?L\? GQIK4/C.#6/%GP?^&WB+5H_B+H]IX?\
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MS'X.TOXZ:'^T+\0/@?\ M Z:G[1=UJ7PB^&^C_#?X(?!#]IS6?B-\,OB/;_
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MF^+?BKP7=^*('NH_'/A[X_V/A#XK>!])UYK>>=_B%<Z/XCDM/$VG0:3UJ_\
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M<1P6MM&K3W,TC$*D4,;RN2-B,>#]/_"O]@;]J/XU7%N=#^'5QX4TB^)9=?\
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MW+6OI8_2D?@,''M]!_+Z]NU+34&U%7.=J@9Y[#'?G\^:=7>>0%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %,=
M ZE2!@\D$ @_4$$=<'I[=":?3-ZXSD?G[9ZG';N<#Z4 :-GJ^JZ< +6]F$8(
M/D2;9X<*",>7-YB@!0!B,IC&05ZCL++QX5 74K':!C]]9ME<<YW6\A8K@#/[
MN=R3T0=&XVSTO5-1 -G9221L5VS/B*W.2,$32[$923P5).,%=S'8.QLO <I
M?4KY3D@_9[(< =?FNYE!)Y(PELF"%99 <F@#JX_%&A2*&_M&"+/\$Y>&08X.
MZ.1 PY[]#V-%-A\*Z%#&J#3X7P/O3%Y7S@9^8N!C/.%55R2<9))* /\ )_\
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M[SJ5)RM?HFHK912.*M?AE%9(L5K=V4$:9"I'IH0 'J!LG7KDYQZD# .*L_\
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M.I7&C30E6^PK96MY#)&^7VM=F>ZE65-FP,L*QL7W8(4C !R/_" 7'_06C_\
M 1__ ))H_P"$ N/^@M'_ . C_P#R376VJ>)Q:7ZWUSHCWS1'^S9+6SOH[2*;
MRY,&]BENY)9H_-\LD02Q/Y>\9#%321Q^*/[.G66YT0ZL9<VTT=I>KIRP_N_E
MF@>[:Y>0;9@'295.^,[/E;(!R?\ P@%Q_P!!:/\ \!'_ /DFC_A +C_H+1_^
M C__ "376.GBC^SHD2YT0:MYX,TS6E\=/-L"Q*1P"Z%RLQ4H-[3LF5?Y?F4
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MI;WR6L<WE29-\DUR\TL7F^20(&1RBR L"5( .3_X0"X_Z"T?_@(__P DT?\
M" 7'_06C_P# 1_\ Y)KK$3Q/_9TRRS:&=7,^8)([>_&G+;?NODEB:X-RTQS/
M^\CE5!^ZR/E;+G7Q,=.A$4VAC5_._P!(>2WOSIQMQY@Q#$)Q<B7_ %1W/*4.
M'P,,N #D?^$ N/\ H+1_^ C_ /R31_P@%Q_T%H__  $?_P"2:ZVZ7Q0;2R%E
M-H:WX3&H/=6]\]G)+Y:?-9I#<+-%'Y@D.V=Y#L9!NW DNOE\2LUI_9LNBQJ(
M\7POX+V5GERGS6AM[B,)&0)"%FWODIDC!! .0_X0"X_Z"T?_ ("/_P#)-'_"
M 7'_ $%H_P#P$?\ ^2:[*Z7Q"=1@-E+I"Z4/L_VF.Z@O'U!\2R_:O(EAF2V0
M/#Y(@\R)MDHD,@*LB@*^(?[3W"32/['R?W?DWG]ID>40/WOG?9 3-AN8L"/Y
M>6YH XW_ (0"X_Z"T?\ X"/_ /)-'_" 7'_06C_\!'_^2:[&V7Q"-1F:\DTA
M])S-]FBMH;Q=17+*;?SI9IVMGVQ^8)C'&H:0KY>T BF62^)0]U_:4NBR1-&P
MLQ8P7T4B2DG:URUQ<.'C"X#+$$?=D@@<  Y'_A +C_H+1_\ @(__ ,DT?\(!
M<?\ 06C_ / 1_P#Y)KK;5?$XL[X7TNB-?F-O[.>TM[];2.;RY"IO8YKAYI8_
M.\K*P/&WE[P&#;2!$\3C3IA)-H?]K&?,$D=O?_V<L'[KY98FG-RTI_?$M'*J
M#<G'RMN .2_X0"X_Z"T?_@(__P DT?\ " 7'_06C_P# 1_\ Y)KK'7Q/_9T2
MQS:'_:_G9GE>WO\ ^SC;Y?Y8HUN/M(FV^6-S2% 0_P H!2BY7Q0;.R%G-H8U
M (?[0>ZMK]K-Y-@ -E'%<+/&GF;R1/([%-H!!)- ')_\(!<?]!:/_P !'_\
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M;YDXA591=B;!B_UC%.).#\M ')?\(!<?]!:/_P !'_\ DFC_ (0"X_Z"T?\
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MP^01-Y>_S"?M/S;=F/FR: -\* %&,[0 /P& ?KBG  = !]/IC^0 ^@K!OO\
MA)=]K_9O]AA?+(O?MXO]QDW)_P >OV8E1'C=CSOGX4D %P%N/^$C&H6WV3^Q
MO[*'D?:OM/V\ZD0)9/M)@,)^RY,&SR!)D";=YA*[: -VBN8O?^$S^TR?V8/#
M(LOE\D7_ /:ANQE1O\TVW[D_O-VW9@;-N1G-% '^5O\ \%OO''CW3_\ @KA^
MWII^F^/_ !_I>GV7QAT&&TT_2?&_BK2]/M8F^$7PTG,5M8:?J]O:01M)-(Y2
M*%%WN[$$G-?EA_PL/XDG./B=\4">W_%R/&X'.,?\QT]R!C@Y/:OTJ_X+D?\
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M>%=5L/#5U\'HO%W@;5OB%\7;WP=_X)3?M#?!GX8Q67P]7]F#X=?$WX-_!/\
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MI-G)(LOB[0];^'_BKP5(JD@2R>)="U>\LM)C?Y1$/$8T6:5FS%"RKN/SLO\
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MMN*4*F29U' 8V]Y))8.>:PEHX5YJ7)3_ **1_P %[O@Z1G_AG_XO9YX_MSP
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MONG'SVL?!8G!XO!RE#%8:K0E%M/GBW%J]KJI'FIR3TLXS=[VW1]!?\)]:_\
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MZ/\ A/K7_H'7?_?4/_Q=>;44 >D_\)]:_P#0.N_^^H?_ (NC_A/K7_H'7?\
MWU#_ /%UYM10!Z3_ ,)]:_\ 0.N_^^H?_BZ/^$^M?^@==_\ ?4/_ ,77FU%
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M?C;>?#77?C(UYHWBW]NS5=.\,_##Q!X:O;GX(6_P9T>W87]GX^E\ ZU\5_\
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MZ[9W7ASQYX.\->(K0V6IVZ37.E0VUXES82W-I/YK\*_V,_V</@M)X9O?A_X
MGM=>\*Z]\0O%=MXS\4>-?B%\1_B)XB\7?%32]%T'X@>,/B1\2?B/XL\6>/\
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M'\9?^"L/A?\ 9_UCPYX-^+'[*7[4&A?%"]^'WBCXP>-?A;H9_9V\<>*_AO\
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M\2__ !ZC_A K_P#Z"5O_ -^)?_CU '$T5VW_  @5_P#]!*W_ ._$O_QZC_A
MK_\ Z"5O_P!^)?\ X]0!Q-%=M_P@5_\ ]!*W_P"_$O\ \>H_X0*__P"@E;_]
M^)?_ (]0!Q-%=M_P@5__ -!*W_[\2_\ QZC_ (0*_P#^@E;_ /?B7_X]0!Q-
M%=M_P@5__P!!*W_[\2__ !ZC_A K_P#Z"5O_ -^)?_CU '$T5VW_  @5_P#]
M!*W_ ._$O_QZC_A K_\ Z"5O_P!^)?\ X]0!Q-%=M_P@5_\ ]!*W_P"_$O\
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M/Y<'.'_JMXJ)6_UGC9W7_)08Q>NV6?H-9CPV]\M]5]1H[?\ A1Z[?B?WD?\
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M-MYA^9OFM?M$?[ML,<KNWSCC(&1R!QP>@_PI %^[M4=3@ 8/3)Z8!Y'7D]:
M,6YU+4(=0M;2'0K^^M9A 9=5@NM*BL[8RS21R>;!<W\-_(+9%2>0V]K,'25!
M!YKAE4;4]0&I_8AH5^;+*XUC[3I9LQ^[#Y^SB^_M(@N?)&+(G?\ , 8SNK;
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MR21_Z1<27D4R>0$$MP4MI%2*1&!<E@N[M&",#'3 &, @#'^<<8%+M7T'7/
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MGGX9:W\9?%G@&(_!/X6>,?!*_#SQ-8?"OPA\(_AE\)_AEIGC#6/"<%KH]_\
M%7Q-X%\5?%6ZTR"71KCQI+H6J:WI6IE%>&=Y%\7O^"67[+_QGU3PQKOB!OB-
MX?U[0/V4O%/[%NJ:UX+\5V>AZEXZ^ /BSP_)X3N?#OC>:70;]=1UW0O#&L_$
M+0_!GB_2H]%\1^"K?XM?$J\\+:AI6K:[9:CI/L?@7]A/]EWX1_&?P;\=/@A\
M(O ?P&\8>$_AYXY^%5_I_P $_ ?@#X:^%O'_ (#\=:KX&U^30OB)HOAOPI:?
M\)&OA#Q!\/=!UGX>WR75AJ/@VXO/%5EI5VFC>,_%6EZN44 >=>*O^"=7PQU.
MZTSQ%\/OBU\?_@1\2=,\5?M.ZTGQ;^$/BWP7:>/KGPE^V'\3+7XO_'WX4SOX
M\^'?C[PG!X'\3_$/1?!WB3P]K&F^%+#XJ_#G4/ ^@7/PY^)7A6XO/%,WB3W/
MX"?LK?![]FF3Q##\'M(U+PUHFN>%?@SX*M/"\VJSZIH/A?PG\!_AQI?PI^'.
MA>&UOUFU6"UTWP;HFGV5[-JFJZK?:A<PF\FNQ+))DHH \$\9?\$V?@KXF^'7
MPG\":#XR^*'PZU?X*:G\4;KX?_$_PR?A5XH\>Z=H_P :/$&I^)?B9X3O;/XP
M_"KXH_#75- \1:G?64MO/>?#N3Q+X9D\/Z%>^$O$6@ZI:W%_=\Y\4_\ @EI\
M!?C-JGC.Y\?^//C=K6@^+OV;_B)^S!I_A:Y\2^"+E? W@3XK_!:+X#>.]3\*
M?$&_^'5Y\:;S5-;\"Q/>2>&/''Q0\9?"6#Q]<W7Q-@^&:>/9F\0444 7OB#_
M ,$ROA'\3/B!\;OBCXF^*_QV;QQ\8?#<'A;1/$.G:G\*-/U;X*Z;:_$[P!\9
MK,?#O5X?A#_;'C5-&^)OPM\">(_!FF?M)ZC\?O#_ ,-+'2]9\&?##1O!G@'Q
M[\1?"WBW!7_@E!^SXWC#XQ^*[KQU\9[RV^-'AK]IOP[K?A9]3^%]GH^A2?MA
M^+/AQX]_:"\0Z-KFE?"C3OB'K7B'Q?XV^%WAK7=#G^(OCCQWIWPWL/M'@7X9
M:9X.^&5MHG@G1RB@#T[X@_L _#3QEX_UWXO^&?B;\;/@[\;-4\5Z'XMT/XO?
M##7O Q\5>"KK3/@]8_ O5]&T#1?B-\//B'\.]6\+>-?AWI5C;^*_#GC[P/XU
MTM_%.GZ%X]\/0>'?&_A/PAK^@1_#K_@GW\+OAE\<8_CEX6^(WQCCN[K6CXY\
M5^ K[4OAQ<^#_'GQ?O/A[I7PVU[XP^*==7X9P_%T>)?%GAW1=(U#Q5X'\.?%
M+P]\#=9\<6MW\2)_A(OC_7O$OB76BB@#[SHHHH **** /F[]J'X M^T-X&\+
MZ#IOC2X^'?C/X??%+X??&/X;>-4\/Z?XPL- ^(/PXUI=7T&XU_P;JEUI]CXK
M\/W,;WVG:GI#:GI%ZL=XFI:+K6C:[IVF:I:?%WQ*_P""=GQ"^,7Q6^$_Q6^*
MG[4EYXHO/AYXD^"/C"^\.6_PMN-,\)6WC#X+_%S7?BS!JOPH\(-\4K_P=\+;
MCXDG4M'\-?$_Q-=^'/'7Q)UK3/"^GQZ;X\TJQF73+$HH HZU_P $KO!&L?#[
MPQX%C^+GB72I?!WP[_:5\(>'M?L?!OA=Y4\6?M!?M??!S]LW2O'6K:/=R3Z1
MK<?@#XF?!O1-/N_"6J076D?$+1-8UY/$DT,M_.)*_P >O^":7BK]H_4-.\9_
M%;X^>%]<^)4_PV^('P4^(NIVWP4\1Z1\./&GP9\<^*+'Q*/"D?PKT;X^:;:?
MVMIRV=SH^H:EXZ\2?$7PMXNTS4[FW\3^!;^UM[*T@** /NS]G3X Z#^SY:_%
MS3] U635H/BS\<OB+\=+YI=(L-(?2KWX@2Z2D?AQ/L#.=4M?#NFZ/I^D6&K7
MS?;Y]/M+2WF1([6%1]&444 !_P !^?%8/B74K[2=$U'4--L[74+ZVM9GM+&]
MOY=+M+JY48AAN=2AT[5Y;*!V.)+B/2]0>-3E;64_*2BLZK<83:=FJ562>FCC
M3FT]4UHTGJFKK5-73THQC.M2C)7C*K2C):J\92LU=--76ETTU=V:=FOQN_:7
M^*W_  4CO[?4%^'6M?LT?!?0&66*'4M%U+Q?\0?'@MY#M5HM4\9?"V#PK8W!
M6,I(\7A"X8+M>WEMYE65?PB^)GP(_:)\<:_/KWQ2^*-I\1O$3%8I-9\8^./&
M_BF^ B>5XXK>XUS0Y_LEI"6<VME:16]E:[V6VM859MQ17\\YWP=@>+*=+$\0
MYKQ1F7-.*6%J<18VEEU-.2?+2RS#X?#Y?!1YGROZK4G&RM4;5Y?V/P/XGYQX
M?4\/1X-X>X R*I4RVE5K9AAN",HK9UB:DG&$I8C/<;B\;G-52Y>9PCF.'@IM
MRC"#=EYXW[,/Q$?/_$U\%_WO^0GKO8%>WAP'IQUZ8Z8 J-_V7OB*$8G5O!1S
ME0/[2US@%LD\>&QR2J^P&<"BBO&H^#7 W-./U;-4E"$DEG.)5FXINUL)9+7X
M4DET/N8?2:\6*]*$ZF8</N4JG+)KAC+E=.[;?^UR;E=+WG*3WUN[E5?V6/B.
M0675? ^-SD[M4UXG.XENGAD#&2<<>I/)-0R?LK_$J63:-7\#@J.^J:]CD*W3
M_A&3GMZ$'.#116M;P@X)I4HSAALTYE"4ES9QB6KJS6GU9::O2_E<E_21\4Y\
M\98[(+6MIPSER?PJ6ZQ7?RVT*[?LF_$MV7&L>!AL4MSJFO<@E,Y_XI<X.2.G
M  XQFJ!_9&^*)7 UGP%C('.K>("1\N#T\*#L3SG/T))HHKGAX7<(>X_JV87O
M_P!#7$_RW_Y\[:''7^D3XG<K?U[([R4FW_JY@-7>^O\ M7<K-^Q[\4W)*ZWX
M!V_*,'5_$(QM';'A,]<\\Y],8%49?V,_BN[$+KGP]4D[S_Q-_$A^\%)&3X2Z
M= .!W/4T45U4O#'A+F3^KYAHX_\ ,TQ/?_KT<-7Z0?B7-QA+&Y):6DK<.X%-
MIWOJL5Y*W8SF_8F^+DB[1K_PYX(4YU?Q,,@<#D>$>VX@9'(Y/.,9TO[$/Q@(
M##Q!\-\;D7G6/$X.>F<#P?CO_P#6S@@HKN?AQPK1Y%##8[5IN^9XIZZ=H1WO
MUOT/*K>/?B-.+YL9DSM%M?\ &/X'JXI_\Q)DR?L)_&-@CCQ#\-,988.M>*<\
M#T_X0PC^(\9],YYK.G_8(^,[AMOB+X8#:DB'_B=^*AU&#T\$GC X/N<CO117
M=1X"X;45;#XS227_ ",<6]%))?@_ZL>+7\<?$"I*K*6+RB\6U&V1X2-DG9:+
M%VT2LKWZ]S*G_P""?'QLG"LOB3X6 ;6BP=<\6C ^4DC_ (H=LGGCIC)QC&3E
M3_\ !.[XYS[RGB7X3ABO.[7O%^W 4MQCP(3D;N,\9]@***[Z?!/#]-1<:&+3
M<DG?'XEJRE*UD]$>76\8N.*TXQGB<KM*>O+D^&C\2N]L4]GJKII=GL8MS_P3
M?^/4K.$\3_"+DN!N\0^,EY"NIR5\ $8QDCY3DGGBLNY_X)G?M!2KA?%7P<W.
MQ^]XB\:J NT C*_#PYXQCCDC)Z@ HKT</PGDL4FJ.(NH*2OC*[LTTTUVW.#%
M^)?%=27++$9?:4VG;*\*GJHK_GXU=6TNFO)[&++_ ,$O_P!HB9]Z>+/@P,-C
M#>)/'']U>X^')[#'(/)!&,<[O@+_ ()(_%WQ5K$\'C'XE_#GP_H]M<I#(WA@
M^)/$FIW0E@MY9/+&K^'/#EI9,L<Z*DCC4 T@9FB 502BO6P/#V51K12HU&N5
MW4L16:ERW<>975[7?5;L^5SOCOB3ZG7E'$X6$E!\LX9?A8RB^:-G%VE9KF;3
ML[-WU/VI_9>_X(6_!2SGL-5U*U\.>--63RI!J_C^YU+Q2T4R,DAEL/#UQI%O
MX3T^42*LEO>#1;G5[7YTAU4))('_ '4^&?\ P3S^'O@>UL0]GHNHM#&BQ1LL
ML=M$8@J@PVZV"11;54!0B*!C "J< HK]"P^&P^&A[+#T*-"$5%*-&E"G>\8R
M;DXQ4I-N4KN4FW?5GX]B\PQV95(5L?C,3C*LX1DY8BM4J\NL6E3C*7LZ<4VV
ME"G&W=JR7UCH_P (+/0X$M]*L-!LXXL"-8DE3 ."=Q2S4DE?D//*\'.*Z#_A
M"=6'2YTX?26Z'X#%L !]***Z+'(ME_7<</!>L=!=:=V'^LN>Y _Y]?4\GKU[
MT?\ "&:Q_P _6G?]]W'_ ,BT44 '_"&:Q_S]:=_WW<?_ "+1_P (9K'_ #]:
M=_WW<?\ R+110 ?\(9K'_/UIW_?=Q_\ (M'_  AFL?\ /UIW_?=Q_P#(M%%
M!_PAFL?\_6G?]]W'_P BT?\ "&:Q_P _6G?]]W'_ ,BT44 '_"&:Q_S]:=_W
MW<?_ "+1_P (9K'_ #]:=_WW<?\ R+110 ?\(9K'_/UIW_?=Q_\ (M'_  AF
ML?\ /UIW_?=Q_P#(M%% !_PAFL?\_6G?]]W'_P BT?\ "&:Q_P _6G?]]W'_
M ,BT44 '_"&:Q_S]:=_WW<?_ "+1_P (9K'_ #]:=_WW<?\ R+110 ?\(9K'
M_/UIW_?=Q_\ (M'_  AFL?\ /UIW_?=Q_P#(M%% !_PAFL?\_6G?]]W'_P B
MT?\ "&:Q_P _6G?]]W'_ ,BT44 '_"&:Q_S]:=_WW<?_ "+1_P (9K'_ #]:
M=_WW<?\ R+110 ?\(9K'_/UIW_?=Q_\ (M'_  AFL?\ /UIW_?=Q_P#(M%%
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MY!X'NGB5IM1ACD.[<D4#S(/F.TB1WA8[DP2#&H1B54LJAC+_ ,(+-_T%$_\
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%BB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>chart_022.jpg
<TEXT>
begin 644 chart_022.jpg
M_]C_X  02D9)1@ ! 0$ 9 !D  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" &# ^@# 2(  A$! Q$!_\0
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M4O%>L>/M+\3::)_!OC_P%)H5OH=MI_\ :FO:9K=AXB6'3;2VO[>W_+G]I_\
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M\/[K5K"*VNH;#Q'HVH:>!?6]SI>OZ]I3)J+^S_LA?\%VG\8?M::+_P $]_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M1XK\4:&UKJ]U]X5_/)^WY_P;I?LB?M*:_?\ [1?[(]WKO_!/;]NS0[B]\3^
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M_&7]L34?V>/VS/V%OB7I7P2_X*.?L2>(9_$GP0\6:T(+'PO\4_!MW<I?:_\
M!SQSK$=A>S6UO/+]ON?"G]OVNN> -2M_$7C_ .'/CKP_%X7^*FK>,O!O[I6V
MKZ=>,4M;RSN749*6]Y:W#]"?N02R,!QR2 !US6E1Y:IZ.S33UVT:3UMIW",H
MR5XRC):J\7&2NMU>,I*ZZZZ=;;'\P'A__@M]_P %.?AEI]GX"_:F_P"" /[<
M5[\;]*@M=*UO6OV6+.X^,OP-\3Z[!:6T5_K6C^,/#OA_Q9H?A#0M0U5Y'L],
M/CWXC1Z3IC!I/&.N26T\Q\^T7]C7_@I'_P %IOVJ/@/\??\ @J-\%M#_ &)O
M^"?/[,'C+3OBU\(?V 3XXTSXH_$/XY?%/3+*U;0O%WQ[O=-@M_#XT6VN+G4]
M/OK7Q7X?\.Z_IO@]=<^&>A?#/3HOB+XR^*FH_P!7Y /4 YZY I:!GR=^WM\.
M_&?Q=_87_;0^$_PXT.;Q1\0_B?\ LF_M%_#OP'X:@N]-T^X\1>,_&OP?\8^&
MO"^APW^L7FFZ/8S:OKFIV-A'=ZIJ%AIML]P)KZ\M;5)9X_D'_@A)^S_\8_V6
MO^"3O['OP&_: \":E\,OB]X!\+_$.#QCX&UB\T:_U/09=?\ C1\2?%>CQ7MQ
MH&I:OI?G7OA[7=(U(V\5_+<68O19ZA%::C!=V<'ZWT4 ?A]_P7#_ .">OQA_
M;!^#/PC^/W[&EQ9Z!_P4,_88^)=A\<?V4M<FU6ST*/Q;MO-+;XC?!;5]3UF[
MMO"JZ/\ $32M)TN_M[;Q:J>'=8\1>%=&\(>)-8\/>!O%_C74JM?\&[W[+WQV
M_8[_ ."3_P"SY\"OVD?A]J'PM^+?A_Q%\:=:U[P-J]_HVHZMHMAXK^,?C?Q#
MX>.HS:!J.K:9%<ZCH5_I^J"UBOYI[6"]AAODM;Y;BT@_;>B@#^0GQ]9_\%0O
MV#?^"V'_  4K_:]_9^_X)8>._P!N+X0_M;^$/V9/#W@CQ/X;_:&^'7P<TFQM
M?AG\%OA]H>OWI.K^&O'^LWMXGBK2=9T"?3-2T7PU-:-I#ZE;OJFEZIIEY)]1
MK_P5R_X+5.RH/^#;[XJ@NRH"W[?OPJ106(4%G?X#JB*"<L[LJ*,LQ"@D?TIT
M4 ?DY_P4B^)W_!5GX%^*?@;\8_\ @GS\ _A-^U]\)-!L?'.D_M/?LO\ B?Q3
MIWPQ^+OB*WNYO#&L>#_'7P@^(^LW\&C6>IZ!9Z)XK\/7NDR6OBBX=_$ML;+X
M:_$.^O['4OA_^<6L?\%K?^"IWQ:T#4/AS^S#_P $"OVS/#'[1>J:==Z9I>O?
MM0/_ ,*Q_9V\%^(I-.NUAUZ^^('BGP_\/M%^(FA:1J<<<K:/;^+/AP_B.Q79
M;>)-&N;FV23^H"D"J,84#'3 '&>N* /R/_X(O?\ !.3Q;_P39_9)U;P!\7_B
M%:?%G]I7XZ_%[QO^TG^TY\0]-,DVAZQ\8OB+#H]GJVF^%[R\TK1]6O?#FB:5
MX?TJ$:AJEG:S:YXFN/%'BBWTS0;3Q!!H&F?KC110 4444 %%%% !1110 454
MGU"PMG$=S>VENY (2>YAA<@C(^61U;D<]*L))'*JO&Z2(PRKHP96''*LI(8<
MCD$B@!]%%12SPP(9)YHH8P<&25UC3/)QO<JN<*3C.< F@"6BJ\%Y:76?LUU;
MW&!D^1/%+@<<GRV; Y')]1ZU8HW_ *M^8!1110 4444 %%%% !1110 4444
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M)KX"OEN(K3Q/]EYE2H?6Z2PN)K7KSP&+PJJ^SI8BI5K86OAIP]M5H5:<J?\
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M==+II:_>.3]UM:^:Z>9\,ZKXF\0^+M4?7_%OB#7?%6O/*)9M:\1ZQ?Z[JSG
M^==0U.XNKI%0!!$(Y8TAC58XA&B(!^AW[&W[>WQ*^ ?B[0M"\;^*-9\7?!C4
M+^TL?$&DZ]?7&L7?A:QN'2!M?\,WEV\U]!'I2$7-QHHN#87EG!)%;0V]T!(_
MYC65QC;ALC(5@3G*/CDC=RP! )/ !(Y %=-;^9./LT,4US/,RVUM;6ZF:>ZE
MGQ';6\,()::>>5UABC09D:01H"6KJ<5)6:5K=+*WIIIMTU]3)-K6[_'_ #/[
M+?VH/VB] _9P^#>H_$^[ABUR\N[BRT+P7I,<^VW\0>)M:M+J[TJW>[C#K'I\
M5A9WVM7TZ$LVEZ==?9BT[PAOYC_B?\?OBU\<-8O-6^(WC;6M:6ZG:>'0([ZY
MM/"VF AF6WT[P[!,NG0I$K-%%++!->,N\27# [:_0G_@I]H/B_PG\%_V+?#.
MO22R+X<\*:UX<\7S1S+<6K^,]*\'?#FPM)7NE#I/*Z6?BHVTX8>=%]ID7*DD
M?D+;2G/! ;(4D$@Y)4*00<\J3CKSOZC-94HQY6[7NVM==$]-U^/4J;=TO)/Y
MM'NWPV^*OQ"^%FIVNL?#SQAK_A.>&6.8VNEZC<1:5=/ [E8M1T4R-I6H1,'E
M3R[NTFVF9O*,;N7K^D/]CO\ :9A_:3^'5SJ.IVMOIWCOPA<VFD^--/LUD6RF
MDO(9I=*U[3E?<8['6X[2\'V4R.]I?V&H6RM);QV\\W\M]I*"0 QP_P T?(PK
M#).>>#ZA<_-NSS@U^@W[$WQ \0?"^P_:6^(ND+*+/PQ\"[^6!FC9K-?&5]XG
MTBT\&1W97*JS7$NKO$,EQ;)?2)')L<552"E'HG'5.R79-.R7=6%&33[KK^)^
MKW[0W[<WP_\ @OJE[X/T*QD\=^.K-0E_I]E=16^B:%/(A:.+6-4 E+7291KC
M3[-'G@1OWTD4NV-OD2P_X*7_ !*_M%Y[SX?>#9=.EVE+&&_U:&:%&>,EEO"L
MAGD2,2##PHC&0.0H0 _E9_:5[J%Y=:EJ%Y/J-_J=U<ZEJ5_=S/<7=]?7LK7-
M_=W<SNSS75S<RR3RR2,S/+)([L2<UT%I-P 3RF#@GDIQE?O$GY>@ "[ASQ25
M&"5G&,GU;3?ZH?._+[C^C[X"?M0> /CS;/:Z49]!\6VEL;G4/"NJO$;D0H[*
M]SI5TFV+5K1 (WF>%(YK8RA980JF4_2M?S%_##QMJG@/QAX:\6Z-=O:ZAH6J
MVE['*AW>9 LP%W;3(K#S;>ZMC-#/ [>5.C&-\H37],NEZC;ZOIFG:M:[Q:ZI
M8VFH6PE"K)Y%]!'<P"159U$GERJ'"NPW9 )&#6%6"@U;9W:7:SV_'3T+C*ZU
MW+]%85[XH\-Z;*(-0U_1K.=KB.T$-SJ=G#+]JESY<#1R3*ZROM;"LH/RDG %
M:=I?65^AEL;RUO(E.UI+2XBN$#?W2\+NH/L3FL_O^Y_Y6*+5%%% !1110 44
M44 %%%!X!/I0 'H>]<ZOB[PN^N'PPGB/0'\2JC2-X=76M-;70B1/<,YTA;DZ
MAM6W1YRQMP!$K2'"*6'\W7_!PE_P4B^*/[-.@?#_ /9@^ GBC4? ?CCXNZ'J
MGBGX@_$#0;BXL/%?A[P%8W::;9:!X6U:WEMY] U7Q3J#7#7FNZ?(^I6NCZ?=
M6=C/IUQ>_:E_BXTWQ5KT6LKKZZ]K*:^E^NI+KZZOJ":TNJ"7[1_:*:HEQ]L&
MH"X/GB[-Q]H$O[PN&Y/[EP+X)8[B_(Z>>XO.J634,:JSRR@L#/&UJ].E.I16
M*Q'^T8:%##U:]*I"E"#J5YTZ<ZWN1=-2_ ?$'QXP'!6?3R'!Y%5SNO@W1_M.
MO+'PP%"A.K3IU?JV&MAL5.OB(4JD'5E45*A3J3A2]]QJN/\ K6JP;I^(P1@^
MG('<5^67_!5O]OR7]A?X(:==^#H+'4?C)\3;Z\\/?#NUU!4N+#1%M;;SM8\7
M:G9>8LEU!H\,L*6%HP$%YJ<\,<K>5%*C_#O_  0,_P""A_Q+_:B\%>/?V=OC
MOXFOO&WQ(^"^BZ)XB\%^.]9DNKSQ3XR^&E[=MHM[;^,=7EDD;6]?\':U+HUD
M/$-XR:MK^F:_8G5&U#5=+U'6-0^6?^#E?PIXGB\<_LL?$'R)F\%KX:^('@TW
M(=?(@\4S:IHVN1V^W[QFN](MI9%9U("6C)&07=6X>$/#^EA?%S+^"^+5AZ]#
M"8BOB:L(RE'"9Q1P^ K9EE\(*HZ=5X7,8THRG1E:LZ5'$X:=_P!ZY;<>^)5?
M%>"6;<=\&2Q.&Q.*PE##4JKA&6-R6KB<QI97F4Y*FJM)8O+'4J0I5X\U%5*V
M&QD%;V4%^"7Q%^-7Q3^.WB&\\5_&3XA^*_B1KM_<R7<EWXLUJ\U.WMI978F/
M2M*GE.EZ-;1[F2&STNSM+:%6*I%ACN^JOV0?V^?VA/V0O&&DZGX)\;Z]K?@2
M*\MU\0_"KQ%JU]J?@W7M&#@7=KI^GWLTT7AW57MRQM-6T-;&Y2XCMQ<&YMHC
M!7YS:?=CAP0N-O(.['.">#C<02#GJ<=*[2*</&K@E3$IEW-PI"@9+8)(P#DC
M(['Y<8/]_P!;)LBS'*YY%C\IRW$Y/4H?5GEM3!858.G3<73C[&C3P]..%E""
M3IU<)'#5Z4XPJTJL:D$W_EW/.N),KS>'$N49YFV"XCP^)^MQS:CF&,^O5JRJ
M*I+ZQ7J8FK+%PK._M:&-6+PU>G)TJ]"5-\L?]%:7]KCX5P?LJ1?M=R7TP^&<
M_P /XO'D2*0^H2M*JVT?AJ/:I1]7_MYCX?(13']L227'DH6'\?7[3/[?_P"T
M!^U=XKU+4/%?B[6O#'@1[F8>'OACX8U:^TKPSI>F-*1:1:I!9SPOXCU1H/+>
M\O\ 5VNU>Z$K6L%M"J1)][_%/PM\0O"/_!!KX26VJ17\']J?$/PMXFO+0B?[
M18^"-8\1:Y<Z:MP@PL%C/*MM>.DB&/R[RWE'EF0&OP0L;Q?[Q4_+A<C<K +G
M&3@-@DCH=Q.1DU^-_1_\.^%,KQ'%^?PHX7.<?EW&>?\ #>38O%PH8UY;EN35
MU1ISPRJQJT88[&_6$Z^-C15=TL&H8:K2A4JU)?L?TK?%?CG.\'P'PQ4Q&.R#
M+,T\/>&.+.(LOP-3%9<LXSC/\$\17IXSV-7#UJN7X!8:V%R^=:6&A6Q]2>*H
MUZL*5.E[]X%\>>,/AUJ]MXA^'_BOQ!X-UNWDBG34?#&KW^B7+&,B0>8VGW%O
M]HB9ODDAN/-AE1GBG22.1E/]3O\ P2\_X* Z[^TK9:K\(_B[=VUU\6O">DKJ
MVE^(((HK;_A-_#=N\-O>7%W:PA((]=T>2:V&HRVT45M>074-ULBE$BM_(YIE
MWDJKN?E* ECP1P, #G8V3C/7@C^*OT=_X)C:UJF@_MA_#S7['[0=*\.Z!\0/
M$GBTVH.]?">B>"-:U#52^T9$(N8]/+;LIYAB!W':I_4O&S@C(.,> .(\3CL%
MA8YYDN4XO-<CS?V-&&/H8K+Z?MX8%XQ0A7K83,?>P4\'7K5J#J8G#5*,:&(A
M&<_YY^CEXD<7>&OBYP;1R?,L>^%N)N(<NR#BGAQXC$5,HQ6"S>J\+5S;^SY5
M:F&H9CE3<<QIYAAL/A\3"G@L33KU<3A*M3#P_ID_:^_;Z^$'[)-M:Z/KJW?C
M#XE:K9K?:3\/M!NK:*^CL))-D>J^(-0F+PZ'ILNR5K0213WVH&%EM;0Q-]I3
M\B+G_@MG\;9M66YL?A1\.K/1U<;=,GO]>N;B2(,1^]U#SHF\QEVEVC@C"%F*
M+\JEOR ^+'Q3\3?&7XG>-_B=XQOWU'7_ !EX@U'6+R:1I&BAADG>/3M/LTE=
MS:Z=I>FQ6NFZ?9J1%9V5I;6\0$<2@<;%+]W#<C Y/&"PZ#=_D<'M7D\!?1C\
M.\BR'"0XJR:CQ3Q!B<+2J9KB\?B<;]3P^*K48.OA<LPN$Q>!I4L-AIS=*EBJ
MGML7B)498F4Z,:E.A37C#].?QJXIXMS*MP!Q-B> ^#\%CL11R'+\HP66?7\7
M@<-B*D,-F&>8_'X#,Z^)QF.ITX8FM@Z/U;+\)#$0P<*5=T*V)K_UK?LA?\%-
M/A?^T?K=CX#\4:3)\,OB9J$1CTG2KW4DOO#GB>Z1 \MKH>KRK;R0ZD5C=K?2
MK^$372(_V2YN)F\BOT]!R 1W /YU_ AH^JWFE7UEJ6G7U[IVHZ;>6NH:=J%C
M</:W=C>V-Q!=VUY97,4B2V]U;W$4=Q;3Q,LD<Z(ZD,H8?VT?LJ?%.^^,_P"S
MS\)?B=JS*=8\4^#--N-?,89(3XBL"^E:^UM$S,4@?6+&^:),G;&44%@!C^:/
MI'^"N3^&]7*.(^%5B*'#V>8K$9?B,KQ%:IBO[)S.E1>,I+"XFM>O/ 8S#*M[
M.EB:E:KAL1AYTXUZU&I&4/[?^A#]*/B?QLH\1\$>(3PN+XQX6R_!YS@<_P )
MAJ.!EQ!D5?%K+,3_ &E@<-&.$I9OEN.EA74Q&"IX?#X_!8V%2>$P^+P]5XGZ
M(HKBO$OQ'\!>#3CQ9XQ\,^&V^4B/7->TG2Y2&.$(AO;R&8J_56$>"OS9P,U8
M\/>//!OBV(3^%O$V@^)(<;FDT+6=+U58DW,F^86-W.T2;E*@NJY;Y1SD5_,;
MPF+6&6,>$Q2P<I<JQDL+BHX1R=[16*EAEA6W9V2Q-WTN]#^\%G&42QSRN.;9
M5+-$G)Y9'-,MEF2BKMMY=',)8]))-N^!5DFY<J39UM%(#D \\@'G@\^H]:6N
M<]$**** "BBB@ HHHH ,@8]^E8UIXC\/7^HW>D6.NZ->ZM8&07VEVFIV5SJ-
MF8G\J475C#.]S;F.0&.031(4<%&PW%?S@_\ !:#]N[XD>%OB+:_LH_"7Q5J?
M@S2M/\.:3KWQ8USP_<W>D^)-7U'Q'$U[H_@V+6+6>&YLO#:^'Y;#5-82P:.7
M6Y=5CTV[E6QLKFVO_P"?OPSXGU[PQJ]AKWAS7];\/Z[I\Z7FGZYHFKWVEZOI
MUY'ADN+/4;*XAO+:XC=F(DCF$@SG<#DUK&BYJ_-RZ]KO_AG]_8F4E%VM<_T6
M^O2ORN_X*8_MR:M^S#X:T#X<_#.6U3XO?$;3;W48-7N(X[A? WA"&:33I/$4
M-E*#%=:YJVHI<Z=X<6XCELK:33M5U"[25K*VL[R[_P $K/VO_%7[4_P1U:P^
M)-Y%J?Q*^%6JV?AK7-=2#[/-XGTBZLEN-"UV_1':"36'@CEMM8N;=;>*ZNXA
M<FVCEFE>3\I_^"T'ASQ'I/[5'A;Q-J4=TWA_Q3\*]%@\,7C"4V@?PYJVJP:]
MI$#L%C^T65U?VNI75O$S%(]=LII0OVI"2$/WJC+H[V[]5;UWUZ)IA)^[==;?
MB?F[XA\:>*_'VL2Z_P".O$^O>,-;N9VFEU;Q-K%]K5Z+AF#!X9K^:;[*G_/*
M&U$%O @6."..-41?MS]DS]NCXK_LX>*=+BU#Q%KGC#X5R75M!XG\%:UJ-UJR
MVFF2.%N-1\*/>SRRZ7J-C!NN+>SMY8["],7V66%&F,Z?G5:S+SG&& '7IR-N
M,MC XX]0X! %=+!<A(S([$")6,G\0*;6VD#!W+R0 0S'D<Y-=3C%Z.*L_)+\
M4E8R3=UJ]^__  3^U#XW?M%>"/@Q\#-3^.%Y<QZUHLFC:==>#K2SE0-XOU?Q
M';(_A;3;&4\+#J;S17-U=JK_ &'28;[4C')':/&W\Q?Q<_:7^,?Q[UR[UCXA
M>,=4GT^XGD:S\(Z;>76F^$M(M&>;996FB6\L=O=&!6\L7NI)=7\SNQDG59/*
M7[\_;P\.^-/"/[!7[%/AO6HKRVC\/6?@#1O%MI<&,FR\6VGPEN(-+LY_)2,;
MK&"+Q/9P.R,XC1EGGFN9#)/^/5I<@G=D8R-P8XV,&+]VP RCDY(9^AQS65&$
M>7FLF^:2O;9)V25]M-^MRIMM]5;S_P CVGX>_$3QM\-M3MM8\ >+=<\):C92
M1SQ2:'J,]G!.48N%N]/5SI^HP$!"]O?VES QR6B8A2/Z-OV(_P!JV3]I+P;K
M%EXIAL+#XE>"9+*/Q'%IR_9]/UW2]16;^S?$NEVDCM);K+/:W=CJMC&T\>GW
MD-O*)EM]5LHQ_,):3G*'^)1QGN 02F,DG",#UW ANH K]"?V!/&6I^ /'_Q>
M\?Z?&ES9>!_V=/B5XJUB!ERD]EHDN@ZG:6N_876276+/3<"$I.;>.Y*LT:S*
M:JP4HMV7,K6=M=U=77>_6^PHRL]=C]A?VC_VT_A]\ [T^%8+:3QG\0#;K/+X
M=TVYBAM=#CG0/:2^(M0/F"SEN5:.>#38HY+Z2T9;F5;>&:UDG^(H?^"FGQ,E
MOUN6^'O@M=/P%;3AJ&L-(& PSB_*"0?.0X46Y13B/.WYC^6%YK^K>(]6U+Q!
MKU]-J>NZQ?W>K:QJ-PQ>>^OM0E:YO+IFW$!I)G)1%VPQ)LCB1415&O:S\(V<
MA@5<;A@<#YA\QQSU)/)()&<4HT8)>\E)]6[^>RNK:6[ZC<W?3;T/Z-_V?/VL
MO GQX,FBQ0R>%O&UM;FYE\-:E<0R'4;>%"US=Z%=J$74([?:TEQ:;$O;:W(G
M:.:".>:'ZKK^6'PAXGU3PEK^D>)=%O9+#5]#U"TU.PNK=V26&>TE21""5?(D
M ,<B'*.A*L'5BI_I\\(:X?$_A/POXE:%;=O$/A[1=<:W4DI VK:;;7YA5FR2
ML1N/+4DDD*"236-6"@TUL]/1KS\]RXRNO0Z*BN?U/Q9X8T4LNK^(=%TUD<1N
ME[J=E;.DC E4>.699%9@K%05YP:U+/4=/U!7>POK.^2,JKO9W,-RJ,PRH=H7
M<*6 )4$@D#(K+[_N=OOM;\2BY1110 4444 %%%% !115+4;^TTNPO-2OYTMK
M'3[6YO;VYD#%+>SM()+BZG8(K.5A@BDD(568A2%4G H]$V^RW?DO-[+S$W97
M[?U?T6[[),+_ %*QTNTN;_4KRTT^PLXFGO+V_N8;.TM8$SNFN;FX>.&"%<<R
MRNB#NV0:HZ%XDT#Q18C5/#6N:-XATPRR0?VEH6JV.KV'GQ!#)!]KT^>XM_.C
M$D9>+S-Z!U+* PS_ )BO_!4O_@IQ\<OV^?V@O'PU/QIX@T/]GSP=XJU;P_\
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MUL(;6TMHB(H((XPJK^AG_!=(:['_ ,%-_C<VL_:18S>&_A _AIYO-2V.B?\
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M]9U/2=>MH6"A3:1:I]LTVXV',C+,(VDVE4=<Y7^<"PG*E3D\ *RD#G.."!@
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MK+J$5P?#^IZYIT<>H2_Z*]>5?'4E/@E\9'4E67X5?$)@RDA@5\(ZN000>""
M01@@BOSCPS\3,]X$S"6'P=.AF.5YOC<+]?R[&SK13Q%2K1PRQV&Q-)RJX?%J
MG7<:LG"K2Q<(QCB8N485X_HGBSX1\/>(^5QKXNK7RK.,FP.+679I@:5";^K4
MZ-;$_4,9A:BA2Q.#=3#PE249T:^$G*4L+4C&4Z,O\U/X3_"WXH?&7Q%9^$OA
M-\/?&?Q)\2W;PK%HG@OP]J?B&]0$A/.NA86\L.GV83+7%_J$MK8V\2O+=7,,
M*.Z_V7_\$KO^"5EW^S%\._&WC7]H".QG^,WQD\&W_@75?#VD7EM?P_#?X?ZW
M T6I^'HM:A2XM;_Q+K#-#<:[=V#7&DVYL[&RM)M0CMFN7^*_^#8R0MX5_:XC
M).U=5^!Y"9.T'^R/B$ 0"3R1G)QU8GOQ_5+@8Q@8SG';.<_SYK]0\=/%+B#^
MU,WX P$*.6Y7A:F >.QE"I5GF&9J>%R_,Z=&<Y1C3P>%IUYTO:4L.ISQ3P]+
MV]944Z$_QSZ.O@SPR\HR7Q,S.=?-<VQ]',XX#+\32HPRW*7#%9AD]6O"$'*K
MC<75P\*ZIU\1*G#"QQ=9T*'MW]8A_FX?'+X->,_V=?C1\1?@OX]L'L/$O@+Q
M)?:9*6ADC@U/2VD%YH/B#3/."M-H_B/1;BPUG2;G:!<:?>VTA"2;XTY'3YB3
MM0YZ%3CT&>6!P>X(YZ #& !_>3^VK_P3O^ G[;^DV$GQ"T^[\-?$/P[I\FF^
M$OBIX66VA\4:3I[O/<IHFJ13J;7Q)X:BO[FXU"/1M1*M9W4]W)I-[ICZCJ37
MG\EWQ?\ V#[[X/\ [<?@_P#8S@^)%IK;^,M1\&6VG^.YM$FLDLK3QD;TP/?:
M-'<SL]U8)9DSI;7#PS22 1R!5W/^_P#A9XV\/\:9?]6S"I6RWB/*\GKYCG>&
MJ4*\\)5P^68>-3,<UP6*I*K&6'E3I2Q4\)5C#&49U:E"G#$PC2J'\C>-_P!'
M#BOP^SAXS*J-#-^$,[XAPV5<.XRGB\/#'4<9GF+G2RO)<RPE:5&I3Q"JU88.
MEC:7M<!7IT:=>I4PDY5:,/DKPMI&M>)M9T3P[X;TN_UWQ'XAU6PT+P_HFFPB
MXU#6=8U:YCL=-TNQM\CS;N]O9HK>",, 6=<LJY(_I7_:F_:T\1_\$^_V<_@5
M^Q5\(M2M$^-^F_"?0Y/B3XTMQ'>0> XM3@EFU,Z%!+%Y3>)?%.ORZ]>:5/=@
MR^'=!AMM1-M+>ZQI5]:?<G[&/_!+/X&?L@ZBGCE;J]^*?Q;A@FM[/QSXHLK6
MTMO#,=U"\%XG@[P_ ]S;Z3=7=K<365SK%Q<WNJ26C-;6TUA;75[!/_,Y^WSX
MAUKQ!^VY^TY>Z\TS:A9_%C7M!MO.,A9="\+^3X;\,1J&.5MT\-Z5IBVR+B,0
M"+R\(0!Y66\5\+>//B!@<DI826-X-X"P=?B:<,RH.C#B3/L17H9/E[JX"HW4
M_L;+(5,3B%0Q3]ICL7.$L32I8&,,/B>G/>!..?HN^%.:\1U\=#*O$'Q2Q^'X
M+IU,FQ/UBMPCPMAL/B^(<V5+-:$(4%Q!G-:&#PBQ."E*GE>$C5C@<35S!RQ>
M$^?M9\3Z]XQU6[UWQ9K>K>)=;OI9)+O5==O[K5;^XDDD9Y7DN[Z6:9E,I9E4
M,$4-\J*, =?\/OB)XW^&6O67BGX?>*]>\'Z]I]W!<P:EH.I76G3+) 59!<)!
M+''=P$EE>"Y1XF4D84X9?+87VR Y'7( /RG=QS^0.?0$^@K9A<YQ_?VD_B5!
M!^G '^\>*_KA87!8K /+ZF%PM7+Y4/JL\%/#X>>"=!PY'A_JDZ$L+[%0?+['
MZNJ:5DJ:25O\VL;B\SP.;2S"CC\PHYIA\9]<I9G2QN+IYC#%JK[>&+ACZ>)A
MC%BE4Y:OUF.+59U+R=9R<W+^P3_@G'^W&_[67@/5/#WCF.TLOC/\/8;(>)EL
M8TMK#Q=H5R1:V/C+3;(%%L[A[M?L7B/3+5&L[#4)[&ZLS!9ZS:Z?8?I57\B?
M_!(W6]8TW]MKP'8:8\Z6/B/PK\0]'\1>69 DFE6OA#4?$$$=QMX\K^W=%T64
M&4%#/'  OF;&3^NRO\K?I#<#Y1P%XDXW+<AI0PN4YIEV!S_"9?3E)T\M>/GC
M*6*P5)2<I0PT,7@ZU;!TG*7L<+B(4(R=*C1M_O9]#/Q6XB\6_!/+LXXMKU,?
MQ%P]G>:<(YCF]5)5LZCE5++L5@,RQ+C"$:F.J9=F>'P^85XQBL1C,&\3*,:V
M(Q"D4445^'']6A7S3^T#^V+^S'^RQ#IS_'WXR^$?AU=ZQ"MUI&A7TU]K'BS5
M;$S36QU/3O!OAJRUKQ9>Z2ES;S6TNK6^BR:;#<QM!)=+*-E?2I__ %_3_P#7
MBO\ -!_:0^+GC[XV?M ?%OXG_$_4K_4O&7B/QWXA74!J%S=S?V19Z;J5SIND
MZ!I\5X[O8:-H&G6MKIFD:9&L5KI]E;P6]M#'$BJ:C'F]$)NS2[W_  /]$7X$
M?M0?L_?M-Z'=>(O@/\5O"?Q)T_3S$NK0:)>R0:YH9N#(+;^W_"^K0:=XFT 7
M?E2FR;6-(L5O%C=[4RHC,/>J_P ]/_@FQ\5O'7PG_;1^ &L> 9]1:^\1>/M"
M\!^(-#TZ>>,>+?"_BB]AT_5/#][;PB1;R*>)EO+5)[>Y6UU"TM+Z"(7-O#(G
M^A91*/*_)[?\$9_)I_P6?_9!\>^!_CQK/[4'AG0]2UWX4_$ZQT2;Q;JNF65U
M=0_#[QMH]CI_AZYMO$)B-Q]BT;Q1:VFGZGI&N7+V]G+K5]JVA20V9M=,?5?Q
MHT"SU'6M1L='T73]0UC5=5NHK/2M*TFSN-0U/4[^[<0VME86-G'+<WEY<2MY
M4-O%&\TDA1(U8D@_Z+=S;P7<$UM=00W-M<Q26]Q;W$:307%O.OES030R*T<L
M,T;-'+%(K)(C,C*5)!_EX_X(K6=A)^V]^U(#8V6=*\*^.O[*Q:0 Z8I^+]E9
M,NGX3_00;5VM2MMY0-LQ@QY7R5M"I:#32?):UV_>N]O*U]+$2C=JW7=GZU_\
M$N?V6O%/[+W[.$>G_$&R.E?$3XCZ_-XZ\5:']I6X.@+/96FGZ#HMTJ1A(-5L
MM&M+8:O!'/<QPW[RPB0/'(B^P?MD?L;> OVPO 5EX=\07;^%_&7AJ[DU'P/\
M0+"PM[W4M N)XQ'?Z7>6\KP-JGAG6D2$:OH_VNU\V>UL;^UN+:_L+:X3[#HK
M'F?,Y=6V]//]"K*UNA_%?^T#^R1\4OV9/B=X;^%GC:[\+:UJWC9K?_A#M5\,
M:G=S:9K%K>ZM;:'8S7::I8:9=Z/=M?7-NMS:SQW$-H7E,5_>PQBYD_;#]BW_
M ()8-\*/$^C?%7]H/5= \4>+- DBO_"W@+P^]QJ/A?0]6A=)+36]?U6_M+)_
M$&KZ:R>;IUC;V,.C6%XPNVEU2X@LY[?YZ_X*T-C]L#]E0<<P>'.O7_DIVB]/
MY?0U_1+6LZDN6&J7/!.5E9W;Z:Z;=.Y*BN9^27XW/G?]J']GCPW^TW\(]8^&
MFO71TF],]OK?A3Q+';+=3^&O%.FQSKIVJ+;%XC<VLD5S=:;JMFDL#WFDW][;
MQ3V\[Q7$/\N_Q=_9T^-'P"UJZTGXF^"-5TJTAN6M[7Q986UUJ/@O6DC=DAN]
M%\310)9.MP"LRV5^++5[9'5;_3K21A&?[$*^-?\ @H$Q3]D+XTX) ;P[;HV#
M@%3JMAPW(^7."?ITXJ:=1P:C:Z;7JF[*Z^]76VE]PE%--]4C^;CX5_"'XI?&
M+5X=$^&G@?Q#XKNWF1)KK3K*:/1]++G#2ZSK]P(M&T:V4@YFU"^@5F811++.
MZ1'^@/X<_L/6?P[_ &5OB;\(VO\ 3M7^)7Q2\.W4_B7Q)&+J+28_$UK83'PM
MI>F$Q)>R^'O"]^[-:RW,$=UJ=S=ZIJ$]I91Z@FF661_P2JD>3]E2QRV57QYX
MX  )VJQU;Y@ 3P>.2!S7Z2TZLY<SCI:,NBZJS5^_33N@C%6UW>_]?J?Q^26>
MI:-J&H:/K%E<:;JVCWMUI^IZ;=QM'=V%_9SM;7=A<QEAMF@FBDC9!P60D,5.
M3NVLV L@8_* 2"22R$?+D;OF(W<\@ @@9Q7]"O[1/[$/PP^/NI/XK^T77@CQ
MZ\:1W/B71+:WFAUI(4"0#7]*D,46H7,,:101:BD\%\MLB0S27$<-LD/Y _#;
M]FJX\8_M*>(?V>KCQ9%8?\(QJ/B:UO\ Q+!ISS_:[;PS-!'<M9V$LRJMQ<).
M6@CGE\F-D(D?:03M&K&2;=TTKRT[6NU;N]EN0XM/UV_R.(^%'@S6_B1X]\,^
M!_#UK)>:AKFJVL+*@D=+738Y%GU*_NF0MY5I86237%Q,R[(HTWD$<5^F_P"T
MU^T]J?AW5&^"_P +-2FTO3O"EG9Z%XC\16[JVH7,T%I%!_8UA=+'L@CM+7RE
MU"\M@)9;AWMT:'RI4'U[\$OV;/A_^SMX?U5_"4%SJOBB]TZ5=5\6:N(Y=6U!
M((Q<1V%O'&/(T[2Q=PQW(L;=6:6<(]W<71AMS%^!MYJ]YJ/B+7M1U$LVHZCX
M@UB^OM^ PO+S5+F>Z#(N /WTD@"@!$P%555<&8N-63=M(6M?JV[W:U5K+9[7
M&TXQ\WH_3_,]AL+^6[G>ZNYI+NZG??/=74C7-S.[E2SS3R[I9F)))9W);N1G
M->Z_#OQ[XD\$ZE;:AX;U2XL9(I%=K59&.FW2#!DBO+/BWFCD!*LQ0. Q,;J^
M#7S!HUT/D))QQQR#T0;1SA03DG&3C'<\^IZ3=@!/0[=P!(P,KC ';@?FQSR#
M6DUS1MT73IHGMV\K$W?=_>_\S]MOAA\0]/\ B5X5M=?M8TM+L.UIJFG>='*]
ME?Q >8H"L9!;SJ1/:-,D<DD#*VTX+'T2O@_]C?4;F:_\:6)F?[(MAH]Z+?<W
ME"Z::ZMVF"?<$GDHD9(&XH ,X %?>%<<E9V-HNZN%%%%2,*\$_:%_:C_ &>?
MV3_!7_"P_P!HWXO>"/A!X1DGDL['4O&&L0V5SK>H1PM<OI?AG1(1<:]XIU@6
MZ/.-(\.:7JNIF%'E%H8U9A[TW0]NG/ISR?P%?YC?_!?_ ..OQ-^+?_!4K]H/
MPOX^O]27P_\  F]\.?"_X6^%[NXN3IGA_P */X/\.>*KK4M.L786D5YXMUCQ
M!>:UJ>IVT*7.HVR:/:7<MQ%HUIY/VG G"<>,,ZEE];%RP>%PV$GC<75I1ISQ
M$J4:M*A"E0C4?(IU*M5*56:E&E3C*?).3C$^9XKS^?#V6?6Z-".(Q-6M'#X>
MG4YU14Y0E.52JX6DXPA%M0BXNI)J/-%*37^@5^R__P %'_V'_P!LW5+[0/V:
MOVC/ GQ*\3Z=;SWMUX.4:WX0\<?V=:F-;O5[7P/X]TCPMXNU'1;1IH8[O6=.
MT6[TNVDFACGNXY)8U;[:X(X.01U'<'N#7^.7\*_BUXY^!OQ$\#_&7X7Z]?\
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MN=,\5:/;"2.%+[5_!?B&UTCQ?I6FSS2K!::I?Z';Z=>3AX;6ZFEBD1/H^O\
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MM[)C)8Z?>ZMI?BNX\'Z[<6\5K<Z[Y_A5-0N+E/#>F01_Z# Z#Z"OE^,.'/\
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MJOX)PZ/I_P 7_">DN+?2O&&BZG&;?0_B[X,TZ5C);Z#KUY;7FF^(]%@EN_\
MA$?$L(MYY(=)U[PPUW]6?\%A>?\ @F!^V^>@_P"&?O&9Y_ZY6YK\JRF.=<*<
M7X/!RE5R_,:&98/!8F,&IPK8;%XO!TYP3<94L3A,7AZRG3ERR4HRISA[.K3?
ML_9QD<)F665IRC&O0EAZM:G=-.-2E3J2A)-6E"I3FK-)W3YHM2B[/^/'_@V\
M_P""0GP5_;3>\_;0^/7B;4O$?A;X _&>ST#PK\ [;2;2+PYXL\9^&M&\+>,]
M)\2?$7Q!=7%W-K?A'3[C6;=O^%?6&E:?#K6H:;;OX@U^^\/RZCX6U3_0S (
M!Z@ 'ZXK^3K_ (-!VW?L%?'W)R1^U-K&><D#_A6'PYQ^@K^L:NWQ)S+'8[BW
M-</BL14JT,MQ,L)@:$G:GA</[+"594Z4+*SG5JSG5G+FJ5)*//-J$(QX^&<+
M0P^4X:I2I1A5Q4/;8BI;WZM3GJQ3G)J[48I1A%6C%7Y5>3;*_AE^$Y/_ !%C
M,,_\U;^/)QGL/V3/BP>GH.W^-?W-5_"]\)9!_P 19C)N&?\ A;?Q\P.__)I?
MQ:'3T&"?ID^F>WP\_P!WX\?_ %0N<+_P)22_&W57TZGD<:1YJG"GEQ7ELMKZ
M*]^CM9=?Z7]T"]!]!_*EI%S@9_SZ?I2U^;'VRV7HOR1_*]_P=1''[/'[+?O\
M9_%V.><_\(%,/ZGWZ5^\'_!/3_DP/]AS_LS[]F?_ -4OX*K\&/\ @ZH8+^SQ
M^RSD@9^-/BX<_P#8@S'IWS@>O7GOC]YO^">7_)@/[#?_ &9[^S-_ZI;P37ZK
MG;_XU!P)&Z_Y*CBEI7_Z<4E=+HN_=KKT_)LABUXQ\>RZ2X4X42T?V<376]K>
M=DWYZGV%7E/QW_Y(?\9?^R4_$/\ ]1'6*]6KRCX\_P#)#?C/C@_\*H^(F#Z?
M\4AK%?FV7?\ (PR__L/P'_J=@C].S#_D7YA?3_8,?KV_V'&Z_+<_FH_X-A7\
MSPO^UTW'RZI\#0>N3_Q*?B&,\_0?IGG)K^JZOY2/^#7Y]_A?]KQL8!U3X&XZ
M9.=*^(9)('3E3]>WK7]6]?I7C=_R<_B?_'E72W_,CRG^K]3\H^C^DO"+A!)[
M4\XZI[\09MV$;H?H?Y5_*=^V.^W_ (+G_ L'I_:GP/!XR?F76P.XQDYY]NG%
M?U8,<*2?I^? _4U_*-^V4Q'_  75^!4??^T_@4S#D=M=08]?F.<=<GG QGT_
M QVXAXM\_#;C7_U55$_S2^?8^7^DK%RX5X(2U:\7/#B5O\.>P?Z_>?U;;0ZR
MJ>C,0?R6OY=O^"S7[&?BGPQ\4;C]K/P)HMUJO@+QU9Z38_%6/3+;S6\%^,]'
MT^WT>P\2:A!;J'@\-^+=(LK""?4A$T%CXHT^]?5KM+GQ/I*3?U&*,;O=B1^0
M'\P:J:AI]CJEE>Z=J5E:ZC8:A:7-A?Z??6\5W97UE>0M;W=E>6EPLEO=6EU
M[P7-O/&\,\+O%*C(S*?D?#;C[,_#;BG"\29=2ABZ:IU,%FF6U:DJ5+,LLQ$H
M2KX?VL8S="O"I2HXG"8A4Y^QQ-"#G"=&K7@_M_&/PIR;QCX(QO"&;5ZF K.M
M1S+)LVHTHUJN4YQA(5H8;%>PDXK$8>K2KU\'CL+STW7P>(J*G5I8BCA:D?\
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MLL+B2-U5TD4AHY$<91XW4E)$8<JZ,RL"""0:_@*MSGT)X([8! X7H0-I((!
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MI;>"_P#$GA+Q)H%E->/+':0WFLZ->:=:RW3PPW$R6T<UPCSO%!/*L09HX97
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M7][9W.N:YK/B77535M<U>:TL/#6B>&_V* P,#H.!6/X>_P"0!H?_ &!],_\
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MA].+;QS\5_A]X3N6;8MMK_B[0M-N"W)*F&YODD4@ DAE4C'(%?@U_P %&O\
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M]X>\0>!M9UW2;2_&UDFLM*\?^&O!GBAH6!#3Z# 4,<H1T_U#_B7\-? GQC\
M^*/A?\3O#.F^,OA_XXT:Y\/^+?"FL)))I>OZ+>J!=:;?QPS02O;3;5,BQ2HY
M"X#!2P/^<S_P:F?L>^+?C3^W]+^U/<Z3/'\*/V3/"/B:YFUVYLEFTG6/BS\3
M?"VJ^!O"O@^TEN5$4FI:5X8U_P 2>.;FXM#/-H<NC>&WN([:37=*G?\ MO\
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M^!;O7HF@O4EMG-NEIX;O9(7#1V]P\=V%CEE,C^4_MT_&W6?^"H7Q=\(?L/\
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M,KAM2D\):=\/= O?!T=TV[SFL8]9UCQW)8%V,9N9M3* 2B?'U_\ LV_LR?\
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M'6GP\^'?@;P)9R1S6_@[PIH/AM+J.+R$O'T;3;>PFOA#D^6;Z:&6[9,DJTS
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MXGF\1Z7X+\=ZGI$EN\_C2U:SEUVP\/ZM;&-I8%F:UDU"(,\*R>2?+#5_)-7
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MOAUX2\,1SF0I'X5M?!MAK-HEJLBLJ6[ZMK>M39BPC3M,>9"Y/Y0:=<_,@ST
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M)XGA^R:-X?34+(V,4>JZ8;:3[2Y,S$R[U51P 5?]U*_E&_X.E'*_#3]E'O\
M\5U\0<# SD^$XNY^@[]O6EX5Y=E^;>('#679I@\/C\!BL5B(8G!XJG[6A6A'
M 8R<8U(<]/FY9PC./O*TXQ?0Y?%O,LQR?P\XES+*<;B,OS#"X;"2PV,PM3V=
M>C*>98&E-TY\D^7FIU)P?NN\9-:)L_IK^"?BK5_'?P<^%/C;Q ]M)KOC#X<^
M"O$^LO9V_P!ELVU77O#>FZIJ!M+7?*;>V-U=2F" RRF*+:AD<KN/IU>&?LP\
M_LV_L_GU^"WPP_\ 4*T2O<Z^(QT(4\=C:=.*A3IXW&4X02LH0AB\5"$4KNRC
M"$(I7>D5J]W]UE\YU<OP%6I)SJ5,!@:E2<OBG4J8'!5*DY623E.=2<I.RNY-
MV5['D'[0/C37/AQ\#?BYX^\,M:)XB\&_#SQ;XET1[^V-[9+JFC:+>7UD;NT$
ML!N;<7$*>;")HC(F5WKG(_,?_@CO^VI\;OVW/A[\7?&_QPG\(W&M^"O&VC>%
M=#;PAX<;PW:C2;_PYIVMSB\MY-1U-KFZ%[/)MF6:)5B/EB,\,/T,_:\('[+7
M[0PS@_\ "G/B%C@\G_A&=1QCCGG%?AY_P;;MO^!G[1)P<CXL>&@2>A/_  @F
MC]. #C('&:_2LARG*\1X2\?9Q7P&&JYKE_$/">%P.8RI\V*PF'QDJWUNC1J\
MZ4*6(Y(JJO9R<K)*4&V?DG$N=9OA_&[PTR+#YEBZ.2YGPQQIC,RRRG6Y<'C<
M5@%AW@J^(H\C52KA>><J,N>#IJ6TDW;^DZL;Q!KNB^&M%U37O$6JZ?H6AZ18
MW&H:KK.K7<&GZ7IMC;(9+B[OKZZ>*WMK>%%+22RR*J\#.2!6S7XF?\%VO%7C
MG0/V2O#VD^&I+VV\+>*_B9HVD>/[NR,\8;2H;*[O]*TR^FA95.GZGJD"^?:S
MAX;M[6)64B,X^1X,X<EQ=Q7P_P ,QQ<,#_;>9X? SQDXJ?U>E-5:E:I"FY15
M6LJ.'K*A2<HJK7E1@VHN9]IXB<71X"X&XIXRE@9YE_J[D^)S&& A)T_K=:$J
M%'#T:E6,9RH8>6(Q=!XK$*$G0PL*]51<E!'Y;>-/VG_@?J/_  5_T7]H^P\<
MV]Y\%=.\;^%Y+KQQ!IVJO9+;:5\,?^$0OM0BLELCJMQ8PZR0@E@LG>:T'VN"
M&1-JM_6WX6\5>&_&_A[2/%7A'7-+\2^&M?LH]0T?7=$O8-1TO4[*;(6XM+RU
M=X94WJ\3X8/#-')#,L<T;HO^<792ME26P0N[@ YQNW,/EQR</C!P?E'M_5S_
M ,$(O%/C;5/@9\7/#FKO>S^!?"WQ#T@^"I[E9&M8-3UO1I[OQAI&FROE(K>S
M:VT#49=.MRL-M>:U=7KQK<:G*[_UM](GPOP& X'X=XDP.9XERX&RK(^$/JN-
M]@_[1RRIB:F'PV(4Z<*;CF=/$R]I4HPC["MA95>2%.KAN>I_ GT1O&W-,R\3
M>+>#<SR7"\GB7GO$G'TLPR]8M/*<\C@H8K%X25*M.K">35L+"5&A6JU%C,-B
MH8=UJM:&-]G#[$_;@_X)W_#O]KJWB\4V-XG@3XOZ3IPL-.\9VUJMS9ZY80AO
MLVC>++)6CFO;2V)_T'4+>5-0T]6,2&XML6Z_@/XU_P""6G[:/@O5);&P^%L7
MCJRBD<1:OX,\2:!=V4\*G;#*8=9U'1KZ.21,&2%;9C"Y>)RP7S6_L0(!!!Z$
M8/T-1F*,G)!Z8^\V,>PS@?A7XIX?_2$\0_#S+J>2X#$9?G62X?F6#RS/Z%?$
MPP$92<W2P.,PN)PV.P^'YY3E'".K7PU.4Y.C"@I.F?T'XP?0Y\'/&/.:_$N:
MX/-^&.)L9*,\RSKA/%X7!3S><8Q@JV:9=CL%CLLQ.,<(PC/,*=#"XZO&$%B:
MN)E&-<_D[^#_ /P27_:L\=ZM:1>.-$TCX1Z )E_M#4_$NK:=JVJQ0*0<V&B^
M'+^_2ZG*@B(2ZE;)&=KR[@2M?T9_LP_LM?#7]ECP"G@OP)9/=7UXT5UXH\6Z
ME'"=?\4ZG&A07-_-%E8+.W3]WIVEP,+6QAW;1)<2W%Q-])*BJ<@<^I)/\R:?
M7E^(OC?QYXFT*>7YYB\'@<EI5H8B.29+AYX/ U<13YO9UL;4JU\3C,?*DY.5
M"&*Q'U>A-NI2PWM;58>QX*_12\(O O&5<ZX6RS'9KQ36H5<*^*>)L51S+-L-
MA:^E?#Y73H83!Y=E%/$04:>*J8#"1Q>*I15"MC5A^;#U2BBBOR(_I,**** "
MBBB@#^1[_@Z;_P""6WCW]J?X6> /VV_@!X4O_&'Q9_9L\,ZQX1^+'@S0K*XU
M+Q1XU^ 4M_<^*;36O#UE \L^IZI\(/$EYXFUMO#^GV9OM8\->-_%=]#)<7WA
MW2]*U#_.[LYXY%66.1'CD0;)$8.LBG!."N1\X( (/'4=:_W)",X[8Z$5^)'[
M87_!O?\ \$R?VRO&&J_$?Q7\'M5^$?Q)\0WUQJ?B;QM\ =?B^'-UXHU*Y53+
MJ'B#PV^F:UX(N]2N+D2WNH:M:>&-/UK6+VZN[S5]3OKN8S+^R\!^*%#A_+:>
M1YYA\36P.&G4> QV$C"K6PU.K.526%KX>4Z<JU&%24Y4*M*I&I252=.<)P4)
M+YO-<CGBL1+%X64(U:D5&O3J-QA4<4E&I&2349Z*,E)<K6J:=C_*IA8*PPPV
M]2Q( *D*O.>5Y ;/ &,$\DC^E3_@WR_85U#Q#\3/$7_!4'X[:+?^'?V1_P!A
MG0?&'Q<T;Q#J6G3QV_Q0^+?@'1K[4].L?"CO+:R76D?#!K:7Q9XB\16:WEC#
MXGTSP_X16"[FU#79O#_]0GP._P"#6_\ X)8_"#Q/8>*?$WA?XN?'>;3Y1-!X
M>^+WQ$%UX-:>)@]K+=Z#X,T7P?-J(MY%25K74M3O=,O"HAOK"YM'FMI?U3_;
MD_9]C^('_!._]JO]F?X.>&=!\+CQA^RK\7OA/\.?"/AG2--T#P[HK:Q\-]<T
M'P_H>AZ)ID%CI6E:;;M+;VMEI]E;VUI;H(XH8XT  ]OB7Q5RS-:,,FR6GC*=
M/,:U#!8_-,93AA8X; 8NO0PV-^JT74JU76EAJU:*KU7"G1IRJRC"53EE#@P7
M#E:C4>+Q<Z<I4%.K1P]-NISU::G.BZDK05HSC&7LX\SFU&+:6C_RI_VR_P!L
M_P",7[>W[1/C?]H[XTZW?7NJ^*]2OCX3\,27DL^B?#;P/YS2>'? _ANU)$%K
M8Z/IY@BOKB""*76M3%SJMZ'N+@A/GFRE.W9NY4 IQSN7)(Z<XVYYZ]JXR%9X
M':*[MYK*]@DE@N[.[A>"YL[N#]W=6EU;RJLD%Q:SQR03P2*LD,L;QN@92!TU
MG+L9.,]<\]20  !@@'!"YZ]SP:_<,+AZ&#PU#"X6C"AAL-3A1P]&E%1A3I4H
MQA",$K67*E)O5R;<W*3DV_RW-%4K2G6JMU*M23G4J2]Z4I\_O<TFFW=723;M
M9QBE%)+[^_8!_;;^*G[ W[2'@CX\_#'6[NWL;#4].LOB1X2-W<1^'_B)\/Y;
ME%\0>&O$-C&6AND^PO<76DWS1->Z1JB07VGRPSH2W^I7\6?VR?V?/@7^S1:?
MM9?%;QU;>"_@UJ'A'PSXPTG5M4@D_M?6X/&>D6^L^%?#^AZ'!YU[K'BO7;>[
M@BL="L5FG,OG2SR06-K=WD'^0)I5A?ZU>V6B:7:RWFJ:O>VNE:99P*TDUY?Z
MK<)8V5I%'&&>1Y[F:*-552S%L 5_0Q_P7;^*7Q#T#QC^R'^POKMW?6GAS]D[
M]D[X+'6M"DNF>&Y^+'C'P;:?\)/?7\"DV[WN@6NFKH%C+"2D-G)/$QDE9Y3^
M<\=<&X+BKB'A:DZBPM>O#,O[4Q-&--XJKE& I82I%1OI*M'%XF.#P]:JIQI*
MO-.\:,:;[N'N(\5P]E&?58Q^L4Z3P2P%*LY^PAF.,J8B#5XV:HNA2>*JTX2@
MZDJ*2Y95)3-?_@L7_P %DO#_ /P4STWX?_#GP!\&=8^''P[^%GC?6_%6A>)O
M%WB&TU#QCXM;4=*DT."34/#^E6HT?PQ";-UN7TZ/6?$4R3@#^U6C)6OV-_X)
M7_\ !PG\ ]/\ ?L_?LB_M'^"-0^"X^'7PT^&'P4\)?&:UUF+Q%X UIO!'A72
M/!6D7WCBS>RL=6\"G58M(M9;C5(I/$.CP7UYB\_L?3H9;Y?XA;1UPP!R<;E]
MB&)S@CH3QC_9YYKH+>56W!]K(058,.&7D.&Q@D?,,@8SG'T^RQ7ASPMF7#V$
MX:GAL1AL#@*F(Q.7U:&+KO%X7%XN*A6Q7/5E.&)G45O:4:]/V$^514:.DH_F
MCX\XERO/\1Q%3KT:V*QM*AA\?2K86E]7Q.$PU12HX:5.G&$Z$:4I5%"K0JQK
M4^92<JK3B_\ 8VM;NVO;6WO;2X@NK.[ABN;6ZMI4N+:YMIXQ+!<6\\3/%/!-
M"RRQ31,T4L;*Z,58$_ 7_!03]MS]EK]E;X.^./#OQS^,'ASP=XN^(?PY\;:/
MX)\#1+J'B'QUXCNM6\.ZQI=A<V7A#P[9ZIKEOHDNH'[%+XGU2TT_PQ:796WO
M-8MY713^0G_!)/\ X*(ZUX/_ .",?Q?^+/Q)O9O$VM?L76GBWP=H5QJRS7@U
M:QBT^RD^$V@:K)%);WES;0ZIK>EZ%>W0O#<QZ44$+QBWA0?QD?%3XN_$3X\_
M$[QK\9?BOXDO_%_Q%^(>NS^(O%/B#4F#7%W>S8CMK6WC7$-CIFE6$,.DZ+I5
MHD.GZ1I%I9:;IUO;6-I# GXSP+X05\VXESO#YOCJF&R[A7-H8.=7"0@L1F>+
MI.CC</"C*MSPP]'ZJ\'B,34<*M2+KK#TH<[=2'Z-X@^,-+).&,GKY1@:>*S+
MBC*:N+IT\7.;P^782K&O@:TJ\:#A4Q%?ZT\5A\/3C4I0<:#Q%6:C:E/^D'_@
MW*_;'_9M_9FO?CW\._CW\5-#^%OB'XP:M\(8?A_<>*K?4[/PSJT_AS3_ !K:
M:K#J/B^.QF\->&'CGUNP$$WBG4M&L[D2%+>ZDF4QU_;?;7-O>00W5K/%<VUS
M%'/;W%O(LT%Q!,@DAG@FC+1S0RQLLD4L;,DD;*Z,RD$_Y%UHRDJ,*P8HI4C<
M"C'<1T*X&=O?A#V.*_LP_P"#;O\ ;-\9>.-#^(/['WC_ ,07>MV/PUT#3O&W
MP=;4&>YN='\)3WSZ?XD\(6UTV]ET?1M1N+"_TBUE<)90ZG+96:);P!!]EXW>
M&<JE+,_$#+<76JUHO!U,ZRZM&G*$<+"GA<OCC,#4@H5(K#J.'>)P]=5$Z<YU
MJ-5.$J)\!X$^*GL:N4^'.9X.A3H3>,IY)F5&4XU)8JK5Q>82P6/I5)2IR]NY
M8E87$4'3<9PIX>M1DIPK+]3/^"M7_!0B^_8)^!VAW7@C3].U7XU?%[5-6\-?
M#"WUB*.ZT?0K?0;2PO/%OCG5-/=XVU6#PW#JVC65AI8<07.N:]I4E_YFG6]W
M:W'\1/BC]I/XY_$/XP0?M >,?BAXIUGXR6E_IVI:7\09+M(==T>?1VD.CKHT
MEO#';Z=;:+YC1Z7;6\ AM(G,:(5)%?T^_P#!QS^S;X[^(7PI^"?[1'@S1]2U
M_2?@7?\ CO0?B18Z9:S7LVC>$?'T'A>_L_&MS%"&>#1/#NJ^#WT_7KM8Y!;1
M>(K&_NC;Z=I][<Q?R#6$H&0"&7(VE<-E"#R#TQP"#GWYK[_Z/>1\,QX)IYKA
ML-@\5G688C,L)GN*JTJ-;%4H0Q3HT\IE[3VCHX&>"5"O]7Y*=+&?6:E6JL2D
MH4?R'Z4&?\65./ZN38O%8["9%EF&RO'<.X.C6Q%#"5JCPL*U;-X>QE16(Q]/
M'_6*,<3S5*V7RPU*C0>%E*52O_;7_P $;_\ @IEXT_:VMO$GP+^.5S::E\7_
M  'H,/B;0_&-K;V]C)X]\&Q7=KI5_+JUA"JQCQ#X>O;JP34=0M4B@U*UU.QF
MFB2^%Q+/^\3#((_SZU_(+_P;R_L^^-=8^-WCC]IB]TO4-/\ AUX3\":Q\.]"
MUBXMIH;'Q1XL\4:KH]QJD&E7+;8[R+PU8:$$U1HEE@6\U:"#SDN;&>&OZ^Z_
MF[QIRGA_)?$'-L#PY3HX;!?5\!7Q6!PUEAL!F>(H5*F/PE"$925&$9.A6EAH
MM0PU3$SHPA3BE2I?U?\ 1^SOB7B'PNR7,>*JV)Q6.EB<SPV#Q^,YOK>891A<
M5"CE^+Q%2<8SQ$VEB:$<7).6*IX6G6E.K*]>M^-O[7W_  1N^#7[2OC_ %?X
MK^#/%VK?!KQ]XDN%O/%7]EZ+8Z_X1\1ZBY7[3K=UH$MQIEU::W>( +R[L-5@
MANY!Y]S;2SEI6]0_8E_X);_"#]CK7A\01K^K_$_XJFQFT^T\6:]866EZ;X:M
MKQ'M]1'A/0[1IVTVXU"TDEM+N^O=0U&^:TFFM8ITMII(G_4*BO'K>*/B!B.&
MEPA6XIS*?#_U>.#>"O0C4G@8J,88"KCXT(YC5P,80A36$J8R5)TH0HS=2A%4
M5ZV'\$?"G"<8_P"OV'X(R:EQ4L5+,(9C&&)]C1S*I*I.IF>'RQXIY5A\RG4J
MU:CQM' 0JQJU)UZ<*.(E+$R!Q_GK]:***^!/U0**** /XJ_^#B[_ ()Z^,O"
M_P 59/V[_AKX=NM:^&WC73](T?XX1Z3:2SS>!O%VDPQZ5H_C35XX_-D7P[XH
ML19:7>ZOC[-INKVEG;W:VT=]:R2_S%6-P&56W!Q^[3/K\P*OG'(.5; SG@$X
M!K_6]U'3M/U>POM*U:QL]3TO4[.YT_4M-U"V@O;#4-/O87MKVQOK.Y26VN[.
M[MI)+>ZM;B.2">&1XI49&*G\5?C7_P &_O\ P3L^+_B*_P#%.D>"O&?P7U34
MII+J\LOA!XL&A^&)KN:X:::X7POK>F>(=,TY7#O''9:&-(TVV4K]FLXEC5*N
M,[*S^5O^'(E"[NOG<_@9LKA54&1@H53YA;  !V%P21T4MYA/3&5'&<?TC_\
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MLZ;IWA21I;5[O2?A4]G-XV\3^(;3[990>)]'\->#U@NY]2U^3P[_ %"? _\
MX-:_^"5_PA\3V'BCQ-X9^+WQXDT^;S[?P[\7OB*;GP<T\;;[::[T/P7HG@VX
MU#[/)ME-KJ.J7>EWC((K[3[FU:6WD_5_]M/]GV/Q[_P3Y_:G_9C^#'A?P]X3
MC\:?LH?&;X0?#;PCX8T?3?#_ (9T.;Q%\,?$?AKPYHNB:'I4-AI.DZ9:S7=K
M;6=A906MG;QA(HDC0#'M<3>*V6YI0AE&1TL93IYC5P^"Q^9XNG##+#X#%8C#
MT,:\+1<ZU3VSPM;$15>K*-.C'GG",IM.'#@N&ZE"H\7BI4Y/#QE6HT(+VG/6
MI0G4I.HTHIJ-2$&J<5S3=ES);_Y5G[:'[:_QA_;Z_:'\;?M&?&;6KV?5/%&I
MW8\&>$Y+N2YT7X9^!FN9#X<\">&K=@MO;6FCZ;Y$6HWL,,,VO:J+K6+T&XN0
M(_G>UN-P5BQ(.0V>@PQPV,<@8P3P2,9QFO/(OM5O(8;RVN+"\MY)+>]L;J*2
MVN[.]@=H;JRNK>94FM[BTN5DM[B"55DBFB>*15D1E'2V=SDAB2>HP>2P(R "
M!P< ''&01FOW+"8?#X/#4,)A*4*&&PM*G0HTJ:484Z4(048PBM+<J3;UE.3E
M.<ISG.<_RS-</5KU*M>JY3J3G.I4G/6<Y<TW-MV=][1L[)Q459127Z#_ +!7
M[;7Q6_8+_:*\$?'SX6ZS=VR:5JEC8_$/PD;NXA\/_$7P!+=(VN^%?$MFA:&[
MAEL7N)M)OFA>^T34U@U+398+F++?ZD_Q._;*_9[^#'[,UC^UM\4?'MGX,^"^
MJ>"_"OC?2=;U:%QJFL6?C?1[/6O"FB:+HMN)KW6/%.NV]];PV&A:<D]S+.TC
M.8K2"XNH?\@+2[>\U>YL]*TR"6[U#5;BVTS3K2)7EEN;R_F2TM+:&*,,[RR3
MS1QJ%!+%L '-?T._\%U/BE\1?"^O_L7_ +"'B&\O;+0/V4OV1/@K>>)-!:Y+
MP77Q>\8>$(+;Q)<W\0)MY;KPS::.="TR:,;8K:\NHG,D^9:_-^.N#<!Q5G_"
M]'G6$K5EF;S.O05..)JY1E]+"U4HIVC*K'$XB&%P]6I&:IK$5$G)48TGV\-\
M0XOA[*<_J0I_6*=)X/ZE0JN?L*>88JK6I7:BN90GAZ,J]:E2<?:3HQ=HN=2H
MNE_X+"_\%EO#G_!2O2_ OPU^'_P9UGX=_#SX7^-]8\5:)XI\8>(+6_\ %_BT
MWVER:- ]_P"'-'M3I7AB%K.07#:>FM^(9XY@H_M1E+(OZ\?\$L/^#@WX"Z)\
M._V>_P!D7]H_P1J/P<A^&WPQ^%_P3\*_&NSU9/$/@+61X#\):+X'T;4/'6GR
M6-EJ_@8:M%I%M+<ZM;/XATBWO[O_ $V/1]+BFOH_XCK:XR5P1QD@D')('<D9
M.,,?3 ]QCHK6;("LJLK @!C\A#@CE<@$,"%8' R<8QFOML1X=<*9APYAN&9X
M7$4,!E]3$8G 5:&,KO%X;&XJFX5\8JM64X8FI5LO:TL11E0<>:%.G0O&2_,'
MQQQ1E/$&*XCI8JE6QF/AAL/CZ=;"4?JN)PF$JRG1PLJ<(PG1A2BY>SJX:I&M
M3E)3G.M;E?\ L7VEW:W]K;7MC<V]Y97D$-U:7=K-'<6MU:W$:S6]S;3PL\4]
MO/$Z2PS1.T<L;+)&S(P)^#?V^OVU_P!E[]E;X1>,M$^.GQ?\-^#/$_C_ .'_
M (RTCP7X+1=0U_QOXCN]5\/ZMIMA<6'A'P[9ZIKD6C27^;*7Q+J-I8>&K.[*
M6]]K%M(ZJ?QW_P""0?\ P4-UCPC_ ,$<OC-\3?B1>3^(]3_8ILO%?AK0;G4U
MDN_[1T5-+M[SX7>']2E22WO+FVM-5U*VT2YN6O&N8M',,<$D26L,8_C8^*OQ
MF^(GQ^^*/C/XR_%GQ'>^+?B'\1-;N=?\3:W?R;YI;F8+':V5HB@0V6DZ19QV
MND:/I=JL-AIFF65I96,$%M!'&OXOP/X/5LVXFSW#9QC:F'RSA7-88.I5PD::
MQ.9XN#IXW#0H.LIT\/1^I_5<3BJDHU*D/K$</1CSOVL/TKQ \9(9%PODF)RC
M+Z6)S7BC*ZF+IT<9*<L+EF%DJN#Q,L1&BZ=3$U?K2Q6'PU-3HTYQHRQ%::@G
M3E_2!_P;O?MB?LW_ +-.K?'[P/\ 'OXJ:'\+M:^,5]\'+7X?W7BFWU*S\,:K
M=>&H/'UKJ\&I^+H[*;PYX7,4GB#2A#<^*-2T:PN#,R0WAE3RF_MBM;JVO;>"
M[L[B"[M;J"*YMKJVE2>WN;>>-989[>:-FCF@FB=)(I8V9)(W5T8JP)_R0["Y
M# QOAE(VG<<@@[5R0P(Y.[C&>HSSS_8Q_P &XG[9OC'Q?IOC_P#8Z\=:_=:S
MI?P]\.V?CGX.'4#)<W.C>&I=0:R\3>$;2Z969-'TZ]N;/5-*M)76*R2]N;:S
M2.(;3]IXW^&?MJ>:^(66XVK4KQ>%J9UEM:,'3CA:=/#Y?'&9?5IQC.*PZ6'E
MB<-7512ISG7HUHN$J!^=^ OBI]6JY1X;9I@:%'#26,I9'FE"555)8NK5Q>92
MP.84:DI4Y?6)2Q,,)B</[+DG2IX>O1DJL*Y^KW_!5O\ X* 7'["7P-T74?!E
MCI^J_&3XL:KJOACX96^KQK<:1HR:/:6EUXI\:ZI8,8VU2W\-0:GI-M9:8)$A
MN];UO26OC+IT-Y;3_P 4_B;]I'XW?$CXMV_QV\:?$OQ/K/Q?M+[3]1TSQ[)<
M16NLZ-<:-+)-HJZ.]M#%!IUMHQE:/3+:"(0VD9V*K MN_IA_X.*/V</'GQ!^
M$'P9_: \&:3J6NZ3\"]2\;:3\1=.TRSEOKG1_"/CNW\/7L/C::.'?)#HOAW5
M/":V&O7"HXM(/$%I?W#0:?I]Y<1?R(Z=><*ZR;E*J<YR-I4<C:2"/3/MT')_
M0/H[Y)PU#@B.;X7#8/%9SF.)S+!YWB:M&E6Q=&"JRH0RFI[53E1P53 ^RKO#
MJ$*&.6*G4K+%QC&%#\?^E1GO%=?Q J9)C<7C\'P_EF&RG'</X.C4K8?"5:LL
M,JU7.H.E*$<1CJ>8/$48XISE7R[ZK0HT'A)SE.I_:G_P1]_X*6>-/VJ5\0_
MCXY75MJ?Q;\$^'U\2^'_ !I#!;V4_CKPE;3VNGZA_;%C;I'"?$.@W-Q9F]U&
MUBBM]0M-0M))HQ>B:6?]W,!U7))X!X)&21UZ#ZC@?3M7\B7_  ;\_L^>.-?^
M.'BW]I>YTS4=.^&_@_P-KO@'1=;N+1H;#Q5XI\37VDR:C9:/<NR_;%\-V.E#
M^TI(4EMH[G48K9KA;JW:$?UW@8 'H /\]:_FSQMRGA[)?$3-L#PW3PV'P:PV
M7XC&8+!\OU3 9MB:,ZN/PF'A&<X480?U:M/"P?)A:V)JT8QI14:%#^L?H[9U
MQ5G_ (6Y/C^+:N*Q>-^MYGAL!F&.4_KN99+AL11IY;C,34J*-3$SM]:PT,;.
M\L;1P='$2J5F_K%;\B?VM_\ @D/\(OVD?'FK?%7PEXOU;X/^/?$=R+OQ2=+T
M>RUWPIXCU%R?M&MWV@RW&GW-OK5T@5;N\T_5+6.]E N+R">;+5Z%^QG_ ,$Q
M/A)^R5XA'Q!FUW5?B;\3TLI[*R\4:Y8V>F:;X=BNE>&];PQHEHUQ]@N;ZUEE
MM+J]N[Z_O'M7DMXYHH))$D_36BO&K>*?B%B.&8\'UN*\TJ</+#K!RP+E052I
M@(J,8Y?6QZPZS&M@(QA""PE3&RI.E3IT)N>'A&@>M0\"/"+#\:KQ"H\"9)#B
MV.-EF=/,E#$NC1S6<ISGFU#*WBO[(H9I*I4J5OKU++HUE7J5,3"-/%3>) #
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MQPQQQ11I%%$B1QQQHJ1QQQJ%2-$0!41% 544!54 * !BGT44AA1110 4444
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M[.?P,_:/\,?\(?\ '3X6>#?B?X?C,KV=KXJT>WOKG2;B5 C7NAZH%CU70=0
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MG\9?#WA[Q)XYTSQ/]@K]B7QC_P $\YM:7X0_LN>*?$6GWW@KPU\.M$@U^_\
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M ^'X*Z_KOQQTOX_ZS\'$^/'A#P'<>"_"]SKEC>Q>,OAIJ'AG7](\9:+K^J>
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MNO\ @KC\;[7_ ()<7?[14W@+X/P?MW6>K:Y\,7^$\T'C1?@L_P 0]!^"U_\
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MTN]&I:9+=VEO<R:=J*V]S:+?V#SQR/9WJVMY=VRW5L8IQ;W5Q )!%-(C7@
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M? ,?Q)^/6L>.='\&>*]1\5?LY?#;Q)\</AO\-? GQ&^(?BGX2^ O'_Q-\?>
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MO\)_&W]C?X:ZQ\)/$GP9\7_!OXC7'PU_;4^,UM\)/A-\?M"\/_$S2]&U&_\
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MC>(+C2-,O;^6"/Q'0O\ @CKX)C\ :K\,OB+^US^UG\9?"C?LE>(?V)?!</Q
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MIXBU_P <Z;;^ [W0]7\1?;7Q&_X)R_!SQ]>>)?$NF>._C#\,OB=K7[0'B?\
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MTI4G57-%3HNM%7Y9*,Z#K*#34^1J-914FJCA**FU.[/RK_9^_P""PW@CP_\
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M^",'[+GACPWXO\%VWC[]H74/!7B'X&?$#]FGPMX1U/QUX1?1/A1\#_B#\0_
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M-?@Y^U5\#A]N\1:5.W_"%_MA?&:Q^.GQ5GS'X=@_XGUAXRT^"U\&:@ +?1]
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MZ.VJN][+F7-IU?+S65UK;5;C7Z/RUL[:J]M;:V=MVFKH^&[[_@LM\$KOX9>
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MRM&3B7VZ7O:_DE)_^ IIMNR5XW=Y)/Z'HJ,2Q$R 21DQ2+%* ZDQRND<B1R
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M=^#?"UYKMW=:=X'U_P 9'1/$$NE?*WAC_@J]^SOXD_9Q\8_M9W/PY_:G\'_
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M\$LO@1XH^%GPU\)_M-^(/B;^T9\2O!W@#QU\+_&7Q=N?C7^TC\.]<^+?PO\
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M ;64G@?B#\4O ?PNTS0=9\=>*-+\-Z7XG\>>!_AAH5[?FXDBU/Q_\2?%^F>
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MZGH'A2QU#6K3Z!^#7QS\*?&^'XD3>%K#7]-'PO\ C#\1O@GKR>(K73K*2_\
M%/POU6'1O$6IZ$FGZMJOVSPS/>W$0TJ_O#I^H3QDF^TG3I"D3).ZNME?7IHT
MGKY76]NZNM0_*]K]+M2:7JU&3TOL[VZ^T45$)X&61EFB98FD25A(A6)XO]:L
MA!PC1_\ +16(*?Q 4IFB'E RQ@S-LA!=?WK^4\VR+G]XWDQO-M7)\I'DQL4D
M $E%>3>+?C1X'\$_%#X1_"+7[R^A\8_&^7QW!\/[6VTN\O+*^E^''AF/Q=XI
M&I:E"AM-(6VT65);0WCJ+^?-M;[I1MK:TKXI> =;^(7C?X5:5XHTZ]^('PVT
M'P1XG\<^&(Q<K?>&]!^([^+8_!&I7\LL,=F8?$+^!?%GV1+>YGFB31;B2\CM
MDEM6N%>Z4NC<DGT;@XQG9]>24X*5MG.*>XFTM]/AW_O<W+_X%RRY>_*[;6._
MHKB;7QUI]WX_\0_#U=&\707GASP;X4\:W7BF\\*:W:_#S4;/Q9KGCC08M"T'
MQ]-:+X8UKQEX>N/ 5_?>,O"-AJ$VN^$]%\0>"M8UNSM+#Q?H<UWPWB?X\>$_
M"OQX^#O[/E]8:]<^+OC=X#^,GQ$\):M86NG3^%[/0O@=>_"BQ\6V^O:A+J]O
MJ5KJ>HR_&+PO)X:AT[1=5L[Z"QU]]2OM(:UTY-4I)MI)-MWLO12?Y0D_2+8.
M22;;TC:[Z).4(W?ES5*:;ULYQ[Z>WT444AA1110 4444 %%%% !1110 4444
M %?!/_!37XE3?#7]BCX[-9VW@*ZU;XB^!/%/P;T&/XE?&OX9? 'PG#KOQ7\,
M:WX,TK4M3^(GQ;UK0?"-K9:+=ZHFM:OIL=]<>);[P_I^L2>$]$\3>(+6P\-Z
MM][5X/\ M.?'W0OV7?@1\2OCWXF\,^)_&6B?#30!KEYX4\%_V!_PE?B&2;4;
M#2;#2-!/BK7?#'AJ._OM1U*T@2;7/$.C:9 CO/=W\$4;-455"5.4*E^2:]G)
M1OS255JBX1LF^:I[;V<;)RYJL>5<W*5"4H3C.&DX252+LG:5-^TC*STM%TU)
MWTM!WTN?S0_$CQ_\,?#VM^+/A'X%_:._8&^)OP^^+M__ ,$H?%NN_&N/]O']
MF_PAIW@.;]A/XG_"6[^+7AW5? GB#Q2WB_Q'K6M>'?AAI_B7X8W&BQ2:%K,&
ML:]I?BC6O!&K^&M$MO'/6_"_2?V(?AS\2?A!\<O!?[3?_!/_ .&?[1&K?\%&
M_P#@IW\3OCS\?O#_ .U)^S9=_$C4/V4_VD/^'C&K? ;3==UI/B3%J/C3P1'X
MT^)/[(WCI/@FE_-I/AWQOI-KXNO_  YI?B70_%.M0?O?8?M@>#O!7P@_X7'^
MV/H%O_P3VT1O&1\%6]A^UU\:/V8_#D5Y?W-E%>:)<6WC?X;_ !Q^)7PN9O$8
M35HM&T*3QS'XLE;0-5GN?#]M9K:7-U[CK'QE^$/AZT\8W_B#XI_#C0K#X=_#
MC3_C'\0+W6/''AC3+/P+\(M6C\6S:5\5/&-S>ZI!#X8^&^IP^ /'DNG^.=;>
MQ\,7L7@CQ=);:I(OAO6#9[5ZDZZJJK.2=6I5G4G3;IOGK?6)U.64':%WBZTD
MD[I2C>_)%F5.$*3IJ"TIQIPA!VG%JDJ5.GS1FGSV]A075-P763O_ "^_\$:Y
M/V5/V+?%_C+7?BI^V'^SOX.\4O\ !+P%\)OB-KUS^V3_ ,$PKCX9?M!_$CPQ
MJ,=_JGQDTNT_9F^$OP=^-'Q7U".]3Q'=^'OC1^VEXHU']H273OB#XGTWQ1H^
ML:YKOB+Q;<=7\1?VIOA)^V!\>/VK?#7[1'Q(_9I^''@_QG\"_P!KO]B_]E#X
MY:3^W=^PCXI^%'P3^"7Q?\)S:#K/QSU7POIO[0__  O#Q;\:/VE];\)^!-3U
M6&?X=:-IWP8\ Z-X)^%'AZQLKQ_CE\4?B[_1Q%^T=^S[/\5K7X$P_'7X-2_&
M^^&L-9_!J/XG>"7^+%TOAW3+/6O$!M_ATNN'QA-_8.C:A8:OK7EZ,W]E:9>V
ME_?_ &>TN(97\>_X;?\ @GJ_[4_@W]E'X?\ C3X>_$[QUJ6E_&FX^)J>!?B;
MX/\ $6L? S7_ (.P?#RX;PC\3_"&BWFIZUX:\0>*(?'DKZ?8Z]_8=Y9IX?OG
M>TNEFS;Q-*K[LHWYZ=6G%0BH\JG&NIRARI1BXPG6BI>]&G%N#M=(TA)T)>UB
MY1E"K2K<\N9M3A4H2I\R:]Y2G3H2<9*\W%25[-GXW_!W]NGP-8?$BW_:K^+'
MCO\ 8TT3QK^S_P#L=:5^REX(^ WPZ_X*#?L<^)?$GQY\:>)OB3X \5_%KXA>
M%/&&N_%3P5X"\)?"C18/AKX2?X2P_$C7O"GQ!\1V>I^._P#A+_ GP\O['P_I
MWBGYV^%_CG0?'_[ G[!_PDU#]O#_ ()]?LK_ !/_ &'_ ($ZI\)M:^#_ ,<?
MBW^SM^U%X1^,?Q,T/]G+PO\ !7P/\;?!_B7X"_MX_!FU\('PQI^K_&72? &G
M^/\ 6?%NFVVI^/+?QWXF^&NG^+/A]\._$-C_ $H:1^V/^R/K_P --8^-&A?M
M3?LX:U\'?#NOZOX3\0?%G2?CA\,M2^&>A>*?#^EG7-=\,ZSX\L_%$_A73/$.
MB:*KZQJ^BWNJP:EIVE(VH7EM#:*TPZ/PK^TS^SEX[\?:?\*O!'Q_^"7C+XH:
MM\.])^+^E_#;PI\5O GB+Q_J?PFU^+39M!^*&G^#M(UZ[\0WGPZUJ#6M'GTG
MQO;Z=+X9U*#5M-EL]4FCOK5I74G*K&K";;]M[3VCLE[U:>*KU))<MN:I/&UZ
MK4DX<LXN$8TU&3F$52=/DO'V/+&FGKRQI4J&'IQ?,G=4Z>%HT[V;<HOVCE.4
MHOXS_94^%NO_ !J_X)Q?LM_#F+]K=M,\0^$OAG\.O#&L_'3]A3Q'\/++1KK4
M/ACI+^#=1\"Z#X@US4_VF_"&J6OAR;3!X/\ '>I:=K^J+XA\7^%]3UK2E\(6
M-\OA32_J#X*_L_:_\#_#OC?2M5_:-_:%_:(G\5^3+9WO[0_B+X>^(;SPR]KI
MU[9K8>&I? 7PS^'%M::?J<MU'<:I'JEMJTDEQ;6SV]Q:1+/'/<U[X^7%I^U/
M\.?V9/#GA2'7[K7_ (.?$SXW_$KQ:^N26</PR\*^%/%'@;P)\/--GTBWT?4?
M[3U[XP^*_%7BH^$H;_4_#UE_8'P<^*6H)=7U]H]II=W\U7'_  4H\(Z=^TAK
MGP)UG]GSX_:7X%T3]I7PS^Q_/^U"5^#.H_!"+]HCQE\)O"OQ=\*>!=2T+2?C
M#??'[2+'Q'IOC;PKX3TOQM=_!3_A!T\<:_I.C:KXATNUN9-2@C$7Q<<1&?-?
M%QQ//RI\S5>I4HU)1YKZNMBG"FY.\ZK45SS;C-PC[-0459452<59OE2@JD.:
MRO\ PZ:E*][0]YM;Q_*3X1?\$P_VJOV=?V:+3X?^"?AGX$^.WB7XK_\ !*K]
MFSX)_%#PG^U=\0K+]I#2?@O^T#\!-7^'EO\ %CX)?"*/XZ:_X_\ #,OPK^.O
M@[QY\2O$OPN^%:O_ ,,E?#CXX?L\^![KQ!X<T?X;>/O[/@ZC]E7_ ()T_M.?
M"OPSX!T;6_A-+I7@OP/^U#^V#\3?!OPWD^)_P"^%>N>$OA!\;O\ @GW9_"7P
MAX<LKW]CSX;_  D^#7P:\4:]\<=3\667BE?V=?A9I>G^!O%6O>(?B'87OQ#O
MKJ_^*7C;]X-%_:A_9L\1W'Q4M/#_ .T+\"]=N_@5K=KX9^-]KHWQ:\ ZI<_!
MKQ)?7UYI=EX>^*T%CX@GD^'>MW>IZ??:=:Z5XO71[^XU"RN[**W>YMI8UH6'
M[6_[*^K?#F;XPZ7^TO\ L^ZE\([;7=>\+7/Q4L/C-\.;SX;V_B?PM8:GJGB?
MPY/XYM_$DGA>+7_#FF:+K&HZ]HSZH-2T>PTG4KW4+:VMK&ZEBU=6<G4FU']Z
MFW%1ERQISJ8BK",5S.2BOK4X1O)WBE%RG)3DSETY4FKNS:3YG)>R<E>SM*]&
M#DDE)>]>,(M6_FEUG_@D[^T?J/[-_P "_AQ:_LU:%X:^"/P?^/'Q@\03_LL>
M"O!G_!+=/C7\2]"\9?!'X)^"_AU\?OC_ .%OB'^SQX__ .";WQ;^/GP^\>>#
MOC#X0'B?2? W@+QM>?L^>-_ 7B6W\7V?Q4T'QWX,\:>I_'__ ()<?'37_!*>
M"X_V6O!_[4OBR[_81_9&^!_P)^.?QX^./PZU;XH?L8^./V=;3QM)\4?#\?Q#
MU+P)H.LZ[XD^)?\ PDNE76F_$;X->"/!^F?'OQ39WO@W]H#_ (5C\-=*\-^(
MD_H,N_VL?V6[#0_@YXFO?VD_@#9^'?VBM9TKPY^S[K]W\9/AU;Z)\=?$&O7%
MI::'H7P;U67Q&EC\3]9UJYO[&WTK2_!$^N7VHW%[:0V=O-+<PH_!?M&_MH?!
M_P" G[+?Q8_:<TSQ7X"^)NF^!?@?\?/C-X"\+^'?B1X7@?XU']GWX;>,OB3X
MM\)> ->MY=9M]5U"#3O!&L6^L7FBZ?K_ /PC,5K?:CJ>GO#IMU$)4YQJ>UNW
M-5X5[RBV_:1EAFFWRQE=2P]-J2<)TX\T8.-+W(R[-.-^6].4-+KW&JBT2=G&
MU1IJ2E&=HRDG*,9'@/\ P4J\)W/B?PS\&;FR_9+^*W[2&L6/Q!OM,\$>.?V=
MOV@+_P#9N_:#_9X^(/CBR@\ ^'?''A'XC:'K?@KQ%H?P]UW2O$7B73/C+K%C
MXYCTK3?"=I!:^+?AQ\3?"^J:K8:/\9_'W]CW]LOX@>$_V?K2;X:WOB'_ (*
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MV5U%<\7&2<VE-.:0YIU+*5[Q7*N6^SIM<MGS73BW/EDK2MS.,HIM?F;\!_\
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M4KY_UA\+_P#!-W]A7P7\-?B)\(/"_P"R]\)]'^'?Q;TGP-H_Q+\/6^@22?\
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M:'X.\;:KX/UG7--T33M1TBZ@N_AV^O-\.[?PSKNGZG;^(/!&B_#V/Q7XMM/
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M-QY96G>-2--RO./-/^1OX(_\$@OVI/!7P+_:K^'WC'P;XWU7XV?$3]D'Q?\
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MC_9S^ O[;G[/&K_M(?L?_&/4/V9M6\17OBZ+]F/0?V;/CAX \%?!;QEX>O\
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MM'^)UK<_%K0_%GP:>#QSI]_J/AF[T/X7VFD^--:T"?P1X%L]3_?2BEJE!)_
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MX&\+ZK;W/@_/A_1=!TWQ1K/Z.^.O^"J_["_@33OV9?$4_P =/"GB;P5^U?\
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M(-3T:!_#5CXDU--7O=<M].T36;?BC]N3]F/2_&'Q:^$'A?XW?"/QC^T+\(_
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M^&U5N6T;TZLZ=E)M0;:ISD[SA:25-.=24(R_=*BOY_\ X=?M,_M'?$;X2?\
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M9IXC;X67/A[5?!&O:?X9T2/Q!JGB.#7=:TNQP+']HGXO^/;C]K?]KKQ4=>\
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M-9N+YDXIDY<GMFTW"C*<7*W\E2<&VG91TI5*B]YWIP;5K-G]+-%%%(H****
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M\7Z4=0@C\2^'/C%\+/"'Q@\ ^,S9[9=,\"_%_P#M70[:/QUX3T/5+3=^(?\
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MN62VYN:]I080DZ;52&G+*=5-).TL(J4Y.SO_  TJ?NVL^5QM=-'F'C?]D_\
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MR+^QM\*?@7\"OV;_ (?_ !6T3XG_ /"TOA?X/\&_#+2?A-\:?B\ESX5UJT\
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M9[G X)R<$]L]@3^%?S[6_P =?V^?B%\4_A];>&?VM_!7@CP3\>_^"DW[<'[
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M-:IXH^(%]X#\=?%ZZN+[X)^&?AEX6^*WQ7O=5U/X4_$D:-XGO/B7\\_M;?\
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M_%?P[\6_"=W_ ,$[?V-?VDOA\VD_#G1_AP?AA)XT/CSX;ZW\-]$32M5UV_\
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M)2TO:^BM:6\))M3A[ZLFD5UDM?=:6J:O=-[/5-6:E%^]%V4M6%%%% !1110
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MX1BCEC!.IRI>Q<5=?83E*G*5U:T(_5OWEWS*GRR<%";D=!^SK_P2X\)? 4_
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M>>#?B_?^'_AGXB\?_L)_&OQKX%D\$VFHZ1J?Q_\ V+_CO\$_B]X@^+7AA?\
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M/@C^S%^TO\;_ (?>)OVF_P!GK]G[P9J>G^$O#OA#3_B/H/QQ^-.F_!^3XK>
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M8^%7AT^&9?'6J?%[P;-\,?#7AJS\>ZUK_P 4_&*>!O&6L:1KNN_ 2ST.QO\
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MK'1/"OQS^,/P_P#A1\*OA]X,_8:_90^!W[4G[7GP0^,VD>,_$7Q@\6ZC\0O
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MM6TVY*7NGRH+6XCC*A!^(W[8'[&7Q4_;)_;I_:K^%=OJ?PT\"? #XD?L)_\
M!/OPC\5_B!XW^"FN_$;XEJGAW]I3_@HMXH>']ESQHWC7PGX,^&GQE\*PW6G:
MI%X]UK2/'^H_#+Q!K_PQ^(^E^%YM1T/3=/UWGO@=X4_:0^%G[3.A?$CP]\3O
MCW;_  _^+W_!7G]L/X3_ !"^ %[X'\'#X)Q? OQ!\&/VB/B+8_$69O\ A6"?
M$6#5=1^,WPW^&_B#0?B[J'Q';3%34T^&VB^5X4\47&D:IC3:GO))OFM%JVU6
M-*.K2M>4GH[N2M./NNTJEI%R71I23B[->RK5G9JZ<E&A=)I+:',ZDHV_H$-O
M Q8M!"Q=XI')C0EY("C0R,2OS/"T<;1,<M&8T*$%5PXQ1%TE,<9EC22..0HI
M=$E*&5$<C<J2&*,R*" YC0L"47'\D_P5_:K_ &Y/''@O]L"YU#XE?M8? CPC
M=? 3X6?$?0/$?QK^&WQ^^-?Q,^$?Q4;]H/0M$^*?PLU.:Q_X)D?!/_A4GCK6
M/AKKR_#+XNVWP(\#?MA_#+]E256_:"T/4+O1?!FJ3^.(/B[^U!_P4DNX?V;U
M^&.K?M(?!O0-6_9G\&:A\'M=^-.G_M!^)+KQY^T_;_';]H/P9XUF^+6D?!C_
M ()+_'KQY^T3X(OOAKX0^!_C#P-\,_BGH?[!WQ$\4? GXF3^/[OPOIGQAN_$
MWB#]FS1QLJ=[?O%2DDM7%5)5H)RZ)QE2:M>[YX22C&2<B_O2BK7BYIN_6*IN
MUE=^\IIW:Y4E9N4O=C_5]JGB'PKH>J^&]%U?6/#VDZSXMU2_T_PAI6I:EING
MZGXFUNRT35O$.J6/AJQNIHKO6M5M/#>E:[KNH6VF17%W;Z'IVK:I<HEA9WD\
M>WY=N5,'DPF($L(_+3RRRN)20FW;D2'S"V/OD-G<<U\ ?M8Z%J^J?M8_\$M]
M3TS1-6U+3?#7[3?QVU/Q#JEAI=]J%AX:TV^_8)_:OT*RU'7K^TMY[70]/O=9
MU/3M%M+[4Y[6UN]6U"PTN":2_OK6WE_,C]N/3_BU\'/VPO\ @I;\8?A%\1_V
ML?#_ ,8?'O\ P24^$_B#]F*P\(>"?%?C7X/ZK\3/A!JG[<NF>,M'T633?AEK
M?@R;Q%\&9O$GPE^(_A_P#X@\86NM3>./CSJ]_!IOB"V\<Z5I&F9I-Q@[V<YU
MH*-H>ZJ56A3BVM'RS=7G;;C&,8.2=H3E%OE3LY12Y(3N[VM/VETVE*UHTW96
MO.4E"UY13_H:'BOPC/XKE\#CQ%X<F\<:?H5IXNF\(#5]-D\5V7AG4K[4="L?
M%,N@"=M7MM O]3T_5M&M-<>T33KN^L=1TZ&ZDN+:YA3/UOQIX T#Q-X-\!Z_
MXC\,:5XM\?GQ*_@3PIJ>H:?:ZUXM/AG31J?BU_#>DSNMSJS:)I%]]NUPV,,I
ML[&Z,UV4AF9F_#/]JS5?C_\ LQZG^T'HWASQ=^UA\;=.\*_L=_LN)9?%_3O^
M$?TKXOS>)_B9^WE\6-*^*'C#7/BW\,/V3?BR= \(_#3X<Z[I^N_%"Q^&'[.W
MC76?AE\!?#FH:[X#^'NF>(H;#Q,G(?L5^,?VD_C'XP_X)L>-/CUHGQ+UCQ%X
M)^+'_!3;PC+XL\:>%OB%'K-K\,[.QGTSX*WGC3Q'X[^ _P"S=XHU8ZEX)_L+
M1?#/CSQU\"OA#XD^(^G:?8Z_K'AB?Q)J&JZGJ5PIRDUK&,;1YFW%63EB8M+X
M?MT(;KE49\U_A1G.:BJE[<T=(:<UWR86IJHWDDXUYQY4N9NG;571_1:(XP[2
M"-!(X17D"*'=8]WEAGQN8)O?8"2%WMMQN.2...)2L4:1J7DD*QHJ*9)I'FFD
M(4 %Y97>61R-SR.[L2S$E]%(T(DMX(MGEPQ1^7$L*;(T39"I!6%-JC;$I *Q
MC" @8 J6BB@ HHHH **** "O//BC\5/A1\%?"%[\1_C3\1_AY\)O .ASV4&I
M>//BCXP\-^ _!^CW.KW<6DZ=#?>*?%>H:5HNGW&J7UY!IMC'<7T,E[=W45G
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MXA^)Z^'/AKXR^'\MQI$7AZU3XJ6'B^[*,X4^=-R4;M1]V#G)J$6ULTG%2O\
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MM\9;"^UV'2/B5??'N?6?B7XJT;XB:GHGC7XX^-(H+70?#6A?"+PYH/AO2O\
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M\+>$?"FD6>@^&_#FB:=;JD%AI&B:-I]EIFFV4*K%:V5K!!&JI&H'4$@ DG
M))/0 <DGZ5_*5\3_ -H?]NG0_A&LGPF^)G[4?CO]CZY_;+^)?AWPS^TW\6M
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MN^UZOKVC7FM>./'6@Z,+#5_C'X.?"C]J_P#98_8^^#&@^%O W[<7Q.TSQO\
M\$E?V7[KXR?"+7/BU^U+X>NOA-^T!X3\;_ 'P5X@M?AJOPQCE^+W[/\ XD^$
MOP<\>_$_6?&?[.?[*%AX)^*'Q8\(_!:V\+>$?"=W\9&'BC4,XN_*FO>E3HS2
MM%1C.I3K5)0;U<'&$+.4F^63C&2C*LH0<[14FK2C&I.+M?FY54ITN9+E2F^:
MIS/E2<HJ;5U3=2?]0?AS0=/\*^'M"\,:2VI/I7AS1M+T'3'UG6]:\3:PVGZ/
M8P:?9-JWB3Q+J&K>(_$&I-;6\1OM;U_5=3UK5KHRW^JZA>WUQ/<R:YC0YRB'
M)).5!R2 "3QR2  3W  [5_--^S3\/OVQOBY\._V8OA%\9/$_[<.C_#$?\%%/
MVB=-\4^*M(\2?MK_ +/7Q"UK]D?_ (8Y^*GQ&^$[>,OB)\3?B%J'[8GAGX6Z
MS\=-1\.:5X:U/XS?%QOBGI.OCP]\--6U[PWXBTJ'P5HOH'A3]F;]I#QK\3?A
M!XA\??%K_@HI8Z1\:_\ @H'_ ,%//AS\?= T[]H+]H;P%X+\+_L>>'/B[^UU
MXZ_99T_P]I_A?5_#TWP/\':CJ?PQ^ LOPM^.7@#4?!GQ3\0^!/B"GPJ\/_%N
M^^"7C'PC\/--U47S)7C=M*+YE;WJ<*EV].5)2<97VG!QU;C9-I+7=:M6;VE-
M:-*2;M!25DM)I7NF?T-8 Z #G/0=?7ZTFQ/[J],?='3TZ=/;I7\G/Q>\1_\
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M/D2M9148[1CR_CQ^T7_P1?\ @!^TLB)XO^)_Q3T5O^%E?M6?$29[3P?^R_\
M$:W*_M@ZCX(U/XH:+I>B_M!_LY_&CPWX5U/2'\ Z-IOP\^)_A#1=!^,'@K0=
M2\7Z)IGCTV/C+74G^W/$7[)'@3Q+X-_9,\$W_B#Q8=+_ &0/'?P\\?\ @:42
MZ#+<^+-3^&_PH\9_"+2+'QQ]JT*XMKK3K[1/&VH:MJ8T*VT*\?7++3YK.[L[
M)+BRN/JNBIU2Y;NRE2DEII*A&,:4E=/6G&,5'I[J;3:N4]7=MM\LX[_9J-N:
MTMHW)^G2VO-\R_$W]E[PC\4OBQ9_%_6O$7BJPU^R_9I^/?[+\>EZ5<:/'HC^
M#OV@_$OP@\4>*?$4D=[HM]?_ /"6:)>?!GP_;>')TOET6*SU76UU71=4F?3Y
MK#X(UC_@BO\  +5OBO\ !+XN?\+3^*T.L_!-?V.Y-/TZ[\)_LR^);GQ!??L2
MZU\/M8^%)'Q1\8_L\>(_C]\./#FNGX>VD?Q"^'OP5^+_ ,,_AYXDO=>\6:[!
MX8TS6?&7CBZ\5?LC11&\'&492C*#4HM/6,HNHU):/5.M4=]5>3:2>H-MW5W9
MIJVEK2C"+:33L^6G35][0BKNQ^,_BO\ X(I_ _XB?\+VUKXG_&[XR?$CXD?&
M_P <? _XA_\ "S/%'P\_8S%_X)\5?L^R_%&W\!ZZ/ASH?[)^C? WXP^(M2\+
M?&3Q[\._'?BS]H_X5_&3Q7XL^']SX>T(ZUIEYX,\):OHWUA#^P;\/O\ AA#X
MA_L"WWC+Q%=?#[XG_";XO_"+Q3X]T+P+\ _A3XO.C_&BV\5V?B/6M'\&_ KX
M-?"KX%>']:TFU\67%KH3:)\(K&UN$TW3]0\60^*/$,^MZ[K/W112Y=+7=O<V
M;7\-Q<'I:SBX0::2=XIW;NV-MRYF_>O*5]G>5^9Z6WN]-ET22235# ?-C=DD
MXSCDD\9 /2G444)6279):[Z)+7S>[[MM]= ****8!1110 4444 %?G]_P4\_
M9G^)7[7G['?CGX$?"NW\!:CXF\1^-O@?XENM ^).HZ1I'A7Q3X:^&'QN^'WQ
M1\2^%;G4?%7P<_:*\ PWGB'2?!MQI=A:_$[]G_XT_#+6)[@:'X\^'VK>'-3O
M[BR_0&BDU>WDT_FFFOEIJNJNO-"T:?:]OFI1OTU2D[=G9]+'X<_ '_@E-XFU
MK]F6X^$7[4WB?1/!MU_PS1^W7^QKX%\%?L\VGP6TK0OAC^S?^W8/@/?>-+._
MU?X9_LI?LN?"GQ;\7O"WB?X*7/B7P[XJ\%_LR_"?P990^-[WP[XJ\*_%36]$
MG^*7B[ZX\;_\$[/!OCCXM^+_ ![<?&WXVZ'\,?BC\8/A!^T)\9_V8]%7X+R?
M!CXM_&WX$VGP6L?ASXX\2:UKGP9UGXZ:%9Q6W[/?P@/B_P #^ OC'X2\#^.9
M?!%FFOZ#-8>)?B18>//T.HJW.;:DI2BXM-.+<;./*T]-WS0C4?-S?O8QJI1J
M0A*$*G!<WNI\]^92U33BXM-:*W(W3TL_9WIW<'*,ORY\&?\ !+3P1X:\4)J7
MB+]H[]I#XD^!/#GB;]J/XA?"/X->,;OX)VWP]^"WQ3_:_O\ XOO\7?B-X0U#
MP9\$_"7Q-\3ZW!H'QV^*GA#P'IOQ8^(GQ$\->#/#_CKQ+;Z?HDLLGAZ7PUY7
MHW_!$O\ 9ZT+XT_!KXVV/Q4^+,FN_!>X_9=U/1]+U+PC^R_K-SKFL_LG_#SP
M%\+/ $E[\5]8_9SO_P!HGPQX2UCPEX LKCQ1\*OAO\9_!'PIN?&'B#QKXST[
MP;INN>-_%D^L?LU14P_=N+@W%P<'"UO==./)3DM'[T(VC&3O*RC=RY8VN5Y.
M3;;<E-2=]U5:E479*<DG)14;N^UW?\F++_@DQX.@\)?M 66H?M1?M$:O\5?V
M@?B5^S/\8-9^/B>%/V1/!GCWPW\2OV1/B_;_ !M^"GCFU\'_  O_ &6? 7P/
M\<>-!XQLM/M/B9XW^+'PG\?>,_BEX1TK0/!OB37QX<\(^"-/\,=QI_\ P3-\
M'VGQ5@\8WW[1/[1FO?!\?M!:/^UKJ/[*>K7WP5C^!VL?M-Z+/IOB6#XLW^JZ
M/\$=(^-T4=Q\8-(L?VA[CX:Z/\7M(^%*?'))/$UIX+MO#+KX+3]+Z*-=&FTX
MM.+5KKE<)1M[KM9TZ;5K-.G"2:E",D6M>VEW)NVCO*Z>JL]>:2WVE*.L92C+
MX7^%/[!?PW^$6H? /4="\8>/M5F_9[^#/[4'P1\+#6[SPW(NM>&_VK/B7\(O
MBCXWU7Q$MAX7L?-UWP[K7P:\.Z=X1DTLZ9I\&D:GK<>M6&LWDMC=V/QY:_\
M!#O]GFQ\;?LX^.+3XL_%XWO[-^@_L3:)HMKJOA3]F'Q/J?BI_P!@S4OAS?\
MP?N+KXH>+/V=->^.WPXTCQ$OPYLU^)7@'X&_%?X6_#GQ+J&O>*M<M?"NEZIX
MO\:S>*?VKHH5XN#4I?NW!P3=U%TX.G3=G%J\(-QBW>R?5V:=W::YI?O&W/5^
M\W*<F_G*I-NUE><M-;+YB^+7[)WPO^-_Q-L/B+\2(M5\06<?[,W[1_[)^O>
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MD5M!;:I+HMU>)I.IZ7?F"^@^;_AA_P $[OA7\+M<^&,MAXP\?>)OA[\%K/\
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MA/XF>&O@_P".?$MUX3\-_8O#7IGC?]C7XROXP.K?&K]CGXJ_M:_LX77[2_\
MP4P\;:M^S/\ #'XM_!GP]J>K>,OCY\=O@YXJ_98_:4UCP_\ $G]HSX&_#7Q)
MH_A3X:^'OC;HVCR:SXX;XD_"/Q)\3M(\3:1X%CU*75/$'@G5TX1]M^\A-TI5
M(1Y.5*HXU)J-2":]I)3A2E&,/9I^TK4VIU*2E5%&;DJ3Y''VJIRE=<TX<U)2
ME&2BU&\9U(^_SWY*-;FITYN,'_1QE<'"$\@$!1U)SR/8X)].#3&D1%)"%BA&
M579N5CC .6503NR,L 0>#R,_Q#_M%/;>!OVMOV*?V?\ _@H#X\MOC'XV^#'[
M/W_!*'P[XZMKJ[^&'Q>^/&H?&OP=\:?%WBOQ['\"K;XV_MK?LZ_&'XC1?&_6
M9? GPS_:4\:? G]C;]N#Q9^T/\/=#N[":_\ !_Q7TA?!/@S]OOV+_AA\0Q^W
M3^T'\,M=GU'4OV?_ /@GCXU^+]C\!=;E\0/K-CXK\:?\%"W\ ?M3ZAX1UO3D
MU*=O#WB7]BWX<^)=9^"WP]T6^BEC7X$_'_P;J-H(A>116LJ-X\W-%+]ZUI?2
MDVK*[LZFM-J,7*+<VE4M'FFY2Y>91O)Q4=K)RYW**<8RL^1-.[:YTFFZ?Q\G
MZA> OVCO GQ*^-'QJ^!_A/1_B!>:]\ +WPMH7Q&\7W/@?6[#X96WC3Q3X/\
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M\17ISH*&'A3H.AB%6A.5>I-57B*<J"@IT5A^6BHU)SG&O[5NFH>RES<GX_\
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MDE;"KR:_-KX@_ GXB:A_P4@NOBO\1_V7/BG^T+X+D@_9OG_9@^/O@GXV^!?
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M18OV2)?$'Q;\._M5^-_VD)4^$*W_ ,+];^$^B:]^R+\/+3]F:#POK_@3X?\
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MH **** "BBB@ HHHH **** "BBB@ HHHH *\W^,'Q>^&_P  OA?X\^-'Q?\
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MK#QKX5U;0/$.BM/8ZS:%_P"=?XE?\$O_ (\ZAX]TFWU?]G7X:?M,>++37O\
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M6TU6_LTCO9M#P%\8OAA\4+3QG?> _&.C^([+X>>-?&7P[\;W%K)+!'X9\9^
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MG3=:UKX_>'M+^,WPXO\ 7?@;HWAS[:?$&K_&+1[;Q++J/PQTS0ET[4&UJ_\
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MDU!N,4I.RYI))S;=[M146ES?K#\/OVN/V5?BWXE\,^#/A5^TM\ /B9XP\:^
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M$GQSX8_X)X^$M5\6WGQK^+GQ%A\9ZE^QK^VUI7[3OQ!^(5IX?U?X*_#[PE\
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MMW_L%:E\0?C9^RY>66G_ +='_!13P?X1_92\%>#]8T/]ISX&VW[.OP9_;7^
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MP=H_CF[\2Z'^S3\-?VG_ -FN]_9ZU3PU::=\6O#GAVV\0?&#]E_4?#/CF_\
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M *\MN@PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\*>&[22QGN+C7=7\>0:[H-W\-K/P_;ZK+\2[#7]!O_ (\1V6M:9/=?E7:?\
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M].U&PTC1_!_[2.F?&R7P'XDTN7QW/XF\<:7K6J_#67]._P!E/X"WO[.OP_\
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MJ>MQZYX;\.Z5X\\7K;0:AJMOJ=U%<P_:=4Y>Q_8)^,G@+]M_XW?MS_"CQ?\
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M_:-_:2T]/V._AM^V)\3/@9^SI^S/\*_#'A3XP?%/Q=\'? G@SX9_$CXH^/\
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M7_VD_&?[!&J?$KXR?"?]H'PIX,_X*SOX>^&/Q5^'_P 8_P!FCXS>*[NUOO\
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MNI/CG^SQHMEX#U:R^%7CKQ!\!?"_A/X=>.?!46MW/B+Q7\.'^/WA#P[\>?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
1HH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>logo_001.jpg
<TEXT>
begin 644 logo_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !% )T# 2(  A$! Q$!_\0
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M)6$KS3XQ>(=6\/:7I$ND7CVLDUYY<A0 [EV].:]+KQ_]H#G0-%4'!:^(!_X
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M'?Z5X9\,7.LSV-L8[9/,CB$:C<YP !QP2<<UXU\3=+\7V%GI#^)M>MM2@:\
MA2&$(4;'))P,\5L_&'Q!%=ZOH_A@K/+:PE+J_2W3>Y'90/ID_B*2II\MOF#E
MN=G\.?'%KXT^WNVF1:?J$##S$4@LZ-T;. >H-9?B'X@7UAX^N=#TOPI'J=[
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MZ7J,9DMI@-P4X((.00>QR*?H>CVVA:1;Z9:&5K:W7;'YK[F ],UI44KNPQC
M$8(R#67%X:T."\^V0Z18QW.<B5+=0P/KG%%%-,DUZ***113O-/L]3MS#>VL-
MQ$?X)4##]:SM-\*:%I<IFL=+MH9 ?OA,L/H3THHIPG+EW,Y1CS;&[BBBBD:!
:1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>ex5-1_001.jpg
<TEXT>
begin 644 ex5-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  F ,P# 2(  A$! Q$!_\0
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M^)M7L-.\77MH;1GD/G7<N-N_  VYKLO^%1_$O_H?W_\  RXJC\ O^2@^*/\
MKFW_ *-KZ&H ^>-1T+XR>!X7U&WUR75K6 ;I%28SX4=24D&<?2O1OA;\3(?'
M^FS1W$*6VK6@!GB0_*ZGHZY[=B.WXUZ 2 "20 .N:^;O@_Y4GQQUR32Q_P 2
M[;=%=GW?+,HV_P!,4 >W^-_&%GX(\,SZO=KYC B."$'!ED/1<]NA)/H#7BND
MV_Q0^+>_4CK#:1HS,1'Y;M$AP>BJOS/CU)_&MG]I;SO[(T#&?)\^7=Z;MJX_
M3=7K'@S[)_PA&A_8=OV7[##Y>WI]P?KG- 'DC_ 7Q';J9;+QW.+GKDK(@)_W
M@Y(_*LW3O'_C7X8>)H=&\<-)?:;+C$[-YC!,XWH_5@.ZGGZ5]$UXK^TE]E_X
M1/2-^W[5]M/E>NS8=WX9V?I0![/#+'<0QS1.'CD4,C*<A@1D$5\\_&^ZU1OB
M=H^F6&J75FMW;0Q_NIG50S2LNX@'_.*]@^&IG/PU\._:-WF?88_O==N/E_3%
M>*_'8W8^*^AFPP;W[-!]GSC_ %GFMMZ\=<=: -G_ (4AXT_Z'R7_ +^3?_%4
MR7X)^.HXF>#QU(\JC*J9YER?KDXJ26[^/L43R&&%@@+$)';$G'H!U-<IHOQ)
M^*/BS4GT33]5MTO75AL>*&%^.H!8#YAZ=>* .\^"7CC7-5U+5/"_B"=[JYL%
M+QSR'<XVML9&;^+DC!^OM7IWBWQ#%X4\+:AK<T1E6UCW",'&]B0%&>W)%<9\
M)OAE<>"([S4=6N4GU>] 5_+)98TSDC<?O$GDGV%=YKVB6?B/0KS2+]6-M=1F
M-]IP1W!'N" ?PH \(T:;XL?%*!]5LM;BTG3&D9$\J0Q+D=0-H+G'J36@_P )
MOB=$#+#X^=I1S@WDXS^-4_\ A3_Q#\)3R_\ "(^)5:U=B=BSM"3]4.5)]\T\
MO\>])Y(:[5>HQ;RY_K0!N^#-(^+^F>*K2WUO4EN-%!S<2R2I+E0.BD_/DG K
MV2O$O!OQFUE_%5OX9\9:0+.[GD$23+&T3*Y^Z'1NQX&17MM 'S+K#>+/$WQI
MUCPYI/B6\L09Y#&#=2+&@5<X 7I70_\ "I/B;_T/S?\ @9<?X5Q^J:+JWB#X
M^ZUI^B:D=.OGN)62X$C)M 3)&5YY%=A_PJ3XF_\ 0_R?^!MQ0 ?\*D^)O_0_
M-_X&7'^%>NZ1H,MOX.M]#U6]FOI1;^3<7/F,'D)ZD-G<.O!SGBIO#&G:AI/A
MNQL-5U ZA?0Q[9KDYS(<GUY.!@9/7%:U 'S+>:GXH^#/Q%07M]>ZEHLYROGR
MLXGASSC)P)%_SP:^C]+U.SUG2[;4K"=9[2X021R+W!_KVQ6/XV\'6'C?PY-I
M5Z K_?MYP,M#)V8>W8CN*^7F\1^,_A[!JW@GSFMUD<HZ[<LN[^*)NP88_P#K
M&@#N_B?\0M5\6^*H/!W@V>;8LWEO+;2%3<2]P&'\"\Y/3@GH!7L/A#P='X=\
M.V]C>7<^H7GW[BXFE9BSD#.,GA1C ']2:Y3X.?#-?"&E#5M4A']MWB<JPYMH
MSSL'^T>_Y=N?4Z /E/PMJ'C/P'XGUB_T_P )7UV;MGC/FV<VW&_.1@5V7_"X
M?B/_ -"!)_X!W%>]44 ?.^HZM\8OB! VFPZ*^DV,XVRD1&W!7N&=SNQ[#K7I
MOPR^&]M\/]*E#S+<ZI=8-Q.HPH Z(OL/7O\ E7;S3PVZAII8XU)P"[ #]:(I
MX;A2T,J2*."48$?I3L]Q75[&!XX\'V?C?PS/I%VWEL2)()@,F*0=&QW')!'H
M37BNDWGQ.^$2OILFC-J^C(Q,916D1<\Y5EY0'KAA^%?0T5Y:SR&.*YAD<=55
MP2/PI&O[-)#&]W K@X*F0 Y^E'*^PN:.]SP]OC[KUPOE67@>=KD\ %W<9_W0
M@-9UAX \;?%'Q+!K/C=7T_3(_NP,-C;.NR-.JY[LW/UKZ#GN[:VQY]Q%%GIO
M<+G\Z&N[9(5F:XB$3?=<N,'Z&BS'S+N/AACMX(X(4"11J$1%'"J!@ 5X5\5?
M#^L:I\8O#=U8Z7>7-M&MOOFBA9D3$S$Y;H,#GFO<DN[:1=T=Q"RY"Y5P1D]!
M4F]/,\O<N_&=N><>N*+,$T]AU>,_%KX5S:A,?%GA9'BUB$B6>&#AIB.=Z8_C
M'Z_7K[-TIGG18SYB8P#G<.AZ&D,XCX8^*=<\0Z(T'B+1[VQU*T"J\T]NT:7
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MV4!XX69>W<#%?2J7EK))Y:7,+/\ W5<$_E4U-IK<2:>P4444AA1110!C:_\
M(;&<Q)*D,Q9HW. V48>A]:IP6$FIK>W$"0V2SVQMU6(DY;.=S8 Z=/Q-%%=*
MDXTDT<4HJ59Q>W_ L,MR-0O+2VAL[>U>RD#O(A[#JJ\#@^],NM%G>WOYA<*%
M>Y=I(MJX:,GD!BI(..]%%7*;C.R\B(4XSA>7G^&@_7!!;7<$PCE5O)$:R1RC
M..P(92/QIM_;3C1=,:X\MFBF+L(L)D%6QCY<9Y&>/6BBJB]($R2<JG]=O\C0
MTY+;4],FM9;55BX5OF!+>^0!S[U+H5B]M:F>YD\Z\E)$DQ.20"0HZ#C'ZYHH
MK"HVG**V.BE%249/>Q/86,UK+=/+=R3K-)O57QA1@#T]JP+[2+B"[!M?L[16
MQ\V))=PX9A\AQ_"&!8?@****=22E<=6E%P2-%]%*G3HDN'4Q-(\LRMAW9EY/
M3N:AGTF58-4C68R><\)5IFRWRD9R<>W%%%"JR_KU"5&&NG]6L7;W2[>?5+*8
MVUN0K.9=R#+97 [<U%<:2TVL/<0S&V9+=$A:/^$@MD%>A7D<?RHHJ54DON*=
M*#>W4S[NQGAT&!)S&TD=ZTLGEG:#EG/&0<=:OZ4+;4+">UDM%$6 KY(8OG/7
M '-%%;-MTV_,YU%1K**VM_F2Z)I[6L<D]Q(9[IV*&5CD[%)"K^77WS4VMPO/
MI$R1[=^48;C@<,#_ $HHK'F;J7.E02I<J[%;[7/J=C>V[01Q%H&"D2EN2".?
ME%.TN_GD,5K);1(%CQO64MT'IM'\Z**T:5FK&,92O%W_ *N4M-\.%;>U,\\?
C[MA)MCA4'(.1\^,_XUTE%%95)RD]3>E3C"/NA11169J?_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
